Number xx

Lower Limb Prosthesis

Prepared for:

Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov

This information is distributed solely for the purposes of predissemination peer review. It has not been formally disseminated by the Agency for Healthcare Research and Quality. The findings are subject to change based on the literature identified in the interim and peer-review/public comments and should not be referenced as definitive. It does not represent and should not be construed to represent an Agency for Healthcare Research and Quality or Department of Health and Human Services (AHRQ) determination or policy.

Contract No.

Prepared by:

Investigators:

AHRQ Publication No. xx-EHCxxx <Month Year>

Purposes of Review

Assess validity of measures used in adults with lower limb amputation, whether patient characteristics can predict relative effectiveness of different lower limb prosthesis (LLP) components, and long-term use of LLPs.

Key Messages

- 61 ambulatory and functional outcomes, and other measures, have been evaluated, of which 19 have been validated and found reliable in studies applicable to the Medicare population. However, many studies use nonvalidated measures.
- A small number of studies, only half of which used validated measures generally did not find patient or other characteristics that may predict who would most benefit from a given LLP component.
- The few studies that assessed long-term use of LLP found that between 11% and 22% of patients abandoned their LLP after 1 year; people with transfemoral (above the knee) amputations are more likely to abandon their prostheses than those with transtibial (below the knee) amputations. About 11% to 37% of people with LLP use them only indoors 1 to 7 years after they first received the prostheses.

This report is based on research conducted by an Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. xxx-xxxx). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.

The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.

This report is made available to the public under the terms of a licensing agreement between the author and the Agency for Healthcare Research and Quality. This report may be used and reprinted without permission except those copyrighted materials that are clearly noted in the report. Further reproduction of those copyrighted materials is prohibited without the express permission of copyright holders.

AHRQ or U.S. Department of Health and Human Services endorsement of any derivative products that may be developed from this report, such as clinical practice guidelines, other quality enhancement tools, or reimbursement or coverage policies, may not be stated or implied.

This report may periodically be assessed for the currency of conclusions. If an assessment is done, the resulting surveillance report describing the methodology and findings will be found on the Effective Health Care Program Web site at www.effectivehealthcare.ahrq.gov. Search on the title of the report.

Persons using assistive technology may not be able to fully access information in this report. For assistance contact EffectiveHealthCare@ahrq.hhs.gov.

Suggested citation [pending]:

Preface

The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-based Practice Centers (EPCs), sponsors the development of systematic reviews to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States. These reviews provide comprehensive, science-based information on common, costly medical conditions, and new health care technologies and strategies.

Systematic reviews are the building blocks underlying evidence-based practice; they focus attention on the strength and limits of evidence from research studies about the effectiveness and safety of a clinical intervention. In the context of developing recommendations for practice, systematic reviews can help clarify whether assertions about the value of the intervention are based on strong evidence from clinical studies. For more information about AHRQ EPC systematic reviews, see www.effectivehealthcare.ahrq.gov/reference/purpose.cfm.

AHRQ expects that these systematic reviews will be helpful to health plans, providers, purchasers, government programs, and the health care system as a whole. Transparency and stakeholder input are essential to the Effective Health Care Program. Please visit the Web site (www.effectivehealthcare.ahrq.gov) to see draft research questions and reports or to join an email list to learn about new program products and opportunities for input.

If you have comments on this systematic review, they may be sent by mail to the Task Order Officers named below at: Agency for Healthcare Research and Quality, 5600 Fishers Lane, Rockville, MD 20857, or by email to epc@ahrq.hhs.gov.

Gopal Khanna, M.B.A	Arlene S. Bierman, M.D., M.S.
Director	Director
Agency for Healthcare Research and Quality	Center for Evidence and Practice Improvement Agency for Healthcare Research and Quality
Stephanie Chang, M.D., M.P.H.	Lionel L. Bañez, M.D.
Director	Task Order Officer
Evidence-based Practice Center Program	Center for Evidence and Practice Improvement
Center for Evidence and Practice Improvement Agency for Healthcare Research and Quality	Agency for Healthcare Research and Quality
	Elise Berliner, Ph.D.
	Task Order Officer
	Center for Evidence and Practice Improvement
	Agency for Healthcare Research and Ouality

Acknowledgments

The authors gratefully acknowledge the following individuals for their invaluable assistance in scoping and refining the protocol; understanding the clinician, provider, and patient perspectives regarding lower limb prostheses, their comparisons, and patient-centered outcomes of interest, among other issues: [pending]

Key Informants and Technical Expert Panel

[pending]

The list of Technical Experts who provided input to this report:

* Provided input on Draft Report.

Peer Reviewers

Prior to publication of the final evidence report, we [are seeking] input from independent Peer Reviewers without financial conflicts of interest. However, the conclusions and synthesis of the scientific literature presented in this report do not necessarily represent the views of individual reviewers.

Peer Reviewers must disclose any financial conflicts of interest greater than \$10,000 and any other relevant business or professional conflicts of interest. Because of their unique clinical or content expertise, individuals with potential nonfinancial conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any potential nonfinancial conflicts of interest identified.

The list of Peer Reviewers [will] follows:

Lower Limb Prosthesis

Structured Abstract

Background. Lower limb prosthesis (LLP) candidates are a heterogeneous group. Many LLP options exist and how to best match an amputee with a LLP is unclear. Optimal selection of devices is hampered by limited studies, as well as use of a wide range of evaluation metrics, some of which have not been validated in this population.

Methods. We addressed questions pertaining to: assessing validity, reliability, and related metrics for assessment techniques, predictor tools, and outcome measures in lower limb amputees; determining which patient and other characteristics may predict which LLP component may be best for different lower limb amputees (i.e., assessing heterogeneity of treatment effect); determining whether patient expectations align with their outcomes with LLPs; evaluating whether patients are satisfied with the process of obtaining their LLPs; and describing the long-term continued use of LLPs by those prescribed a prosthesis. We searched six databases and other sources through November 30, 2016 [to date] for eligible studies.

Results. We found 92 eligible studies that assessed performance characteristics of 61 measures (assessment techniques, prediction tools, and outcome measures). Of these, 29 have been both validated and found reliable, but only 19 are generally applicable to the Medicare population. These measures mostly assess ambulation and function in people with lower limb prostheses. Of 11 studies that provide data to allow assessment of heterogeneity of treatment effect, five used both validated predictors and outcomes, three of which assessed microprocessor knees. These studies mostly included younger men with unilateral transfemoral amputations due to trauma. Overall, studies did not identify participant characteristics that predict which lower limb amputees would most benefit from a given component (low strength of evidence), whether restricted to validated predictor and outcome measures, assessing all predictors and measures, or based on a multivariable prediction model. Two studies provide low strength evidence that people are satisfied with their encounters with their prosthetists. No eligible study addressed how study participants' preprescription expectations of ambulation align with their functional outcomes. Based on eight eligible studies there is moderate strength of evidence that about 11 to 22 percent of lower limb amputees who receive a LLP prescription abandon the prosthesis at about 1 year and that people with unilateral transfemoral amputations are about twice as likely to abandon their LLP than those with unilateral transtibial amputations. There is low strength of evidence that 11 to 37 percent of LLP recipients use their prostheses only indoors.

Conclusions. Numerous measures of ambulation, function, quality of life, and other patientcentered outcomes exist for people with lower limb amputations: however, relatively few have evidence of reliability and validity in studies representative of the Medicare population. The validated measures should be used to form a core set of measures for use in future research studies of LLP. Currently, there is not evidence to support the selection of specific components for patient subgroups to maximize ambulation, function, and quality of life or to minimize abandonment or limited use. Further high quality research in representative samples of people with LLPs is needed to inform optimal matching of prosthetic components to patients and to assess patient expectations and satisfaction with care.

Structured Abstract	V
Introduction	1
Objectives of the Systematic Review	
Key Questions	4
Analytic Framework	8
Methods	
Search Strategy	
Study Eligibility Criteria	
Population of Interest	10
Interventions or Predictors of Interest (and Measures for KQ 1-3)	
Comparators of Interest	12
Outcomes of Interest	12
Eligible Study Designs	13
Setting	14
Study Selection	14
Data Extraction	15
Risk of Bias Assessment	17
Data Synthesis	18
Narrative and Tabular Synthesis	18
Post Hoc Analyses	18
Summarizing Findings Across Studies	18
Grading the Strength of Evidence	19
Peer Review	19
Results	20
Summary of Studies	20
Key Question 1	
Summary of Studies and Participant Characteristics	
Assessment Techniques	22
Key Question 2	25
Summary of Studies and Participant Characteristics	25
Predictive Tools	25
Timed Up and Go	
Key Question 3	32
Summary of Studies and Participant Characteristics	32
Outcome Measures	
Key Questions 1 to 3 Summary	
Key Question 4	73
Overall Summary of Studies	73
Studies That Evaluated Validated Outcomes	97
Studies Using Nonvalidated Measures	
Summary	102
Key Question 5	104
Key Question 6	104
Key Question 7	108

Contents

Overall Summary of Studies	108
Failure to Maintain Bipedal Ambulation	114
Use of Prostheses Only for Transfers	114
Use of Prostheses Only Indoors	114
Abandonment of Prostheses	115
Major Problems with Prostheses	116
Reasons for Abandoning Prostheses	116
Summary	116
Discussion	120
Evidence Summary	121
Evidence and Analysis Limitations	122
Future Research Recommendations	124
General Recommendations	124
Studies of Heterogeneity of Treatment Effect	125
Studies on Expectations, Satisfaction With Services, and Long-Term Followup.	126
Conclusions and Clinical Implications	126
References	127

Tables

Table 1. Lower limb extremity prosthesis function levels, per CMS (K levels)	2
Table 2. Metrics for Evaluation of Reliability, Validity, and Related Measures	. 16
Table 1.1. Assessment Techniques: Studies, and Participant Characteristics	. 24
Table 1.2. Assessment Techniques: Reliability, Validity, and Other Characteristics	. 24
Table 2.1. Prediction Tools: Studies, and Participant Characteristics	. 29
Table 2.2. Prediction Tools: Reliability, Validity, and Other Characteristics	. 30
Table 3.1. Outcome Measures: Studies, and Participant Characteristics	. 51
Table 3.2. Outcome Measures: Reliability, Validity, and Other Characteristics	. 54
Table 1-3.1. Summary of Performance of Measures in People With Lower Limb	
Amputations	. 70
Table 4.1. Study Design and Participant Characteristics of Studies Comparing	
Components	. 75
Table 4.2. Comparative Study Components	. 77
Table 4.3. Comparative Study Risk of Bias / Study Quality	. 78
Table 4.4. Summary of Subgroup Comparisons	. 79
Table 4.5. Subgroup analyses. Alaranta 1994, Comparing Energy-Storing Versus	
Conventional Ankle/Foot Component	. 81
Table 4.6. Subgroup analyses. De Asha 2014, Comparing Hydraulic Versus Rigid	
Ankle/Foot Component	. 82
Table 4.7. Subgroup analyses. Gard 2003, Comparing Shock-Absorbing Versus Non	-
Shock-Absorbing Pylon	. 83
Table 4.8. Subgroup analyses. Hafner 2009, Comparing Microprocessor Versus	
Mechanical Knee Component	. 84
Table 4.9. Subgroup analyses. Hahn 2016, Comparing Genium Microprocessor Vers	us
Prior Knee Components (Mostly C-Leg Microprocessor Knee)	. 85
Table 4.10. Subgroup analyses. Isakov 1985, Comparing Locking Versus Open Knee	Э
Component	. 86

Table 4.11. Subgroup analyses. Kahle 2008, Comparing Microprocessor (C-Leg) Versus Mechanical Knee Component	87
Table 4.12. Subgroup analyses. Silver-Thorn 2009, Comparing Locking (Total Knee	
2000) Versus Hydraulic Knee Component	90
Table 4.13. Subgroup analyses. Theeven 2011, Comparing Microprocessor (2 Settin	ıgs)
Versus Mechanical Knee Component	92
Table 4.14. Subgroup analyses. Traballesi 2011, Comparing Marlo Anatomic vs. Iscl	nial
Component Socket Component	94
Table 4.15. Subgroup analyses. Wong 2015, Comparing Microprocessor Versus	
Mechanical Knee Component	95
Table 4.16. Key Question 4 Evidence Profile	103
Table 5-6.1. Key Questions 5 and 6 Evidence Profile	107
Table 7.1. Study Design and Participant Characteristics of Studies Reporting Long-	
Term Followup After Prosthesis Prescription	110
Table 7.2. Long-Term Followup Study Risk of Bias / Study Quality	111
Table 7.3. Long-Term Followup Results	112
Table 7.4. Key Question 7 Evidence Profile	118

Figures

Figure 1. Analytic framework for assessment and assignment of lower limb prostl	neses,
including Key Questions	8
Figure 2. Literature flow	21

Appendixes

- Appendix A. Search Strategy Appendix B. Excluded Studies
- Appendix D. Study Results KQ 1-3 Appendix D. Study Results KQ 4

Evidence Summary

Background

An estimated 1.9 million people in the U.S. are living with limb loss, a number expected to double by 2050 mostly due to the rising prevalence of diabetes.^{1, 2} The management of lower limb amputees with respect to lower limb prostheses (LLPs) is a complicated problem. LLP candidates are a heterogeneous group with distinct needs dependent upon age, etiology of limb loss, level of amputation, comorbidities and health status, postoperative stage, and rehabilitation status. Many LLP options exist, comprising numerous permutations of components, the anatomy they replace, their sophistication, and other attributes, including those pertaining to cosmesis and comfort.

The current standard approach for matching patients to prostheses relies heavily on performance-based assessments, self-assessments, and wearable monitoring technologies that record patient activity;³ although prosthetists often rely on clinical judgment to match patients to prostheses. Numerous metrics exist to assess the patient functional status, but no consensus "gold standard" assessment schema exists.

The major contextual challenges in providing data to inform matching of LLPs to patients pertain to the large heterogeneity in patient characteristics and attributes of the LLPs; the fact that it is unclear which patient characteristics and LLP attributes are important to best match a patient to a specific LLP; disagreements about what constitutes an optimal matching of patients with LLPs; and poor clinical outcomes and wasted resources associated with suboptimal LLP allocations.

Objectives of the Systematic Review

This review's Key Questions and study eligibility criteria were designed to assist CMS to better understand the state of the evidence regarding how best to match patients with LLPs that would yield best outcomes for them, and related issues. It is important to note that this review does not fully cover the field of evaluation of LLPs. Specifically, it excludes from evaluation biomechanical and other nonpatient-centered intermediate outcomes. It also does not attempt to review all evidence about comparisons between specific components. Instead, it largely focuses on those comparisons, which provide within-study data to allow assessment about how components compare in different subpopulations of patients based on their characteristics. The review also focuses on people who may be eligible to be covered by CMS, whether due to age or disability. Therefore the review is restricted to adults with an emphasis on those with dysvascular, cancer, or trauma-related amputations, but excluding studies of exclusively military amputees with battle-related trauma (who are generally covered by Department of Defense and/or Veterans Health Administration insurance). Furthermore, the review excludes studies from low-income or resource settings not applicable to the U.S.

Key Questions

Preliminary Key Questions (KQ) and protocol were discussed in depth with a panel of key informants (stakeholders representing patients [amputees], clinicians, prosthetists, rehabilitation, and physical therapy), with the sponsor, and were publicly posted in December, 2016. Based on

feedback from commenters and further discussion with the sponsor the Key Questions (and study eligibility criteria) were revised to improve clarity, focus the topics more closely with the sponsor's needs, and to evaluate measures and outcomes of interest to stakeholders. The following are the Key Questions (KQ) addressed by the review:

- **KQ 1.** What **assessment techniques** used to measure functional ability of adults with major lower limb amputation have been evaluated in the published literature?
 - 1a. What are the measurement properties of these techniques, including: reliability, validity, responsiveness, minimal detectable change, and minimal important difference?
 - 1b. What are the characteristics of the participants in these studies?
- **KQ 2.** What **prediction tools** used to predict functional outcomes in adults with major lower limb amputation have been evaluated in the published literature?
 - 2a. What are their characteristics, including technical quality (reliability, validity, responsiveness), minimal detectable change, and minimal important difference?
 - 2b. What are the characteristics of the participants in these studies?
- **KQ 3.** What **functional outcome measurement tools** used to assess adults who use a LLP have been evaluated in the published literature?
 - 3a. What are their characteristics, including technical quality (reliability, validity, responsiveness), minimal detectable change, and minimal important difference?
 - 3b. What are the characteristics of the participants in these studies?
- KQ 4. In adults who use a lower limb prosthesis, how do the relative effects on ambulatory, functional, and patient-centered outcomes of different prosthetic components or levels of components/prostheses vary based on study participant characteristics?
 - 4a. What **assessment techniques** that have been evaluated for measurement properties were used in these studies?

- 4a.i. How do the characteristics of the participants in eligible studies that used these specific assessment techniques compare to the characteristics of the participants in the studies that evaluated the assessment techniques (as per KQ 1b)?
- 4a.ii. What is the association between these preprescription assessment techniques and validated outcomes with the LLP in these studies?
- 4b. What **prediction tools** that have been evaluated for measurement properties were used in these studies?
 - 4b.i. How do the characteristics of the participants in eligible studies that used these specific prediction tools compare to the characteristics of the participants in the studies that evaluated the prediction tools (as per KQ 2b)?
 - 4b.ii. What is the association between preprescription assessment techniques and validated outcomes with the LLP in these studies?
- 4c. What **functional outcome measurement tools** that have been evaluated for measurement properties were used in these studies?
 - 4a.i. How do the characteristics of the participants in eligible studies that used these specific functional outcomes compare to the characteristics of the participants in the studies that evaluated the outcomes (as per KQ 3b)?
- **KQ 5.** How do study participants' preprescription **expectations of ambulation** align with their functional outcomes?
 - 5a. How does the level of agreement vary based on the characteristics listed in KQ 4, including level of componentry incorporated into their LLP?
- **KQ 6.** What is the level of patient **satisfaction with the process** of accessing a LLP (including experiences with both providers and payers)?
 - 6a. How does the level of patient satisfaction vary based on the characteristics listed in KQ 4, including level of componentry incorporated into their LLP?

KQ 7. At 6 months, 1 year, and 5 years after receipt of a LLP,

(accounting for intervening mortality, subsequent surgeries or injuries) what percentage of individuals...?

- i. Maintain bipedal ambulation
- ii. Use their prostheses only for transfers
- iii Use prostheses only indoors
- iv. Have abandoned their prostheses
- v. Have major problems with prosthesis
- 7a. How do these percentages vary based on the following characteristics?
- 7b. What were the reasons for suboptimal use of the prosthetic device?

Methods

Search Strategy

We conducted literature searches of studies in PubMed, both the Cochrane Central Trials Registry and Cochrane Database of Systematic Reviews, EMBASE, and CINAHL/PSYCInfo databases to identify primary research studies and systematic reviews meeting our criteria. The searches were conducted on November 30, 2016. [The searches will be updated in all databases upon submission of the draft report for peer and public review.] No publication date or language restrictions were applied.

Study Eligibility Criteria

Specific eligibility criteria varied for each KQ, but criteria for populations, interventions, and study designs of interest were the same for most KQ. Fuller criteria details are in the full report.

Population of Interest

Adults with lower limb amputation (KQ 1 and 2) or who are being evaluated for or already have a lower limb prosthesis (LLP) (all KQ)

Exclude if study includes *only* participants with battle-related trauma

Exclude if study includes *only* congenital amputations (and not otherwise Medicare eligible)

Exclude if study includes *only* children ≤18 years old

• If a study has a mixed population (related to battle trauma, congenital amputations, or pediatrics) and they report subgroup data based on these factors, include analyses of relevant populations (exclude substudy data on excluded populations). If study reports only combined data (e.g., adults and children), include overall study, but note issue related to population.

Exclude if study conducted in low income or low resource country

Interventions or Predictors of Interest

KQ 1-3 Measures:

- Assessment techniques (measures or tools used prior to prescription to assess patient's overall functional status) (KQ 1)
 - *Exclude* single factors (e.g., time since surgery, fasting blood glucose)
- Predictor tools (used prior to prescription to predict functional outcomes with prosthesis) (KQ 2)
 - *Exclude* single factors (e.g., time since surgery, fasting blood glucose)
- Outcome measures (assessed in people using LLP) (KQ 3)
 Functional, patient centered, or ambulatory outcomes per KQ 4

KQ 4-7:

Custom fabricated lower limb prosthesis

- Specific prosthetic component, including foot/ankle, knee, socket, liner, pylon and suspension, or components with specific characteristics (e.g., shock absorbing, torque, multiaxial, computer assisted, powered, flexion, microprocessor)
- New or existing definitive or replacement prosthetics
- *Exclude* immediate postoperative prosthetics (used temporarily prior to definitive or replacement prostheses immediately after amputation surgery)
- *Exclude* studies comparing only rehabilitation, physical therapy, or training techniques or regimens
- *Exclude* evaluation of orthotics and of implanted devices

Outcomes of Interest

KQ 1-3:

• Assessments of reliability, validity, responsiveness, minimal detectable change, or minimal important difference, and floor/ceiling effect

KQ 4, 5:

- Functional or patient-centered outcomes (measured or related to status in the community)
 - *Exclude* (simple) preference
- Ambulatory functional outcomes

 Exclude biomechanical measures
- Adverse effects of LLP

KQ 6:

• Patient satisfaction measures with process of accessing LLP

KQ 7:

- Maintenance of bipedal ambulation
- Use of prostheses only for transfers
- Use of prostheses only indoors

- Abandonment of prostheses (not using prosthesis)
- Major problems with prosthesis
- Reasons for suboptimal use of LLP (as defined by above outcomes)

Eligible Study Designs

All KQ:

- Published, peer reviewed study
- Any language (that can be read by research team or machine translated)
- No publication or study date restriction
- *Exclude* case reports

KQ 1-3:

- Any assessment of validity, reliability, and related characteristics
- *Exclude* studies of validation of translations of non-English scales, indexes, etc.
- Any study design
- N≥20 lower limb amputees
- No minimum followup time

KQ 4:

- Direct comparison between any two components, any relevant study design
- Must include an analysis or reporting of differences in relative effect between components by a patient characteristic of interest (see text of KQ 4) or report sufficient participant-level data to allow such an analysis
- No minimum sample size (other than excluding case reports)
- No minimum followup time

KQ 5, 6:

- Any study design, including qualitative studies
- No minimum sample size (other than excluding case reports)
- No minimum followup time

KQ 7:

- Either longitudinal with followup since original lower limb prosthesis prescription or cross-sectional at timepoint after amputation or prescription
- Minimum followup time
 - $\circ \geq 6$ month followup from time of LLP prescription, or
 - $\circ \geq 1$ year followup from time of amputation, if no data reported about time since LLP prescription
- Minimum sample size: $N \ge 100$

Setting

• Any except *exclude exclusively* postacute (postsurgical) setting or inpatient rehabilitation (immediately postamputation)

Results

Summary of Studies

The literature searches yielded 10,285 citations and an additional 224 references were screened from review articles and existing systematic reviews. Of these, 331 articles were retrieved in full text. We excluded 236 articles. Of note, 79 studies compared lower limb prosthesis components but did not report subgroup analyses, regression analyses, or individual patient data which would allow subgroup analyses. Thus, we found 92 eligible studies, of which 72 provided validation or related analyses addressing KQ 1 to 3, 11 provided data relevant to KQ 4, no studies for KQ 5, two studies for KQ 6, and 8 studies relevant to KQ 7.

Key Questions 1 to 3

Pertaining to KQs 1 to 3, we summarize 72 studies addressing the validity, reliability, and related metrics for 61 measures (assessment techniques, prediction tools, and outcome measures) and subscales of many of these.

Table A summarizes the findings regarding reliability, (overall) validity, the minimal detectable change (MDC), the minimal (clinical) important difference (MID), the responsiveness, and floor or ceiling effects. Most notable is that while some measure of validity has been assessed for most measures (n=53), other characteristics are less frequently evaluated. Reliability has been assessed for 40 measures and the MID was estimated for only one measure (the L test of Functional Mobility).

All 40 measures that have been assessed for reliability were found to be reliable (at least to an adequate extent). Of the 53 measures assessed for validity, 47 have been validated (either as a single measure, or for all or most of their subscales); although four of these were found to be only weakly validated. Among the 47 validated measures, seven have been validated for only some or most of their subscales (marked as "mixed" in A, or with footnotes). Furthermore, only 29 measures have evidence to support both reliability and validity; seven of these, though, have been found to have either floor or ceiling effects in whole or in part.

However, among the 61 measures, only 35 have been evaluated in samples of lower limb amputees deemed to be generally applicable to the Medicare population, based primarily on either the percentage of participants with dysvascular conditions or their ages. These are highlighted in Table 1-3.1 by having bold text in the Population column. Among these 35, 27 have evidence of validity, in whole or in part, and 25 have evidence of reliability. In total, 19 measures have been found to have evidence of both reliability and validity in study participants generally applicable to the Medicare population. These include:

- 2 minute walk test (2MWT)
- Activities-specific Balance Confidence (ABC)
- Amputee Body Image Scale, revised (ABIS-R)
- Berg Balance Scale (BBS)
- Climbing Stairs Questionnaire
- Frenchay Activities Index, 15 item (FAI-15)
- Houghton Score
- Locomotor Capabilities Index (LCI)

- Patient-Reported Outcomes Measurement Information System 29-item profile (PROMIS-29)
- Prosthesis Evaluation Questionnaire (PEQ)
- Quality of Life in Neurological Conditions Applied Cognition/General Concerns (NQ-ACGC)
- Rising and Sitting Down Questionnaire
- Satisfaction with Prosthesis (SAT-PRO)
- Special Interest Group of Amputation Medicine/Dutch Working Group on Amputations and Prosthetics (SIGAM/WAP)
- Trinity Amputation and Prosthesis Experience Scale (TAPES)
- Timed Up and Go (TUG)
- Transfemoral Fitting Predictor (TFP)
- Walking speed, 10 meters
- Walking Questionnaire

Of these 19 measures, only the Houghton Score has been evaluated for and found to demonstrate responsiveness. Floor or ceiling effects have been found for four of these measures (or their subscores): LCI, PROMIS-29, PEQ, and NQ-ACGC.

Measure	N ^A	Population ^B	Reliability	Validity ^c		MID	Responsiveness	Floor/Ceiling
180 Degree Turn Test	1	U, TT		Weak				
2MWT	5	B/U, TF, TT, Vasc	Yes	Yes	Yes ^D			
6MWT	3	U, TF, TT, Tr	Yes	Yes	Yes ^D			
AAS	2	U, TF, TT, Mix		Yes				
ABC	5	B/U, TF, TT, Mix	Yes	Yes	Yes ^D			No
ABIS	1	B/U, TF, TT, Vasc	Yes	No				
ABIS-R	2	B/U, TF, TT, Vasc	Yes	Yes				
AMP	2	U, TF, TT, Tr	Yes	Yes	Yes ^D			
AMPSIMM	1	U, TF, TT, TM, Vasc		Yes			Yes	No
ADAPT	1	U, TF, Tr	Yes					
AQoL	1	U, TF, TT, Mix		Weak				
Barthel Index	2	U, TF, Mix		Yes				
BBS	5	U, TF, TT, Vasc	Yes	Yes				No
BIQ	1	TF, TT, Vasc	Yes					
CAPE CAS	1	TF, TT		Yes				
Climbing Stairs Questionnaire	4	B/U, TF, TT, Vasc	Yes	Yes				
FAI-15	2	U, TF, TT, Vasc	Yes	Yes				
FAI-18	1	U, TF, TT, Mix	Yes	Yes				
FIM	5	U, TF, TT, Vasc	No	No			Yes	Yes [⊦]
FSST	1	U, TT		Yes				
Harold Wood/Stanmore Mobility Grade	3	TF, TT, Mix		No				
HADS	1	B/U, TF, TT		Yes				
Houghton Score	5	B/U, TF, TT, Vasc	Yes	Yes			Yes	No
IES subscales	1	U, TF, TT, Tr		Yes				
IPAQ	1	TF, TT, Mix	Adequate					
LCI (various)	15	B/U, TF, TT, Mix	Yes	Yes ^H				Yes
L test	2	TF, TT, Mix	Yes	Yes		Yes ^D	Yes	
OPCS	1	U, TF, TT		Yes				
OPUS	1	U, TF, TT	Yes				Yes	No
PGI	1	U, TF, Vasc	No	No				
PROMIS-29	2	U, TF, TT, Mix	Yes	Mix ^ĸ	Yes ^D			Yes (most)
PSFS	1	U, TF, TT	Yes		Yes ^D			No
PFI	1	U, TF, TT	Yes	Yes			Yes	Yes (most)
PEQ (various)	8	B/U, TF, TT, Mix	Yes	Mix	Yes ^D			Mix
PLUS-M	4	B/U, TF, TT, Mix	Yes		Yes ^D			No
PROS	1	TF, TT, Vasc		Yes				
NQ-ACGC	2	U, TF, TT, Mix	Yes	Yes	Yes ^D			Yes
Q-TFA	1	U, TF, Tr	Yes	Yes				Mix ^L
Rising and Sitting Down Questionnaire	3	B/U, TF, TT, Vasc	Yes	Yes				

Table A. Summary of Performance of Measures in People With Lower Limb Amputations

Measure	N ^A	Population ^B	Reliability	Validity ^c		MID	Responsiveness	Floor/Ceiling
RMDQ	1	TF, TT, Tr		Yes				
RMI	2	B/U, TF, TT, Mix	Yes	Yes			Yes	No
Russek's Code	1	TF, TT,		No				
SAT-PRO	1	U, Vasc	Yes	Yes				
SF-12	6	B/U, TF, TT, Mix		Yes				
SF-36	17	B/U, TF, TT, Mix		Mixed ^N			Yes (PF) ⁰	
SF-36V	1	B/U, TF, TT	Yes		Yes ^D			No
SIP	4	U, TF, TT	Yes	Mix ^P			Yes	Yes ^Q
SSQN6	1	Vasc		No				
SCS	3	U, TF, TT, Mix	Yes		Yes ^D			No
SIGAM/WAP	2	B/U, TF, TT, Vasc	Yes	Yes				
Step Activity Monitors	2	U, TF, TT, Mix		Yes				
TAPES	6	B/U, TF, TT, Mix	Yes (various)	Yes ^R				
TMMS	1	U, TF, TT, Tr		Weak				
TUG	8	U, TF, TT, Vasc	Yes	Yes	Yes ^D			
TFP	1	U, TF, Vasc	Yes	Yes				
Walking speed, 10 meters	2	U, TF, TT, Vasc	Yes	Yes				
Walking speed, 15.2 meters (50 feet)	1	U, TM, Vasc		Yes				
Walking Questionnaire	3	TF, TT, Vasc	Yes	Yes				
WHODAS 2	1	nd		Weak				
WHOQOL-BREF subscales	5	U, TF, TT, Mix	Yes	Yes				No

Abbreviations: 180 Degree Turn Test, 2MWT = 2 minute walk test, 6MWT = 6 minute walk test, AAS = Amputees activity survey, ABC = Activitiesspecific Balance Confidence, ABIS(-R) = Amputee Body Image Scale (revised), ADAPT = Assessment of Daily Activity Performance in Transfemoral amputees, AIMS = Arthritis Impact Measurement Scale, AMP = Amputee Mobility Predictor, AMPSIMM = Amputee Single Item Mobility Measure, AQoL = Assessment of Quality of Life, BBS = Berg Balance Scale, CAPE = Clifton Assessment Procedures for the Elderly, Census and Surveys, FAI = Frenchay Activities Index, FIM = Functional Independence Measure, HADS = Hospital Anxiety and Depression Scale, IES = Impact of Event Scale, IPAQ = International Physical Activity Questionnaire, L Test = L Test of Functional Mobility, LCI = Locomotor Capabilities Index, MDC = minimal detectable change, MIC = minimal (clinical) important difference, Neuro-QoL ACGC = Neurological Disorders Applied Cognition General Concerns Short Form, NQ-ACGC = Quality of Life in Neurological Conditions – Applied Cognition/General Concerns, OPCS = Office of Population, OPUS = Orthotic Prosthetic User's Survey, PAM = Patient activity monitor, PEQ = Prosthesis Evaluation Questionnaire, PFI = Physical Function Index, PGI = Patient Generated Index, PLUS-M = Prosthetic Limb Users Survey of Mobility, PMQ = Prosthetic Mobility Questionnaire, PROMIS-29 = Patient-Reported Outcomes Measurement Information System 29-item profile. PROS = Prosthetist's Perception of Client's Ambulatory Abilities, PSFS = Patient Specific Functional Scale, Q-TFA = Questionnaire for Persons with a Transfemoral Amputation, QoL = Quality of Life, RMDQ = Roland Morris Disability Questionnaire, RMI = Rivermead Mobility Index, SAT-PRO = Satisfaction with Prosthesis, SCS = Socket Comfort Score, SF = Short Form Health Survey, SIGAM = Special Interest Group in Amputee Medicine, SIP = Sickness Impact Profile, SSQN6 = Saranson's 6-item Social Support Questionnaire, TAPES = Trinity Amputation and Prosthesis Experience Scales, TFP = Transfemoral Fitting Predictor, TMMS = Trait Meta Mood Scale, TUG = Timed Up and Go.15D HRQoL = 15D Health Related Quality of Life instrument. WHODAS 2 = World Health Organization Disability Assessment Schedule version 2. WHOQOL-BREF = World Health Organization Quality of Life abbreviated.

^A Number of studies

- ^B Bold text signifies that the study samples were deemed generally applicable to the Medicare population; text in italics if deemed not applicable. B = bilateral amputations, B/U = both bilateral and unilateral amputations, CA = cancer amputations, nd = no data reported describing participants, TF = transfemoral amputations, TM = transmetatarsal amputations, Tr = at least a plurality of trauma amputations, TT = transibilial amputations, Mix = a mix of amputation etiologies, nd = no data on amputation characteristics, U = unilateral amputations, Vasc = at least a plurality of dysvascular etiologies. If a category was omitted (i.e., unilateral vs. bilateral, amputation level, amputation etiology), there were insufficient data reported to summarize that category.
- ^c Weak indicates that there is weak evidence of validity. Measures for which validity was assessed and no evidence was found to support validity are highlighted in bold.
- ^D Yes indicates that and MDC or MID have been reported. ^E Motor score validated at discharge from inpatient rehabilitation, but not at admission to rehabilitation. Subscales also not validated.
- ^F Chair transfer subscale has a ceiling effect. Other subscales and total do not.
- ^G Average prosthetic use per day validated; average falls per month and average prosthetic use per week were not validated.
- ^H Most variations found to be valid; Basic LCI was not.
- ¹Validated: Mobility, Mobility modified, Ambulation, Social burden, and Wellbeing subscales. Not validated: Appearance, Frustration, Perceived responses, Residual limb health, Sounds, Transfer, and Usefulness subscales.
- ^J Ceiling effects found for Transfer and Wellbeing, but not for Ambulation, Mobility, or Usefulness subscales. These subscales did not have floor effects.
- ^K Validated: Depression, Physical Function, and Social Role Satisfaction subscales. Not validated: Anxiety, Fatigue, Pain Interference, and Sleep Disturbance subscales.
- ^L Ceiling effect for Prosthetic Use subscale, not for Global or Prosthetic Mobility subscales. No floor effects.
- ^N Except Emotional Problems, Emotional Role Limitations, Energy/Fatigue subscales.
- ^o Reported only for Physical Functioning (PF) subscale.
- ^P Validated: Ambulation, Body Care and Movement, Emotional Stability subscales, and overall score. Inconsistent validation for Physical Scale subscale. Not validated: Physical Autonomy and Communication, Social Behavior, Somatic Autonomy, Mobility Control, Mobility Range, and Mobility subscales.
- ^Q Floor effects for Bodily Care and Movement and Mobility subscales. No floor effects for Ambulation subscale and overall score. No ceiling effects for these measures.
- ^R Except Gender subscale. Only weak evidence for total overall score validity.

Key Question 4

In adults who use a lower limb prosthesis, how do the **relative effects** on ambulatory, functional, and patient-centered outcomes **of different prosthetic components** or levels of components/prostheses **vary based on study participant characteristics**?

Overall Summary of Studies

In total, we found 11 studies (in 12 articles) that directly compared different LLP components and provided sufficient data to allow subgroup analyses based on participant characteristics. Ten studies included between 5 and 168 users of LLP; one included 899 amputees. Five studies evaluated microprocessor knees (compared to mechanical knees), two evaluated other knee components, two evaluated ankle/foot components, and one each evaluated pylons or sockets. The largest study developed a regression model to evaluate predictive ability of a wide range of participant characteristics. An older study reported a correlation analysis between participant characteristics and outcomes and also subgroup analyses without statistical comparisons between subgroups. One study provided subgroup comparisons with statistical analyses; three studies reported subgroup results but did not statistically compare subgroups and six studies reported individual patient data which allowed *post hoc* subgroup analyses Overall, the studies do not provide evidence that any specific subgroup of patients consistently have differentially better outcomes with any specific component than other subgroups of patients.

Only one study was randomized; no study attempted to blind patients or providers (which may have been impossible for many components), but studies also did not blind outcome assessors (which may have been difficult for most studies); since all studies were one- or two-way crossover studies, by definition the groups of patients evaluating each component were equivalent; dropout rates were low across studies; only one study conducted multivariable analyses comparing subgroups; and only two studies statistically evaluated heterogeneity of treatment effect (differences among subgroups).

There is an important caveat about the determination of whether outcome measures have been validated (in Table 4.4 and for the text sections following the tables). We consider variations and modifications of measures to be separate measures that would each need to be validated. This applies both to modifications of existing measures (which, by definition, are no longer the same measure) and to variations such as walking and cadence tests conducted over different lengths of time or distance walked. Thus, the 2 minute walk test is distinct from the 6 minute walk test and from walking tests of other times or distances. In addition, when determining whether a measure used in a study has been validated we did not give the study the benefit of the doubt when measures were inadequately defined. For example, walk tests for which no time or distance was reported are, by definition, considered to be not validated.

A relatively small percentage of comparative studies report sufficient data to allow subgroup analysis and evaluation of heterogeneity of treatment effect (12%, 11 of 90 otherwise eligible studies) Of these 11 studies, only five used validated measures. Only one of the eligible studies was a randomized trial, but it did not evaluate validated subgroups. Only two studies evaluated heterogeneity of treatment effect; most reported individual participant level data without conducting their own subgroup analyses. Across studies, a scattering of statistically significant differences in relative effects of different components were found based on different subgroup

comparisons. However, these were not consistent across, and often within, studies. Only one study analyzed the most important aspect of the KQ, namely whether any study participant characteristics (or set of characteristics) can accurately and effectively predict which patients will most benefit from a given component. However, the study was methodologically and analytically flawed and compared a specific microprocessor knee (Genium) to any prior used knee (mostly another microprocessor knee, C-Leg). This study was conducted in largely younger men (average age 49 years, 83% men) two-thirds of whom had traumatic etiologies for their amputations. Despite finding numerous statistically significant associations between participant characteristics and functional outcomes, the study concluded that no model accurately predicted relative outcome (between the Genium microprocessor knee and, mostly, the C-Leg microprocessor knee).

Overall studies that investigated subgroup effects did not identify participant characteristics that predict which lower limb amputees would most benefit from a given component. Based on the methodology used to assess strength of evidence, the studies warrant a low strength of evidence that evaluated patient characteristics do not predict which patients would most benefit from a given LLP component (Table B). However, it may be more accurate to conclude that the evidence is currently sparse and fails to adequately address whether different subgroups of amputees are more or less likely to benefit from given specific components. Most studies were very underpowered to find statistically significant evidence of differences among subgroups, with on average only about 30 participants per study (excepting one larger regression analysis). Only five of the 11 studies used validated outcomes. Similar conclusions are reached for this subset of studies. In fact, these studies were even smaller, with on average only about 12 participants each. One large study attempted to develop a model to predict success with microprocessor knees; however the study failed to use a validated outcome and had several methodological and analytic flaws, and thus provides insufficient additional evidence regarding who would most benefit from a microprocessor knee. Furthermore, across all studies, study participants were in general not likely to be representative of the Medicare population, being both mostly young and with amputations due to trauma, with relatively few people with dysvascular disease.

Outcome	No. Studies (N)	Study Limitations	Consistency	Precision	Reporting Bias	Directness*	Other Issues	Findings	SoE Grade
Validated outcomes (univariable)	5 (64)	Medium †	Consistent	Imprecise	Undetected	Indirect ‡	High degree of multiple testing; mostly evaluations of knee components; mostly K2 or K3 level, unilateral transfemoral amputations due to traumatic etiologies	Mostly no significant differences in relative effect based on participant characteristics	Low
All outcomes (univariable)	10 (296)	Medium †	Consistent	Imprecise	Undetected	Indirect ‡	Nonvalidated outcomes, high degree of multiple testing; mostly K2 to K4 level, unilateral transfemoral amputations due to traumatic etiologies	Mostly no significant differences in relative effect based on participant characteristics	Low
Ambulatory and functional outcomes, nonvalidated (multivariable model)	1 (899)	High §	NA	Precise	Undetected	Indirect #	K2 to K4 (mostly K3) level, mostly traumatic etiologies	Flawed study concluded no model accurately predicted relative outcomes. A large set of variables individually were associated with better outcomes with the microprocessor knee.	Insufficient

Table B. Key Question 4 Evidence Profile

Abbreviations: KQ = Key Question, NA = not applicable, RoB = risk of bias, SoE = strength of evidence.

* Representative of either (or both) older adults (≥65 years old) or those with dysvascular amputations.

+ Nonrandomized studies, univariable analyses (mostly individual participant data reports), generally lack of evaluation of heterogeneity of treatment effect, mostly small studies.

‡ Both relatively young age amputees and primarily people with amputations due to trauma in most studies. Almost all (that reported) had unilateral transfermoral amputations.

§ Nonrandomized, likely biased sample of participants, nonvalidated outcomes, unclear which outcome(s) used in final models,, unclear and possibly flawed analytic methods. See text.

Highly selected participants who had been assessed as likely to benefit from a microprocessor knee, possibly biased dropouts, relatively young and two-thirds had trauma etiology.

Key Question 5

How do study participants' preprescription **expectations of ambulation** align with their functional outcomes?

KQ 5 asked how study participants' preprescription expectations of ambulation align with their functional outcomes. We found no study that addressed this issue.

Key Question 6

What is the level of patient **satisfaction with the process** of accessing a LLP (including experiences with both providers and payers)?

Two studies addressed this question. One surveyed individuals about satisfaction with upper or lower prosthetic limbs and related services. The second reported data about satisfaction with the prosthetist appointments in a study designed to assess the reliability and construct validity of the Orthotics and Prosthetics National Office Outcomes Tool in clients with LLPs.⁴

A moderate risk of bias study (of generally younger adults about one-third of whom had dysvascular disease) found that at least three-quarters of people receiving a LLP were satisfied with the process of accessing their LLP and a high risk of bias study (in which about half had Medicare or Medicaid insurance) found that on average clients were satisfied with their visits to their prosthetists' offices (average score about 83 of 100). Together, the studies provide low strength evidence that people are satisfied with their encounters with their prosthetists (Table C).

Table C. I	Key Questions	5 and 6 Evidence F	Profile
------------	---------------	--------------------	----------------

Outcome	No. Studies	Study	Consistency	Precision	Reporting	Directness*	Other Issues	Findings	SoE Grade
	(N)	Limitations			Bias				
Alignment of outcomes	0	NA	NA	NA	NA	NA	NA	None	Insufficient
with expectations (KQ 5)									
Satisfaction with process	2 (~1663)	Medium	Consistent	Precise	Undetected	Direct †	Nonvalidated	Clients generally satisfied	Low
(KQ 6)							outcomes	with their encounters with	
								their prosthetists	

Abbreviations: KQ = Key Question, NA = not applicable, SoE = strength of evidence.

* Representative of either (or both) older adults (≥65 years old) or those with dysvascular amputations. † One study included a wide range of prosthetics practices; about half the participants had Medicare or Medicaid as a primary payer. The other study was less representative.

Key Question 7

At 6 months, 1 year, and 5 years after receipt of a LLP, (accounting for intervening mortality, subsequent surgeries or injuries) what percentage of individuals...?

- i. Maintain bipedal ambulation
- ii. Use their prostheses only for transfers
- iii Use prostheses only indoors
- iv. Have abandoned their prostheses
- v. Have major problems with prosthesis

We found eight studies with at least 100 participants who were followed for at least 6 months after prescription of a LLP. Most studies of amputees with outcomes of interest were rejected because the analyses were not restricted to people with prescribed prostheses and were thus mostly analyses of predictors for not receiving a prescription for LLP. The studies analyzed between 109 and 555 participants for between 1 and 7 years (except for two studies that implied long-term followup, but did not report a timeframe. The studies only sparsely covered the subquestions pertaining to specific outcomes, particularly related to questions about different outcomes in different subgroups of amputees.

Table D summarizes the strength of evidence for each outcome and subgroup analysis with data. For most outcomes of interest, there is low strength of evidence because studies mostly had methodological limitations, the populations analyzed were often not directly applicable to the Medicare population, some studies were inconsistent with each other, and few studies reported the outcomes of interest. Subgroup analyses in single studies tended to be underpowered to detect differences, mostly leading to determinations that the evidence was insufficient. However, we found a moderate strength of evidence, based on six studies, that about 11 to 22 percent of lower limb amputees who receive a LLP prescription abandon the prosthesis (stop using it) at about 1 year; these studies are generally representative of people with LLP, in particular older adults and those with dysvascular etiologies. Three of these studies provide low strength of evidence that people with unilateral transfemoral amputations are about twice as likely to abandon their LLP than those with unilateral transtibial amputations. Potential differences among other subgroups had insufficient evidence due to conflicting results among three studies or only a single, imprecise study with data. Also based on four, generally representative studies, there is low strength of evidence that 11 to 37 percent of LLP recipients use their prostheses only indoors; however, these studies are somewhat inconsistent and imprecise. There is low strength of evidence about how likely different subgroups of people use their prostheses only indoors, suggesting that people with transfemoral amputations, or who are older, or with bilateral amputations are more likely to be limited to indoor use. There is insufficient evidence about why people abandon their prostheses.

Outcome	Subgroup	No. Studies (N)	Study Limitations	Consistency	Precision	Reporting Bias	Directness*	Other Issues	Findings	SoE Grade
Failure to maintain bipedal ambulation	All participants	1 (148)	High	NA	Precise	Undetected	Indirect	Unclear outcome,	7% (95% CI 4, 12) at 7 years	Low
Use of prosthesis only for transfers	All participants	2 (316)	High	Inconsistent	Precise	Undetected	Indirect	Old studies	4% (95% CI 2, 8) at 1 year, 22% (95% CI 15, 30) at unknown time	Low
	TF vs. TT	1 (196)	High	NA	Imprecise	Undetected	Indirect	25 years old	No significant difference	Insufficient
	Bilateral vs. unilateral	1 (110)	High	NA	PImprecise	Undetected	Indirect	None	No significant difference	Insufficient
	Age	1 (196)	High	NA	Imprecise	Undetected	Indirect	25 years old	Nonsignificantly higher limited used with older age	Insufficient
Use of prosthesis only indoors	All participants	4 (1040)	Medium	Inconsistent	Imprecise	Undetected	Direct	None	11-37% at 1 to 7 years	Low
	TF vs. TT	2 (337)	High	Inconsistent	Precise	Undetected	Direct	None	Twice as many TF use only indoors (1 study, P=0.008)), no difference (1 study)	Low
	Age	1 (196)	High	NA	Precise	Undetected	Direct	None	Older more likely to use only indoors (P=0.042)	Low
	Bilateral vs. unilateral	1 (141)	High	NA	Precise	Undetected	Direct	None	Bilateral more than twice as likely to use only indoors (P=0.0006)	Low
Abandonment of prosthesis	All participants	6 (1153)	Medium	Consistent †	Precise	Undetected	Direct	None	11-22% at 1 year (or undefined)†	Moderate
	TF vs. TT	3 (538)	High	Consistent	Precise	Undetected	Direct	None	TF more likely to abandon prosthesis than TT	Low
	Bilateral vs. unilateral	3 (452)	High	Inconsistent	Imprecise	Undetected	Direct	None	Nonsignificant, but conflicting directionality	Insufficient
	Age	2 (397)	High	Inconsistent	Imprecise	Undetected	Direct	None	Older nonsignificantly more likely to abandon (1 study), no difference in age (1 study)	Insufficient
	Multiple	1 (201)	High	NA	Imprecise	Undetected	Indirect	Multiple testing	No significant associations	Insufficient
Major problems with prosthesis	All participants	0	NA	NA	NA	NA	NA	NA	None	Insufficient
Reasons for poor outcomes	All participants	1 (201)	High	NA	Imprecise	Undetected	Indirect	None	Various general categories of reasons reported	Insufficient

Table D. Key Question 7 Evidence Profile

Abbreviations: NA = not applicable, RoB = risk of bias, SoE = strength of evidence, TF = transfemoral amputation, TT = transibilities amputation.

* Applicability to the Medicare population (based on mean age and percent with dysvascular amputations).

† Except that one outlier study from Taiwan found that only 0.9% of study participants abandoned their prostheses at a mean of 28 months.

Discussion

A large number of studies have evaluated lower limb prostheses (LLP) for people with major lower limb amputations. We found nearly 100 studies that compare at least two prostheses or components that likely report ambulatory, functional, or other patient-centered outcomes. There are many additional studies that evaluated only biomechanical properties of the components and likely several hundred studies that evaluate just a single component. However, we found few studies that evaluated (or at least provided data to allow evaluation of) heterogeneity of treatment effect. From the amputee's and the clinician's perspective, among the most important questions is which prosthesis (comprised of which prosthetic components) would best enable maximal function for a given individual? Given the large number of component types (knee, foot/ankle, socket, etc.) and the range of features for each of these, the process of determining which LLP configuration is best for individuals is quite complex. The majority of the evidence addresses the question of which components maximize ambulation and function in the average patient, as opposed to which component would best suit the needs of a given individual. Suboptimal matching of patients to LLPs may unnecessarily increase health care utilization, prevent attainment of maximal patient function, and defer realization of improved quality of life attainable with an appropriate prosthetic.

Further limiting and complicating the evidence base, there are a very large number of measures that are used in the surgical, rehabilitation, and prosthesis literature to assess overall patient function, predict future outcomes, and measure various aspects of ambulation, function, quality of life issues, and other patient-centered outcomes. While some of the scales and scores used in these studies were developed specifically to assess lower limb amputees, many were designed for other populations. Many of the measures used in LLP research studies have either not been validated in the population of interest or were created *ad hoc* for each study. This review found that among the small number of comparative studies that provided heterogeneity of treatment effects data, fewer than half used both validated predictors (or subgroups based on basic participant characteristics) and validated outcomes.

We found that a large number of measures that have been validated (to a lesser or greater extent), 33 of which have, in whole or in part, been found to be both reliable and validated in lower limb amputees. These measures address many aspects of patients' function, ambulation, and quality of life. To improve the accuracy, interpretability, and, importantly, the reproducibility of the literature, we would strongly encourage future researchers to maximize the use of validated measures. Where validated measures of interest are lacking, proposed research measures should first be validated before use in future studies. We would also encourage journal editors to require use of validated measures.

However, the studies were highly variable in who was analyzed and how instruments and measures were validated, etc. We, therefore, recommend that researchers who are using this report to determine which measures to use for their own studies also review the primary studies to determine whether the measures have been sufficiently validated for their needs and have been tested in a sample of people representative to their study population.

Evidence and Analysis Limitations

Despite the large literature base for research on LLP, relatively few studies address the questions of interest for this review, particularly related to heterogeneity of treatment effect, patient expectations and satisfaction, and long-term use of LLP after prescription.

Assessment of reliability, validity, and other measure properties is open to interpretation. By the strictest definition, a measure would be considered to be valid and appropriate for use in a given study, only if there is good evidence regarding he multiple aspects of validity for the specific population, conditions, and outcomes under evaluation. For example, that a measure demonstrates convergent validity with a given related measure does not imply that it also can distinguish differences related to subgroups of patients or an intervention effect. We took a liberal approach in our literature synthesis. We considered a measure to be validated if there was evidence of any type of validity (other than face/content). We, thus, categorized the evidence and dichotomized data so that measures were classified as valid or not valid. The overall logic for our approach was that the question of interest for this general review of all measures used in LLP research is whether a measure has been validated for any purpose. It is incumbent on each study's researchers to determine whether given measures are valid—and appropriate—for their study purposes.

This review attempts to particularly highlight the evidence applicable to the Medicare population. This is a challenge to do and requires judgment, which many may disagree with. Very few of the studies were limited to participants over the age of 65 years. None was limited to people with disabilities, at least in terms of what would allow them to qualify for Medicare. Extremely few studies reported the type of medical insurance study participants had (although, many of the studies were conducted in Europe and other countries other than U.S.). We categorized studies to be likely generalizable to the Medicare population based on having a relatively large percentage of participants with dysvascular etiologies for their lower limb amputations (also including diabetes) and/or likely including about half or more of participants over age 65 years. This system, though, is imperfect.

Although not a limitation, per se, it should be noted that this review makes no attempt to make conclusions about the overall effects of different LLP components. Key Question 4 addressed whether there is evidence regarding heterogeneity of treatment effects, particularly with validated measures, in the field of LLP research. As previously described, the evidence base addressing heterogeneity of treatment effect, particularly with validated measures, is quite small. Only a single study attempted to truly address the question at hand, but did not use a validated outcome measure, and was methodologically and analytically flawed. The applicability of these studies to the general population of people with LLPs may be somewhat limited, as the studies mostly evaluated knees and were mostly conducted in younger men with unilateral transfemoral amputations due to trauma. Furthermore, implicitly or explicitly, most of these studies included only people who were deemed (by their prosthetists) to be likely to benefit from their new (generally more complex) component. This may bias these studies toward finding no difference between subgroups of individuals in relative effect of the compared components since everyone was more likely than average to do better with the new component. In all of these studies, all patients used all evaluated LLPs. However, most of the studies that analyzed heterogeneity of treatment effect or provided data to allow subgroup analyses were observational and did not control for underlying differences during use of one component or the other. For example, studies did not describe or control for rehabilitation, training, or acclimation with each of the components. In particular, in the pre-post studies (where everyone switched from an old (simpler) to a new (more complex) LLP, one would expect that patient characteristics such as age, strength, and mobility will also have changed. These are important issues for the underlying analyses comparing the components; although, the effect of this limitation of the comparative studies on assessing heterogeneity of treatment effect is unclear. If the bias is similar in different

subgroups (e.g., the new component is favored in part due to bias equally among transtibial and transfemoral amputees), then the bias would cancel out when assessing differences in relative effect (of the two components) between the two subgroups (transtibial versus transfemoral). As discussed, the single large study with regression modeling is likely highly biased and may be analytically flawed, so it is insufficient to provide reliable evidence.

No or very few studies were found to address questions about patient expectations and satisfaction with care.

Few studies met eligibility criteria regarding long-term LLP use after prescription. The primary reason why potentially relevant studies were excluded was that they evaluated long-term ambulation and function after surgery including patients who never received an LLP. We also restricted the studies to those with at least 100 people to allow for some degree of precision in estimates. Smaller studies may have provided additional data, but their estimates would have been less precise (and subgroup analyses in these studies would be even less likely to be statistically significant due to lack of power). Among the eligible studies, the most common outcome of interest was LLP abandonment (or lack of use). Studies generally failed to report on indoor-only use of LLPs and other outcomes. Studies also mostly did not report information on why people limited or stopped their use of LLPs.

Future Research Recommendations

General Recommendations

Future research is needed to adequately address most of the questions in this review. While numerous measures have been validated, at least in part, additional studies are needed to confirm the measurement properties and to better generalize their validity (etc.) to more scenarios of people with lower limb amputations.

To as great an extent as possible, studies should assess validated, patient-centered outcomes related to ambulation, function, quality of life, and related outcomes. Continued use of ad hoc and nonvalidated measures greatly limits the interpretability, usability, representativeness, and overall value of the studies. Ideally, studies should use a core set of validated, patient-centered outcomes (in addition to other study-specific outcomes, as needed). This would allow comparability across studies and pooling of study findings (e.g., meta-analysis). A large body of individual, one-off analyses with unique outcomes will provide a much weaker evidence base than a smaller body of comparable studies. Noncomparable studies will continue to be more likely to be of little use to prosthetists, treating physicians, patients, policymakers, and other decisionmakers, and therefore will more likely be ignored.

Studies of Heterogeneity of Treatment Effect

Particularly for a clinical field as varied as lower limb prosthetics, there is a great need to understand how best to choose among the myriad LLP and component choices for an individual patient. Lower limb amputees are clearly a highly heterogeneous group with distinct needs dependent upon age, etiology of limb loss, level of amputation, comorbidities and health status, postoperative stage, and rehabilitation status. Better understanding of which component would be best for which patient could both maximize individual's ambulation, function, and quality of life and minimize waste due to either abandonment or due to "over-prescription," where people are given LLPs with specific capabilities that they cannot benefit from. Therefore, many more

studies are needed to adequately assess heterogeneity of treatment effect. The goal of these studies should not be to simply find subgroup differences, but instead should be to predict which set of characteristics best predicts which component is best for which patient. This will require generally larger studies to allow for meaningful regression analyses. As with all studies, these should take care to include a representative and unbiased sample of lower limb amputees. Eligibility criteria and analytic methods should be employed to maximize participation and inclusion in final models. Robust analytic methods and complete and transparent reporting are essential. Appropriate, and clear, measures of model performance should be used and reported. We recommend the following specific metrics, although others may be more appropriate based on specific analyses conducted.^{5, 6} The most useful metrics of global performance are the (root) mean square error or Brier score. Less useful metrics are global statistics of fit, and the various pseudo- R^2 metrics. These global metrics are difficult to interpret correctly, particularly if there is class imbalance when a small percentage of participants experience a given outcome. Metrics of discrimination should also be reported, including the receiver operating characteristics (ROC) curve, area under the ROC curve (AUC), and accuracy measures (e.g., sensitivity and specificity). It is also important to report analyses of calibration. Assessments of calibration are numerous, but the most common is a simple calibration plot that orders observations in percentiles of increased predicted risk, and plots the observed percent of responders in each percentile. Conclusions about predictive performance require a thorough evaluation of the performance itself.

Studies on Expectations, Satisfaction With Services, and Long-Term Followup

Studies on the relationship between patient expectations and outcomes are needed, as are additional studies of patient satisfaction with prosthetic services (and how to improve prosthetic services to improve satisfaction).

Additional large, long-term followup studies are needed to understand problems and limitations people are having with their prostheses, rates of abandonment or limited use, and reasons for these limitations and abandonment. Explanations of the prevalence of abandonment and limited use of LLPs and of why this occurs can yield further research in how to minimize underuse of LLP and resultant limited ambulation.

Conclusions and Clinical Implications

Numerous measures of ambulation, function, quality of life, and other patient-centered outcomes exist for people with lower limb amputations and LLPs. Those that have been validated should be used to form a core set of measures for use in future research studies of LLP. This would enhance the value, interpretability, reproducibility, and comparability of the future studies, and would allow more coherent summarization of the evidence. Researchers should minimize the use of nonvalidated or *ad hoc* measures, but instead should validate the new measures before their use. In particular, researchers with an interest in assessing LLPs for the Medicare population would be best served to focus on those measures with evidence of reliability and validity for this population. The majority of the evidence addresses the question of which components maximize ambulation and function in the average patient, as opposed to which component would best suit the needs of a given individual. A small evidence base does not support which components should be selected for which patient to maximize their

ambulation, function, and quality of life or to minimize abandonment or limited use. However, this does not imply that there is evidence that no patient characteristics could effectively predict which patients would most benefit from one or another specific component. There is low strength of evidence that patients are generally satisfied with the prosthetic services they receive. However, further high quality research is needed to better assess the properties of measures (assessment techniques, prediction tools, and outcome measures), particularly for the Medicare population, and to answer all these questions and to assess patient expectations and satisfaction with care.

References

1. Boyle JP, Thompson TJ, Gregg EW, et al. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010 Oct 22;8:29. doi: 10.1186/1478-7954-8-29. PMID: 20969750.

2. Ziegler-Graham K, MacKenzie EJ, Ephraim PL, et al. Estimating the prevalence of limb loss in the United States: 2005 to 2050. Arch Phys Med Rehabil. 2008 Mar;89(3):422-9. doi: 10.1016/j.apmr.2007.11.005. PMID: 18295618.

 Borrenpohl D, Kaluf B, Major MJ. Survey of U.S. Practitioners on the Validity of the Medicare Functional Classification Level System and Utility of Clinical Outcome Measures for Aiding K-Level Assignment. Arch Phys Med Rehabil. 2016 Jul;97(7):1053-63. doi: 10.1016/j.apmr.2016.02.024. PMID: 27016261. 4. Hart DL. Orthotics and Prosthetics National Office Outcomes Tool (OPOT): Initial Reliability and Validity Assessment for Lower Extremity Prosthetics. JPO: Journal of Prosthetics and Orthotics. 1999;11(4):101-11.

5. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010 Jan;21(1):128-38. doi: 10.1097/EDE.0b013e3181c30fb2. PMID: 20010215.

6. Vickers AJ, Cronin AM. Everything you always wanted to know about evaluating prediction models (but were too afraid to ask). Urology. 2010 Dec;76(6):1298-301. doi: 10.1016/j.urology.2010.06.019. PMID: 21030068.

Introduction

Background

An estimated 1.9 million people in the U.S. are living with limb loss, a number expected to double by 2050 mostly due to the rising prevalence of diabetes.^{1, 2} The management of lower limb amputees with respect to lower limb prostheses (LLPs) is a complicated problem. LLP candidates are a heterogeneous group with distinct needs dependent upon age, etiology of limb loss, level of amputation, comorbidities and health status, postoperative stage, and rehabilitation status. Many LLP options exist, comprising numerous permutations of components, the anatomy they replace, their sophistication, and other attributes, including those pertaining to cosmesis and comfort. In addition, patients may require multiple LLPs (initial, preparatory, definitive, or replacement prosthetics, or those for specific types of activities). Compared to the general population, LLP patients exhibit lower overall physical and emotional health (e.g., increased risk for cardiovascular disease,³ anxiety, and depression⁴) and higher mortality (estimated 5-year mortality rates for amputees range between 50⁵ and 74 percent⁶; estimated 1-year mortality is 36% for amputees >65 years old⁷).

The most common cause of major lower limb loss among adults is dysvascular disease, primarily due to diabetes and peripheral artery disease, accounting for about 81 percent of lower limb amputees.² Trauma accounts for about 17 percent of major lower limb amputation. Cancer is a relatively uncommon cause of lower limb amputation in adults (2%). About two-thirds or all amputees are men; although among older adults (\geq 65 years), 46 percent are women. Dysvascular disease is a more common amputation etiology among older than younger adults. Amputation etiology has an important impact on patient survival and functional ability. Among Medicare recipients, about the same percentage of lower limb amputees have transfemoral as transtibial amputations.⁸

The current standard approach for matching patients to prostheses relies heavily on performance-based assessments, self-assessments, and wearable monitoring technologies that record patient activity;⁹ although prosthetists and other clinicians often rely on clinical judgment to match patients to prostheses. Numerous outcome measurement tools (OMTs) exist to assess the patient functional status, but no consensus "gold standard" assessment schema exists. Similarly, numerous instruments (or techniques) are used to assess current amputee function or status and tools have been developed to predict future outcomes, including successful use of LLPs. Constructs of reliability (e.g., test-retest, interrater, internal consistency) or validity (e.g., face, content, construct, criterion) of existing OMTs, assessment techniques, and prediction tools have been evaluated in the amputee population for the most frequently used measures.¹⁰ However, it is unclear to what degree studies with functional and patient-centered outcomes use validated instruments and outcomes. It is also unclear whether the population of amputees included in validation (etc.) studies is generalizable to the population of participants in studies of LLP components and, in turn, whether these study populations are applicable to the more general population of users of LLPs.

LLPs replace the functionality of a missing limb to as great a degree as possible. Medicare covers custom fabricated LLPs in accordance with Local Coverage Determination (LCD): Lower Limb Prostheses (L33787).¹¹ As for all items to be covered by Medicare, it must: 1) be eligible for a defined Medicare benefit category, 2) be reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member, and 3) meet all other applicable Medicare statutory and regulatory requirements. A LLP is covered

when the beneficiary: 1) will reach or maintain a defined functional state within a reasonable period of time; and 2) is motivated to ambulate. Potential functional ability is based on the reasonable expectations of the prosthetist and treating physician, considering factors including, but not limited to, the beneficiary's past medical history, the beneficiary's current overall health condition including the status of the residual limb and the nature of other medical problems. Some prosthetic components are limited to beneficiaries with a functional ability at or above a certain level.

As indicated by Medicare coverage guidance,¹² clinical assessments of beneficiary rehabilitation potential must be based on the classification levels listed in Table 1. The Medicare Functional Classification Level (MFCL or K level) system broadly defines five classification levels that can be attained with an LLP and range from 0 (no ability or potential to ambulate or transfer; LLP will not enhance quality of life or mobility) to 4 (ability or potential to exceed basic ambulation skills). The classification level assigned is used to determine the medical necessity of certain componentry, and thus to match the ultimate LLP to the beneficiary's clinical needs.

Level 0:	Does not have the ability or potential to ambulate or transfer safely with or without assistance and a prosthesis does not enhance their quality of life or mobility
Level 1:	Has the ability or potential to use a prosthesis for transfers or ambulation on level surfaces at fixed cadence. Typical of the limited and unlimited household ambulator.
Level 2:	Has the ability or potential for ambulation with the ability to traverse low level environmental barriers such as curbs, stairs, or uneven surfaces. Typical of the limited community ambulator.
Level 3:	Has the ability or potential for ambulation with variable cadence. Typical of the community ambulator who has the ability to traverse most environmental barriers and may have vocational, therapeutic, or exercise activity that demands prosthetic utilization beyond simple locomotion.
Level 4:	Has the ability or potential for prosthetic ambulation that exceeds basic ambulation skills, exhibiting high impact, stress, or energy levels. Typical of the prosthetic demands of the child, active adult, or athlete.

Definitions per CMS (Centers for Medicare and Medicaid Services).¹¹

In practice it is difficult for clinicians to assess medical necessity for a patient to receive the most appropriate component (whether of higher or lower level or sophistication). Determination of a patient's potential functional abilities requires an assessment of current condition and ability and potential to ambulate. In practice, therefore, OMTs must both assess and predict function to help guide prosthetists, treating physicians, and beneficiaries. However, it is unclear to what extent measures of current function and status are able to predict future function.

A major methodological challenge in addressing selection of OMTs for routine use pertains to the assessment of predictive validity. Predictive tests should be valued with respect to their ability to predict future important outcomes. However, outcomes are determined by the whole patient management strategy which involves the baseline assessment, the LLP that a patient is given based on this assessment, patient health and changes in patient health, and any additional care (e.g., physical therapy, rehabilitation) that the patient receives. Thus, it is inherently challenging to assess the value of a baseline OMT assessment by itself, particularly if the choice of LLP is influenced by the initial OMT assessment.

Variability and subjectivity in assigning or predicting the K level of prospective LLP recipients may inadvertently lead to inefficient or inappropriate LLP matching.¹³ This can occur if a person receives a LLP allowed for lower K levels when a LLP allowed only for higher K levels would enable better function, or if a person receives a LLP approved for higher K levels, which might be unnecessarily complex for an individual who would have equivalent or better function with a simpler component.

Options for configuring LLPs are abundant, as LLP are highly customized devices, comprising combinations of components that replace missing anatomy and function. Components of a given type can differ in terms of functional sophistication (e.g., articulated componentry may be passive, with undamped movement, have mechanical or hydraulic dampening, or have electronic control), materials used, weight, aesthetics, comfort, and other factors. A major question is how to match patients with LLPs (both by K levels as well as by other characteristics) to optimize functional and other patient-centered outcomes. Because there are many different patients and many possible LLPs, there are numerous possible matchings. However, it is unclear which patient-level characteristics or LLP-level attributes predict a good matching, or how to weigh patient functional potential against their current functional level in the matching process.

The major contextual challenges in providing data to inform matching of LLPs to patients pertain to the large heterogeneity in patient characteristics and attributes of the LLPs; the fact that it is unclear which patient characteristics and LLP attributes are important to best match a patient to a specific LLP; disagreements about what constitutes an optimal matching of patients with LLPs; and poor clinical outcomes and wasted resources associated with suboptimal LLP allocations. Specifically, patients who are in need of LLPs are heterogeneous in terms of etiology of limb loss, amputation type (level of amputation, uni- or bilateral), age, comorbidities, frailty, general health status factors, expected life span, mental health status (e.g., depression, posttraumatic stress syndrome), family and social support, and many other factors, including whether they have fragile skin or allergies towards socket liners or other materials. These factors may affect their actual and perceived current and maximum attainable functional ability, and the likelihood that they will receive and use an LLP.^{8,16}

Objectives of the Systematic Review

The purposes of this systematic review are to 1) identify validated patient assessment techniques, prediction tools and OMTs that have been validated for use in persons with lower limb amputation; 2) identify and summarize studies that compare the differential relative effect of LLP components based on LLP users' characteristics; 3) determine whether these studies use instruments and OMTs that have been validated in the lower limb amputee population; 4) determine whether patient expectations align with their outcomes with LLPs; 5) evaluate whether patients are satisfied with the process of obtaining their LLPs; and 6) describe the long-term continued use of LLPs by those prescribed a prosthesis. This systematic review may also identify areas where evidence gaps exist related to the prescription of LLP so that recommendations may be made concerning the study designs and outcome measures that best inform patient oriented function, quality of life and service satisfaction in this realm.

This review's Key Questions and study eligibility criteria were designed to assist CMS to better understand the state of the evidence regarding how best to match patients with LLPs that
would yield best outcomes for them, and related issues. It is important to note that this review does not fully cover the field of evaluation of LLPs. Specifically, it excludes from evaluation biomechanical and other nonpatient-centered intermediate outcomes. It also does not attempt to review all evidence about comparisons between specific components. Instead, it largely focuses on those comparisons, which provide within-study data to allow assessment about how components compare in different subpopulations of patients based on their characteristics. The review also focuses on people who may be eligible to be covered by CMS, whether due to age or disability. Therefore the review is restricted to adults with an emphasis on those with dysvascular, cancer-, or trauma-related amputations, but excluding studies of exclusively military amputees with battle-related trauma (who are generally covered by Department of Defense and/or Veterans Health Administration insurance). Furthermore, the review excludes studies from low-income or resource settings not applicable to the U.S.

Key Questions

Preliminary Key Questions (KQ) and protocol were discussed in depth with a panel of key informants (stakeholders representing patients [amputees], clinicians, prosthetists, rehabilitation, and physical therapy), with the sponsor, and were publicly posted in December, 2016. Based on feedback from commenters and further discussion with the sponsor the Key Questions (and study eligibility criteria) were revised to improve clarity, focus the topics more closely with the sponsor's needs, and to evaluate measures and outcomes of interest to stakeholders. The following are the Key Questions (KQ) addressed by the review:

- **KQ 1.** What **assessment techniques** used to measure functional ability of adults with major lower limb amputation have been evaluated in the published literature?
 - 1a. What are the measurement properties of these techniques, including: reliability, validity, responsiveness, minimal detectable change, and minimal important difference?
 - 1b. What are the characteristics of the participants in these studies?
- **KQ 2.** What **prediction tools** used to predict functional outcomes in adults with major lower limb amputation have been evaluated in the published literature?
 - 2a. What are their characteristics, including technical quality (reliability, validity, responsiveness), minimal detectable change, and minimal important difference?
 - 2b. What are the characteristics of the participants in these studies?
- **KQ 3.** What **functional outcome measurement tools** used to assess adults who use a LLP have been evaluated in the published literature?

- 3a. What are their characteristics, including technical quality (reliability, validity, responsiveness), minimal detectable change, and minimal important difference?
- 3b. What are the characteristics of the participants in these studies?
- KQ 4. In adults who use a lower limb prosthesis, how do the relative effects on ambulatory, functional, and patient-centered outcomes of different prosthetic components or levels of components/prostheses vary based on study participant characteristics?

Prosthetic components include:

- Foot/ankle
- Knee
- Socket
- Liner
- Suspension
- Pylon
- Other

Study participant characteristics of interest include:

- K level
- Level of amputation
- Etiology of amputation
- Prior function (prior to new or replacement LLP)
- Current function
- Expected potential function/level of activity and activities (e.g., athletics, uneven surface walking)
- Time since amputation
- Initial vs. subsequent limb LLP
- Unilateral vs bilateral LLP
- Time since last assessment
- Age
- Comorbidities that may affect use of LLP (e.g., congestive heart failure, vascular dysfunction, skin ulceration/damage, visual dysfunction, peripheral neuropathy, local cancer treatment, other lower limb disease)
- Type, setting, and description of rehabilitation, physical therapy, training

- Periamputation surgery information, including surgical details, inpatient rehabilitation details, wound status
- Residence setting
- Use of assistive devices
- Comfort of existing prosthesis (for patients receiving replacement LLP)
- Psychosocial characteristics
- Cognitive function
- Family (etc.) support system
- Training and acclimation with LLP
- 4a. What **assessment techniques** that have been evaluated for measurement properties were used in these studies?
 - 4a.i. How do the characteristics of the participants in eligible studies that used these specific assessment techniques compare to the characteristics of the participants in the studies that evaluated the assessment techniques (as per KQ 1b)?
 - 4a.ii. What is the association between these preprescription assessment techniques and validated outcomes with the LLP in these studies?
- 4b. What **prediction tools** that have been evaluated for measurement properties were used in these studies?
 - 4b.i. How do the characteristics of the participants in eligible studies that used these specific prediction tools compare to the characteristics of the participants in the studies that evaluated the prediction tools (as per KQ 2b)?
 - 4b.ii. What is the association between preprescription assessment techniques and validated outcomes with the LLP in these studies?
- 4c. What **functional outcome measurement tools** that have been evaluated for measurement properties were used in these studies?
 - 4a.i. How do the characteristics of the participants in eligible studies that used these specific functional outcomes compare to the characteristics of the participants in the studies that evaluated the outcomes (as per KQ 3b)?

- **KQ 5.** How do study participants' preprescription **expectations of ambulation** align with their functional outcomes?
 - 5a. How does the level of agreement vary based on the characteristics listed in KQ 4, including level of componentry incorporated into their LLP?
- **KQ 6.** What is the level of patient **satisfaction with the process** of accessing a LLP (including experiences with both providers and payers)?
 - 6a. How does the level of patient satisfaction vary based on the characteristics listed in KQ 4, including level of componentry incorporated into their LLP?

KQ 7. At 6 months, 1 year, and 5 years after receipt of a LLP,

(accounting for intervening mortality, subsequent surgeries or injuries) what percentage of individuals...?

- i. Maintain bipedal ambulation
- ii. Use their prostheses only for transfers
- iii Use prostheses only indoors
- iv. Have abandoned their prostheses
- v. Have major problems with prosthesis
- 7a. How do these percentages vary based on the following characteristics?
 - Patient residence and setting
 - Living situation (e.g., homebound, institutionalized, community ambulation)
 - Setting for rehabilitation, physical therapy, or training (e.g., in-home or at facility)
 - Patient characteristics
 - o Age
 - Level of amputation
 - Number of lower limbs amputated (unilateral vs. bilateral)
 - Prior level of function (prior to onset of extremity disability)
 - o Current level of function
 - Etiology of amputation
 - Time since amputation
 - o Comorbidities (e.g., diabetes, CVD, PVD)
 - Operative treatment
 - Use of assistive device

- o Cosmesis of the prosthesis
- o Comfort of the prosthesis
- Cognitive function
- o Other
- Prosthetic componentry
- 7b. What were the reasons for suboptimal use of the prosthetic device?

Analytic Framework

The following analytic framework (Figure 1) graphically illustrates the synthesis of the KQs and their elements

Figure 1. Analytic framework for assessment and assignment of lower limb prostheses, including Key Questions



Abbreviations: KQ = key question(s), LLP = lower limb prosthesis.

* Components include: feet/ankles, knees, sockets, liners, suspension, pylons, and others.

- † Functional and patient-centered outcomes include: quality of life, disability measures, activities of daily living, mobility measures, including use of prostheses only for transfers, self-care, pain, fatigue after use (e.g., end of day), daily activity, time LLP worn per day, falls, satisfaction with LLP, and others (but not simple preference of one component over another).
- ‡ Ambulatory outcomes include: gait speed, step count, walk distance; uneven or wet surface, low lighting walking; ramps and incline traversing; step/stair climbing function; ambulatory function measured in the community setting (e.g., self-report or activity monitors); achievement of bipedal ambulation; and other patient-centered ambulatory function measures.
- § Adverse events include: skin ulcers and infections, injuries from falls due to mechanical failure, and other problems with prostheses.

Methods

The Evidence-based Practice Center (EPC) conducted the review based on a systematic review of the published scientific literature, using established methodologies as outlined in the Agency for Healthcare Research and Quality (AHRQ) Methods Guide for Effectiveness and Comparative Effectiveness Reviews.¹⁴ Prospero registration number pending.

Search Strategy

We conducted literature searches of studies in PubMed, both the Cochrane Central Trials Registry and Cochrane Database of Systematic Reviews, EMBASE, and CINAHL/PSYCInfo databases to identify primary research studies and systematic reviews meeting our criteria. The searches were conducted on November 30, 2016. [The searches will be updated in all databases upon submission of the draft report for peer and public review.] No publication date or language restrictions were applied. Appendix A presents the literature search strategies (for each searched database). We perused the reference lists of published relevant systematic reviews. Any comparative studies (Key Question [KQ] 4) or long-term followup studies (KQ 7) found from existing systematic reviews were assessed and incorporated *de novo* from the original article. For KQ 1-3, we searched for existing systematic reviews (about validation of instruments and measures) and for additional primary studies. Peer and public review [will provide] an additional opportunity for experts in the field and others to ensure that no relevant publications have been missed.

Study Eligibility Criteria

Specific eligibility criteria varied for each KQ, but criteria for populations, interventions, and study designs of interest were the same for most KQ. For each criterion category, we state which KQ each set of criteria apply to.

Population of Interest

All KQ:

- Adults with lower limb amputation who are being evaluated for or already have a lower limb prosthesis (LLP)
 - *Exclude* if study includes *only* participants with battle-related trauma
 - *Exclude* if study includes *only* congenital amputations (and not otherwise Medicare eligible)
 - **Exclude** if study includes *only* children ≤ 18 years old
 - If a study has a mixed population (related to battle trauma, congenital amputations, or pediatrics) and they report subgroup data based on these factors, include analyses of relevant populations (exclude substudy data on excluded populations). If study reports only combined data (e.g., adults and children), include overall study, but note issue related to population.
 - *Exclude* if study conducted in low income or low resource country

KQ 1-2:

• Also allow studies of amputees, whether or not they use LLPs (i.e., allow studies evaluating assessment techniques and predictor tools in amputees who do not [yet] have a LLP)

Interventions or Predictors of Interest (and Measures for KQ 1-3)

All KQ:

- Custom fabricated lower limb prosthesis
- Specific prosthetic component, including foot/ankle, knee, socket, liner, pylon and suspension, or components with specific characteristics (e.g., shock absorbing, torque, multiaxial, computer assisted, powered, flexion, microprocessor)
- New or existing definitive or replacement prosthetics
 - *Exclude* immediate postoperative prosthetics (used temporarily prior to definitive or replacement prostheses immediately after amputation surgery)
 - *Exclude* immediate postoperative prosthetics (used temporarily prior to definitive or replacement prostheses immediately after amputation surgery)
 - *Exclude* evaluation of orthotics and of implanted devices

KQ 1-3 Measures:

- Assessment techniques (measures or tools used prior to prescription to assess patient's overall functional status) (KQ 1)
 - Tests, scales, questionnaires that assess current functional or health status
 - Include patient history and physical examination
 - Measures of physical function and functional capacity (e.g., parallel bar ambulation without LLP)
 - *Exclude* single factors (e.g., time since surgery, fasting blood glucose)
- Predictor tools (used prior to prescription to predict functional outcomes with prosthesis) (KQ 2)
 - Tests, scales, questionnaires
 - *Exclude* single factors (e.g., time since surgery, fasting blood glucose)
- Outcome measures (assessed in people using LLP) (KQ 3)
 - o Functional, patient centered, or ambulatory outcomes per KQ 4

KQ 4:

• As listed for all KQ

KQ 5, 7:

• Receipt of a definitive or replacement LLP (regardless of componentry)

KQ 6:

• Undergo process of accessing a definitive or replacement LLP (regardless of componentry)

Comparators of Interest

KQ 1-3:

• Reference standards, as applicable

KQ 4:

• LLPs with different components (e.g., feet/ankles, knees, sockets, pylons, liners, suspension), or that differ in other ways (studies must be comparative)

KQ 5-7:

• No comparators required

Outcomes of Interest

KQ 1-3:

• Assessments of reliability, validity, responsiveness, minimal detectable change, or minimal important difference, and floor/ceiling effect

KQ 4, 5:

- Functional or patient-centered outcomes (measured or related to status in the community)
 - Quality of life
 - o Disability measures
 - Activities of daily living
 - Mobility measures, including use of prostheses only for transfers
 - o Self-care
 - o Pain
 - Fatigue after use (e.g., end of day)
 - o Daily activity
 - Time LLP worn per day
 - o Falls
 - Satisfaction with LLP
 - *Exclude* (simple) preference
- Ambulatory functional outcomes
 - o Gait speed, step count, walk distance
 - Uneven or wet surface, low lighting walking
 - Ramps and incline traversing
 - Step/stair climbing function
 - Ambulatory function measured in the community setting (e.g., self-report or activity monitors)
 - Achievement of bipedal ambulation

- Other patient-centered ambulatory function measures
 - *Exclude* biomechanical measures
- Adverse effects of LLP
 - o Skin ulcers/infections, (injuries from) falls due to mechanical failure, etc.
 - Other problems with prosthesis

KQ 6:

• Patient satisfaction measures with process of accessing LLP

KQ 7:

- Maintenance of bipedal ambulation
- Use of prostheses only for transfers
- Use of prostheses only indoors
- Abandonment of prostheses (not using prosthesis)
- Major problems with prosthesis
- Reasons for suboptimal use of LLP (as defined by above outcomes)

Eligible Study Designs

All KQ:

- Published, peer reviewed study or publicly available theses, dissertations, etc.
- Any language (that can be read by research team or machine translated)
- No publication or study date restriction
 - o *Exclude* case reports

KQ 1-3:

- Any assessment of validity, reliability, and related characteristics
 - *Exclude* studies of validation of translations of non-English scales, indexes, etc.
- Any study design
- N \geq 20 lower limb amputees
- No minimum followup time

KQ 4:

- Direct comparison between any two components, any relevant study design
- Must include an analysis or reporting of differences in relative effect between components by a patient characteristic of interest (see text of KQ 4) or report sufficient participant-level data to allow such an analysis
- No minimum sample size (other than excluding case reports)
- No minimum followup time

KQ 5, 6:

- Any study design, including qualitative studies
- No minimum sample size (other than excluding case reports)

• No minimum followup time

KQ 7:

- Either longitudinal with followup since original lower limb prosthesis prescription or cross-sectional at timepoint after amputation or prescription
- Minimum followup time
 - $\circ \geq 6$ month followup from time of LLP prescription, or
 - $\circ \geq 1$ year followup from time of amputation, if no data reported about time since LLP prescription
- Minimum sample size: $N \ge 100$

Setting

- Any residence including community ambulation, homebound, and institutionalized
- Clinical or laboratory setting (for evaluation of specific ambulatory function outcomes)
- Rehabilitation setting (e.g., physical therapy clinic, in-home)
 - *Exclude exclusively* postacute (postsurgical) setting or inpatient rehabilitation (immediately postamputation)

Study Selection

All citations (abstracts) found by literature searches and other sources were independently screened by two researchers. At the start of abstract screening, we implemented a training session, in which all researchers screened the same articles and conflicts were discussed. During double-screening, the team met regularly to reconcile conflicts and continue training. All screening was done in the open-source, online software Abstrackr (http://abstrackr.cebm.brown.edu/). During abstract screening, liberal eligibility criteria were applied to minimize the risk of rejecting pertinent studies. All potentially relevant studies were entered into an evidence map, in which basic study data were extracted from the abstract (KQ addressed, study design, country, sample size, measure(s) being validated or assessed [for KQ 1-3), and rejection reason [as applicable]). Remaining studies relevant to KQ 1-3 were reviewed in full text and measures being validated by the studies were entered into the evidence map; we also noted whether these studies were already included in known existing systematic reviews. Studies pertaining to KQ 4 (subgroup comparisons) were reviewed in full-text and information regarding whether the articles reported subgroup or regression analyses or individual patient level characteristics and results were entered into the evidence map; full-text articles were also reviewed to determine whether outcomes of interest were reported. Studies pertaining to KQ 7 (long-term follow-up) were also reviewed in full text to confirm that outcomes of interest were reported and to enter duration of follow-up into the evidence map. Studies pertaining to KQ 5 and 6 were also reviewed in full text to confirm eligibility, but no additional data were entered into the evidence map.

Data Extraction

For all KQ, we extracted publication information, study design, eligibility and population descriptions including details about lower limb status (e.g., amputation level), outcome descriptions, and results.

For KQ 1 to 3, data were extracted into a specially designed spreadsheet form. We captured sample descriptors (amputation level, amputation etiology, mean age, sample size), measure/instrument type (assessment techniques, prediction tools, and outcome measures), measure/instrument name, instrument subscale/subquestion as appropriate, measure/instrument description or definition, evaluated property (validity, reliability, responsiveness, minimal detectable change, minimal important difference, and floor/ceiling effect), aspect of the measure (e.g., internal consistency, test-retest reliability, interrater reliability, content/face validity, criterion validity, convergent/concurrent validity, divergent/discriminant validity, predictive validity, construct validity, structural validity), the comparator (what the measure is being compared to), the metric used to assess the measure (e.g., Spearman r or effect size), the value of the metric, and the strength of the property (if relevant). Based on criteria summarized in Table 2, we determined whether each aspect is supported within each study.

Reliability addresses whether the tool gives a consistent answer. For the reliability property, we determined that measures were "reliable" with each study if any reliability metric (internal consistency, test-retest, interrater, or intrarater) was deemed to be adequate.

Validity addresses whether a tool measures what it claims to measure. There are several aspects of validity. Content (or face) validity considers the common sense and intrinsic meaning of the measure (e.g., that steps per day measures walking activity). Criterion validity addresses the extent to which a measure is related (e.g., correlated) to the "gold standard"; however, since "gold standards" do not exist for the functional outcomes of interest, this specific metric is largely theoretical for our purposes. Convergent (or concurrent) validity assesses the degree to which two measures hypothesized to be related are actually related. Predictive validity refers to the comparison with a future outcome (e.g., current health status and future mortality). Divergent (or discriminant) validity tests whether measures that are theoretically not related are, in fact, statistically unrelated (e.g., lack of correlation between age and comfort measures). Construct validity, assessed through factor analysis, Rasch or item response theory methods, assesses the fit of a model (a set of questions or traits). Rasch analysis may be conducted to maximize the homogeneity of the trait and to allow greater reduction of redundancy (i.e., increase simplicity) without sacrificing information.

For the validity property, we noted content validity, but did not use it to determine overall validity. If a study had an *a priori* hypothesis about the criteria necessary to determine validity, we used these criteria. Otherwise, we required evidence of either criterion validity, convergent validity, or construct validity. Similar to content validity, presence of divergent or structural validity was noted, but were not, alone, considered sufficient for overall validity. For KQ 2 (predictive tools), if a study found predictive validity, this was also deemed sufficient for overall validity.

Responsiveness addresses whether an instrument is sufficiently sensitive to capture important changes in the measure. Measures were "responsive" if they met any of the predetermined cutoffs for metrics such as effect size and standardized response mean.

Minimal detectible change and minimum (clinical) important difference were both extracted as reported.

Floor/ceiling effects were deemed to be present if more than 15 percent of the sample had the minimum or maximum possible value for the given scale (i.e., they hit the floor or ceiling of the scale). When this occurred, we captured a description of the sample characteristics.

Each study was assessed to determine whether the measures being evaluated were assessment techniques, prediction tools, or outcome measures. Although conceptually these categories of measures are distinct (see *Study Eligibility Criteria/Interventions or Predictors of Interest (and Measures for KQ 1-3)/KQ 1-3 Measures*), in practice distinguishing which category a study and measure belongs in is open to interpretation. To categorize outcomes we used the following approach: For KQ 1 (assessment techniques), we included measures described by studies as assessment techniques and studies that included lower limb amputees either prior to prosthesis use or at the time of evaluation for a new or replacement LLP. For KQ 2 (prediction tools), we included measures for which predictive validity was assessed. For KQ 3 (outcome measures), we included all other measures, which were evaluated in people with existing LLPs or were described (explicitly or implicitly) as outcome measures.

Table 2. Metrics for Evaluation of Reliability, Validity, and Related Measures

,,
Reliability
Internal consistency
Cronbach alpha
Excellent ≥0.80
Adequate 0.60-0.79
Poor ("not reliable") <0.60
Rasch analysis person-separation reliability index
Excellent ≥0.90
Good 0.80-0.89
Test-retest, interrater, intrarater
Intraclass correlation coefficient (ICC) for continuous data
Kappa for categorical data
Excellent ≥0.80
Good 0.60-0.79
Poor ("not reliable") <0.60
Require: Test-interval be defined, large enough, and well justified
Require: N ≥30
Require: Defined training of testers and test administration
Validity
(If an <i>a priori</i> hypothesis is reported, describe that and whether valid based on the hypothesis; otherwise use
criteria below)
Content validity
Content of measure either has face validity (e.g., steps per day) or is based on evidence-based or
consensus-based process (e.g., patient survey, expert panel, Delphi process, focus groups, interviews) or
well-documented decision process
Not sufficient for "overall" validity
Criterion validity*
Criterion standard scores (for norm-based scores, cited age-matched normative values, etc.)
Well defined and justified criterion standard ("gold standard")
Convergent (concurrent) validity
Strength and direction of <i>a priori</i> correlation (r or r _s [standardized])
Large ≥0.5
Moderate 0.3-0.5
Small 0.1 to 0.29
Intraclass correlation coefficient for continuous data
Excellent ≥0.80
Good 0.60-0.79
Poor ("not reliable") <0.60
Statistical significant association of a priori hypothesis in regression analysis
Would be weak evidence, if only this analysis is reported
Divergent (discriminant) validity

Low correlation (<0.1) in testing different constructs
Predictive validity (only for Key Question 2)
Correlation or regression strength with future outcome (with prosthesis)
Construct validity
Differences between known groups hypothesized to be different in the key construct
Diagnostic test measures (e.g., compared to concurrent controls, nonamputees)
Factor analysis or principal component analysis
N ≥10 per item
Root mean square error of approximation ≤0.05-0.08
Standardized response means ≤0.08
Model fit measures ≥0.95
Structural validity (Rasch testing)
Evidence from factor analysis
Fit statistics are between 0.05 and 1.5 (i.e., items fit the model)
Responsiveness
Whether responsiveness statistics have been reported
Effect size with pooled standard deviation
Effect size with baseline standard deviation
Standardized response mean
Guyatt responsiveness index
Receiver operating characteristic curve
Minimal detectable change / Minimum (clinical) important difference
Record values reported derived from
Test-retest analyses
90% or 95% confidence interval
Floor/ceiling effect
≥15% of sample within the margin of error of the minimum or maximum value

* Criterion validity is largely theoretical for the measures of interest since there are not "gold standards" to compare to.

For KQs 4 and 7, data were extracted into the Systematic Review Data Repository (SRDR, https://srdr.ahrq.gov) into specially-designed data extraction forms. Studies that reported comparisons of interest were fully extracted into SRDR; however, for studies that reported only individual patient data, we extracted those data into spreadsheet forms. From these data, we calculated means and ran t-tests to compare subgroups of interest.

Studies pertaining to KQs 5 and 6 were extracted qualitatively directly into text describing the studies.

Risk of Bias Assessment

For KQs 4-7, we assessed risk of bias with the Cochrane Risk of Bias tool (assessing randomization, allocation concealment, blinding, intention-to-treat analysis, reporting bias, attrition bias, and other biases), and selected questions from the Newcastle-Ottawa Scale for observational studies (assessing representativeness of the study sample, outcome assessment, comparability of the people in compared study groups, and analytic method^{15, 16}—in particular whether multivariable analyses were conducted). For each risk of bias/study quality question, we assessed whether there was high risk of bias (e.g., lack of blinding), low risk of bias (e.g., adequate randomization), or unclear risk of bias (if there was inadequate reporting to assess). For KQ 4, we also assessed whether adequate heterogeneity of treatment effect analyses were conducted.

For each study, we determined an "overall quality" based on the risk of bias for each assessed factor. The overall quality assessment was based on the best judgment of the reviewers. Special emphasis was placed on whether outcome assessors were blinded and, for KQ 4, whether

outcomes were validated and multivariable analyses were conducted. Overall quality was assessed as high, moderate, or low risk of bias.

Data Synthesis

Narrative and Tabular Synthesis

Included studies are presented in summary tables with the important features of the study populations, design, intervention, and risk of bias. All outcome results [will be] available in SRDR and [will be] publically available (<u>http://srdr.ahrq.gov</u>).

For KQ 1 to 3, each measure assessed by the eligible studies are described in terms of their validity, reliability, and related metric.

For KQ 4, studies are organized by whether they used and reported validated measures, as per KQ 1 to 3). Findings of the studies are summarized within this construct. Studies for KQ 5 and 6 are briefly summarized. Studies for KQ 7 are summarized, with an emphasis on between-group comparisons, where available.

Post Hoc Analyses

For KQ 4, most studies did not report statistical analyses comparing subgroups. Either they reported subgroup findings without statistically comparing the subgroups or they reported individual patient data for both participant characteristics and outcomes. In these cases, we compared subgroups of interest with t tests or chi-squared tests. For all analyses (reported or conducted by us), we report the P value of the comparison between subgroups. Where P<0.05, we provide the quantitative difference between subgroup effects in the Appendix results data tables and, in the main text tables summarizing each study, a narrative description of which subgroup has a greater effect with which LLP component. Where P \geq 0.05, we omit the comparative data.

We further calculated a Bonferroni-corrected P value for each study. To calculate the corrected P value we divided 0.05 by the total number of statistical analyses reported in the articles and those conducted for this review. Most studies had a large number of individual analyses (up to 135 comparisons). Without correcting P values, a large number of analyses would be statistically significant at the P=0.05 level due to chance alone. We chose the Bonferroni correction since it is relatively conservative (although, arguably overconservative) and we could not attempt to correct for correlations between analyses within studies. In the overall summary table of the findings of the comparative studies and in the text we describe only the comparisons which are statistically significant after correction of the P value threshold.

Summarizing Findings Across Studies

For KQ 4 to 7, for each comparison of interventions, we determined a conclusion (or summary of findings across studies) for each outcome with sufficient evidence (i.e., not insufficient evidence, see *Grading the Strength of Evidence*).

For KQ 4, we concluded the evidence "favors" one intervention (over the other) when

- when the preponderance of studies found a statistically significant difference in the same direction, and/or
- when the preponderance of studies found statistically nonsignificant effect sizes that were either greater than 1.25 or less than 0.80.

- However, if the 95 percent confidence intervals were highly imprecise (beyond *both* 0.50 and 2.00), the conclusion was "unclear" regardless of the magnitude of the point estimate.
- If a conclusion was based on a statistically nonsignificant effect size, the strength of evidence (see below) was low (it could not be moderate or high).

We concluded that interventions had similar effects (noted in tables as favoring "either") when the preponderance of studies' effect sizes were between 0.80 and 1.20, were not statistically significant, and were not highly imprecise, as defined in the bullets above, or inconsistent (across studies).

When studies were sparse, effect size estimates were highly imprecise, or studies were highly inconsistent (e.g., with point estimates ranging from 0.14 to 3.03), we deemed the findings to be "unclear" (with an insufficient strength of evidence).

Grading the Strength of Evidence

For KQ 4 to 7, we graded the strength of the body of evidence (SoE) as per the AHRQ Methods Guide on assessing the SoE.¹⁷ We assessed the SoE for each outcome of interest. Following the standard AHRQ approach, for each intervention and comparison of intervention, and for each outcome, we assessed the number of studies, their study designs, the study limitations (i.e., risk of bias and overall methodological quality), the directness of the evidence to the KQs, the consistency of study results, the precision of any estimates of effect, the likelihood of reporting bias, and the overall findings across studies. Throughout the report, all estimates with 95 percent confidence or credible interval beyond 0.5 and 2.0 were considered to be highly imprecise. Based on these assessments, we assigned a SoE rating as being either high, moderate, low, or having insufficient evidence to estimate an effect. Outcomes with highly imprecise estimates, highly inconsistent findings across studies, or with data from only one study were deemed to have insufficient evidence to allow for a conclusion (with the exception that particularly large, generalizable single studies could provide at least low SoE). The data sources, basic study characteristics, and each SoE dimensional rating are summarized in "Strength of Evidence" tables detailing our reasoning for arriving at the overall SoE ratings.

Peer Review

A draft version of this report [is being] reviewed (from Xxx # to Xxx #, 2017) by invited and public reviewers, including [pending]. These experts were either directly invited by the Evidence-based Practice Centered or offered comments through a public review process. Revisions of the draft [will be] made, where appropriate, based on their comments. The draft and final reports [will also be] reviewed by the Task Order Officers and an Associate Editor from another Evidence-based Practice Center. However, the findings and conclusions are those of the authors, who are responsible for the contents of the report.

Results

Summary of Studies

The literature searches yielded 10,285 citations and an additional 224 references were screened from review articles and existing systematic reviews (Figure 2). Of these, 331 articles were retrieved in full text. We excluded 236 articles for the reasons listed in Figure 2 (see Appendix B). Of note, 79 studies compared lower limb prosthesis (LLP) components but did not report either subgroup analyses, regression analyses, or individual patient data which would allow subgroup analyses. Thus, we found 92 eligible studies (in 95 articles), of which 72 provided validation or related analyses addressing Key Questions (KQ) 1 to 3, 11 (in 12 articles) provided data relevant to KQ 4, no studies for KQ 5, two studies for KQ 6, and 8 studies (in 9 articles) relevant to KQ 7.

Pertaining to KQs 1 to 3, we summarize 92 studies addressing the validity, reliability, and related metrics for a large number of measures or instruments. Across the 92 studies, studies included between 20 to 1291 lower limb amputees (with or without prostheses). Among studies reporting age, the mean age of participants ranged from 35 to 73 years. Across studies, approximately 91 percent of participants had unilateral amputations (and 9 percent had bilateral amputations). Approximately 63 percent had transtibial amputations and 31 percent had transfemoral amputations; amputations at other levels were rare (about 6% of participants). About half (48%) of participants had vascular etiologies for their amputation and the same percentage had traumatic amputations; other causes were relatively rare.

Figure 2. Literature flow



* 3 articles that were included for KQ 3 were potentially relevant for KQ 4 or 7, but were not eligible for them.
† No analyses of interest (N=2), pediatric population (N=2), unclear technology (N=2), battle injury (N=1), retracted publication (N=1), not primary publication (n=1).
‡ 1 study was included for both KQ 2 and KQ 3.

Abbreviations: CCTR = Cochrane Central Trials Registry, CDSR = Cochrane Database of Systematic Reviews, IPD = individual patient data, KQ = Key Question, LLP = lower limb prosthesis.

Key Question 1

What **assessment techniques** used to measure functional ability of adults with major lower limb amputation have been evaluated in the published literature?

The distinction between assessment techniques (used to assess patient function prior to new or replacement prescription of a LLP), prediction tools (used to assess future outcomes) and outcome measures (used to assess patient function, etc. with their new or replacement LLP) is not as clear-cut as their definitions would imply. Most, if not all, outcome measures can be used as an assessment technique, and in studies this is routinely done at study baseline. It is also reasonable for most measures that have been designed as assessment techniques to be used to assess patient function, etc. with their LLP (i.e., as an outcome measure). Here we limit the list of assessment techniques to those measures either described by studies as assessment techniques or studies that explicitly included lower limb amputees prior to prosthesis use or at the time of evaluation for a new or replacement LLP.

Summary of Studies and Participant Characteristics

Three tools have been evaluated as assessment techniques among people with lower limb amputations (Tables 1.1 and 1.2). More detailed study-level data are in Appendix C.

The evaluated assessment techniques were

- Prosthetist's Perception of Client's Ambulatory Abilities (PROS)
- Short Form Health Surveys (SF-12 and SF-36, and components, including a newly derived score PF-15)
- Transfemoral Fitting Predictor (TFP)

Assessment Techniques

Prosthetist's Perception of Client's Ambulatory Abilities

The PROS is one of the subscales developed for the Orthotics and Prosthetics National Office Outcomes Tool (OPOT). The PROS consists of a series of questions asked of the prosthetist to assess the client's ability to climb stairs, walk, and use assistive devices.

In Hart 1999,¹⁸ PROS was administered in a convenience sample of patients who were being evaluated for their first or replacement prosthesis and then readministered at follow-up 8 weeks later. About two-thirds of the study participants had dysvascular amputation etiologies. Mean age was about 56 years. About half had Medicare or Medicaid as their primary insurance. Although moderately correlated, the analyses did not support the *a priori* hypotheses about the strength of correlations between the PROS with the physical component summary scale (PCS) of the SF-36 or the PF-10. However, PROS demonstrated construct validity, differentiating patients by age group, amputation level, and K level. Moderate to small effect sizes were reported for transtibial and transfemoral amputees respectively.

Short Form Health Survey

The SF-12 and SF-36 are generic measures of health-related QoL designed originally for the general population. The SF-36 can be scored as two summary measures, called the physical

component score (PCS) and the mental component score (MCS) and eight subscales (physical functioning, bodily pain, role limitations due to physical health problems [role physical], role limitations due to personal or emotional problems [role emotional], emotional well-being, social functioning, energy/fatigue, and general health perceptions). Among people with LLPs, the SF instruments have been analyzed as a whole and parsed into numerous components subsets (from pairs of specific questions to the whole score). We summarize across all variations of the analyses.

Original SF-36

Several components of SF-36 have been shown to be internally consistent and reliable (Table 1.2). It is not clear if other components were not reliable or if they were not analyzed for reliability. Overall in Hart 1999,¹⁸ SF-36 and its components was found to be validated among a representative sample of patients who are being evaluated for their first or a replacement prosthesis (about half with Medicare or Medicaid insurance). There is evidence of convergent, construct, and structural validity for various subcomponents of the SF-36 scale. Similar to the reporting on reliability, it is unclear whether unreported subcomponents were not validated or were not analyzed. Responsiveness was demonstrated for both the PCS and MCS summary measures. Other aspects of validity, and MDC, MID, and floor/ceiling effects were not reported or analyzed.

PF-15: A Derivation of SF-36

Hart 1999 also added 11 questions to the physical functioning (PF) scale with the goal of reducing their expectation of a floor and ceiling effect of the PF-10 (a subscale from SF-12) and to improve its construct validity; the 21 questions were streamlined to 15 through Rasch analysis.¹⁸ The PF-15 demonstrated construct validity and internal consistency at initial to followup timepoints (alpha = 0.89-90). The PF-15 had a more normal distribution than the original PF-10, with slight ceiling effect, but it could not distinguish between K levels.

Transfemoral Fitting Predictor

The TFP is a 9-item instrument with two subscales that describes graded tasks and aims to assess the prosthetic potential of transfemoral amputees.

One study (Condie 2011) evaluated this instrument in 92 adults (age not reported) with unilateral transfemoral amputations, most of whom were dysvascular amputees undergoing postoperative rehabilitation.¹⁹ Principal component analysis demonstrated that there were two constructs within the nine items, and thus two subscales were identified; less demanding activities, and more demanding activities. In this population, both subscales had very good interrater reliability and internal consistency. TMP scores were different for patients who did and did not receive a prosthesis. Other aspects validity of the instrument were not assessed.

See section, below, Key Questions 1 to 3 Summary for overall summary.

Instrument: Subscale	Studies, n	Studies	Total N	Bi	Uni	TF	Kn	TT	ТМ	Trau	Vasc	CA	Other	NR	Age*
PROS	1	Hart 1999 18	840	nd	nd	171	nd	653	29†	260	516	nd	114	0	56.3
SF-12/36 ‡	1	Hart 1999 18	840	nd	nd	171	nd	653	29†	260	516	nd	114	0	56.3
TFP	1	Condie 2011 ¹⁹	92	0	92	92	0	0	0	nd	76	nd	11	5	nd

Table 1.1. Assessment Techniques: Studies, and Participant Characteristics

* Mean and range within studies in parentheses, in years.

† Ankle disarticulation. There were 37 classified as "other".

‡ Also evaluated for Key Question 3.

Abbreviations: Bi = bilateral amputation, CA = cancer etiology, Kn = through the knee amputation, NA = not applicable (no subscale), nd = no data reported, NR = etiology not reported, Other = other etiology, PROS = Prosthetist's Perception of Client's Ambulatory Abilities, SF-12/36 = 12/36-Item Short Form Health Survey (and its components), TF = transfemoral amputation, TFP = Transfemoral Fitting Predictor, TM = transmetatarsal amputation, Trau = trauma etiology, TT = transtibial amputation, Uni = unilateral amputation, Vasc = dysvascular etiology.

Table 1.2. Assessment Techniques: Reliability, Validity, and Other Characteristics

Instrument	Reliability	Overall Valid?	Content Validity	Criterion Validity	Convergent Validity	Divergent Validity	Construct Validity	Structural Validity	MDC	MID	Responsive- ness	Floor Effect	Ceiling Effect
PROS	nr	Yes	nr	nr	No (Pearson r < hypothesized)	nr	Yes (P<0.05 by age, amputation level, K level)	nr	nr	nr	Yes	nr	nr
SF-12/36*, **	Yes‡ (Cronbach α 0.61-0.92)	Yes	nr	nr	Yes§ (Pearson r P<0.05)	nr	Yes# (P<0.05 by age, amputation level, K level)	Yes, PF-10 & PF-21 (Rasch)	nr	nr	Yes, PCS and MCS	nr	No (PF- 15)
TFP	Yes (interrater ICC >0.8; Cronbach α 0.92)	Yes	nr	nr	nr	nr	Yes (PCA, by prosthetic receipt)	nr	nr	nr	nr	nr	nr

* Including subscores.

† Pearson product moment correlations statistically significant with SF-36 physical component summary scale and most of its components, but not the mental components summary scale and most of its components.

‡ PF-10 (physical functioning questions), BP-2 (bodily pain questions), RP-2 (role physical questions), RE-2 (role emotional questions), MH-2 (mental health questions). Also PF-15.

§ Pearson product moment correlations mostly statistically significant between different subscales/components of SF-12/36

Various subscales, including physical and mental components summary scales.

** Also evaluated for Key Question 3.

Abbreviations: DAM = Discriminant Analysis Model, ICC = Intraclass correlation coefficient, MCS = Mental Component Score, MDC = minimal detectable change, MIC = minimal (clinical) important difference, nr = not reported PCA = principal component analysis, PCS = Physical Component Score, PF = physical functioning subscales, PROS = Prosthetist's Perception of Client's Ambulatory Abilities, SF-12/36 = 12/36-Item Short Form Health Survey (and its components), TFP = Transfemoral Fitting Predictor.

Key Question 2

What **prediction tools** used to predict functional outcomes in adults with major lower limb amputation have been evaluated in the published literature?

Summary of Studies and Participant Characteristics

Eleven prediction tools or subscales have been evaluated in people with lower limb amputations. The tools are summarized in Tables 2.1 and 2.2. More detailed study-level data are in Appendix C.

The evaluated prediction tools were the

- 180 Degree Turn Test
- 2 Minute Walk Test (2MWT)
- Activities-specific Balance Confidence scale (ABC)
- Barthel Index
- Berg Balance Scale (BBS)
- Clifton Assessment Procedure for the Elderly (CAPE) and the CAPE component score Cognitive Assessment Scale (CAS)
- Four Square Step Test
- Functional Independence Measure (FIM)
- Houghton Scale
- Locomotor Capabilities Index (LCI)
- Timed Up and Go (TUG)

Predictive Tools

180 Degree Turn Test

The 180 Degree Turn Test is a video evaluation of the 180° turn of the Timed Up and Go (TUG) test, evaluating number of steps, time to complete, and turn steadiness.

In Dite 2007,²⁰ 40 people, two-thirds with dysvascular conditions (mean age 61.6 years), were evaluated first at discharge from inpatient rehabilitation. Number of steps to turn differed between persons with dysvascular amputation who had multiple falls at 6 months and those who did not, with 100 percent sensitivity and 74 percent specificity. Turn time also yielded relatively high sensitivity (85%) and specificity (78%); however, turn steadiness had low sensitivity (31%), but high specificity (85%).

2 Minute Walk Test

The 2MWT measures the distance walked along a straight, uncarpeted hallway for a 2minute time period. Rest periods are permitted in order for participants to reach the farthest distance possible within the specified amount of time without further encouragement.

In Brooks 2001,²¹ predictive validity of an initial 2MWT for future distance walked was demonstrated in a subgroup of 69 patients who had participated in a rehabilitation program, the majority of whom had dysvascular amputation etiology. The 2MWT, administered immediately

after initial prosthetic fitting was correlated with distance walked at 3 months (r = 0.568). Convergent validity was demonstrated through correlations between the 2MWT and both the Houghton score (r = 0.493) and the PF-10 (r = 0.479). Age was negatively correlated with the 2MWT (r = -0.289). Known-group validity was found in the 2MWT differentiating among men and women with transtibial amputations (P<0.001). The 2MWT changed significantly between baseline measures, hospital discharge and 3 month followup, providing evidence of responsiveness.

Activities-Specific Balance Confidence scale

The ABC scale assesses self-reported balance confidence.

The scale was found to have predictive validity to predict failure to reach community walking with a LLP after 1 year. The area under the curve (AUC) was 0.927 among 40 participants of mean age 57 years old with transfemoral or transtibial amputations (5 bilateral) and unreported amputation etiology. (The AUC is a measure of diagnostic test accuracy evaluating test sensitivity and specificity; the closer the AUC approaches 1.0, the more accurate the test.)

Barthel Index

The Barthel Index is a measure of basic activity of living (ADL) performance, where higher scores represent greater levels of functional independence.

In multivariate analysis of data from 48 patients (mean age 75.2 years old, the majority of whom had dysvascular unilateral transfermoral, through-knee, or transtibial amputation $(total)^{22}$ premorbid and discharge Barthel Index scores were significantly different for patients who achieved successful rehabilitation (defined as discharge from a skilled nursing facility [SNF] to an independent living situation) 1 year after SNF admission for participants of mean age 75.2 years old with primarily dysvascular unilateral transfermoral, through knee, or transtibial amputation etiology (P<0.001).

Berg Balance Scale

The BBS assesses static and dynamic balance ability with 14 tasks.

In Wong 2016,²³ a study of 40 participants of mean age 57 years old with transfemoral or transtibial amputations and unreported amputation etiology, two items of the BBS subscale were strongly associated with failure to reach community prosthetic walking level after 1 year: retrieve object from the floor (AUC=0.771) and look behind over shoulders (AUC=0.875), supporting the predictive validity of these two items.

Clifton Assessment Procedures for the Elderly and Cognitive Assessment Scale

The CAPE scale assesses cognitive and psychomotor functions. The CAS score is obtained by adding the scores of all the mental functioning items.

One study of 32 patients with transfemoral or transtibial amputations (mean age 66.4 years but no data on amputation etiology) demonstrated predictive validity of the CAS reporting a correlation of 0.45 between the total CAPE score administered 2 to 4 weeks after amputation and the Harold Wood Stanmore mobility grade achieved 8 to 14 months after amputation.²⁴ The correlation between CAPE and mobility was 0.92 for a subset of patients with no medical comorbidities.

Four Square Step Test

The FSST is a timed physical assessment of a sequence of steps.

In Dite 2007,²⁰ 40 people, two-thirds with dysvascular conditions (mean age 61.6 years), were evaluated first at discharge from inpatient rehabilitation. Scores on the FSST test differed between persons with dysvascular amputation who had multiple falls at 6 months and those who did not, with 92 percent sensitivity and 93 percent specificity. In addition, FSST scores were significantly different for persons who lower limb amputees with a history of multiple falls, as compared to those with no such history, supporting construct validity of the measure.

Functional Independence Measure

The FIM score assesses functional independence and is used widely in inpatient rehabilitation facilities. The score is made up of 18 items, which are used to calculate a motor subscore and a cognitive subscore.

In Leung 1996,²⁵ total FIM and motor FIM scores at admission and discharge from inpatient rehabilitation facilities were used to predict a dichotomized version of the Houghton Scale of Prosthetic mobility Scale (successful and failed prosthetic ambulators) administered 3 to 12 months after discharge. In 41 patients with lower limb amputation (the majority unilateral tranfemoral or transtibial, but no data on etioloty or age), the only significant correlation observed was between the discharge motor FIM scale and prosthetic mobility score (r= 0.58). There were no significant correlations between the admission motor FIM score and high versus low Houghton scores.

Houghton Scale

The Houghton scale of prosthetic use for mobility is a self-reported scale that quantifies daily prosthesis wear, use of prosthesis, use of assistive devices, and perceived stability when using the prosthesis on various terrains.

Wong 2016,²³ a study of 40 participants of mean age 57 years old with transfermoral or transtibial amputations (5 bilateral) and unreported amputation etiology, evaluated whether the current score on the scale could predict failure to maintain or obtain community prosthetic walking level after 1 year. The scale was found to have predictive validity with an AUC of 0.885.

Locomotor Capabilities Index

The LCI assesses an individual's perceived independence in performing 14 activities while wearing a prosthesis. The LCI is one of the scales of originally developed as part of the Prosthetic Profile of the Amputee (PPA). The entire LCI may be summed to provide a single score, or two 7-item subscales of the LCI can be calculated: basic items and advanced items. The original version used a 4-point ordinal scale; hence it is often called the LCI-4. The LCI-5 was designed to reduce potential ceiling effects of the LCI, by employing a 5-level response scale instead of a 4-level scale.

Two studies evaluated LCI as a prediction tool. Study participants were mostly under about age 62 and about half, overall, had dysvascular amputation etiologies. In Dite 2007,²⁰ at discharge from inpatient rehabilitation in 40 participants, two-thirds with dysvascular lower limb amputation, scores on the LCI advanced test differed between persons with dysvascular amputation who had multiple falls at 6 months and those who did not, with 43 percent sensitivity and 91 percent specificity. A study of 50 people aged 38 to 62 years with with unilateral

transfemoral or transtibial amputations, about half from trauma (Franchignoni 2004²⁶), provided evidence of concurrent validity of the the LCI and LCI-5 with strong correlations with the Rivermead Mobility Index (RMI) (r = 0.735) and FIM (r=0.612). Convergent validity was found as the LCI had large correlations with RMI (r = 0.735) and FIM (0.612). Convergent validity among the LCI and LCI-5 was also found to be large (r = 0.994). The LCI was found to have known group validity by differentiating participants by age (r = -0.554) and by amputation level (transfemoral vs. transtibial, P<0.001). The LCI was found to have predictive validity for the RMI (r = 0.752), the TWT (r = -0.667), the FIM instrument (0.617), LCI (0.765), and LCI-5 (0.622).

LCI-5

In Franchignoni 2004,²⁶ correlations between the LCI and LCI-5 were (r=0.994) The LCI-5 was correlated with the RMI (r = 0.757), the TWT (r = -0.708), the FIM instrument (0.622). The LCI-5 was found to be responsive to change after training with an effect size of 1.40, which was larger than the ES for the LCI. Excellent reliability among a subgroup of 37 participants was found for the LCI-5 (ICC 0.984). Construct validity for the LCI-5 was supported with differences in scores by age and amputation level.

Timed Up and Go

The TUG test measures the amount of time it takes an amputee to get up from an armless chair.

In Dite 2007,²⁰ 40 people, two-thirds with dysvascular conditions (mean age 61.6 years), were evaluated first at discharge from inpatient rehabilitation. At discharge from inpatient rehabilitation in 40 persons with dysvascular lower limb amputation the TUG test differed between persons with dysvascular amputation who had multiple falls at 6 months and those who did not, with 85 percent sensitivity and 74 percent specificity.

See section, below, Key Questions 1 to 3 Summary for overall summary.

Instrument: Subscale	Studies, n	Studies	Total N	Bi	Uni	TF	Kn	TT	TM	Trau	Vasc	CA	Other	NR	Age†
180 Degree Turn Test	1	Dite 2007	40	0	40	0	0	40	0	0	0	0	26	14	61.6 (nd)
2MWT †	1	Brooks 2001 ²¹	69 (290*)	51	239	60	0	179	0	0	194	0	0	96	66.3 (21-
			. ,												94)
ABC †	1	Wong 2016 ²³	40	5	35	13	0	24	0	0	0	0	0	40	57 (nd)
Barthel Index †	1	Eijk 2012 ²²	48	0	48	17	5	23	0	1	45	1	1	0	75.2 (nd)
BBS †: Item 9—Retrieve object from floor,	1	Wong 2016 ²³	40	5	35	13	0	24	0	0	0	0	0	40	57 (nd)
Item 10—Look behind/over shoulder															
CAPE	1	Hanspal 1997 ²⁴	32	nd	nd	17	0	15	0	0	0	0	0	32	66.4 (54-
															72)
FSST	1	Dite 2007	40	0	40	0	0	40	0	0	0	0	26	14	61.6 (nd)
FIM †	1	Leung 1996 ²⁵	33	1	32	8	0	24	0	0	0	0	0	33	nd
Houghton Scale †	1	Wong 2016 ²³	40	5	35	13	0	24	0	0	0	0	0	40	57 (nd)
LCI †	2	Dite 2007, ²⁰	90	0	90	30	0	60	0	29	42	0	5	14	51 (38-62),
		Franchignoni 2004 ²⁶													61.6 (nd)
TUG †	1	Dite 2007	40	0	40	0	0	40	0	0	0	0	26	14	61.6 (nd)

Table 2.1. Prediction Tools: Studies, and Participant Characteristics

* Total study included 290 participants, for whom amputation details are provided; however, 2MWT evaluated at followup in only 69. † Also evaluated for Key Question 3.

Abbreviations: 2MWT = 2 minute walk test, ABC = Activities-specific Balance Confidence, BBS = Berg Balance Scale, Bi = bilateral amputation, CA = cancer etiology, CAPE = Clifton Assessment Procedures for the Elderly, CAS = Cognitive Assessment Scale, FIM = Functional Independence Measure, FSST = Four Square Step Test, Kn = through the knee amputation, LCI = Locomotor Capabilities Index, NA = not applicable (no subscale), nd = no data reported, NR = etiology not reported, Other = other etiology, TF = transfemoral amputation, TM = transmetatarsal amputation, Trau = trauma etiology, TT = transfemoral amputation, TUG = Timed Up and Go, Uni = unilateral amputation, Vasc = dysvascular etiology.

Instrument	Subscale	Reliability	Overall Valid?	Content Validity	Criterion Validity	Convergent Validity	Divergent Validity	Predictive Validity	Construct Validity	Structural Validity	MDC	MID	Responsive- ness	Floor Effect	Ceiling Effect
180 Degree Turn Test		nr	Yes (weak)	nr	nr	nr	nr	Yes: Sn 31- 100%, Sp 78- 85%	Yes: P<0.001	nr	nr	nr	nr	nr	nr
2MWT*		nr	Yes	nr	nr	Yes: Pearson r -0.289 to 0.493	nr	Yes: Pearson r 0.568	Yes: P<0.001	nr	nr	nr	nr	nr	nr
ABC*		nr	Yes	nr	nr	nr	nr	Yes: AUC 0.927	nr	nr	nr	nr	nr	nr	nr
Barthel Index*		nr	Yes	nr	nr	nr	nr	Yes: Beta = 0.53, R ² = 56.6, P <0.001	nr	nr	nr	nr	nr	nr	nr
BBS*	Item 9: retrieve object from floor	nr	Yes	nr	nr	nr	nr	Yes: AUC 0.771	nr	nr	nr	nr	nr	nr	nr
	Item 10: look behind/over shoulder	nr	Yes	nr	nr	nr	nr	Yes: AUC 0.875	nr	nr	nr	nr	nr	nr	nr
CAPE		nr	Yes	nr	nr	nr	nr	Yes: Pearson r 0.93	nr	nr	nr	nr	nr	nr	nr
	CAS	nr	Yes	nr	nr	nr	nr	Yes: Pearson r 0.81	nr	nr	nr	nr	nr	nr	nr
FSST		nr	Yes	nr	nr	nr	nr	Yes: Sn 92%, Sp 93%	Yes	nr	nr	nr	nr	nr	nr
FIM*	Admission motor subscore	nr	No	nr	nr	nr	nr	No: Spearman r 0.18	nr	nr	nr	nr	nr	nr	nr
	Discharge motor subscore	nr	Yes	nr	nr	nr	nr	Yes: Spearman r 0.58	nr	nr	nr	nr	nr	nr	nr
Houghton scale*		nr	Yes	nr	nr	nr	nr	Yes: AUC 0.885	nr	nr	nr	nr	nr	nr	nr
LCI*		Yes: ICC 0.984	Yes	nr	nr	Yes: Spearman r 0.612 to 0.994	nr	Yes: Spearman r - 0.667 to 0.765	Yes: P<0.001	nr	nr	nr	Yes: ES 1.09	nr	Yes: 46%
LCI-5*		Yes: ICC 0.984	Yes	nr	nr	Yes: Spearman r 0.618 to 0.746	nr	Yes: Spearman r - 0.708 to 0.788	Yes: P<0.001	nr	nr	nr	Yes: ES 1.40	nr	nr
TUG*		nr	Yes	nr	nr	nr	nr	Yes: Sn 85%, Sn 74%	Yes	nr	nr	nr	nr	nr	nr

Table 2.2. Prediction Tools: Reliability, Validity, and Other Characteristics

Abbreviations: 2MWT = 2 minute walk test, ABC = Activities-specific Balance Confidence scale, AUC = area under the curve, BBS = Berg Balance Scale, FIM = Functional Independence Measure, LCI = Locomotor Capabilities Index, nr = not reported (no data), MDC = minimal detectable change, MIC = minimal (clinical) important difference, Sn = sensitivity, Sp = specificity.

* Also evaluated for Key Question 3.

Key Question 3

What **functional outcome measurement tools** used to assess adults who use a LLP have been evaluated in the published literature?

Summary of Studies and Participant Characteristics

Fifty-three tools have been evaluated as outcome measures in people with lower limb amputations and LLPs (Tables 3.1 and 3.2). Some of these have also been evaluated under Key Questions 1 and 2. More detailed study level data are in Appendix C.

The evaluated functional outcome measurement tools were:

- 2 minute walk test (2MWT)
- 6 minute walk test (6MWT)
- Amputees Activity Survey (AAS)
- Activities-Specific Balance Confidence (ABC) scale
- Amputee Body Image Scale (ABIS)
- Amputee Body Image Scale-Revised (ABIS-R)
- Amputee Mobility Predictor (AMP)
- Amputee Single Item Mobility Measure (AMPSIMM)
- Assessment of Daily Activity Performance in Transfemoral Amputees (ADAPT)
- Assessment of Quality of Life (AQoL)
- Barthel Index
- Berg Balance Scale (BBS)
- Body Image Questionnaire (BIQ)
- Climbing Stairs Questionnaire
- Frenchay Activities Index (FAI)
- Functional Independence Measure (FIM)
- Harold Wood/Stamore Mobility Grade
- Hospital Anxiety and Depression Scale (HADS)
- Houghton scale
- Impact of Events Scale (IES)
- International Physical Activity Questionnaire (IPAQ)
- Locomotor Capabilities Index (LCI)
- L Test of Functional Mobility
- Office of Population Censuses and Surveys Scale (OPCS)
- Orthotics and Prosthetics Users' Survey (OPUS)
- Patient Generated Index (PGI)
- Patient-Reported Outcomes Measurement Information System 29-item profile (PROMIS-29)
- Patient-Specific Functional Scale (PSFS)
- Physical Function Index (PFI)
- Prosthesis Evaluation Questionnaire (PEQ)
- Prosthetic Limb Users Survey of Mobility (PLUS-M)

- Quality of Life in Neurological Conditions Applied Cognition/General Concerns (NQ-ACGC)
- Questionnaire for Persons with a Transfemoral Amputation (Q-TFA)
- Rising and Sitting Down Questionnaire
- Roland Morris Disability Questionnaire (RMDQ)
- Rivermead Mobility Index (RMI)
- Russek's Code
- Satisfaction with Prosthesis (SAT-PRO)
- Short Form Health Surveys (SF-12, SF-36, SF-36V)
- Sickness Impact Profile (SIP)
- Six-Item Brief Social Support Questionnaire (SSQN6)
- Socket Comfort Score (SCS)
- Special Interest Group of Amputation Medicine/Dutch Working Group on Amputations and Prosthetics (SIGAM/WAP)
- Six-Item Brief Social Support Questionnaire (SSQN6)
- Step Activity Monitors
- Trinity Amputation and Prosthesis Experience Scale (TAPES)
- Trait Meta Mood Scale (TMMS)
- Timed Up and Go (TUG) test
- Walking Speed, 10 meters
- Walking Speed, 15.2 meters (50 feet)
- Walking Questionnaire
- World Health Organization Disability Assessment Schedule 2.0 (WHODAS2)
- World Health Organization Quality-of-Life Scale (WHOQOL-BREF)

Outcome Measures

2 Minute Walk Test

The 2MWT is a test used to measure the functional ability of amputees by measuring the distance they walk in 2 minutes.

Nine studies evaluated the 2MWT.^{21, 27-34} Participants mostly had unilateral, transtibial amputations due vascular disease, with a wide age range. The 2MWT displayed reliability, convergent validity, and construct validity. Additionally, the 2MWT demonstrated an MDC 90 of 112.5.

6 Minute Walk Test

The 6MWT is a test used to measure the functional ability of amputees by measuring the distance they can walk in 6 minutes.

Three studies evaluated the 6MWT.^{13, 34, 35} Participants mostly had unilateral amputations, about one-third transfemoral and about one-half transtibial. Only about 10 percent had vascular etiologies for their amputations, with a wide age range. The 6MWT displayed both convergent and construct validity. Additionally, the 2MWT demonstrated an MDC 90 of 147.5.

Amputee Activities Survey

The AAS is a 20-item questionnaire that allows amputee subjects to describe their average daily activity level.

In two studies of mostly people with unilateral transfemoral or transtibial amputations, 17 percent due to vascular conditions,^{13, 36} the survey was assessed to determine if it showed differences among amputees with different K levels. The AAS was shown to have construct validity and concurrent validity.³⁶ Preliminary evidence of responsiveness was presented, with statistically significant differences observed, however no responsiveness statistics were provided.

Activities-Specific Balance Confidence

The ABC scale assesses self-reported balance confidence.

In nine studies with over 2000 participants with mostly unilateral transfemoral or transtibial amputations were evaluated. About had dysvascular conditions, with a wide age range. The ABC displayed reliability, construct validity, and content validity. ABC scores were significantly worse for patients who did not achieve community ambulation as measured by the Houghton scale.³⁷ Additionally, the ABC demonstrated an MDC 90 of 0.49 and a MDC 95 of 0.58.³⁸ Floor and ceiling effects were not found.

Amputee Body Image Scale

The ABIS is a 20-item scale that uses a 5 level rating scale to assess ampute perception and feeling of bodily experience.

In a sample of 145 participants with lower limb amputation, of whom about had dysvascular etiologies,³⁹ the ABIS displayed internal consistency reliability and moderate correlations with several TAPES subscales. However the ABIS did not fit a Rasch model well, and six items were deleted to produce the revised ABIS (ABIS-R).

Amputee Body Image Scale-Revised

The ABIS-R measure is an adaptation of the ABIS that includes 14 items and 3-level rating scale.

Two studies evaluated ABIS-R, about half of whom had dysvascular disease and who had a wide age range.^{39, 40} In the study that developed ABIS-R after evaluating ABIS,³⁹ Rasch analysis from data from 145 persons lower limb amputee prosthesis users demonstrated demonstrated good reliability and internal consistency. Additionally, in both studies the ABIS-R was moderately correlated with several related TAPES subscales and the Depression subscale of the ABIS-R displayed reliability and moderate convergent validity.

Amputee Mobility Predictor

The AMP measures functional capabilities of an amputee both with a prosthesis (AMPPRO) and without (AMPnoPRO).

In a study of 160 lower limb amputees, with mostly amputation etiologies other than dysvascular conditions, the AMPnoPRO and the AMPPRO were found to have reliability, convergent validity, and construct validity.¹³ In another study of mostly older adults (mean age 66 years) with unreported amputation etiologies, the AMP Total was found to have reliability and had an MDC 90 of 3.4.³⁴

Amputee Single Item Mobility Measure

The AMPSIMM is a single-item self-reported mobility measure wherein amputees select one statement about their level of mobility from 6 potential responses.

The AMPSIMM, tested in a sample of 113 lower limb amputees, most with dysvascular conditions, was demonstrated concurrent validity with measures such as the LCI-5 and TAPES functional restriction score, and hours of prosthesis use.⁴¹ AMPSIMM scores were significantly different by amputation level. Responsiveness was demonstrated by large changes in scores from 6 weeks to 12 months post amputation. No significant floor or ceiling effects were observed.

Assessment of Daily Activity Performance in Transfemoral Amputees

The ADAPT test measures the functional ability of transfemoral amputees in regard to daily activities.

In a small study of 20 mostly younger unilateral transfemoral amputees, six of whom had dysvascular disease, the ADAPT test was found to have reliability.⁴²

Assessment of Quality of Life

The AQoL consists of 15 questions covering five domains of health-related quality of life: illness, independent living, social relationships, physical senses, and psychologic wellbeing.

One study (Miller 2008) evaluated the instrument in 58 adults with unilateral transfemoral or transtibial amputations, half with dysvascular conditions.⁴³ The test was found to be associated with a measures of arm muscle area (a nutritional assessment) by regression analyses only (Table 1.2). Thus, there is weak evidence of validity of the AQoL as an assessment technique among unilateral lower limb amputees. Other measures of validity, along with reliability and other aspects have not been assessed.

Barthel Index

The Barthel Index measures independence in activities of daily living.

In a sample of 45 patients with unilateral transfemoral amputation for vascular disease and also with hemiparesis. Barthel index change scores during inpatient rehabilitation were greater for persons with mild versus moderate hemiparesis, providing evidence of construct validity. The Barthel Index was found to have mixed construct validity.⁴⁴ Note, though, as described under Key Question 1, a study reported evidence of predictive validity for the Barthel index.²²

Berg Balance Scale

The BBS is a 14-item performance measure designed to assess balance.

Three studies of mostly unilateral amputees, about half of whom had dysvascular conditions, with a wide range of ages, evaluated BBS.^{29, 30, 37} The BBS displayed strong interrater reliability and internal consistency, convergent validity with measures of related constructs, and construct validity (distinguishing between scores of mobility aid users, and those afraid of falling). BBS scores were significantly different for amputees who did and did not achieve community ambulation as measured by the Houghton scale. No floor or ceiling effects were demonstrated.

Body Image Questionnaire

The BIQ was derived from a Body Shape Questionairre for Eating Disorders to assess body image dissatisfaction.

In a study of 107 participants with a mix of amputations, 40 percent of which were due to dysvascular conditions, internal consistency was reported with alpha=0.90.⁴⁵

Climbing Stairs Questionnaire

The Climbing Stairs Questionnaire consists of 15 items with dichotomous response options that assess perceived limitations in walking and climbing stairs among those with lower limb amputations who live at home.

Across four studies of mostly unilateral transtibial or transfemoral amputees from dysvascular conditions, with a wide age range,⁴⁶⁻⁴⁹ the Climbing Stairs Questionnaire demonstrated reliability and convergent validity. Construct validity for the Climbing Stairs Questionnaire was largely supported.

Frenchay Activities Index FAI-15

The FAI-15 is a 15-item self-report measure that assesses frequency of participation in domestic chores, work/leisure and outdoor activities.

Two studies evaluated FAI-15 in participants with transtibial or transfemoral amputations, about half of who had dysvascular conditions, with a wide age range.^{31, 50} The FAI-15 displayed acceptable internal consistency and test-retest reliability and convergent validity with related measures. There was some evidence to indicate construct validity with group differences observed by etiology of amputation, mobility device use, age and years as an amputee, but no differences in scores between BK and AK amputees as hypothesized.

FAI-18

The FAI-18 is a modified version on the FAI-15 which includes three additional items to improve the utility of the measure in younger age groups with traumatic etiologies.

One study of mostly younger amputees (<55 years), with mostly traumatic amputations (60%) found that the FAI-18 displayed reliability and convergent validity, and structural validity.³¹ There was some evidence to support hypotheses related to construct validity, however there were no differences in scores between transfemoral and transtibial subgroups, as hypothesized.

Functional Independence Measure, Amputation Function Subscore

The FIM is an 18-item observational measure that assesses function in terms of need for assistance and level of independence. It addresses six life areas: self-care, sphincter control, mobility, locomotion, communication and social cognition. It can be scored overall, or using the 13-item motor score or 5-item cognitive score.

Three studies of mostly younger amputees, only 25 percent of whom were reported to have dysvascular conditions evaluated FIM.^{25, 36, 51} Concurrent validity of the FIM is supported through correlations with related measures. Preliminary evidence of responsiveness was demonstrated through changes observed between admission to and discharge from inpatient rehabilitation facilities, but no responsiveness statistics were reported.

Overall Score

The subscore displayed responsiveness but did not display reliability, convergent, or construct validity. The overall score did not demonstrate either a floor or ceiling effect.

FIM Amputation Function Subscore

An amputation subscore is composed of three mobility items: transferring, walking on level surfaces, climbing stairs.

In one study of 107 generally young adults (mean age 35 years) for whom amputation etiology was not reported, internal consistency of the FIM Amputation Function Subscore was not acceptable (alpha=0.55).⁵¹ Concurrent validity was demonstrated with the SIP-PD, LCI, and PFI and reported standardized response means and effect sizes for changes in scores from 3 to 12 months, and 12 to 24 months after amputation, providing evidence of individual items and the combined items that supported responsiveness of the FIM Amputation Function Subscore.

Chair Transfer

The subscore displayed reliability and responsiveness but did not display convergent or construct validity. The subscore did not demonstrate a floor effect but did demonstrate a ceiling.

Climb Stairs

The subscore displayed reliability and responsiveness but did not display convergent or construct validity. The subscore did not demonstrate either a floor or ceiling effect.

Walk on a Level Surface

The subscore displayed reliability and responsiveness but did not display convergent or construct validity. The subscore did not demonstrate either a floor or ceiling effect.

Harold Wood/Stanmore Mobility Grades

The Harold Wood/Stanmore Mobility Grades measure achieved prosthetic mobility. In three studies whose populations were incompletely described, but with a wide range of ages, evidence to support convergent validity was not found.^{45, 54, 55} Although mobility scores for working and not-working amputees were significantly different., these data were not considered as evidence supporting construct validity.

Hospital Anxiety and Depression Scales

The HADS measures symptoms of Anxiety and Depression on 7-item subscales each of their respective symptomologies.

A study of 38 people, mostly with unilateral transtibial amputations, all related to diabetes (mean age 66 years), found evidence of convergent validity for both the Anxiety and Depression subscores.⁴⁰

Houghton Scale

The 4-question self-reported Houghton Scale reflects a person's perceptions of daily prosthesis use and function in various walking conditions.

Across four studies,^{28, 37, 56-58} of generally older adults, about half of whom had dysvascular conditions, the Houghton scale displayed reliability, criterion validity, convergent

validity, construct validity, and responsiveness with reported effect sizes of 0.29 to 1.62. There was no evidence of either a floor or a ceiling effect.

Impact of Event Scale

The IES is a self-report measure that can be used to assess impact of any specific life event.

One study evaluated two of the scale's categories: Intrusion and Avoidance. The study included mostly younger adults with non-dysvascular amputation etiologies.⁵³ The Avoidance subscale and the Intrusion subscale were found to have convergent validity with moderate to large correlations with TAPES, as hypothesized by the study authors. No evidence supporting reliability, other aspects of validity or responsiveness was found.

International Physical Activity Questionnaire

The IPAQ is a 25 item self-report measure that evaluates physical activity within four categories: Leisure time, Domestic and gardening (yard), Work-related, and Transport-related.

In a study of 22 lower limb amputees with mostly traumatic causes, the IPAQ was found to have poor to adequate internal consistency (alpha=0.53-0.53).⁵⁹ No evaluation of validity was reported.

Locomotor Capabilities Index

The LCI assesses an individual's perceived independence in performing 14 activities while wearing a prosthesis. The LCI is one of the scales of originally developed as part of the Prosthetic Profile of the Amputee (PPA). The entire LCI may be summed to provide a single score, or two 7-item subscales of the LCI can be calculated: basic items and advanced items. The original version used a 4-point ordinal scale; hence it is often called the LCI-4. The LCI-5 was designed to reduce potential ceiling effects of the LCI, by employing a 5-level response scale instead of a 4-level scale.

In addition to the two studies that were deemed to have evaluated LCI (or LCI-5) as prediction tools, 13 studies more generally evaluated LCI (or LCI-5). Among 1447 total participants, about 40 percent had dysvascular etiologies and the median study had a mean age of 59 years.^{20, 36, 44, 47, 51, 52, 57, 60-65}

Overall Score

The subscore displayed evidence of reliability, convergent validity, and divergent validity. The LCI-4 demonstrated a strong floor effect., with more than half of the sample in one large study, scoring the highest possible score. There was no evidence of construct validity or a ceiling effect.

Advanced

The subscore displayed reliability, convergent validity, and floor effects. There was no evidence of construct, validity or ceiling effects.

Basic

The subscore displayed evidence of reliability and a floor effect. There was some evidence of convergent validity and no evidence of construct validity or a ceiling.

L Test of Functional Mobility

The L Test is a modified version of the Timed Up & Go (TUG) test where the time it takes an individual to rise from an armless chair, walk 3 meters, perform a right-angle turn, and continue walking 7 meters before turning around 180° and walking back along the same path and sitting down is recorded in seconds.

In two studies with 126 lower limb amputees,^{66, 67} one-third with dysvascular disease (mean age about 57 years), the L Test was moderately to strongly correlated to related measures including the TUG, the 2MWT, the 10 meter walk, BBS and other performance measures, as hypothesized. However, the correlation between the PEQ mobility subscale and the L Test was small. L test scores differed for clinically different groups as hypothesized. An MCID of 4.5 seconds was reported with AUC of 0.67 for discriminating between persons who had and had not undergone a minimally clinically important change. Inter- and intrarater reliability were reported to be excellent.

Office of Population Censuses and Surveys Scale

The OPCS assesses disability and impairment in the community.

One study of 34 mostly unilateral transtibial and transfemoral amputees, with a mean age of 57 years, but for whom amputation etiology was not reported,³⁶ found convergent validity for the OPCS with statistically significant associations between the OPCS and related measures; although no correlation coefficients were provided. Preliminary evidence of responsiveness was presented, with statistically significant differences observed between admission and discharge to inpatient rehabilitation, however no responsiveness statistics were provided.

Orthotics and Prosthetics Users' Survey

The OPUS is a self-report survey that contains separate subscales that assess measures Lower-limb function, Health-related quality of life, and Satisfaction with an orthotic or prosthetic device specifically for individuals who use orthotic or prosthetic devices.

In a study of mostly older adults (mean age 66 years) with unreported amputation etiologies,³⁴ the subscales had variable test-retest reliability: for Lower Limb Function the ICC was 0.67 (adequate reliability), for Quality of Life the ICC was 0.85 (excellent reliability), and for Satisfaaction the ICC was 0.50 (poor reliability). MDC values were reported and no floor or ceiling effects were reported.

Patient Generated Index

Patient-centered quality of life is assessed through the PGI, in which patients are asked to list important areas of their life that have been impacted by their condition, and then rate those areas, and the importance of those areas to them.

In a study of 42 people with unilateral transfemoral amputations, almost all due to dysvascular conditions,⁶⁸ the PGI was found to have poor reliability and weak convergent validity with the SF-12 PCS and moderate correlation with the SF-12 MCS.

Patient-Reported Outcomes Measurement Information System

PROMIS-29 is a compilation of self-report instruments that measure eight symptom and quality of life constructs across patient populations: physical function, anxiety, depression, fatigue, sleep disturbance, social role satisfaction, pain interference, and pain intensity.
Two studies evaluated PROMIS-29, with over 1000 unilateral transtibial and transfemoral amputees, about half with dysvascular etiologies.^{69, 70} Evidence for reliability of all subscales in the lower limb amputee population was demonstrated. MDCs for subscales were reported. The depression, physical function, and pain intensity subscales displayed construct validity. The remaining subscales showed some evidence of construct validity. The anxiety, depression, and pain interference subscales displayed a floor while only the social role satisfaction subscale displayed a ceiling.

Patient-Specific Functional Scale

The PSFS is an individualized assessment of patient-specific activities, which they find difficult to perform due to their amputation and how they would rate their current abilities to complete those activities.

In a study of mostly older adults (mean age 66 years) with unreported amputation etiologies,³⁴ the PSFS was assessed for reliability and responsiveness per item as well as by a total score. Items 1-5 demonstrated good reliability, and the total score was found to have excellent reliability. The MDC 90 for the items and the total scores ranged from 3.1 (Items 3 and 5) to 11 (Total). No data on convergent validity, construct validity or responsiveness was identified.

Physical Function Index

The PFI is a generic measure consisting of 14 self-report items related to ability to perform various physical tasks.

In a study of 107 generally young (mean age 35 years) unilateral amputees whose etiologies were not reported,⁵¹ overall PFI internal consistency was greataer than 0.70, no floor or ceiling effects were observed for the overall score. Evidence for PFI reliability, convergent validity, and responsiveness has been reported. Data have been reported for five individual PFI items as follows:

Overall Score

This item displaced reliability, convergent validity, and responsiveness. There was no evidence of construct validity, a floor, or a ceiling.

Climb Stairs

This item displaced reliability, convergent validity, responsiveness, a floor, and a ceiling. There was no evidence of construct validity.

Run at Steady Pace

This item displaced reliability, convergent validity, responsiveness, and a ceiling. There was no evidence of construct validity or a floor.

Squat to Pick Up Object

This item displaced reliability, convergent validity, responsiveness, and a ceiling. There was no evidence of construct validity or a floor.

Walk at Steady Pace

This item displaced reliability, convergent validity, responsiveness, a floor, and a ceiling. There was no evidence of construct validity.

Prosthesis Evaluation Questionnaire

The original PEQ is a questionnaire designed to evaluate prothesis function and prosthesis-related quality of life in individuals with lower limb loss. It consists of 82 items and uses a linear analog scale response format. Nine scales are computed from 42 items (ambulation, appearance, frustration, perceived response, residual limb health, social burden, sounds, utility, well being). The 40 remaining items pertain to other evaluation areas and are not grouped into scales. However, several investigators have combined the ambulation scale with transfer items to create a mobility subscale. Several investigators have modified the response format of several PEQ scales and used Likert scales of various lengths.

Overall, eight studies have evaluated PEQ and its variations in people with lower limb amputations.^{34, 57, 58, 70-73} These included about 2000 people with mostly unilateral transtibial amputations, over one-third related to dysvascular conditions. Most studies had mean ages in the 60s. The original validation paper reported that all scales except transfers, had acceptable internal consistency.⁷² All scales (both visual analog and Likert 7-response formats), except perceived responses had adequate test-retest reliability.^{34, 72}

Mobility Scale: Original Visual Analog Scale, 7-point Likert Scale, and 10-Point Likert Scale Versions

Evidence of reliability and convergent validity of the mobility subscale (both the 12 item and 13 item versions) was provided in several papers. The mobility subscale displayed evidence of concurrent validity, and MDC has been reported. Neither the original nor the Likert-7 mobility subscale showed evidence of a floor or a ceiling.

Mobility Scale- 12/5 Version

Rasch analysis of the PEQ mobility scale resulted in recommendations to delete one item and change the response scale. This new version of the scale, the PEQ-MS 12/5, demonstrated excellent internal consistency, construct and convergent validity.

Perceived Response Visual Analog Scale and Modified by 7-Point Likert Scale

ICC for test retest reliability was poor for both the original (visual analog) and Likert 7 versions (ICC = 0.41-0.56).

Residual Limb Health Visual Analog Scale and Modified by 7-Point Likert Scale

ICC for test retest reliability was acceptable for both the original (visual analog) and Likert 7 versions (ICC = 0.79-0.80).

Social Burden Visual Analog Scale and Modified by 7-Point Likert Scale

ICC for test retest reliability was acceptable for both the original (visual analog) and Likert 7 versions (ICC = 0.64-0.81).

Sounds Visual Analog Scale and Modified by 7-Point Likert Scale

ICC for test retest reliability was acceptable for both the original (visual analog) and Likert 7 versions (ICC = 0.79-0.84).

Transfer 7-Point Likert Scale

This is a 5-item scale assessing difficulty in performing various transfer tasks. ICC for test retest reliability was acceptable for both the original (visual analog) and Likert 7 versions (0.73-0.75). One study used the transfer items to create a transfer scale, but found a strong ceiling effect.

Utility Visual Analog Scale and Modified by 7-Point Likert Scale

ICC for test retest reliability was acceptable for both the original (visual analog) and Likert 7 versions (ICC = 0.79).

Well-Being Visual Analog Scale and Modified by 7-Point Likert Scale

ICC for test retest reliability was acceptable for both the original (visual analog) and Likert 7 versions (ICC = 0.70-0.87). A strong ceiling effect was observed in the Likert version of this scale.

Prosthetic Limb Users Survey of Mobility

The PLUS-M is a 44-item self-report measure that assesses perceived mobility in people with lower limb amputation.

Four studies with more than 1700 amputees have included both unilateral and bilateral amputees with mostly transtibial and transfemoral amputations,^{38, 70, 74, 75} about 40 percent due to dysvascular conditions. Significant differences in PLUS-M scores were reported by Medicare Functional Classification level. Several fixed, short form versions and a computer adaptive test (CAT) version of the PLUS-M have been developed.

12-Item Short Form

The subscale displayed reliability, a MDC 90 of 4.50, and a MDC 95 of 5.36. No floor or ceiling effects were found.

7-Item Short Form

The subscale displayed reliability, a MDC 90 of 4.69, and a MDC 95 of 5.59. No floor or ceiling effects were found.

Computerized Adaptive Test

The CAT displayed reliability, a MDC 90 of 6.42, and a MDC 95 of 7.65. No floor or ceiling effects were found.

Quality of Life in Neurological Conditions – Applied Cognition/General Concerns

The NQ-ACGC short form of a larger item bank consists of 8 items that measure general cognitive abilities, including memory, attention, and decision-making.

In two studies of over 1200 unilateral amputees, about 40 percent of whom had dysvascular conditions,^{70, 76} the NQ-ACGC short form displayed reliability and construct

validity. The NC-ACGC demonstrated a MDC 90 of 6.67 and a MDC 95 of 7.94. A ceiling effect was observed.

Questionnaire for Persons With a Transfemoral Amputation

The Q-TFA measures use, mobility, problems, and global health, both as separate scores and as a total score, for nonelderly transfemoral amputees.

In a study of 156 unilateral transfemoral amputees, mostly related to trauma,⁷⁷ the Q-TFA was found to have excellent reliability for all subscales and the Global score. Content validity was demonstrated in the Prosthetic Mobility subscale. Each of the subscales demonstrated concurrent validity. The prosthetic use subscale had a ceiling effect, with 31 percent of participants with the highest score. Other subscales did not have floor or ceiling effects.

Rising and Sitting Down Questionnaire

The Rising and Sitting Down Questionnaire is a 39 item self-report measure assessing limitations in the activities of rising and sitting down, using a dichotomous response format.

In three studies with almost 400 mostly unilateral amputees with dysvascular etiologies,⁴⁷⁻⁴⁹ the Rising and Sitting Down Questionnaire was found to have good reliability. Convergent validity of the Questionnaire was demonstrated. Construct validity was largely supported, however there were no differences between scores of bilateral versus unilateral amputees as hypothesized.

Roland Morris Disability Questionnaire

The RMDQ is a measure of functional capacity.

In a single study of 46 amputees, none with dysvascular conditions and mostly younger (mean age 48 years), convergent validity was found for the RMDQ.⁷⁸

Rivermead Mobility Index

The RMI assesses mobility as a cumulative index.

In two studies of 340 lower limb amputees, about one-third with dysvascular conditions, with a wide range of ages, reliability of the RMI was found to be excellent.^{79, 80} Evidence for convergent validity was also found. There was also evidence of responsiveness, but no ceiling effect.

Russek's Code

Russek's Code is a classification index developed for lower limb amputations and used to assess functional abilities with a prosthesis.

A single study of 772 lower limb amputees with undescribed age and amputation etiology evaluated Russek's Code.⁶⁵ Weak evidence for construct validity was found.

Satisfaction with Prosthesis

The SAT-PRO questionnaire is 15 item self-report tool measuring satisfaction with a prosthesis.

One study of 55 unilateral transfemoral and transtibial amputees, all due to dysvascular dysfunction and all at least 60 years old evaluated the SAT-PRO.⁸¹ It displayed reliability and construct validity.

Short Form Health Surveys

The SF-12 and SF-36 are generic measures of health-related QoL designed originally for the general population. The SF-36 can be scored as two summary measures, called the physical component score (PCS) and the mental component score (MCS) and eight subscales (physical functioning, bodily pain, role limitations due to physical health problems [role physical], role limitations due to personal or emotional problems [role emotional], emotional well-being, social functioning, energy/fatigue, and general health perceptions). Among people with LLPs, the SF instruments have been analyzed as a whole and parsed into numerous components subsets (from pairs of specific questions to the whole score). A summary across variations is presented here.

In addition to the evaluation of SF-12 and SF-36 as an assessment technique (Key Question 1) by one study, 16 studies with almost 2500 lower limb amputees evaluated these scales as outcome measures.^{34, 78, 82-95} Only 17 percent of the study participants were reported to have dysvascular conditions and study participants were generally young adults (mean ages generally <50 years). Convergent validity was supported for the General Health subscale of the SF-36. Four subscales did not support construct validity (SF-36 Emotional Problems, SF-36 Emotional Role Limitations, SF-36 Energy/Fatigue, SF-36 Mental Health Composite Scale score [MCS]); all other SF-36 subscales presented mixed evidence for construct validity. Construct validity was found for the SF-12 MCS and SF-12 Physical Health Composite Scale score (PCS). Other metrics of validity were not reported.

The SF-36V is a version of the SF-36 that has been adapted for greater precision in assessing the health status among the veteran population. This adaptation includes minor alterations to the scoring of two sections such that the precision to identify differences at the lower end of the health status continuum may be achieved. The SF-36V was found to be a reliable instrument. For the three component scores presented, MDCs were displayed ranging from 17.1 to 34.2. Other metrics of validity were not reported.

Sickness Impact Profile

The SIP is a generic, self-report measure used to assess the impact of illness on healthrelated functional status. There are 136- and 68-item versions; the longer version has been evaluated among amputees.. The SIP is divided into several subscales, included physical dimension (SIP-PD), ambulation, mobility, body care and movement, among others, and overall score.

Overall, four studies have evaluated the various SIP measures in 290 unilateral amputees, who were generally younger adults (mean age about 44 years) and whose amputation etiologies were not described.^{49, 51, 96, 97}

Overall Score

In a single study with 20 amputees, the SIP-136 overall score demonstrated reliability, convergent validity, divergent validity, and responsiveness.⁹⁶ There was no evidence of construct validity, a floor, or a ceiling.

SIP-PD

Three studies have evaluated the Physical Dimension subscore in amputees.^{51, 96, 97} The three studies differed in whether they found evidence of construct validity regarding whether the SIP-PD score was associated with a wide range of patient and amputation characteristics. However, there is evidence of convergence with LCI and PFI scores and associations with

walking speeds and return to usual activity. Evidence of responsiveness was reported. No floor effect was found.

Ambulation

This subscale demonstrated reliability, convergent validity, and responsiveness. There was no evidence of construct validity, a floor, or a ceiling.

Body Care and Movement

This subscale demonstrated reliability, convergent validity, responsiveness, and a floor. There was no evidence of construct validity or a ceiling.

Mobility

This subscale demonstrated reliability, but a large floor effect (63%). There was no evidence of construct validity or a ceiling. There was some evidence for convergent validity.

Six-Item Brief Social Support Questionnaire

The SSQN6 is a tool to measure perceived social support.

One study of 59 lower limb amputees with dysvascular conditions reported that construct validity was not supported, though the SSQN6 was found to have convergent validity.⁸⁹

Socket Comfort Score

The SCS is a one-item measure of prosthetic socket comfort that is scored from 0-10. Three studies, with 345 mostly unilateral transtibial and transfemoral amputees, about one-third of whom had dysfunctional conditions evaluated the Socket Comfort Score.^{54, 70, 98} Test-retest reliability ICC ranged from 0.63 to 0.79, depending upon mode of administration. MDC values were published. Potential ceiling effects were observed (14% of sample).

Special Interest Group of Amputation Medicine/Dutch Working Group on Amputations and Prosthetics

The SIGAM/WAP scale measures ambulation mobility (with walking aids if necessary) among lower limb amputees.

In two studies of 372 lower limb amputees, at least half of whom had dysvascular conditions, the SIGAM/WAP overall score was found to have adequate reliability.^{48, 99} Convergent validity of the SIGAM/WAP was also supported. Evidence for construct validity was mixed.

Step Activity Monitors

Step Activity Monitors are commercially available walking activity monitors. The evaluated monitors are specifically targeted towards evaluation of amputee gait patterns. Three separate items were assessed in two studies with 74 mostly yonger (mean age 54 years), mostly unilateral lower limb amputees, of whom about one-quarter had dysvascular conditions.^{33, 100} One study evaluated the Patient Activity Monitor (PAM, Ossur, Reykjavik, Iceland).¹⁰⁰ One study evaluated the StepWatch 3 Activity Monitor (Orthocare Innovations, Mountlake Terrace, Washington, U.S.).³³

PAM: Total Step Count

PAM step counts were found to be higher than those quantified by simulatenous 3dimensional motion assessment. The item displayed convergent validity with multiple measures.

PAM: Medium Step Length

PAM step length was strongly correlated with measures of step length measured by motion capture (r = 0.77-0.95).

PAM: Walking Velocity

PAM walking velocity was strongly correlated with velocity determined by motion capture (r = 0.95-0.99).

SAM: Steps Per Day

The SAM measure of steps/day correlated with the 2 MWT (r = 0.78).

Trinity Amputation and Prosthesis Experience Scales

The TAPES is a multidimensional self-report instrument that evaluates the experience of amputation and adjustment to a lower limb prosthesis. The TAPES is divided into multiple subscales to assess various aspects of amputation experience and lower limb prosthesis adjustment. In total, 26 domains and domain-subscales (Activity Restriction, Activity Restriction Item 10, Activity Restriction Item 9, Adjustment to Limitation, Age, Aesthetic Satisfaction, Athletic Activity Restriction, Functional Activity Restriction, Functional Satisfaction, Gender, General Adjustment, Health Rating, Length of Time Living with Prosthesis, Level of Amputation, Other Medical Problems, Phantom Limb Pain, Physical Capabilities, Prosthetic Use, Psychosocial Adjustment, Residual Limb Pain, Satisfaction with the Prosthesis, Satisfaction Items 1-4, Satisfaction Items 5-9, Social Adjustment, Social Restriction, Weight Satisfaction) as well as the TAPES Total Overall Score have been evaluated.

The six studies included almost 1000 mostly unilateral lower limb amputees, of whom about one-third had dysvascular conditions.^{33, 39, 53, 101-103}

Total Overall Score

The TAPES Total Overall Score was only evaluated for and displayed convergent validity. Therefore TAPES regarded as a Total Overall Score demonstrated only weak evidence of validity.

Activity Restriction

This domain displayed reliability, convergent validity, construct validity and structural validity. This domain was found to be valid.

Activity Restriction Item 9

This domain subscale displayed was evaluated for and displayed structural validity. Therefore, this domain subscale demonstrated weak evidence of validity.

Activity Restriction Item 10

This domain subscale displayed was evaluated for and displayed structural validity. Therefore, this domain subscale demonstrated weak evidence of validity.

Adjustment to Limitation

This domain displayed reliability, convergent validity, divergent validity, construct validity and structural validity. This domain was found to be valid.

Age

This domain displayed was evaluated for and displayed convergent validity. Therefore, this domain demonstrated weak evidence of validity.

Athletic Activity Restriction

This domain displayed reliability, convergent validity and structural validity. This domain was found to be valid.

Esthetic Satisfaction

This domain displayed was evaluated for and displayed convergent validity. Therefore, this domain demonstrated weak evidence of validity.

Functional Activity Restriction

This domain displayed reliability, convergent validity, content validity and structural validity. This domain was found to be valid.

Functional Satisfaction

This domain displayed reliability, convergent validity and structural validity. This domain was found to be valid.

Gender

This domain displayed was evaluated for convergent validity. There was no evidence of validity for this domain.

General Adjustment

This domain displayed reliability, convergent validity and structural validity. This domain was found to be valid.

Health Rating

This domain displayed was evaluated for and displayed convergent validity. Therefore, this domain demonstrated weak evidence of validity.

Length of Time Living with Prosthesis

This domain displayed was evaluated for and displayed convergent validity. Therefore, this domain demonstrated weak evidence of validity.

Level of Amputation

This domain displayed was evaluated for and displayed convergent validity. Therefore, this domain demonstrated weak evidence of validity.

Other Medical Problems

This domain displayed was evaluated for and displayed convergent validity. Therefore, this domain demonstrated weak evidence of validity.

Phantom Limb Pain

This domain displayed was evaluated for convergent validity. There was no evidence of validity for this domain.

Physical Capabilities

This domain displayed was evaluated for and displayed convergent validity. Therefore, this domain demonstrated weak evidence of validity.

Prosthetic Use

This domain displayed was evaluated for and displayed convergent validity. Therefore, this domain demonstrated weak evidence of validity.

Psychosocial Adjustment

This domain displayed reliability and structural validity. Therefore, this domain demonstrated weak evidence of validity.

Residual Limb Pain

This domain displayed was evaluated for and displayed convergent validity. Therefore, this domain demonstrated weak evidence of validity.

Satisfaction Items 1 to 4

This domain subscale displayed reliability and structural validity. Therefore, this domain subscale demonstrated weak evidence of validity.

Satisfaction Items 5 to 9

This domain subscale displayed reliability and structural validity. Therefore, this domain subscale demonstrated weak evidence of validity.

Satisfaction With the Prosthesis

This domain displayed reliability and structural validity. Therefore, this domain demonstrated weak evidence of validity.

Social Adjustment

This domain displayed reliability, convergent validity and structural validity. This domain was found to be valid.

Social Restriction

This domain displayed reliability, convergent validity and structural validity. This domain was found to be valid.

Weight Satisfaction

This domain displayed reliability, convergent validity and structural validity. This domain was found to be valid.

Trait Meta Mood Scale

The TMMS is a measure of individual differences in the ability to reflect on and manage one's emotions. Two subdomains of the TMMS were evaluated, the Clarity of Feelings and the Mood Repair domains. Items in the clarity of feelings domain refer to the ability to understand one's mood, while items on the mood repair domain evaluate ability to counteract unpleasant moods or maintain pleasant ones.

One study of 60 mostly younger (mean age 47 years) unilateral lower limb amputees amputees, few of whom had dysvascular conditions, evaluated both TMMS subdomains.⁵³ Both Clarity of Feelings and Repair domains of the TMMS demonstrated evidence of convergent validity, but no other aspect of validity was evaluated. Therefore, there is weak evidence of validity for the TMMS subdomains.

Timed Up and Go

The TUG test measures the amount of time it takes an amputee to get up from an armless chair.

Seven studies have evaluated TUG among 292 lower limb amputees, mostly with unilateral transtibial amputations, at least 40 percent of whom had dysvascular conditions.^{20, 29, 32-34, 60, 104} The TUG displayed reliability, convergent validity, and construct validity. The MDC90 was 3.6.

Walking Speed, 10 Meters

Walking speed is measured on a 10 meter walkway.

In two studies of 163 lower limb amputees, almost half with dysvascular conditions,^{79, 105} 10 meter walking speed displayed reliability with an ICC of 0.83 to 0.98. The test was inversely correlated with the Rivermead Mobility Index (Spearman r = -0.70, P < 0.0001).

Walking Speed, 15.2 Meters

Walking speed is measured on a 15.2 meter (50 foot) walkway.

In one study of 30 participants with diabetes and transmetatarsal amputations,¹⁰⁶ 15.2 meter walking speed was correlated with lower extremity strength.

Walking Questionnaire

The Walking Questionnaire is a self-report measure of activity limitations when walking inside and outside the house.

In three studies of 389 lower limb amputees, mostly with dysvascular conditions (75%),⁴⁷⁻⁴⁹ the questionnaire has demonstrated evidence of reliability, convergent, and construct validity. There were mixed evidence of the questionnaire's convergent validity. Overall, the Walking Questionnaire was found to be reliable and valid.

World Health Organization Disability Assessment Schedule 2.0

The WHODAS 2 is a standardized measure that measures the extent of activity limitation experienced by an individual.

One study of 65 lower limb amputees, without further description,¹⁰⁷ evaluated three of the WHODAS 2 subscales: Getting Around, Participation in Society, and Self Care. Only the construct validity of these scales was evaluated in this study. All three subscales displayed evidence of construct validity. Therefore there was weak evidence that the WHODAS 2 subscales were valid.

World Health Organization Quality-of-Life Scale (WHOQOL-BREF)

The WHOQOL-BREF is an instrument containing 26 items that measure the quality of life of amputees. The instrument has several subscales, such as environment, physical health, psychological, social relationships, and General Health and Overall Quality-of-Life.

These measures have been studied by four studies with 257 lower limb amputees, of whom only about 10 percent had dysvascular conditions.^{53, 59, 103, 108, 109}

Overall QoL and General Health

The overall score was evaluated together with the General Health subscale. It displayed reliability and convergent validity. No other aspect of validity was evaluated. There was no evidence of floor or ceiling effects. In one study the subscales (environment, physical health, psychological, and social relationships) each displayed convergent validity.

Instrument:	Studies,	Studies	Total N	Bi	Uni	TF	Kn	TT	TM	Trau	Vasc	СА	Other	NR	Age
Subscale	n														-
2MWT*	9	Newton 2016 0; Brooks 2002 12422326; Gremeaux 2012 22389424; Resnik 2011 21310896; Brooks 2001 11588757; Major 2013 23856150; Miller 2004 15180125; Devlin 2004; Parker 2010 2010632385	468 (33- 290)	51	417	109	2	306	0	16	352	3	13	84	64.7 (21-94)
6MWT	3	Reid 2015 25588644; Gailey 2002 11994800; Resnik 2011 21310896	297 (44- 167)	3	294	103	12	164	6	102	30	29	92	44	58 (18-100)
AAS	2	Gailey 2002 11994800; Panesar 2001 11330761	201 (34- 167)	2	199	85	7	97	0	61	34	24	82	0	56.9 (18-100)
ABC*	9	Hafner 2016 28273329; Kelly 2016 27756174; Sakakibara 2011 21704978; Miller 2003 12736877 (sample 1 & sample 2); Major 2013 23856150; Miller 2004 15180125; Asano 2008 18569891; Hafner 2017; Wong 2016	2319 (209- 1291)	205	2114	721	0	1341	0	909	1052	28	330	0	58.4 (18-nd))
ABIS	1	Gallagher 2007 17314705	145	17	128	52	3	73	0	37	78	7	23	0	60.5 (nd)
ABIS-R	2	Coffey 2009 19900240, Gallagher 2007 17314705	183 (38- 145)	26	157	56	3	96	0	37	78	7	61	0	63.5 (18-nd)
AMP	2	Gailey 2002 11994800; Resnik 2011	211	6	205	90	9	101	2	61	nd	24	82	44	60 (18-100)
AMPSIMM	1	Norvell 2016 27496697	113	0	113	28	0	59	26	0	81	0	32	0	63.5 (18-nd)
ADAPT	1	Theeven 2010 20809056	20	0	20	20	0	0	0	12	6	2	0	0	50.3 (18-75)
AQoL	1	Miller 2008 43	58	0	58	21	0	37	0	13	29	nd	16	0	66.4 (21-91)
Barthel Index*	1	Brunelli 2006 16813789	45	0	45	45	0	0	0	0	45	0	0	0	69 (38-87)
BBS*	2	Major 2013 23856150; Gremeaux 2012 22389424; Wong, 2016	94 (30-64)	3	91	31	0	60	0	30	49	2	10	3	56.7 (21-87)
BIQ	1	Fisher 1998	107	nd	nd	32	4	64	2	37	43	5	22	0	55.5 (40-88)
Climbing Stairs Questionnaire	4	de Laat 2010, de Laat 2011, de Laat 2012, Yari 2008	561 (46- 172)	36	525	164	24	279	9	45	435	45	41	0	60.4 (18-nd)
Frenchay Activities Index (& Index-18)	2	Miller 2004 15180125; Asano 2008 18569891	499 (84- 415)	0	499	136	0	363	0	50	254	0	195	0	61 (20-nd)
FIM*	3	Cyril 2001; Leung 1996 8831480; Panesar 2001 11330761	269 (34- 107)	5	264	73	12	185	0	nd	57	nd	87	125	43.7 (35-89)
Harold Wood/Stanmore Mobility Grade	2	Fisher 1998, Hanspal 1991	307 (100- 107)	nd	nd	126	4	163	9	102	66	0	39	100	58.4 (17-88)
HADS	1	Coffey 2009 19900240	38	9	29	6	0	23	0	0	38	0	0	0	66.4 (18-nd)
Houghton*	5	Devlin 2004 15295762; Houghton 1992 1393461; Miller 2000 0; Miller 2001 11552197, Wong 2016 26874230, Brooks 2001	793 (76- 435)	160	630	421	6	296	4	91	381	nd	nd	321	60.7 (23-91)
IES (various)	1	Gallagher 2000	60	1	59	20	3	29	2	27	7	13	13	0	47.1 (18-nd)
IPAQ	1	da Silva 2011	22	nd	nd	7	1	13	0	15	2	0	6	0	nd (18-69)

Table 3.1. Outcome Measures: Studies, and Participant Characteristics

Instrument:	Studies,	Studies	Total N	Bi	Uni	TF	Kn	TT	TM	Trau	Vasc	CA	Other	NR	Age
Subscale	n														Ű
LCI* (various)	13	Arwert 2007 17943683, Brunelli 2006 16813789; Callaghan 2002 12227445; Cyril 2001 0; de Laat 2011 0; Dite 2007 0; Franchignoni 2007 18050010; Gauthier-Gagnon 1994 7993169; Miller 2001 11588750 (sample 1); Miller 2001 11588750 (sample 2); Norvell 2011 21531528; Panesar 2001 11330761;	1447 (23- 329)	58	1194	352	47	858	56	205	618	17	209	539	58.8 (18-80)
L-Test	3	Iraballesi 2007 16955063; Ireweek 1998 0 Rushton 2015 25134533; Deathe 2005 15982169, Major 2013 23856150	126 (33-93)	0	33	30	0	96	0	8	44	2	4	68	57 (55.9-60)
OPCS	1	Panesar 2001	34	2	32	17	0	14	0	0	0	0	0	34	67 (44-85)
OPUS (various)	1	Resnik 2011	44	0	44	23	2	19	0	0	0	0	0	44	66 (31-85)
PGI	1	Callaghan 2003 14682557	42	0	42	42	0	0	0	0	38	0	0	4	69 (36-87)
PROMIS-29 (various)	2	Amtmann 2015 25917819; Hafner 2016 28273329	1292 (201- 1091)	0	1292	456	0	836	0	725	533	8	26	0	55.8 (18-nd)
PSFS	1	Resnik 2011	44	0	44	23	2	19	0	0	0	0	0	44	66 (31-85)
PFI (various)	1	Cyril 2001 0	107	0	107	24	12	82	0	0	0	0	0	107	35 (nd)
PEQ (various)	2	Legro 1998 9710165; Resnik 2011 21310896	159 (23-92)	0	159	81	5	65	8	62	23	1	22	44	67.3 (20-85)
PEQ	5	Resnik 2011 21310896; Miller 2000 0 & Miller 2001 11588750 (sample 1); Miller 2000 0 & Miller 2001 11588750 (sample 2); Hafner 2016 28273329; Miller 2001 11552197	1507 (23- 435)	0	1507	424	2	1081	0	121	726	8	409	44	61.4 (31-85)
PEQ Mobility (Likert 5)	1	Franchignoni 2007 17351696	123	14	109	65	0	44	0	69	43	nd	11	0	54 (36-65)
PEQ (Modified)	1	Van de Weg 2005 16466153	220	0	220	0	0	220	0	0	0	0	0	220	62.1 (nd)
PLUS-M (various)	4	Kelly 2016 27756174; Hafner 2017 27590443; Hafner 2016 25944625; Hafner 2016 28273329	1728 (37- 1291)	214	1514	551	1	1128	4	842	753	10	150	4	55 (19.3-88.7)
Quality of Life NQ-ACGC	2	Hafner 2016 28273329; Morgan 2016 26836953	1287 (201- 1086)	0	1287	413	52	822	0	723	530	32	26	2	55.7 (18-88.7)
Q-TFA (various)	1	Hagberg 2004 15558399	156	0	156	156	0	0	0	86	13	48	9	0	51 (20-70)
Rising and Sitting Down Questionnaire	3	de Laat 2011, de Laat 2012, Yari 2008	389 (46- 172)	24	365	109	16	186	6	28	292	42	28	0	60.4 (37-92)
RMDQ	1	Hammarlund 2011 21515895	46	nd	nd	19	9	18	0	33	0	13	0	0	48 (19-78)
RMI	2	Franchignoni 2003 12809197, Ryall 2003 12648004	340 (140- 200)	25	175	161	8	175	7	69	92	34	20	0	54.9 (19-78)
Russek's Code	1	Treweek 1998	772	nd	nd	201	0	571	0	0	0	0	0	772	nd
SAT-PRO	1	Bilodeau 1999 10462879	55	0	55	nd	0	nd	0	0	55	0	0	0	71.3 (60-nd)
SF-12 † (various)	2	Happich 2008, Hoffman 2002 11833020	106 (35-71)	nd	nd	35	nd	nd	nd	0	0	35	71	0	43.3 (34-89)
SF-36 † (various)	14	Aksnes 2008 18539673, Boutoille 2008 18026199, Davidson 2010, Hagberg 2001, Hammarlund 2011 21515895, Pezzin 2000, Sinha 2011 21515894, Smith 1995 7745656, van der Slius 2009, Willrich 2005, Schoppen 2001 11239317, van der Schans 2002, Remes 2010, Resnik 2011	2315 (25- 652)	38	845	777	131	1226	25	1203	393	212	405	98	49.1 (19-85)
3F30V	11	Reshik 2011	44	U	44	23	1 4	19	U	U	U	U	0	44	00(31-85)

Instrument:	Studies,	Studies	Total N	Bi	Uni	TF	Kn	TT	TM	Trau	Vasc	CA	Other	NR	Age
Subscale	n														
SIP (various)	4	Cyril 2001 0; Greive 1996 8876000; Mackenzie 2005 16085622; Yari 2008 19052251	290 (20- 107)	0	173	53	31	164	7	2	6	36	2	244	43.8 (16-nd)
SSQN6	1	Remes 2010	59	nd	nd	nd	nd	nd	nd	0	59	0	0	0	75.2 (nd)
SCS	3	Hafner 2016 28273329; Fisher 2003 12601268; Hanspal 2003 14617445	345 (44- 201)	7	338	129	0	207	0	195	99	16	43	0	57.3 (17-88)
SIGAM/WAP	2	Ryall 2002 12851094, de Laat 2012	372 (172- 200)	25	175	55	8	93	1	32	192	19	69	0	61.1 (18-nd)
Step Activity Monitor (various)	2	Ramstrand 2007 17520493; Parker 2010 2010632385	74 (22-52)	6	68	28	0	46	0	26	20	0	6	22	53.7 (20.1- 88.7)
TAPES (various)	6	Desmond 2008 18569892, Gallagher 2000, Gallagher 2004 15129396, Gallagher 2007 17314705, Gallagher 2010 20489393, Parker 2010 2010632385	951 (63- 498)	46	679	317	26	509	2	318	298	89	195	6	54 (18-nd)
TMMS	1	Gallagher 2000	60	1	59	20	3	29	2	27	7	13	13	0	47.1 (18-nd)
TUG*	7	Schoppen 1999 10414769; Newton 2016 0; Arwert 2007 17943683; Dite 2007 17207685; Gremeaux 2012 22389424; Parker 2010 2010632385; Resnik 2011 21310896	292 (23-37)	6	286	70	2	220	0	42	117	2	7	121	62.4 (18-69)
Walking Speed, 10 meters	2	Boonstra 1993 8233772; Franchignoni 2003 12809197	163 (23- 140)	0	118	87	0	61	0	45	44	17	4	53	30, 57
Walking Speed, 15.2 meters	1	Salsich 1997 9065361	30	0	30	0	0	0	30	0	30	0	0	0	61.7
Walking Questionnaire	3	de Laat 2011, de Laat 2012, Yari 2008	389 (46- 172)	nd	nd	109	16	186	2	28	291	42	28	0	60.4 (18-nd)
WHODAS 2 (various)	1	Gallagher 2011	65	nd	nd	nd	nd	nd	nd	0	0	0	0	65	nd
WHOQOL-BREF (various)	4	da Silva 2011, Deans 2008, Gallagher 2000, Gallagher 2004	257 (22-87)	1	59	78	4	194	2	69	34	27	128	0	60.4 (18-69)

Abbreviations: 180 Degree Turn Test, 2MWT = 2 minute walk test, 6MWT = 6 minute walk test, AAS = Amputees activity survey, ABC = Activities-specific Balance Confidence, ABIS(-R) = Amputee Body Image Scale (revised), ADAPT = Assessment of Daily Activity Performance in Transfemoral amputees, AIMS = Arthritis Impact Measurement Scale, AMP = Amputee Mobility Predictor, AMPSIMM = Amputee Single Item Mobility Measure, AQoL = Assessment of Quality of Life, BBS = Berg Balance Scale, BIQ = Body Image Questionnaire, CAPE = Clifton Assessment Procedures for the Elderly, Census and Surveys, FAI = Frenchay Activities Index, FIM = Functional Independence Measure, HADS = Hospital Anxiety and Depression Scale, IES = Impact of Event Scale, IPAQ = International Physical Activity Questionnaire, L Test = L Test of Functional Mobility, LCI = Locomotor Capabilities Index, MDC = minimal detectable change, MIC = minimal (clinical) important difference, Neuro-QoL ACGC = Neurological Disorders Applied Cognition General Concerns Short Form, NQ- ACGC = Quality of Life in Neurological Conditions – Applied Cognition/General Concerns, OPCS = Office of Population, OPUS = Orthotic Prosthetic User's Survey, PAM = Patient activity monitor, PEQ = Prosthesis Evaluation Questionnaire, PFI = Physical Function Index, PGI = Patient Generated Index, PLUS-M = Prosthetic Limb Users Survey of Mobility, PROMIS - 29 = Patient-Reported Outcomes Measurement Information System 29-item profile, PROS = Prosthetist's Perception of Client's Ambulatory Abilities, PSFS = Patient Specific Functional Scale, Q-TFA = Questionnaire for Persons with a Transfemoral Amputation, QoL = Quality of Life, RMDQ = Roland Morris Disability Questionnaire, RII = Rivermead Mobility Index, SAT-PRO = Satisfaction with Prosthesis, SCS = Socket Comfort Score, SF = Short Form Health Survey, SIGAM = Special Interest Group in Amputee Medicine, SIP = Sickness Impact Profile , SSQN6 = Saranson's 6-item Social Support Questionnaire, TAPES = Trinity Amputation and Prosthesis Experience Scales, T

* Also evaluated for Key Question 2.

† Also evaluated for Key Question 1.

Instrument	Subscale	Reliability	Overall Valid?	Content Validity	Criterion Validity	Convergent Validity	Divergent Validity	Construct Validity	Structural Validity	MDC	MID	Responsive- ness	Floor Effect	Ceiling Effect
2MWT*		Yes: ICC 0.83 to 0.99	Yes	nr	nr	Yes: Pearson r 0.22 to 0.48	nr	Yes	nr	MDC90 112.5	nr	nr	nr	nr
6MWT		Yes: ICC 0.97	Yes	nr	nr	Yes: Pearson r -0.72 to 0.95; R^2 0.79 to 0.89	nr	Yes	nr	MDC90 147.5	nr	nr	nr	nr
AAS		nr	Yes	nr	nr	Yes (p<0.0001)	nr	Yes	nr	nr	nr	Unclear	nr	nr
ABC*		Yes: ICC 0.91-0.95; Cronbach's α 0.93	Yes	Yes	nr	Yes: Pearson r -0.72 to 0.72	nr	Yes	nr	MDC90 0.49: MDC95 0.58	nr	nr	No (<10% implied)	No (<10% implied)
ABIS		Yes: Cronbach's α 0.90; Spearman r 0.30 to 0.74; Kaiser- Meyer- Olkin measure 0.87	No	nr	nr	No	nr	nr	No	nr	nr	nr	nr	nr
ABIS-R	Depression	Yes: Item- separation index 4.59; Item- separation reliability 0.95; Person- separation index 2.33; Person- separation reliability 0.84	Yes	nr	nr	Yes: Spearman r - 0.51 to -0.36	nr	nr	nr	nr	nr	nr	nr	nr
AMP	noPRO	Yes: ICC 0.86 to 0.99	Yes	nr	nr	Yes: Pearson r - 0.433 to 0.818	nr	Yes: Pearson r - 0.378 to 0.263; P=0.001	nr	nr	nr	nr	nr	nr
	PRO	Yes; ICC 0.97 to 0.99	Yes	nr	nr	Yes: Pearson r - 0.594 to 0.818	nr	Yes: Pearson r - 0.433 to 0.292; P=0.001	nr	nr	nr	nr	nr	nr

Table 3.2. Outcome Measures: Reliability, Validity, and Other Characteristics

Instrument	Subscale	Reliability	Overall Valid?	Content Validity	Criterion Validity	Convergent Validity	Divergent Validity	Construct Validity	Structural Validity	MDC	MID	Responsive- ness	Floor Effect	Ceiling Effect
	Total	Yes: ICC 0.88	Yes	nr	nr	nr	nr	nr	nr	MDC90 3.4	nr	nr	nr	nr
AMPSIMM		nr	Yes	nr		Yes: Spearman r 0.72 to 0.86	nr	Yes	nr	nr	nr	SRM 1	No	No
ADAPT		Yes: Pearson r 0.69 to 0.96	nr	nr	nr	nr	nr	nr	nr	nr	nr	nr	nr	nr
AQoL		nr	Yes (weak)	nr	nr	Yes (P<0.05)	nr	nr	nr	nr	nr	nr	nr	nr
Barthel Index*		nr	Yes (weak)	nr	nr	nr	nr	Mixed	nr	nr	nr	nr	nr	nr
BBS*		Yes: ICC 0.945; Cronbach's α 0.827	Yes	nr	nr	Yes: Spearman r -0.8 to 0.675; AUC 0.88	nr	Yes	nr	nr	nr	nr	No	No
BIQ		Yes: Cronbach's α 0.90	nr	nr	nr	nr	nr	nr	nr	nr	nr	nr	nr	nr
Climbing Stairs Questionnaire		Yes: ICC 0.79	Yes	nr	nr	Yes: Spearman r 0.42 to 0.60	nr	Yes	nr	nr	nr	nr	nr	nr
FAI-15		Yes: Cronbach's α 0.81; ICC 0.79	Yes	nr	nr	Yes: Pearson r -0.49 to 0.526; Beta 0.19	nr	Mixed	nr	nr	nr	nr	nr	nr
FAI-18		Yes: Cronbach's α 0.84; ICC 0.78	Yes	nr	nr	Yes: Pearson r -0.46 to 0.548	nr	Mixed	nr	nr	nr	nr	nr	nr
FIM*	Overall Score	nr	No	nr	nr	No: Pearson r -0.06 to 0.13; p<0.00001	No: Pearson r -0.12	Yes	nr	nr	nr	SRM -0.49; Kazis ES -0.51; p<0.00001	No	No
	Amputation Function	No: Cronbach's α 0.55	No	nr	nr	No: Pearson r -0.03 to 0.13	nr	No	nr	nr	nr	SRM -0.20- 0.52; Kazis ES -0.23- 0.52	No	Chair transfer Yes (53%)
	Discharge motor subscore	nr	Yes (weak)	nr	nr	Yes: Spearman r 0.58	nr	nr	nr	nr	nr	nr	nr	nr
Harold Wood/Stanmore Mobility Grade		nr	No	nr	nr	No: Kendall tau - 0.04 to 0.21, P>0.05	nr	nr	nr	nr	nr	nr	nr	nr
HADS	Anxiety	nr	Yes	nr	nr	Yes: Spearman r - 0.58 to 0.77	nr	nr	nr	nr	nr	nr	nr	nr
	Depression	nr	Yes	nr	nr	Yes: Spearman r - 0.49 to 0.75	nr	nr	nr	nr	nr	nr	nr	nr

Instrument	Subscale	Reliability	Overall Valid?	Content Validity	Criterion Validity	Convergent Validity	Divergent Validity	Construct Validity	Structural Validity	MDC	MID	Responsive- ness	Floor Effect	Ceiling Effect
Houghton*		Yes: Cronbach α 0.68 to 0.71; ICC 0.85 to 0.96	Yes	nr	Yes	Yes: Pearson r -0.6 to 0.67; undefined r 0.235 to 0.653; Spearman r -0.76 to 0.73	nr	Yes: ES 0.29 to 1.62	nr	nr	nr	ES 0.6	No	No
IES	Avoidance	nr	Yes	nr	nr	Yes: Correlation r - 0.453 to -0.266	nr	nr	nr	nr	nr	nr	nr	nr
	Intrusion	nr	Yes	nr	nr	Yes: Correlation r - 0.623 to -0.265	nr	nr	nr	nr	nr	nr	nr	nr
IPAQ		Poor to adequate: Cronbach α 0.55 to 0.63	No	nr	nr	nr	nr	nr	nr	nr	nr	nr	nr	nr
LCI*	Advanced	Yes: Cronbach α 0.95	Yes	nr	nr	Yes: Pearson r -0.48 to 0.54	nr	No	nr	nr	nr	nr	Yes (nr)	No
	Basic	Yes: Cronbach's α 0.97	No	nr	nr	Mixed: Pearson r -0.24 to 0.31	nr	No	nr	nr	nr	nr	Yes (nr)	No
		Yes: Cronbach's α 0.89; ICC 0.88	Yes	nr	nr	Yes: Pearson r -0.64 to 0.83	nr	Yes: ES 0.13 to 1.66	nr	nr	nr	nr	No	Yes (nd)
	Overall Score	Yes: Cronbach's α 0.83	Yes	nr	nr	Yes: Pearson r -0.15 to 0.59	Yes: Pearson r -0.08	No	nr	nr	nr	nr	Yes (23-50%)	No
	LCI10-4	Yes: Item separation 0.98 Person separation 0.94	nr	nr	nr	nr	nr	nr	nr	nr	nr	nr	nr	nr
	LCI-4	Yes: Cronbach's α 0.95; ICC 0.74-0.8	Yes	Yes	nr	Yes	nr	Yes	nr	nr	nr	nr	No	Yes (nd)
	LCI-5	nr	Yes	nr	nr	Yes: Spearman r -0.84 to 0.50	nr	Yes	Yes	nr	nr	nr	No	Yes (50%)
L Test of Functional Mobility		Yes: ICC 0.96- 0.97	Yes	nr	nr	Yes: Spearman r 0.27 to 0.28 Pearson r -0.86 to 0.97	nr	Yes	nr	nr	4.5	Yes: AUROC 0.67	nr	nr
OPCS		nr	Yes	nr	nr	Yes: P<0.001	nr	nr	nr	nr	nr	nr	nr	nr

Instrument	Subscale	Reliability	Overall Valid?	Content Validity	Criterion Validity	Convergent Validity	Divergent Validity	Construct Validity	Structural Validity	MDC	MID	Responsive- ness	Floor Effect	Ceiling Effect
OPUS	Lower Limb Function	Yes: ICC 0.67	No	nr	nr	nr	nr	nr	nr	nr	nr	MDC90 10.3	No	No
	Quality of Life	Yes: ICC 0.85	No	nr	nr	nr	nr	nr	nr	nr	nr	MDC90 9.2	No	No
	Satisfaction	No: ICC 0.50	No	nr	nr	nr	nr	nr	nr	nr	nr	MDC90 15.7	No	No
PGI		No: ICC 0.48	No	nr	nr	Mixed: Pearson r 0.11 to 0.56	nr	nr	nr	nr	nr	nr	nr	nr
PROMIS-29	Anxiety	Yes: ICC 0.86	No	nr	nr	nr	nr	Mixed	nr	MDC90 7.81; MDC95 9.31	nr	nr	Yes (34%)	nr
	Depression	Yes: ICC 0.88	Yes	nr	nr	nr	nr	Yes	nr	MDC90 6.71; MDC95 8.00	nr	nr	Yes (42%)	nr
	Fatigue	Yes: ICC 0.84	No	nr	nr	nr	nr	Mixed	nr	MDC90 7.74; MDC95 9.22	nr	nr	nr	nr
	Pain Interference	Yes; ICC 0.82	No	nr	nr	nr	nr	Mixed	nr	MDC90 8.51; MDC95 10.1	nr	nr	Yes (28%)	nr
	Physical Function	Yes: ICC 0.88	Yes	nr	nr	nr	nr	Yes	nr	MDC90 6.13; MDC95 7.31	nr	nr	nr	No (14%)
	Sleep Disturbance	Yes: ICC 0.85	No	nr	nr	nr	nr	Mixed	nr	MDC90 7.61; MDC95 9.07	nr	nr	nr	nr
	Social Role Satisfaction	Yes: ICC 0.79	Yes	nr	nr	nr	nr	Yes	nr	MDC90 9.53; MDC95 0.79	nr	nr	nr	Yes (16%)
	Pain Intensity	Yes: ICC 0.87	nr	nr	nr	nr	nr	nr	nr	MDC90 1.97; MDC95 2.35	nr	nr	No (12%)	nr
PSFS	Item 1	Yes: ICC 0.82	nr	nr	nr	nr	nr	nr	nr	MDC90 3.3	nr	nr	No	No
	Item 2	Yes: ICC 0.66	nr	nr	nr	nr	nr	nr	nr	MDC90 4.2	nr	nr	No	No
	Item 3	Yes: ICC 0.79	nr	nr	nr	nr	nr	nr	nr	MDC90 3.1	nr	nr	No	No
	Item 4	Yes: ICC 0.56	nr	nr	nr	nr	nr	nr	nr	MDC90 4.5	nr	nr	No	No

Instrument	Subscale	Reliability	Overall Valid?	Content Validity	Criterion Validity	Convergent Validity	Divergent Validity	Construct Validity	Structural Validity	MDC	MID	Responsive- ness	Floor Effect	Ceiling Effect
	Item 5	Yes: ICC 0.77	nr	nr	nr	nr	nr	nr	nr	MDC90 3.1	nr	nr	No	No
	Total	Yes: ICC 0.83	nr	nr	nr	nr	nr	nr	nr	MDC90 11	nr	nr	No	No
PFI	Overall score	Yes: Cronbach's α 0.71	Yes	nr	nr	Yes: Pearson r -0.55 to 0.57	nr	No	nr	nr	nr	SRM 0.89; Kazis ES 1.06	No	No
	Climb Stairs	Yes: Cronbach's α 0.78	Yes	nr	nr	Yes: Pearson r -0.15 to 0.41	nr	No	nr	nr	nr	SRM 0.74; Kazis ES 0.79	Yes (41%)	Yes (17%)
	Run at steady pace	Yes: Cronbach's α 0.87	Yes	nr	nr	Yes: Pearson r -0.3 to 0.37	nr	No	nr	nr	nr	SRM 0.36	No	No
	Squat to pick up object	Yes: Cronbach's a 0.82	Yes	nr	nr	Yes: Pearson r -0.53 to 0.46	nr	No	nr	nr	nr	SRM 0.55; Kazis ES 0.67	No	Yes (36%)
	Walk at steady pace	Yes: Cronbach's α 0.74	Yes	nr	nr	Yes: Pearson r -0.41 to 0.45	nr	No	nr	nr	nr	SRM 0.65; Kazis ES 0.98	Yes (18%)	Yes (32%)
PEQ (Likert 5)	Mobility	Yes: Cronbach α 0.96; Rasch Person separation 0.95; Rasch Item separation 0.98	Yes	nr	nr	Yes: Spearman r 0.77	nr	nr	nr	nr	nr	nr	nr	nr
	Mobility modified (MS12/5)	Yes: Cronbach α 0.96; Rasch Person separation 0.95; Rasch Item separation 0.98	Yes	nr	nr	Yes: Spearman r 0.78	nr	nr	nr	nr	nr	nr	nr	nr
PEQ	Ambulation	Yes: Cronbach's α 0.89: ICC 0.81 to 0.90	Yes	nr	nr	Yes: Pearson r 0.61	nr	Yes: Spearman r 0.61 to 0.81; P<0.05	nr	MDC90 1.1	nr	nr	No	No
	Appearance	Yes: Cronbach's α 0.73: ICC 0.70 to 0.84	No	nr	nr	nr	nr	No	nr	MDC90 1.4	nr	nr	nr	nr

Instrument	Subscale	Reliability	Overall Valid?	Content Validity	Criterion Validity	Convergent Validity	Divergent Validity	Construct Validity	Structural Validity	MDC	MID	Responsive- ness	Floor Effect	Ceiling Effect
	Frustration	Yes: Cronbach's α 0.82: ICC 0.64 to 0.82	No	nr	nr	nr	nr	No	nr	MDC90 1.6	nr	nr	nr	nr
	Mobility	Yes: Cronbach's α 0.95); ICC 0.77 to 0.99	Yes	nr	nr	Yes: Pearson r -0.5 to 0.85; Beta -0.31	nr	Yes: ES 0.11 to 1.57	nr	MDC90 0.3 to 0.55; MDC95 0.65	nr	nr	No (<10% implied)	No (<10% implied)
	Perceived responses	No: Cronbach's α 0.89: ICC 0.41 to 0.56	No	nr	nr	nr	nr	No	nr	MDC90 0.9	nr	nr	nr	nr
	Prosthesis utility	Yes: ICC 0.79	nr	nr	nr	nr	nr	nr	nr	MDC90 1.2	nr	nr	nr	nr
	Residual limb health	Yes: Cronbach's α 0.8: ICC 0.79 to 0.80	No	nr	nr	nr	nr	No	nr	MDC90 0.8	nr	nr	nr	nr
	Social burden	Yes: Cronbach's α 0.83: ICC 0.64 to 0.81	Yes	nr	nr	Yes: Pearson r -0.52 to 0.59	nr	No	nr	MDC90 1.4	nr	nr	nr	nr
	Sounds	Yes: Cronbach's α 0.78: ICC 0.79 to 0.84	No	nr	nr	nr	nr	No	nr	MDC90 1.7	nr	nr	nr	nr
	Transfer	Yes: Cronbach's α 0.47: ICC 0.73 to 0.75	No	nr	nr	nr	nr	No	nr	MDC90 1.3	nr	nr	No	Yes (25%)
	Usefulness	Yes: Cronbach's α 0.89; ICC 0.86	No	nr	nr	nr	nr	No	nr	nr	nr	nr	No	No
	Wellbeing	Yes: Cronbach's α 0.87: ICC 0.70-0.87	Yes	nr	nr	Yes: Pearson r -0.49	nr	No	nr	MDC90 1.4	nr	nr	No	Yes (strong)
PEQ (Modified)	Problems	Yes: Cronbach's α 0.76	nr	nr	nr	nr	nr	nr	nr	nr	nr	nr	nr	nr
	Satisfaction	Yes: Cronbach's a 0.88	nr	nr	nr	nr	nr	nr	nr	nr	nr	nr	nr	nr

Instrument	Subscale	Reliability	Overall Valid?	Content Validity	Criterion Validity	Convergent Validity	Divergent Validity	Construct Validity	Structural Validity	MDC	MID	Responsive- ness	Floor Effect	Ceiling Effect
PLUS-M	12-item short form	Yes: ICC 0.96	nr	nr	nr	nr	nr	nr	nr	MDC90 4.50; MDC95 5.36	nr	nr	No (<10% implied)	No (<10% implied)
	7-item short form	Yes: ICC 0.95	nr	nr	nr	nr	nr	nr	nr	MDC90 4.69; MDC95 5.59	nr	nr	No (<10% implied)	No (<10% implied)
	CAT	Yes: ICC 0.92	nr	nr	nr	nr	nr	nr	nr	MDC90 6.42; MDC95 7.65	nr	nr	No (<10% implied)	No (<10% implied)
Quality of life NQ-ACGC		Yes: ICC 0.88-0.90	Yes	nr	nr	nr	nr	Yes: nr	nr	MDC90 6.67; MDC95 7.94	nr	nr	nr	Yes (17%)
Q-TFA	Global	Yes: ICC 0.89	Yes	nr	nr	Yes: Spearmans r 0.27 to 0.62	nr	nr	nr	nr	nr	nr	No	No
	Problem	Yes: ICC 0.89	Yes	nr	nr	Yes: Spearmans r -0.65 to -0.30	nr	nr	nr	nr	nr	nr	nr	nr
	Prosthetic Mobility	Yes: ICC 0.97	Yes	Yes	nr	Yes: Spearmans r 0.10 to 0.79	nr	nr	nr	nr	nr	nr	No	No
	Prosthetic Use	Yes: ICC 0.94	Yes	nr	nr	Yes: Spearman r 0.11 to 0.36	nr	nr	nr	nr	nr	nr	No	Yes (31%)
Rising and Sitting Down Questionnaire		Yes: ICC 0.83	Yes	nr	nr	Yes: Spearman r 0.40 to 0.57	nr	Yes	nr	nr	nr	nr	nr	nr
RMDQ		nr	No	nr	nr	Yes: Spearman r - 0.74 to -0.05	nr	nr	nr	nr	nr	nr	nr	nr
RMI		Yes: Cronbach's α 0.85	Yes	nr	nr	Yes: Spearman r - 0.58 to 0.85	nr	nr	nr	nr	nr	ES 0.35	nr	No (11%)
Russek's Code		nr	No	nr	nr	nr	nr	Weak	nr	nr	nr	nr	nr	nr
SAT-PRO		Yes: Cronbach α 0.90; ICC 0.87	Yes	Yes	nr	nr	nr	Yes	nr	nr	nr	nr	nr	nr
SF-12 †	MCS	nr	Yes	nr	nr	nr	nr	Yes	nr	nr	nr	nr	nr	nr
	PCS	nr	Yes	nr	nr	nr	nr	Yes	nr	nr	nr	nr	nr	nr
SF-36 †	Bodily Pain	nr	Yes	nr	nr	nr	nr	Yes	nr	nr	nr	nr	nr	nr
	Emotional Problems	nr	No	nr	nr	nr	nr	No	nr	nr	nr	nr	nr	nr
	Emotional Role Limitations	nr	No	nr	nr	nr	nr	No	nr	nr	nr	nr	nr	nr
	Emotional													1
	vvelibeing		No	pr	pr	pr.	pr	No	pr.	pr	nr	nr	pr	nr
	Energy/Fatigue	111	INU	111		111	111	INU	111	111	L UL	1 01	111	111

Instrument	Subscale	Reliability	Overall	Content	Criterion	Convergent	Divergent	Construct	Structural	MDC	MID	Responsive-	Floor	Ceiling
	Canaral Llasth		Valid?	validity	validity							ness	Ellect	Ellect
		nr	Tes No	n	ni	res. P<0.05	nr	res No	n	nr	nr	n	n	n
	Montal Health	nr	Voc	nr	nr	nr	nr	Mixed	nr	nr	nr	nr	nr	nr
	Overall	nr	Yes	nr	nr	nr	nr	Mixed	nr	nr	nr	nr	nr	nr
	PCS	nr	Yes	nr	nr	nr	nr	Mixed	nr	nr	nr	nr	nr	nr
	Physical	nr	Yes	nr	nr	nr	nr	Mixed	nr	nr	nr	Yes: P<0.05	nr	nr
	Functioning		100					mixed				100.1 0.00		
	Physical Role Limitations	nr	Yes	nr	nr	nr	nr	Mixed	nr	nr	nr	nr	nr	nr
	Social	nr	Yes	nr	nr	nr	nr	Mixed	nr	nr	nr	nr	nr	nr
	Functioning													
	Vitality	nr	Yes	nr	nr	nr	nr	Mixed	nr	nr	nr	nr	nr	nr
SF-36V	General Health	Yes: ICC 0.80	Yes	nr	nr	nr	nr	nr	nr	MDC90 17.1	nr	nr	No	No
	Physical Functioning	Yes: ICC 0.61	Yes	nr	nr	nr	nr	nr	nr	MDC90 34.2	nr	nr	No	No
	Role Physical	Yes: ICC 0.81	Yes	nr	nr	nr	nr	nr	nr	MDC90 26.3	nr	nr	No	No
SIP	Overall Score	Yes: Cronbach's α 0.76	Yes	nr	nr	Yes: Pearson r -0.53 to 0.58	Yes: Pearson r 0.004	No	nr	nr	nr	SRM 0.80; Kazis ES 0.77	No	No
	Ambulation	Yes: Cronbach's a 0.88	Yes	nr	nr	Yes: Pearson r -0.54 to 0.49	nr	No	nr	nr	nr	SRM 0.81; Kazis ES 0.95	No	No
	Body care and movement	Yes: Cronbach's α 0.81	Yes	nr	nr	Yes: Pearson r -0.45 to 0.32	nr	No	nr	nr	nr	SRM 0.69; Kazis ES 0.95	Yes	No
	Physical Dimension	nr	Mixed	nr	nr	nr	nr	Mixed	nr	nr	nr	nr	nr	nr
	Emotional stability	nr	Yes	nr	nr	nr	nr	Yes	nr	nr	nr	nr	nr	nr
	Psychological autonomy and communication	nr	No	nr	nr	nr	nr	No	nr	nr	nr	nr	nr	nr
	Social behavior	nr	No	nr	nr	nr	nr	No	nr	nr	nr	nr	nr	nr
	Somatic autonomy	nr	No	nr	nr	nr	nr	No	nr	nr	nr	nr	nr	nr
	Mobility Control	nr	No	nr	nr	nr	nr	No	nr	nr	nr	nr	nr	nr
	Mobility Range	nr	No	nr	nr	nr	nr	No	nr	nr	nr	nr	nr	nr
	Mobility	Yes: Cronbach's a 0.91	No	nr	nr	Mixed: Pearson r -0.4 to 0.3	nr	No	nr	nr	nr	SRM 0.42; Kazis ES 0.48	Yes	No
SSQN6		nr	No	nr	nr	Yes: P<0.05	nr	No	nr	nr	nr	nr	nr	nr
SCS	All modes	Yes: ICC 0.0.63-0.79	nr	nr	nr	nr	nr	nr	nr	MDC90 2.73; MDC95 3.26	nr	nr	nr	No (14%)

Instrument	Subscale	Reliability	Overall Valid?	Content Validity	Criterion Validity	Convergent Validity	Divergent Validity	Construct Validity	Structural Validity	MDC	MID	Responsive- ness	Floor Effect	Ceiling Effect
	Electronic mode only	Yes: ICC 0.79	nr	nr	nr	nr	nr	nr	nr	MDC90 2.31; MDC95 2.75	nr	nr	nr	nr
	Mixed mode	Yes: ICC 0.63	nr	nr	nr	nr	nr	nr	nr	MDC90 3.03; MDC95 3.61	nr	nr	nr	nr
		Yes: Kendall's tau 0.97 to 0.99	Yes	nr	nr	Yes: Kendall's tau 0.48 to 0.51	nr	nr	nr	nr	nr	nr	nr	nr
	Paper mode only	Yes: ICC 0.77	nr	nr	nr	nr	nr	nr	nr	MDC90 2.82; MDC95 3.36	nr	nr	nr	nr
SIGAM/WAP	Total Overall Score	Yes: ICC 0.79; Rasch Item Separation Index 0.98; Rasch Person Separation Index 0.87	Yes	nr	nr	Yes: Spearman r 0.37; P<0.001	nr	Mixed	nr	nr	nr	nr	nr	nr
Step Activity Monitors	PAM: Step count, total	nr	Yes	nr	nr	Yes: Pearson r 0.90 to 0.98	nr	nr	nr	nr	nr	nr	nr	nr
	PAM: Step length (medium)	nr	Yes	nr	nr	Yes: Pearson r 0.36 to 0.99	nr	nr	nr	nr	nr	nr	nr	nr
	PAM: Walking velocity	nr	Yes	nr	nr	Yes: Pearson r 0.95 to 0.99	nr	nr	nr	nr	nr	nr	nr	nr
	SAM: Steps/day	nr	Yes	nr	nr	Yes: Spearman r 0.718- 0.966	nr	No	nr	nr	nr	nr	nr	nr
TAPES	Total Overall Score	nr	Yes	nr	nr	Yes; Spearman r 0.42 to 0.84	nr	nr	nr	nr	nr	nr	nr	nr

Instrument	Subscale	Reliability	Overall Valid?	Content Validity	Criterion Validity	Convergent Validity	Divergent Validity	Construct Validity	Structural Validity	MDC	MID	Responsive- ness	Floor Effect	Ceiling Effect
	Activity Restriction	Yes: Cronbach's a 0.89; Person separation index 2.51; Person separation reliability 0.86; Item separation index 18.48; Item separation reliability 1	Yes	nr	nr	Yes: Spearman r - 0.663 to 0.424; P<0.001	nr	Yes	Yes: Rasch MnSQ 0.6 to 1.4; CFI 0.98; MNFI 0.97; RMSEA 0.1; SRMR	nr	nr	nr	nr	nr
	Activity Restriction Item 10	nr	Yes	nr	nr	nr	nr	nr	Yes: Rasch outfit MnSq 1.84	nr	nr	nr	nr	nr
	Activity Restriction Item 9	nr	Yes	nr	nr	nr	nr	nr	Yes: Rasch outfit MnSq3.13	nr	nr	nr	nr	nr
	Adjustment to Limitation	Yes: Cronbach's α 0.86; Person separation index 1.98; Person separation reliability 0.80; Item separation index 6.91; Item separation reliability 0.98	Yes	nr	nr	Yes: Spearman r 0.14 to 0.62; P<0.001	Yes: P<0.001	Yes: P<0.05	Yes: Factor analysis 25.3%	nr	nr	nr	nr	nr
	Age	nr	Yes	nr	nr	Yes: Pearson r - 0.22 to 0.1	nr	nr	nr	nr	nr	nr	nr	nr
	Athletic Activity Restriction	Yes: Cronbach's α 0.76	Yes	nr	nr	Yes: Pearson r - 0.63 to -0.18	nr	nr	Yes: Factor analysis 21.3%	nr	nr	nr	nr	nr

Instrument	Subscale	Reliability	Overall Valid?	Content Validity	Criterion Validity	Convergent Validity	Divergent Validity	Construct Validity	Structural Validity	MDC	MID	Responsive- ness	Floor Effect	Ceiling Effect
	Esthetic Satisfaction	nr	Yes	nr	nr	Yes: Pearson r 0.28 to 0.47; Spearman r -0.27 to 0.22	nr	nr	nr	nr	nr	nr	nr	nr
	Functional Activity Restriction	Yes: Cronbach's α 0.87	Yes	Yes	nr	Yes: Spearman r 0.30 to 0.31	nr	nr	Yes: Factor analysis 25.1%	nr	nr	nr	nr	nr
	Functional Satisfaction	Yes: Cronbach's α 0.85	Yes	nr	nr	Yes: Pearson r - 0.64 to -0.24	nr	nr	Yes: Factor analysis 30.1%	nr	nr	nr	nr	nr
	Gender	nr	No	nr	nr	No: Pearson r - 0.11 to 0.13	nr	nr	nr	nr	nr	nr	nr	nr
	General Adjustment	Yes: Cronbach's a 0.90; Person separation index 2.17; Person separation reliability 0.82; Item separation index 6.0; Item separation reliability 0.97	Yes	nr	nr	Yes: Pearson r 0.46 to 0.79; Spearman r -0.57 to -0.54; P<0.001	nr	nr	Yes: Factor analysis 23.6%	nr	nr	nr	nr	nr
	Health Rating	nr	Yes	nr	nr	Yes: Pearson r 0.35 to 0.67	nr	nr	nr	nr	nr	nr	nr	nr
	Length of Time Living with Prosthesis	nr	Yes	nr	nr	Yes: Pearson r 0.19 to 0.33	nr	nr	nr	nr	nr	nr	nr	nr
	Level of Amputation	nr	Yes	nr	nr	Yes: Pearson r - 0.14 to 0.17	nr	nr	nr	nr	nr	nr	nr	nr
	Other Medical Problems	nr	Yes	nr	nr	Yes: Pearson r - 0.33 to -0.15	nr	nr	nr	nr	nr	nr	nr	nr
	Phantom Limb Pain	nr	No	nr	nr	Yes: Pearson r 0.07 to 0.08	nr	nr	nr	nr	nr	nr	nr	nr
	Physical Capabilities	nr	Yes	nr	nr	Yes: Pearson r 0.33 to 0.69	nr	nr	nr	nr	nr	nr	nr	nr
	Prosthetic Use	nr	Yes	nr	nr	Yes: Pearson r 0.21 to 0.50	nr	nr	nr	nr	nr	nr	nr	nr

Instrument	Subscale	Reliability	Overall	Content	Criterion	Convergent	Divergent	Construct	Structural	MDC	MID	Responsive-	Floor	Ceiling
	Psychosocial Adjustment	Yes: Cronbach's α 0.89	Yes	nr	nr	nr	nr	nr	Yes: Rasch MnSQ 0.6 to 1.4; CFI 0.99; MNFI 0.98; RMSEA 0.057; SRMR 0.059	nr	nr	nr	nr	nr
	Residual limb pain	nr	Yes	nr	nr	Yes: Pearson r - 0.25 to -0.11	nr	nr	nr	nr	nr	nr	nr	nr
	Satisfaction Items 1-4	Yes: Cronbach's a 0.85; Person separation index 1.61; Person separation reliability 0.72; Item separation index 0.91; Item separation reliability 0.46	Yes	nr	nr	nr	nr	nr	Yes: Factor analysis 19%	nr	nr	nr	nr	nr
	Satisfaction Items 5-9	Yes: Cronbach's a 0.86; Person separation index 1.83; Person separation reliability 0.77; Item separation index 8.32; Item separation reliability 0.00	Yes	nr	nr	nr	nr	nr	Yes: Factor analysis 13%	nr	nr	nr	nr	nr

Instrument	Subscale	Reliability	Overall Valid?	Content Validity	Criterion Validity	Convergent Validity	Divergent Validity	Construct Validity	Structural Validity	MDC	MID	Responsive-	Floor Effect	Ceiling Effect
	Satisfaction with the Prosthesis	Yes: Cronbach's a 0.95	Yes	nr	nr	nr	nr	nr	Yes: Rasch MnSQ 0.6 to 1.4; CFI 0.98; MNFI 0.97; RMSEA 0.089; SRMR 0.057	nr	nr	nr	nr	nr
	Social Adjustment	Yes: Cronbach's a 0.89; Person separation index 1.92; Person separation reliability 0.79; Item separation index 5.43; Item separation reliability 3.97	Yes	nr	nr	Yes: Pearson r 0.33 to 0.69; Spearman r -0.44 to -0.40	nr	No	Yes: Factor analysis 13%; Rasch infit MnSq 1.94	nr	nr	nr	nr	nr
	Social Restriction	Yes: Cronbach α 0.84	Yes	nr	nr	Yes; Spearman r 0.40 to 0.43	nr	nr	Yes: Factor analysis 23.7%	nr	nr	nr	nr	nr
	Weight Satisfaction	nr	Yes	nr	nr	Yes; Spearman r - 0.23; Pearson 0.26 to 0.44	nr	nr	Yes: Factor analysis 13.7%	nr	nr	nr	nr	nr
TMMS	Clarity of Feelings	nr	Weak	nr	nr	Yes; Correlation r 0.41 to 0.56	nr	nr	nr	nr	nr	nr	nr	nr
	Repair	nr	Weak	nr	nr	Yes; Correlation r 0.34 to 0.55	nr	nr	nr	nr	nr	nr	nr	nr
TUG*		Yes: Spearman r 0.93 to 0.96; ICC 0.88	Yes	nr	nr	Yes: Spearman r -0.841 to 0.46; Pearson r 0.35 to 0.80	nr	Yes: Spearman LCI- 5=-0.65; P- value<0.05	nr	MDC90 3.6	nr	nr	nr	nr
Walking speed, 10 meters		Yes: ICC 0.83 to 0.98	Yes	nr	nr	Yes: Spearman r -0.70	nr	nr	nr	nr	nr	nr	nr	nr

Instrument	Subscale	Reliability	Overall	Content	Criterion	Convergent	Divergent	Construct	Structural	MDC	MID	Responsive-	Floor	Ceiling
			Valid?	Validity	Validity	Validity	Validity	Validity	Validity			ness	Effect	Effect
Walking speed,		nr	Yes	nr	nr	Yes:	nr	nr	nr	nr	nr	nr	nr	nr
15.2 meters						Pearson r -0.47 to								
						0.77								
Walking		Yes: ICC	Yes	nr	nr	Yes: Spearman r -		Mixed	nr	nr	nr	nr	nr	nr
Questionnaire		0.73				0.47 to 0.57								
WHODAS 2	Getting Around	nr	Weak	nr	nr	nr	nr	Yes:	nr	nr	nr	nr	nr	nr
	-							P<0.05						
	Participation in	nr	Weak	nr	nr	nr	nr	Yes:	nr	nr	nr	nr	nr	nr
	Society							P<0.05						
	Self Care	nr	Weak	nr	nr	nr	nr	Yes:	nr	nr	nr	nr	nr	nr
								P<0.05						
WHOQOL-	Overall QoL	Yes:	Yes	nr	nr	Yes: P<0.01	nr	nr	nr	nr	nr	nr	No	No
BREF	and General	Cronbach α												
	Health	0.84 to 0.89												
	Environment		Yes	nr	nr	Yes: P<0.01	nr	nr	nr	nr	nr	nr	No	No
	Physical Health		Yes	nr	nr	Yes: Correlation r -	nr	nr	nr	nr	nr	nr	No	No
						0.62 to 0.63;								
						P<0.01								
	Psychological		Yes	nr	nr	Yes: P<0.01	nr	nr	nr	nr	nr	nr	No	No
	Social		Yes	nr	nr	Yes: Correlation r -	nr	nr	nr	nr	nr	nr	No	No
	Relationships					0.62 to 0.73;								1
						P<0.01								

Abbreviations: 180 Degree Turn Test, 2MWT = 2 minute walk test, 6MWT = 6 minute walk test, AAS = Amputees activity survey, ABC = Activities-specific Balance Confidence, ABIS(-R) = Amputee Body Image Scale (revised), ADAPT = Assessment of Daily Activity Performance in Transfemoral amputees, AIMS = Arthritis Impact Measurement Scale, AMP = Amputee Mobility Predictor, AMPSIMM = Amputee Single Item Mobility Measure, AQoL = Assessment of Quality of Life, BBS = Berg Balance Scale, BIQ = Body Image Questionnaire, CAPE = Clifton Assessment Procedures for the Elderly, Census and Surveys, ES = effect size, FAI = Frenchay Activities Index, FIM = Functional Independence Measure, HADS = Hospital Anxiety and Depression Scale, IES = Impact of Event Scale, IPAQ = International Physical Activity Questionnaire, L Test = L Test of Functional Mobility, LCI = Locomotor Capabilities Index, MDC = minimal detectable change, MIC = minimal (clinical) important difference, Neuro-QoL ACGC = Neurological Disorders Applied Cognition General Concerns Short Form, NQ- ACGC = Quality of Life in Neurological Conditions – Applied Cognition/General Concerns, nr = not reported, OPCS = Office of Population, OPUS = Orthotic Prosthetic User's Survey, PAM = Patient activity monitor, PEQ = Prosthesis Evaluation Questionnaire, PFI = Physical Function Index, PGI = Patient Generated Index, PLUS-M = Prosthetic Limb Users Survey of Mobility, PROMIS - 29 = Patient-Reported Outcomes Measurement Information System 29-item profile, PROS = Prosthetist's Perception of Client's Ambulatory Abilities, PSFS = Patient Specific Functional Scale, Q-TFA = Questionnaire for Persons with a Transfemoral Amputete Medicine/Duth Working Group on Amputations and Prosthetics, SIP = Sickness Impact Profile , SRM = standardized response mean, SQNA6 = Saranson's 6-item Social Support Questionnaire, TAPES = Trinity Amputation and Prosthesis Experience Scales, TFP = Transfemoral Fitting Predictor, TMMS = Trait Meta Mood Scale, TUG = Timed Up and Go, WHODAS 2 = World Health Organizatio

* Also evaluated for Key Question 2.

† Also evaluated for Key Question 1.

Key Questions 1 to 3 Summary

In total, we have summarized the evidence on the performance characteristics of 61 measures (assessment techniques, prediction tools, and outcome measures) and subscales of many of these. As discussed above, the distinctions among these categories was, to a degree, arbitrary, based on interpretation of the original purpose of the measure, the hypotheses of the studies, and the analyses reported. Here we summarize them together. Here we also group together assessments of scales, their subscales, and variations.

Table 1-3.1 summarizes the findings regarding reliability, (overall) validity, the minimal detectable change (MDC), the minimal (clinical) important difference (MID), the responsiveness, and floor or ceiling effects. Most notable is that while some measure of validity has been assessed for most measures (n=53), other characteristics are less frequently evaluated. Reliability has been assessed for 40 measures and the MID was estimated for only one measure (the L test of Functional Mobility).

All 40 measures that have been assessed for reliability were found to be reliable (at least to an adequate extent). Of the 53 measures assessed for validity, 47 have been validated (either as a single measure, or for all or most of their subscales); although four of these were found to be only weakly validated. Among the 47 validated measures, seven have been validated for only some or most of their subscales (marked as "mixed" in Table 1-3.1, or with footnotes). Furthermore, only 29 measures have evidence to support both reliability and validity; seven of these, though, have been found to have either floor or ceiling effects in whole or in part.

However, among the 61 measures, only 35 have been evaluated in samples of lower limb amputees deemed to be generally applicable to the Medicare population, based primarily on either the percentage of participants with dysvascular conditions or their ages. These are highlighted in Table 1-3.1 by having bold text in the Population column. Among these 35, 27 have evidence of validity, in whole or in part, and 25 have evidence of reliability. In total, 19 measures have been found to have evidence of both reliability and validity in study participants generally applicable to the Medicare population. These include:

- 2 minute walk test (2MWT)
- Activities-specific Balance Confidence (ABC)
- Amputee Body Image Scale, revised (ABIS-R)
- Berg Balance Scale (BBS)
- Climbing Stairs Questionnaire
- Frenchay Activities Index, 15 item (FAI-15)
- Houghton Score
- Locomotor Capabilities Index (LCI)
- Patient-Reported Outcomes Measurement Information System 29-item profile (PROMIS-29)
- Prosthesis Evaluation Questionnaire (PEQ)
- Quality of Life in Neurological Conditions Applied Cognition/General Concerns (NQ-ACGC)
- Rising and Sitting Down Questionnaire
- Satisfaction with Prosthesis (SAT-PRO)
- Special Interest Group of Amputation Medicine/Dutch Working Group on Amputations and Prosthetics (SIGAM/WAP)

- Trinity Amputation and Prosthesis Experience Scale (TAPES)
- Timed Up and Go (TUG)
- Transfemoral Fitting Predictor (TFP)
- Walking speed, 10 meters
- Walking Questionnaire

Of these 19 measures, only the Houghton Score has been evaluated for and found to demonstrate responsiveness. Floor or ceiling effects have been found for four of these measures (or their subscores): LCI, PROMIS-29, PEQ, and NQ-ACGC.

Measure	N ^A	Population ^B	Reliability	Validity ^c		MID	Responsiveness	Floor/Ceiling
180 Degree Turn Test	1	U, TT		Weak			-	
2MWT	5	B/U, TF, TT, Vasc	Yes	Yes	Yes ^D			
6MWT	3	U, TF, TT, Tr	Yes	Yes	Yes ^D			
AAS	2	U, TF, TT, Mix		Yes				
ABC	5	B/U, TF, TT, Mix	Yes	Yes	Yes ^D			No
ABIS	1	B/U, TF, TT, Vasc	Yes	No				
ABIS-R	2	B/U, TF, TT, Vasc	Yes	Yes				
AMP	2	U, TF, TT, Tr	Yes	Yes	Yes ^D			
AMPSIMM	1	U, TF, TT, TM, Vasc		Yes			Yes	No
ADAPT	1	U, TF, Tr	Yes					
AQoL	1	U, TF, TT, Mix		Weak				
Barthel Index	2	U, TF, Mix		Yes				
BBS	5	U, TF, TT, Vasc	Yes	Yes				No
BIQ	1	TF, TT, Vasc	Yes					
CAPE CAS	1	TF, TT		Yes				
Climbing Stairs Questionnaire	4	B/U, TF, TT, Vasc	Yes	Yes				
FAI-15	2	U, TF, TT, Vasc	Yes	Yes				
FAI-18	1	U, TF, TT, Mix	Yes	Yes				
FIM	5	U, TF, TT, Vasc	No	No			Yes	Yes [⊦]
FSST	1	U, TT		Yes				
Harold Wood/Stanmore Mobility Grade	3	TF, TT, Mix		No				
HADS	1	B/U, TF, TT		Yes				
Houghton Score	5	B/U, TF, TT, Vasc	Yes	Yes			Yes	No
IES subscales	1	U, TF, TT, Tr		Yes				
IPAQ	1	TF, TT, Mix	Adequate					
LCI (various)	15	B/U, TF, TT, Mix	Yes	Yes ^H				Yes
L test	2	TF, TT, Mix	Yes	Yes		Yes ^D	Yes	
OPCS	1	U, TF, TT		Yes				
OPUS	1	U, TF, TT	Yes				Yes	No
PGI	1	U, TF, Vasc	No	No				
PROMIS-29	2	U, TF, TT, Mix	Yes	Mix ^ĸ	Yes ^D			Yes (most)
PSFS	1	U, TF, TT	Yes		Yes ^D			No
PFI	1	U, TF, TT	Yes	Yes			Yes	Yes (most)
PEQ (various)	8	B/U, TF, TT, Mix	Yes	Mix	Yes ^D			Mix
PLUS-M	4	B/U, TF, TT, Mix	Yes		Yes ^D			No
PROS	1	TF, TT, Vasc		Yes				
NQ-ACGC	2	U, TF, TT, Mix	Yes	Yes	Yes ^D			Yes
Q-TFA	1	U, TF, Tr	Yes	Yes				Mix ^L
Rising and Sitting Down Questionnaire	3	B/U, TF, TT, Vasc	Yes	Yes				

Table 1-3.1. Summary of Performance of Measures in People With Lower Limb Amputations

Measure	N ^A	Population ^B	Reliability	Validity ^c		MID	Responsiveness	Floor/Ceiling
RMDQ	1	TF, TT, Tr		Yes				
RMI	2	B/U, TF, TT, Mix	Yes	Yes			Yes	No
Russek's Code	1	TF, TT,		No				
SAT-PRO	1	U, Vasc	Yes	Yes				
SF-12	6	B/U, TF, TT, Mix		Yes				
SF-36	17	B/U, TF, TT, Mix		Mixed ^N			Yes (PF) ⁰	
SF-36V	1	B/U, TF, TT	Yes		Yes ^D			No
SIP	4	U, TF, TT	Yes	Mix ^P			Yes	Yes ^Q
SSQN6	1	Vasc		No				
SCS	3	U, TF, TT, Mix	Yes		Yes ^D			No
SIGAM/WAP	2	B/U, TF, TT, Vasc	Yes	Yes				
Step Activity Monitors	2	U, TF, TT, Mix		Yes				
TAPES	6	B/U, TF, TT, Mix	Yes (various)	Yes ^R				
TMMS	1	U, TF, TT, Tr		Weak				
TUG	8	U, TF, TT, Vasc	Yes	Yes	Yes ^D			
TFP	1	U, TF, Vasc	Yes	Yes				
Walking speed, 10 meters	2	U, TF, TT, Vasc	Yes	Yes				
Walking speed, 15.2 meters (50 feet)	1	U, TM, Vasc		Yes				
Walking Questionnaire	3	TF, TT, Vasc	Yes	Yes				
WHODAS 2	1	nd		Weak				
WHOQOL-BREF subscales	5	U, TF, TT, Mix	Yes	Yes				No

Abbreviations: 180 Degree Turn Test, 2MWT = 2 minute walk test, 6MWT = 6 minute walk test, AAS = Amputees activity survey, ABC = Activitiesspecific Balance Confidence, ABIS(-R) = Amputee Body Image Scale (revised), ADAPT = Assessment of Daily Activity Performance in Transfemoral amputees, AIMS = Arthritis Impact Measurement Scale, AMP = Amputee Mobility Predictor, AMPSIMM = Amputee Single Item Mobility Measure, AQoL = Assessment of Quality of Life, BBS = Berg Balance Scale, CAPE = Clifton Assessment Procedures for the Elderly, Census and Surveys, FAI = Frenchay Activities Index, FIM = Functional Independence Measure, HADS = Hospital Anxiety and Depression Scale, IES = Impact of Event Scale, IPAQ = International Physical Activity Questionnaire, L Test = L Test of Functional Mobility, LCI = Locomotor Capabilities Index, MDC = minimal detectable change, MIC = minimal (clinical) important difference, Neuro-QoL ACGC = Neurological Disorders Applied Cognition General Concerns Short Form, NQ-ACGC = Quality of Life in Neurological Conditions – Applied Cognition/General Concerns, OPCS = Office of Population, OPUS = Orthotic Prosthetic User's Survey, PAM = Patient activity monitor, PEQ = Prosthesis Evaluation Questionnaire, PFI = Physical Function Index, PGI = Patient Generated Index, PLUS-M = Prosthetic Limb Users Survey of Mobility, PMQ = Prosthetic Mobility Questionnaire, PROMIS-29 = Patient-Reported Outcomes Measurement Information System 29-item profile. PROS = Prosthetist's Perception of Client's Ambulatory Abilities, PSFS = Patient Specific Functional Scale, Q-TFA = Questionnaire for Persons with a Transfemoral Amputation, QoL = Quality of Life, RMDQ = Roland Morris Disability Questionnaire, RMI = Rivermead Mobility Index, SAT-PRO = Satisfaction with Prosthesis, SCS = Socket Comfort Score, SF = Short Form Health Survey, SIGAM = Special Interest Group in Amputee Medicine, SIP = Sickness Impact Profile, SSQN6 = Saranson's 6-item Social Support Questionnaire, TAPES = Trinity Amputation and Prosthesis Experience Scales, TFP = Transfemoral Fitting Predictor, TMMS = Trait Meta Mood Scale, TUG = Timed Up and Go.15D HRQoL = 15D Health Related Quality of Life instrument. WHODAS 2 = World Health Organization Disability Assessment Schedule version 2. WHOQOL-BREF = World Health Organization Quality of Life abbreviated.

^A Number of studies

- ^B Bold text signifies that the study samples were deemed generally applicable to the Medicare population; text in italics if deemed not applicable. B = bilateral amputations, B/U = both bilateral and unilateral amputations, CA = cancer amputations, nd = no data reported describing participants, TF = transfemoral amputations, TM = transmetatarsal amputations, Tr = at least a plurality of trauma amputations, TT = transtibial amputations, Mix = a mix of amputation etiologies, nd = no data on amputation characteristics, U = unilateral amputations, Vasc = at least a plurality of dysvascular etiologies. If a category was omitted (i.e., unilateral vs. bilateral, amputation level, amputation etiology), there were insufficient data reported to summarize that category.
- ^c Weak indicates that there is weak evidence of validity. Measures for which validity was assessed and no evidence was found to support validity are highlighted in bold.
- ^D Yes indicates that and MDC or MID have been reported.
- ^E Motor score validated at discharge from inpatient rehabilitation, but not at admission to rehabilitation. Subscales also not validated.
- ^F Chair transfer subscale has a ceiling effect. Other subscales and total do not.
- ^G Average prosthetic use per day validated; average falls per month and average prosthetic use per week were not validated.
- ^H Most variations found to be valid; Basic LCI was not.
- ¹ Validated: Mobility, Mobility modified, Ambulation, Social burden, and Wellbeing subscales. Not validated: Appearance, Frustration, Perceived responses, Residual limb health, Sounds, Transfer, and Usefulness subscales.
- ^J Ceiling effects found for Transfer and Wellbeing, but not for Ambulation, Mobility, or Usefulness subscales. These subscales did not have floor effects.
- ^K Validated: Depression, Physical Function, and Social Role Satisfaction subscales. Not validated: Anxiety, Fatigue, Pain Interference, and Sleep Disturbance subscales.
- ^L Ceiling effect for Prosthetic Use subscale, not for Global or Prosthetic Mobility subscales. No floor effects.
- ^N Except Emotional Problems, Emotional Role Limitations, Energy/Fatigue subscales.
- ^o Reported only for Physical Functioning (PF) subscale.
- ^P Validated: Ambulation, Body Care and Movement, Emotional Stability subscales, and overall score. Inconsistent validation for Physical Scale subscale. Not validated: Physical Autonomy and Communication, Social Behavior, Somatic Autonomy, Mobility Control, Mobility Range, and Mobility subscales.
- ^Q Floor effects for Bodily Care and Movement and Mobility subscales. No floor effects for Ambulation subscale and overall score. No ceiling effects for these measures.
- ^R Except Gender subscale. Only weak evidence for total overall score validity.

Key Question 4

In adults who use a lower limb prosthesis, how do the **relative effects** on ambulatory, functional, and patient-centered outcomes **of different prosthetic components** or levels of components/prostheses **vary based on study participant characteristics**?

Overall Summary of Studies

In total, we found 11 studies (in 12 articles) that directly compared different LLP components and provided sufficient data to allow subgroup analyses based on participant characteristics.¹¹⁰⁻¹²⁰ Ten studies included between 5 and 168 users of LLP; one included 899 amputees. Five studies evaluated microprocessor knees (compared to mechanical knees), two evaluated other knee components, two evaluated ankle/foot components, and one each evaluated pylons or sockets. The largest study (Hahn 2016) developed a regression model to evaluate predictive ability of a wide range of participant characteristics.¹¹⁴An older study (Alaranta 1994) reported a correlation analysis between participant characteristics and outcomes and also subgroup analyses without statistical comparisons between subgroups.¹¹⁰ One study (De Asha 2014) provided subgroup comparisons with statistical analyses¹¹¹; three studies reported subgroup results but did not statistically compare subgroups (Gard 2003, Hafner 2009, Theeven 2011)^{112, 113, 117}; and six studies reported individual patient data which allowed *post hoc* subgroup analyses (Gard 2003, Isakov 1985, Kahle 2008, Silver-Thorn 2009, Traballesi 2011, Wong 2015).^{112, 115, 116, 119, 120} Overall studies that investigated subgroup effects did not identify participant characteristics that predict which lower limb amputees would most benefit from a given component (low strength of evidence).

The following summary tables present summaries of all eligible studies for reference in the next sections. Detailed results summaries are tabulated separately for each study to improve formatting and readability. Table 4.1 summarizes the study design and participant characteristics of the 11 studies. In all studies, all patients were assessed with all components being compared either per a study design protocol or through the natural history of people being prescribed a new prosthesis. Among studies that reported prior prosthesis use history, people were all experienced LLP users, with at least 3 month, but generally longer, experience. The large majority of study participants were male (85% across studies with reported data) with unilateral amputations (100% in 8 of 11 studies). The level of amputation varied depending on the components being tested. The studies of knees, and the study of sockets, included almost all patients with transfemoral amputations. The study of pylons included only patients with transtibial amputations. The two ankle/foot studies included both patients with transtibial and transfemoral amputations. Nine of the 11 studies reported the K level of included patients. Except for two studies that included only K2 level patients, most study participants were at K3 (or K4) level. Only Wong 2015 explicitly included people at K1 level. The amputation etiologies across studies varied more widely, although with one exception at least about half of patients had traumarelated amputations. Isakov 1985 was the only study that included a majority of people with dysvascular disease-related amputations (14/17, 82%). The study participants were relatively young, with mean ages ranging from 34 to 61 years, suggesting that well over half the amputees were less than 65 years old.

Table 4.2 describes the components that were compared in the studies. Table 4.3 describes the risk of bias (study quality) of the studies. Six of the studies were deemed to be at moderate risk of bias overall and five studies at high risk of bias. Briefly, only one study was randomized; no study attempted to blind patients or providers (which may have been impossible for many components), but studies also did not blind outcome assessors (which may have been difficult for most studies); since all studies were one- or two-way crossover studies, by definition the groups of patients evaluating each component were equivalent; dropout rates were low across studies; only one study conducted multivariable analyses comparing subgroups; and only two studies statistically evaluated heterogeneity of treatment effect (differences among subgroups).

Table 4.4 provides an overall summary of subgroup comparisons across all studies and Tables 4.5-4.15 provide the summary results for each study individually. Narrative summaries follow the tables.

There is an important caveat about the determination of whether outcome measures have been validated (in Table 4.4 and for the text sections following the tables). We consider variations and modifications of measures to be separate measures that would each need to be validated. This applies both to modifications of existing measures (which, by definition, are no longer the same measure) and to variations such as walking and cadence tests conducted over different lengths of time or distance walked. Thus, the 2 minute walk test is distinct from the 6 minute walk test and from walking tests of other times or distances. In addition, when determining whether a measure used in a study has been validated we did not give the study the benefit of the doubt when measures were inadequately defined. For example, walk tests for which no time or distance was reported are, by definition, considered to be not validated.

Study Year (PMID) Country	Study design	Funding Source	Components	Amputation and Prosthesis Use History	N enrolled	Mean Age (SD) [Range]	Male	K Level	Amputation Level	Unilateral	Etiology
Alaranta 1994 (7991366) Finland	NRCS, retrospective	Not reported / unclear	Foot/Ankle, energy- storing vs. conventional	Prosthesis ≥6 mo	208	58.4	93%	K3-4 100%	TT 84%, TF 16%	93%	Trauma 86%, dysvascular 5%, other 9%
De Asha 2014 (24997811) UK	NRCS, prospective	Industry provided materials	Foot/Ankle, hydraulic vs. rigid	Amputation ≥2 y prior, prosthesis ≥6 mo	19	44.5 (12.5)	nd	K3-4 100%	TT 58%, TF 42%	100%	Trauma 84%, dysvascular 0%, cancer 16%
Gard 2003 (15077637) USA	Pre-post, prospective	Nonindustry	Pylon, shock- absorbing vs. conventional	Prosthesis ≥6 mo	10	54 (17) [31-79]	90%	nd	TT 100%	100%	Trauma 70%, dysvascular 30%
Hafner 2009 (19675993) USA	RCT (crossover)	Industry funded	Knee, microprocessor vs. conventional	Amputation ≥2 y prior	17	49.1 (16.4)	76%	K2 47%, K3 53%	TF 100%	100%	Trauma 59%, dysvascular 6%, cancer 18%, infection 12%, other 6%
Hahn 2016 (27828871) Austria	Single group, retrospective	Industry provided materials	Knee, microprocessor, hydraulic vs. conventional	nd	899	49.0 (12.9)	83%	K2 13%, K3 64%, K4 23%	Knee 19%, TF 80%	nd	Trauma 69%, dysvascular 6%, cancer 16%, other 10%
lsakov 1985 (3868034) Israel	Pre-post, prospective	Not reported / unclear	Knee, locking vs. open	nd	17	55.6 (12.1)	94%	nd	TF 100%	100%	Trauma 18%, dysvascular 82%
Kahle 2008 (18566922) USA	Pre-post, prospective	Nonindustry	Knee, microprocessor vs. conventional	Prosthesis ≥90 d	15	51 (19)	nd	K2 60%,* K3 33%,* K4 7%	nd	100%	Trauma 47%, dysvascular 47%, other 6%
Silver-Thorn 2009 (none) USA	NRCS, prospective	Nonindustry	Knee, locking vs. hydraulic	nd	5	44.8 (9.3)	nd	K2 100%	TF 100%	100%	Trauma 80%, dysvascular 0%, cancer 20%
Theeven 2011 (21947182, 22549656) Netherlands and Belgium	RCT (crossover)	Nonindustry	Knee, microprocessor (2 types) vs. conventional	Amputation ≥1 y prior	41	59.1 (12.6)	73%	K2 100%	TF 100%	100%	Trauma 77%, dysvascular 20%, other 3%
Traballesi 2011 (21684165) Italy	Pre-post, prospective	Not reported / unclear	Socket, Marlo vs. ischial containment	Prosthesis ≥1 y	12	33.9 (9.4)	86%	K3-4 100%	TF 100%	100%	Trauma 86%, dysvascular 0%, cancer 14%
Wong 2015 (25768067) USA	NRCS, prospective	Industry funded	Knee, microprocessor vs. conventional	nd	8	60.8 (11.3)	nd	K1 25%, K2 25%, K3 50%	TF 100%	75%	nd

Table 4.1. Study Design and Participant Characteristics of Studies Comparing Components
* 4 of 9 patients who were K2 when evaluated with their conventional knee were K3 when evaluated with the microprocessor knee; 3 of 5 patients who were K3 when evaluated with their conventional knee were K4 when evaluated with the microprocessor knee.

Abbreviations: Knee = at level of knee amputation, nd = no data (not reported), NRCS = nonrandomized comparative study, RCT = randomized comparative study, SD = standard deviation, TF = transfemoral amputation, TT = transfibial amputation.

Study Year (PMID)	Component Type	Arm	Component Name/Description (Manufacturer)
Alaranta 1994 (7991366)	Foot/Ankle	Energy storing prostheses	Flexible plastic/carbon fiber leaf spring
		Conventional prostheses	Solid-ankle-cushion-heel
De Asha 2014 (24997811)	Foot/Ankle	Hydraulic	Echelon (Endolite)
		Rigid	Varied, habitual
Gard 2003 (15077637)	Pylon	Shock-absorbing pylon	Telescopic-Torsion Pylon (Endolite)
		Conventional pylon	Varied, habitual
Hafner 2009 (19675993)	Knee	Microprocessor	C-Leg Model 3C98 (Otto Bock)
		Nonmicroprocessor	Varied, habitual
Hahn 2016 (27828871)	Knee	Microprocessor, hydraulic	Genium (Otto Bock)
		Conventional prostheses	Varied, habitual
Isakov 1985 (3868034)	Knee	Locking system	3R17 (Otto Bock)
		Load-dependent brake ("open")	3R15 (Otto Bock)
Kahle 2008 (18566922)	Knee	Microprocessor	C-Leg (Otto Bock)
		Nonmicroprocessor	Varied, habitual*
Silver-Thorn 2009 (none)	Knee	Locking system	Total Knee 2000 (Össur)
		Hydraulic	3R80 (Otto Bock)
Theeven 2011 (21947182, 22549656)	Knee	Microprocessor (stance and swing phases)	C-Leg (Otto Bock)
		Microprocessor (stance phase)	C-Leg Compact (Otto Bock)
		Nonmicroprocessor	Varied, habitual†
Traballesi 2011 (21684165)	Socket	Marlo Anatomical Socket	Lower anterior and posterior trim lines
		Ischial Containment Socket	Typical socket shape
Wong 2015 (25768067)	Knee	Microprocessor	C-Leg (n=5) or C-Leg Compact (n=3) (Otto Bock)
		Nonmicroprocessor	Varied, habitual‡

Table 4.2. Comparative Study Components

* 4-bar multiaxial knee joint with hydraulic swing-phase control (n=5), Total Knee 2000® Polycentric knee with geometric locking system (Össur) (n=5), Mauch Single axis hydraulic knee system with swing and stance control SNS® (Össur) (n=4), Weight-activated stance-phase brake mechanism with pneumatic swing-phase control (n=3), Single axis friction (n=1), Weight-activated stance-phase brake mechanism with pneumatic swing-phase control (n=3), Single axis friction (n=1), Weight-activated stance-phase brake mechanism with pneumatic swing-phase control (n=3), Single axis friction (n=1), Weight-activated stance-phase brake mechanism with pneumatic swing-phase control (n=3), Single axis friction (n=1), Weight-activated stance-phase brake mechanism with pneumatic swing-phase control (n=3), Single axis friction (n=1), Weight-activated stance-phase brake mechanism with pneumatic swing-phase control (n=3), Single axis friction (n=1), Weight-activated stance-phase brake mechanism with pneumatic swing-phase control (n=3), Single axis friction (n=1), Weight-activated stance-phase brake mechanism with pneumatic swing-phase control (n=3), Single axis friction (n=1), Weight-activated stance-phase brake mechanism with pneumatic swing-phase control (n=3), Single axis friction (n=1), Weight-activated stance-phase brake mechanism with pneumatic swing-phase control (n=3), Single axis friction (n=1), Weight-activated stance-phase brake mechanism with pneumatic swing-phase control (n=3), Single axis friction (n=3

† 3R80, 3R106, 3R60, 3R92 (Otto Bock); Acphapend (Proteval); Ultimate (Ortho Europe); Total Knee, Mauch Knee (Össur); Graph-Lite (Teh Lin); or manual locking knee.

 ¹/₂ 3R60 or 3R80 (n=3), Mauch Knee (Össur) (n=2), Total Knee 1900 or 2000 (Össur) (n=2), or Locking 3R41 (Otto Bock) (n=1)

	-	-			-						
Study Year	Randomization	Allocation	Blinding,	Blinding,	Blinding,	Outcome	Equivalent	Dropouts	Multivariable	HTE	Overall
(PMID)		concealment	Patients	Providers	Outcome	Assessment,	Groups	-		Analyzed?	Quality
					Assessors	Validation				_	_
Alaranta 1994	High RoB	NA (crossover)	High RoB	High RoB	High RoB	Low RoB,	Low RoB	Low RoB	High RoB	Partially*	High RoB
(7991366)	(nonrandomized)			-		not validated	(pre-post)		(no)		_
De Asha 2014	High RoB	NA (crossover)	High RoB	High RoB	High RoB	Low RoB,	Low RoB	Low RoB	High RoB	Yes	High RoB
(24997811)	(nonrandomized)					not validated	(pre-post)		(no)	(interaction)	
Gard 2003	High RoB	NA (crossover)	High RoB	High RoB	High RoB	Low RoB,	Low RoB	Low RoB	High RoB	No (IPD	High RoB
(15077637)	(nonrandomized)					not validated	(pre-post)		(no)	reported)	
Hafner 2009	High RoB	NA (crossover)	High RoB	High RoB	Unclear RoB	Low RoB,	Low RoB	Low RoB	High RoB	Indirectly†	Moderate
(19675993)	(nonrandomized)					validated	(crossover)		(no)		RoB
Hahn 2016	High RoB	NA (crossover)	High RoB	High RoB	High RoB	Low RoB,	Low RoB	Low RoB	Low RoB	Yes (model)	Moderate
(27828871)	(nonrandomized)					not validated	(pre-post)		(yes)		RoB
Isakov 1985	High RoB	NA (crossover)	High RoB	High RoB	Unclear RoB	Low RoB,	Low RoB	Low RoB	High RoB	No (IPD	Moderate
(3868034)	(nonrandomized)					validated	(crossover)		(no)	reported)	RoB
Kahle 2008	High RoB	NA (crossover)	High RoB	High RoB	High RoB	Low RoB,	Low RoB	Low RoB	High RoB	No (IPD	Moderate
(18566922)	(nonrandomized)					validated	(pre-post)		(no)	reported)	RoB
Silver-Thorn	High RoB	NA (crossover)	High RoB	High RoB	High RoB	Low RoB,	Low RoB	Low RoB	High RoB	No (IPD	High RoB
2009 (none)	(nonrandomized)			-	-	not validated	(crossover)		(no)	reported)	-
Theeven 2011	Low RoB	NA (crossover)	High RoB	High RoB	High RoB	High RoB	Low RoB	Low RoB	High RoB	Indirectly†	High RoB
(21947182,						(outcome	(crossover)		(no)		
22549656)						definition					
						unclear),					
						not validated					
Traballesi	High RoB	NA (crossover)	High RoB	High RoB	High RoB	Low RoB,	Low RoB	Low RoB	High RoB	No (IPD	Moderate
2011	(nonrandomized)					validated	(pre-post)		(no)	reported)	RoB
(21684165)											
Wong 2015	High RoB	NA (crossover)	High RoB	High RoB	High RoB	Low RoB,	Low RoB	Low RoB	High RoB	No (IPD	Moderate
(25768067)	(nonrandomized)					validated	(pre-post)		(no)	reported)	RoB

Table 4.3. Comparative Study Risk of Bias / Study Quality

Abbreviations: HTE = heterogeneity of treatment effect (difference in effect/association between different subgroups of participants), IPD = individual participant data, NA = not applicable, RoB = risk of bias.

* Reported transtibial and transfemoral analyses separately; did not report statistical analyses comparing subgroups; correlations of differences in effect of two components with other outcomes reported.

† Reported subgroup analyses separately; did not report statistical analyses comparing subgroups.

Table 4.4. Summar	ry of Subgroup	Comparisons
-------------------	----------------	-------------

Study	Components	Total N	Subgroups	Subgroups Validated?	Outcomes	Outcomes Validated? §	Subgroup Comparison Findings (P value*)
Alaranta 1994 (PMID 7991366)	Energy-storing vs. conventional ankle/foot	168	TF vs. TT Age Age at amputation Body weight/BMI	Yes, all	Movement disability index subquestions and total	No	Younger age weakly correlated with favoring energy-storing for total movement disability (<0.01†). Lighter body weight weakly correlated with favoring energy-storing for total movement disability (<0.01†).
De Asha 2014 (PMID 24997811)	Hydraulic vs. rigid ankle/foot	19	TF vs. TT	Yes	Gait speed (8 meters) Cadence (8 meters)	No#	Nonsignificant
Gard 2003 (PMID 15077637)	Shock-absorbing vs. non-shock-absorbing pylon	10	Vascular vs. traumatic Sex Age Height Time since amputation	Yes, all	Walking speed (distance undefined) Fast walking speed (distance undefined)	No#	One woman favored the shock-absorbing pylon more than men did for self-selected walking speed (0.0002) and fast walking speed (<0.0001).
Hafner 2009 (PMID 19675993)	Microprocessor vs. mechanical knee	17	K2 vs. K3	Yes	PEQ subscales Falls & stumbles, reported Walking speeds, various Stair Assessment Index Hill Assessment Index Self-reported abilities/difficulties	Yes Yes No No No	Nonsignificant
Hahn 2016 (PMID 27828871)	Microprocessor, hydraulic vs. mechanical knee	899	Multiple (not all explicitly listed)	Yes, mostly	Ambulatory, functional, other activities, and speed measures	No	"None of the variables and none of the regression models yield explanatory predictive power."
lsakov 1985 (PMID 3868034)	Locking vs. open knee	17	Vascular vs. nonvascular Sex Age	Yes, all	Gait speed (6 min)	Yes	Nonsignificant
Kahle 2008 (PMID 18566922)	Microprocessor (C- Leg) vs. mechanical knee	15	K level (2, 3, 4) Age Vascular vs. nonvascular Height Employment status Prosthesis use duration Residual limb firmness Residual limb length	Yes Yes Yes Yes Yes No Yes	Falls & stumbles, reported Walking speeds, varied Montreal Rehabilitation Performance Profile	Yes No No	Nonsignificant

Study	Components	Total N	Subgroups	Subgroups Validated?	Outcomes	Outcomes Validated? §	Subgroup Comparison Findings (P value*)
Silver-Thorn 2009 (PMID none)	Locking (Total Knee 2000) vs. hydraulic knee	5	Age Time since amputation Height Residual limb length	Yes, all	Gait speed (distance undefined) Cadence (distance undefined) Comfort measures Confidence Stability, perceived Borg Rating of Perceived Exertion	No#	Nonsignificant
Theeven 2011 (PMID 21947182, 22549656)	Microprocessor (2 settings) vs. mechanical knee	30	K2 subgroups (high, intermediate, low)	No	Activity measures PEQ subscales Perceived difficulties Performance times	No Yes No No	Nonsignificant
Traballesi 2011 (PMID 21684165)	Marlo anatomic vs. ischial component socket	7	Sex Age Height Time since amputation	Yes, all	PEQ mobility subscale	Yes	Nonsignificant
Wong 2015 (PMID 25768067)	Microprocessor vs. mechanical knee	8	K level (1, 2, 3) Age Time since ambulation Bilateral vs. unilateral	Yes, all	ABC balance, Berg Balance Scale Houghton scale TUG walking Falls, reported Fear of falling	Yes	K2-3 favored microprocessor knee more than K1 did on TUG walking scale (0.0001)

Abbreviations: ABC = Activities-Specific Balance Confidence, PEQ = Prosthesis evaluation questionnaire, TF = transferoral amputation, TT = transtibial amputation, TUG = timed up and go test.

* Whether statistically significant difference in effect/association by subgroup, based on Bonferroni P-value.

† P value reported as <0.01; Bonferroni P value threshold = 0.0036.

§ The decisions in this column may change as additional studies are review during the literature search update process.

For gait speed and cadence, we included the distance or time walked as an integral part of the measure. To be considered validated, the specific time or distance walk had to have evidence of validity. Walking tests without reported time or distance are considered to be nonvalidated.

 Table 4.5. Subgroup analyses. Alaranta 1994, Comparing Energy-Storing Versus Conventional Ankle/Foot

 Component

Outcome	Overall	Ν	Subgroup	Ν	Comparator	Ν	P Difference†	P Difference†	Findings
	Favors*	Total		Subgroup	-	Comparator	(Categorical)	(Continuous)	-
	(P value)					-			
Movement disability index: Indoors	ES (<0.001)	168	Transfemoral	27	Transtibial	141	1.00		
Movement disability index: Upstairs	ES (<0.001)	168	Transfemoral	27	Transtibial	141	0.59		
Movement disability index: Downstairs	ES (<0.001)	168	Transfemoral	27	Transtibial	141	0.86		
Movement disability index: Upstairs	ES (<0.001)	168	Transfemoral	27	Transtibial	141	0.59		
Movement disability index: Uneven ground	ES (<0.001)	168	Transfemoral	27	Transtibial	141	0.51		
Movement disability index: Upstairs	ES (<0.001)	168	Transfemoral	27	Transtibial	141	0.59		
Movement disability index: Uphill street	ES (<0.001)	168	Transfemoral	27	Transtibial	141	0.89		
Movement disability index: Upstairs	ES (<0.001)	168	Transfemoral	27	Transtibial	141	0.59		
Movement disability index: Swift walking	ES (<0.001)	168	Transfemoral	27	Transtibial	141	0.79		
Movement disability index: Upstairs	ES (<0.001)	168	Transfemoral	27	Transtibial	141	0.59		
Movement disability index: Total	no data	168	Age					<0.01	Younger age weakly correlated with favoring ES
		168	Age at amputation					NS	
		168	Body weight					<0.01	Lighter body weight weakly correlated with favoring ES
		168	Body mass index					NS	

Data for Alaranta 1994 (PMID 7991366).¹¹⁰ Additional details in Appendix D.: P values <0.05 are bolded and associated "findings" are noted; however see footnote about Bonferroni P value threshold. Italic bold P values are statistically significant below the Bonferroni P value. Abbreviations: ES = energy storing prosthesis

* Statistically significant difference favoring listed component over comparator. "Neither" does not distinguish between evidence of no difference and lack of statistical power to find a difference (due to imprecision).

+ Bonferroni P = 0.0036 (due to multiple testing, to be considered to be statistically significant, the P values for differences between subgroups had to be less than this value). A separate Bonferroni P value was calculated for each study based on the number of analyses (including subgroup analyses) analyzed by the study researchers and by this review.

Table 4.6. Subgroup analyses. De Asha 2014, Comparing Hydraulic Versus Rigid Ankle/Foot Component

Outcome	Overall Favors*	Ν	Subgroup	N	Comparator	Ν	P Difference†	P Difference†	Findings
	(P value)	Total		Subgroup	-	Comparator	(Categorical)	(Continuous)	_
Gait speed (m/s), 8 m	Hydraulic (0.005)	19	Transfemoral	8	Transtibial	11	0.12		
Cadence (steps/min), 8 m	Neither (0.84)	19	Transfemoral	8	Transtibial	11	0.53		

Data for De Asha 2014 (PMID 24997811).¹¹¹ Additional details in Appendix D. P values < 0.05 are bolded and associated "findings" are noted; however see footnote about Bonferroni P value threshold. Italic bold P values are statistically significant below the Bonferroni P value.

* Statistically significant difference favoring listed component over comparator. "Neither" does not distinguish between evidence of no difference and lack of statistical power to find a difference (due to imprecision).

† Bonferroni P = 0.005 (due to multiple testing, to be considered to be statistically significant, the P values for differences between subgroups had to be less than this value). A separate Bonferroni P value was calculated for each study based on the number of analyses (including subgroup analyses) analyzed by the study researchers and by this review.

Outcome	Overall Favors* (P. value)	N Total	Subgroup	N Subgroup	Comparator	N Comparator	P Difference† (Categorical)	P Difference† (Continuous)	Findings
Self-selected walking speed (m/s), distance undefined	Neither (NS)	10	Vascular	3	Traumatic	7	0.87		
		10	Male	9	Female	1	0.0002		One woman favored SAP more than men did
		10	Age 31-46 y	5	57-79 y	5	0.78	0.81	
		10	Height 1.73-1.81 m	5	1.82-1.88 m	5	0.022	0.010	Shorter favored SAP more than taller did
		10	Time since amputation 1-2 y	4	4-50 y	6	0.34	0.76	
Fast walking speed (m/s), distance undefined	Neither (NS)	10	Vascular	3	Traumatic	7	0.67		
		10	Male	9	Female	1	<0.0001		One woman favored SAP more than men did
		10	Age 31-46 y	5	Age 57-79 y	5	0.64	0.84	
		10	Height 1.73-1.81 m	5	1.82-1.88 m	5	0.077	0.17	
		10	Time since amputation 1-2 y	4	4-50 y	6	0.045	0.096	More recent amputation favored SAP more than more distant did

Table 4.7. Subgroup analyses. Gard 2003, Comparing Shock-Absorbing Versus Non-Shock-Absorbing Pylon

Data for Gard 2003 (PMID 15077637).¹¹² Additional details in Appendix D. P values < 0.05 are bolded and associated "findings" are noted; however see footnote about Bonferroni P value threshold. Italic bold P values are statistically significant below the Bonferroni P value.

Abbreviations: NS = not statistically significant, SAP = shock-absorbing pylon

* Statistically significant difference favoring listed component over comparator. "Neither" does not distinguish between evidence of no difference and lack of statistical power to find a difference (due to imprecision).

Bonferroni P = 0.0028 (due to multiple testing, to be considered to be statistically significant, the P values for differences between subgroups had to be less than this value). A separate Bonferroni P value was calculated for each study based on the number of analyses (including subgroup analyses) analyzed by the study researchers and by this review.

Outcome	Overall Favors*	N	Subgroup	N	Comparator	Ν	P Difference†	P Difference†	Findings
	(P value)	Total		Subgroup	-	Comparator	(Categorical)	(Continuous)	
Stair Assessment Index	Microprocessor (<0.001)	17	K level 2	8	K level 3	9	0.96		
Hill Assessment Index	Microprocessor (<0.001)	17	K level 2	8	K level 3	9	0.41		
Hill speed (m/s)	Microprocessor (<0.001)	17	K level 2	8	K level 3	9	0.24		
Obstacle course speed (m/s)	Microprocessor (<0.001)	17	K level 2	8	K level 3	9	0.65		
Attention speed (m/s)	Microprocessor (<0.001)	17	K level 2	8	K level 3	9	0.14		
Attention accuracy (% correct)	Neither (>0.05)	17	K level 2	8	K level 3	9	0.97		
PEQ Ambulation	Microprocessor (0.008)	17	K level 2	8	K level 3	9	0.14		
PEQ Appearance	Neither (0.50)	17	K level 2	8	K level 3	9	0.90		
PEQ Frustration	Neither (0.11)	17	K level 2	8	K level 3	9	0.16		
PEQ Perceived response	Neither (0.07)	17	K level 2	8	K level 3	9	0.75		
PEQ Residual limb health	Neither (0.50)	17	K level 2	8	K level 3	9	0.93		
PEQ Social burden	Neither (0.54)	17	K level 2	8	K level 3	9	1.00		
PEQ Sounds	Neither (0.07)	17	K level 2	8	K level 3	9	0.25		
PEQ Utility	Neither (0.07)	17	K level 2	8	K level 3	9	0.14		
PEQ Well-being	Microprocessor (0.016)	17	K level 2	8	K level 3	9	0.83		
Mental Energy expenditure (VAS)	Microprocessor (0.02)	17	K level 2	8	K level 3	9	0.43		
Confidence while walking (VAS)	Microprocessor (0.001)	17	K level 2	8	K level 3	9	0.47		
Multitasking while walking (VAS)	Microprocessor (0.002)	17	K level 2	8	K level 3	9	0.82		
Difficulty with concentration (VAS)	Neither (0.07)	17	K level 2	8	K level 3	9	0.98		
Activity avoidance (VAS)	Neither (0.10)	17	K level 2	8	K level 3	9	0.11		
Frustration with falls (VAS)	Microprocessor (0.005)	17	K level 2	8	K level 3	9	0.81		
Embarrassment with falls (VAS)	Neither (0.23)	17	K level 2	8	K level 3	9	0.87		
Stumbles (VAS)	Microprocessor (0.05)	17	K level 2	8	K level 3	9	0.49		
Stumbles (number, reported)	Microprocessor (0.003)	17	K level 2	8	K level 3	9	0.40		
Semicontrolled falls (VAS)	Neither (0.64)	17	K level 2	8	K level 3	9	0.91		
Semicontrolled falls (number, reported)	Microprocessor (0.03)	17	K level 2	8	K level 3	9	0.53		

Table 4.8. Subgroup analyses. Hafner 2009, Comparing Microprocessor Versus Mechanical Knee Component

Data for Hafner 2009 (PMID 19675993).¹¹³ Additional details in Appendix D. P values <0.05 are bolded and associated "findings" are noted; however see footnote about Bonferroni P value threshold. Italic bold P values are statistically significant below the Bonferroni P value.

Abbreviations: PEQ = Prosthesis evaluation questionnaire, VAS = visual analogue scale.

* Statistically significant difference favoring listed component over comparator. "Neither" does not distinguish between evidence of no difference and lack of statistical power to find a difference (due to imprecision).

Bonferroni P = 0.0018 (due to multiple testing, to be considered to be statistically significant, the P values for differences between subgroups had to be less than this value). A separate Bonferroni P value was calculated for each study based on the number of analyses (including subgroup analyses) analyzed by the study researchers and by this review.

Table 4.9. Subgroup analyses. Hahn 2016, Comparing Genium Microprocessor Versus Prior Knee Components (Mostly C-Leg Microprocessor Knee)

Outcomes*	Overall	Ν	Study Conclusions‡
	Favors†	Total	
	(P value)		
Functional benefits (safety, harmonization of gait pattern, relief of the contralateral limb, possibility to divide attention, capability to vary gait speed, reduction of overall effort, reduction in number of aids, and change of mobility grade) Perception (of safety) Advanced maneuvers (assessed by prosthetist) Variable gait speed (capability to vary speed) Toileting Walking stairs alternatingly (up/down)	Genium (implied <0.05)	899	Many variables were statistically significant in multivariable regression analyses for different outcomes (see text). However, "None of the variables and none of the regression models yield explanatory predictive power" regarding who would most benefit from a microprocessor knee. These variables included: age, years wearing prosthesis, distance walked per day, gender, vascular disease etiology, amputation level, bilateral amputation, no comorbidity, diabetes mellitus, cardiovascular disease, "distortion circulation leg", hip problem, "further disability", profession, residual limb condition, residual limb length, residual limb loading, adhesion, number of falls per year, mobility grade. In addition, these variables were determined to have no overall predictive value: body mass index, neuropathy, visual impairment, artificial hip, back pain, paresis lower extremity, paresis upper extremity, further amputation, malformation, contralateral joint instability/joint replacement/nain ostenarthritis of the lower limb ionits, bin contracture scarted residual limb and
			annual falls (yes/no).

Data for Hahn 2016 (PMID 27828871).¹¹⁴ Additional details in Appendix D. * Listed outcomes. Unclear which outcomes were used in the final models.

Statistically significant difference favoring listed component over comparator. "Neither" does not distinguish between evidence of no difference and lack of statistical power to find a difference † (due to imprecision).

[‡] There were many important biases and other concerns with the study and analyses.

		,		, e e	<u> </u>	<u> </u>			•
Outcome	Overall Favors*	Ν	Subgroup	N	Comparator	Ν	P Difference†	P Difference†	Findings
	(P value)	Total		Subgroup	-	Comparator	(Categorical)	(Continuous)	-
Gait speed (m/min),	Neither (0.060)	17	Vascular	14	Nonvascular	3	0.016		Nonvascular favored open
6 minutes									knee more than vascular did
		17	Male	16	Female	1	0.59		
		17	Age 26-50 y	8	55-75 y	9	0.004	0.014	Younger favored open knee
					-				more than older did

Table 4.10. Subgroup analyses. Isakov 1985, Comparing Locking Versus Open Knee Component

Data for Isakov 1985 (PMID 3868034).¹¹⁵ Additional details in Appendix D. P values <0.05 are bolded and associated "findings" are noted; however see footnote about Bonferroni P value threshold. Italic bold P values are statistically significant below the Bonferroni P value.

* Statistically significant difference favoring listed component over comparator. "Neither" does not distinguish between evidence of no difference and lack of statistical power to find a difference (due to imprecision).

† Bonferroni P = 0.010 (due to multiple testing, to be considered to be statistically significant, the P values for differences between subgroups had to be less than this value). A separate Bonferroni P value was calculated for each study based on the number of analyses (including subgroup analyses) analyzed by the study researchers and by this review.

Outcome	Overall Favors*	Ν	Subgroup	Ν	Comparator	Ν	P Difference†	P Difference†	Findings
	(P value)	Total		Subgroup		Comparator	(Categorical)	(Continuous)	-
Stumbles, reported	Microprocessor (0.006)	15	K level 2	10	K level 3-4	5	0.14		
		15	K level 2-3	4	K level 4	11	0.030		K2-3 favored C- Leg more than K4 did
		15	Age 28-57 y	8	58-83 y	7	0.53	0.38	
		15	Vascular	7	Nonvascular	8	0.056		
		15	Height 160-170 cm	5	173-188 cm	10	0.44	0.93	
		14	Employed	7	Not employed	7	0.75		
		15	Prosthesis use 6-12 mo	9	>12 mo	6	0.13		
		15	Residual limb "firm"	7	"soft" or "medium"	8	0.38		
		15	Residual limb "medium" or "firm"	13	"soft"	2	0.51		
		15	Residual limb length 32-43 cm	8	11-31 cm	7	0.19	0.71	
		15	Residual limb as percent of femur 74-100%	8	27-73%	7	0.40	0.74	
Falls, reported	Microprocessor (0.03)	15	K level 2	10	K level 3-4	5	0.48		
	,	15	K level 2-3	4	K level 4	11	0.089		
		15	Age 28-57 y	8	58-83 y	7	0.48	0.10	
		15	Vascular	7	Nonvascular	8	0.24		
		15	Height 160-170 cm	5	173-188 cm	10	0.48	0.48	
		14	Employed	7	Not employed	7	0.15		
		15	Prosthesis use 6-12 mo	9	>12 mo	6	0.29		
		15	Residual limb "firm"	7	"soft" or "medium"	8	0.20		
		15	Residual limb "medium" or "firm"	13	"soft"	2	0.84		
		15	Residual limb length 32-43 cm	8	11-31 cm	7	0.37	0.68	
		15	Residual limb as percent of femur 74-100%	8	27-73%	7	0.48	0.80	
Self-selected walking speed, 75 m	Microprocessor (0.03)	15	K level 2	10	K level 3-4	5	0.84		
		15	K level 2-3	4	K level 4	11	0.75		
		15	Age 28-57 y	8	58-83 y	7	0.82	0.80	
		15	Vascular	7	Nonvascular	8	0.27		
		15	Height 160-170 cm	5	173-188 cm	10	0.20	0.33	
		14	Employed	7	Not employed	7	0.67		

Table 4.11. Subgroup analyses. Kahle 2008, Comparing Microprocessor (C-Leg) Versus Mechanical Knee Component

Outcome	Overall Favors*	Ν	Subgroup	Ν	Comparator	Ν	P Difference†	P Difference†	Findings
	(P value)	Total	5	Subgroup	•	Comparator	(Categorical)	(Continuous)	J J
		15	Prosthesis use 6-12 mo	9	>12 mo	6	0.46		
		15	Residual limb "firm"	7	"soft" or "medium"	8	0.51		
		15	Residual limb "medium" or "firm"	13	"soft"	2	0.70		
		15	Residual limb length 32-43 cm	8	11-31 cm	7	0.63	0.50	
		15	Residual limb as percent of femur 74-100%	8	27-73%	7	0.16	0.49	
Fastest walking on even terrain, 75 m	Microprocessor (0.005)	15	K level 2	10	K level 3-4	5	0.64		
		15	K level 2-3	4	K level 4	11	0.93		
		15	Age 28-57 y	8	58-83 y	7	0.75	0.41	
		15	Vascular	7	Nonvascular	8	0.41		
		15	Height 160-170 cm	5	173-188 cm	10	0.18	0.26	
		14	Employed	7	Not employed	7	0.76		
		15	Prosthesis use 6-12 mo	9	>12 mo	6	0.43		
		15	Residual limb "firm"	7	"soft" or "medium"	8	0.34		
		15	Residual limb "medium" or "firm"	13	"soft"	2	0.60		
		15	Residual limb length 32-43 cm	8	11-31 cm	7	0.34		
		15	Residual limb as percent of femur 74-100%	8	27-73%	7	0.18	0.46	
Fastest walking on uneven terrain, 38 m	Microprocessor (<0.001)	15	K level 2	10	K level 3-4	5	0.76		
		15	K level 2-3	4	K level 4	11	0.068		
		15	Age 28-57 v	8	58-83 v	7	0.77	0 071	
		15	Vascular	7	Nonvascular	8	0.13		
		15	Height 160-170 cm	5	173-188 cm	10	0.44	0.41	
		14	Employed	7	Not employed	7	0.41		
		15	Prosthesis use 6-12 mo	9	>12 mo	6	0.94		
		15	Residual limb "firm"	7	"soft" or "medium"	8	0.12		
		15	Residual limb "medium" or "firm"	13	"soft"	2	0.052		
		15	Residual limb length 32-43 cm	8	11-31 cm	7	0.30	0.17	
		15	Residual limb as percent of femur 74-100%	8	27-73%	7	0.77	0.13	
Fastest walking on even terrain, 6 m	Microprocessor (0.001)	15	K level 2	10	K level 3-4	5	0.38		

Outcome	Overall Favors*	Ν	Subgroup	Ν	Comparator	Ν	P Difference†	P Difference†	Findings
	(P value)	Total	5 .	Subgroup		Comparator	(Categorical)	(Continuous)	J J
		15	K level 2-3	4	K level 4	11	0.98		
		15	Age 28-57 y	8	58-83 y	7	0.71	0.48	
		15	Vascular	7	Nonvascular	8	0.65		
		15	Height 160-170 cm	5	173-188 cm	10	0.64	0.79	
		14	Employed	7	Not employed	7	0.030		Employed favored C-Leg more than not employed did
		15	Prosthesis use 6-12 mo	9	>12 mo	6	0.44		
		15	Residual limb "firm"	7	"soft" or "medium"	8	0.50		
		15	Residual limb "medium" or "firm"	13	"soft"	2	0.71		
		15	Residual limb length 32-43 cm	8	11-31 cm	7	0.14	0.72	
		15	Residual limb as percent of femur 74-100%	8	27-73%	7	0.36	0.78	
Montreal Rehabilitation Performance Profile	Microprocessor (<0.001)	15	K level 2	10	K level 3-4	5	0.15		
		15	K level 2-3	4	K level 4	11	0.38		
		15	Age 28-57 y	8	58-83 y	7	0.20		
		15	Vascular	7	Nonvascular	8	0.21		
		15	Height 160-170 cm	5	173-188 cm	10	0.44	0.88	
		14	Employed	7	Not employed	7	0.32		
		15	Prosthesis use 6-12 mo	9	>12 mo	6	0.37		
		15	Residual limb "firm"	7	"soft" or "medium"	8	0.16		
		15	Residual limb "medium" or "firm"	13	"soft"	2	0.30		
		15	Residual limb length 32-43 cm	8	11-31 cm	7	0.12	0.97	
		15	Residual limb as percent of femur 74-100%	8	27-73%	7	0.19	0.998	

Data for Kahle 2008 (PMID 18566922).¹¹⁶ Additional details in Appendix D. P values < 0.05 are bolded and associated "findings" are noted; however see footnote about Bonferroni P value threshold. Italic bold P values are statistically significant below the Bonferroni P value.

* Statistically significant difference favoring listed component over comparator. "Neither" does not distinguish between evidence of no difference and lack of statistical power to find a difference (due to imprecision).

+ Bonferroni P = 0.00040 (due to multiple testing, to be considered to be statistically significant, the P values for differences between subgroups had to be less than this value). A separate Bonferroni P value was calculated for each study based on the number of analyses (including subgroup analyses) analyzed by the study researchers and by this review.

Table 4.12. Subgroup analyses. Silver-Thorn 2009, Comparing Locking (Total Knee 2000) Versus Hydraulic Knee Component

Outcome	Overall Favors* (P value)	N Total	Subgroup	N Subgroup	Comparator	N Comparator	P Difference† (Categorical)	P Difference† (Continuous)	Findings
Borg Rating of Perceived Exertion test	Neither (1.00)	4	Age 33-41 y	2	43-58 y	2	0.47	0.91	
		4	Time since amputation 8-20 y	2	31-34 y	2	0.20	0.30	
		4	Height 171-173 cm	2	178-184 cm	2	0.47	0.15	
		4	Residual limb length 23-28 cm	2	43-58 y	2	0.20	0.029	Shorter residual limb favored Total Knee 2000 more than longer residual did
Confidence (Likert)	Neither (0.32)	4	Age 33-41 y	2	31-34 y	2	0.77	0.34	
		4	Time since amputation 8-20 y	2	178-184 cm	2	0.31	0.075	
		4	Height 171-173 cm	2	32-36 cm	2	0.77	0.80	
		4	Residual limb length 23-28 cm	2	43-58 y	2	0.31	0.46	
Perceived stability	Neither (0.32)	4	Age 33-41 y	2	31-34 y	2	0.77	0.34	
		4	Time since amputation 8-20 y	2	178-184 cm	2	0.31	0.075	
		4	Height 171-173 cm	2	32-36 cm	2	0.77	0.80	
		4	Residual limb length 23-28 cm	2	43-58 y	2	0.31	0.45	
Comfort on uneven terrain	Neither (0.19)	4	Age 33-41 y	2	31-34 y	2	0.81	0.56	
		4	Time since amputation 8-20 y	2	178-184 cm	2	0.037	0.1	More recent amputation favored Total Knee 2000 more than more distant amputation did
		4	Height 171-173 cm	2	32-36 cm	2	0.81	0.41	
		4	Residual limb length 23-28 cm	2	43-58 y	2	0.037	0.051	Longer residual limb favored Total Knee 2000 more than more shorter did
Comfort up stairs	Neither (0.092)	4	Age 33-41 y	2	31-34 y	2	0.29	0.88	
		4	Time since amputation 8-20 y	2	178-184 cm	2	0.29	0.52	

Outcome	Overall Favors* (P value)	N Total	Subgroup	N Subgroup	Comparator	N Comparator	P Difference† (Categorical)	P Difference† (Continuous)	Findings
		4	Height 171-173 cm	2	32-36 cm	2	0.29	0.085	
		4	Residual limb length 23-28 cm	2	43-58 y	2	0.29	0.046	Shorter residual limb favored Total Knee 2000 more than more longer did
Comfort in a crowd	Neither (0.39)	4	Age 33-41 y	2	31-34 y	2	0.42	0.95	
		4	Time since amputation 8-20 y	2	178-184 cm	2	0.42	0.39	
		4	Height 171-173 cm	2	32-36 cm	2	0.42	0.14	
		4	Residual limb length 23-28 cm	2	43-58 y	2	0.42	0.19	
Gait speed (m/s), distance undefined	Neither (0.072)	5	Age 33-41 y	2	31-34 у	3	0.67	0.53	
		5	Time since amputation 8-20 y	3	178-184 cm	2	0.14	0.10	
		5	Height 171-173 cm	2	32-36 cm	3	0.50	0.87	
		5	Residual limb length 23-28 cm	3	43-58 y	2	0.071	0.20	
Cadence (steps/min), distance undefined	Neither (0.20)	5	Age 33-41 y	2	31-34 y	3	0.74	0.39	
		5	Time since amputation 8-20 y	3	178-184 cm	2	0.37	0.36	
		5	Height 171-173 cm	2	32-36 cm	3	0.16	0.48	
		5	Residual limb length 23-28 cm	3	43-58 y	2	0.30	0.28	

Data for Silver-Thorn 2009 (PMID none).¹²⁰ Additional details in Appendix D. P values < 0.05 are bolded and associated "findings" are noted; however see footnote about Bonferroni P value threshold. Italic bold P values are statistically significant below the Bonferroni P value.

* Statistically significant difference favoring listed component over comparator. "Neither" does not distinguish between evidence of no difference and lack of statistical power to find a difference (due to imprecision).

† Bonferroni P = 0.00078 (due to multiple testing, to be considered to be statistically significant, the P values for differences between subgroups had to be less than this value). A separate Bonferroni P value was calculated for each study based on the number of analyses (including subgroup analyses) analyzed by the study researchers and by this review.

Outcome	Overall Favors ^{*,†}	Ν	Subgroups	Ν	Comparator	Ν	P Difference§	P Difference#	Findings†
	(P value)	Total		Subgroups‡		Comparator	(Categorical)	(Continuous)	
Activity time (% of up time)	Neither (0.86, 0.90)	30	K2 High, Intermediate§	12, 12	K2 Low§	6		>0.42 (all§)	
Bouts of activity (number)	Neither (0.99, 0.95)	30	K2 High, Intermediate§	12, 12	K2 Low§	6		>0.42 (all§)	
Daily activity "counts"	Neither (0.94, 0.89)	30	K2 High, Intermediate§	12, 12	K2 Low§	6		>0.31 (all§)	
PEQ Ambulation	Microprocessor A (0.01, 0.14)	30	K2 High, Intermediate§	12, 12	K2 Low§	6		>0.018 (all§)	High K2 favored microprocessor knee B more than low K2 subgroup; other comparisons P>0.13
PEQ Appearance	Neither (0.55, 0.33)	30	K2 High, Intermediate§	12, 12	K2 Low§	6		>0.69 (all§)	
PEQ Residual limb health	Microprocessors (0.003, <0.001)	30	K2 High, Intermediate§	12, 12	K2 Low§	6		>0.29 (all§)	
PEQ Satisfaction with prosthesis	Neither (0.05, 0.14)	30	K2 High, Intermediate§	12, 12	K2 Low§	6		>0.28 (all§)	
PEQ Satisfaction with walking	Microprocessor A (0.003, 0.19)	30	K2 High, Intermediate§	12, 12	K2 Low§	6		>0.006 (all§)	Intermediate K2 favored both microprocessor knees more than low K2 subgroup (P=0.28, 0.006), high K2 favored microprocessor knee B more than intermediate K2 subgroup (P=0.041); other comparisons P=0.066-0.44
PEQ Sounds	Neither (0.52, 0.33)	30	K2 High, Intermediate§	12, 12	K2 Low§	6		>0.33 (all§)	·
PEQ Utility	Microprocessors (0.006, 0.02)	30	K2 High, Intermediate§	12, 12	K2 Low§	6		>0.25 (all§)	
PEQ Well-being	Neither (0.30, 0.93)	30	K2 High, Intermediate§	12, 12	K2 Low§	6		>0.54 (all§)	
Perceived difficulty ambulation requiring prosthesis skill	Neither (0.63, 0.72)	30	K2 High, Intermediate§	12, 12	K2 Low§	6		>0.48 (all§)	
Perceived difficulty balance	Neither (0.56, 0.60)	30	K2 High, Intermediate§	12, 12	K2 Low§	6		>0.69 (all§)	
Perceived difficulty sitting and standing	Neither (0.62, 0.57)	30	K2 High, Intermediate§	12, 12	K2 Low§	6		>0.54 (all§)	
Performance time ambulation requiring prosthesis skill (min)	Microprocessor B (NS, 0.023)	30	K2 High, Intermediate§	12, 12	K2 Low§	6		>0.68 (all§)	

 Table 4.13. Subgroup analyses. Theeven 2011, Comparing Microprocessor (2 Settings) Versus Mechanical Knee

 Component

Outcome	Overall Favors ^{*,†}	Ν	Subgroups	Ν	Comparator	Ν	P Difference§	P Difference#	Findings†
	(P value)	Total		Subgroups‡	-	Comparator	(Categorical)	(Continuous)	-
Performance time	Microprocessors	30	K2 High, Intermediate§	12, 12	K2 Low§	6		>0.31 (all§)	
requiring balance	(<0.001, 0.002)								
(min)									
Performance time	Neither (0.87, 1.00)	30	K2 High, Intermediate§	12, 12	K2 Low§	6		>0.51 (all§)	
requiring sitting and									
standing (min)									

Data for Theeven 2011 (PMID 21947182, 22549656).^{117, 118} Additional details in Appendix D. P values < 0.05 are bolded and associated "findings" are noted; however see footnote about Bonferroni P value threshold. Italic bold P values are statistically significant below the Bonferroni P value.

Abbreviations: PEQ = Prosthesis evaluation questionnaire.

* Statistically significant difference favoring listed component over comparator. "Neither" does not distinguish between evidence of no difference and lack of statistical power to find a difference (due to imprecision).

† The two values for statistical significance indicate the separate analyses for the two microprocessor settings ("A" and "B").

[‡] The numbers of participants in each of the two subgroups (high K2 and intermediate K2).

Bonferroni P = 0.00037 (due to multiple testing, to be considered to be statistically significant, the P values for differences between subgroups had to be less than this value). A separate Bonferroni P value was calculated for each study based on the number of analyses (including subgroup analyses) analyzed by the study researchers and by this review.

§ 6 comparisons summarized: "High" vs. "intermediate" K2, "high" vs. "low" K2, and "intermediate" vs. "low" K2 for both microprocessor knees A and B vs. mechanical knee. "High," "intermediate," and "low" functional mobility levels were assigned by "three independent experts (a physical therapist, a rehabilitation physician and a prosthetist) based on participants' daily activity level, mean comfortable walking speed, past medical history, psychosocial status and current physical condition."

 Table 4.14. Subgroup analyses. Traballesi 2011, Comparing Marlo Anatomic vs. Ischial Component Socket

 Component

Outcome	Overall Favors*	Ν	Subgroup	N	Comparator	Ν	P Difference†	P Difference†	Findings
	(P value)	Total		Subgroup	-	Comparator	(Categorical)	(Continuous)	_
PEQ Mobility	Marlo Anatomic Socket (0.018)	7	Male	6	Female	1	0.022		One woman favored Marlo Anatomic Socket more than men did
		7	Age 25-28 y	3	41-46 y	4	0.42	0.28	
		6	Height 174- 180 cm	2	184-185 cm	4	0.074	0.017	Shorter favored Marlo Anatomic Socket more than taller did, among men
		7	Time since amputation 2-9 y	3	10-26 y	4	0.56	0.69	

Data for Traballesi 2011 (PMID 21684165).¹¹⁹ Additional details in Appendix D. P values < 0.05 are bolded and associated "findings" are noted; however see footnote about Bonferroni P value threshold. Italic bold P values are statistically significant below the Bonferroni P value.

Abbreviations: PEQ = Prosthesis evaluation questionnaire.

* Statistically significant difference favoring listed component over comparator. "Neither" does not distinguish between evidence of no difference and lack of statistical power to find a difference (due to imprecision).

+ Bonferroni P = 0.0071 (due to multiple testing, to be considered to be statistically significant, the P values for differences between subgroups had to be less than this value). A separate Bonferroni P value was calculated for each study based on the number of analyses (including subgroup analyses) analyzed by the study researchers and by this review.

Outcome	Overall Favors*	Ν	Subgroup	Ν	Comparator	N	P Difference†	P Difference†	Findings
	(P value)	Total		Subgroup		Comparator	(Categorical)	(Continuous)	
Falls, number	Microprocessor (0.020)	8	K level 1	6	K level 2-3	2	0.12		
		8	K level 1-2	4	K level 3	4	0.040		K1-2 favored microprocessor knee more than K3 did
		8	Age 43-61 y	4	63-74 y	4	0.040	0.027	Older favored microprocessor knee more than younger did
		8	Time since amputation 0.5-2 y	4	4-47 y	4	0.73	0.67	
		8	Bilateral	2	Unilateral	6	0.12		
ABC Balance	Microprocessor (0.012)	8	K level 1	6	K level 2-3	2	0.016		K2-3 favored microprocessor knee more than K1 did
		8	K level 1-2	4	K level 3	4	0.16		
		8	Age 43-61 y	4	63-74 y	4	0.10	0.021	Younger favored microprocessor knee more than older did
		8	Time since amputation 0.5-2 y	4	4-47 y	4	0.22	0.96	
		8	Bilateral	2	Unilateral	6	0.016		Bilateral favored microprocessor knee more than unilateral did
Houghton Scale	Neither (0.058)	8	K level 1	6	K level 2-3	2	0.61		
		8	K level 1-2	4	K level 3	4	0.37		
		8	Age 43-61 y	4	63-74 y	4	0.37	0.10	
		8	Time since amputation 0.5-2 y	4	4-47 y	4	0.13	0.47	
		8	Bilateral	2	Unilateral	6	0.61		
BBS Balance	Neither (0.11)	8	K level 1	6	K level 2-3	2	0.81		
		8	K level 1-2	4	K level 3	4	0.51		
		8	Age 43-61 y	4	63-74 y	4	0.95	0.93	
		8	Time since amputation 0.5-2 y	4	4-47 y	4	0.77	0.33	
		8	Bilateral	2	Unilateral	6	0.81		
TUG Walking	Microprocessor (0.043)	8	K level 1	6	K level 2-3	2	0.0001		K2-3 favored microprocessor knee more than K1 did
		8	K level 1-2	4	K level 3	4	0.24		
		8	Age 43-61 y	4	63-74 y	4	0.28	0.17	

Table 4.15. Subgroup analyses. Wong 2015, Comparing Microprocessor Versus Mechanical Knee Component

Outcome	Overall Favors*	Ν	Subgroup	N	Comparator	Ν	P Difference†	P Difference†	Findings
	(P value)	Total	. .	Subgroup		Comparator	(Categorical)	(Continuous)	
		8	Time since amputation 0.5-2 y	4	4-47 y	4	0.37	0.78	
		8	Bilateral	2	Unilateral	6	0.0001		Bilateral favored microprocessor knee more than unilateral did
Fear of falling	Microprocessor (0.042)	8	K level 1	6	K level 2-3	2	0.11		
		8	K level 1-2	4	K level 3	4	0.62		
		8	Age 43-61 y	4	63-74 y	4	0.35	0.24	
		8	Time since amputation 0.5-2 y	4	4-47 y	4	0.48	0.51	
		8	Bilateral	2	Unilateral	6	0.11		

Data for Wong 2015 (PMID 25768067).¹²¹ Additional details in Appendix D. P values < 0.05 are bolded and associated "findings" are noted; however see footnote about Bonferroni P value threshold. Italic bold P values are statistically significant below the Bonferroni P value.

Abbreviations: ABC = Activities-Specific Balance Confidence, BBS = Berg Balance Scale, TUG = timed up and go test.

* Statistically significant difference favoring listed component over comparator. "Neither" does not distinguish between evidence of no difference and lack of statistical power to find a difference (due to imprecision).

+ Bonferroni P = 0.0010 (due to multiple testing, to be considered to be statistically significant, the P values for differences between subgroups had to be less than this value). A separate Bonferroni P value was calculated for each study based on the number of analyses (including subgroup analyses) analyzed by the study researchers and by this review.

Studies That Evaluated Validated Outcomes

Of the 11 studies that directly compared different LLP components and provided sufficient data to allow subgroup analyses, nine reported on basic patient characteristics such as age, sex, limb length, amputation level, and amputation etiology. We considered these to be potentially important predictors and therefore handle them as if they were validated predictors. A tenth study (Hafner 2009) and two other studies (Kahle 2008, Wong 2015) evaluated K levels, ^{113, 116, 121} which we assumed to be equivalent to validated, although we found no studies assessing K level validity, per se. One study (Theeven 2011) evaluated only K2 level subgroups ("high," "intermediate," and "low"), which were unique to the study and we considered to be *not* validated. ^{117, 118} Likewise, here we omit evaluation of residual limb firmness (an *ad hoc* descriptor) as a validated outcome predictor as was reported by one study (Kahle 2008). ¹¹⁶ None of the validated assessment techniques or predictor tools were used to characterize subgroups.

Studies evaluated numerous outcomes, most of which have not been validated in lower limb amputees. Only five of the studies analyzed validated outcomes (Hafner 2009, Isakov 1985, Kahle 2008, Traballesi 2011, and Wong 2015). These five studies were all deemed to be at moderate risk of bias. Four of the five studies reported data on subgroups based on patient characteristics that we considered valid; the fifth studies reported subgroup results separately but did not statistically analyze between-group differences (we calculated these differences based on reported data). Studies also reported events (e.g., falls) that we considered to be valid, by definition. The validated outcomes among these studies include 6 minute walk test (6MWT, gait speed measured during 6 minutes), reported falls, the PEQ, ABC, BBS, Houghton scale, and TUG walking.

The applicability of these studies to the overall population of people receiving LLPs varies. Most patients in the studies were on the younger side (less than about 50 years old), particularly in the Traballesi 2011 study comparing sockets, in which the average age was 34 years. Most included study participants were men; however, the percentage of men varied from 76 to 94 percent (among the three studies that reported patient sex). Among four studies that characterized patients K levels at baseline, only one study (Wong 2015) included people at K1 level (25%), three studies included people at K2 level (25-60%), one study (Traballesi 2011) included people at either K3 or K4 level, three additional studies included people at K3 level (33-53%), and one additional study included one additional patient (7%) at K4 level. These studies all evaluated knees or sockets; thus all patients had undergone transfemoral amputations. The four studies that reported amputation etiologies displayed wide heterogeneity across studies. In three studies, trauma accounted for about half or more of amputations (47-86%). In one study (Isakov 1985), 82 percent had dysvascular causes and only 18 percent trauma. In contrast, in Traballesi 2011, 86% had trauma as an etiology and the remainder cancer (none had dysvascular disease). Similarly, Hafner 2009 had a majority of people with trauma (59%), but only 6 percent with dysvascular etiologies. On the other hand, in Kahle 2008, about half each had trauma or dysvascular etiologies (excluding patients with congenital amputations).

Microprocessor Knees

Hafner 2009 (Table 4.8) compared the C-Leg microprocessor knee and mechanical knees in 17 people with unilateral transfemoral amputations, 59 percent due to trauma (and only 6 percent due to dysvascular disease). The participants were split approximately equally between K2 and K3. The study reported subgroup analyses by K level, but did not report statistical analyses

comparing the subgroups. Among the outcomes reported, they reported PEQ subscales, which have been validated, and the numbers of reported stumbles and falls. Overall, people using the microprocessor knee had fewer stumbles and falls and also scored better on PEQ Ambulation and Well-being subscales, compared to mechanical knees, but no differences were found between knees on the other PEQ subscales. Post hoc analyses comparing the K2 and K3 subgroups found no differences in effect (microprocessor vs. mechanical knee) between the subgroups. Overall, the study does not support differences in benefit of the microprocessor between people classified as K2 or K3.

Kahle 2008 (Table 4.11) compared a microprocessor knee (C-Leg) with a mechanical knee in 15 people with unilateral amputations (amputation level not described), excluding four people with congenital amputations. The participants had with K2 or greater function, but half of them moved up a K level when using the microprocessor knee. About one-third each had dysvascular and traumatic causes of their amputations. Overall, people reported fewer stumbles and falls (as separate outcomes) with the microprocessor knee. Other nonvalidated outcomes were also assessed. The article reported individual participant data which allowed multiple subgroup analyses based on K level, amputation etiology, age, height, employment status, and residual limb length. The study also reported on a nonvalidated measure of residual limb firmness. After accounting for multiple testing, no statistically significant differences were found between subgroups regarding relative benefit of the microprocessor knee to prevent stumbles and falls. While not statistically significant after accounting for multiple testing, K2 or K3 participants tended to have relatively fewer stumbles with the microprocessor knee than K4 amputees did. Overall, however, the study does not support any differences in benefit of microprocessor knees based on patient or residual limb characteristics.

Wong 2015 (Table 4.15) compared the C-Leg microprocessor and mechanical knees in 8 people classified as K1 to K3 with transfemoral amputations, three-quarters of which were unilateral. Overall, the study found mostly better outcomes with the microprocessor knee. The article reported individual participant data which allowed multiple subgroup analyses based on K levels, age, time since amputation, and bilateral versus unilateral amputation. The study analyzed several validated outcomes along with reported falls. For the TUG Walking outcome, the study found that those classified as K2 or K3 did relatively better with the microprocessor knee compared to mechanical knees than those classified as K1. People with bilateral amputations also did relatively better with the microprocessor knees compared to those with unilateral amputations. No differences were found in effect between older and younger patients or based on time since amputation. Across the other validated outcomes (reported falls, ABC Balance, BBS, fear of falling, and Houghton scale) no statistically significant differences were found between subgroups after accounting for multiple testing. For several subgroup comparisons, there was a tendency for one subgroup to perform relatively better with the microprocessor knee than another subgroup (i.e., P<0.05, but not significant after accounting for multiple testing); however, there was not consistency across subgroups or outcomes (see Table 4.15). Overall, there was evidence of subgroup differences in the effect of microprocessor knees on TUG walking based on K level and bilateral versus unilateral amputation, but no consistent patterns were found across subgroups and outcomes.

Other Components

Isakov 1985 (Table 4.10) compared two Otto Bock prostheses with a locking system knee (model 3R17) and with an "open" load-dependent brake knee (model 3R15) in 17 people with

unilateral transfemoral amputations, 82 percent of which were due to dysvascular disease. Overall, people had similar gait speeds with both knees. They reported gait speed averaged over 6 minutes and provided individual participant data that allowed subgroup analyses based on amputation etiology, sex, and age. Those 50 years or younger were more likely to have faster walking speed with the open knee, in contrast to those who were 55 years and older (P=0.004); however linear regression failed to find a significant association (after accounting for multiple testing). Participants with nonvascular amputation etiologies also tended to walk faster with the open knee, in contrast to those with vascular amputations; however, this finding was not statistically significant after accounting for multiple testing. Differences in gait speed between the two prostheses were similar in the one woman and the 16 men in the study. Overall, younger lower limb amputees favored the open knee over the locking knee significantly more than older amputees.

Traballesi 2011 (Table 4.14) compared the Marlo Anatomic Socket with an ischial component socket in 7 people with unilateral transfemoral amputations with K3 to K4 function; the large majority (86%) had amputations due to trauma. Overall, people had better mobility, per the PEQ mobility subscale, with the Marlo Anatomic Socket. The article reported individual participant data, which allowed multiple subgroup analyses based on patient characteristics and time since amputation. After accounting for multiple testing, no statistically significant differences were found between subgroups regarding relative benefit of the Marlo Anatomic Socket. The single woman in the study did tend to have even better mobility with the Marlo Anatomic Socket than the ischial component socket than the six men did; but the woman differed from the men in more ways than just her sex and the clinical significance of this finding is questionable. Shorter men also tended to have relatively better mobility with the Marlo Anatomic Socket than taller men, but this finding was also not statistically significant after accounting for multiple testing. Overall, the study does not support any differences in benefit of the Marlo Anatomic Socket over the ischial component socket based on patient characteristics.

Studies Using Nonvalidated Measures

All studies

Six studies reported analyses based only on nonvalidated measures (Alaranta 1994, De Asha 2014, Gard 2003, Hahn 2016, Silver-Thorn 2009, and Theeven 2011); two other studies reported subgroup analyses with some nonvalidated measures in addition to the validated measures discussed above (Hafner 2009, Kahle 2008). Theeven 2011 reported subgroup data only for *ad hoc* subclassifications of the K2 level (high, intermediate, and low). Kahle 2008 categorized patients based on firmness of their residual limb. These nine studies all used nonvalidated outcomes.

As summarized in Table 4.4, studies generally found no significant differences in the relative effectiveness of different components based on subgroup classification.

Study With Regression Analysis

Hahn 2016 was the largest eligible study, which conducted the most comprehensive analysis.¹¹⁴ It was the only eligible study to attempt to assess heterogeneity of treatment effect (how effects may differ in different people). The study created multivariable regression models with the goal of predicting which patients would most benefit from a Genium® microprocessor

knee compared to people's prior knee (mostly an alternative microprocessor knee, the C-Leg; both from Otto Bock Healthcare Products Austria).

Given the large size of the study (899 people with knee or higher amputations, mostly due to trauma (69%) who were classified as K2 to K4) and the use of regression analyses to investigate heterogeneity of treatment effect, the study was included for review. However, because of the imprecise comparison among LLP components used, strictly speaking, an argument could have been made to reject the study from the review. The study did not compare distinct components (or even types of components). Instead, they compared newly-prescribed Genium knees to participants' prior knee prosthetics. Among the 899 participants, 689 (76.6%) had used the C-Leg (a similar microprocessor knee), 38 (4.2%) used mechanical hydraulic knees, 22 (2.4%) pneumatic knees, 15 (1.7%) 4-axis polycentric knees, 19 (2.1%) other polycentric knees, 9 (1.0%) brake knees, and 3 (0.3%) locked knees. The article failed to report anything regarding the other 104 (11.7%) of the prior knees. Thus, the analysis is mostly a comparison of two different microprocessor knees, but in reality is an evaluation of just the Genium knee without a specific comparator. Of note, a somewhat similar study was conducted by the same group analyzing the C-Leg (or C-Leg compact) in 1223 participants, but this study was rejected since there was no description of, or clear comparison with, the prior knees.

The participants in the Genium study were all considered to be candidates most likely to benefit from the Genium prosthesis by their prosthetist's assessment. Thus, these people were deemed more likely to respond to the Genium prosthesis than other amputees. As noted, 77 percent were already users of microprocessor knees (the C-Leg or C-Leg compact). Furthermore, the analytic method used further limited the number of people included in the model. The researchers required complete datasets for all selected variables and did not impute missing data. Thus, at most the 425 people with data about their residual limb condition were included in the model; likely the actual number included was much smaller because of missing data for other variables. The final numbers analyzed in the models were not reported.

The study outcomes were based primarily on prosthetists' and participants' ratingsassessments as indicated in an existing database. (NB. The outcomes reported in this paper were assessed by a 2008 thesis conducted at the Universitätsklinikum Münster in Germany, which is not available). However, the authors state that "the data do not rely on validated outcomes as recommended in controlled trials. This limits the accuracy of the findings specifically with respect to magnitude of the effects."

Across the various specific outcomes evaluated, the total responsiveness ranged from 67 to 96 percent. Total responsiveness ranged from 95 to 97 percent, suggesting that few people failed to have some improvement with the Genium prosthesis. For inclusion in their models, the researchers chose the most responsive items within each of the performance areas: safety, harmonization of gait pattern, relief of contralateral limb, possibility to divide attention, capability to vary gait speed, reduction of overall effort, reduction in number of aids, change of mobility grade, perceived safety on stairs and slopes, variation of gait speed, walking with small steps, more difficult walking requirements, and more difficult walking enviroements. However, the study does not report the percentage of patients who were responsive for each modeled outcome; in part this is due to the fact that the actual outcome(s) used in the final model are unclear. If the percentage was indeed high, there may be "class imbalance" where the proportion of failures is so small, there is little room for a model to improve over an intercept-only model that simply classifies everyone as a responder. In other words, the "best" model may not differentiate people as likely responders and nonresponders much better than an assumption that

all will respond, since in reality almost all did respond. However, it is not clear which "responsiveness" outcome(s) were used in their final model(s).

A very large set of variables related to patient characteristics, amputation and residual limb characteristics, and current type of prosthesis used, among others were tested for inclusion as predictors in the models. The analyses found numerous highly statistically significant predictors of the outcomes. However, overall, the authors reported that "none of the variables and none of the regression models yield[ed] explanatory predictive power." They were also not able to determine a coherent, stable, reproducible variable set.

The paper, though, does not, in fact, perform an analysis of the predictive performance of logistic regression models to identify people with better or clearly better outcomes with a Genium knee. The only metric of predictive performance reported was an R^2 value, which is not sufficient to make conclusions for several reasons. While the R^2 value can be considered as a metric of global predictive performance, it is not generally a very informative one. For logistic regression there are several pseudo- R^2 statistics. These statistics have different interpretations, and not all of them have a maximum of 1 (i.e., 100%) in a given dataset. The various pseudo- \hat{R}^2 from the same logistic regression can differ greatly because each is calculated differently. For example, it is possible for a logistic regression to have a e.g., Nagelkerke pseudo R^2 of 0.99, and a McFadden pseudo- R^2 of 0.40. The studies does not report which R^2 was used, so one cannot determine if it really indicates that there is no predictive ability at all. It is conceivable that the reported R² values of 0.263 indicates that the model is explanatory. Finally, the study does not report a thorough evaluation of the discriminatory performance (ability of a model to correctly discriminate those at higher risk from those at lower risk) and calibration performance (among those predicted to have a given probability of response — x per 100 — do around x per 100 actually respond?). For these reasons, the study does not provide compelling evidence that their model has no predictive performance.

The article does not report the actual final model(s), and as noted, it is not abundantly clear which outcomes were used in the final models. However, they report linear regressions between a long list of participant and component variables and outcomes. It is implied that the outcomes are the differential response to the Genium knee (whether there was a relative difference with the Genium and the prior prostheses—mostly C-Leg). In addition, many of the associations were highly statistically significant. Among these, for the outcome "variable gait speed", younger age, longer distance walked per day (presumably on their old knee), nonvascular etiology, amputation level (unclear how defined), unilateral amputation, no comorbidities, no diabetes, no cardiovascular disease, no leg peripheral vascular disease, no further disability, profession (not defined), better residual limb condition, longer residual limb length, greater residual limb loading, greater number of falls per year, and higher mobility grade were all statistically significantly associated with better variable gait speed with the Genium knee (than people with the opposite states). P values for these variables ranged from 10⁻²⁶ (mobility grade) to 0.025 (further disability). Similar findings were reported for toileting and walking up stairs alternatingly.

In brief, while relative effectiveness of the Genium microprocessor knee was highly statistically significantly different for many subgroups versus prior knee prostheses (mostly the C-Leg microprocessor knee), the study reported that no set of variables were found to accurately predict which patients would most benefit from the microprocessor knee. However, there are numerous concerns about a number of critical issues. There was likely selection bias: the included subpopulation was chosen based on their assessed likelihood of succeeding with the

microprocessor knee, and analyzed participants had to have available data for all included variables. The primary comparison was between newly prescribed microprocessor Genium knees and a mix of prior prosthetic knees, mostly another microprocessor knee, the C-Leg, but also various mechanical knees and a large number of unknown prosthetic types. The average participant may have been too likely to respond well to the microprocessor knee to allow for the possibility of determining who, on average, would be likely to fail with the knee. The study's analytic methodology and findings were too incompletely reported to assess how the model faired and if correct methodologies were used.

Summary

Table 4.16 summarizes the study findings. A relatively small percentage of comparative studies report sufficient data to allow subgroup analysis and evaluation of heterogeneity of treatment effect (12%, 11 of 90 otherwise eligible studies). Of these 11 studies, only five used validated measures. Only one of the eligible studies was a randomized trial (Theeven 2011), but it did not evaluate validated subgroups. Only two studies (De Asha 2014, Hahn 2016) evaluated heterogeneity of treatment effect (analysis of differences in effect across subgroups); most reported individual participant level data without conducting their own subgroup analyses. Across studies, a scattering of statistically significant differences in relative effects of different components were found based on different subgroup comparisons. However, these were not consistent across, and often within, studies. Only one study (Hahn 2016) analyzed the most important aspect of the KQ, namely whether any study participant characteristics (or set of characteristics) can accurately and effectively predict which patients will most benefit from a given component. However, the study was methodologically and analytically flawed and compared a specific microprocessor knee (Genium) to any prior used knee (mostly another microprocessor knee, C-Leg). This study was conducted in largely younger men (average age 49 years, 83% men) two-thirds of whom had traumatic etiologies for their amputations. Despite finding numerous statistically significant associations between participant characteristics and functional outcomes, the study concluded that no model accurately predicted relative outcome (between the Genium microprocessor knee and, mostly, the C-Leg microprocessor knee).

Overall studies that investigated subgroup effects did not identify participant characteristics that predict which lower limb amputees would most benefit from a given component. Based on the methodology used to assess strength of evidence, the studies warrant a low strength of evidence that evaluated patient characteristics do not predict which patients would most benefit from a given LLP component. However, it may be more accurate to conclude that the evidence is currently sparse and fails to adequately address whether different subgroups of amputees are more or less likely to benefit from given specific components. Most studies were very underpowered to find statistically significant evidence of differences among subgroups, with on average only about 30 participants per study (excepting one larger regression analysis). Only five of the 11 studies used validated outcomes. Similar conclusions are reached for this subset of studies. In fact, these studies were even smaller, with on average only about 12 participants each. One large study attempted to develop a model to predict success with microprocessor knees; however the study failed to use a validated outcome and had several methodological and analytic flaws, and thus provides insufficient additional evidence regarding who would most benefit from a microprocessor knee. Furthermore, across all studies, study participants were in general not likely to be representative of the Medicare population, being both mostly young and with amputations due to trauma, with relatively few people with dysvascular disease.

Outcome	No. Studies (N)	Study Limitations	Consistency	Precision	Reporting Bias	Directness*	Other Issues	Findings	SoE Grade
Validated outcomes (univariable)	5 (64)	Medium †	Consistent	Imprecise	Undetected	Indirect ‡	High degree of multiple testing; mostly evaluations of knee components; mostly K2 or K3 level, unilateral transfemoral amputations due to traumatic etiologies	Mostly no significant differences in relative effect based on participant characteristics	Low
All outcomes (univariable)	10 (296)	Medium †	Consistent	Imprecise	Undetected	Indirect ‡	Nonvalidated outcomes, high degree of multiple testing; mostly K2 to K4 level, unilateral transfemoral amputations due to traumatic etiologies	Mostly no significant differences in relative effect based on participant characteristics	Low
Ambulatory and functional outcomes, nonvalidated (multivariable model)	1 (899)	High §	NA	Precise	Undetected	Indirect #	K2 to K4 (mostly K3) level, mostly traumatic etiologies	Flawed study concluded no model accurately predicted relative outcomes. A large set of variables individually were associated with better outcomes with the microprocessor knee.	Insufficient

Table 4.16. Key Question 4 Evidence Profile

Abbreviations: KQ = Key Question, NA = not applicable, RoB = risk of bias, SoE = strength of evidence.

* Representative of either (or both) older adults (≥65 years old) or those with dysvascular amputations.

† Nonrandomized studies, univariable analyses (mostly individual participant data reports), generally lack of evaluation of heterogeneity of treatment effect, mostly small studies.

‡ Both relatively young age amputees and primarily people with amputations due to trauma in most studies. Almost all (that reported) had unilateral transfermoral amputations.

§ Nonrandomized, likely biased sample of participants, nonvalidated outcomes, unclear which outcome(s) used in final models,, unclear and possibly flawed analytic methods. See text.

Highly selected participants who had been assessed as likely to benefit from a microprocessor knee, possibly biased dropouts, relatively young and two-thirds had trauma etiology.

Key Question 5

How do study participants' preprescription **expectations of ambulation** align with their functional outcomes?

KQ 5 asked how study participants' preprescription expectations of ambulation align with their functional outcomes. We found no study that addressed this issue.

Key Question 6

What is the level of patient **satisfaction with the process** of accessing a LLP (including experiences with both providers and payers)?

We found two studies that addressed this question. Pezzin 2004 surveyed individuals about satisfaction with upper or lower prosthetic limbs and related services.¹²² Hart 1999 reported data about satisfaction with the prosthetist appointments in a study designed to assess the reliability and construct validity of the OPOT in clients with LLPs.¹⁸

In the more recent study (Pezzin 2004) study participants were asked 12 questions about the prosthetist from whom they received care in the past 12 months.¹²² Based on their responses, 3 dimensions of prosthetist quality assessment were examined: technical skills, information giving, and interpersonal manner. These questions were answered by approximately 823 study participants who had seen a prosthetist in the past 12 months. Participant descriptive data were given for 935 adults in the U.S., including the 12 percent who had not recently seen a prosthetist. Overall, the study was deemed to be at moderate risk of bias. Approximately 30 percent of potentially eligible patients could not be reached or refused to participate; no assessment of whether they were systematically different than respondents. However, multivariable analyses were conducted where appropriate.

Study participants were 18 to 84 years old (mean 50.5 years) who had either a lower limb amputation (\geq 78.9%) or upper limb amputation (\geq 10.0%); the 10.8 percent of participants with bilateral amputations were not further categorized as having upper or lower limb amputations (but people with both upper and lower limb amputations were excluded). Amputation was due to dysvascular diseases (37.8%), trauma (38.7%), or cancer (23.4%). Lower limb amputees were almost evenly split between above-knee (38.5%) and below-knee (40.4%) amputations. Amputation occurred during childhood in 12.5 percent and after age 64 years in 8.8 percent of participants. Among participants, 20.7 percent had Medicare insurance and 15.4 percent Medicaid (participants were categorized as having only a single type of insurance). Most participants (94.6%) were currently using a prosthesis. They used their prostheses for an average of 71 (SD 41) hours per week and had a mean 9 (SD 11) visits to a prosthetist in the past 12 months, but a median of 5 visits; 12 percent did not visit a prosthetist in the past year.

The study found that more than 75 percent consistently agreed or strongly agreed with positive statements across all items related to prosthetist technical skills, information giving, and interpersonal manner. Participants were most satisfied with prosthetist's technical skills: they agreed or strongly agreed that prosthetists check everything (93%), are competent (95%), understand patients' medical history (89%), understand what is wrong (86%), and are current on technology (90%). Participants were also mostly satisfied with prosthetists' information giving:

they agreed or strongly agreed that prosthetists tell them all they want to know (88%), answer all questions (93%), have the patients' confidence (88%), and, to a lesser extent, can be depended on (75%). Regarding interpersonal skills, participants agreed or strongly agreed that prosthetists were not in a hurry (83%), explained things (87%), and discussed things (85%). Less favorable ratings related to being able to depend on the prosthetist for the individual's physical wellbeing (26% disagreed or strongly disagreed).

Multivariable regression models were used to examine the correlates of positive perceptions of a prosthetist's quality for the three summary dimensions of provider care (technical skills, information giving, and interpersonal manner); however, numerical data regarding the models were not reported. Females, whites, those with higher levels of education, those with above-knee amputation or bilateral amputation, and those who had undergone an amputation more recently were more likely to have favorable perceptions about their prosthetist (P<0.05). Patients with Medicaid insurance had lower satisfaction (P<0.05, implied) than those with private or commercial insurance, but no differences were found among those with Medicare, other public insurance, or the uninsured. No differences in satisfaction were found based on amputation etiology or geographic region of residence (in the U.S.). The study did not evaluate satisfaction with payers.

In the older study validating OPOT, Hart 1999 surveyed 840 adults requiring LLP who were seen in 56 practices in the U.S.¹⁸ Almost half had Medicare (43.6%) or Medicaid (7.2%) as a primary payer. The clients were on average about 56 years old (men 55.6 ± 16.2 years, women 58.1 ± 17.9 years), ranging from K0 (0.4%) to K4 (14.0%) K level; about half were classified as K3 (47.6%) and about one-quarter K2 (29.8%). Seventy percent were men. About three-quarters (73.4%) had transtibial or below-knee amputations and most of the rest (19.2%) had transfemoral amputations. Nearly two-thirds had dysvascular causes of amputation (58.2%) and nearly one-third trauma (29.2%). About two-thirds were being evaluated for a replacement prosthesis (67.6%), as opposed to first prosthesis (32.4%).

Clients were surveyed at initial fitting (of their first or new prosthesis) and at followup on average 82 days later (SD 44). Clients were asked five questions covering receiving an appointment within a reasonable time period, location of office, courtesy from staff, waiting room staff, and ability to express client concerns about the limb; other questions pertained to satisfaction with their LLP and function. These questions were transformed into a single client satisfaction with prosthetist performance score ranging from 0 to 100 (best). The average scores were similar at both visits at 81.9 ± 12.3 and 84.6 ± 10.8 . Of note, client satisfaction was not correlated with SF-12, SF-12 subscales, or a measure or overall health status. Also of note, the clients mostly found the question of satisfaction to be important (mean 86 ± 16 , also on a scale of 0-100).

A limitation of this study was that a high percentage of clients did not answer the survey questions at both initial and followup visits. Of 840 included clients, only 417 (50%) gave answers at the initial visit and only 348 (41%) at followup; only 203 (24%) answered both surveys. Overall, the study was deemed to be at high risk of bias due to nonresponse without an assessment or full description of who did not answer the survey. No analyses were conducted to assess which clients were satisfied or dissatisfied, or why.

In summary, a moderate risk of bias study (of generally younger adults about one-third of whom had dysvascular disease) found that at least three-quarters of people receiving a LLP were satisfied with the process of accessing their LLP and a high risk of bias study (in which about half had Medicare or Medicaid insurance) found that on average clients were satisfied with their

visits to their prosthetists' offices (average score about 83 of 100). Together, the study provides low strength evidence that people are satisfied with their encounters with their prosthetists (Table 5-6.1).

Outcome	No. Studies	Study	Consistency	Precision	Reporting	Directness*	Other Issues	Findings	SoE Grade
	(N)	Limitations			Bias				
Alignment of outcomes	0	NA	NA	NA	NA	NA	NA	None	Insufficient
with expectations (KQ 5)									
Satisfaction with process	2 (~1663)	Medium	Consistent	Precise	Undetected	Direct †	Nonvalidated	Clients generally satisfied with	Low
(KQ 6)							outcomes	their encounters with their	
								prosthetists	

Table 5-6.1. Key Questions 5 and 6 Evidence Profile

Abbreviations: KQ = Key Question, NA = not applicable, SoE = strength of evidence.

* Representative of either (or both) older adults (≥65 years old) or those with dysvascular amputations. † One study included a wide range of prosthetics practices; about half the participants had Medicare or Medicaid as a primary payer. The other study was less representative.

Key Question 7

At 6 months, 1 year, and 5 years after receipt of a LLP, (accounting for intervening mortality, subsequent surgeries or injuries) what percentage of individuals...?

- i. Maintain bipedal ambulation
- ii. Use their prostheses only for transfers
- iii Use prostheses only indoors
- iv. Have abandoned their prostheses
- v. Have major problems with prosthesis

Overall Summary of Studies

We found eight studies (in nine articles) with at least 100 participants who were followed for at least 6 months after prescription of a LLP.¹²³⁻¹³¹ Most studies of amputees with outcomes of interest were rejected because the analyses were not restricted to people with prescribed prostheses and were thus mostly analyses of predictors for not receiving a prescription for LLP. The studies analyzed between 109 and 555 participants for between 1 and 7 years (except for two studies that implied long-term followup, but did not report a timeframe.^{125, 127} The studies only sparsely covered the subquestions pertaining to specific outcomes, particularly related to questions about different outcomes in different subgroups of amputees.

Table 7.1 summarizes the study design and participant characteristics of the eight studies. The studies mostly included older adults, 65 to 80 percent of whom were men. However, they were each representative of different cohorts of lower limb amputees as indicated by their amputation level and etiologies. Four studies were restricted to all (or almost all) unilateral amputees, ¹²³⁻¹²⁶ while four included about 10 to 20 percent bilateral amputees. ^{127-129, 131} Three of the studies included approximately similar percentages of people classified as having transfemoral and transtibial amputations (and no amputations at other levels). ^{124, 126, 127} One study was restricted to people with transtibial amputations. ¹²⁵ Four studies included at least twice as many people with transtibial than transfemoral amputations. ^{127-129, 131} One of these latter studies included a small percentage of people with amputations at the hip and 11 percent with foot or ankle amputations. ¹²⁸ This study (Matsen 2000) also included 12 percent of people who had congenital amputations. Five of the studies evaluated people who mostly (about 80-95%) had diabetes or other vascular diseases as the etiology of their amputation. ^{123-126, 129} In addition to congenital amputations, Matsen 2000 also included an atypically large percentage of people with traumatic (50%) and infectious (21%) etiologies. ¹²⁸ Roffman 2016 similarly had large percentages with traumatic (57%) and infectious (43%) etiologies. ^{130, 131} Marmann 1994 did not report amputation etiologies. ¹²⁷

Table 7.2 describes the risk of bias (study quality) of the studies. In addition to the studies each being representative of different types of amputees, most studies failed to include between about 25 and 85 percent of potentially eligible participants, mostly due to failure of people to respond to surveys. These studies did not attempt to demonstrate that the included participants were representative of their populations and were deemed to have high risk of sample bias. This was the primary concern for three studies, which were deemed to be at moderate risk of bias

(Davies 2003, Gauthier-Gagnon 1999, and Roffman 2016).^{124, 126, 131} Notably, Matsen 2000 had a very low survey response rate and self-described their population as nonrepresentative; the study also poorly defined its outcomes and did not clearly report the results for the outcomes of interest; this study was deemed to have high overall risk of bias.¹²⁸ Dudkiewicz 2011 and Marmann 1994 did not report when their surveys were done in relation to LLP prescription, and were deemed to have high overall risk of bias.^{125, 127} Only two studies were deemed to be at overall low risk of bias (Chen 2008 and Pohjolainen 1990).^{123, 129} However, only four studies reported subgroup (predictor) analyses (Davies 2003, Marmann 1994, Pohjolainen 1990, and Roffman 2016); none of them reported multivariable analyses for the predictors and outcomes of interest. Thus, the four subgroup analyses were all deemed to be subject to high risk of bias.

Table 7.3 provides the outcome results of interest across studies.

Study Year (PMID) Country	Study design*	N Surveyed (Eligible)	Population	Mean Age (SD) [Range]	Male	K level	Amputation Level	Unilateral	Etiology
Chen 2008 (18724135) Taiwan	Retrospective	109 (120)	Major lower limb amputation, received prosthesis	64.3 (12.9) [28- 85]	65%	nd	TF 14%, TT 86%	97%	Vascular 94%, trauma 6%
Davies 2003 (14727699) UK	Retrospective	281 (357)	Unilateral lower limb amputation with prosthesis	68	70%	nd	TF 49%, TT 51%	100%	Vascular 88%, other 12%
Dudkiewicz 2011 (21303214) Israel	Retrospective	557 (717)	Below knee amputation with prosthesis	64.2	75%	nd	TT 100%	94%	Vascular/DM 83%, trauma 3%, infection 11%, other 3%
Gauthier-Gagnon 1999 (10378500) Canada	Retrospective	396 (nd)	Unilateral lower limb amputation, completed 1 y prosthetic training	62.6 (15.9)	74%	nd	TF 42%, TT 58%	100%	Vascular/DM 78%, trauma 17%, other 5%
Marmann 1994 (none) Germany	Retrospective	110 (399)	Lower limb prosthesis able to walk	73	nd	nd	TF 60%, TT 40%	90%	nd
Matsen 2000 (10954097) USA	Retrospective	148 (1035)	Lower limb amputation, with prosthesis (implied)	50.1 (16.2)	72%	nd	Hip 3%, TF 23%, Knee 9%, TT 55%, Foot/ankle 11%	87%	Vascular/DM 21%, trauma 50%, infection 21%, cancer 2%, congenital 12%†
Pohjolainen 1990 (2235304) Finland	Retrospective	175 (175)	Lower limb amputation, with prosthesis	62.2 [14-87]	73%	nd	TF 36%, TT 64%	89%	Vascular 81%, trauma 10%, cancer 6%, other 3%
Roffman 2016 (26637652, 25450484) Australia	Prospective (n=66), retrospective (n=135)	201 (nd)	Lower limb amputation, previously ambulatory, prosthesis rehab	55	80%	1-4	TF 27%, Knee 3%, TT 70%	85%	Vascular 26%, trauma 27%, infection 43%, cancer 4%

Table 7.1. Study Design and Participant Characteristics of Studies Reporting Long-Term Followup After Prosthesis Prescription

Abbreviations: DM = diabetes mellitus, TF = transfemoral amputation, TT = transtibial amputation. * Funding source for all studies was nonindustry. † Some patients listed more than one reason for amputation.

Study Year (PMID)	Sample	Outcome Assessment	Predictors/Variables	Multivariable	Other	Overall Quality
	Bias		Definitions	Analysis		
Chen 2008 (18724135)	Low RoB	Low RoB	NA*	NA*		Low RoB (no subgroup analyses)
Davies 2003 (14727699)	High RoB	Low RoB	Low RoB	High RoB (no)		Moderate RoB, except high RoB
						for subgroup analyses
Dudkiewicz 2011	High RoB	Low RoB	NA*	NA*	Followup time not reported	High RoB (no subgroup analyses)
(21303214)						
Gauthier-Gagnon 1999	Unclear	Low RoB	NA*	NA*		Moderate RoB (no subgroup
(10378500)	RoB					analyses)
Marmann 1994 (none)	High RoB	Low RoB	Low RoB	High RoB (no)	Followup time not reported	High RoB
Matsen 2000 (10954097)	High RoB	High RoB (outcomes	NA*	NA*	Incomplete reporting of results;	High RoB (no subgroup analyses)
		poorly described)			12% congenital amputees	
Pohjolainen 1990	Low RoB	Low RoB	Low RoB	High (no)	¥ .	Low RoB, except high RoB for
(2235304)				,		subgroup analyses
Roffman 2016	Unclear	Low RoB	Low RoB	High (no)		Moderate RoB, except high RoB
(26637652, 25450484)	RoB			/		for subgroup analyses

Table 7.2. Long-Term Followup Study Risk of Bias / Study Quality

Abbreviations: NA = not applicable, RoB = risk of bias. * No predictor/subgroup analyses reported; only overall rate reported.
Author	Outcome	Outcome Description	Subgroup	Timepoint	% (n/N)	P Subgroups
Chen 2008 (18724135)	Abandoned prostheses	•	All Participants	28.3 mo	0.9% (1/109)	
Davies 2003 (14727699)	Abandoned prostheses	Stanmore Harold Wood Mobility Grade 1	All Participants	1 y	12.2% (24/196)	
		("has abandoned limb wearing or uses only a cosmetic limb)	Transfemoral		15.7% (14/89)	
		,	Transtibial		9.3% (10/107)	0.19
			Age <50 y		0% (0/16)	
			50-64 y		14.2% (7/49)	-
			65-79 y		11.3% (13/115)	-
			>80 y		25% (4/16)	0.18
	Only use for transfers	Stanmore Harold Wood Mobility Grade 2	All Participants		4% (8/196)	
		(wears a prosthesis only for transfers or to help with nursing; walks only with a therapist or carer)	Transfemoral		5.6% (5/89)	
			Transtibial		2.8% (3/107)	0.47
			Age <50 y		0% (0/16)	
			50-64 y		2% (1/49)	
			65-79 y		5.2% (6/115)	
Indoor use onl			>80 y		6.2% (1/16)	0.62
	Indoor use only of prosthesis	Stanmore Harold Wood Mobility Grade 3	All Participants		24.4% (48/196)	
		(Walks indoors only, using walking aids; negligible walking outdoors)	Transfemoral		33.7% (30/89)	
			Transtibial		16.8% (18/107)	0.0076
			Age <50 y		6.2% (1/16)	
			50-64 y		14.2% (7/49)	
			65-79 y		30.4% (35/115)	
			>80 y		31.2% (5/16)	0.042
Dudkiewicz 2011 (21303214)	Indoor use only of prosthesis	Functional Usage at home	All Participants§	nd	37.1% (75/555)	
Gauthier-Gagnon 1999 (10378500)	Abandoned prostheses		All Participants	5 y	15% (~58/396)*	
Marmann 1994 (none)	Abandoned prostheses		All Participants	nd	22% (24/110)	
			Bilateral		27% (3/11)	
			Unilateral		21% (21/99)	0.70
	Only use for transfers		All Participants		15% (16/110)	
			Bilateral		18% (2/11)	
			Unilateral		14% (14/99)	0.66
Matsen 2000 (10954097)	Unable to walk		All Participants	7 y after	7% (10/148)	
				surgery		
	Indoor use only of prosthesis		All Participants		11% (16/148)	
Pohjolainen 1990 (2235304)	Abandoned prostheses		All Participants	1 y	10.6% (15/141)	
			Bilateral		0% (0/16)	
			Unilateral		12.0% (15/125)	0.22
			Transfemoral unilateral		23.9% (11/46)	

Table 7.3. Long-Term Followup Results

Author	Outcome	Outcome Description	Subgroup	Timepoint	% (n/N)	P Subgroups
			Transtibial, unilateral		5.0% (4/79)	0.0032
	Indoor use only of prosthesis		All Participants		29% (41/141)	
			Bilateral		68.7% (11/16)	
			Unilateral		24.0% (30/125)	0.0006
			Transfemoral unilateral		23.9% (11/46)	
			Transtibial, unilateral		24.1% (19/79)	1.00
Roffman 2016 (26637652, 25450484)	Abandoned prostheses		All Participants	1 y	17.9% (36/201)	
			Sex			0.19 †
			Age at amputation (continuous)			0.98 †
			Home vs. residential care			0.19 †
			Charlson Comorbidity			0.24 †
			Index (continuous)			
			Diabetes, types 1/2			0.15/0.45 †
			Peripheral artery disease			0.46 †
			Cardiac condition		28.0% (21/75)	_
			No cardiac condition		11.9% (15/126)	0.04 †, ‡
			Renal failure			0.25 †
			Stroke			0.98 †
			Arthritis			0.80 †
			Remaining limb			0.055 †
			pathology			
			Amputation cause			0.26 †
			Bilateral		29.0% (9/31)	
			Unilateral		15.9% (27/170)	0.08 †
			Transfemoral unilateral		33.9% (21/62)	4
			Transtibial or knee,		14.1% (24/170)	0.0013 †, ‡
			unilateral			

* Data not clearly reported. † Univariable analyses. ‡ Bonferonni P value =0.0020

§ Analyzed predictors pertain to time of survey, not to status at time of amputation or prosthesis prescription and are therefore omitted here.

Failure to Maintain Bipedal Ambulation

No study explicitly reported maintenance of bipedal ambulation, per se. Matsen 2000 reported, for only the full sample, that 7 percent (10/148) were "not able to walk" at a mean of 7 years after surgery.¹²⁸ The estimated exact 95 percent confidence interval about this estimate is 4 to 12 percent. This study was potentially not fully representative of typical adult amputees in the U.S. given that half the amputations occurred due to trauma, one-fifth due to infection, and only one-fifth due to vascular disease or diabetes. The study was deemed to be at high risk of bias, primarily due to inclusion of only a small percentage (14%) of potentially eligible patients being included and for poor description of their outcome. The authors note that their institution predominantly serves individuals in poor health and with a low economic status. In addition, only 14% of potentially eligible amputees responded to their survey, which required completing a five-page self-assessment packet.

Use of Prostheses Only for Transfers

Two studies, Davies 2003 and Marmann 1994,^{124, 127} reported on use of prostheses only for transfers in a total of 316 study participants. One study included only people with unilateral amputations; the second study included 11 people (10%) with bilateral amputations; roughly half of patients had transtibial and half transfemoral amputations. In the study of only unilateral amputees, the cause of amputation was vascular or diabetes in 88 percent of the amputees; etiology was not reported in the second study. Davies 2003 was deemed to be at overall moderate risk of bias and Marmann 1994 at high risk of bias. Both studies had high percentages of potentially eligible patients who were not included and neither demonstrated that the survey respondents were representative of their populations; Marmann 1994 also did not report when the survey was conducted in relation to either amputation date or first LLP prescription. Neither study performed multivariable analyses to compare subgroups.

The more recent study conducted in the UK, Davies 2003, found that at 1 year eight participants (4%; estimated exact 95% confidence interval 2% to 8%) used their prostheses only for transfers (and walked only with a therapist or carer). The earlier study conducted in Germany, Marmann 1994, found a higher percentage of patients used their prostheses only for transfers (22%, 24/110; estimated exact 95% confidence interval 15% to 30%) at an unreported time after LLP prescription. Neither study found significant differences in rates of use of prostheses only for transfers based on level of amputation (transtibial vs. transfemoral), unilateral or bilateral amputation, or by age; however, the studies were greatly underpowered for subgroup analyses.

Use of Prostheses Only Indoors

Four studies reported on rates of prosthesis use only indoors.^{124, 125, 128, 129} The studies were deemed to be of low (Pohjolainen 1990), moderate (Davies 2003) and high risk of bias (Dudkiewicz 2011, Matsen 2000), primarily due to failure to include a large or demonstrably representative proportion of their eligible population), failure to describe their outcomes poorly (Matsen 2000), and failure to report timing in relation to LLP prescription (Dudkiewicz 2011). Overall, about 90 percent of included patients had unilateral amputations. In three of the studies about 80 to 90 percent of patients had vascular etiologies for their amputations, but Matsen 2000 had a less typical population in whom half of amputations were due to trauma, and only about 20

percent were due to diabetes or other dysvascular diseases. The distribution of levels of amputations varied widely across the four studies.

Three of the four studies reported that between 24 and 37 percent of amputees used their prostheses only indoors; Matsen 2000 (described above under *Maintenance of Bipedal Ambulation*) reported a substantially lower rate of use only indoors at 11 percent.¹²⁸ The major difference between Matsen 2000 and the other three studies (Davies 2003, Dudkiewicz 2011, and Pohjolainen 1990) is that participants in Matsen 2000 were much less likely to have had a vascular or diabetes amputation etiology (21% vs. 81-88%). Two of the studies provided withinstudy subgroup data to allow univariable analyses. Davies 2003 (described above under *Use of Prostheses Only for Transfers*) found that significantly more people with transfemoral amputations (34%) were restricted to indoor use than those with transtibial amputees' age (<50 years 6%, 50-64 years 14%, ≥65 years 31%; P=0.042 across age groups). Pohjolainen 1990, in contrast, found no difference in indoor restriction between unilateral transfemoral and transtibial amputees (both 24%), but it found that almost three times as many people with bilateral amputations (69%) were restricted to indoor use than those with unilateral amputations (24%, P=0.0006).¹²⁹

Abandonment of Prostheses

Six studies reported on rates of prosthesis abandonment (no longer using).^{123, 124, 126, 127, 129-131} Among these studies, between 85 and 100 percent of study participants had unilateral amputations. The patients' amputation levels varied widely across studies, with between 14 and 60 percent with transfemoral amputations and between 40 to 86 percent with transtibial amputations. Among four of five studies that reported amputation etiologies, the large majority (78-94%) had amputations due to dysvascular conditions; Roffman 2016 had an atypical population in which about one-quarter of amputations were due to dysvascular etiologies and one-quarter due to trauma; 43 percent had infectious etiologies. Half the studies were deemed to have moderate risk of bias, primarily due to high or unclear percentage of potentially eligible patients not being included (and no demonstration that included participants were representative of the eligible population). One study was at high risk of bias; Marmann 1994 also did not report when the study was conducted in relation to LLP prescription. Two studies were at low risk of bias.

All but one study were relatively consistent, reporting that between 11 and 22 percent of amputees had stopped using their prosthesis at 1 year in 3 studies and 5 years in one study (15%). The highest rate of abandonment (22%) was reported in an older, high risk of bias study from Germany with no information about how long people had been using LLPs. A low risk of bias outlier study from Taiwan (Chen 2008) reported only a single person (0.9%) who abandoned their prosthesis.

Four of the studies reported subgroup data. Three compared unilateral transfemoral and transtibial amputees, finding that people with transfemoral amputations were more likely to abandon their prostheses (16-34%) than people with transtibial amputations (5-14%). Two of the analyses (Pohjolainen 1990, Roffman 2016) were statistically significant (P=0.0013 and 0.003). The nonsignificant study, Davies 2003, (P =0.22) was hampered by the small number of bilateral amputees in the study (n=16).

Three studies found no significant difference in likelihood of abandonment between unilateral and bilateral amputees; although their findings were conflicting. Pohjolainen 1990 found many more unilateral amputees (12%) had abandoned their prostheses than bilateral amputees (0%), but the difference was nonsignificant (P=0.22). Roffman 2016 found about twice as many people with bilateral amputation abandoned their prostheses (29%) than people with unilateral amputation (16%), but again the difference was nonsignificant (P=0.08). Marmann 1994 found similar percentages of people abandoned their prostheses among unilateral (21%) and bilateral (27%) amputees (P=0.70).

Two studies also found no significant differences based on age. Davies 2003 found that the rate of abandonment did rise with age from 0 percent of those under age 50 years to 25 percent of those over age 80 years, but was nonsignificant (P=0.18). Roffman 2016 found no significant association with age at amputation in linear regression (P=0.98).

Roffman 2016 reported a large number of subgroup analyses in addition to the analyses described above, although all were univariable for this outcome.¹³¹ This study included amputees who were more likely to have transtibial amputations and were more likely to have infection or trauma as an amputation etiology, compared to most studies. Most analyses found no significant difference between subgroups (see Table 7.3). People with a history of a "cardiac condition" were more likely (28%) to have abandoned their prosthesis than those with no such history (12%, P=0.04); however the study evaluated many comparisons and after applying the Bonferroni correction (P value threshold 0.002), this difference between unilateral transfemoral amputation and transtibial or at-knee amputation, described above.

Major Problems with Prostheses

None of the studies reported outcomes that could be construed as having "major problems" with their prostheses.

Reasons for Abandoning Prostheses

Only Roffman 2016 reported reasons for prosthetic nonuse (or other outcomes of interest).¹³¹ Study participants were able to list multiple reasons for nonuse; however, the reported reasons were summarized in general categories lacking precise definitions. Among the 36 of 201 amputees who abandoned their prostheses, reasons for abandonment included "issues with residual limb" (36%, n=13), "prosthetic issues" (28%, n=10), "medical comorbidities" (28%, n=10), "issues with remaining lower limb" (25%, n=9), "pain issues" (25%, n=9), falls or fear of falling (14%, n=5), "high energy cost" (8%, n=3), "unmotivated" (8%, n=3), unable to don prosthesis (6%, n=2), and "balance issues" (6%, n=2).

Summary

Table 7.4 summarizes the strength of evidence for each outcome and subgroup analysis with data. For most outcomes of interest, there is low strength of evidence because studies mostly had methodological limitations, the populations analyzed were often not directly applicable to the Medicare population, some studies were inconsistent with each other, and few studies reported the outcomes of interest. Subgroup analyses in single studies tended to be underpowered to detect differences, mostly leading to determinations that the evidence was insufficient. However, we found a moderate strength of evidence, based on six studies, that about 11 to 22 percent of lower limb amputees who receive a LLP prescription abandon the prosthesis

(stop using it) at about 1 year; these studies are generally representative of people with LLP, in particular older adults and those with dysvascular etiologies. Three of these studies provide low strength of evidence that people with unilateral transfemoral amputations are about twice as likely to abandon their LLP than those with unilateral transtibial amputations. Potential differences among other subgroups had insufficient evidence due to conflicting results among three studies or only a single, imprecise study with data. Also based on four, generally representative studies, there is low strength of evidence that 11 to 37 percent of LLP recipients use their prostheses only indoors; however, these studies are somewhat inconsistent and imprecise. There is low strength of evidence about how likely different subgroups of people use their prostheses only indoors, suggesting that people with transfemoral amputations, or who are older, or with bilateral amputations are more likely to be limited to indoor use. There is insufficient evidence about why people abandon their prostheses.

Outcome	Subgroup	No. Studies (N)	Study Limitations	Consistency	Precision	Reporting Bias	Directness*	Other Issues	Findings	SoE Grade
Failure to maintain bipedal ambulation	All participants	1 (148)	High	NA	Precise	Undetected	Indirect	Unclear outcome,	7% (95% CI 4, 12) at 7 years	Low
Use of prosthesis only for transfers	All participants	2 (316)	High	Inconsistent	Precise	Undetected	Indirect	Old studies	4% (95% CI 2, 8) at 1 year, 22% (95% CI 15, 30) at unknown time	Low
	TF vs. TT	1 (196)	High	NA	Imprecise	Undetected	Indirect	25 years old	No significant difference	Insufficient
	Bilateral vs. unilateral	1 (110)	High	NA	Imprecise	Undetected	Indirect	None	No significant difference	Insufficient
	Age	1 (196)	High	NA	Imprecise	Undetected	Indirect	25 years old	Nonsignificantly higher limited used with older age	Insufficient
Use of prosthesis only indoors	All participants	4 (1040)	Medium	Inconsistent	Imprecise	Undetected	Direct	None	24-37% at 1 to 7 years	Low
	TF vs. TT	2 (337)	High	Inconsistent	Precise	Undetected	Direct	None	Twice as many TF use only indoors (1 study, P=0.008)), no difference (1 study)	Low
	Age	1 (196)	High	NA	Precise	Undetected	Direct	None	Older more likely to use only indoors (P=0.042)	Low
	Bilateral vs. unilateral	1 (141)	High	NA	Precise	Undetected	Direct	None	Bilateral more than twice as likely to use only indoors (P=0.0006)	Low
Abandonment of prosthesis	All participants	6 (1153)	Medium	Consistent †	Precise	Undetected	Direct	None	11-22% at 1 year (or undefined)†	Moderate
	TF vs. TT	3 (538)	High	Consistent	Precise	Undetected	Direct	None	TF more likely to abandon prosthesis than TT	Low
	Bilateral vs. unilateral	3 (452)	High	Inconsistent	Imprecise	Undetected	Direct	None	Nonsignificant, but conflicting directionality	Insufficient
	Age	2 (397)	High	Inconsistent	Imprecise	Undetected	Direct	None	Older nonsignificantly more likely to abandon (1 study), no difference in age (1 study)	Insufficient
	Multiple	1 (201)	High	NA	Imprecise	Undetected	Indirect	Multiple testing	No significant associations	Insufficient
Major problems with prosthesis	All participants	0	NA	NA	NA	NA	NA	NA	None	Insufficient
Reasons for poor outcomes	All participants	1 (201)	High	NA	Imprecise	Undetected	Indirect	None	Various general categories of reasons reported	Insufficient

Table 7.4. Key Question 7 Evidence Profile

Abbreviations: NA = not applicable, RoB = risk of bias, SoE = strength of evidence, TF = transfermoral amputation, TT = transtibial amputation.

* Representative of either (or both) older adults (≥65 years old) or those with dysvascular amputations.

† Except that one outlier study from Taiwan found that only 0.9% of study participants abandoned their prostheses at a mean of 28 months.

Discussion

A large number of studies have evaluated lower limb prostheses (LLP) for people with major lower limb amputations. We found nearly 100 studies that compare at least two prostheses or components that likely report ambulatory, functional, or other patient-centered outcomes. There are many additional studies that evaluated only biomechanical properties of the components and likely several hundred studies that evaluate just a single component. However, we found few studies that evaluated (or at least provided data to allow evaluation of) heterogeneity of treatment effect. From the amputee's and the clinician's perspective, among the most important questions is which prosthesis (comprised of which prosthetic components) would best enable maximal function for a given individual? Given the large number of component types (knee, foot/ankle, socket, etc.) and the range of features for each of these, the process of determining which LLP configuration is best for individuals is quite complex. The majority of the evidence addresses the question of which components maximize ambulation and function in the average patient, as opposed to which component would best suit the needs of a given individual. Suboptimal matching of patients to LLPs may unnecessarily increase health care utilization, prevent attainment of maximal patient function, and defer realization of improved quality of life attainable with an appropriate prosthetic.

Further limiting and complicating the evidence base, there are a very large number of measures that are used in the surgical, rehabilitation, and prosthesis literature to assess overall patient function, predict future outcomes, and measure various aspects of ambulation, function, quality of life issues, and other patient-centered outcomes. While some of the scales and scores used in these studies were developed specifically to assess lower limb amputees, many were designed for other populations. Many of the measures used in LLP research studies have either not been validated in the population of interest or were created *ad hoc* for each study. This review found that among the small number of comparative studies that provided heterogeneity of treatment effects data, fewer than half used both validated predictors (or subgroups based on basic participant characteristics) and validated outcomes.

We found that a large number of measures that have been validated (to a lesser or greater extent), 29 of which have, in whole or in part, been found to be both reliable and validated in lower limb amputees. Many of the studies that evaluated measure properties, however, were conducted in samples of participants who were not well-applicable to the large number of amputees with dysvascular conditions, including diabetes and peripheral vascular disease, or who are older and are, thus, more typical of lower limb amputees with Medicare insurance. We found only 35 of the 61 measures have been evaluated in studies deemed generally generalizable to the Medicare population, of which 19 were found to have evidence of both reliability and validity.

These measures address many aspects of patients' function, ambulation, and quality of life. To improve the accuracy, interpretability, and, importantly, the reproducibility of the literature, we would strongly encourage future researchers to maximize the use of validated measures. Where validated measures of interest are lacking, proposed research measures should first be validated before use in future studies. We would also encourage journal editors to require use of validated measures.

However, the studies were highly variable in who was analyzed and how instruments and measures were validated, etc. We, therefore, recommend that researchers who are using this report to determine which measures to use for their own studies also review the primary studies

to determine whether the measures have been sufficiently validated for their needs and have been evaluated in a sample of people representative to their study population.

Evidence Summary

- In practice, it is difficult to cleanly make the distinction between assessment techniques (to evaluate function etc. prior to LLP prescription), prediction tools (to predict likelihood of a future outcome, such as ambulation with a prosthesis), and outcome measures (to determine actual or change in ambulation, function, etc.). Many specific measures can be used for at all stages of evaluation of function.
- Among 61 measures for which we found assessments of measurement characteristics, we found 40 to be reliable, 47 validated in whole or in part, and 29 both reliable and validated. However, seven of these have evidence of floor or ceiling effects. Responsiveness, minimal detectable change, and minimal (clinical) important difference have relatively infrequently been assessed.
- Restricting to studies deemed to be generally generalizable to the Medicare population, 35 measures have been evaluated. Of these, 27 have evidence of validity, in whole or in part, and 25 have evidence of reliability. In total, 19 measures have been found to have evidence of both reliability and validity.
- We found 11 studies that compared LLP components and provided data to compare differences in effect among different subgroups (i.e., heterogeneity of treatment effect). However, most were small, underpowered studies, reported only participant-level data, were nonrandomized, and did not evaluate heterogeneity of treatment effect. These studies mostly evaluated knee components and mostly included younger men at K2 or K3 level, with unilateral transfemoral amputations with traumatic etiologies; populations not highly applicable to the Medicare population. In addition, only five of the studies reported on both validated predictors (or basic patient characteristic subgroups) and validated outcomes. Only a single study, using nonvalidated outcomes, attempted to comprehensively evaluate whether any or a set of patient characteristics predicted which component would yield best function for individual patients. In summary,
 - Studies that used validated measures mostly evaluated knee components and were conducted in mostly younger men, at K2 or K3 level, unilateral transfemoral amputations due to trauma. These studies did not identify participant characteristics that predict which lower limb amputees would most benefit from a given component. There is low strength of evidence that evaluated patient characteristics do not predict which patients would most benefit from a given LLP component based on validated outcomes. However, it may be more accurate to conclude that the evidence is currently sparse and fails to adequately address whether different subgroups of amputees are more or less likely to benefit from given specific components.
 - Overall, studies did not identify participant characteristics that predict which lower limb amputees would most benefit from a given component, regardless of whether validated measures were used. There is low strength of evidence that evaluated patient characteristics do not predict which patients would most benefit from a given LLP component. However, it may again be more accurate to conclude that the evidence is currently sparse and fails to adequately address

whether different subgroups of amputees are more or less likely to benefit from given specific components.

- One large study of highly selected, mostly younger men with mostly traumarelated amputations, evaluated multivariable prediction models to determine who would most benefit from a microprocessor knee based on nonvalidated outcomes. The study concluded that they failed to identify participant characteristics that predict whether individual patients would have better function with a microprocessor or mechanical knee; however, they did report numerous patient characteristics that were statistically significantly associated with differential effects between knee components. The study had several methodological and analytic flaws, and thus provides insufficient additional evidence regarding who would most benefit from a microprocessor knee.
- We found no evidence regarding how study participants' preprescription expectations of ambulation align with their functional outcomes.
- Two studies provided low strength of evidence that people are satisfied with their encounters with their prosthetists. This conclusion is applicable to people who have Medicare or Medicaid as their primary payers, based principally on one of the two studies.
- Based on six eligible studies of long-term followup at least 1 year after LLP prescription,
 - There is insufficient evidence regarding failure to maintain bipedal ambulation
 - There is insufficient evidence regarding how many people use LLP only for transfers
 - There is low strength of evidence that 11 to 37 percent of people use their LLP only indoors at 1 to 7 years after prescription, but insufficient evidence to assess differences in indoor-only use in different subpopulations
 - There is moderate strength of evidence that 11 to 18 percent of people have abandoned their prostheses (no longer used them) at 1 year.
 - There is also moderate strength of evidence that people with transfemoral amputations are more likely to abandon their prostheses than those with transtibial prostheses, but still the majority of amputees continue to use their prostheses, regardless of level of amputation
 - There is insufficient evidence to assess differences in abandonment in other subgroups of patients
 - o There is insufficient evidence regarding reported major problems with LLP
 - There is insufficient evidence regarding reasons why people with LLP have poor outcomes (in terms of use of prostheses).

Evidence and Analysis Limitations

Despite the large literature base for research on LLP, relatively few studies address the questions of interest for this review, particularly related to heterogeneity of treatment effect, patient expectations and satisfaction, and long-term use of LLP after prescription.

Assessment of reliability, validity, and other measure properties is open to interpretation. By the strictest definition, a measure would be considered to be valid and appropriate for use in a given study, only if there is good evidence regarding the multiple aspects of validity for the specific population, conditions, and outcomes under evaluation. That a measure demonstrates convergent validity with a given related measure does not imply that it also can distinguish

differences related to subgroups of patients or an intervention effect. That a measure has predictive validity regarding one outcome, such as future successful use of a LLP, does not imply predictive validity for other ambulatory outcomes, such as speed of walking or community ambulation. Despite these challenges, and the lack of a universal gold standard for determining absolute validity, we took a liberal approach in our literature synthesis. We considered a measure to be validated if there was evidence of any type of validity (other than face/content). We, thus, categorized the evidence and dichotomized data so that measures were classified as valid or not valid. We made no attempt to rank or compare measures. Some measures may be better than others (e.g., because they have less error associated with repeat administration or they are more responsive to change), but the relative importance of these issues will be study-dependent. The overall logic for our approach was that the question of interest for this general review of all measures used in LLP research is whether a measure has been validated for any purpose. Since the actual validity of a measure for use in a specific study may vary based on the study question, eligibility criteria, and hypotheses, we could not address all levels of validity. It is incumbent on each study's researchers to determine whether given measures are valid-and appropriate-for their study purposes.

As discussed above, the distinction between assessment techniques, prediction tools, and outcome measures is arguably somewhat artificial in actual application. Most, if not all, measures can be used for any of these contexts. Readers may disagree with how the measures were categorized across Key Questions 1 to 3.

This review attempts to particularly highlight the evidence applicable to the Medicare population. This is a challenge to do and requires judgment, which many may disagree with. Very few of the studies were limited to participants over the age of 65 years. None was limited to people with disabilities, at least in terms of what would allow them to qualify for Medicare. Extremely few studies reported the type of medical insurance study participants had (although, many of the studies were conducted in Europe and other countries other than U.S.). We categorized studies to be likely generalizable to the Medicare population based on having a relatively large percentage of participants with dysvascular etiologies for their lower limb amputations (also including diabetes) and/or likely including about half or more of participants over age 65 years. This system, though, is imperfect.

Although not a limitation, per se, it should be noted that this review makes no attempt to make conclusions about the overall effects of different LLP components. Key Question 4 addressed whether there is evidence regarding heterogeneity of treatment effects, particularly with validated measures, in the field of LLP research. As previously described, the evidence base addressing heterogeneity of treatment effect, particularly with validated measures, is quite small. Only a single study attempted to truly address the question at hand, but did not use a validated outcome measure, and was methodologically and analytically flawed. The applicability of these studies to the general population of people with LLPs may be somewhat limited, as the studies mostly evaluated knees and were mostly conducted in younger men with unilateral transfemoral amputations due to trauma. Furthermore, implicitly or explicitly, most of these studies included only people who were deemed (by their prosthetists) to be likely to benefit from their new (generally more complex) component. This may bias these studies toward finding no difference between subgroups of individuals in relative effect of the compared components since everyone was more likely than average to do better with the new component. In all of these studies, all patients used all evaluated LLPs. However, most of the studies that analyzed heterogeneity of treatment effect or provided data to allow subgroup analyses were observational and did not

control for underlying differences during use of one component or the other. For example, studies did not describe or control for rehabilitation, training, or acclimation with each of the components. In particular, in the pre-post studies (where everyone switched from an old (simpler) to a new (more complex) LLP, one would expect that patient characteristics such as age, strength, and mobility will also have changed. These are important issues for the underlying analyses comparing the components; although, the effect of this limitation of the comparative studies on assessing heterogeneity of treatment effect is unclear. If the bias is similar in different subgroups (e.g., the new component is favored in part due to bias equally among transtibial and transfemoral amputees), then the bias would cancel out when assessing differences in relative effect (of the two components) between the two subgroups (transtibial versus transfemoral). As discussed, the single large study with regression modeling is likely highly biased and may be analytically flawed, so it is insufficient to provide reliable evidence.

No or very few studies were found to address questions about patient expectations and satisfaction with care.

Few studies met eligibility criteria regarding long-term LLP use after prescription. The primary reason why potentially relevant studies were excluded was that they evaluated long-term ambulation and function after surgery including patients who never received an LLP. We also restricted the studies to those with at least 100 people to allow for some degree of precision in estimates. Smaller studies may have provided additional data, but their estimates would have been less precise (and subgroup analyses in these studies would be even less likely to be statistically significant due to lack of power). Among the eligible studies, the most common outcome of interest was LLP abandonment (or lack of use). Studies generally failed to report on indoor-only use of LLPs and other outcomes. Studies also mostly did not report information on why people limited or stopped their use of LLPs.

Future Research Recommendations

General Recommendations

Future research is needed to adequately address most of the questions in this review. While numerous measures have been validated, at least in part, additional studies are needed to confirm the measurement properties and to better generalize their validity (etc.) to more scenarios of people with lower limb amputations. For example, additional studies are needed that compare responsiveness of validated measures to specific prosthetic interventions. Some metrics may be better choices because they are more responsive to the types of changes provided by specific components. For microprocessor knees, for example, metrics that include items related to walking on uneven surfaces, stairs, balance confidence, stumbles and/or falls, would likely be more responsive than metrics that focus on specific physical performance such as distance walked or speed of ambulation. These latter metrics may be more responsive in assessment of foot, ankle, and powered componentry.

To as great an extent as possible, studies should assess validated, patient-centered outcomes related to ambulation, function, quality of life, and related outcomes. Continued use of *ad hoc* and nonvalidated measures greatly limits the interpretability, usability, representativeness, and overall value of the studies. Ideally, studies should use a core set of validated, patient-centered outcomes (in addition to other study-specific outcomes, as needed). This would allow comparability across studies and pooling of study findings (e.g., meta-analysis). A large body of individual, one-off analyses with unique outcomes will provide a much weaker evidence base

than a smaller body of comparable studies. Noncomparable studies will continue to be more likely to be of little use to prosthetists, treating physicians, patients, policymakers, and other decisionmakers, and therefore will more likely be ignored. Similarly, researchers should emphasize trying to include a well-representative sample of patients with LLPs, so that their studies will be applicable to the population at large.

Studies of Heterogeneity of Treatment Effect

Particularly for a clinical field as varied as lower limb prosthetics, there is a great need to understand how best to choose among the myriad LLP and component choices for an individual patient. Lower limb amputees are clearly a highly heterogeneous group with distinct needs dependent upon age, etiology of limb loss, level of amputation, comorbidities and health status, postoperative stage, and rehabilitation status. Better understanding of which component would be best for which patient could both maximize individual's ambulation, function, and quality of life and minimize waste due to either abandonment or due to "over-prescription," where people are given LLPs with specific capabilities that they cannot benefit from. Therefore, many more studies are needed to adequately assess heterogeneity of treatment effect. The goal of these studies should not be to simply find subgroup differences, but instead should be to predict which set of characteristics best predicts which component is best for which patient. This will require generally larger studies to allow for meaningful regression analyses. As with all studies, these should take care to include a representative and unbiased sample of lower limb amputees. Eligibility criteria and analytic methods should be employed to maximize participation and inclusion in final models. Robust analytic methods and complete and transparent reporting are essential. Appropriate, and clear, measures of model performance should be used and reported. We recommend the following specific metrics, although others may be more appropriate based on specific analyses conducted.^{132, 133} The most useful metrics of global performance are the (root) mean square error or Brier score. Less useful metrics are global statistics of fit, and the various pseudo- R^2 metrics. These global metrics are difficult to interpret correctly, particularly if there is class imbalance when a small percentage of participants experience a given outcome. Metrics of discrimination should also be reported, including the receiver operating characteristics (ROC) curve, area under the ROC curve (AUC), and accuracy measures (e.g., sensitivity and specificity). It is also important to report analyses of calibration. Assessments of calibration are numerous, but the most common is a simple calibration plot that orders observations in percentiles of increased predicted risk, and plots the observed percent of responders in each percentile. Conclusions about predictive performance require a thorough evaluation of the performance itself.

We recommend that consideration be given to reanalyze the dataset evaluated by either or both of the studies by Hahn et al. (2015 and 2016).^{114, 134} However, the value of these datasets may still be highly limited, as they appear to have relatively few comparisons between microprocessor and mechanical knees, but instead, at least in the case of Hahn 2016, are comparisons of different microprocessor knees, a question of less generalizable interest. Nevertheless, ideally the largest, least biased sample of participants available should be included, minimizing exclusions based on strict eligibility criteria and analytic methods. The selected outcome (or outcomes) should be clearly stated and defined; it should clearly represent a difference in effect between the two components and should occur in a low enough percentage of participants to avoid class imbalance. Ideally, it should also be validated. Full reporting of the model and its predictive performance are necessary. However, if the available sample for reanalysis remains highly biased and it is in fact the case that the large majority of participants performed better with the microprocessor knee in part because they were preselected based on their high likelihood of succeeding with the new knee, then a reanalysis may not be warranted as it would still represent a biased, nonrepresentative group of lower limb amputees. Study conclusions would still not be applicable to the average person considering which type of knee prosthesis to use.

Studies on Expectations, Satisfaction With Services, and Long-Term Followup

Studies on the relationship between patient expectations and outcomes are needed, as are additional studies of patient satisfaction with prosthetic services (and how to improve prosthetic services to improve satisfaction).

Additional large, long-term followup studies are needed to understand problems and limitations people are having with their prostheses, rates of abandonment or limited use, and reasons for these limitations and abandonment. Explanations of the prevalence of abandonment and limited use of LLPs and of why this occurs can yield further research in how to minimize underuse of LLP and resultant limited ambulation.

Conclusions and Clinical Implications

Numerous measures of ambulation, function, quality of life, and other patient-centered outcomes exist for people with lower limb amputations and LLPs. Those that have been validated should be used to form a core set of measures for use in future research studies of LLP. This would enhance the value, interpretability, reproducibility, and comparability of the future studies, and would allow more coherent summarization of the evidence. Researchers should minimize the use of nonvalidated or *ad hoc* measures, but instead should validate the new measures before their use. In particular, researchers with an interest in assessing LLPs for the Medicare population would be best served to focus on those measures with evidence of reliability and validity for this population. The majority of the evidence addresses the question of which components maximize ambulation and function in the average patient, as opposed to which component would best suit the needs of a given individual. A small evidence base does not support which components should be selected for which patient to maximize their ambulation, function, and quality of life or to minimize abandonment or limited use. However, this does not imply that there is evidence that no patient characteristics could effectively predict which patients would most benefit from one or another specific component. There is low strength of evidence that patients are generally satisfied with the prosthetic services they receive. However, further high quality research is needed to better assess the properties of measures (assessment techniques, prediction tools, and outcome measures), particularly for the Medicare population, and to answer all these questions and to assess patient expectations.

References

1. Boyle JP, Thompson TJ, Gregg EW, et al. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010 Oct 22;8:29. doi: 10.1186/1478-7954-8-29. PMID: 20969750.

 Ziegler-Graham K, MacKenzie EJ, Ephraim PL, et al. Estimating the prevalence of limb loss in the United States: 2005 to 2050. Arch Phys Med Rehabil. 2008 Mar;89(3):422-9. doi: 10.1016/j.apmr.2007.11.005. PMID: 18295618.

3. Naschitz JE, Lenger R. Why traumatic leg amputees are at increased risk for cardiovascular diseases. Qjm. 2008 Apr;101(4):251-9. doi: 10.1093/qjmed/hcm131. PMID: 18281705.

4. Frugoli BA, Guion KW, Joyner BA, et al. Cardiovascular Disease Risk Factors in an Amputee Population. JPO: Journal of Prosthetics and Orthotics. 2000;12(3):80-7.

5. Affairs DoV. Preservation-Amputation Care And Treatment (PACT) Program. VHA Directive.96-007.

6. Robbins JM, Strauss G, Aron D, et al. Mortality rates and diabetic foot ulcers: is it time to communicate mortality risk to patients with diabetic foot ulceration? J Am Podiatr Med Assoc. 2008 Nov-Dec;98(6):489-93. PMID: 19017860.

7. Dillingham TR, Pezzin LE, Shore AD. Reamputation, mortality, and health care costs among persons with dysvascular lower-limb amputations. Arch Phys Med Rehabil. 2005 Mar;86(3):480-6. doi: 10.1016/j.apmr.2004.06.072. PMID: 15759232.

8. Goodney PP, Tarulli M, Faerber AE, et al. Fifteen-year trends in lower limb amputation, revascularization, and preventive measures among medicare patients. JAMA Surg. 2015 Jan;150(1):84-6. doi: 10.1001/jamasurg.2014.1007. PMID: 25409197.

 Borrenpohl D, Kaluf B, Major MJ. Survey of U.S. Practitioners on the Validity of the Medicare Functional Classification Level System and Utility of Clinical Outcome Measures for Aiding K-Level Assignment. Arch Phys Med Rehabil. 2016 Jul;97(7):1053-63. doi: 10.1016/j.apmr.2016.02.024. PMID: 27016261. 10. Condie E, Scott H, Treweek S. Lower limb prosthetic outcome measures: a review of the literature 1995 to 2005. JPO: Journal of Prosthetics and Orthotics. 2006;18(6):P13-P45.

11. Local Coverage Determination (LCD): Lower Limb Prostheses (L33787). Centers for Medicare and Medicaid Services. . <u>https://www.cms.gov/medicarecoverage-database/details/lcd-</u> details.aspx?LCDId=33787&ContrId=140&ver=9&C ontrVer=2&CntrctrSelected=140*2&Cntrctr=140&n ame=CGS+Administrators%2c+LLC+(18003%2c+D ME+MAC)&DocType=Active&LCntrctr=140*2&bc =AgACAAQAAAAAAA%3d%3d& and http://www.oandp.org/olc/course_extended_content.a sp?frmCourseId=ACA066EC-443A-4822-822C-89BC1CBD684E&frmTermId=k-levels.

12. Heinemann AW, Connelly L, Ehrlich-Jones L, et al. Outcome instruments for prosthetics: clinical applications. Phys Med Rehabil Clin N Am. 2014 Feb;25(1):179-98. doi: 10.1016/j.pmr.2013.09.002. PMID: 24287247.

13. Gailey RS, Roach KE, Applegate EB, et al. The amputee mobility predictor: an instrument to assess determinants of the lower-limb amputee's ability to ambulate. Arch Phys Med Rehabil. 2002 May;83(5):613-27. PMID: 11994800.

14. AHRQ Methods for Effective Health Care. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011.

15. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928. doi: 10.1136/bmj.d5928. PMID: 22008217.

16. Wells GAS, B.;O'Connell, D.;Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. <u>http://www.ohri.ca/programs/clinical_epidemiology/</u>oxford.asp.

17. Berkman ND, Lohr KN, Ansari MT, et al. Grading the strength of a body of evidence when assessing health care interventions: an EPC update. J Clin Epidemiol. 2015 Nov;68(11):1312-24. doi: 10.1016/j.jclinepi.2014.11.023. PMID: 25721570.

18. Hart DL. Orthotics and Prosthetics National Office Outcomes Tool (OPOT): Initial Reliability and Validity Assessment for Lower Extremity Prosthetics. JPO: Journal of Prosthetics and Orthotics. 1999;11(4):101-11.

19. Condie ME, McFadyen AK, Treweek S, et al. The trans-femoral fitting predictor: a functional measure to predict prosthetic fitting in transfemoral amputees--validity and reliability. Arch Phys Med Rehabil. 2011 Aug;92(8):1293-7. doi: 10.1016/j.apmr.2011.03.021. PMID: 21807149.

20. Dite W, Connor HJ, Curtis HC. Clinical identification of multiple fall risk early after unilateral transtibial amputation. Arch Phys Med Rehabil. 2007 Jan;88(1):109-14. doi: 10.1016/j.apmr.2006.10.015. PMID: 17207685.

21. Brooks D, Parsons J, Hunter JP, et al. The 2minute walk test as a measure of functional improvement in persons with lower limb amputation. Arch Phys Med Rehabil. 2001 Oct;82(10):1478-83. doi: 10.1053/apmr.2001.25153. PMID: 11588757.

22. Eijk MS, van der Linde H, Buijck BI, et al. Geriatric rehabilitation of lower limb amputees: a multicenter study. Disabil Rehabil. 2012;34(2):145-50. doi: 10.3109/09638288.2011.591888. PMID: 21958418.

23. Wong CK, Young RS, Ow-Wing C, et al. Determining 1-Yr Prosthetic Use for Mobility Prognoses for Community-Dwelling Adults with Lower-Limb Amputation: Development of a Clinical Prediction Rule. Am J Phys Med Rehabil. 2016 May;95(5):339-47. doi: 10.1097/phm.000000000000383. PMID: 26390393.

24. Hanspal RS, Fisher K. Prediction of achieved mobility in prosthetic rehabilitation of the elderly using cognitive and psychomotor assessment. Int J Rehabil Res. 1997 Sep;20(3):315-8. PMID: 9331580.

25. Leung EC, Rush PJ, Devlin M. Predicting prosthetic rehabilitation outcome in lower limb amputee patients with the functional independence measure. Arch Phys Med Rehabil. 1996 Jun;77(6):605-8. PMID: 8831480.

26. Franchignoni F, Orlandini D, Ferriero G, et al. Reliability, validity, and responsiveness of the

locomotor capabilities index in adults with lowerlimb amputation undergoing prosthetic training. Arch Phys Med Rehabil. 2004 May;85(5):743-8. PMID: 15129398.

27. Brooks D, Hunter JP, Parsons J, et al. Reliability of the two-minute walk test in individuals with transtibial amputation. Arch Phys Med Rehabil. 2002 Nov;83(11):1562-5. PMID: 12422326.

28. Devlin M, Pauley T, Head K, et al. Houghton Scale of prosthetic use in people with lowerextremity amputations: Reliability, validity, and responsiveness to change. Arch Phys Med Rehabil. 2004 Aug;85(8):1339-44. doi: 10.1016/j.apmr.2003.09.025. PMID: 15295762.

29. Gremeaux V, Damak S, Troisgros O, et al. Selecting a test for the clinical assessment of balance and walking capacity at the definitive fitting state after unilateral amputation: a comparative study. Prosthet Orthot Int. 2012 Dec;36(4):415-22. doi: 10.1177/0309364612437904. PMID: 22389424.

30. Major MJ, Fatone S, Roth EJ. Validity and reliability of the Berg Balance Scale for community-dwelling persons with lower-limb amputation. Arch Phys Med Rehabil. 2013 Nov;94(11):2194-202. doi: 10.1016/j.apmr.2013.07.002. PMID: 23856150.

31. Miller WC, Deathe AB, Harris J. Measurement properties of the Frenchay Activities Index among individuals with a lower limb amputation. Clin Rehabil. 2004 Jun;18(4):414-22. doi: 10.1191/0269215504cr7280a. PMID: 15180125.

32. Newton KL, Evans C, Osmotherly PG. The Timed Up and Go and Two-Minute Walk Test: Exploration of a method for establishing normative values for established lower limb prosthetic users. European Journal of Physiotherapy. 2016;18(3):161-6.

33. Parker K, Kirby RL, Adderson J, et al. Ambulation of people with lower-limb amputations: relationship between capacity and performance measures. Arch Phys Med Rehabil. 2010 Apr;91(4):543-9. doi: 10.1016/j.apmr.2009.12.009. PMID: 20382285.

34. Resnik L, Borgia M. Reliability of outcome measures for people with lower-limb amputations: distinguishing true change from statistical error. Phys Ther. 2011 Apr;91(4):555-65. doi: 10.2522/ptj.20100287. PMID: 21310896.

35. Reid L, Thomson P, Besemann M, et al. Going places: Does the two-minute walk test predict the six-minute walk test in lower extremity amputees? J Rehabil Med. 2015 Mar;47(3):256-61. doi: 10.2340/16501977-1916. PMID: 25588644.

36. Panesar BS, Morrison P, Hunter J. A comparison of three measures of progress in early lower limb amputee rehabilitation. Clin Rehabil. 2001 Apr;15(2):157-71. PMID: 11330761.

37. Wong CK, Gibbs W, Chen ES. Use of the Houghton Scale to Classify Community and Household Walking Ability in People With Lower-Limb Amputation: Criterion-Related Validity. Arch Phys Med Rehabil. 2016 Jul;97(7):1130-6. doi: 10.1016/j.apmr.2016.01.022. PMID: 26874230.

38. Hafner BJ, Morgan SJ, Abrahamson DC, et al. Characterizing mobility from the prosthetic limb user's perspective: Use of focus groups to guide development of the Prosthetic Limb Users Survey of Mobility. Prosthet Orthot Int. 2016 Oct;40(5):582-90. doi: 10.1177/0309364615579315. PMID: 25944625.

39. Gallagher P, Horgan O, Franchignoni F, et al. Body image in people with lower-limb amputation: a Rasch analysis of the Amputee Body Image Scale. Am J Phys Med Rehabil. 2007 Mar;86(3):205-15. doi: 10.1097/PHM.0b013e3180321439. PMID: 17314705.

40. Coffey L, Gallagher P, Horgan O, et al. Psychosocial adjustment to diabetes-related lower limb amputation. Diabet Med. 2009 Oct;26(10):1063-7. doi: 10.1111/j.1464-5491.2009.02802.x. PMID: 19900240.

41. Norvell DC, Williams RM, Turner AP, et al. The development and validation of a novel outcome measure to quantify mobility in the dysvascular lower extremity amputee: the amputee single item mobility measure. Clin Rehabil. 2016 Sep;30(9):878-89. doi: 10.1177/0269215516644308. PMID: 27496697.

42. Theeven P, Hemmen B, Stevens C, et al. Feasibility of a new concept for measuring actual functional performance in daily life of transfemoral amputees. J Rehabil Med. 2010 Sep;42(8):744-51. doi: 10.2340/16501977-0591. PMID: 20809056.

43. Miller M, Wong WK, Wu J, et al. Upper-arm anthropometry: an alternative indicator of nutritional health to body mass index in unilateral lowerextremity amputees? Arch Phys Med Rehabil. 2008 Oct;89(10):2031-3. doi: 10.1016/j.apmr.2008.03.025. PMID: 18929034.

44. Brunelli S, Averna T, Porcacchia P, et al. Functional status and factors influencing the rehabilitation outcome of people affected by aboveknee amputation and hemiparesis. Arch Phys Med Rehabil. 2006 Jul;87(7):995-1000. doi: 10.1016/j.apmr.2006.04.004. PMID: 16813789.

45. Fisher K, Hanspal R. Body image and patients with amputations: does the prosthesis maintain the balance? Int J Rehabil Res. 1998 Dec;21(4):355-63. PMID: 9926350.

46. de Laat FA, Rommers GM, Geertzen JH, et al. Construct validity and test-retest reliability of the climbing stairs questionnaire in lower-limb amputees. Arch Phys Med Rehabil. 2010 Sep;91(9):1396-401. doi: 10.1016/j.apmr.2010.06.013. PMID: 20801258.

47. de Laat FA, Rommers GM, Geertzen JH, et al. Construct validity and test-retest reliability of the questionnaire rising and sitting down in lower-limb amputees. Arch Phys Med Rehabil. 2011 Aug;92(8):1305-10. doi: 10.1016/j.apmr.2011.03.016. PMID: 21807151.

48. de Laat FA, Rommers GM, Geertzen JH, et al. Construct validity and test-retest reliability of the walking questionnaire in people with a lower limb amputation. Archives of physical medicine and rehabilitation. 2012;93(6):983-9.

49. Yari P, Dijkstra PU, Geertzen JH. Functional outcome of hip disarticulation and hemipelvectomy: a cross-sectional national descriptive study in the Netherlands. Clin Rehabil. 2008 Dec;22(12):1127-33. doi: 10.1177/0269215508095088. PMID: 19052251.

50. Asano M, Rushton P, Miller WC, et al. Predictors of quality of life among individuals who have a lower limb amputation. Prosthet Orthot Int. 2008 Jun;32(2):231-43. doi: 10.1080/03093640802024955. PMID: 18569891.

51. Cyril JK. Characterizing prosthetic device use and satisfaction, and evaluating measures of physical function among individuals with lower extremity amputation secondary to trauma: Johns Hopkins University; 2002.

52. Callaghan BG, Sockalingam S, Treweek SP, et al. A post-discharge functional outcome measure for lower limb amputees: test-retest reliability with transtibial amputees. Prosthet Orthot Int. 2002 Aug;26(2):113-9. doi: 10.1080/03093640208726633. PMID: 12227445.

53. Gallagher P, MacLachlan M. Positive meaning in amputation and thoughts about the amputated limb. Prosthet Orthot Int. 2000 Dec;24(3):196-204. PMID: 11195354.

54. Fisher K, Hanspal RS, Marks L. Return to work after lower limb amputation. Int J Rehabil Res. 2003 Mar;26(1):51-6. doi:

10.1097/01.mrr.0000054806.81886.d7. PMID: 12601268.

55. Hanspal RS, Fisher K. Assessment of cognitive and psychomotor function and rehabilitation of elderly people with prostheses. Bmj. 1991 Apr 20;302(6782):940. PMID: 2032036.

56. Houghton AD, Taylor PR, Thurlow S, et al. Success rates for rehabilitation of vascular amputees: implications for preoperative assessment and amputation level. Br J Surg. 1992 Aug;79(8):753-5. PMID: 1393461.

57. Miller WC, Deathe AB, Speechley M. Lower extremity prosthetic mobility: a comparison of 3 selfreport scales. Arch Phys Med Rehabil. 2001 Oct;82(10):1432-40. doi: 10.1053/apmr.2001.25987. PMID: 11588750.

58. Miller WC, Deathe AB, Speechley M, et al. The influence of falling, fear of falling, and balance confidence on prosthetic mobility and social activity among individuals with a lower extremity amputation. Arch Phys Med Rehabil. 2001 Sep;82(9):1238-44. doi: 10.1053/apmr.2001.25079. PMID: 11552197.

59. da Silva R, Rizzo JG, Gutierres Filho PJ, et al. Physical activity and quality of life of amputees in southern Brazil. Prosthet Orthot Int. 2011 Dec;35(4):432-8. doi: 10.1177/0309364611425093. PMID: 22042373.

60. Arwert HJ, van Doorn-Loogman MH, Koning J, et al. Residual-limb quality and functional mobility 1 year after transtibial amputation caused by vascular insufficiency. J Rehabil Res Dev. 2007;44(5):717-22. PMID: 17943683.

61. Franchignoni F, Giordano A, Ferriero G, et al. Rasch analysis of the Locomotor Capabilities Index-5 in people with lower limb amputation. Prosthet Orthot Int. 2007 Dec;31(4):394-404. doi: 10.1080/03093640701253952. PMID: 18050010. 62. Gauthier-Gagnon C, Grise MC. Prosthetic profile of the amputee questionnaire: validity and reliability. Arch Phys Med Rehabil. 1994 Dec;75(12):1309-14. PMID: 7993169.

63. Norvell DC, Turner AP, Williams RM, et al. Defining successful mobility after lower extremity amputation for complications of peripheral vascular disease and diabetes. J Vasc Surg. 2011 Aug;54(2):412-9. doi: 10.1016/j.jvs.2011.01.046. PMID: 21531528.

64. Traballesi M, Porcacchia P, Averna T, et al. Prognostic factors in prosthetic rehabilitation of bilateral dysvascular above-knee amputee: is the stump condition an influencing factor? Eura Medicophys. 2007 Mar;43(1):1-6. PMID: 16955063.

65. Treweek SP, Condie ME. Three measures of functional outcome for lower limb amputees: a retrospective review. Prosthet Orthot Int. 1998 Dec;22(3):178-85. doi: 10.3109/03093649809164482. PMID: 9881605.

66. Deathe AB, Miller WC. The L test of functional mobility: measurement properties of a modified version of the timed "up & go" test designed for people with lower-limb amputations. Phys Ther. 2005 Jul;85(7):626-35. PMID: 15982169.

67. Rushton PW, Miller WC, Deathe AB. Minimal clinically important difference of the L Test for individuals with lower limb amputation: A pilot study. Prosthet Orthot Int. 2015 Dec;39(6):470-6. doi: 10.1177/0309364614545418. PMID: 25134533.

68. Callaghan BG, Condie ME. A post-discharge quality of life outcome measure for lower limb amputees: test-retest reliability and construct validity. Clin Rehabil. 2003 Dec;17(8):858-64. doi: 10.1191/0269215503cr6890a. PMID: 14682557.

69. Amtmann D, Morgan SJ, Kim J, et al. Healthrelated profiles of people with lower limb loss. Arch Phys Med Rehabil. 2015 Aug;96(8):1474-83. doi: 10.1016/j.apmr.2015.03.024. PMID: 25917819.

70. Hafner BJ, Morgan SJ, Askew RL, et al. Psychometric evaluation of self-report outcome measures for prosthetic applications. J Rehabil Res Dev. 2016;53(6):797-812. doi: 10.1682/jrrd.2015.12.0228. PMID: 28273329.

71. Franchignoni F, Giordano A, Ferriero G, et al. Measuring mobility in people with lower limb amputation: Rasch analysis of the mobility section of the prosthesis evaluation questionnaire. J Rehabil Med. 2007 Mar;39(2):138-44. doi: 10.2340/16501977-0033. PMID: 17351696.

72. Legro MW, Reiber GD, Smith DG, et al. Prosthesis evaluation questionnaire for persons with lower limb amputations: assessing prosthesis-related quality of life. Arch Phys Med Rehabil. 1998 Aug;79(8):931-8. PMID: 9710165.

73. Van de Weg FB, Van der Windt DA. A questionnaire survey of the effect of different interface types on patient satisfaction and perceived problems among trans-tibial amputees. Prosthet Orthot Int. 2005 Dec;29(3):231-9. doi: 10.1080/03093640500199679. PMID: 16466153.

74. Hafner BJ, Gaunaurd IA, Morgan SJ, et al. Construct Validity of the Prosthetic Limb Users Survey of Mobility (PLUS-M) in Adults With Lower Limb Amputation. Arch Phys Med Rehabil. 2017 Feb;98(2):277-85. doi: 10.1016/j.apmr.2016.07.026. PMID: 27590443.

75. Kelly VE, Morgan SJ, Amtmann D, et al. Association of self-reported cognitive concerns with mobility in people with lower limb loss. Disabil Rehabil. 2016 Oct 19:1-8. doi: 10.1080/09638288.2016.1243162. PMID: 27756174.

76. Morgan SJ, Kelly VE, Amtmann D, et al. Self-Reported Cognitive Concerns in People With Lower Limb Loss. Arch Phys Med Rehabil. 2016 Jun;97(6):912-8. doi: 10.1016/j.apmr.2016.01.010. PMID: 26836953.

77. Hagberg K, Branemark R, Hagg O. Questionnaire for Persons with a Transfemoral Amputation (Q-TFA): initial validity and reliability of a new outcome measure. J Rehabil Res Dev. 2004 Sep;41(5):695-706. PMID: 15558399.

78. Hammarlund CS, Carlstrom M, Melchior R, et al. Prevalence of back pain, its effect on functional ability and health-related quality of life in lower limb amputees secondary to trauma or tumour: a comparison across three levels of amputation. Prosthet Orthot Int. 2011 Mar;35(1):97-105. doi: 10.1177/0309364610389357. PMID: 21515895.

79. Franchignoni F, Brunelli S, Orlandini D, et al. Is the Rivermead Mobility Index a suitable outcome measure in lower limb amputees?--A psychometric validation study. J Rehabil Med. 2003 May;35(3):141-4. PMID: 12809197. Ryall NH, Eyres SB, Neumann VC, et al. Is the Rivermead Mobility Index appropriate to measure mobility in lower limb amputees? Disabil Rehabil. 2003 Feb 04;25(3):143-53. doi: 10.1080/0963828021000024951. PMID: 12648004.

81. Bilodeau S, Hebert R, Desrosiers J.
[Questionnaire on the satisfaction of persons with lower-limb amputations towards their prosthesis: development and validation]. Can J Occup Ther.
1999 Feb;66(1):23-32. doi:
10.1177/000841749906600103. PMID: 10462879.

82. Aksnes LH, Bauer HC, Jebsen NL, et al. Limbsparing surgery preserves more function than amputation: a Scandinavian sarcoma group study of 118 patients. J Bone Joint Surg Br. 2008 Jun;90(6):786-94. doi: 10.1302/0301-620x.90b6.19805. PMID: 18539673.

83. Boutoille D, Feraille A, Maulaz D, et al. Quality of life with diabetes-associated foot complications: comparison between lower-limb amputation and chronic foot ulceration. Foot Ankle Int. 2008 Nov;29(11):1074-8. doi: 10.3113/fai.2008.1074. PMID: 19026199.

84. Davidson JH, Khor KE, Jones LE. A crosssectional study of post-amputation pain in upper and lower limb amputees, experience of a tertiary referral amputee clinic. Disabil Rehabil. 2010;32(22):1855-62. doi: 10.3109/09638281003734441. PMID: 20345252.

85. Hagberg K, Branemark R. Consequences of nonvascular trans-femoral amputation: a survey of quality of life, prosthetic use and problems. Prosthet Orthot Int. 2001 Dec;25(3):186-94. PMID: 11860092.

86. Happich M, John J, Stamenitis S, et al. The quality of life and economic burden of neuropathy in diabetic patients in Germany in 2002--results from the Diabetic Microvascular Complications (DIMICO) study. Diabetes Res Clin Pract. 2008 Aug;81(2):223-30. doi: 10.1016/j.diabres.2008.03.019. PMID: 18602714.

87. Hoffman RD, Saltzman CL, Buckwalter JA. Outcome of lower extremity malignancy survivors treated with transfemoral amputation. Arch Phys Med Rehabil. 2002 Feb;83(2):177-82. PMID: 11833020.

88. Pezzin LE, Dillingham TR, MacKenzie EJ. Rehabilitation and the long-term outcomes of persons

with trauma-related amputations. Arch Phys Med Rehabil. 2000 Mar;81(3):292-300. PMID: 10724073.

89. Remes L, Isoaho R, Vahlberg T, et al. Quality of life three years after major lower extremity amputation due to peripheral arterial disease. Aging Clin Exp Res. 2010 Oct-Dec;22(5-6):395-405. doi: 10.3275/6712. PMID: 20009496.

90. Schoppen T, Boonstra A, Groothoff JW, et al. Employment status, job characteristics, and workrelated health experience of people with a lower limb amputation in The Netherlands. Arch Phys Med Rehabil. 2001 Feb;82(2):239-45. doi: 10.1053/apmr.2001.18231. PMID: 11239317.

91. Sinha R, van den Heuvel WJ, Arokiasamy P. Factors affecting quality of life in lower limb amputees. Prosthet Orthot Int. 2011 Mar;35(1):90-6. doi: 10.1177/0309364610397087. PMID: 21515894.

92. Smith DG, Horn P, Malchow D, et al. Prosthetic history, prosthetic charges, and functional outcome of the isolated, traumatic below-knee amputee. J Trauma. 1995 Jan;38(1):44-7. PMID: 7745656.

93. van der Schans CP, Geertzen JH, Schoppen T, et al. Phantom pain and health-related quality of life in lower limb amputees. J Pain Symptom Manage. 2002 Oct;24(4):429-36. PMID: 12505212.

94. van der Sluis CK, Hartman PP, Schoppen T, et al. Job adjustments, job satisfaction and health experience in upper and lower limb amputees. Prosthet Orthot Int. 2009 Mar;33(1):41-51. doi: 10.1080/03093640802555917. PMID: 19235065.

95. Willrich A, Pinzur M, McNeil M, et al. Health related quality of life, cognitive function, and depression in diabetic patients with foot ulcer or amputation. A preliminary study. Foot Ankle Int. 2005 Feb;26(2):128-34. doi: 10.1177/107110070502600203. PMID: 15737254.

96. Greive AC, Lankhorst GJ. Functional outcome of lower-limb amputees: a prospective descriptive study in a general hospital. Prosthet Orthot Int. 1996 Aug;20(2):79-87. doi: 10.3109/03093649609164423. PMID: 8876000.

97. MacKenzie EJ, Bosse MJ, Pollak AN, et al. Long-term persistence of disability following severe lower-limb trauma. Results of a seven-year followup. J Bone Joint Surg Am. 2005 Aug;87(8):1801-9. doi: 10.2106/jbjs.e.00032. PMID: 16085622. 98. Hanspal RS, Fisher K, Nieveen R. Prosthetic socket fit comfort score. Disabil Rehabil. 2003 Nov 18;25(22):1278-80. doi: 10.1080/09638280310001603983. PMID: 14617445.

99. Ryall NH, Eyres SB, Neumann VC, et al. The SIGAM mobility grades: a new population-specific measure for lower limb amputees. Disabil Rehabil. 2003 Aug 05;25(15):833-44. doi: 10.1080/0963828021000056460. PMID: 12851094.

100. Ramstrand N, Nilsson KA. Validation of a patient activity monitor to quantify ambulatory activity in an amputee population. Prosthet Orthot Int. 2007 Jun;31(2):157-66. doi: 10.1080/03093640600988617. PMID: 17520493.

101. Desmond D, Gallagher P, Henderson-Slater D, et al. Pain and psychosocial adjustment to lower limb amputation amongst prosthesis users. Prosthet Orthot Int. 2008 Jun;32(2):244-52. doi: 10.1080/03093640802067046. PMID: 18569892.

102. Gallagher P, Franchignoni F, Giordano A, et al. Trinity amputation and prosthesis experience scales: a psychometric assessment using classical test theory and rasch analysis. Am J Phys Med Rehabil. 2010 Jun;89(6):487-96. doi: 10.1097/PHM.0b013e3181dd8cf1. PMID: 20489393.

103. Gallagher P, Maclachlan M. The Trinity Amputation and Prosthesis Experience Scales and quality of life in people with lower-limb amputation. Arch Phys Med Rehabil. 2004 May;85(5):730-6. PMID: 15129396.

104. Schoppen T, Boonstra A, Groothoff JW, et al. The Timed "up and go" test: reliability and validity in persons with unilateral lower limb amputation. Arch Phys Med Rehabil. 1999 Jul;80(7):825-8. PMID: 10414769.

105. Boonstra AM, Fidler V, Eisma WH. Walking speed of normal subjects and amputees: aspects of validity of gait analysis. Prosthet Orthot Int. 1993 Aug;17(2):78-82. doi: 10.3109/03093649309164360. PMID: 8233772.

106. Salsich GB, Mueller MJ. Relationships between measures of function, strength and walking speed in patients with diabetes and transmetatarsal amputation. Clin Rehabil. 1997 Feb;11(1):60-7. doi: 10.1177/026921559701100109. PMID: 9065361.

107. Gallagher P, O'Donovan MA, Doyle A, et al. Environmental barriers, activity limitations and participation restrictions experienced by people with major limb amputation. Prosthet Orthot Int. 2011 Sep;35(3):278-84. doi: 10.1177/0309364611407108. PMID: 21937573.

108. Cox PS, Williams SK, Weaver SR. Life after lower extremity amputation in diabetics. West Indian Med J. 2011 Oct;60(5):536-40. PMID: 22519229.

109. Deans SA, McFadyen AK, Rowe PJ. Physical activity and quality of life: A study of a lower-limb amputee population. Prosthet Orthot Int. 2008 Jun;32(2):186-200. doi: 10.1090/02002640902016514. PMUD: 18560987

10.1080/03093640802016514. PMID: 18569887.

110. Alaranta H, Lempinen VM, Haavisto E, et al. Subjective benefits of energy storing prostheses. Prosthet Orthot Int. 1994 Aug;18(2):92-7. doi: 10.3109/03093649409164390. PMID: 7991366.

111. De Asha AR, Munjal R, Kulkarni J, et al. Impact on the biomechanics of overground gait of using an 'Echelon' hydraulic ankle-foot device in unilateral trans-tibial and trans-femoral amputees. Clin Biomech (Bristol, Avon). 2014 Aug;29(7):728-34. doi: 10.1016/j.clinbiomech.2014.06.009. PMID: 24997811.

112. Gard SA, Konz RJ. The effect of a shockabsorbing pylon on the gait of persons with unilateral transtibial amputation. J Rehabil Res Dev. 2003 Mar-Apr;40(2):109-24. PMID: 15077637.

113. Hafner BJ, Smith DG. Differences in function and safety between Medicare Functional Classification Level-2 and -3 transfemoral amputees and influence of prosthetic knee joint control. J Rehabil Res Dev. 2009;46(3):417-33. PMID: 19675993.

114. Hahn A, Lang M, Stuckart C. Analysis of clinically important factors on the performance of advanced hydraulic, microprocessor-controlled exoprosthetic knee joints based on 899 trial fittings. Medicine (Baltimore). 2016 Nov;95(45):e5386. doi: 10.1097/md.00000000005386. PMID: 27828871.

115. Isakov E, Susak Z, Becker E. Energy expenditure and cardiac response in above-knee amputees while using prostheses with open and locked knee mechanisms. Scand J Rehabil Med Suppl. 1985;12:108-11. PMID: 3868034. 116. Kahle JT, Highsmith MJ, Hubbard SL. Comparison of nonmicroprocessor knee mechanism versus C-Leg on Prosthesis Evaluation Questionnaire, stumbles, falls, walking tests, stair descent, and knee preference. J Rehabil Res Dev. 2008;45(1):1-14. PMID: 18566922.

117. Theeven P, Hemmen B, Rings F, et al. Functional added value of microprocessor-controlled knee joints in daily life performance of Medicare Functional Classification Level-2 amputees. J Rehabil Med. 2011 Oct;43(10):906-15. doi: 10.2340/16501977-0861. PMID: 21947182.

118. Theeven PJ, Hemmen B, Geers RP, et al. Influence of advanced prosthetic knee joints on perceived performance and everyday life activity level of low-functional persons with a transfemoral amputation or knee disarticulation. J Rehabil Med. 2012 May;44(5):454-61. doi: 10.2340/16501977-0969. PMID: 22549656.

119. Traballesi M, Delussu AS, Averna T, et al. Energy cost of walking in transfemoral amputees: Comparison between Marlo Anatomical Socket and Ischial Containment Socket. Gait Posture. 2011 Jun;34(2):270-4. doi: 10.1016/j.gaitpost.2011.05.012. PMID: 21684165.

120. Silver-Thorn B GC. Functional Stability of Transfemoral Amputee Gait Using the 3R80 and Total Knee 2000 Prosthetic Knee Units. JPO Journal of Prosthetics and Orthotics. 2009;21(1).

121. Wong CK, Rheinstein J, Stern MA. Benefits for Adults with Transfemoral Amputations and Peripheral Artery Disease Using Microprocessor Compared with Nonmicroprocessor Prosthetic Knees. Am J Phys Med Rehabil. 2015 Oct;94(10):804-10. doi: 10.1097/phm.00000000000265. PMID: 25768067.

122. Pezzin LE, Dillingham TR, Mackenzie EJ, et al. Use and satisfaction with prosthetic limb devices and related services. Arch Phys Med Rehabil. 2004 May;85(5):723-9. PMID: 15129395.

123. Chen MC, Lee SS, Hsieh YL, et al. Influencing factors of outcome after lower-limb amputation: a five-year review in a plastic surgical department. Ann Plast Surg. 2008 Sep;61(3):314-8. doi: 10.1097/SAP.0b013e3181571379. PMID: 18724135.

124. Davies B, Datta D. Mobility outcome following unilateral lower limb amputation. Prosthet Orthot Int.

2003 Dec;27(3):186-90. doi: 10.1080/03093640308726681. PMID: 14727699.

125. Dudkiewicz I, Pisarenko B, Herman A, et al. Satisfaction rates amongst elderly amputees provided with a static prosthetic foot. Disabil Rehabil. 2011;33(21-22):1963-7. doi: 10.3109/09638288.2011.553705. PMID: 21303214.

126. Gauthier-Gagnon C, Grise MC, Potvin D. Enabling factors related to prosthetic use by people with transtibial and transfemoral amputation. Arch Phys Med Rehabil. 1999 Jun;80(6):706-13. PMID: 10378500.

127. Marmann C. Der geriatrisch Amputierte nach Entlassung aus erfolgreicher stationärer Rehabilitation; 1991.

128. Matsen SL, Malchow D, Matsen FA, 3rd. Correlations with patients' perspectives of the result of lower-extremity amputation. J Bone Joint Surg Am. 2000 Aug;82-a(8):1089-95. PMID: 10954097.

129. Pohjolainen T, Alaranta H, Karkkainen M. Prosthetic use and functional and social outcome following major lower limb amputation. Prosthet Orthot Int. 1990 Aug;14(2):75-9. doi: 10.3109/03093649009080326. PMID: 2235304.

130. Roffman CE, Buchanan J, Allison GT. Predictors of non-use of prostheses by people with lower limb amputation after discharge from rehabilitation: development and validation of clinical prediction rules. J Physiother. 2014 Dec;60(4):224-31. doi: 10.1016/j.jphys.2014.09.003. PMID: 25450484.

131. Roffman CE, Buchanan J, Allison GT. Locomotor Performance During Rehabilitation of People With Lower Limb Amputation and Prosthetic Nonuse 12 Months After Discharge. Phys Ther. 2016 Jul;96(7):985-94. doi: 10.2522/ptj.20140164. PMID: 26637652.

132. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010 Jan;21(1):128-38. doi: 10.1097/EDE.0b013e3181c30fb2. PMID: 20010215.

133. Vickers AJ, Cronin AM. Everything you always wanted to know about evaluating prediction models (but were too afraid to ask). Urology. 2010 Dec;76(6):1298-301. doi: 10.1016/j.urology.2010.06.019. PMID: 21030068. 134. Hahn A, Lang M. Effects of mobility grade, age, and etiology on functional benefit and safety of subjects evaluated in more than 1200 C-Leg trial fittings in Germany. JPO: Journal of Prosthetics and Orthotics. 2015;27(3):86-94.

Appendix A

PUBMED

("Recovery of Function" [Mesh] OR "functional assessment" OR "functional status" OR "Mobility Limitation" [Mesh] OR function OR mobility OR ambulation OR stair* OR locomotion OR "treatment outcome" OR walking OR (abandonment and prosthe*) OR (rejection* and prosthe*) OR Quality of Life OR Health Status) AND ("Artificial limb" OR "Artificial limbs" OR "Artificial Limbs" [Mesh] OR prosthe* [text term] **OR** Artificial Limbs) AND

("lower limb"[Mesh] OR "leg"[Mesh] or lower extremity or foot or ankle or tibia or fibula or femur or thigh or "Membrum inferius" or leg or lower limb)

NOT

("Arthroplasty"[Mesh] or "Prosthesis Implantation"[Mesh] or "Vascular Surgical Procedures"[Mesh] or "Osteotomy"[Mesh]) OR Aneurysm*[tiab] OR Aorta*[tiab] OR Aortic*[tiab] OR Arthroplast*[tiab] OR "avascular necrosis"[tiab] OR Bypass*[tiab] OR Cement*[tiab] OR endoprosth*[tiab] OR fixat*[tiab] OR fracture*[tiab] OR Graft*[tiab] OR Implant*[tiab] OR total hip replacement*[tiab] OR total knee replacement*[tiab] OR ((Orthot*[tiab] OR Orthos*[tiab]) NOT (amput*[tiab] OR prosth*[tiab])) OR "addresses"[pt] OR "autobiography"[pt] OR "bibliography"[pt] OR "biography"[pt] OR "case reports"[pt] OR "comment"[pt] OR "congresses"[pt] OR "dictionary"[pt] OR "directory"[pt] OR "editorial"[pt] OR "festschrift"[pt] OR "government publications"[pt] OR "historical article"[pt] OR "interview"[pt] OR "lectures"[pt] OR "legal cases"[pt] OR "legislation"[pt] OR "letter"[pt] OR "news"[pt] OR "newspaper article"[pt] OR "patient education handout"[pt] OR "periodical index"[pt] OR "comment on" OR ("Animals"[Mesh] NOT "Humans"[Mesh]) OR rats[tw] OR cow[tw] OR cows[tw] OR chicken*[tw] OR horse[tw] OR horses[tw] OR mice[tw] OR mouse[tw] OR bovine[tw] OR sheep OR ovine OR murine

PUBMED: 2757 on 11/30/16

EMBASE

#24 NOT #20	#39
#31 NOT #38	<u>4,449</u> #38
#32 OR #33 OR #34 OR #35 OR #36 OR #37	<u>561,702</u>
orthot* OR orthos* NOT (amput* OR prosth*)	#37
aneurysm* OR aorta* OR aortic* OR arthroplast* OR 'avascular	#36
necrosis' OR bypass* OR cement* OR endoprosth* OR fixat* OR fracture* OR graft* OR implant* OR replacement* OR totalAND knee AND replacement*	total AND hip AND
'osteotomy'/exp	#35
'vascular surgen/'/evp	<u>37,235</u> #34
	<u>384,960</u> #33
'prosthesis implantation'/exp	<u>2,151</u> #32
'arthroplasty'/exp	63,011
#24 AND #27 AND #30	#31
#28 OR #29	#30
lower AND extremity OR foot OR ankle OR tibia OR fibula OR femur OR thigh OR 'membrum	<u>377,525</u> #29
inferius' OR leg OR lower AND limb	<u>83,740</u>
'leg'/exp OR 'leg'	#28
#25 OR #26	#27
artificial AND limh* OR prosthe*	<u>287,601</u> #26
	<u>287,569</u> #25
'limb prosthesis'/exp OR 'limb prosthesis'	<u>7,731</u> #24
#17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23	<u>4,097,920</u>
quality AND of AND life OR health AND status	#23 474 604
rejection* AND prosthe*	#22
abandonment AND prosthe*	<u>1,092</u> #21
	<mark>80</mark> #20
tunction OR mobility OR ambulation OR stair* OR locomotion OR 'treatment outcome' OR walking	3,662,274

'walking difficulty'/exp OR 'walking difficulty' OR 'mobility'/exp OR mobility AND limitation	#19
	<u>2,685</u>
'functional assessment'/exp OR 'functional assessment' OR 'functional status'/exp OR 'functional status'	#18
	103,884 #17
'convalescence'/exp OR 'convalescence' OR 'recovery'/exp OR recovery AND of AND ('function'/exp OR function)	#17
	<u>92,026</u>

Cochrane

Recovery of Function OR functional assessment OR functional status OR Mobility Limitation OR function. OR mobility OR ambulation OR stair OR stairs OR locomotion OR treatment outcome OR walking OR (abandonment and prosthesis) OR (rejection and prosthesis) OR Quality of Life OR Health Status

AND

Artificial limb or Artificial limbs or prosthesis or prosthetic

AND

lower limb OR leg or lower extremity or foot or ankle or tibia or fibula or femur or thigh or "Membrum inferius"

NOT (Arthroplasty or Prosthesis Implantation or Vascular Surgical Procedures or Osteotomy OR Aneurysm OR Aorta OR Aortic OR Arthroplast OR avascular necrosis OR Bypass OR Cement OR endoprosth OR fixat OR fracture OR Graft OR Implant OR total hip replacement OR total knee replacement)

CINAHL/PSYCInfo

(Recovery of Function OR functional assessment OR functional status OR Mobility Limitation OR function OR mobility OR ambulation OR stairs OR locomotion OR treatment outcome OR walking OR (abandonment and prosthesis) OR (rejection and prosthesis) OR Quality of Life OR Health Status) AND

(Artificial limb or Artificial limbs or prosthesis or prosthetic)

ÀND

(lower limb OR leg or lower extremity or foot or ankle or tibia or fibula or femur or thigh or "Membrum inferius")

Appendix B

		7:0-	mark mark al 1 d	Delection
authors	journal	l itie	pubmed Id	Reason
Agrawal V and Gailey R and O'Toole C and Gaunaurd I and Finnieston A	Influence of gait training and prosthetic foot category on external work symmetry during unilateral transtibial amputee gait.	Prosthetics and orthotics international	23364890	KQ 4-7: No outcome of interest
Agrawal V and Gailey RS and Gaunaurd IA and O'Toole C and Finnieston A and Tolchin R.	Comparison of four different categories of prosthetic feet during ramp ambulation in unilateral transtibial amputees	Prosthet Orthot Int	24925671	KQ 4-7: No outcome of interest
Agrawal V and Gailey RS and Gaunaurd IA and O'Toole C and Finnieston AA.	J Rehabil Res Dev	Comparison between microprocessor-controlled ankle/foot and conventional prosthetic feet during stair negotiation in people with unilateral transtibial amputation	24301431	KQ 4-7: No outcome of interest
Agrawal Veena R and Skrabek Ryan Q and Embil John M and Gross Patrick and Trepman Elly			107899203. Language:	KQ 7: N<100
Agrawal Vibhor Ramchandra		A comparison of gait kinetics between prosthetic feet during functional activities Symmetry in External Work (SEW) approach	2011-99080-196	KQ 1-3: N<20
Akkaya N and Akkaya S and �_im��ir Atalay N and Findiko��lu G and Alkan H and Ardil¤ F.		Demographic and clinical features of our lower limb amputee patients		Low resource country
Albert MV and Deeny S and McCarthy C and Valentin J and Jayaraman A.		Monitoring daily function in persons with transfemoral amputations using a commercial activity monitor: a feasibility study	24954402	KQ 1-3: N<20
Albert MV and McCarthy C and Valentin J and Herrmann M and Kording K and Jayaraman A.		Monitoring functional capability of individuals with lower limb amputations using mobile phones	23750254	KQ 1-3: N<20
Ali S and Abu Osman NA and Arifin N and Gholizadeh H and Abd Razak NA and Wan Abas WAB.	Comparative study between Dermo, Pelite, and seal-in X5 liners: Effect on patient's satisfaction and perceived problems	Scientific World Journal	25184154	Low resource country

Ali S and Abu Osman NA and Eshraghi A and Gholizadeh H and Abd Razak NA and Wan Abas WA.	Clin Biomech (Bristol, Avon)	Interface pressure in transtibial socket during ascent and descent on stairs and its effect on patient satisfaction	24161521	Low resource country
Ali S and Osman NA and Mortaza N and Eshraghi A and Gholizadeh H and Wan Abas WA.	Clin Biomech (Bristol, Avon)	Clinical investigation of the interface pressure in the trans-tibial socket with Dermo and Seal-In X5 liner during walking and their effect on patient satisfaction	22795863	Low resource country
Ali S and Osman NA and Razak A and Hussain S and Wan Abas WA.	The effect of Dermo and Seal-In X5 prosthetic liners on pressure distributions and reported satisfaction during ramp ambulation in persons with transtibial limb loss	Eur J Phys Rehabil Med	24963603	Low resource country
Altner PC and Rusin JJ and DeBoer A.			7369844	KQ 7: N<100
Azuma Y and Chin T and Takase I and Tezuka Y and Nakatsuka A and Fujie H and Fujiwara Y and Kurokawa M and Ochi T and Hara M and Oyabu H and Miura Y.	Relation between balance function evaluated using berg balance scale and walking ability in transfemoral amputees	Physiotherapy (United Kingdom)		Not peer reviewed publication
Baker R and McGinley JL and Schwartz MH and Beynon S and Rozumalski A and Graham HK and Tirosh O.	The Gait Profile Score and Movement Analysis Profile	Gait and Posture		Pediatric
Barr JB and Wutzke CJ and Threlkeld AJ.	Physiotherapy theory and practice	Longitudinal gait analysis of a person with a transfemoral amputation using three different prosthetic knee/foot pairs	22191438	Case report/series
Berg KO, Maki BE, Williams JI, Holliday PJ, Wood-Dauphinee SL		Clinical and laboratory measures of postural balance in an elderly population	1444775	Not amputees
Bilodeau S and Hebert R and Desrosiers J.			11061199	KQ 7: N<100
Bischoff HA and Stahelin HB and Monsch AU and Iversen MD and Weyh A and von Dechend M and Akos R and Conzelmann M and Dick W and Theiler R		Identifying a cut-off point for normal mobility: a comparison of the timed 'up and go' test in community- dwelling and institutionalised elderly women.	12720619	Not amputees
Blum C and Ehrler S and Isner ME.	Ann Phys Rehabil Med	Assessment of therapeutic education in 135 lower limb	27676838	Not peer reviewed

		amputees		publication
Brunelli S and Fusco A and losa M and Delussu AS and Paolucci S and Traballesi M.			23072255	KQ 7: N<100
Burger H and Marincek C and Isakov E.	Mobility of persons after traumatic lower limb amputation	Disabil Rehabil	9246543	Low resource country
Buttenshaw P and Dolman J.				KQ 7: N<100
Callaghan B and Condie E and Johnston M.		Using the common sense self-regulation model to determine psychological predictors of prosthetic use and activity limitations in lower limb amputees	18825576	KQ 7: Included amputees without LLP
Callaghan BG and Johnston M and Condie ME.		Using the theory of planned behaviour to develop an assessment of attitudes and beliefs towards prosthetic use in amputees	15497923	KQ 4-7: No outcome of interest
Campbell WB and Ridler BM.			8896478	KQ 7: N<100
Chamlian TR.	Einstein (Sao Paulo)	Use of prostheses in lower limb amputee patients due to peripheral arterial disease	25628194	KQ 7: Unclear followup time
Chan KM and Tan ES.			2130743	KQ 7: N<100
Chan T and Wu J and Bowring G.	Functional outcomes of major lower limb amputation 1994- 2006: A modern series	Internal Medicine Journal		KQ 7: <6 mo f/up post-prescription
Chou TGR and Webster JB and Shahrebani M and Roberts TL and Bloebaum RD.		Characterization of step count accuracy of actigraph activity monitor in persons with lower limb amputation	105317621	KQ 1-3: N<20
Chou YL and Shi SS and Huang GF and Lin TS.	Interface pressure and gait analysis in different walking speeds and on the below-knee amputees with multiple axis prosthetic foot prosthesis	Biomedical Engineering - Applications, Basis and Communications		KQ 4: Noncomparative
Coelho A and Espanha M and Bruno PM.		Six-minute walk test and timed up & go test in persons with transfemoral amputations		Not peer reviewed publication
Coffey L and Gallagher P and Desmond D and Ryall N and Wegener ST			24907639	KQ 7: N<100
Cohen E and Dickstien R and Schwarz V and Pillar T.	Harefuah	Evaluation of the rehabilitation of geriatric amputees		Not primary study
Coleman KL and		Step activity monitor: long-	10659890	Not amputees

Smith DG and Boone DA and Joseph AW and del Aguila MA		term, continuous recording of ambulatory function.		
Collin C and Wade DT and Cochrane GM				KQ 7: N<100
Correy MR and St Julien J and Miller C and Fisher B and Cederstrand SL and Nylander WA and Guzman RJ and Dattilo JB	Am J Surg. 2012 Nov;204(5):626-30	Patient education level affects functionality and long term mortality after major lower extremity amputation.	22906244	KQ 7: Included amputees without LLP
Crea S and Cipriani C and Donati M and Carrozza MC and Vitiello N.	Providing time- discrete gait information by wearable feedback apparatus for lower- limb amputees: usability and functional validation	IEEE Trans Neural Syst Rehabil Eng	25373108	Not amputees
Cull DL and Taylor SM and Hamontree SE and Langan EM and Snyder BA and Sullivan TM and Youkey JR.	Am J Surg	A reappraisal of a modified through-knee amputation in patients with peripheral vascular disease	11532414	KQ 7: Excluded some LLP recipients
Cutti AG and Raggi M and Parel I.	Assessment of Transtibial Amputees walking in real-life environments: Inter- rater reliability of a protocol based on inertial and magnetic sensors	Gait and Posture		Not peer reviewed publication
Davie-Smith F and Scott H.	The scottish physiotherapy amputee research group (SPARG)	Physiotherapy (United Kingdom)		Not peer reviewed publication
De Luccia N and Pinto MA and Guedes JP and Albers MT	Rehabilitation after amputation for vascular disease: a follow-up study.	Prosthetics & Orthotics International. 16(2):124-8, 1992 Aug.	1408671	Low resource country
Dillingham TR and Pezzin LE and MacKenzie EJ and Burgess AR.			11475475	KQ 7: N<100
Diogo MJ	[Functional evaluation of elderly patients with lower limb amputation followed at a university hospital].	Revista latino-americana de enfermagem	12733244	Low resource country
Dite W and Temple VA		A clinical test of stepping and change of direction to identify multiple falling older adults.	12422327	Not amputees
Dolezal Jeanette M and Vernick Sanford H and Khan Nusrat and Lutz David and	Factors associated with use and nonuse of an AK prosthesis in a rural, southern,	International Journal of Rehabilitation & Health	2001-06721-005	KQ 7: Unclear followup time

Tyndall Carl	geriatric population			
Duff L and Jarvis H.	Walking speed and oxygen consumption of a unilateral hip disarticulation amputee during level walking using a C-leg vs a Genium	Prosthetics and Orthotics International		Case report/series
Ehrler S and Blum- Demans C and Coulon S and Isner- Horobeti ME.	Assessment of therapeutic education in lower-limb amputees	Prosthetics and Orthotics International		Not peer reviewed publication
Ehrler S and Coulon S.	Under limb amputation for people with mobility 1 or 2; choice of fitting with prosthetic	Annals of Physical and Rehabilitation Medicine		Not peer reviewed publication
Eshraghi A and Abu Osman NA and Karimi MT and Gholizadeh H and Ali S and Wan Abas WA	American journal of physical medicine & rehabilitation / Association of Academic Physiatrists	Quantitative and qualitative comparison of a new prosthetic suspension system with two existing suspension systems for lower limb amputees.	23168378	Low resource country
Fernandez A and Formigo J.			16281726	KQ 7: N<100
Fisher K and Hanspal R.		Body image and patients with amputations: does the prosthesis maintain the balance?	9926350	KQ 7: No outcome of interest
Fisher K and Hanspal RS and Marks L		Return to work after lower limb amputation.	12601268	KQ 7: No outcome of interest
Frlan-Vrgoc L and Vrbanic TS and Kraguljac D and Kovacevic M.	Functional outcome assessment of lower limb amputees and prosthetic users with a 2-minute walk test	Coll Antropol	22397262	Low resource country
Fusetti C and Senechaud C and Merlini M	[Quality of life of vascular disease patients following amputation].	Annales de chirurgie	11447794	KQ 7: Unclear followup time
Gardiner MD and Faux S and Jones LE		Inter-observer reliability of clinical outcome measures in a lower limb amputee population.	11926262	KQ 1-3: N<20
Gatt A and Chockalingam N.	Validity and reliability of a new ankle dorsiflexion measurement device	Prosthetics and Orthotics International	23211471	Not amputees
Gaunaurd I and Gailey R and Salem R and Hafner B.	Construct validity of the Prosthetic Limb Users Survey of Mobility (PLUS-M)	Prosthetics and Orthotics International		Duplicate publication
Gaunaurd I, Spaulding S, Amtmann D, Salem R, Gailey R, Morgan S, Hafner B		Use of and Confidence Administering Outcome Measures among Clinical Prosthetists: Results from a National Survey and Mixed- Methods Training Program	24827935	Not amputees
Gholizadeh H and Abu Osman NA and	PLoS One	The effects of suction and pin/lock suspension	24827560	Low resource country

Eshraghi A and Ali S.		systems on transtibial		
Gong SY and Yang P	Application of	Journal of Clinical		Low resource
and Liu QD and Song	intelligent lower limb	Rehabilitative Tissue		country
L.	prostheses sensor	Engineering Research		
Guarita ML and	Long-term prosthetic	PM and R		Not peer
Gaspar AP and	outcome of bilateral			reviewed
Inghan S.	lower limb amputees:			publication
	A case series			
Hafner B and Morgan	Reliability of self-	Prosthetics and Orthotics		Not peer
S and Askew R.	reported outcome	International		reviewed
	measures in people			publication
	with lower limb loss:			
	Implications to clinical			
	care and research	-		
Hafner BJ and	Characterizing	Prosthetics and orthotics	25944625	KQ 1-3: Not
Morgan SJ and	mobility from the	international		validation
Abrahamson DC and	prosthetic limb user's			
Amtmann D	perspective: Use of			
	development of the			
	Prosthetic Limb Llears			
	Survey of Mobility			
Hafner BJ, Spaulding	Carvey of Wobility.	Prosthetists' perceptions	27638012	Not amputees
SE. Salem R. Morgan		and use of outcome		patooo
SJ. Gaunaurd IA.		measures in clinical		
Gailey RS		practice: long-term effects		
2		of focused continuing		
		education		
Hagberg K and			11860092	KQ 7: N<100
Branemark R.				**INCLUDED
				FOR KQ 3**
Hahn Andreas and	Effects of Mobility	Journal of Prosthetics &	103452300.	KQ 4:
Lang Michael	Grade, Age, and	Orthotics (JPO)	Language:	Noncomparative
	Etiology on			
	Functional Benefit			
	and Safety of			
	Subjects Evaluated III			
	Leg Trial Fittings in			
	Germany			
Ham R and de	Patterns of recovery	Clinical Rehabilitation	107397632	KO 7 [.] <6 mo f/up
Trafford J and Van de	for lower limb		Language:	post-prescription
Ven C.	amputation		Language.	poor procemption
Hansen SE.	Ugeskrift for Laeger	A follow-up examination of	695031	Unclear
	- 3	elderly amputees fitted with		technology
		prostheses		0,
Harness N and			11210955	KQ 7: N<100
Pinzur MS.				
Harris KA and van		Rehabilitation potential of	1864873	KQ 7: N<100
Schie L and Carroll		elderly patients with major		
SE and Deathe A and		amputations		
Maryniak O and				
Meads GE and				
Sweeney JP.		Devend the 10 m time of	11011540	
Hattleid AG.		Beyond the 10-m time: a	11911519	KQ 1-3: N<20
		pilot study of timed walks in		
Hefferman GM and	Integration of ourfood	Prosthet Orthot Int	24460420	Case
Zhang F and Nunnery	electromyographic		24403430	report/series
	sensors with the			reportacilea
MU and HUAND H				

	transfemoral amputee socket: a comparison of four differing configurations			
Hellstrand Tang U and Z�_gner R and Lisovskaja V and Karlsson J and Hagberg K and Tranberg R.	Comparison of plantar pressure in three types of insole given to patients with diabetes at risk of developing foot ulcers - A two-year, randomized trial	Journal of Clinical and Translational Endocrinology		Not LLP
Hermodsson Y and Ekdahl C and Persson BM.	Outcome after trans- tibial amputation for vascular disease. A follow-up after eight years	Scand J Caring Sci	9801627	KQ 7: N<100
Hershkovitz A and Dudkiewicz I and Brill S.		Rehabilitation outcome of post-acute lower limb geriatric amputees	22686166	KQ 7: N<100
Highsmith Michael Jason	Comparative outcomes assessment of the C- Leg and X2 knee prosthesis		2013-99220-100	Not peer reviewed publication
Highsmith Mj and Kahle Jt	Functional effects of the genium knee in transfemoral amputees measured with the continuous scale physical functional performance-10 (CS- PFP10) assessment	Prosthetics and orthotics international	CN-01131588	Not peer reviewed publication
Holden JM and Fernie GR.		Extent of artificial limb use following rehabilitation	3681530	KQ 7: No outcome of interest
Houghton AD and Taylor PR and Thurlow S and Rootes E and McColl I	The British journal of surgery	Success rates for rehabilitation of vascular amputees: implications for preoperative assessment and amputation level.	1393461	KQ 7: Unclear followup time **INCLUDED FOR KQ 3**
Howard C and Wallace C and Stokic D.	Mechanical knee users improve motor function with rheo3 knee: Single-subject design	Prosthetics and Orthotics International		Not peer reviewed publication
Huang GF and Chou YL and Su FC.	Gait analysis and energy consumption of below-knee amputees wearing three different prosthetic feet	Gait Posture	10998614	Retracted publication
Inderbitzi R and Buettiker M and Enzler M.			12819649	KQ 7: N<100
Jarl G and Heinemann AW and Lindner HY and Norling Hermansson LM.		Cross-Cultural Validity and Differential Item Functioning of the Orthotics and Prosthetics Users' Survey With Swedish and	25804528	KQ 1-3: Not validation

		United States Users of		
Jayakaran P and Johnson GM and Sullivan SJ		Concurrent validity of the Sensory Organization Test measures in unilateral	22760518	KQ 1-3: N<20
Jayakaran P and Johnson GM and Sullivan SJ.		transtibial amputees. Reliability and concurrent validity of the step quick turn test in older persons with a unilateral transtibial	21862909	KQ 1-3: N<20
Johannesson A and Larsson GU and Ramstrand N and Lauge-Pedersen H and Wagner P and Atroshi I.		amputation Outcomes of a standardized surgical and rehabilitation program in transtibial amputation for peripheral vascular disease: a prospective cohort study	20134308	KQ 7: No outcome of interest
Johansson JL and Sherrill DM and Riley PO and Bonato P and Herr H.	A clinical comparison of variable-damping and mechanically passive prosthetic knee devices	Am J Phys Med Rehabil	16034225	KQ 4-7: No outcome of interest
Jones L and Hall M and Schuld W			8219247	KQ 7: N<100
Jordan RW and Marks A and Higman D.		The cost of major lower limb amputation: a 12-year experience	22440579	KQ 7: No outcome of interest
Kark L and Vickers D and McIntosh A and Simmons A.		Use of gait summary measures with lower limb amputees	22000790	KQ 1-3: N<20
Kent JA and Stergiou N and Wurdeman SR		Step activity and stride-to- stride fluctuations are negatively correlated in individuals with transtibial amputation.	26319219	KQ 1-3: Not validation
Kuntze Ferreira AE and Neves EB.	Gait Posture	A comparison of vacuum and KBM prosthetic fitting for unilateral transtibial amputees using the Gait Profile Score	25684145	Low resource country
Kurichi JE and Kwong P and Vogel WB and Xie D and Cowper Ripley D and Bates BE	Effects of prosthetic limb prescription on 3-year mortality among Veterans with lower-limb amputation.	Journal of Rehabilitation Research & Development. 52(4):385-96, 2015.	26348602	KQ 4-7: No outcome of interest
Lacraz A and Turcot K and Sagawa Y and Lenoir J and Carmona G and Armand S and Assal M.	Swiss Medical Weekly	CR- EQUIPEMENTS�� SACH foot versus otto BOCK�� SACH foot		Duplicate publication
Larsson J and Agardh CD and Apelqvist J and Stenstrl¦m A.		Long term prognosis after healed amputation in patients with diabetes	9602814	KQ 7: N<100
Lee WC and Zhang M and Chan PP and Boone DA	Gait analysis of low- cost flexible-shank transtibial prostheses.	IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE	17009497	KQ 4-7: No outcome of interest

		Engineering in Medicine		
Leung HB and Wong WC and Wu FC and Guerin JS.	J Orthop Surg (Hong Kong)	Perioperative and rehabilitation outcome after lower-limb amputation in elderly Chinese patients in Hong Kong	15237131	KQ 7: Unclear followup time
Lim TS and Finlayson A and Thorpe JM and Sieunarine K and Mwipatayi BP and Brady A and Abbas M and Angel D			16768686	KQ 7: N<100
Lindberg K and Kristensen MT.	Construct validity and responsiveness of functional measures used in lower limb amputees following an outpatient prosthetic rehabilitation program	Prosthetics and Orthotics International		Not peer reviewed publication
Major MJ and Johnson WB and Gard SA		Interrater reliability of mechanical tests for functional classification of transtibial prosthesis components distal to the socket.	26360815	KQ 1-3: Not validation
Mateos Torres E and Clar�� A and Muniesa-Portol̩s JM and Vidal- Barraquer F.	The natural history of ischaemic patients who undergo below- knee amputation: A long way to autonomous walking	Angiologia		KQ 4-7: No outcome of interest
McWhinnie DL and Gordon AC and Collin J and Gray DW and Morrison JD.			7827880	KQ 7: N<100
Met R and Janssen LI and Wille J and Langezaal AE and van de Mortel RW and van de Pavoordt ED and de Vries JP.			18458050	KQ 7: N<100
Meulenbelt HE and Geertzen JH and Jonkman MF and Dijkstra PU.	Arch Phys Med Rehabil	Determinants of skin problems of the stump in lower-limb amputees	19154832	No analyses of interest
Miller WC and Deathe AB and Speechley M and Koval J.	The influence of falling, fear of falling, and balance confidence on prosthetic mobility and social activity among individuals with a lower extremity amputation	Arch Phys Med Rehabil	11552197	KQ 7: Excluded some LLP recipients **INCLUDED FOR KQ 3**
Miyazaki S.		Long-term unrestrained measurement of stride length and walking velocity utilizing a piezoelectric gyroscope	9254988	Unclear technology

Mizuno N and Aoyama T and Nakajima A and Kasahara T and Takami K.		Functional evaluation by gait analysis of various ankle-foot assemblies used by below-knee amputees	1491951	No analyses of interest
Monteiro RP and Pfeifer LI and Soares I and Dos Santos Ade A and Sousa N.	Validation of the functional and social performance - DSF- 84 checklist: preliminary study	Disabil Rehabil	23323959	Low resource country
Moore TJ and Barron J and Hutchinson F3rd and Golden C and Ellis C and Humphries D.	Prosthetic usage following major lower extremity amputation	Clin Orthop Relat Res	2910604	KQ 7: Excluded some LLP recipients
Morgan S and Askew R and Hafner B.	Equivalence of electronic and paper administration for four self-report instruments used in prosthetic clinical care	Prosthetics and Orthotics International		Not peer reviewed publication
Morgan SJ, Amtmann D, Abrahamson DC, Kajlich AJ, Hafner BJ		Use of cognitive interviews in the development of the PLUS-M item bank	24442531	KQ 1-3: Not validation
Morgan SJ, Friedly JL, Amtmann D, Salem R, Hafner BJ		A cross-sectional assessment of factors related to pain intensity and pain interference in lower limb prosthesis users	27742450	KQ 1-3: Not validation
Moustapha A and Sagawa Junior Y and Watelain E and Thevenon A.	Epidemiological cross-sectional survey of outcome in lower-limb amputees in the Nord-Pas de Calais region	Annals of Physical and Rehabilitation Medicine		Not peer reviewed publication
Muniesa JM and Pou M and Marco E and Boza R and Guill̩nn A and Duarte E and Escalada F and Belmontey R and Tejero M.	Health-related quality of life in patients with lower limb amputations	Rehabilitacion	105502435. Language:	KQ 4-7: No outcome of interest
Naylor H and Russell P.	A scoring tool to predict functional outcome in lower limb amputees (BLARt)-a pilot study	Prosthetics and Orthotics International		Not peer reviewed publication
Nehler MR and Coll JR and Hiatt WR and Regensteiner JG and Schnickel GT and Klenke WA and Strecker PK and Anderson MW and Jones DN and Whitehill TA and Moskowitz S and Krupski WC.		Functional outcome in a contemporary series of major lower extremity amputations	12844082	KQ 7: N<100
O'Neill BF and Evans JJ.			19280435	KQ 7: N<100
OConnell PG and Gnatz S	Hemiplegia and amputation: rehabilitation in the dual disability.	Archives of physical medicine and rehabilitation	2730308	KQ 7: Excluded some LLP recipients
--	---	---	----------	--
Pernot HF and Winnubst GM and Cluitmans JJ and De Witte LP.			11061195	KQ 7: N<100
Pinzur MS and Littooy F and Daniels J and Arney C and Reddy NK and Graham G and Osterman H.			1499219	KQ 7: N<100
Pohjolainen T and Alaranta H.		Predictive factors of functional ability after lower-limb amputation	1888111	KQ 4-7: No outcome of interest
Popielarz S and Lacroix J and Munoz M and Fargeas-Gluck MA and Salle JY and Mandigout S.	Science and Sports	Shock absorbers for vascular trans-tibial amputees in environmental situations seem more efficient on comfort than on oxygen consumption		KQ 4: Noncomparative
Powell LE, Myers AM	The Activities-specific Balance Confidence (ABC) Scale	J Gerontol		Not amputees
Raya MA and Gailey RS and Gaunaurd IA and Ganyard H and Knapp-Wood J and McDonough K and Palmisano T.		Amputee mobility predictor- bilateral: a performance- based measure of mobility for people with bilateral lower-limb loss	24301433	Battle injury
Redfield MT and Cagle JC and Hafner BJ and Sanders JE.		Classifying prosthetic use via accelerometry in persons with transtibial amputations	24458961	KQ 1-3: N<20
Remes L and Isoaho R and Vahlberg T and Viitanen M and Rautava P.		Predictors for institutionalization and prosthetic ambulation after major lower extremity amputation during an eight- year follow-up	19448384	KQ 7: N<100
Rispin K and Wright V and Andrysek J.	Assessing the test- retest reliability of the lower limb function questionnaire (LLFQ)	Prosthetics and Orthotics International		Pediatric
Roffman CE and Buchanan J and Allison GT.	Long term locomotor function in individuals with lower limb amputation following discharge from rehabilitation	Prosthetics and Orthotics International		Not peer reviewed publication
Rosenberg DE and Turner AP and Littman AJ and Williams RM and Norvell DC and Hakimi KM and Czerniecki JM			23094934	KQ 7: N<100
Rushton PW and Miller WC.		Goal attainment scaling in the rehabilitation of patients	12048654	KQ 1-3: N<20

		with lower-extremity		
Saraf A.	Mobilization status of diabetics versus non- diabetics after below knee amputation: A comparison	Prosthetics and Orthotics International		Not peer reviewed publication
Schaffalitzky E and Gallagher P and Maclachlan M and Ryall N.	Understanding the benefits of prosthetic prescription: exploring the experiences of practitioners and lower limb prosthetic users	Disabil Rehabil	21050130	KQ 1-3: Not validation
Schoppen T and Boonstra A and Groothoff JW and van Sonderen E and Goeken LN and Eisma WH.		Factors related to successful job reintegration of people with a lower limb amputation	11588749	KQ 7: No outcome of interest
Schoppen T, Boonstra A, Groothoff JW, de Vries J, Göeken LN, Eisma WH		Physical, mental, and social predictors of functional outcome in unilateral lower- limb amputees	12808530	KQ 7: N<100
Scopes J and Van Der Linden M and Gleeson N.	Minimal detectable change values of common outcome measures used in lower limb prosthetic rehabilitation in the UK	Physiotherapy (United Kingdom)		Not peer reviewed publication
Seker A and Kara A and Camur S and Malkoc M and Sonmez MM and Mahirogullari M.	Int J Surg	Comparison of mortality rates and functional results after transtibial and transfemoral amputations due to diabetes in elderly patients-a retrospective study	27475745	Low resource country
Singh R and Venkateshwara G.		Effect of fluid collections on long-term outcome after lower limb amputation	22244246	KQ 7: N<100
Sinha R and van den Heuvel WJ and Arokiasamy P	Adjustments to amputation and an artificial limb in lower limb amputees.	Prosthetics and orthotics international	23722600	Low resource country
Sinha R and van den Heuvel WJ and Arokiasamy P and van Dijk JP.	Influence of adjustments to amputation and artificial limb on quality of life in patients following lower limb amputation	Int J Rehabil Res	24157864	Duplicate publication
Siriwardena GJ and Bertrand PV.	Factors influencing rehabilitation of arteriosclerotic lower limb amputees	J Rehabil Res Dev	1880748	KQ 4-7: No outcome of interest
Steinberg FU and Garcia WJ and Roettger RF and Shelton DJ.			0 (PMID:4810416)	KQ 7: N<100

Steinberg FU and		Prosthetic rehabilitation of	4062526	KQ 7: N<100
Roettger RF.		a follow-up study		
Tang KT, Spence		Validity of method to	22773201	KQ 1-3: N<20
WD, Maxwell D,		quantify transtibial		
Stansfield BVV.		amputees' free-living		
		and physical activity levels		
		when using suction		
		suspension sockets		
Taylor SM and		Preoperative clinical factors	16102618	KQ 7: Included
Kalbaugh CA and		predict postoperative		amputees
Hamontree SE and		major lower limb		
Cull DL and Messich		amputation: an analysis of		
HS and Robertson		553 consecutive patients		
RT and Langan				
EM3rd and York JW				
and Snyder BA and				
Jackson MR and				
Youkey JR.				
Taylor SM and		'Successful outcome' after	18646478	KQ 7: Included
Kalbaugh CA and		below-knee amputation: an		amputees
NM and Daly CA and		influence of clinical		
Cull DL and Youkey		variables.		
JR				
Tezuka Y and Chin T				KQ 7: N<100
and Takase Land				
Nakatsuka A and				
Fujie H and				
Kurokawa M and				
Fujiwara Y and Ochi				
T and Oyabu H and				
Hand Miura Y.				
Topuz Semra and	Effects of different	Turkish Journal of	104947410.	Low resource
Ulcer Ozlem and	prosthetic feet on the	Physiotherapy	Language:	country
Sener Gul	ambulation activities	Rehabilitation		
	and gait in transtibial			
Ulger O and Topuz S	Turkish Journal of	Effects of a hydraulic knee	105160169.	Low resource
and Bayramlar K.	Physiotherapy	joint on energy	Language:	country
	Rehabilitation	consumption, gait and		
		patient satisfaction in trans-		
van der Water G.I	Comparison of the	Prosthet Orthot Int	9747994	Case
and De Vries J and	lightweight Camp		0141004	report/series
Mulder MA.	Normal Activity Foot			
	with other prosthetic			
	feet in trans-tibial			
	study			
van Eiik MS and van	Predicting prosthetic	Prosthet Orthot Int	22252778	KQ 7: <6 mo f/up
der Linde H and	use in elderly patients		-	post-prescription
Buijck B and Geurts	after major lower limb			
A and Zuidema S and	amputation			
Wan Hazmy CH and		Functional outcome after	17042220	
Chia WYE and Fong		major lower extremity		country

TS and Ganendra P.		amputation: A survey on lower extremity amputees		
Webster JB and Hakimi KN and Williams RM and Turner AP and Norvell DC and Czerniecki JM.			23516053	KQ 7: N<100
Williams RM and Turner AP and Green M and Norvell DC and Henderson AW and Hakimi KN and Blake DJ and Czerniecki JM.			25357146	KQ 7: N<100
Wong A and Heinemann A and Ehrlich-Jones L and Connelly L and Semik P and Fatone S.	Comparison of the opus and FOTO's functional status measures for persons with lower limb amputation	Archives of Physical Medicine and Rehabilitation		Not peer reviewed publication
Wong CK and Chen CC and Blackwell WM and Rahal RT and Benoy SA.		Balance ability measured with the Berg balance scale: a determinant of fall history in community- dwelling adults with leg amputation	25223891	KQ 1-3: Not validation
Wong CK and Chen CC.		A prognostic clinical prediction rule to identify adults with lower limb loss not likely to achieve successful prosthetic function within one year		Duplicate publication
Yigiter K and Bayar K and Ulger OG and Akdogan S and Erbahceci F and Yakut Y and Sener G.	The effect of flexible and hard sockets on the ambulation of above knee amputees	Fizyoterapi Rehabilitasyon		Low resource country
Yiğiter K, Sener G, Bayar K.	Comparison of the effects of patellar tendon bearing and total surface bearing sockets on prosthetic fitting and rehabilitation	Prosthetics and Orthotics International	12562067	Low resource country
Zidarov D and Swaine B and Gauthier-Gagnon C.	Arch Phys Med Rehabil	Life habits and prosthetic profile of persons with lower-limb amputation during rehabilitation and at 3-month follow-up	19887223	KQ 7: <6 mo f/up post-prescription

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
			Transfemoral (n=79)	peripheral vascular diseases (52.9%), trauma (32.1%), tumour (12.1%) infective diseases					Total Overall			
Franchignoni,	2003		Transtibial (n=61)	(2.9%)	57	nd	140	10 Meter Walk Test	Score		Validity	Convergent
Mazari	2010							10 Meter Walk Test	Score		Validity Ability to	Known group/Discriminant
Mazari	2010							10 Meter Walk Test	Total Overall Score Total Overall		measure change	Responsiveness Concurrent/convergent/criteri
Ryall et al,	2002							10 Meter Walk Test	Score		Validity	a Validity criterion
Ryall et al,	2003			norisheral artes				10 Meter Walk Test	Total Overall Score		Validity	a Validity criterion
Remes et al,	2010		nd	disease	75.17	nd	59	15D HRQoL	nd		Validity	Known group/Discriminant
Damaa	2010		nd	peripheral artery	75 47		50				Volidity	Known are un/Discriminant
Remes	2010		na	uisease	/ 5. 1/		28	15D HRQOL			validity	Known group/Dischminant
Dite	2007		Transtibial	nd	61.6	Unilateral	40	180 degree turn test			Validity	Known group/Discriminant
			Transtibiai (n=179), Transfermoral (n=60).	Vascular (n=194.		Able to walk, had been fit with						
Brooks	2001		Bilateral (n=51)	n=165 DM)	66.3	prosthesis	290	2 min walk test			Validity	Concurrent/convergent
			Transtibial (n=179),	Manager (* 101		Able to could be diverged for the						
Brooks	2001		Bilateral (n=51)	n=165 DM)	66.3	Able to walk, had been fit with prosthesis	290	2 min walk test			Validity	Concurrent/convergent
Brooke	2001		Transtibial (n=179),		00.0	production	200				validity	Concentration
Brooks	2001		Transfermoral (n=60), Bilateral (n=51)	Vascular (n=194, n=165 DM)	66.3	Able to walk, had been fit with prosthesis	290	2 min walk test			Validity	Concurrent/convergent
Brooks	2001		Transfermoral (n=179), Transfermoral (n=60), Bilateral (n=51)	Vascular (n=194, n=165 DM)	66.3	Able to walk, had been fit with prosthesis	290	2 min walk test			Validity	Predictive
Brooks	2001		Transtibial (n=179), Transfermoral (n=60), Bilateral (n=51)	Vascular (n=194,	66.3	Able to walk, had been fit with	200	2 min walk test			Validity	Predictive
DIOOKS	2001		Transtibial (n=179), Transfermoral (n=60),	Vascular (n=194,	00.0	Able to walk, had been fit with	230				Validity	
Brooks	2001		Bilateral (n=51)	n=165 DM)	66.3	prosthesis	290	2 min walk test			Validity	Concurrent/convergent
Brooks	2001		Transtibial (n=179), Transfermoral (n=60), Bilateral (n=51)	Vascular (n=194,	66.3	Able to walk, had been fit with	200	2 min walk test			Validity	
DIOOKS	2001		Transtibial (n=179).	II=105 DW)	00.5	prostriesis	230	2 min waik test			validity	
			Transfermoral (n=60),	Vascular (n=194,		Able to walk, had been fit with						
Brooks	2001		Bilateral (n=51)	n=165 DM)	66.3	prosthesis	290	2 min walk test			Validity	Predictive
			Transfermoral (n=60),	Vascular (n=194,		Able to walk, had been fit with						
Brooks	2001		Bilateral (n=51)	n=165 DM)	66.3	prosthesis	290	2 min walk test			Validity	Construct
			Transtibial (n=179),	Veccular (n=104		Able to walk had been fit with						
Brooks	2001		Bilateral (n=51)	n=165 DM)	66.3	prosthesis	290	2 min walk test			Validity	Construct
											Ability to	
Dev. et al.	0007							O Minute Minille Tarat	Total Overall		measure	Deserve
Rau et al,	2007							2 Minute Walk Test	Scale		change	Responsiveness
									Total Overall			
Frlan-Vrgoc	2011							2 Minute Walk Test	Score		Validity	Known group/Discriminant
Gremeaux	2012							2 Minute Walk Test	Score		Validity	a Validity criterion
Resnik and Borgia	2011							2 Minute Walk Test	Total Overall Score		Reliability	Test-retest
Salavati et al	2011							2 Minute Walk Test	Total Overall Score		Validity	Construct
e ruu or ui,									2.50.0		. Shory	
			Transtibial (n=179),									
Brooks	2001	11588757	Transfermoral (n=60), Bilateral (n=51)	Vascular (n=194, n=165 DM)	66 3	Able to walk, had been fit with	290	2MWT			Validity	Concurrent/convergent
DIJUKS	2001	11300/37	Transtibial (n=179)		50.5	producedo	200	2.1VIV I	1		valiuity	oonourrenvoorivergent
			Transfermoral (n=60),	Vascular (n=194,		Able to walk, had been fit with						
Brooks	2001	11588757	Bilateral (n=51)	n=165 DM)	66.3	prosthesis	290	2MWT			Validity	Convergent

			Comparator/Criterion/Outc	I imepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Franchignoni	2003		Rivermead Mobility Index (RIM)		Spearman r	0.69				Spearmans: RIM=0.69
i farlenigrioni,	2000		(rum)		opeannann	0.00				significant differences between articulated
Mozori	2010									and non articulated walking aid users at
Widzdii	2010									VISIT
M	0040									significant improvements over time with
Mazari	2010									grades of SIGAM were significantly
Ryall et al,	2002									different
Ryall et al,	2003									Spearman: RMI=-0.58
Demonstrat	0040				Bushus	-0.004				
Remes et al,	2010		amputees vs control group		P value	<0.001				
Remes	2010		amputees vs control group		P value	<0.001				
					Vs nonmultiple					differentiated between multiple and
Dite	2007				Fallers	P Value	<0.001			nonmultiple fallers
			PF of SE-36 at rehab							
Brooks	2001		discharge		Pearson r	0.22	Small	Yes		Hypothesis: moderate correlation; p=0.008
			PE of SE-36 at 3 month							
Brooks	2001		follow-up		Pearson r	0.479	Moderate	Yes		Hypothesis: moderate correlation; p<0.001
										Hypothesis of moderate correlation;
Brooks	2001		Houghton		Pearson r	0.493	Moderate	Yes		p<0.001; n=56
			distance walked at							
Brooks	2001		discharge		Pearson r	0.72	Large	Yes		n=197
Brooks	2001		distance walked at follow up		Pearson r	0.568	Large	Yes		n=69
Brooks	2001									
Brooks	2001									
Brooks	2001		distance walked at follow up		Pearson r	0.568	Large	Yes		
Brooks	2001		Transtibial vs total group							
Brooks	2001									
Rau et al,	2007									significant improvement after intervention
										significant differences between age groups,
Frlan-Vrgoc	2011									prosthetic experience
Grammanius	2012									All scores were highly correlated with
Gremeaux	2012									eachother. Pearsons 0.35-0.60
Resnik and Borgia	2011									ICC=0.83
Salavati et al,	2011									Spearman: LCI-5=0.71
										Hypothesis: moderate correlation;
										Provide the provided at discharge only; p<0.001; n=56. For subgroup of unilateral
Brooks	2001	11588757	Houghton		Pearson r	0.493	Moderate	Yes		transtibial: r = .53, p=0.02
										Change in distance walked baseline to discharge, p<0.001. For transtibial group, r
Brooks	2001	11588757	Age		Pearson r	-0.289	Small	Yes		=358, p<0.001

											1	
				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
			Transtibial (n=179),									
			Transfermoral (n=60),	Vascular (n=194,		Able to walk, had been fit with	1					
Brooks	2001	11588757	Bilateral (n=51)	n=165 DM)	66.3	prosthesis	290	2MWT			Validity	Convergent
			Transfermoral (n=60)	Vascular (n=194		Able to walk had been fit with						
Brooks	2001	11588757	Bilateral (n=51)	n=165 DM)	66.3	prosthesis	290	2MWT			Validity	Convergent
			Transtibial (n=179),									g
			Transfermoral (n=60),	Vascular (n=194,		Able to walk, had been fit with	ı					
Brooks	2001	11588757	Bilateral (n=51)	n=165 DM)	66.3	prosthesis	290	2MWT			Validity	Known group
			Transtibial (n=179),									
Desister	0004	44500757	Transfermoral (n=60),	Vascular (n=194,	00.0	Able to walk, had been fit with	1	OL BACT			A contraction of	Des distinct
Brooks	2001	11588757	Bilateral (n=51)	n=165 DM)	66.3	prostnesis	290	ZIVIVV I			validity	Predictive
						A MINIMUM OF 2 WEEKS OF						
				Peripheral vascular		minutes of walking: no						
				disease (n=20).		prosthetic modifications						
				diabetes (n=11),		planned; no other medical						
				osteomyelitis (n=1),		restrictions preventing them						
Brooks	2002	12422326	Transtibial	sarcoma (n=1)	63.6	from participating in the test	33	2MWT			Reliability	Interrater
						A minimum of 2 weeks of						
				Desinherel vessuler		rehabilitation; tolerate 2						
				Peripheral Vascular		minutes of waiking; no						
				disease (n=20),		planned: no other medical						
				osteomvelitis (n=1),		restrictions preventing them						
Brooks	2002	12422326	Transtibial	sarcoma (n=1)	63.6	from participating in the test	33	2MWT			Reliability	Intrarater
				Vascular (n=42),								
				trauma (n=16),								
			Transfemoral (n=17,	cancer (n=2), other								
Gremeaux	2012	22389424	transtibal (n=47)	(n=1)	58 (22-87)	unilateral	64	2MWT			Validity	Convergent
				Vascular (n=42),								
			Transformeral (n=17	trauma (n=16),								
Gremeaux	2012	22380424	transiemoral (n=17,	(n=1)	58	unilatoral	64	2M/M/T			Validity	Convergent
Greinieaux	2012	22303424	Transtibial (n=28)	(1-1)	50	comfortable and well fitted	04	2101001			validity	Convergent
Newton	2016		Transfemoral (n=9)	nd	40-69	prostheis for at least 12 mo	37	2MWT			Validity	Construct
			Transfemoral (n=16),				-					
			Transtibial (n=30),	Vascular (n=20),								
			Bilateral transtibial	Trauma (n=26),								
Parker	2010	2010632385	(n=6)	Other (n=6)	55.2		52	2MWT			Validity	Convergent
			Transfemoral (n=13),									
			Franstibial (n=63),							Lice the 6MM/t in LEAs to access longer		
			disarticulation (n=3)							use the owiwit in LEAS to assess longer		
Reid	2015	25588644	Bilateral (n=3)	Multiple	60		86	2MWT		LEAs to achieve distances greater than 300 m	Validity	Convergent
i tolu	2010	20000011	Transfemoral (n=13).	manipio							Valially	Sonroigent
			Transtibial (n=63),									
			Syme (n=4), Knee							Use the 6MWt in LEAs to assess longer		
			disarticulation (n=3),							walking distance ability, since 6 min allow		
Reid	2015	25588644	Bilateral (n=3)	Multiple	60		86	2MWT		LEAs to achieve distances greater than 300 m	Validity	Convergent
			Transfemoral (n=13),									
			Transtibial (n=63),									
			Syme (n=4), Knee							Use the 600000 in LEAS to assess longer		
Reid	2015	25588644	Bilateral (n=3)	Multiple	60		86	2MWT		LEAs to achieve distances greater than 300 m	Validity	Convergent
i tolu	2010	20000011	Transfemoral (n=13)	manipio				2			Validity	Controlgent
			Transtibial (n=63),									
			Syme (n=4), Knee		1		1			Use the 6MWt in LEAs to assess longer		
			disarticulation (n=3),		1		1			walking distance ability, since 6 min allow		
Reid	2015	25588644	Bilateral (n=3)	Multiple	60		86	2MWT		LEAs to achieve distances greater than 300 m	Validity	Convergent
			Transfemoral (n=13),		1		1					
			Transtibial (n=63),		1		1					
			Syme (n=4), Knee		1		1			Use the 6MWt in LEAs to assess longer		
Reid	2015	25588644	Bilateral (n=3)	Multiple	60		86	2MWT		I EAs to achieve distances greater than 300 m	Validity	Convergent
	2010	20000044	Transfemoral (52%)	manupio			30		1	Les la to dome ve distances greater than 500 m	Minimal	Controlyon
			through knee (5%)		1		1				Detectible	
Resnik	2011		transtibial (43%)		66	unilateral	44	2MWT			Change	MDC90
	1		Transfemoral (52%);								Ť	
		1	through knee (5%);				1					
Resnik	2011		transtibial (43%)		66	unilateral	44	2MWT			Reliability	Test-retest
Calley Decition At	2002	1					1	C Minute Mall: To at	Total Overall			Known grown/Directoria
Galley, Roach et. Al.	2002		1	1	1	1	1	b Minute Walk Test	Score		validity	Known group/Discriminant

			Comporator/Critorion/Outo	Timepoint			Strongth of			
Author	Year	PMID	ome	(predictive	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Aution	rear	1 1112	onic	valia)	Metric Oscu	Value	rioperty	oupporteu :	Conclusion	Hypothesis: moderate correlation: p<0.001.
										For subgroup of unilateral transtibial: r =
Brooks	2001	11588757	PF of SF-36		Pearson r	0.479	Moderate	Yes		.29, p=0.005
Deviation	0004	44500757	Age, Gender (using		D	0.000				0 001
BIOOKS	2001	11000/07	stepwise regression)		Pearson	0.369	woderate	res		p<0.001
			transtibial men vs transtibial							change in distance walked also significantly
Brooks	2001	11588757	women		р	<0.001		Yes		greater in men p=0.001
Dreeke	2001	11500757	2 min wells test	2 months	Deersen r	0.500	Lorno	Vee		
Brooks	2001	11588757	2 min waik test	3 months	Pearson r	0.568	Large	res		n=69
									The 2MWT exhibits good within-	-
									and between-rater reliability in	
Brooks	2002	12/22326	nd		ICC	0.08 to 0.00	Excellent	Vec	individuals with transtibial	
DIOOKS	2002	12422320	nu		100	0.30 10 0.33	LYCellellt	163	amputation	
									The 2MWT exhibits good within-	
									and between-rater reliability in	
Brooks	2002	12/22326	nd		ICC	0 0 to 0 06	Excellent	Vec	amputation	
Brooks	2002	12422020	10		100	0.0 10 0.00	Execution	103	ampatation	
Gremeaux	2012	22389424	nd			AUC	0.93			
			TUG, BBS, Modified							All scores were highly correlated with
Gremeaux	2012	22389424	Houghton		Pearson r	0.35-0.8				eachother: Pearsons 0.35-0.80
Newton	2016		Transfemoral vs. Transtibial		P, univariate	0.11		No		known group
Parker	2010	2010632385	LCI-5		Spearman's r	0.819	Large			
									The 2MWt was strongly	
Reid	2015	25588644	6-minute walk test		Pearson r	0.95	Large	Yes	predictive of the 6MWt	
							Ŭ			
					correlation					
Reid	2015	25588644	6-minute walk test		strength (R	0.79	Large	Yes	nedictive of the 6MWt	K1 and K2 amoutee level (n=30)
ricid	2010	20000044	o minute wait test		Squareu)	0.75	Large	103	predicate of the owner	
					correlation					
Daid	2015	25500644	C minute wells test		strength (R	0.07	Lorgo	Vee	The 2MWt was strongly	K2 and K4 amputes layer (n=50)
Reid	2015	25588644	6-minute waik test		squared)	0.87	Large	res	predictive of the bivivit	K3 and K4 amputee level (n=56)
					correlation					
					strength (R				The 2MWt was strongly	
Reid	2015	25588644	6-minute walk test		squared)	0.82	Large	Yes	predictive of the 6MWt	Amputation aetiology: Vascular (n=21)
					correlation					
					strength (R				The 2MWt was strongly	
Reid	2015	25588644	6-minute walk test		squared)	0.89	Large	Yes	predictive of the 6MWt	Amputation aetiology: Trauma (n=41)
								1		
Pesnik	2011		NA			112.5		1		
I VESHIN	2011	+		1	NDC90	112.0	+	-		
					1	0.83 (0.71,				
Resnik	2011		NA		ICC (95% CI)	0.90)				
	000-									differentiated between MFCL Medicare
Gailey, Roach et. Al.	2002				1			1		comon procedure coding system groups

				Amputation		Other Population					
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale Description	Property	Aspect
Calley Deach at Al	2002							6 Minute Wells Test	Total Overall	Validity	Concurrent/convergent/criteri
Galley, Roach et. Al.	2002							o minute waik rest	Total Overall	validity	Concurrent/convergent/criteri
Kark and Simmons	2011							6 Minute Walk Test	Score	Validity	a Validity criterion
									Total Overall		
Raya et al	2010							6 Minute Walk Test	Score	Validity	Construct
Resnik and Borgia	2011							6 Minute Walk Test	Total Overall Score	Reliability	Test-retest
								6-item Brief Social Support	t		
				peripheral artery				Questionnaire, and Self- reported Life Satisfaction			
Remes et al,	2010		nd	disease	75.17	nd	59	score (SSQN6)	nd	Validity	Known group/Discriminant
								6-item Brief Social Support	rt		
				peripheral artery				reported Life Satisfaction			Concurrent/convergent
Remes et al,	2010		nd	disease	75.17	nd	59	score (SSQN6)	nd	Validity	criterion
			Transfemoral (n=13), Transfibial (n=63).								
			Syme (n=4), Knee						Use the 6MWt in LEAs to assess longer		
Reid	2015	25588644	disarticulation (n=3), Bilateral (n=3)	Multiple	60	nd	86	6-minute walk test	walking distance ability, since 6 min allow ILEAs to achieve distances greater than 300 m	Validity	Convergent
	2010	20000011	Transfemoral (n=13),	manpio		10		o minuto Munt toot		Validity	Controlgont
			Transtibial (n=63),								
			disarticulation (n=3),						walking distance ability, since 6 min allow		
Reid	2015	25588644	Bilateral (n=3)	Multiple	60	nd	86	6-minute walk test	nd LEAs to achieve distances greater than 300 m	Validity	Convergent
			Transfemoral (n=13), Transfibial (n=63).								
			Syme (n=4), Knee						Use the 6MWt in LEAs to assess longer		
Reid	2015	25588644	disarticulation (n=3), Bilateral (n=3)	Multiple	60	nd	86	6-minute walk test	walking distance ability, since 6 min allow ILEAs to achieve distances greater than 300 m	Validity	Convergent
T CIU	2010	20000044	Transfemoral (n=13),	Manapie	00		00	o minute wait test		validity	Convergent
			Transtibial (n=63),								
			disarticulation (n=3),						walking distance ability, since 6 min allow		
Reid	2015	25588644	Bilateral (n=3)	Multiple	60	nd	86	6-minute walk test	nd LEAs to achieve distances greater than 300 m	Validity	Convergent
			Transfemoral (n=13), Transtibial (n=63).								
			Syme (n=4), Knee						Use the 6MWt in LEAs to assess longer		
Reid	2015	25588644	disarticulation (n=3), Bilateral (n=3)	Multiple	60	nd	86	6-minute walk test	walking distance ability, since 6 min allow ILEAs to achieve distances greater than 300 m	Validity	Convergent
			Transfemoral (n=13),								
			Transtibial (n=63), Syme (n=4) Knee						Lise the 6MWt in LEAs to assess longer		
			disarticulation (n=3),						walking distance ability, since 6 min allow		
Reid	2015	25588644	Bilateral (n=3)	Multiple	60	nd	86	6-minute walk test	nd LEAs to achieve distances greater than 300 m	Validity	Construct
			Transtibial (n=63),								
			Syme (n=4), Knee						Use the 6MWt in LEAs to assess longer		
Reid	2015	25588644	Bilateral (n=3)	Multiple	60	nd	86	6-minute walk test	nd LEAs to achieve distances greater than 300 m	Validity	Construct
			Transfemoral (n=13),								
			Transtibial (n=63), Syme (n=4) Knee						Use the 6MWt in LEAs to assess longer		
			disarticulation (n=3),						walking distance ability, since 6 min allow		
Reid	2015	25588644	Bilateral (n=3)	Multiple	60	nd	86	6-minute walk test	nd LEAs to achieve distances greater than 300 m	Validity	Construct
			Transtibial (n=63),								
			Syme (n=4), Knee						Use the 6MWt in LEAs to assess longer		
Reid	2015	25588644	Bilateral (n=3)	Multiple	60	nd	86	6-minute walk test	nd LEAs to achieve distances greater than 300 m	Validity	Construct
			Transfemoral (n=13),								
			Syme (n=4), Knee						Use the 6MWt in LEAs to assess longer		
	aa / -	05500	disarticulation (n=3),			1.			walking distance ability, since 6 min allow		
Reid	2015	25588644	Bilateral (n=3)	Multiple	60	na	86	6-minute walk test	nd LEAs to achieve distances greater than 300 m	Validity	Convergent
			Transtibial (n=63),								
			Syme (n=4), Knee						Use the 6MWt in LEAs to assess longer		
Reid	2015	25588644	Bilateral (n=3)	Multiple	60	nd	86	6-minute walk test	nd LEAs to achieve distances greater than 300 m	Validity	Convergent

				Timepoint						
A	¥		Comparator/Criterion/Outc	(predictive			Strength of	Is Aspect	O	No. 10 - 10 - 10 - 10 - 10 - 10 - 10 - 10
Author	rear	PINID	ome	valid)	wetric Used	value	Property	Supported?	Conclusion	Pearsons: AMPPRO=0.69
Gailey, Roach et. Al.	2002									AMPnoPRO=0.82
Kark and Simmons	2011									no signiificant correlation with PEQ items
										Pearsons: Hip Extension=0.69, Hip
Raya et al	2010									grip=0.54
Resnik and Borgia	2011									ICC=0.97
Remes et al	2010		amputees vs control group		P value	0.071				
Remes et ui,	2010		umpatees vs control gloup		1 Value	0.071				
										All the QoL scores had a significant
Remes et al,	2010									corelation with the SSQ6N score
Poid	2015	25599644	Two minuto wolk toot		Booroop r	0.05	Lorgo	Voo	The 2MWt was strongly	
Reiu	2015	2000044	Two minute walk test		realson	0.95	Laige	165	Adequate to excellent	
									correlation between the 6MWt	
									and previously validated measures of ambulation in	
Reid	2015	25588644	Timed up and go		Pearson r	-0.72	Large	Yes	lower extremity amputees	
									Adequate to excellent	
									correlation between the 6MWt	
			Locomotor Capabilities						measures of ambulation in	
Reid	2015	25588644	Index version 5		Pearson r	0.61	Large	Yes	lower extremity amputees	
									Adequate to excellent	
									and previously validated	
									measures of ambulation in	
Reid	2015	25588644	Houghton		Pearson r	0.57	Large	Yes	lower extremity amputees	
									Adequate to excellent	
									and previously validated	
			Activity-Specifc Balance						measures of ambulation in	
Reid	2015	25588644	Confdence scale		Pearson r	0.6	Large	Yes	lower extremity amputees	
									the results of the study also	
Reid	2015	25588644	Level of Amputation (K1+K2		P	<0.0001		Yes	suggest that the 6MWt has	P-value based on ANOV/A
	2010	20000044	Aetiology of amputation		ľ	-0.0001		103	good discriminative validity.	
			(Diabetes vs Infection not							
			related to diabetes vs						the results of the study also	
Reid	2015	25588644	vs Trauma and congenital)		Р	<0.0001		Yes	good discriminative validity.	P-value based on ANOVA
			<u> </u>							
									the regulte of the study also	
									suggest that the 6MWt has	
Reid	2015	25588644	Age >=50 vs <50		Р	<0.0001		Yes	good discriminative validity.	
									As has been shown in previous	
									walked further than women, this	
									result was not statistically	
Reid	2015	25588644	Male vs female		Р	0.24		No	signifcant in the present study.	
					correlation strength (R				The 2MWt was strongly	
Reid	2015	25588644	Two minute walk test		squared)	0.79	Large	Yes	predictive of the 6MWt	K1 and K2 amputee level (n=30)
					correlation					
					strength (R				The 2MWt was strongly	
Reid	2015	25588644	Two minute walk test		squared)	0.87	Large	Yes	predictive of the 6MWt	K3 and K4 amputee level (n=56)

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Reid	2015	25588644	Transfemoral (n=13), Transtibial (n=63), Syme (n=4), Knee disarticulation (n=3), Bilateral (n=3)	Multiple	60	nd	86	6-minute walk test	nd	Use the 6MWt in LEAs to assess longer walking distance ability, since 6 min allow LEAs to achieve distances greater than 300 m	Validity	Convergent
Reid	2015	25588644	Transfemoral (n=13), Transtibial (n=63), Syme (n=4), Knee disarticulation (n=3), Bilateral (n=3)	Multiple	60	nd	86	6.minute walk test	nd	Use the 6MWt in LEAs to assess longer walking distance ability, since 6 min allow LEAs to achieve distances greater than 300 m	Validity	Convergent
	2010		Ankle disarticulation (n=2) Transtibial (n=82), Knee disarticulation (n=7), Transfemoral (n=67), Hip disarticulation (n=7), Transpelvic	Disease (n=76), Trauma (n=61), Tumor (n=24),		At peak of prosthetic independence, no longer in					, and y	unit of the second s
Gailey	2002	11994800	(n=2)	Congenital (n=6)	54.8	rehab	167	6MWT			Validity	Known group
Gailey	2002	11994800	ankle (2), TT (82), KD (7), TF (67), hip disarticulation (7), transpelvic (2)	disease (76), trauma (61), tumor (24), congenital (6)	54.84 +- 18.6	At peak of prosthetic independence, no longer in rehab	167	6MWT			validity	construct
Reid	2015	25588644	Transtemoral (n=13), Transtibial (n=63), Syme (n=4), Knee disarticulation (n=3), Bilateral (n=3)	Multiple	60		86	6MWT		Use the 6MWt in LEAs to assess longer walking distance ability, since 6 min allow LEAs to achieve distances greater than 300 m	Validitv	Construct
Reid	2015	25588644	Transfemoral (n=13), Transtibial (n=63), Syme (n=4), Knee disarticulation (n=3), Bilateral (n=3)	Multiple	60		86	6MWT		Use the 6MWt in LEAs to assess longer walking distance ability, since 6 min allow LEAs to achieve distances greater than 300 m	Validity	Construct
			Transfemoral (n=13), Transtibial (n=63), Syme (n=4), Knee disarticulation (n=3),							Use the 6MWt in LEAs to assess longer walking distance ability, since 6 min allow		
Reid	2015	25588644	Bilateral (n=3) Transfemoral (n=13), Transtibial (n=63), Syme (n=4), Knee disarticulation (n=3),	Multiple	60		86	6MWT		LEAs to achieve distances greater than 300 m Use the 6MWt in LEAs to assess longer walking distance ability, since 6 min allow	Validity	Construct
Reid	2015	25588644	Bilateral (n=3) Transfemoral (n=13), Transtibial (n=63), Syme (n=4), Knee disarticulation (n=3), Bilateral (a=2)	Multiple	60		86	6MWT		LEAs to achieve distances greater than 300 m Use the 6MWt in LEAs to assess longer walking distance ability, since 6 min allow	Validity	Construct
Reid	2015	25588644	Transfemoral (n=3) Transtibial (n=63), Syme (n=4), Knee disarticulation (n=3), Biloteroi (n=2)	Multiple	60		86	CAMMT		Use the 6MWt in LEAs to assess longer walking distance ability, since 6 min allow	Validity	Convergent
Reiu	2015	25566644	Transfemoral (n=3) Transfemoral (n=13), Transtibial (n=63), Syme (n=4), Knee disarticulation (n=3),	мицре	80		00			Use the 6MWt in LEAs to assess longer walking distance ability, since 6 min allow	validity	Convergent
Reid	2015	25588644	Bilateral (n=3) Transfemoral (n=13), Transtibial (n=63), Syme (n=4), Knee disarticulation (n=3),	Multiple	60		86	6MWT		LEAs to achieve distances greater than 300 m Use the 6MWt in LEAs to assess longer walking distance ability, since 6 min allow	Validity	Convergent
Reid	2015	25588644	Bilateral (n=3)	Multiple	60		86	6MWT		LEAs to achieve distances greater than 300 m	Validity	Convergent
Resnik	2011		Transfemoral (52%); through knee (5%); transtibial (43%)		66	unilateral	44	6MWT			Minimal Detectible Change	MDC90
			through knee (5%);									
Resnik	2011		transtibial (43%)		66	unilateral	44	6MWT			Reliability	Test-retest
Ginsbera.					Adolescents and Young				Total Overall			
Rai,Marchese	2007				Adults			9 minute run walk	Score		Validity	Known group/Discriminant

				Timepoint			Consumable of			
Author	Vear	PMID	comparator/Criterion/Outc	(predictive	Metric Used	Value	Strength of Property	IS Aspect	Conclusion	Notes/Caveats
Aution	rear	r with	ome	validy	wethe osed	value	rioperty	Supported	Conclusion	Notes/Caveats
					correlation					
					strength (R				The 2MWt was strongly	
Reid	2015	25588644	Two minute walk test		squared)	0.82	Large	Yes	predictive of the 6MWt	Amputation aetiology: Vascular (n=21)
					correlation					
					strength (R				The 2MWt was strongly	
Reid	2015	25588644	Two minute walk test		squared)	0.89	Large	Yes	predictive of the 6MWt	Amputation aetiology: Trauma (n=41)
					MFCL levels in					
					ability to					
Gailey	2002	11994800			ambulate	P value	0.001			
Calley	2002	11004000			known groups	p, 1 way	0.0001		Vaa	
Galley	2002	11994600			D/W K level	anova	0.0001		res	
									the results of the study also	
			Level of Amputation (K1+K2						suggest that the 6MWt has	
Reid	2015	25588644	vs K3 vs K4)		Р	<0.0001		Yes	good discriminative validity.	P-value based on ANOVA
			Aetiology of amputation							
			(Diabetes vs Infection not							
			Vascular disease vs Cancer						suggest that the 6MWt has	
Reid	2015	25588644	vs Trauma and congenital)		Р	<0.0001		Yes	good discriminative validity.	P-value based on ANOVA
			<u> </u>						5	
									the results of the study also	
Delia	0045	05500044	A			-0.0004			suggest that the 6MWt has	
Reid	2015	25588644	Age >=50 Vs <50		٢	<0.0001		res	good discriminative validity.	
									examinations of the 6MW/t men	
									walked further than women, this	
									result was not statistically	
Reid	2015	25588644	Male vs female		Р	0.24		No	signifcant in the present study.	
									Adequate to excellent	
									correlation between the 6MWt	
									and previously validated	
Reid	2015	25588644	Timed up and go		Pearson r	-0.72	Large	Yes	lower extremity amoutees	
	2010	20000011	rinioù up una go		. ouroonn	0.72	Laigo	1.00	Adequate to excellent	
									correlation between the 6MWt	
									and previously validated	
			Locomotor Capabilities		_				measures of ambulation in	
Reid	2015	25588644	Index version 5		Pearson r	0.61	Large	Yes	lower extremity amputees	
									correlation between the 6MWt	
									and previously validated	
									measures of ambulation in	
Reid	2015	25588644	Houghton		Pearson r	0.57	Large	Yes	lower extremity amputees	
									Adequate to excellent	
									correlation between the 6MWt	
			Activity Specife Polonee						and previously validated	
Reid	2015	25588644	Confdence scale		Pearson r	0.6	Large	Yes	lower extremity amoutees	
							9-			
Resnik	2011		NA		MDC90	147.5	1			
		1				0.07 (0.05	1			
Pesnik	2011		NA			0.97 (0.95,				
INCOLIN	2011	+			100 (85% 01)	0.33)	1	+		
Ginsberg,										AK amputees had lower scores than BK
Rai,Marchese	2007						<u> </u>			amputees (no statistical analyses).

				Ammudation		Other Benulation						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
, latio			inputation 2010	2.00035	Both Children				Custouro	20001121011	reporty	, lopoor
					and adult							
Marchese, Rai, Carlso	2007				amputees			0 minuto run wolk	Total Overall		Poliobility	latra ratar
etai	2007				Both Children			9 minute run waik	30016		Reliability	initid-fater
					and adult							
Marchese, Rai, Carlso	on .				amputees				Total Overall			
et al	2007				together Both Children			9 minute run walk	Score		Reliability	Inter-rater
					and adult							
Marchese, Rai, Carlso	on				amputees				Total Overall			
et al	2007				together Dath Children			9 minute run walk	Score		Validity	Construct
					and adult							
Marchese, Rai, Carlso	on				amputees				Total Overall			Concurrent/convergent/criteri
et al	2007				together			9 minute run walk	Score		Validity	a Validity criterion
			Syme or Boyd									
Walker	2009		amputation	fibular deficiency	32.5		36	AAOS Lower Limb Module			Validity	Known group
			Ankle disarticulation									
			(n=2) Transtibiai (n=82), Knee									
			disarticulation (n=7),									
			Transfemoral (n=67),	Disease (n=76),		A						
			(n=7). Transpelvic	Tumor (n=24).		independence, no longer in						
Gailey	2002	11994800	(n=2)	Congenital (n=6)	54.8	rehab	167	AAS			Validity	Known group
			ankle (2), TT (82), KD									
			(7), TF (67), hip disarticulation (7)	disease (76), trauma (61), tumor (24)								
Gailey	2002	11994800	transpelvic (2)	congenital (6)	54.84 +- 18.6	18-100	167	AAS			validity	construct
-			Transfemoral (n=17),								-	
			transtibial (n=14),									
			bilateral transtibial									
			(n=1), bilateral							Amputee Activity Score: Ability to measure	Responsiven	
Panesar	2001		transfemoral (n=1)	nd	67		34	AAS		change	ess	nd
			transfemoral (n=17), transfibial (n=14)									
			hindquarter (n=1),									
			bilateral transtibial									
Panesar	2001		(n=1), bilateral transfemoral (n=1)	nd	67		34	AAS		Amputee Activity Score: Ability to measure	Responsiven	nd
i dilocal	2001		Transfemoral (n=17),	ild.	01		04	7010		change	035	10
			transtibial (n=14),									
			hindquarter (n=1),									
			(n=1), bilateral									
Panesar	2001		transfemoral (n=1)	nd	67		34	AAS		Amputee Activity Score	Validity	Convergent
				dysvascular								
				(121/60.2%);								
			above knee (70,	infection (25/12.4%);						16-item instrument that measures		
Hafaar	2016	20272220	34.8%); below knee	tumor (8/4.0%);	60.2 + 11.4	nd	201	ARC	nd	respondents' confidence in performing basic	Poliobility	test retest
пашеі	2010	20213329	(131, 05.2 %)	dysyascular	00.2 +-11.4	nu	201	ABC	nu	anibulatory activities	Reliability	lesi-relesi
				(46\22.9%); trauma								
			-h (70	(121/60.2%);						10 Hore in the second dia to a second		
			above knee (70, 34,8%): below knee	tumor (8/4.0%):						respondents' confidence in performing basic		
Hafner	2016	28273329	(131, 65.2 %)	congenital (1/0.5%)	60.2 +-11.4	nd	201	ABC	nd	ambulatory activities	MDC	
				dysvascular								
				(46\22.9%); trauma								
			above knee (70,	infection (25/12.4%);						16-item instrument that measures		
			34.8%); below knee	tumor (8/4.0%);				150		respondents' confidence in performing basic		
Hatner	2016	28273329	(131, 65.2 %)	congenital (1/0.5%)	60.2 +-11.4	nd	201	ABC	nd	ambulatory activities	MDC	
			below knee 135, U	666, infection 44,						16-item self-report measure that asks people		
			above knee 383, B	congenital 20,						to rate their confidence in performing various		
Kelly	2016	27756174	above knee 70	multiple 15	54.3 (13.7)	nd	1291	ABC	nd	ambulatory activities	validity	Construct

			Comparator/Criterion/Outc	Interior			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
				-						
Marahasa Bai Carlaan										ICCs between 0.02 and 1.00 for bealthy
et al	2007									sample and 0.97 and 0.99 for patients
Marahasa Bai Carlaan										ICCs between 0.02 and 1.00 for bealthy
et al	2007									sample and 0.97 and 0.99 for patients
Marehona Dai Carlana										walk distance increased over time (6, 12,18
et al	2007									surgerv
Marahasa Dai Carlaan										Spearman: MSTS function=0.45, MSTS
et al	2007									SE36 PE=0.49, SE36 RP=0.43, TESS=0.50
						provided in				
			and the second			the				
Walker	2009		fibular deficiency			appendinx (not retreived)				amputation and limb-lengthening groups
Trainer .	2000		indular denoioney			(1101101101101)				anipatation and into longatorining groupo
					MFCL levels in					
Callay	2002	11004800			ability to	Buelue	0.001			
Galley	2002	11994800			ampulate	P value	0.001			
						p, 1 way				
Galley	2002	11994800	known groups b/w k level			anova	0.0001		yes	
									eispificent changes between	
Panesar	2001		P value		<0.00001				admission and discharge	
									g_	
									significant changes between	
Panesar	2001		P value		<0.0001				discharge and follow-up	
Panesar	2001		OPCS AAS EIM		P value	<0.0001				significant kendal correlations coefficients
i anesai	2001		01 03, AA3, 1 11		i value	~0.0001				between each of the measures
										retest on avg 48.9 (5.2) hrs after, presented
										observed. combined ICC, MoAs were
Hafner	2016	28273329			ICC	0.95				satistically constant
										retest on avg 48.9 (5.2) hrs after, presented
										separately by MoA when differences were
Hofoor	2016	20272220				0.40				observed. combined ICC, MoAs were
namer	2016	20213329			IVIDC 90	0.49				
										retest on avg 48.9 (5.2) hrs after, presented
										separately by MoA when differences were
Hafner	2016	28273329			MDC 95	0.58				satistically constant
					P val, multiple				The ABC shows construct	
Kelly	2016	27756174	number of co-morbidities		regression	0.0002		Yes	validity for co-morbidities	
						1 · · · ·	1	1 · · · ·	1 2 2 2 2 2 2 2 2 2 2 2 2	

				Ammudation		Other Denvilation						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
			U below knee 703, B	dysvas 546, trauma	Ū							•
			below knee 135, U above knee 383, B	666, infection 44, concenital 20						16-item self-report measure that asks people to rate their confidence in performing various		
Kelly	2016	27756174	above knee 70	multiple 15	54.3 (13.7)	nd	1291	ABC	nd	ambulatory activities	validity	Construct
			U below knee 703, B	dysvas 546, trauma								
			below knee 135, U above knee 383, B	666, infection 44, concenital 20						16-item self-report measure that asks people to rate their confidence in performing various		
Kelly	2016	27756174	above knee 70	multiple 15	54.3 (13.7)	nd	1291	ABC	nd	ambulatory activities	validity	Construct
			U below knee 703, B	dysvas 546, trauma								
			below knee 135, U	666, infection 44,						16-item self-report measure that asks people		
Kelly	2016	27756174	above knee 70	multiple 15	54.3 (13.7)	nd	1291	ABC	nd	ambulatory activities	validity	Construct
						At least 19 years old, had a						
			Transtibial (n=1200)	Vascular (n=276)		major unilateral amputation,				Modified response scale (Four-, 5-, and 6-		
			Transfemoral (n=112),	Trauma (n=122),		daily basis for at least 6				the original 101-point format were grouped so		
			Bilateral (n=121),	Cancer (n=20),		months, and lived in the				that each revised response option was chosen	ı	
Sakakibara	2011	21704978	Other (n=16)	Other (n=30)	68.1	community	448	ABC	nd	by at least 10 participants	Validity	Content
										The Activities-specific Balance Confidence (ABC) scale assessed balance confidence as		
										selfreported by the prosthetic user. The ABC		
										reports percentage values describing the		
			TT (n=22) TE (n=13)							individual's subjective confidence in		
			BTT (n=2), BTT/BFT	vascular (28),						activities that represent a hierarchy of difficulty	,	
Wong	2016	26390393	(n=2), BFT/BTT (n=1)	nonvascular (12)	57.0 +- 11.9	nd	40	ABC	nd	without redundancy	Validity	predictive
			TT (n=22) TE (n=12)									
			BTT (n=22), TF (n=13), BTT (n=2), BTT/BFT	vascular (28).								
Wong	2016	26390393	(n=2), BFT/BTT (n=1)	nonvascular (12)	57.0 +- 11.9		40	ABC	nd		Validity	predictive
				dysvascular								
				(46\22.9%); trauma								
			above knee (70,	infection (25/12.4%);						16-item instrument that measures		
			34.8%); below knee	tumor (8/4.0%);						respondents' confidence in performing basic		
Hafner	2016	28273329	(131, 65.2 %)	congenital (1/0.5%)	60.2 +-11.4	unilateral	201	ABC		ambulatory activities	Reliability	test-retest
				(46\22.9%): trauma								
				(121/60.2%);								
			above knee (70,	infection (25/12.4%);						16-item instrument that measures		
Hafner	2016	28273329	34.8%); DEIOW KREE (131_65.2%)	tumor (8/4.0%); congenital (1/0.5%)	60 2 +-11 4	unilateral	201	ABC		ambulatory activities	MDC	
i lamor	2010	20210020	(101, 00.2 /0)	dysvascular	00.2 * 11.1	annatora	201	100				
				(46\22.9%); trauma								
			abaya kaca (70	(121/60.2%);						16 item instrument that measures		
			34.8%); below knee	tumor (8/4.0%);						respondents' confidence in performing basic		
Hafner	2016	28273329	(131, 65.2 %)	congenital (1/0.5%)	60.2 +-11.4	unilateral	201	ABC		ambulatory activities	MDC	
			U below knee 703, B	dysvas 546, trauma						16 item colf report measure that asks assault		
			above knee 383. B	congenital 20.						to rate their confidence in performing various		
Kelly	2016	27756174	above knee 70	multiple 15	54.3 (13.7)	nd	1291	ABC		ambulatory activities	validity	Construct
			U below knee 703, B	dysvas 546, trauma						16 item celf report measure that a line and the		
			above knee 383 B	congenital 20						to rate their confidence in performing various		
Kelly	2016	27756174	above knee 70	multiple 15	54.3 (13.7)	nd	1291	ABC		ambulatory activities	validity	Construct
			U below knee 703, B	dysvas 546, trauma								
			below knee 135, U	666, infection 44,						16-item self-report measure that asks people		
Kelly	2016	27756174	above knee 70	multiple 15	54.3 (13.7)	nd	1291	ABC		ambulatory activities	validity	Construct
			U below knee 703, B	dysvas 546, trauma								
			below knee 135, U	666, infection 44,						16-item self-report measure that asks people		
Kelly	2016	27756174	above knee 383, B above knee 70	multiple 15	54.3 (13.7)	nd	1291	ABC		ambulatory activities	validitv	Construct
			Transfemoral (n=12),	Vascular (n=29),		-				,		
Miller	2003	12736877	Transtibial (n=38)	Nonvascular (n=21)	58		50	ABC			Reliability	internal consistency
Miller	2003	12736877	ranstemoral (n=12), Transtibial (n=38)	vascular (n=29), Nonvascular (n=21)	58		50	ABC			Reliability	Test-retest
	2000	12100011		1	~~	1			1		. concomity	

			Comparator/Criterion/Outo	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Kelly	2016	27756174	bilat or unilat		P val, multiple linear regression	0.0002		Yes	the ABC shows construct validity for the number of amputated limbs	
14 - Ib.	0010	07750474			P val, multiple linear	-0.0004		No.	The ABC shows construct validity for the level of	
Kelly	2016	27756174	amp level		regression	<0.0001		Yes	amputation	
Kelly	2016	27756174	etiology		P val, multiple linear regression	<0.0001		Yes	the ABC shows construct validity for amp etiology	
Sakakibara	2011	21704978	nd		nd	nd		Yes	The findings in this study support the internal consistency reliability and validity of the ABC Scale with a 5-option response format	
Word	2016	26200202	predict community			0.027				
Wong	2016	26390393	predict failure to reach	12 months	AUC	0.927		y v	cut off score 65%	The Activities-specific Balance Confidence (ABC) scale assessed balance confidence as selfreported by the prosthetic user. The ABC reports percentage values describing the individual's subjective confidence in maintaining balance when performing 16 activities that represent a hierarchy of difficulty without redundancy
								ŕ		
Hafner	2016	28273329			ICC	0.95				retest on avg 48.9 (5.2) hrs after, presente separately by MoA when differences were observed. combined ICC, MoAs were satistically constant.
Hafner	2016	28273329			MDC 90	0.49				retest on avg 48.9 (5.2) hrs after, presente separately by MoA when differences were observed. combined ICC, MoAs were satistically constant.
Hafner	2016	28273329			MDC 95	0.58				retest on avg 48.9 (5.2) hrs after, presente separately by MoA when differences were observed. combined ICC, MoAs were satistically constant.
					P val, multiple linear				The ABC shows construct	
Kelly	2016	2//561/4	number of co-morbidities		regression	0.0002		res	validity for co-morbidities	
Kelly	2016	27756174	bilat or unilat		P val, multiple linear regression	0.0002		Yes	the ABC shows construct validity for the number of amputated limbs	
Kelly	2016	27756174	amp level		P val, multiple linear regression	<0.0001		Yes	The ABC shows construct validity for the level of amputation	
Kelly	2016	27756174	etiology		P val, multiple linear regression	<0.0001		Yes	the ABC shows construct validity for amp etiology	
Miller	2003	12736877	nd		Alpha	0.93		Yes		
	a	1070			100					
Miller	2003	12736877	nd		ICC	0.91		Yes		

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Miller	2003	12736877	Transtibial (n=243)	(n=174)	59.9		329	ABC			Validity	Construct
Miller	2003	12736877	Transfemoral (n=86), Transtibial (n=243)	Nonvascular (n=174)	59.9		329	ABC			Validity	Construct
Miller	2003	12736877	Transfemoral (n=86), Transtibial (n=243)	Nonvascular (n=174)	59.9		329	ABC			Validity	Construct
Millor	2002	10726977	Transfemoral (n=86), Transtibial (n=242)	Nonvascular	50.0		220	ARC			Volidity	Construct
	2003	12730877	Transfemoral (n=86),	Nonvascular	59.9		529	ABC			validity	Construct
Miller	2003	12736877	Transtibial (n=243) Transfemoral (n=86),	(n=174) Nonvascular	59.9		329	ABC			Validity	Convergent
Miller	2003	12736877	Transtibial (n=243)	(n=174)	59.9	At least 19 years old had a	329	ABC			Validity	Convergent
Sakakibara	2011	21704978	Transtibial (n=1299), Transfemoral (n=112), Bilateral (n=121), Other (n=16)	Vascular (n=276), Trauma (n=122), Cancer (n=20), Other (n=30)	68.1	major unilateral amputation, used their prosthesis on a daily basis for at least 6 months, and lived in the community	448	ABC		Modified response scale (Four-, 5-, and 6- response formats). Response options from the original 101-point format were grouped so that each revised response option was chosen by at least 10 participants	Validity	Content
	2011		Below knee (n=73), Through knee (n=3), Above knee (n=52),	PVD (n=40), Diabetes/PVD (n=38), Accident/trauma (n=37), Infection (n=8), Cancer (n=7), Clot (n=4), Other								
Gallagher	2007	17314705	Bilateral (n=17) Below knee (n=73), Through knee (n=3), Above knee (n=52),	(n=11) PVD (n=40), Diabetes/PVD (n=38), Accident/trauma (n=37), Infection (n=8), Cancer (n=7), Clot (n=4), Other	60.5		145	ABIS			Reliability	Internal consistency
Gallagher	2007	17314705	Bilateral (n=17)	(n=11)	60.5		145	ABIS			Reliability	Internal consistency
Gallagher	2007	17314705	Below knee (n=73), Through knee (n=3), Above knee (n=52), Bilateral (n=12)	Diabetes/PVD (n=38), Accident/trauma (n=37), Infection (n=8), Cancer (n=7), Clot (n=4), Other (n=11)	60.5		145	ARIS			Reliability	Internal consistency
Galagrici	2007	11014100	Transfemoral (n=6),	(1-11)	00.0		140				rendonity	Internal consistency
Coffey	2009	19900240	Transtibial (n=23), bilateral (n=9)	Diabetes-related	68 (median)	nd	38	ABIS-R	depression		Validity	Convergent
			Transfemoral (n=6), Transtibial (n=23)									
Coffey	2009	19900240	bilateral (n=9)	Diabetes-related	68 (median)	nd	38	ABIS-R	depression		Validity	Convergent
			Transtibial (n=23),									
Cottey	2009	19900240	bilateral (n=9) Transfemoral (n=6),	Diabetes-related	68 (median)	nd	38	ABIS-R	depression		Validity	Convergent
Coffey	2009	19900240	Transtibial (n=23), bilateral (n=9)	Diabetes-related	68 (median)	nd	38	ABIS-R	depression		Validity	Convergent
Coffey	2009	19900240	Transfemoral (n=6), Transtibial (n=23), bilateral (n=9)	Diabetes-related	68 (median)	nd	38	ABIS-R	depression		Validity	Convergent
Coffey	2009	19900240	Transfemoral (n=6), Transtibial (n=23), bilateral (n=9)	Diabetes-related	68 (median)	nd	38	ABIS-R	depression		Validity	Convergent
			Transfemoral (n=6), Transtibial (n=23),									
Coffey	2009	19900240	bilateral (n=9)	Diabetes-related	66.4		38	ABIS-R	Depression		Validity	Convergent
Coffey	2009	19900240	Transteinolai (n=0), Transtibial (n=23), bilateral (n=9)	Diabetes-related	66.4		38	ABIS-R	Depression		Validity	Convergent
			Transfemoral (n=6), Transtibial (n=23).									
Coffey	2009	19900240	bilateral (n=9)	Diabetes-related	66.4		38	ABIS-R	Depression		Validity	Convergent
			Transtemoral (n=6), Transtibial (n=23),									
Coffey	2009	19900240	bilateral (n=9)	Diabetes-related	66.4		38	ABIS-R	Depression		Validity	Convergent

				Timepoint			Strongth of	la Asnast		
Author	Year	PMID	comparator/Criterion/Outc	(predictive valid)	Metric Used	Value	Strength of Property	Is Aspect Supported?	Conclusion	Notes/Caveats
Millor	2002	10726977	Transtinial va Transformaral		ttoot p	>=0.0E		No		
	2003	12/ 500//			itesi p					
Miller	2003	12736877	Vascular vs Other Mobility device use yes vs		ttest p	<0.05		Yes		
Miller	2003	12736877	no Automatic stepping ves vs		ttest p	<0.05		Yes		
Miller	2003	12736877	no		ttest p	<0.05		Yes		
Miller	2003	12736877	2MWT		Pearson r	0.72		Yes		
Miller	2003	12736877	TUG		Pearson r	-0.72		Yes		
Sakakibara	2011	21704978	nd		nd	nd		Yes	The findings in this study support the internal consistency reliability and validity of the ABC Scale with a 5-option response format	
Gallagher	2007	17314705				Cronbach's alpha	0.9	Large		
Callacker	2007	17214705					0.2.0.74	Moderate to		
Gallagner	2007	17314705				Spearman's r	0.3-0.74	large		
Gallagher	2007	17314705				Kaiser-Meyer- Oklin measure	0.87	Large		
Coffey	2009	19900240	TAPES general adjustment		Spearman r	-0.48				
Coffey	2009	19900240	TAPES social adjustment		Spearman r	-0.51				
Coffey	2009	19900240	TAPES adjustment to limmitations		Spearman r	-0.45				
Coffey	2009	19900240	TAPES social restriction		Spearman r	0.44				
Coffey	2009	19900240	TAPES weight satisfaction		Spearman r	-0.36				
Coffey	2009	19900240	TAPES functional satisfaction		Spearman r	-0.46				
Coffey	2009	19900240	TAPES general adjustment		Spearman r	-0.48				
Coffey	2009	19900240	TAPES social adjustment		Spearman r	-0.51				
			TAPES adjustment to							
Coffey	2009	19900240	limmitations		Spearman r	-0.45				
Coffey	2009	19900240	TAPES social restriction		Spearman r	0.44				

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
			Transfemoral (n=6),									
Coffey	2009	19900240	hilateral (n=9)	Diabetes-related	66.4		38	ABIS-R	Depression		Validity	Convergent
concy	2000	10000210	Transfemoral (n=6),	Blaboloo Tolalou	00.1				Boprocoloni		valialty	Controlgon
o. "			Transtibial (n=23),					1010 0				
Cottey	2009	19900240	bilateral (n=9)	Diabetes-related	66.4		38	ABIS-R	Depression		Validity	Convergent
Gallagher	2007	17314705	Below knee (n=73), Through knee (n=3), Above knee (n=52), Bilateral (n=17)	Diabetes/PVD (n=38), Accident/trauma (n=37), Infection (n=8), Cancer (n=7), Clot (n=4), Other (n=11)	60.5		145	ABIS-R			Reliability	Internal consistency
Gallagher	2007	17314705	Below knee (n=73), Through knee (n=3), Above knee (n=52), Bilateral (n=17)	PVD (n=40), Diabetes/PVD (n=38), Accident/trauma (n=37), Infection (n=8), Cancer (n=7), Clot (n=4), Other (n=11)	60.5		145	ABIS-R			Reliability	Internal consistency
				PVD (n=40),								
Gallagher	2007	17314705	Below knee (n=73), Through knee (n=3), Above knee (n=52), Bilateral (n=17)	Diabetes/PVD (n=38), Accident/trauma (n=37), Infection (n=8), Cancer (n=7), Clot (n=4), Other (n=11)	60.5		145	ABIS-R			Reliability	Internal consistency
				PVD (n=40),								
Gallagher	2007	17314705	Below knee (n=73), Through knee (n=3), Above knee (n=52), Bilateral (n=17)	Diabetes/PVD (n=38), Accident/trauma (n=37), Infection (n=8), Cancer (n=7), Clot (n=4), Other (n=11)	60.5		145	ARIS-R			Reliability	Internal consistency
Guildgrioi	2001		Dilatoral (in 11)	(00.0		110				rtonability	
Theeven	2010	20809056	Unilateral transfemoral (n=20)	Trauma (n=12), Vascular (n=6), cancer (n=2)	50.3	Age 18–75 years; use of an upper leg prosthesis; completion of the rehabilitation programme; ability to walk at least 500 m	20	ADAPT	nd	A test involving a selection of those circuit stations that best simulate daily life situations.	Reliability	Test-retest
						· ·					, í	
			Unilateral transfemoral	Trauma (n=12), Vascular (n=6),		Age 18–75 years; use of an upper leg prosthesis; completion of the rehabilitation programme;				A test involving a selection of those circuit		
Ineeven	2010	20809056	(n=20)	cancer (n=2)	50.3	ability to walk at least 500 m	20	ADAPT		stations that best simulate daily life situations.	Reliability	I est-retest
									Health			
Lerner	1991		Transtibial	Trauma	41.5	nd	20	AIMS-modified	perception		Validity	Known group
									Health			
Lerner et al,	1991		Transtibial	Trauma	41.5	nd	20	AIMS-modified	perception		Validity	Known group
Lerner	1991		Transtibial	Trauma	41.5	nd	20	AIMS-modified	Pain		Validity	Known aroup
											,	
Lerner et al,	1991		Transtibial	Trauma	41.5	nd	20	AIMS-modified	Pain		Validity	Known group

Andrage Note				Comparator/Criterion/Outo	Timepoint			Strength of	le Asnact		
Coffwy 200 1990240 TAPES weight satisfaction Speammen r 0.3.5 Image	Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
ICMUM ICMUM ICMUM ICANES manyor analysis ICANES manyor analysis ICANES manyor analysis ICANES manyor analysis Callagher 2007 173-4705 ICANES manyor analysis Callagher 2007 173-4705 ICANES manyor analysis Callagher 2007 173-4705 ICANES manyor analysis Callagher 2007 173-4705 ICANES manyor analysis Callagher 2007 173-4705 ICANES manyor analysis Callagher 2007 173-4705 ICANES manyor analysis Callagher 2007 173-4705 ICANES manyor analysis ICANES manyor analysis ICANES manyor analysis ICANES manyor analysis Callagh											
Outry Dots Posterial Outry Dots Cating 2009 HSOCIA Definition in Control Operation	Coffor	2000	10000240	TARES woight actisfaction		Spearman r	0.26				
Delty200TAPES backband spectrum5.44IIIICallagher2677314705II <td< td=""><td>Colley</td><td>2009</td><td>19900240</td><td>TAPES weight satisfaction</td><td></td><td>Spearmann</td><td>-0.30</td><td></td><td></td><td></td><td></td></td<>	Colley	2009	19900240	TAPES weight satisfaction		Spearmann	-0.30				
Control 2009 9800020 estimation Selement 44.4 Image: Control				TAPES functional							
Satisginger 2007 17314705 Image: state in the second of the state in the second of	Coffey	2009	19900240	satisfaction		Spearman r	-0.46				
Callagher 2007 1734705 Image: Callagher 17347											
Galagher 2007 714705 Image: second se											
Gallagher 2007 173 4706 Image and the second of the solution of the so											
Salagene 207 173 k708 Image: spansion of spans							item				
Gallagher2007173 k706173 k706Image: second seco							separation				
Galagher 2007 7314705 Image: selection of the study o	Gallagher	2007	17314705				index	4.59			
Gallagner 2007 17314705 Image: selection of the sele											
Galagher 2007 173 4705 Image: Control of the start of											
Gallagher 2007 7314705 Image: Constraint of the standing of the standi											
Gallager 2007 17314705 Image: Contract of the study index of the study											
Gallagher 2007 17314705 Image: separation separatis separation separation separation separatis separation sep							separation				
Selection Selection Selection Selection Selection Selection Selection Selection Selection Gallagher 2007 17314705 Image: Selection <td>Gallagher</td> <td>2007</td> <td>17314705</td> <td></td> <td></td> <td></td> <td>reliability</td> <td>0.95</td> <td></td> <td></td> <td></td>	Gallagher	2007	17314705				reliability	0.95			
Callagher 2007 17314705 Image: Callagher 2007 17314705 Image: Callagher 2.3 Callagher 2007 17314705 Image: Callagher 2.3 Image: Callagher 2.3 Callagher 2007 17314705 Image: Callagher 2.3 Image: Callagher 2.3 Callagher 2007 17314705 Image: Callagher 2.4 Image: Callagher 2.4 Callagher 2007 17314705 Image: Callagher 2.4 Image: Callagher 2.4 Thereads of this study biologic biologic biologi											
Callagher 2007 17314705 Image: Callagher 2007 17314705 Image: Callagher 2.33 Image: Callagher 2.33 Callagher 2007 17314705 Image: Callagher 2.33 Image: Callagher 2.43 Image: Callagher 2.43 Image: Callagher 2.44 Image: Callagher Image: Calla											
Callagher 2007 17314705 Image: Callagher 2.33 Image: Callagher 2.007 17314705 Image: Callagher 2.33 Image: Callagher 2.007 17314705 Image: Callagher 2.007 10.001 10.0											
Gallagher 2007 17314705 Image: Constraint of the standy indicate that it is forestable to objectively measure functional anywhere using the concept of simulated daily if it is forestable to objectively measure functional anywhere using the concept of simulated daily if it is forestable to objectively measure functional anywhere using the concept of simulated daily if it is forestable to objectively measure functional anywhere using the concept of simulated daily if it is forestable to objectively measure functional anywhere using the concept of simulated daily if it is forestable to objectively measure functional anywhere using the concept of simulated daily if it is forestable to objectively measure functional anywhere using the concept of simulated daily if it is forestable to objectively measure functional anywhere using the funct andi											
Gallagher 2007 17314705 Image: Parson spectral parson spectral parson relability 2.33 Image: Parson spectral parson spectral parson relability 2.33 Image: Parson spectral parson spectral parson relability 2.33 Image: Parson spectral parson relability 2.33 Image: Parson spectral parson relability 2.33 Image: Parson relability 2.33 Imade: Parson relability <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>person</td> <td></td> <td></td> <td></td> <td></td>							person				
Gallagher 2007 17314705 person separation reliability 0.84 Gallagher 2007 17314705 Interesults of this study indicate that it is feasible to objectively measure functional abilities in daily life in transferond amputees using the concept of simulated darbit is necessary to establish the 0.69 All correlation coeffcients (Pearson's r) esceeded 0.80, except for activity 13c (r = 0.69) Theeven 2010 20809056 nd Pearson r 0.69 to 0.96 Yes Indicate that is feasible to objectively measure functional abilities in daily life in transferroral amputees using the concept of simulated darbit is necessary to establish the 0.69) Theeven 2010 20809056 nd Pearson r 0.69 to 0.96 Yes Indicate that is feasible to 0.69) All correlation coefficients (Pearson's r) esceeded 0.80, except for activity 13c (r = 0.69) Theeven 2010 20809056 nd Pearson r 0.69 to 0.96 Yes Indicate that is feasible to 0.69) All correlation coefficients (Pearson's r) esceeded 0.80, except for activity 13c (r = 0.69) Theeven 2010 20809056 nd Pearson r 0.69 to 0.96 Yes Pearson with ostoomyelitis had vorse perceived healt hat how rest perceived healt han those with foradure non-non and escender/ perceived healt han hose with foradu	Gallagher	2007	17314705				index	2.33			
Gallagher 2007 17314705 Image: separation separatevent separating separation separating separation separating sep											
Gallagher200717314705Image: separation separation separation separation separation separation separation separation0.84The results of this study indicate that it is feables to the study indicate that it is feables to the study indicate that it is feables to the study intermastic functional amplifies using the concept of simulated daily life in transference amplifies using the study in the study intermastic functional amplifies using the concept of simulated daily life in the concept of simulated daily life situations. Further research life in the concept of simulated daily life situation coefficients (Pearson's r) exceeded 0.50, except for activity '15 (r = 0.69)Therewen201020809056ndPearson r0.69 to 0.96YesImage: simulated daily life situation coefficients (Pearson's r) exceeded 0.50, except for activity '15 (r = 0.69)Therewen201020809056ndPearson r0.69 to 0.96YesImage: sim											
Gallagher200717314705Image: selection of separation reliability reliability0.84Image: selection of separation reliability reliabilityImage: selection reliability reliability <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>											
Galagher2071731470517314705Image: constraint of the study indicate that its feasible to objectively measure functional abilities in daily life in study line in											
Galagher 2007 17314705 Image: Comparison of the source of							person				
Contagres 2007 17 StrV03 Description The results of this study indicate that it is feasible to objectively measure functional abilities in daly life in transferroral amputates using the concept of simulated daily life situators. Further research is necessary to establish the exceeded 0.80, except for activity 13c (r = 0.69) The results of this study indicate that it is feasible to objectively measure functional abilities in daly life in transferroral amputates using the concept of simulated daily life situators. Further research 0.69) All correlation coefficients (Pearson's r) exceeded 0.80, except for activity 13c (r = 0.69) The results of this study indicate that it is feasible to objectively measure functional abilities in daily life in transferroral amputates using the concept of simulated daily life situators. Further research is necessary to establish the exceeded 0.80, except for activity 13c (r = 0.69) Thereven 2010 20809056 nd Pearson r 0.69 to 0.96 Yes The results of this study indicate that is feasible to objectively measure functional abilities in daily life in transferroral amputates using the concept of simulated daily life is functions. Further research is necessary to establish the exceeded 0.80, except for activity 13c (r = 0.69) Lerner 1991 P <0.05	Gallagher	2007	17314705				separation	0.84			
Theeven 2010 20809056 nd Pearson r 0.69 to 0.96 Yes The results of this study inference in more analytic in any public study is necessary to establish the exceeded 0.80, except for activity 13c (r = 0.69) Theeven 2010 20809056 nd Pearson r 0.69 to 0.96 Yes The results of this study inference in more analytic in any public in any publi in any public in any	Gallagriei	2007	17314703				reliability	0.04		The results of this study	
Image: Problem in the served of the serve										indicate that it is feasible to	
Theeven 2010 20809056 nd Pearson r 0.69 to 0.96 Yes Interseption at myteles using the concept of simulated daily life it situations. Further research is necessary to establish the psychometric properties of the exceeded 0.80, except for activity 13c (r = 0.69) Theeven 2010 20809056 nd Pearson r 0.69 to 0.96 Yes The results of this study indicate that it is feasible to 0.69) 0.69) Theeven 2010 20809056 nd Pearson r 0.69 to 0.96 Yes The results of this study indicate that it is feasible to 0.69) 0.69) Theeven 2010 20809056 nd Pearson r 0.69 to 0.96 Yes Indicate that it is feasible to 0.69) All correlation coeffcients (Pearson's r) psychometric properties of the psychometric properties of the 14 to research										objectively measure functional	
Theeven 2010 20809056 nd Pearson r 0.69 to 0.96 Yes Infe concept of simulated daily pay-tometric properties of the psychometric properties of the psychometric properties of the stable to objectively measure functional abilities in daily tife in transferonal amputees using the concept of simulated daily tife in transferonal amputees using the concept of simulated daily tife in transferonal amputees using the concept of simulated daily tife in transferonal amputees using the concept of simulated daily tife in transferonal amputees using the concept of simulated daily tife in transferonal amputees using the concept of simulated daily tife in transferonal amputees using the concept of simulated daily tife in transferonal amputees using the concept of simulated daily tife in transferonal amputees using the concept of simulated daily tife in transferonal amputees using the concept of simulated daily tife in transferonal amputees using the concept of simulated daily tife in transferonal amputees using the concept of simulated daily tife in transferonal amputees using the concept of simulated daily tife in transferonal amputees using the concept of simulated daily tife in transferonal amputees using the concept of simulated daily tife in transferonal amputees using the concept of simulated daily tife in transferonal amputees using the concept of simulated daily tife in transferonal amputees using the concept of simulated daily tife in transferonal amputees using the concept of simulated daily tife in transferonal amputees using the concept of simulated daily tife in transferonal amputees using the concept of simulated daily tife in transferonal amputees using the concept of simulated daily tife in transferonal amputees using the concept of simulated daily tife in transferonal amputees using the concept of the concept of the concept of simulated daily the concept of the concept of the t										transfemoral amputees using	
Theeven 2010 20809056 nd Pearson r 0.69 to 0.96 Yes iffe situations. Further research psychometric properties of the hal ADAPT test. All correlation coefficients (Pearson's r) exceeded 0.80, except for activity 13c (r = 0.69) The even 2010 20809056 nd Pearson r 0.69 to 0.96 Yes The results of this study indicate that it is feasible to objectively measure functional abilities in daily life in transferroral anyoutees using the concept of simulated daily life situations. Further research is necessary to establish the psychometric properties of the procived health than those with fracture non-union and amputation. Lerner et al, 1991 P P <0.05										the concept of simulated daily	
Theeven 2010 20809056 nd Pearson r 0.69 to 0.96 Yes That ADAPT test. All correlation coefficients (Pearson's 1) Theeven 2010 20809056 nd Pearson r 0.69 to 0.96 Yes The results of this study indicate that it is feasible to objectively measure functional abilities in daily life in transfermoral amputees using the concept of simulated daily life in transfermoral amputees of the next the research is necessary to establish the psychometric properties of the next the research is necessary to establish the psychometric properties of the next the research is necessary to establish the psychometric properties of the next th										life situations. Further research	All an analytic and finite (Decentral of
Theeven 2010 20809056 nd Pearson r 0.69 to 0.96 Yes fnal ADAPT test 0.69 Theeven Image: State of the sta										is necessary to establish the	All correlation coefficients (Pearson's r)
Image: series of the series	Theeven	2010	20809056	nd		Pearson r	0.69 to 0.96		Yes	fnal ADAPT test.	0.69)
Image: here of the second se										The results of this study	
Lerrer 1991 Persons with osteomyelitis had worse perceived health than those with fracture paychmetric properties of the paychmetric properties of the perceived 0.80, except for activity 13c (r = 0.69) All correlation coeffcients (Pearson's r) exceeded 0.80, except for activity 13c (r = 0.69) Lerner et al, 1991 Persons with osteomyelitis had worse perceived health than those with fracture por council on and amputation. Lerner et al, 1991 Persons with osteomyelitis worse perceived health than those with fracture por council on and amputation. Lerner et al, 1991 Persons with osteomyelitis worse perceived health than those with fracture por council on and amputation. Lerner et al, 1991 Persons with osteomyelitis worse perceived health than those with fracture por council on and amputation. Lerner et al, 1991 Persons with fracture non-union and amputation. Lerner et al, 1991 Persons with fracture non-union and steomyelitis as compared to amputates. Lerner et al, 1991 Persons with fracture non-union and steomyelitis as compared to amputates.										indicate that it is feasible to	
Image: Lerner et al, 1991 Image: Lerner et al, 1991 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>abilities in daily life in</td><td></td></td<>										abilities in daily life in	
Image: series of the series										transfemoral amputees using	
Image: Studiotic Properties of the psychometric properties of										the concept of simulated daily	
Theeven 2010 20809056 nd Pearson r 0.69 to 0.96 Yes psychometric properties of the frail ADAPT test. exceeded 0.80, except for activity 13c (r = 0.69) Lerner 1991 Persons with osteomyelitis had worse perceived health than those with fracture non-union and amputation. Persons with osteomyelitis had worse perceived health than those with fracture non-union and amputation. Lerner et al, 1991 Persons Persons with osteomyelitis had worse perceived health than those with fracture non-union and amputation. Lerner te al, 1991 Persons with osteomyelitis had worse perceived health than those with fracture non-union and amputation. Lerner te al, 1991 Persons with osteomyelitis had worse perceived health than those with fracture non-union and amputation. Lerner te al, 1991 Persons with osteomyelitis had worse perceived health than those with fracture non-union and osteomyelitis had worse perceived health than those with fracture non-union and amputation. Lerner te al, 1991 Persons with osteomyelitis had worse perceived for patients with fracture non-union and osteomyelitis as compared to amputees. Lerner te al, 1991 Persons with osteomyelitis had worse perceived for patients with fracture non-union and osteomyelitis had worse perceived for patients with fracture non-union and osteomyelitis as compared to amputees.										is necessary to establish the	All correlation coeffcients (Pearson's r)
Theeven 2010 20809056 nd Pearson r 0.69 to 0.96 Yes fnal ADAPT test. 0.69) Lemer 1991 Persons with osteomyelitis had worse Lemer 1991 Persons with osteomyelitis had worse Persons with osteomyelitis had worse Persons with osteomyelitis had worse Lemer et al, 1991 Persons with osteomyelitis had worse Persons with osteomyelitis had worse Persons with osteomyelitis had worse Lemer et al, 1991 Persons with osteomyelitis had worse Persons with osteomyelitis had worse Persons with osteomyelitis had worse Lemer et al, 1991 Persons with osteomyelitis had worse Persons with osteomyelitis had worse Lemer et al, 1991 Persons with osteomyelitis had worse Persons with osteomyelitis had worse Lemer et al, 1991 Persons with osteomyelitis had worse Persons with osteomyelitis had worse Lemer et al, 1991 Person velocitis Persons with osteomyelitis had worse Persons with osteomyelitis had worse Lemer et al, 1991 Person velocitis Personson with osteomyelitis had worse Person										psychometric properties of the	exceeded 0.80, except for activity 13c (r =
Lerner 1991 P <0.05	Theeven	2010	20809056	nd		Pearson r	0.69 to 0.96		Yes	fnal ADAPT test.	0.69)
Lerner 1991 P <0.05 non-union and amputation. Lerner et al, 1991 Persons with cature percense Persons with racture non-union and amputation. Lerner et al, 1991 Persons with racture percense Persons with racture non-union and amputation. Lerner et al, 1991 Percense Percense Lerner et al, 1991 Percense Percense											perceived health than those with fracture
Lerner et al, 1991 Persons with osteomyelitis had worse perceived health than those with fracture non-union and amputation. Lerner 1991 P <0.05	Lerner	1991				Р	<0.05				non-union and amputation.
Lerrer et al, 1991 per ceived neatin than those with fracture non-union and amputation. Higher pain scores observed for patients with fracture non-union and amputation. Higher pain scores observed for patients with fracture non-union and osteomyelitis as compared to amputees. Lerrer et al, 1991 Higher pain scores observed for patients with fracture non-union and osteomyelitis as compared to amputees.											Persons with osteomyelitis had worse
Lerner et al, 1991 P <0.05 Higher pain scores observed for patients with fracture non-union and osteomyelitis as compared to amputees. Lerner et al, 1991 Image: Compared to ampute and the stores observed for patients with fracture non-union and osteomyelitis as compared to amputees.	l erner et al	1991									perceived health than those with fracture
Lerner 1991 P <0.05 with fracture non-union and osteomyelitis as compared to amputees. Lerner et al, 1991 Image: Compared to ampute and the second secon											Higher pain scores observed for patients
Lerrer 1991 P <0.05 as compared to amputees. Lerrer et al, 1991<											with fracture non-union and osteomyelitis
Lerner et al, 1991	Lerner	1991				Р	<0.05				as compared to amputees.
Lerner et al, 1991 as compared to amputees.											with fracture non-union and osteomvelitis
	Lerner et al,	1991									as compared to amputees.

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Walker et al,	2009		Syme or Boyd amputation	fibular deficiency	32.5	nd	36	American Academy of Orthopaedic Surgeons Lower Limb Module	nd		Validity	Known group
Calley	2002	11004800	ankle (2), TT (82), KD (7), TF (67), hip disarticulation (7),	disease (76), trauma (61), tumor (24),	54.04 + 40.0	10,100	467				Volidity	Converset
Galley	2002	11994800	ankle (2), TT (82), KD (7), TF (67), hip disarticulation (7)	disease (76), trauma	54.04 +- 10.0	16-100	107		AMPROPRO		validity	Convergent
Gailey	2002	11994800	transpelvic (2) ankle (2), TT (82), KD	congenital (6)	54.84 +- 18.6	18-100	167	AMP	AMPnoPRO		validity	construct
Gailey	2002	11994800	(7), TF (67), hip disarticulation (7), transpelvic (2)	disease (76), trauma (61), tumor (24), congenital (6)	54.84 +- 18.6	18-100	167	AMP	AMPnoPRO		validity	construct
Calley	2002	11004800	ankle (2), TT (82), KD (7), TF (67), hip disarticulation (7),	disease (76), trauma (61), tumor (24),	54.04 + 40.0	10,100	167				voliditu	
Galley	2002	11994800	ankle (2), TT (82), KD (7), TF (67), hip disarticulation (7).	disease (76), trauma	54.04 +- 10.0	16-100	107		AMPROPRO		validity	construct
Gailey	2002	11994800	transpelvic (2) ankle (2), TT (82), KD (7), TF (67), hip	congenital (6) disease (76), trauma	54.84 +- 18.6	18-100	167	AMP	AMPnoPRO		validity	convergent
Gailey	2002	11994800	disarticulation (7), transpelvic (2)	(61), tumor (24), congenital (6)	54.84 +- 18.6	18-100	167	AMP	AMPnoPRO		validity	convergent
Gailey	2002	11994800	UTT (10), UTF (8), Bi (6)	disease (19), trauma (5)	68.3 +- 17.8	18-100	24	AMP	AMPnoPRO		reliability	interrater
Gailey	2002	11994800	UTT (10), UTF (8), Bi (6)	disease (19), trauma (5)	68.3 +- 17.8	18-100	24	AMP	AMPnoPRO		reliability	intrarater
Gailey	2002	11994800	Ankle disarticulation (n=2) Transtibial (n=82), Knee disarticulation (n=7), Transfemoral (n=67), Hip disarticulation (n=7), Transpelvic (n=2)	Disease (n=76), Trauma (n=61), Tumor (n=24), Congenital (n=6)	54.8	At peak of prosthetic independence, no longer in rehab	167	AMP	AMPnoPRO	Without Prosthesis	Validity	Concurrent
Gailey	2002	11994800	Ankle disarticulation (n=2) Transtibial (n=82), Knee disarticulation (n=7), Transfemoral (n=67), Hip disarticulation (n=7), Transpelvic (n=2)	Disease (n=76), Trauma (n=61), Tumor (n=24), Congenital (n=6)	54.8	At peak of prosthetic independence, no longer in rehab	167	АМР	AMPnoPRO	Without Prosthesis	Validity	Concurrent
Gailey	2002	11994800	Ankle disarticulation (n=2) Transtibial (n=82), Knee disarticulation (n=7), Transfemoral (n=67), Hip disarticulation (n=7), Transpelvic (n=2)	Disease (n=76), Trauma (n=61), Tumor (n=24), Congenital (n=6)	54.8	At peak of prosthetic independence, no longer in rehab	167	AMP	AMPnoPRO	Without Prosthesis	Validity	Concurrent
Gailey	2002	11994800	Ankle disarticulation (n=2) Transtibial (n=82), Knee disarticulation (n=7), Transfemoral (n=67), Hip disarticulation (n=7), Transpelvic (n=2)	Disease (n=76), Trauma (n=61), Tumor (n=24), Congenital (n=6)	54.8	At peak of prosthetic independence, no longer in rehab	167	AMP	AMPnoPRO	Without Prosthesis	Validity	Concurrent
Gailey	2002	11994800	Ankle disarticulation (n=2) Transtibial (n=82), Knee disarticulation (n=7), Transfemoral (n=67), Hip disarticulation (n=7), Transpelvic (n=2)	Disease (n=76), Trauma (n=61), Tumor (n=24), Congenital (n=6)	54.8	At peak of prosthetic independence, no longer in rehab	167	AMP	AMPnoPRO	Without Prosthesis	Validity	Known group

			Comparator/Criterion/Outo	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
						p[rovided in				
			omputoop va longthoping for			the				no significant differences between the
Walker et al,	2009		fibular deficiency			(not retreived))			amputation and limb-lengthening groups
					Pearson					
					product					
Cailou	2002	11004800	GMMAT		moment	0.604				multiple regression
Galley	2002	11994800	OIVIVV I		correlation	0.094		yes		multiple regression
						p, 1 way				
Gailey	2002	11994800	known groups b/w k level			anova	0.0001		Yes	
Gailey	2002	11994800	time since amp			pearson r	0.263	small	unclear	
Gailev	2002	11994800	comorbidities			pearson r	-0.378	moderate	ves	
Coilou	2002	11004800	GMMAT			nooroon r	0.919	lorgo	100	
Galley	2002	11994800	OIVIVV I			pearsonn	0.010	laige	yes	
Gailey	2002	11994800	AAS			pearson r	0.768	large	yes	
Gailey	2002	11994800				ICC	0 99		Yes	The AMPhoPRO shows excellent interrater
Galloy	2002	11001000				100	0.00		100	The AMPnoPRO shows excellent intrarater
Gailey	2002	11994800				ICC	0.86 - 0.97		Yes	reliability
Cailau	2002	11004000			446	Deersen r	0.667			
Galley	2002	11994600			AAS	Pearson	0.007			
					Comorbidity					
Gailey	2002	11994800			index	Pearson r	-0.433			
Cailou	2002	11004800			4.00	Booroop r	0.696			
Galley	2002	11994800			Age	realson	-0.080			
					Time since					
Gailey	2002	11994800			amputation	Pearson r	0.292			
					MFCL levels in					
Gailey	2002	1100/800			ability to	Pearson r	0.001			
Janey	2002	111994000	1	1	annuludie	1 Calsull	0.001	1	1	1

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Gailey	2002	11994800	Ankle disarticulation (n=2) Transtibial (n=82), Knee disarticulation (n=7), Transfemoral (n=67), Hip disarticulation (n=7), Transpelvic (n=2)	Disease (n=76), Trauma (n=61), Tumor (n=24), Congenital (n=6)	54.8	At peak of prosthetic independence, no longer in rehah	167	AMP	AMPnoPRO		Reliability	Inter-rater
			Ankle disarticulation (n=2) Transtibial (n=82), Knee disarticulation (n=7), Transfemoral (n=67), Hip disarticulation (n=7), Transpelvic	Disease (n=76), Trauma (n=61), Tumor (n=24),		At peak of prosthetic independence, no longer in						
Gailey	2002	11994800	(n=2)	Congenital (n=6)	54.8	rehab	167	AMP	AMPnoPRO		Reliability	Intra-rater
Gailey	2002	11994800	Ankle disarticulation (n=2) Transtibial (n=82), Knee disarticulation (n=7), Transfemoral (n=67), Hip disarticulation (n=7), Transpelvic (n=2)	Disease (n=76), Trauma (n=61), Tumor (n=24), Congenital (n=6)	54.8	At peak of prosthetic independence, no longer in rehab	167	АМР	AMPnoPRO		Validity	Concurrent
			ankle (2), TT (82), KD	diagona (76) trauma								
			disarticulation (7),	(61), tumor (24),								
Gailey	2002	11994800	transpelvic (2)	congenital (6)	54.84 +- 18.6	18-100	167	AMP	AMPPRO		Validity	Convergent
0-1	0000	11001000	(7), TF (67), hip disarticulation (7),	disease (76), trauma (61), tumor (24),	54.04 - 40.0	10,100	107				s on Roll A.	
Galley	2002	11994800	ankle (2), TT (82), KD	congenital (6)	54.84 +- 18.0	18-100	167	AMP	AMPPRO		validity	construct
Gailey	2002	11994800	(7), TF (67), hip disarticulation (7), transpelvic (2)	disease (76), trauma (61), tumor (24), congenital (6)	54.84 +- 18.6	18-100	167	AMP	AMPPRO		validity	construct
Gailey	2002	11994800	ankle (2), TT (82), KD (7), TF (67), hip disarticulation (7), transpelvic (2)	disease (76), trauma (61), tumor (24), congenital (6)	54.84 +- 18.6	18-100	167	АМР	AMPPRO		validity	construct
			ankle (2), 11 (82), KD (7), TF (67), hip	disease (76), trauma								
Gailey	2002	11994800	transpelvic (2)	congenital (6)	54.84 +- 18.6	18-100	167	AMP	AMPPRO		validity	convergent
Gailey	2002	11994800	ankle (2), TT (82), KD (7), TF (67), hip disarticulation (7), transpelvic (2)	disease (76), trauma (61), tumor (24), congenital (6)	54 84 +- 18 6	18-100	167	AMP	AMPPRO		validity	convergent
			UTT (10), UTF (8), Bi	disease (19), trauma								
Gailey	2002	11994800	(6) UTT (10), UTF (8), Bi	(5) disease (19), trauma	68.3 +- 17.8	18-100	24	AMP	AMPPRO		Reliability	Interrater
Gailey	2002	11994800	(6)	(5)	68.3 +- 17.8	18-100	24	AMP	AMPPRO		Reliability	intrarater
Gailey	2002	11994800	Ankle disarticulation (n=2) Transtibial (n=82), Knee disarticulation (n=7), Transfemoral (n=67), Hip disarticulation (n=7), Transpelvic (n=2)	Disease (n=76), Trauma (n=61), Tumor (n=24), Congenital (n=6)	54.8	At peak of prosthetic independence, no longer in rehab	167	AMP	AMPPRO		Reliability	Inter-rater
Gailey	2002	11994800	Ankle disarticulation (n=2) Transtibial (n=82), Knee disarticulation (n=7), Transfemoral (n=67), Hip disarticulation (n=7), Transpelvic (n=2)	Disease (n=76), Trauma (n=61), Tumor (n=24), Congenital (n=6)	54.8	At peak of prosthetic independence, no longer in rehab	167	АМР	AMPPRO		Reliability	Intra-rater

			Comparator/Criterion/Outc	Imepoint			Strength of	ls Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Gailey	2002	11994800			ICC	0.99	Excellent			Among subgroup of n=26
Gailey	2002	11994800			ICC	0.97	Excellent			Among subgroup of n=27
Gailey	2002	11994800			6-min walk test	Pearson r	0.694			
					product					
Cailau	2002	11004800	CAMAT		moment	0.010				
Galley	2002	11994600			correlation	0.010		yes		multiple regression
Gailey	2002	11994800	known groups b/w k level			p, 1 way anova	0.0001		Yes	
Gailey	2002	11994800	time since amp			pearson r	0.292	small	unclear	
Gailey	2002	11994800	comorbidities			pearson r	-0.433	moderate	yes	
Gailey	2002	11994800	6MWT			nearson r	0 694	larne	Ves	
Salley	2002	11001000				pouroonn	0.001	laigo	,	
Gailey	2002	11994800	AAS			pearson r	0.667	large	yes	
Cailov	2002	11004900				100	0.00		Voo	The AMPPRO shows excellent interrater
Galley	2002	11994000				100	0.99		Tes	The AMPPRO shows excellent intrarater
Gailey	2002	11994800				ICC	0.96 - 0.98		Yes	reliability
Gailey	2002	11994800			ICC	0.99	Excellent			Among subgroup of n=24
Gailev	2002	11994800	1	1	ICC	0.96	Excellent	1		Among subgroup of n=25

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Gailey	2002	11994800	Ankle disarticulation (n=2) Transtibial (n=82), Knee disarticulation (n=7), Transfemoral (n=67), Hip disarticulation (n=7), Transpelvic (n=2)	Disease (n=76), Trauma (n=61), Tumor (n=24), Congenital (n=6)	54.8	At peak of prosthetic independence, no longer in rehab	167	AMP	AMPPRO		Validity	Concurrent
Calley	2002	11004800	Ankle disarticulation (n=2) Transtibial (n=82), Knee disarticulation (n=7), Transfemoral (n=67), Hip disarticulation (n=7), Transpelvic (n=7)	Disease (n=76), Trauma (n=61), Tumor (n=24),	E4 9	At peak of prosthetic independence, no longer in	167				Volidity	Consurrant
Gailey	2002	11994800	(n=2) Ankle disarticulation (n=2) Transtibial (n=82), Knee disarticulation (n=7), Transfemoral (n=67), Hip disarticulation (n=7), Transpelvic	Disease (n=76), Trauma (n=61), Tumor (n=24),	54.8	At peak of prosthetic independence, no longer in	167	AMP	AMPPRO		Validity	Concurrent
Gailey	2002	11994800	(n=2) Ankle disarticulation (n=2) Transtibial (n=82), Knee disarticulation (n=7), Transfemoral (n=67), Hip disarticulation (n=7), Transpelvic (n=2)	Congenital (n=6) Disease (n=76), Trauma (n=61), Tumor (n=24), Congenital (n=6)	54.8	rehab At peak of prosthetic independence, no longer in rehab	167	AMP	AMPPRO		Validity	Concurrent
Gailey	2002	11994800	Ankle disarticulation (n=2) Transtibial (n=82), Knee disarticulation (n=7), Transfemoral (n=67), Hip disarticulation (n=7), Transpelvic (n=2)	Disease (n=76), Trauma (n=61), Tumor (n=24), Concenital (n=6)	54.8	At peak of prosthetic independence, no longer in rehab	167	AMP	AMPPRO		Validity	Concurrent
			Ankle disarticulation (n=2) Transtibial (n=82), Knee disarticulation (n=7), Transfemoral (n=67), Hip disarticulation (n=7), Transpelvic	Disease (n=76), Trauma (n=61), Tumor (n=24),		At peak of prosthetic independence, no longer in						
Gailey	2002	11994800	(n=2) Transfemoral (52%):	Congenital (n=6)	54.8	rehab	167	AMP	AMPPRO		Validity	Known group
			through knee (5%);								Detectible	
Resnik	2011		transtibial (43%) Transfemoral (52%); through knee (5%);		66	unilateral	44	AMP	Total		Change	MDC90
Resnik	2011	1	transtibial (43%)		66	unilateral	44	AMP	Total		Reliability	Test-retest
Norvell	2016	27496697	transmetatarsal (26), transtibial (59), transfemoral (28)	nd	63.5 +- 8.1	>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or peripheral arterial disease	113	AMPSIMM	nd	Amputee Single Item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4 months, and 12 months post-amputation	Validity	Criterion validity (concurrent)
Norvell	2016	27496697	transmetatarsal (26), transtibial (59), transfemoral (28)	nd	63.5 +- 8.1	>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or peripheral arterial disease	113	AMPSIMM	nd	Amputee Single Item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4 months, and 12 months post-amputation	Validity	Criterion validity (concurrent)
Netvoll	2016	27406607	transmetatarsal (26), transtibial (59), transfermerel (29)	nd	635+ 01	>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or peripheral atterial discose	113		nd	Amputee Single Item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4 months, and 12 months, not computing.	Validity	
NUIVEII	2010	21400001	a anoicitior di (20)	PIM .	00.0 - 0.1	peripricial anterial disease	110		inu.	monana, anu 12 monana post-amputation	valiuity	concentration valuaty (concurrent)

			Comparator/Criterion/Outc	(predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
0-11	0000	11001000			0	D	0.010			
Galley	2002	11994800			6-min waik test	Pearson r	0.818			
Gailey	2002	11994800			AAS	Pearson r	0.768			
o					Comorbidity	-				
Galley	2002	11994800			index	Pearson r	-0.378			
Gailey	2002	11994800			Age	Pearson r	-0.594			
					Ū.					
					Time since					
Gailey	2002	11994800			amputation	Pearson r	0.263			
					MECL lovels in					
					ability to					
Gailey	2002	11994800			ambulate	P value	0.001			
Guildy	2002	11001000			ambalato	, value	0.001			
Resnik	2011		NA		MDC90	3.4				
						0.88 (0.79,				
Resnik	2011		NA		ICC (95% CI)	0.93)				
									AMPSIMM is concurrently valid	6 weeks, total sample included
NOTVEII	2016	2/49669/	LUI-5		Spearman r	0.72	large	res	with LCI-5	transmetatarsal
							1	1	AMPSIMM is concurrently valid	4 months, total sample included
Norvell	2016	27496697	I CI-5		Spearman r	0.81	large	Yes	with I CI-5	transmetatarsal
	2010	21400001	2010		opeannann	0.01	aige	100		
							1	1		
									AMPSIMM is concurrently valid	12 months, total sample included
Norvell	2016	27496697	LCI-5		Spearman r	0.86	large	Yes	with LCI-5	transmetatarsal

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Nonvoll	2016	27406607	transmetatarsal (26), transtibial (59), transformaral (28)	nd	625+91	>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or peripherel attention disease	112		nd	Amputee Single Item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4 membra and 12 months and amputation.	Volidity	Criterian validity (predictive)
	2016	27496697	transmetatarsal (28) transmetatarsal (26), transtibial (59),		63.5 +- 8.1	>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or	113		na	months, and 12 months post-amputation Amputee Single Item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4	Validity	Criterion validity (predictive)
Norvell	2016	27496697	transfemoral (28)	nd	63.5 +- 8.1	peripheral arterial disease	113	AMPSIMM	nd	months, and 12 months post-amputation	Validity	Criterion validity (predictive)
Norvell	2016	27496697	transmetatarsal (26), transtibial (59), transfemoral (28)	nd	63.5 +- 8.1	>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or perioberal arterial disease	27	AMPSIMM	nd	Amputee Single Item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4 months, and 12 months post-amoutation	Validity	Construct
			transmetatarsal (26), transtibial (59),			>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or				Amputee Single Item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4		
Norvell	2016	27496697	transfemoral (28)	nd	63.5 +- 8.1	peripheral arterial disease	47	AMPSIMM	nd	months, and 12 months post-amputation	Validity	Construct
Norvell	2016	27496697	transmetatarsal (26), transtibial (59), transfemoral (28)	nd	63.5 +- 8.1	>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or peripheral arterial disease	27	AMPSIMM	nd	Amputee Single item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4 months, and 12 months post-amputation	Validity	Construct
Norvell	2016	27496697	transmetatarsal (26), transtibial (59), transfemoral (28)	nd	63.5 +- 8.1	>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or peripheral arterial disease	47	AMPSIMM	nd	Amputee Single Item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4 months, and 12 months post-amputation	Validity	Construct
Norvell	2016	27496697	transmetatarsal (26), transtibial (59), transfemoral (28)	nd	63.5 +- 8.1	>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or peripheral arterial disease	27	AMPSIMM	nd	Amputee Single Item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4 months, and 12 months post-amputation	Validity	Construct
			transmetatarsal (26), transtibial (59),			>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or				Amputee Single Item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4		
Norvell	2016	27496697	transfemoral (28)	nd	63.5 +- 8.1	peripheral arterial disease	47	AMPSIMM	nd	Months, and 12 months post-amputation	Validity	Construct
Norvell	2016	27496697	transmetatarsal (26), transtibial (59), transfemoral (28)	nd	63.5 +- 8.1	>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or peripheral arterial disease	113	AMPSIMM	nd	Single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4 months, and 12 months post-amputation	Validity	Construct
			transmetatarsal (26), transtibial (59),			>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or				Amputee Single Item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4		
Norvell	2016	27496697	transfemoral (28)	nd	63.5 +- 8.1	peripheral arterial disease	113	AMPSIMM	nd	months, and 12 months post-amputation	Validity	floor/ceiling
Norvell	2016	27496697	transmetatarsal (26), transtibial (59), transfemoral (28)	nd	63.5 +- 8.1	>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or peripheral arterial disease	27	AMPSIMM		single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4 months, and 12 months post-amputation	Validity	Construct
Norvell	2016	27496697	transmetatarsal (26), transtibial (59), transfemoral (28)	nd	63.5 +- 8.1	>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or peripheral arterial disease	47	AMPSIMM		Amputee Single Item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4 months. and 12 months post-amputation	Validity	Construct
Norvell	2016	27496697	transmetatarsal (26), transtibial (59), transfemoral (28)	nd	63.5 +- 8.1	>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or peripheral arterial disease	27	AMPSIMM		Amputee Single Item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4 months. and 12 months post-amputation	Validity	Construct
			transmetatarsal (26), transtibial (59),			>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or				Amputee Single Item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4		
Norvell	2016	27496697	transfemoral (28)	nd	63.5 +- 8.1	peripheral arterial disease	47	AMPSIMM	1	months, and 12 months post-amputation	Validity	Construct

			Comparator/Critorion/Outo	Timepoint			Strongth of	la Aspect		
Author	Vear	PMID	ome	(predictive	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Additor	i cai	r Mile	onie	vanu)	wethe Used	value	rioperty	Supported	Conclusion	Notes/Caveals
									6 week AMPSIMM scores are	
			6 week AMPSIMM vs 12						not predictive of 12 month LCI-5	
Norvell	2016	27496697	month LCI-5		Spearman r	0.07	<small< td=""><td>no (p = 0.56)</td><td>scores</td><td>total sample included transmetatarsal</td></small<>	no (p = 0.56)	scores	total sample included transmetatarsal
			4 month AMRSIMM vo 12					voo (n =	4 month AMPSIMM scores are	
Norvell	2016	27496697	month LCI-5		Spearman r	0.4	Moderate	0.004)	score at 12 months	
									There is sufficient evidence of	
									construct validity of the	
			AMPSIMM vs prosthetic use						AMPSIMM with prosthetic use	
Norvell	2016	27496697	@ 4 months		P, spearman r	<0.001		У	at 4 months	
									The sector configuration of the sector of	
									I here is sufficient evidence of	
			AMPSIMM ve prosthetic use						AMPSIMM with prosthetic use	
Norvell	2016	27496697	@ 12 months		P. spearman r	<0.001		v	at 12 months	
			g		.,			,		
									There is sufficient evidence of	
									construct validity of the	
			AMPSIMM vs TAPES @ 4						AMPSIMM with TAPES at 4	
Norvell	2016	27496697	months		P, spearman r	0.003		у	months	
									There is sufficient evidence of	
									CONSTRUCT Validity of the	
Norvell	2016	27496697	AMPSIMM VS TAPES @ 12		P snearman r	<0.001		v	months	
Norven	2010	21400001	inonais		r, speamann	-0.001		y	montais	
									There is sufficient evidence of	
									construct validity of the	
			AMPSIMM vs Satisfaction						AMPSIMM with "satisfaction	
Norvell	2016	27496697	w/ mobility @ 4 months		P, spearman r	<0.001		У	with mobility" at 4 months	
									There is sufficient evidence of	
									construct validity of the	
Norvell	2016	27406607	w/ mobility @ 12 months		P spearman r	-0.001		N.	with mobility" at 12 months	
	2010	27 100007			r, opodimarr			,	that mobility at 12 months	
			known groups (metatarsal							no actual p but authors present different
Norvell	2016	27496697	vs tibital vs femoral)		SRM	1	large	yes		means for each level of amputation
									Two subjects (2.4%) achieved a	
									minimum score and five (6.1%)	
									achieved a maximum score at	
									indicating neither a floor or	
Norvell	2016	27496697			nd	nd		No	ceiling.	
								-	5	
									There is sufficient evidence of	
									construct validity of the	
			AMPSIMM vs prosthetic use						AMPSIMM with prosthetic use	
Norvell	2016	27496697	@ 4 months		P, spearman r	<0.001		У	at 4 months	
									I here is sufficient evidence of	
			AMPSIMM vs prosthetic use						AMPSIMM with prosthetic use	
Norvell	2016	27496697	@ 12 months		P. spearman r	<0.001		v	at 12 months	
				1	,		1	-		
	1								There is sufficient evidence of	
									construct validity of the	
	1		AMPSIMM vs TAPES @ 4						AMPSIMM with TAPES at 4	
Norvell	2016	27496697	months		P, spearman r	0.003		У	months	
	1								These is sufficients in the	
	1								I nere is sufficient evidence of	
	1		AMPSIMM vs TAPES @ 12						AMPSIMM with TAPES at 12	
Norvell	2016	27496697	months		P spearman r	<0.001		v	months	
	2010			1	. , opeannunt	0.001	1	N N		1

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Norvell	2016	27496697	transmetatarsal (26), transtibial (59), transfemoral (28)	nd	63.5 +- 8.1	>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or peripheral arterial disease	27	AMPSIMM		Amputee Single Item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4 months, and 12 months post-amputation	Validity	Construct
Norvell	2016	27496697	transmetatarsal (26), transtibial (59), transfemoral (28)	nd	63.5 +- 8.1	>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or peripheral arterial disease	47	AMPSIMM		Amputee Single Item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4 months, and 12 months post-amputation	Validity	Construct
Norvell	2016	27496697	transmetatarsal (26), transtibial (59), transfemoral (28)	nd	63.5 +- 8.1	>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or peripheral arterial disease	113	AMPSIMM		Amputee Single Item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4 months, and 12 months post-amputation	Validity	Construct
Norvell	2016	27496697	transmetatarsal (26), transtibial (59), transfemoral (28)	nd	63.5 +- 8.1	>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or peripheral arterial disease	113	AMPSIMM		Amputee Single Item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4 months, and 12 months post-amputation	Validity	Criterion validity (concurrent)
Norvell	2016	27496697	transmetatarsal (26), transtibial (59), transfemoral (28)	nd	63.5 +- 8.1	>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or peripheral arterial disease	113	AMPSIMM		Amputee Single Item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4 months, and 12 months post-amputation	Validity	Criterion validity (concurrent)
Nopvell	2016	27406607	transmetatarsal (26), transtibial (59), transfemoral (28)	nd	635 + 91	>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or perioberal arterial disease	113			Amputee Single Item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4 months, and 12 months not amputation	Validity	Criterion validity (concurrent)
	2010	27430097	transmetatarsal (26), transtibial (59),		03.3 +- 0.1	>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or	113			Amputee Single Item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4	validity	
Norvell	2016	27496697	transfemoral (28)	nd	63.5 +- 8.1	peripheral arterial disease	113	AMPSIMM		months, and 12 months post-amputation	Validity	Criterion validity (predictive)
Norvell	2016	27496697	transmetatarsal (26), transtibial (59), transfemoral (28)	nd	63.5 +- 8.1	>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or peripheral arterial disease	113	AMPSIMM		Amputee Single Item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4 months, and 12 months post-amputation	Validity	Criterion validity (predictive)
Norvell	2016	27496697	transmetatarsal (26), transtibial (59), transfemoral (28)	nd	63.5 +- 8.1	>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or peripheral arterial disease	113	AMPSIMM		Amputee Single Item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4 months, and 12 months post-amputation	Validity	floor/ceiling
Norvell	2016	27496697	transmetatarsal (26), transtibial (59), transfemoral (28)	nd	63.5 +- 8.1	>=18, awaiting/underwent amp in last week, primary cause of amp diabetes or peripheral arterial disease	113	AMPSIMM		Amputee Single Item Mobility Measure is a single item measure with scores ranging from 0-6 and is concurrently administered with the LCI-5 other outcome measures at 6 weeks, 4 months, and 12 months post-amputation	Responsiven	
Panesar et al	2001		Transfemoral (n=17), transtibial (n=14), hindquarter (n=1), bilateral transtibial (n=1), bilateral transfemoral (n=1)	nd	67	nd	34	Amputee Activity Score	Total Overall		Validity	Convergent
Panesar et al	2001		Transfemoral (n=1) transtibial (n=14), hindquarter (n=1), bilateral transtibial (n=1), bilateral transfemoral (n=1)	nd	67	nd	34	Amputee Activity Score	Total Overall		Ability to measure	Responsiveness
Panesar et al.	2001		Transfemoral (n=17), transtibial (n=14), hindquarter (n=1), bilateral transtibial (n=1), bilateral transfemoral (n=1)	nd	67	nd	34	Amputee Activity Score (AAS)	Total Overall Scale		Ability to measure change	Responsiveness
							1	Amputee Mobility Predictor				
Gailey, Roach et. Al.	2002							(AMP) Amputee Mobility Predictor	AMPnoPRO		Reliability	i est-retest
Gailey, Roach et. Al.	2002							(AMP)	AMPnoPRO		Reliability	Inter-rater

Author	Vear	РМІЛ	Comparator/Criterion/Outc	Timepoint (predictive valid)	Metric Used	Value	Strength of	Is Aspect	Conclusion	Notes/Caveats
Negroli	2016	27406607	AMPSIMM vs Satisfaction		B encorroop r	-0.001		v	There is sufficient evidence of construct validity of the AMPSIMM with "satisfaction with mehility" of 4 months	
Norvell	2016	27496697	AMPSIMM vs Satisfaction w/ mobility @ 12 months		P, spearman r	<0.001		y v	There is sufficient evidence of construct validity of the AMPSIMM with "satisfaction with mobility" at 12 months	
Norvell	2016	27496697	known groups (metatarsal vs tibital vs femoral)		Mean scores	4.2. 3.2. 2.9		Yes		no actual p but authors present different means for each level of amoutation
									AMPSIMM is concurrently valid	6 weeks, total sample included
Norvell	2016	27496697	LCI-5		Spearman r	0.72	large	Yes	with LCI-5	transmetatarsal
Norvell	2016	27496697	LCI-5		Spearman r	0.81	large	Yes	AMPSIMM is concurrently valid with LCI-5	4 months, total sample included transmetatarsal
Norvell	2016	27496697	LCI-5		Spearman r	0.86	large	Yes	AMPSIMM is concurrently valid with LCI-5	12 months, total sample included transmetatarsal
			6 week AMPSIMM vs 12						6 week AMPSIMM scores are not predictive of 12 month LCI-5	
Norvell	2016	27496697	month LCI-5		Spearman r	0.07	<small< td=""><td>no (p = 0.56)</td><td>scores</td><td>total sample included transmetatarsal</td></small<>	no (p = 0.56)	scores	total sample included transmetatarsal
Norvell	2016	27496697	4 month AMPSIMM vs 12 month LCI-5		Spearman r	0.4	Moderate	yes (p = 0.004)	4 month AMPSIMM scores are moderately predictive of LCI-5 score at 12 months	
									I wo subjects (2.4%) achieved a minimum score and five (6.1%) achieved a maximum score at 12 months post-amputation, indicating neither a floor or	
Norvell	2016	27496697			nd	nd		No	ceiling.	
Norvell	2016	27496697			SRM	1	large	yes	The test is responsive	
										siarificant kondel escelations coefficiente
Panesar et al,	2001		OPCS, AAS, FIM		P value	<0.0001				between each of the measures
										simificant changes between admission and
Panesar et al,	2001		nd		P value	<0.00001				discharge
										significant changes between discharge and
Panesar et al,	2001		na		P value	<0.0001				
Galley, Roach et. Al.	2002									ICC 0.86-0.97
Gailey, Roach et. Al.	2002		1	1				1		ICC: 0.99

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Gailey Roach et Al	2002							Amputee Mobility Predictor	AMPnoPRO		Validity	Known group/Discriminant
Galley, Hodell Ct. 74.	2002							(/um/)			validity	renown group/Dischininant
								Amputee Mobility Predictor				Concurrent/convergent/criteri
Gailey, Roach et. Al.	2002							(AMP)	AMPnoPRO		Validity	a Validity criterion
Gailey Roach et Al	2002							Amputee Mobility Predictor	AMProPRO		Validity	Predictive
Galley, Roach et. Al.	2002										validity	Tredictive
								Amputee Mobility Predictor	Total Overall		Ability to	
Hafner	2007						17	(AMP)	Score		change	Responsiveness
Topuz	2011							Amputee Mobility Predictor (AMP)	Total Overall Score		Validity	Concurrent/convergent/criteri a Validity criterion
Topuz	2011							Amputee Mobility Predictor	with prothesis		Validity	
Gailey, Roach et. Al.	2002							(AMP) Amputee Mobility Predictor	(AMPPRO) with prothesis		Reliability	Test-retest
Gailey, Roach et. Al.	2002							(AMP)	(AMPPRO)		Reliability	Inter-rater
Gailey, Roach et, Al,	2002							Amputee Mobility Predictor (AMP)	with prothesis (AMPPRO)		Validity	Known group/Discriminant
								(*****)	(5.00p.2.00
								Amputee Mobility Predictor	with prothesis			Concurrent/convergent/criteri
Gailey, Roach et. Al.	2002							(AMP)	(AMPPRO)		Validity	a Validity criterion
Gailey, Roach et, Al,	2002							Amputee Mobility Predictor (AMP)	(AMPPRO)		Validity	Predictive
								Amputee Mobility Predictor	with prothesis		5	
Resnik and Borgia	2011			cardiovascular or				(AMP)	(AMPPRO)		Reliability	l est-retest
				diabetic								
				complications (n=29), trauma								
Millen et el	0000		Transfemoral (n=21),	(n=13), infection	00 A	l le lle te cel	50	40-1	Total Overall		N / - 11 -124	Concurrent/convergent
Miller et al	2006		Transubiai (n=37)	Amputation for	00.4	Onnateral	00	AQUL	Score		validity	citteriori
				vascular disease								
				moderate					Total Overall			
Brunelli	2006	16813789	Unilateral transfemoral	hemiparesis	69	nd	45	Barthel Index	Score		Validity	Known group/Discriminant
				vascular disease								
				and mild or					Total Ovarall			
Brunelli	2006	16813789	Unilateral transfemoral	hemiparesis	69	nd	45	Barthel Index	Score		Validity	Known group/Discriminant
			Transfemoral (26%)		67 (nd for		938 (n=546 for Barthel		Total Overall			
Treweek	1998		transtibial (74%)	nd	Barthel Index)	nd	Index)	Barthel Index	Score		Validity	Known group
				Amputation for								
				and mild or								
Brunelli	2006	16813789	I Inilateral transfemoral	moderate	69		45	Barthel Index			Validity	Known group/Discriminant
Brancin	2000	10010100		Amputation for	00		40	Bartier index			validity	renown group/Discriminant
				vascular disease								
				moderate								
Brunelli	2006	16813789	Unilateral transfemoral Transfemoral (n=17)	hemiparesis	69		45	Barthel Index			Validity	Known group/Discriminant
			Transtibial (n=23),									
			transgenual (n=5), hip disarticulation (n=1).	PAD (n=45), astreomyelitis (n=1).								
	001-		minor amputation	tumour (n=1),								
ЕІЈК	2012	21958418	(n=2)	trauma (n=1)	/5.2		48 938 (n=546	Barthel index			Validity	Predictive
- .			Transfemoral (26%),		67 (nd for		for Barthel					
Ireweek	1998	-	transtibial (74%)	na	Barthel Index)		Index)	Barthel Index			validity	Known group
			TT (= 00) TE (10 × 10	The BBS was used to measure physical		
			BTT (n=22), TF (n=13), BTT (n=2), BTT/BFT	vascular (28),					item 10: look behind/over	dynamic balance in 14 tasks, each scored	1	
Wong	2016	26390393	(n=2), BFT/BTT (n=1)	nonvascular (12)	57.0 +- 11.9	nd	40	BBS	shoulder	from 0 to 4 with the total score reported	Validity	predictive

			0	Timepoint			0			
Author	Voor	DMID	Comparator/Criterion/Outc	(predictive	Motrie Lload	Value	Strength of	IS ASpect	Conclusion	Notoo/Coverto
Aution	rear		one	valiuj	wethe osed	value	Froperty	Supporteur	Conclusion	differentiated between MECL Medicare
Gailey, Roach et. Al.	2002									comon procedure coding system groups
										Pearsons: Age=-0.56, Time since
										Amputation=0.26, Comorb=-0.38, 6 min
Gailey Roach et Al	2002									0 21
Galley, Hodon et. 74.	2002									significantly predicts 6 minute walk test in
Gailey, Roach et. Al.	2002									regression model.
			Mechanical control							
			prostnetic knee versus							no significant differences between control
Hafner	2007		prosthetic knee							technology
Topuz	2011									Spearmans: TAPES Activity=-0.30
Gailey, Roach et, Al.	2002									ICC 0.96-0.98
ounoy, riodon ot 7 ti	2002									
Gailey, Roach et. Al.	2002									ICC: 0.99
Cailoy Baash at Al	2002									differentiated between MFCL Medicare
Galley, Rudoll et. Al.	2002									Pearsons: Age=-0.69. Time since
										Amputation=0.29, Comorb=-0.43, 6 min
										walk=0.69, AAS=0.67, pack years smoked=-
Gailey, Roach et. Al.	2002									0.25
Gailey Roach et Al	2002									regression model
ounoy, riodon ot 7 ti	2002									
Resnik and Borgia	2011									ICC=0.88
										Overall scores were associated with a mini-
										nutritional assessment (which included
										questions on well-being), findings from
Miller et al	2008									multiple linear regression
			Laterality of impairment:							
Brunelli	2006	16813789	Ipsilateral vs Contralateral		P value	<0.001				
			Cause of amputation:							
Brunelli	2006	16813789	Atherosclerosis vs Diabetes		P value	>0.05				did nat disaringinata nationta (mann
										Whittney test) by amputation level
Treweek	1998									(transtibial and transfemoral)
			Laterality of impairment:							
Brunelli	2006	16813789	Ipsilateral vs Contralateral		P value	<0.001				
			Cause of amputation:							
Brunelli	2006	16813789	Atherosclerosis vs Diabetes		P value	>0.05				
										significantly correlated with Barthel index
Eijk	2012	21958418	Successful rehabilitation	12 months	P value	<0.001				(Mannwhitney U); beta = .53
										Whittney test) by amputation level
Treweek	1998									(transtibial and transfemoral)
			predict community							
Wong	2016	26390393	ambulation		AUC	0.875		у		

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Wong	2016	26390393	TT (n=22), TF (n=13), BTT (n=2), BTT/BFT (n=2), BFT/BTT (n=1)	vascular (28), nonvascular (12)	57.0 +- 11.9		40	BBS	item 10: look behind/over shoulder		Validity	predictive
Wong	2016	26390393	TT (n=22), TF (n=13), BTT (n=2), BTT/BFT (n=2), BFT/BTT (n=1)	vascular (28), nonvascular (12)	57.0 +- 11.9	nd	40	BBS	item 9: retrieve object from floor	The BBS was used to measure physical balance ability. The BBS challenges static and dynamic balance in 14 tasks, each scored from 0 to 4 with the total score reported	Validity	predictive
Wong	2016	26390393	TT (n=22), TF (n=13), BTT (n=2), BTT/BFT (n=2), BET/BTT (n=1)	vascular (28),	57 0 +- 11 9		40	BBS	item 9: retrieve object from floor		Validity	nredictive
Gremeaux	2012	22389424	Transfemoral (n=17, transtibal (n=47)	Vascular (n=42), trauma (n=16), cancer (n=2), other (n=1)	58	unilateral	64	BBS		The Berg Balance Scale (BBS) is a well- established clinical outcome measure originally designed to assess the balance of elderly individuals	Validity	Convergent
Major	2013	23856150	Unilateral transtibial (n=13), unilateral transfemoral (n=14), or bilateral (n=3)	Dysvascular (n=7), traumatic (n=14), infectious (n=6), congenital (n=3)	54	Used a prosthesis for ambulation with or without an additional mobility aid; did not have an upper-extremity amputation; had a residual limb in good condition	30	BBS		The Berg Balance Scale (BBS) is a well- established clinical outcome measure originally designed to assess the balance of elderly individuals	Floor/ceiling effect	Ceiling
Major	2013	23856150	Unilateral transtibial (n=13), unilateral transfemoral (n=14), or bilateral (n=3)	Dysvascular (n=7), traumatic (n=14), infectious (n=6), congenital (n=3)	54	Used a prosthesis for ambulation with or without an additional mobility aid; did not have an upper-extremity amputation; had a residual limb in good condition	30	BBS		The Berg Balance Scale (BBS) is a well- established clinical outcome measure originally designed to assess the balance of elderly individuals	Validity	Construct
Major	2013	23856150	Unilateral transtibial (n=13), unilateral transfemoral (n=14), or bilateral (n=3)	Dysvascular (n=7), traumatic (n=14), infectious (n=6), congenital (n=3)	54	Used a prosthesis for ambulation with or without an additional mobility aid; did not have an upper-extremity amputation; had a residual limb in good condition	30	BBS		The Berg Balance Scale (BBS) is a well- established clinical outcome measure originally designed to assess the balance of elderly individuals	Validity	Construct
Major	2013	23856150	Unilateral transtibial (n=13), unilateral transfemoral (n=14), or bilateral (n=3)	Dysvascular (n=7), traumatic (n=14), infectious (n=6), congenital (n=3)	54	Used a prosthesis for ambulation with or without an additional mobility aid; did not have an upper-extremity amputation; had a residual limb in good condition	30	BBS		The Berg Balance Scale (BBS) is a well- established clinical outcome measure originally designed to assess the balance of elderly individuals	Validity	Convergent
Major	2013	23856150	Unilateral transtibial (n=13), unilateral transfemoral (n=14), or bilateral (n=3)	Dysvascular (n=7), traumatic (n=14), infectious (n=6), congenital (n=3)	54	Used a prosthesis for ambulation with or without an additional mobility aid; did not have an upper-extremity amputation; had a residual limb in good condition	30	BBS		The Berg Balance Scale (BBS) is a well- established clinical outcome measure originally designed to assess the balance of elderly individuals	Validity	Convergent
Major	2013	23856150	Unilateral transtibial (n=13), unilateral transfemoral (n=14), or bilateral (n=3)	Dysvascular (n=7), traumatic (n=14), infectious (n=6), congenital (n=3)	54	Used a prosthesis for ambulation with or without an additional mobility aid; did not have an upper-extremity amputation; had a residual limb in good condition	30	BBS		The Berg Balance Scale (BBS) is a well- established clinical outcome measure originally designed to assess the balance of elderly individuals	Validity	Convergent
Major	2013	23856150	Unilateral transtibial (n=13), unilateral transfemoral (n=14), or bilateral (n=3)	Dysvascular (n=7), traumatic (n=14), infectious (n=6), congenital (n=3)	54	Used a prosthesis for ambulation with or without an additional mobility aid; did not have an upper-extremity amputation; had a residual limb in good condition	30	BBS		The Berg Balance Scale (BBS) is a well- established clinical outcome measure originally designed to assess the balance of elderly individuals	Validity	Convergent

			Comparator/Criterion/Outc	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Wong	2016	26390393	predict failure to reach community ambulation	12 months	AUC	0.875		y	cut off score <=3	The BBS was used to measure physical balance ability. The BBS challenges static and dynamic balance in 14 tasks, each scored from 0 to 4 with the total score reported
-										
Wong	2016	26390393	predict community ambulation		AUC	0.771		у		
			predict failure to reach							The BBS was used to measure physical balance ability. The BBS challenges static and dynamic balance in 14 tasks, each scored from 0 to 4 with the total score
Wong	2016	26390393	community ambulation	12 months	AUC	0.771		у	cut off score <=3	reported
Gremeaux	2012	22389424	nd			AUC	0.88			
Majar	2012	22856150	~		0/	10		Na	The BBS demonstrated monotonic relationships with the other outcome measures that assess constructs related to balance and mobility, providing evidence that the BBS does assess balance in persons with	
wajor	2013	23656150			70	10		INU	LLA	
Major	2013	23856150	Transfemoral vs transtibial		Р	0.325		No	The BBS was also unable to discriminate between groups on the basis of amputation etiology and level	Mann-Whitney U p-value
Major	2013	23856150	Dysvascular vs other		P	0.061		No	The BBS was also unable to discriminate between groups on the basis of amputation etiology and level	Mann-Whitney I I n-value
Major	2013	23856150	ABC Scale		Spearman r	0.634	Large	Yes	The BBS demonstrated monotonic relationships with the other outcome measures that assess constructs related to balance and mobility, providing evidence that the BBS does assess balance in persons with LLA	
Major	2013	23856150	PEQ-MS		Spearman r	0.584	Large	Yes	The BBS demonstrated monotonic relationships with the other outcome measures that assess constructs related to balance and mobility, providing evidence that the BBS does assess balance in persons with LLA	
Major	2013	23856150	FAI		Spearman r	0.607	Large	Yes	The BBS demonstrated monotonic relationships with the other outcome measures that assess constructs related to balance and mobility, providing evidence that the BBS does assess balance in persons with LLA	
Major	2013	23856150	2MWT		Spearman r	0.675	Large	Yes	The BBS demonstrated monotonic relationships with the other outcome measures that assess constructs related to balance and mobility, providing evidence that the BBS does assess balance in persons with LLA	

Author	Voor	PMID	Amputation Loval	Amputation	A	Other Population	N	Instrument	Subseele	Description	Broporty	Aspect
Aution	i eai		Amputation Level	Lilology	Age	mormation	N	instrument	Subscale	Description	rioperty	Азресс
Major	2013	23856150	Unilateral transtibial (n=13), unilateral transfemoral (n=14), or bilateral (n=3)	Dysvascular (n=7), traumatic (n=14), infectious (n=6), congenital (n=3)	54	Used a prosthesis for ambulation with or without an additional mobility aid; did not have an upper-extremity amputation; had a residual limb in good condition	30	BBS		The Berg Balance Scale (BBS) is a well- established clinical outcome measure originally designed to assess the balance of elderly individuals	Validity	Convergent
			Unilateral transtibial (n=13), unilateral transfemoral (n=14),	Dysvascular (n=7), traumatic (n=14), infectious (n=6),		Used a prosthesis for ambulation with or without an additional mobility aid; did not have an upper-extremity amputation; had a residual				The Berg Balance Scale (BBS) is a well- established clinical outcome measure originally designed to assess the balance of	Floor/ceiling	
Major	2013	23856150	or bilateral (n=3)	congenital (n=3)	54	limb in good condition	30	BBS		elderly individuals	effect	Floor
Maior	2013	23856150	Unilateral transtibial (n=13), unilateral transfemoral (n=14), or bilateral (n=3)	Dysvascular (n=7), traumatic (n=14), infectious (n=6), congenital (n=3)	54	ambulation with or without an additional mobility aid; did not have an upper-extremity amputation; had a residual limb in good condition	30	BBS		The Berg Balance Scale (BBS) is a well- established clinical outcome measure originally designed to assess the balance of elderly individuals	Validity	Internal Consistency
Main	2012	22056150	Unilateral transtibial (n=13), unilateral transfemoral (n=14),	Dysvascular (n=7), traumatic (n=14), infectious (n=6),	54	Used a prosthesis for ambulation with or without an additional mobility aid; did not have an upper-extremity amputation; had a residual	20	DDC		The Berg Balance Scale (BBS) is a well- established clinical outcome measure originally designed to assess the balance of	Deliability	laterater
мајог	2013	23650150	or bilateral (n=3)	congenital (n=3)	54	limb in good condition	30	BBS			Reliability	Interrater
Walker et al,	2009		Syme or Boyd amputation	fibular deficiency	32.5	nd	36	Beck Depression Inventory	nd		Validity	Known group
Walker	2009		Syme or Boyd amputation	fibular deficiency	32.5		36	Beck Depression Inventory	-		Validity	Known group
Major	2013	23856150	Unilateral transtibial (n=13), unilateral transfemoral (n=14), or bilateral (n=3)	Dysvascular (n=7), traumatic (n=14), infectious (n=6), concential (n=3)	54	Used a prosthesis for ambulation with or without an additional mobility aid; did not have an upper-extremity amputation; had a residual limb in good condition	30	Rem Ralance Scale	nd	The Berg Balance Scale (BBS) is a well- established clinical outcome measure originally designed to assess the balance of elderty individuals	Validity	Convergent
Major	2010	20000100	or bilaterar (II-0)	congenitar (n=o)	54	Into in good condition	00	Derg Dalance Ocale	na		validity	Convergent
Major	2013	23856150	Unilateral transtibial (n=13), unilateral transfemoral (n=14), or bilateral (n=3)	Dysvascular (n=7), traumatic (n=14), infectious (n=6), congenital (n=3)	54	Used a prosthesis for ambulation with or without an additional mobility aid; did not have an upper-extremity amputation; had a residual limb in good condition	30	Berg Balance Scale	nd	The Berg Balance Scale (BBS) is a well- established clinical outcome measure originally designed to assess the balance of elderly individuals	Validity	Convergent
Major	2013	23856150	Unilateral transtibial (n=13), unilateral transfemoral (n=14), or bilateral (n=3)	Dysvascular (n=7), traumatic (n=14), infectious (n=6), congenital (n=3)	54	Used a prosthesis for ambulation with or without an additional mobility aid; did not have an upper-extremity amputation; had a residual limb in good condition	30	Berg Balance Scale	nd	The Berg Balance Scale (BBS) is a well- established clinical outcome measure originally designed to assess the balance of elderly individuals	Validity	Convergent
Major	2013	23856150	Unilateral transtibial (n=13), unilateral transfemoral (n=14), or bilateral (n=3)	Dysvascular (n=7), traumatic (n=14), infectious (n=6), congenital (n=3)	54	Used a prosthesis for ambulation with or without an additional mobility aid; did not have an upper-extremity amputation; had a residual limb in good condition	30	Berg Balance Scale	nd	The Berg Balance Scale (BBS) is a well- established clinical outcome measure originally designed to assess the balance of elderly individuals	Validity	Convergent

			Comparator/Critorion/Outo	Timepoint			Strongth of	la Acnost				
Author	Year	PMID	comparator/Criterion/Outc	(predictive valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats		
Major	2013	23856150	L Test		Spearman r	-0.802	Large	Yes	The BBS demonstrated monotonic relationships with the other outcome measures that assess constructs related to balance and mobility, providing evidence that the BBS does assess balance in persons with LLA			
Major	2013	23856150	nd		%	0		No	The BBS demonstrated monotonic relationships with the other outcome measures that assess constructs related to balance and mobility, providing evidence that the BBS does assess balance in persons with LLA			
Major	2013	23856150	nd		Cronbach's alpha	0.827		Yes	The BBS appears to be a valid and reliable clinical instrument for assessing balance in individuals with lower-limb amputation			
Major	2013	23856150	nd		ICC	0.945		Yes	The BBS appears to be a valid and reliable clinical instrument for assessing balance in individuals with lower-limb amputation			
Walker et al,	2009		amputees vs lengthening for fibular deficiency			p[rovided in the appendinx (not retreived)				no significant difference between the amputees and the patients treated with lengthening.		
Walker	2009		amputees vs lengthening for fibular deficiency			provided in the appendinx (not retreived)				no significant difference between the amputees and the patients treated with lengthening.		
Major	2013	23856150	ABC Scale		Spearman r	0.634	Large	Yes	The BBS demonstrated monotonic relationships with the other outcome measures that assess constructs related to balance and mobility, providing evidence that the BBS does assess balance in persons with LLA			
Major	2013	23856150	PEQ-MS		Spearman r	0.584	Large	Yes	The BBS demonstrated monotonic relationships with the other outcome measures that assess constructs related to balance and mobility, providing evidence that the BBS does assess balance in persons with LA			
Major	2013	23856150	FAI		Spearman r	0.607	Large	Yes	The BBS demonstrated monotonic relationships with the other outcome measures that assess constructs related to balance and mobility, providing evidence that the BBS does assess balance in persons with LLA			
Major	2013	23856150	2MWT		Spearman r	0.675	Large	Yes	The BBS demonstrated monotonic relationships with the other outcome measures that assess constructs related to balance and mobility, providing evidence that the BBS does assess balance in persons with LLA			
				Amputation		Other Population						
--------------	-----------------	----------	--	--	------	---	-----	--------------------------	------------------------------	--	---------------------------------	----------------------
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Major	2013	23856150	Unilateral transtibial (n=13), unilateral transfemoral (n=14), or bilateral (n=3)	Dysvascular (n=7), traumatic (n=14), infectious (n=6), congenital (n=3)	54	Used a prosthesis for ambulation with or without an additional mobility aid; did not have an upper-extremity amputation; had a residual limb in good condition	30	Berg Balance Scale	nd	The Berg Balance Scale (BBS) is a well- established clinical outcome measure originally designed to assess the balance of elderly individuals	Validity	Convergent
Major	2013	23856150	Unilateral transtibial (n=13), unilateral transfemoral (n=14), or bilateral (n=3)	Dysvascular (n=7), traumatic (n=14), infectious (n=6), congenital (n=3)	54	Used a prosthesis for ambulation with or without an additional mobility aid; did not have an upper-extremity amputation; had a residual limb in good condition	30	Berg Balance Scale	nd	The Berg Balance Scale (BBS) is a well- established clinical outcome measure originally designed to assess the balance of elderly individuals	Floor/ceiling effect	Floor
Major	2013	23856150	Unilateral transtibial (n=13), unilateral transfemoral (n=14), or bilateral (n=3)	Dysvascular (n=7), traumatic (n=14), infectious (n=6), congenital (n=3)	54	Used a prosthesis for ambulation with or without an additional mobility aid; did not have an upper-extremity amputation; had a residual limb in good condition	30	Berg Balance Scale	nd	The Berg Balance Scale (BBS) is a well- established clinical outcome measure originally designed to assess the balance of elderly individuals	Floor/ceiling effect	Ceiling
Major	2013	23856150	Unilateral transtibial (n=13), unilateral transfemoral (n=14), or bilateral (n=3)	Dysvascular (n=7), traumatic (n=14), infectious (n=6), congenital (n=3)	54	Used a prosthesis for ambulation with or without an additional mobility aid; did not have an upper-extremity amputation; had a residual limb in good condition	30	Berg Balance Scale	nd	The Berg Balance Scale (BBS) is a well- established clinical outcome measure originally designed to assess the balance of elderly individuals	Validity	Construct
Major	2013	23856150	Unilateral transtibial (n=13), unilateral transfemoral (n=14), or bilateral (n=3)	Dysvascular (n=7), traumatic (n=14), infectious (n=6), congenital (n=3)	54	Used a prosthesis for ambulation with or without an additional mobility aid; did not have an upper-extremity amputation; had a residual limb in good condition	30	Berg Balance Scale	nd	The Berg Balance Scale (BBS) is a well- established clinical outcome measure originally designed to assess the balance of elderly individuals	Validity	Construct
Maior	2013	23856150	Unilateral transtibial (n=13), unilateral transfemoral (n=14), or bilateral (n=3)	Dysvascular (n=7), traumatic (n=14), infectious (n=6), congenital (n=3)	54	Used a prosthesis for ambulation with or without an additional mobility aid; did not have an upper-extremity amputation; had a residual limb in good condition	30	Berg Balance Scale	nd	The Berg Balance Scale (BBS) is a well- established clinical outcome measure originally designed to assess the balance of elderiv individuals	Reliability	Interrater
Mojor	2013	22956150	Unilateral transtibial (n=13), unilateral transfemoral (n=14), or bilateral (n=2)	Dysvascular (n=7), traumatic (n=14), infectious (n=6), congonital (n=2)	54	Used a prosthesis for ambulation with or without an additional mobility aid; did not have an upper-extremity amputation; had a residual limb in good condition	20	Para Palanas Sacia	nd	The Berg Balance Scale (BBS) is a well- established clinical outcome measure originally designed to assess the balance of elderby individual.	Volidity	
Berry	2009	23030130	Unilateral transfemoral		54.7	K3	368	Berry 50-question survey	Gait/ maneuverabili ty	Ability to measure change	Responsiven	internal consistency
Berry	2009		Unilateral transfemoral	in article	54.7	кз	368	Berry 50-question survey	Gait/ maneuverabili ty		Reliability	Test-retest
Berry, Olson	and Larntz 2009	0	Unilateral transfemoral	nd	54.7	кз	368	Berry 50-question survey	gait/ manuverabilit y		Reliability	Test-retest
Berry, Olson	and Larntz 2009	0	Unilateral transfemoral	nd	54.7	кз	368	Berry 50-question survey	gait/ manuverabilit y		Ability to measure change	Responsiveness
Hanspal	1997	9331580	Transfemoral (n=17), Transtibial (n=15)	nd	66.4		32	CAPE			Validity	Predictive
Hanspal	1997	9331580	Transtemoral (n=17), Transtibial (n=15)	nd	66.4		32	CAS			Validity	Predictive

			Comparator/Criterion/Outc	Imepoint			Strength of	ls Asnect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Major	2012	22956150	L Toot		Sacarman	0.802		Vee	The BBS demonstrated monotonic relationships with the other outcome measures that assess constructs related to balance and mobility, providing evidence that the BBS does assess balance in persons with	
	2013	23050150			Speaman	-0.002	Laige		The BBS demonstrated monotonic relationships with the other outcome measures that assess constructs related to balance and mobility, providing evidence that the BBS does assess balance in persons with	
Major	2013	23856150	nd		%	10		No	LLA The BBS demonstrated monotonic relationships with the other outcome measures that assess constructs related to balance and mobility, providing evidence that the BBS does assess balance in persons with LLA	
Major	2013	23856150	Transfemoral vs transtibial		P	0.325		No	The BBS was also unable to discriminate between groups on the basis of amputation etiology and level	Mann-Whitney U p-value
Major	2013	23856150	Dysvascular vs other		Р	0.061		No	The BBS was also unable to discriminate between groups on the basis of amputation etiology and level	Mann-Whitney U p-value
Major	2013	23856150	nd		ICC	0.945		Yes	The BBS appears to be a valid and reliable clinical instrument for assessing balance in individuals with lower-limb amputation	
Maior	2013	23856150	nd		Cronbach's alpha	0.827		Yes	The BBS appears to be a valid and reliable clinical instrument for assessing balance in individuals with lower-limb amputation	
Berry	2009								significantly better scores with C Leg then past nonmicroprocessor controlled device	
Berry	2009									94% of questions were answered with identical scores on both surveys, and 6% or questions had a 1 point difference in response (scale of 1–5)
Berry, Olson and Larntz	2009	0								94% of questions were answered with identical scores on both surveys, and 6% of questions had a 1 point difference in response (scale of 1–5)
Berry, Olson and Larntz	2009	0	Clifton Assessment	0.44		D				significantly better scores with C-Leg then past nonmicroprocessor controlled device Clifton Assessment Procedures for the
Hanspal	1997	9331580	Procedures for the Elderly	8-14 months		Pearson r	0.93	Large		Elderiy
Hanspal	1997	9331580	Grade of mobility	8-14 months	Pearson r	0.81	Large			

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
de Laat	2010		Transfemoral (n=55), Transtibial (n=93), Hip disarticulation (n=3), Knee disarticulation (n=8), Syme (n=1), Transtibial (n=2), Transtibial and transtibial (n=2), Syme and transtibial (n=3)	Vascular (n=143), Infection (n=13), Traumatic (n=13), Oncologic (n=3)	65	18 years or older; they were wearing a prosthesis at the end of their rehabilitation treatment after a recent lower limb amputation; and they were able to understand and fill in the questionnaires	172	Climbing Stairs Questionnaire			Reliability	Test-retest
de Laat	2010		Transfemoral (n=55), Transtibial (n=93), Hip disarticulation (n=3), Knee disarticulation (n=8), Syme (n=1), Transtemoral and transtibial (n=2), Transtibial and transtibial (n=7), Syme and transtibial (n=3)	Vascular (n=143), Infection (n=13), Traumatic (n=13), Oncologic (n=3)	65	18 years or older; they were wearing a prosthesis at the end of their rehabilitation treatment after a recent lower limb amputation; and they were able to understand and fill in the questionnaires	172	Climbing Stairs Questionnaire			Validity	Convergent
de Laat	2010		Transfemoral (n=55), Transtibial (n=93), Hip disarticulation (n=3), Knee disarticulation (n=8), Syme (n=1), Transtibial (n=2), Transtibial (n=2), Transtibial and transtibial (n=7), Syme and transtibial (n=3)	Vascular (n=143), Infection (n=13), Traumatic (n=13), Oncologic (n=3)	65	18 years or older; they were wearing a prosthesis at the end of their rehabilitation treatment after a recent lower limb amputation; and they were able to understand and fill in the questionnaires	172	Climbing Stairs Questionnaire			Validity	Convergent
de Laat	2010		Transfemoral (n=55), Transtibial (n=93), Hip disarticulation (n=3), Knee disarticulation (n=8), Syme (n=1), Transtemoral and transtibial (n=2), Transtibial and transtibial (n=7), Syme and transtibial (n=7), Syme	Vascular (n=143), Infection (n=13), Traumatic (n=13), Oncologic (n=3)	65	18 years or older; they were wearing a prosthesis at the end of their rehabilitation treatment after a recent lower limb amputation; and they were able to understand and fill in the questionnaires	172	Climbing Stairs Questionnaire			Validity	Convergent
de Laat	2010		Transfemoral (n=55), Transtibial (n=93), Hip disarticulation (n=3), Knee disarticulation (n=8), Syme (n=1), Transfemoral and transtibial (n=2), Transtibial and transtibial (n=7), Syme and transtibial (n=3)	Vascular (n=143), Infection (n=13), Traumatic (n=13), Oncologic (n=3)	65	18 years or older; they were wearing a prosthesis at the end of their rehabilitation treatment after a recent lower limb amputation; and they were able to understand and fill in the questionnaires	172	Climbing Stairs Questionnaire			Validity	Known group
de Laat	2010		Transfemoral (n=55), Transtibial (n=93), Hip disarticulation (n=3), Knee disarticulation (n=8), Syme (n=1), Transfemoral and transtibial (n=2), Transtibial and transtibial (n=7), Syme and transtibial (n=7),	Vascular (n=143), Infection (n=13), Traumatic (n=13), Oncologic (n=3)	65	18 years or older; they were wearing a prosthesis at the end of their rehabilitation treatment after a recent lower limb amputation; and they were able to understand and fill in the questionnaires	172	Climbing Stairs Questionnaire			Validity	Known group

			Comparator/Criterion/Outc	Timepoint			Strength of	ls Asnect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
de Laat	2010				nd	ICC	0.79			data from 33 participants
					Locomotor					
de l aat	2010				Capabilities	Spearman r	0.52			
	2010				Index (LCI-4)	Opeannann	0.52			
					The Rising and					
					Sitting down					
de Laat	2010				Questionnaire	Spearman r	0.52			
					The Walking					
de Laat	2010				Questionnaire	Spearman r	0.42			
						Mann-				
de l aat	2010				Vascular vs Nonvascular	vvnitney U P	0.6			
	2010				Nonvascular	value	0.0			
				1			1			
		1								
				1			1			
				1			1			
				1			1			
		1								
		1				Mann-				
				1	Bilateral vs	Whitney U P	1			
de Laat	2010				Unilateral	value	0.09			

Ander No					Amputation		Other Population						
An Local Local Loc	Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
data 210 and branche (m) Disclop (m) S Nith in genetionates 1/2 Outering Constraint Value Process group is late 2010 Transball (m), T				Transfemoral (n=55), Transtibial (n=93), Hip disarticulation (n=3), Knee disarticulation (n=8), Syme (n=1), Transfemoral and transtibial (n=2), Transtibial and transtibial (n=7), Syme	Vascular (n=143), Infection (n=13), Traumatic (n=13),		18 years or older; they were wearing a prosthesis at the end of their rehabilitation treatment after a recent lower limb amputation; and they were able to understand and		Climbing Stairs				
bit Lat Difference of the section of the sectin of the section of the sectin of the section of the se	de Laat	2010		and transtibial (n=3)	Oncologic (n=3)	65	fill in the questionnaires	172	Questionnaire			Validity	Known group
Construction Difference of the economic of the economi	de l aat	2011		Transfemoral (n=54), Transtibial (n=93), Hip disarticulation (n=3), Knee disarticulation (n=8), Syme (n=1), Transfemoral and transtibial (n=2), Transtibial and transtibial (n=7), Syme and transtibial (n=7), Syme	Vascular (n=142), Infection (n=13), Traumatic (n=13), Opcologic (n=3)	65	18 years or older; they were wearing a prosthesis at the end of their rehabilitation treatment after a recent lower limb amputation; and they were able to understand and fill in the ouvestionnaires	171	Climbing Stairs			Validity	Convergent
branch Transformation (1958), the transformat		2011			Checklogic (n=0)	00		17.1	Questionnaire			validity	Convergent
de Lat 2012 and framitation (ms) Occologie (ms) 86 fill in the questionnaires (T2 Outestionnaire (mail mathematication) Convergent Valid Ho gentionnaires Toruna (ms) Toruna (ms) Fill (ms)				Transfemoral (n=55), Transtibial (n=93), Hip disarticulation (n=3), Knee disarticulation (n=8), Syme (n=1), Transfemoral and transtibial (n=2), Transtibial and transtibial (n=7), Syme	Vascular (n=143), Infection (n=13), Traumatic (n=13),		18 years or older; they were wearing a prosthesis at the end of their rehabilitation treatment after a recent lower limb amputation; and they were able to understand and		Climbing Stairs				
Yari 2008 Import Results of the state of the sta	de Laat	2012		and transtibial (n=3)	Oncologic (n=3)	65	fill in the questionnaires	172	Questionnaire			Validity	Convergent
Amputes and non- amputes grouped Amputes and non- integration Amputes and non- amputes grouped Community integration Home integration Reliability Internal consistency Hirsh, et al 2011 Amputes and non- amputes grouped Amputes and non- amputes grouped Community integration Home integration Home integration Yalidity Structural Hirsh, et al 2011 Amputes and non- amputes grouped Community integration Home integration Home integration Home integration Yalidity Known group Hirsh, et al 2011 Amputes and non- amputes grouped Community integration integration Home integration Home integration Home integration Yalidity Known group Hirsh, et al 2011 Amputes and non- amputes grouped Community integration itegration Home integration Home integra	Yari	2008		(n=31, hemipelvectomy (n=15)	Vascular (n=6), Trauma (n=2), Other (n=2)	55.8		46	Climbing Stairs Questionnaire			Validity	Known group
Hirsh, et al 2011 Amputes and non- angutes grouped Amputes and non- angutes grouped Suctural Hirsh, et al 2011 Amputes and non- angutes grouped Community Integration Departures grouped Hone Departures grouped Hone Depar	Hirsh, et al	2011		Amputess and non- amputees grouped together					Community Integration Questionnaire	Home Integration		Reliability	Internal consistency
Hirsh. et al 2011 Anputess and non- amputes grouped logether. Anputess and non- amputes grouped logether. Anputess and non- amputes grouped Anputess and non- amputes grouped Anputess and non- logether. Anputess and non- amputes grouped Anputess and non- logether. Anputess and non- amputes grouped Anpu	Hirsh, et al	2011		Amputess and non- amputees grouped together					Community Integration Questionnaire	Home Integration		Validity	Structural
Hirsh, et al 2011 Amputess and non- amputes grouped amputes grouped together Amputess and non- amputes grouped amputes grouped Amputess and non- amputes grouped Reliability Internal consistency Hirsh, et al 2011 together Community integration Amputes grouped Productivity Productivity Reliability Internal consistency Hirsh, et al 2011 together Community integration Amputes grouped Productivity Productivity Reliability Structural Hirsh, et al 2011 together Community integration amputes grouped Productivity Productivity Validity Known group Hirsh, et al 2011 Amputess and non- amputes grouped Community integration amputes grouped Community integration Questionnaire Productivity Validity Concurrent/convergent criterion Hirsh, et al 2011 together Community integration amputes grouped Community integration amputes grouped Scial Community integration integration Scial Reliability Internal consistency Hirsh, et al 2011 <	Hirsh, et al	2011		Amputess and non- amputees grouped together					Community Integration Questionnaire	Home Integration		Validity	Known group
Hirsh, et al Amputess and non- amputess grouped together Amputess and non- amputess grouped Amputess and non- amputess grouped Amputess and non- amputess grouped Reliability Internal consistency Hirsh, et al 2011 Amputess and non- amputess grouped Community Integration Questionnaire Productivity Validity Structural Hirsh, et al 2011 Amputess and non- amputess grouped Community Integration Questionnaire Productivity Validity Known group Hirsh, et al 2011 Community Integration amputess grouped Community Integration Questionnaire Productivity Validity Known group Hirsh, et al 2011 Amputess and non- amputess grouped Community Integration Questionnaire Productivity Validity Concurrent/convergent criterion Hirsh, et al 2011 together Community Integration questionnaire Social integration Reliability Internal consistency Hirsh, et al 2011 Amputess and non- amputes grouped Community Integration questionnaire Social integration Reliability Internal consistency Hirsh, et al 2011 Maputess and non- amputes grouped Community Integration questionnaire Social integration	Hirsh, et al	2011		Amputess and non- amputees grouped together					Community Integration Questionnaire	Home Integration		Validity	Concurrent/convergent criterion
Hirsh, et al 2011 Amputess and non- amputese grouped Amputess and non- amputese grouped Community Integration Questionnaire Productivity Validity Structural Hirsh, et al 2011 Amputess and non- amputes grouped Amputess and non- amputes grouped Community Integration Questionnaire Productivity Validity Known group Hirsh, et al 2011 Amputess and non- amputes grouped Community Integration Questionnaire Productivity Validity Known group Hirsh, et al 2011 Amputess and non- amputes grouped Community Integration Questionnaire Community Integration Questionnaire Productivity Validity Known group Hirsh, et al 2011 Amputess and non- amputes grouped Community Integration Questionnaire Social Integration Reliability Internal consistency Hirsh, et al 2011 together Community Integration amputes grouped Community Integration Questionnaire Social Integration Validity Structural Hirsh, et al 2011 together Community Integration amputes grouped Social Integration Validity Structural Hirsh, et al 2011 together	Hirsh, et al	2011		Amputess and non- amputees grouped together					Community Integration Questionnaire	Productivity		Reliability	Internal consistency
Hirsh, et al 2011 Amputess and non- amputees grouped together Amputess and non- amputees grouped together Image: Community Integration Questionnaire Productivity Productivity Validity Known group Hirsh, et al 2011 Amputess and non- amputees grouped together Community Integration Questionnaire Productivity Productivity Validity Concurrent/convergent criterion Hirsh, et al 2011 Amputess and non- amputees grouped together Community Integration Questionnaire Social integration Reliability Internal consistency Hirsh, et al 2011 Amputess and non- amputees grouped together Community Integration Questionnaire Social integration Social integration Internal consistency Hirsh, et al 2011 Amputess and non- amputees grouped together Community Integration Questionnaire Social integration Social Validity Known group	Hirsh, et al	2011		Amputess and non- amputees grouped together					Community Integration Questionnaire	Productivity		Validity	Structural
Amputess and non- together Amputess grouped together Amputess grouped together Amputess grouped together Concurrent/convergent Questionnaire Hirsh, et al 2011 Amputess and non- amputess grouped together Amputess grouped together Community Integration Questionnaire social integration Social integration Reliability Internal consistency Hirsh, et al 2011 together Community Integration Questionnaire social integration Social integration <td>Hirsh, et al</td> <td>2011</td> <td></td> <td>Amputess and non- amputees grouped together</td> <td></td> <td></td> <td></td> <td></td> <td>Community Integration Questionnaire</td> <td>Productivity</td> <td></td> <td>Validity</td> <td>Known group</td>	Hirsh, et al	2011		Amputess and non- amputees grouped together					Community Integration Questionnaire	Productivity		Validity	Known group
Amputess and non- amputess grouped together Amputess and non- amputess grouped together Community Integration Questionnaire social integration social integration Hirsh, et al 2011 Amputess and non- amputes grouped together Amputess and non- amputes grouped Social Social Hirsh, et al 2011 Amputess and non- amputes grouped Community Integration Questionnaire Social Hirsh, et al 2011 Logether Community Integration Questionnaire Social	Hirsh, et al	2011		Amputess and non- amputees grouped together					Community Integration Questionnaire	Productivity		Validity	Concurrent/convergent criterion
Amputess and non- amputess grouped Amputess and non- amputess grouped Community Integration social integration Validity Structural Hirsh, et al 2011 Amputess and non- amputess grouped Amputess and non- amputess grouped Community Integration Social integration Validity Structural Hirsh, et al 2011 together Community Integration Social Validity Known group	Hirsh, et al	2011		Amputess and non- amputees grouped together					Community Integration	social		Reliability	Internal consistency
Hirsh, et al 2011 together Validity Known group	Hirsh, et al	2011		Amputess and non- amputees grouped together					Community Integration	social		Validity	Structural
	Hirsh, et al	2011		Amputess and non- amputees grouped					Community Integration	social		Validity	Known group

			Comparator/Criterion/Outc	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
de Laat	2010				Higher (transfemoral or knee disarticulation) vs Lower (transtibial or Syme amputation)	Mann- Whitney U P value	0.256			
de l aat	2011		The Rising and Sitting down		Spearman r	0.42				Spearman: Rising and Silting=0.42
	2011		Questionnaire		opeannann	0.42				opeanian. Hising and Ontaing-0.42
de Laat	2012		The Walking Questionnaire		Spearman r	0.6				Spearman: Walking=0.60
Yari	2008		hip disarticulation group vs hemipelvectomy group		ttest P	0.16				no significant difference
Hirsh, et al	2011				Cronbach Alpha	0.84				for all disabilities
Hirsh, et al Hirsh, et al	2011									EFA and CFA suggested that modification of scales and scoring be made Scores for persons with limb loss were compared to scores of persons with SCI, MS and MD, no significant differences wer found.
Hirsh, et al	2011									original scoring: .152
Hireb et al	2011				Cronbach	0.45				a = 45 (for all disabilition)
niisii, et ai	2011				Арпа	0.45				EFA and CFA suggested that modification
	2011									Scores for persons with limb loss were compared to scores of persons with SCI, MS and MD, no significant differences were
Hirsh, et al	2011									rouna.
Hirsh, et al	2011									Correlation with SF 36 General health: original scoring: .341
Hirsh, et al	2011				Cronbach Alpha	0.51				a = .51 (for all disabilities)
Hirsh, et al	2011									EFA and CFA suggested that modification of scales and scoring be made
Hirsh. et al	2011									compared to scores of persons with SCI, MS and MD, no significant differences were found.
	1		1						1	para at

				Amputation	Other Population						
Author	Year	PMID	Amputation Level	Etiology Age	Information	N	Instrument	Subscale	Description	Property	Aspect
			Amputess and non-				O	!-!			0
Hirsh, et al	2011		together				Questionnaire	integration		Validity	concurrent/convergent
			Amputess and non-								
Lizah atal	2011		amputees grouped				Community Integration	Total Overal		Deliebility	Internal consistency
Hirsh, et al	2011		logether				Questionnaire	Score		Reliability	Internal consistency
			Amputess and non-				Community Integration				
Hirsh et al	2011		amputees grouped				Questionnaire- REVISED	Home		Validity	Structural
rinon, or di	2011		logotiloi					mogration		valialty	
			Amputess and non-				Community Integration	11			
Hirsh, et al	2011		together				SCORING	Home Integration		Validity	Known group
			Amputess and non-				Community Integration				
Lizah atal	2011		amputees grouped				Questionnaire- REVISED	Home		Volidity	Concurrent/convergent
Hirsh, et al	2011		together				SCORING	Integration		validity	criterion
			Amputess and non-				Community Integration				
Hirsh et al	2011		amputees grouped				Questionnaire-REVISED	Productivity		Validity	Structural
i mon, or ar	2011		logothor					rioddollwy		validity	
			Amputess and non-				Community Integration				
Hirsh, et al	2011		together				SCORING	Productivity		Validity	Known group
			Amputess and non-				Community Integration				- 3 • •
Hirab at al	2011		amputees grouped				Questionnaire-REVISED	Broductivity		Volidity	Concurrent/convergent
mish, et al	2011		logethei				SCORING	FIDUUCIIVILY		valiuity	citterion
			Amputess and non-				Community Integration	social			
Hirsh, et al	2011		together				SCORING	integration		Validity	Structural
			Amputess and non- amputees grouped				Questionnaire-REVISED	social			
Hirsh, et al	2011		together				SCORING	integration		Validity	Known group
			Amputess and non-				Community Integration	aasial			Consument/consument
Hirsh, et al	2011		together				SCORING	integration		Validity	criterion
								-			
							Graig Handicap Assessment and Reporting				Concurrent/convergent
Resnik, et al	2011						Technique (CHART)	Occupation		Validity	criterion
							Oracia I I an dia an			A 1-1114 - 4 -	
							Assessment and Reporting			measure	
Resnik, et al	2011						Technique (CHART)	Occupation		change	Responsiveness
							Crain Handican				
							Assessment and Reporting	social			Concurrent/convergent
Resnik, et al	2011						Technique (CHART)	integration		Validity	criterion
							Craig Handican			Ability to	
							Assessment and Reporting	social		measure	
Resnik, et al	2011						Technique (CHART)	integration		change	Responsiveness
Resnik, et al	2011						CRIS	Limitation		Reliability	Test-retest
			1					Extent of			
Resnik, et al	2011	1				1	CRIS	Limitation		Validity	Known group

			Comparator/Criterion/Outc	I imepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
										Correlation with SF 36 General health:
Hirsh, et al	2011									original scoring: .300
					Cronbach					
Hirsh, et al	2011				Alpha	0.75				a = .75 (for all disabilities)
Hirsh et al	2011									3 factor solution using the revised scoring fit the data well. The goodness-of-fit indices include: (df 50; RMSEA.05; 90% confidence interval for RMSEA.04 –.06; P for test of close fit [RMSEA.05].23;NNFI .95; Goodness of Fit Index 0.97; and Adjusted Goodness of Fit Index .95)
										Scores for persons with limb loss were compared to scores of persons with SCI, MS and MD, no significant differences were
Hirsh, et al	2011									found.
Hirsh, et al	2011									Correlation with SF 36 General Health and CIQ Revised scoring: .151,
Hirsh, et al	2011									Confirmatory factor analysis showed that a 3 factor solution using the revised scoring fit the data well. The goodness-of-fit indices include: (df 50; RMSEA .05; 90% confidence interval for RMSEA .04, -04; P for test of close fit [RMSEA .05] .23;NNFI .95; Goodness of Fit Index .057; and Adjusted Goodness of Fit Index .95).
Hirsh, et al	2011									Scores for persons with limb loss were compared to scores of persons with SCI, MS and MD, no significant differences were found.
Hirsh, et al	2011									Correlation with SF 36 General Health and CIQ Revised scoring: .306
Hirsh, et al	2011									Confirmatory factor analysis showed that a 3 factor solution using the revised scoring fit the data well. The goodness-of-fit indices include: (df 50; RMSEA.05; 90% confidence interval for RMSEA.0406; P for test of close fit (RMSEA.05].23;NNFI .95; Goodness of Fit Index 0.97; and Adjusted Goodness of Fit Index .95).
										Scores for persons with limb loss were compared to scores of persons with SCI, MS and MD, no significant differences were
Hirsh, et al	2011									found.
Hirsh, et al	2011									Correlation with SF 36 General Health and CIQ Revised scoring: .341
Resnik, et al	2011									No correlation between the CHART Occupational Function subscale and any CRIS scale
Resnik, et al	2011									Resnik reported that the ES for persons undergoing 3 months of outpatient rehabilitation was non-significant.
Resnik, et al	2011									Correlation between the CHART social integration scale and the CRIS satisfaction with participation scale was R=0.26.
Resnik, et al	2011									Resnik reported that the ES for persons undergoing 3 months of outpatient rehabilitation was non-significant.
Resnik, et al	2011									0.91 MDC 95% 5.7
Resnik, et al	2011									Extent scores lower in persons with PTSD TBI, and depression

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology A	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
					-					· · · ·		
									Extent of			Concurrent/convergent
Resnik, et al	2011							CRIS	Limitation		Validity	criterion
									Extent of		Ability to	
Resnik, et al	2011							CRIS	Limitation		change	Responsiveness
											Ability to	
									Extent of		measure	
Resnik, et al	2011							CRIS	Limitation		change	Floor/ceiling effects
Pesnik et	2011							CRIS	Perceived		Peliability	Test retest
itesiik, et	2011							0110	Perceived		rtenability	1631-161631
Resnik, et al	2011							CRIS	Limitation		Validity	Known group
									Perceived			Concurrent/convergent
Resnik, et al	2011							CRIS	Limitation		Validity	criterion
									Demostry 4		Ability to	
Resnik et al	2011							CRIS	Perceived Limitation		change	Responsiveness
rteanit, et ar	2011							0110	Limitation		Ability to	Responsiveness
									Perceived		measure	
Resnik, et al	2011							CRIS	Limitation		change	Floor/ceiling effects
									Satisfaction			
Resnik et al	2011							CRIS	with Limitation		Reliability	Test-retest
rtoorint, ot ar	2011							0110	Satisfaction		rtonability	
									with			
Resnik, et al	2011							CRIS	Limitation		Validity	Known group
									Satisfaction			Canaurantiannuarant
Resnik et al	2011							CRIS	Limitation		Validity	criterion
									Satisfaction		Ability to	
									with		measure	
Resnik, et al	2011							CRIS	Limitation		change	Responsiveness
									Satisfaction		Ability to	
Resnik, et al	2011							CRIS	Limitation		change	Floor/ceiling effects
L												
∠ahlten-Hinguranage et	2004		nd	malignant lower	8.6	nd	22		3 somatic		Validity	Known group
aı,	2004		nu	extremity sarcoma to	0.0	nu	22	EORIC QLQ-C30 COIE V3	Scale		validity	Known group
				malignant lower					3 somatic			
Zahlten-Hinguranage	2004		nd	extremity sarcoma 6	8.6		22	EORTC QLQ-C30 core v3	scales		Validity	Known group
				malignant lower					Behavioral			
Zahlten-Hinguranage	2004		nd	extremity sarcoma 6	8.6		22	EORTC QLQ-C30 core v3	(role)		Validity	Known group
Zahlten Hinguranaga at				malignant lower					Behavioural			
al.	2004		nd	extremity sarcoma	8.6	nd	22	EORTC QLQ-C30 core v3	(role)		Validity	Known group
	1				-							U Str
7-66	000.1			malignant lower			~		0		1 (- 1) -1) t	14 m m m m m m m m m m m m m m m m m m m
∠aniten-Hinguranage	2004		na	extremity sarcoma 6	0.80		22	EURIC QLQ-C30 core v3	Cognitive		validity	Known group

				Timepoint			0			
Author	Voar	PMID	comparator/Criterion/Outc	(predictive	Motric Used	Value	Strength of Property	IS ASpect	Conclusion	Notes/Caveats
Aution	Teal	FINID	one	valiuj	Metric Oseu	value	Froperty	Supported	Conclusion	Correlatons between: Quality of Life Scale
										(QOL) 0.5739: Occupation (CHART) -
										0.0422; Correlations with Social Integration
										(CHART) 0.1690; Role Physical (SF-36)
										0.3247; Role Emotional (SF-36) 0.5432;
										Social Functional (SF-36) 0.4843; Physical
Pesnik et al	2011									Living (ADL) -0.1834
itesiiik, et ai	2011									Small effect after 3 months of rehab
										approximately equivalent to change in QOL
Resnik, et al	2011									and Role Physical
										The ceiling effect using the MDC 90% was
										acceptable (<15%) for Extent of
Resnik, et al	2011									Participation
Resnik et	2011									
reonine, et	2011									Perceived scores lower in persons with
Resnik, et al	2011									PTSD TBI
										Correlations with Quality of Life Scale
										(QOL) 0.6661 Occupation (CHART) -0.1186
										Social Integration (CHART) 0.2168; Role
										Physical (SF-36) 0.2558; Role Emotional (SE-36) 0.3552; Social Eurotional (SE-36)
										0.5009: Physical Function (SE-36) 0.4038:
Resnik, et al	2011									Activities of Daily Living (ADL) -0.2367
										Small effect after 3 months of rehab,
										approximately equivalent to change in QOL
Resnik, et al	2011									and Role Physical
										The ceiling effect using the MDC 90% was
Resnik, et al	2011									acceptable (<15%) for Perceived
Resnik, et al	2011									0.9 MDC 95% 5.81
										Satisfication scores lower in persons with
Resnik, et al	2011									PTSD TBI, and depression
										Correlations with Quality of Life Scale
										(QOL) 0.7946; Occupation (CHART) -
										0.1197; Social Integration (CHART) 0.2607;
										Role Physical (SF-36) 0.3645; Role
										Functional (SF-36) 0.5352: Physical
										Function (SF-36) 0.3709; Activities of Daily
Resnik, et al	2011									Living (ADL) -0.2471
										Small effect after 3 months of rehab,
Boonik of al	2011									approximately equivalent to change in QOL
rtestlik, et di	2011									
										The ceiling effect was 16.2 percent for the
Resnik, et al	2011									Satisfaction with Participation subscale.
			Comparisons between limb							
Zahltan Hinguranaga at			salvage and amputee							Comparisons between limb calvage and
al.	2004		testing					Unclear		amputee patients, but no statistical testing
			Comparisons between limb							<u> </u>
			salvage and amputee							
			patients, but no statistical							Comparisons between limb salvage and
Zahlten-Hinguranage	2004		testing					Unclear		amputee patients, but no statistical testing
			comparisons between limb							
	1		patients, but no statistical							Comparisons between limb salvage and
Zahlten-Hinguranage	2004		testing	<u> </u>				Unclear		amputee patients, but no statistical testing
			Comparisons between limb	1						
Zahltan I lin			salvage and amputee							Comparisons hot year limb actions
∠aniten-Hinguranage et	2004		pauents, but no statistical					Linclear		comparisons between limb salvage and
	2004	1	Comparisons between limb					Choicdi		amparee pariento, but no statistical testing
			salvage and amputee							
	1		patients, but no statistical							Comparisons between limb salvage and
Zahlten-Hinguranage	2004		testing					Unclear		amputee patients, but no statistical testing

Autor Fair Prior Alignet Explore Property Appert Zahlen-Hinguranage el al. 204 nd nd externity sarcoma 86.6 nd 22 EORTC QL Q-C30 core v3 Continue Validity Known group Zahlen-Hinguranage el al. 2004 nd nd externity sarcoma 86.6 nd 22 EORTC QL Q-C30 core v3 Emotional Validity Known group Zahlen-Hinguranage el al. 2004 nd nd externity sarcoma 86.6 nd 22 EORTC QL Q-C30 core v3 Emotional Validity Known group Zahlen-Hinguranage el al. 2004 nd nd externity sarcoma 86.6 nd 22 EORTC QL Q-C30 core v3 Emotional Validity Known group Zahlen-Hinguranage el al. 2004 nd nd externity sarcoma 86.6 nd 22 EORTC QL Q-C30 core v3 Emotional Validity Known group Zahlen-Hinguranage el al. 204 nd nd externity sarcoma </th
Zahlten-Hingurange t 204 nd maignant lower extremity surcome 68.6 nd 22 EORTC QLQ-C30 core v Cognitive Validity Known group Zahlten-Hingurange t 204 nd nd maignant lower extremity surcome 68.6 22 EORTC QLQ-C30 core v Emotional Validity Known group Zahlten-Hingurange t 204 nd nd maignant lower extremity surcome 68.6 nd 22 EORTC QLQ-C30 core v Emotional Validity Known group Zahlten-Hingurange t 204 nd nd maignant lower extremity surcome 68.6 nd 22 EORTC QLQ-C30 core v Emotional Validity Known group Zahlten-Hingurange t 204 nd nd estremity surcome 68.6 nd 22 EORTC QLQ-C30 core v Emotional Validity Known group Zahlten-Hingurange t 204 nd nd estremity surcome 68.6 nd 22 EORTC QLQ-C30 core v Physical Validity Known group Known group Zahlten-Hingurange t 204 nd nd estremit
al. nd ottermity sarcoma 66.6 nd 22 EQRTC QLQ-C30 core v3 Cognitive Validity Known group Zahlen-Hinguranage 204 nd nd malignant lower extremity sarcoma 86.6 22 EQRTC QLQ-C30 core v3 Enotional Validity Known group Zahlen-Hinguranage difference 04 nd malignant lower extremity sarcoma 86.6 nd 22 EQRTC QLQ-C30 core v3 Enotional Validity Known group Zahlen-Hinguranage difference 04 nd malignant lower extremity sarcoma 86.6 nd 22 EQRTC QLQ-C30 core v3 Enotional Validity Known group Zahlen-Hinguranage difference 04 nd malignant lower extremity sarcoma 86.6 nd 22 EQRTC QLQ-C30 core v3 Enotional Validity Known group Zahlen-Hinguranage difference 044 nd malignant lower extremity sarcoma 86.6 nd 22 EQRTC QLQ-C30 core v3 Elobal health and QQL Soleal health and QQL Soleal health and QQL Soleal health and QQL Known group Zahlen-Hinguranage dit 044 nd ma
Zahlen-Hinguranage 204 nd maignant lower externity sarcoma 68.6 22 EORTC QLQ-C30 core v3 Emotional Validity Known group Zahlen-Hinguranage tai. nd maignant lower externity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 Emotional Validity Known group Zahlen-Hinguranage 204 nd maignant lower externity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 Emotional Validity Known group Zahlen-Hinguranage tai. nd maignant lower externity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 Global health acide Calobal health acide Calobal health acide Calobal health acide Known group Zahlen-Hinguranage 204 nd maignant lower externity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 Scale Validity Known group Zahlen-Hinguranage 204 nd maignant lower externity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 Physical Validity Known group Zahlen-Hinguranage 204 nd maignant lower externity sarcoma 68.6
Zahlen-Hinguranage 204 nd malignant lower externity sarcoma 8.6 nd 2.2 EORTC QLO-C30 core v3 metional validaty Known group Zahlen-Hinguranage 2.04 nd malignant lower externity sarcoma 8.6 nd 2.2 EORTC QLO-C30 core v3 metional validaty Known group Zahlen-Hinguranage 2.04 nd malignant lower externity sarcoma 8.6 nd 2.2 EORTC QLO-C30 core v3 metional validaty Known group Zahlen-Hinguranage 2.04 nd malignant lower externity sarcoma 8.6 nd 2.2 EORTC QLO-C30 core v3 sale validaty Known group Zahlen-Hinguranage 2.04 nd malignant lower externity sarcoma 8.6 nd 2.2 EORTC QLO-C30 core v3 sale validaty Known group Zahlen-Hinguranage 2.04 nd malignant lower externity sarcoma 8.6 nd 2.2 EORTC QLO-C30 core v3 sale validaty known group Zahlen-Hinguranage 2.04 nd malignant lower externity sarcoma 8.6 nd 2.2 EOR
Zahlen-Hinguralage Zohl nd Externity satural God Zahlen-Linguranage Enotional Findung Validity Known group Zahlen-Hinguranage 204 nd externity satural 68.6 nd 22 EORTO GLO-C30 core v3 Enotional Validity Known group Zahlen-Hinguranage 204 nd externity satural 68.6 nd 22 EORTO GLO-C30 core v3 Enotional Validity Known group Zahlen-Hinguranage 204 nd extremity satural 68.6 nd 22 EORTO GLO-C30 core v3 Enotional Validity Known group Zahlen-Hinguranage 204 nd extremity satural 68.6 nd 22 EORTO GLO-C30 core v3 sole Validity Known group Zahlen-Hinguranage 204 nd extremity satural 68.6 nd 22 EORTO GLO-C30 core v3 sole Validity Known group Zahlen-Hinguranage 204 nd extremity satural 88.6 nd 22 EORTO GLO-C30 core v3 Physical Validity Known group Sole <
Zahlten-Hinguranage al,204ndmalignant lower extremity sarcomae.8.6nd22EORTC OLO-C30 core v3EmotionalValidityKnown groupZahlten-Hinguranage al,204ndndmalignant lower extremity sarcomae.8.6nd22EORTC OLO-C30 core v3EmotionalvalidityKnown groupZahlten-Hinguranage al,204ndndmalignant lower extremity sarcomae.8.6nd22EORTC OLO-C30 core v3scalevalidityKnown groupZahlten-Hinguranage al,204ndmalignant lower extremity sarcomae.8.6nd22EORTC OLO-C30 core v3scalevalidityKnown groupZahlten-Hinguranage al,204ndmalignant lower extremity sarcomae.8.6nd22EORTC OLO-C30 core v3providescalevalidityKnown groupZahlten-Hinguranage al,204ndndmalignant lower extremity sarcomae.8.6nd22EORTC OLO-C30 core v3provideprovidevalidityKnown groupZahlten-Hinguranage al,204ndndmalignant lower extremity sarcomae.8.6nd22EORTC OLO-C30 core v3providepro
ait, nd extremity sarcoma 68.6 nd 22 EORTC QLQ-G30 core v3 Emotional Validity Known group Zahlten-Hinguranage 2004 nd malignant lower extremity sarcoma 68.6 nd 22 EORTC QLQ-G30 core v3 Global health and Odu Global health and Odu Global health and Odu Global health and Odu Known group Zahlten-Hinguranage 2004 nd malignant lower extremity sarcoma 68.6 nd 22 EORTC QLQ-G30 core v3 scale Validity Known group Zahlten-Hinguranage 2004 nd malignant lower extremity sarcoma 68.6 nd 22 EORTC QLQ-G30 core v3 scale Validity Known group Zahlten-Hinguranage 2004 nd malignant lower extremity sarcoma 68.6 nd 22 EORTC QLQ-G30 core v3 Physical Validity Known group Zahlten-Hinguranage 2004 nd malignant lower extremity sarcoma 68.6 nd 22 EORTC QLQ-G30 core v3 Physical Validity Known group Zahlten-Hinguranage 2004 nd malignant lower extremity sarcoma
Zahten-Hinguranage2004ndmalignant lower extremity sarcomae8.6call22EORTC QLQ-C30 core v3Global health and QoLValidityKnown groupZahten-Hinguranage al,2004ndndmalignant lower extremity sarcomae8.6nd22EORTC QLQ-C30 core v3Global health and QoLZahten-Hinguranage al,2004ndndmalignant lower extremity sarcomae8.6nd22EORTC QLQ-C30 core v3Global health and QoLZahten-Hinguranage al,2004ndndmalignant lower extremity sarcomae8.6nd22EORTC QLQ-C30 core v3PhysicalValidityKnown groupZahten-Hinguranage al,2004ndndmalignant lower extremity sarcomae8.6nd22EORTC QLQ-C30 core v3PhysicalValidityKnown groupZahten-Hinguranage al,ndndmalignant lower extremity sarcomae8.6nd22EORTC QLQ-C30 core v3PhysicalValidityKnown groupZahten-Hinguranage al,ndndmalignant lower extremity sarcomae8.6nd22EORTC QLQ-C30 core v3PhysicalValidityKnown groupZahten-Hinguranage al,2004ndndmalignant lower extremity sarcomae8.6nd22EORTC QLQ-C30 core v3Single Item symptom measuresSingle Item symptom measuresValidityKnown groupZahten-Hinguranage al,2004ndnde
Zahten-Hinguranage 2004 nd extremity sarcoma 68.6 22 EORTC QLQ-C30 core v3 scale validity Known group Zahten-Hinguranage al, nd nd malignant lower extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 scale validity Known group Zahten-Hinguranage 2004 nd malignant lower extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 scale validity Known group Zahten-Hinguranage 2004 nd malignant lower extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 Physical validity Known group Zahten-Hinguranage 2004 nd malignant lower extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 Physical validity Known group Zahten-Hinguranage 2004 nd malignant lower extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 Physical validity Known group Zahten-Hinguranage 2004 nd nd extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3
Zahlten-Hinguranage Zube Ind Externity satisfie Zube Control GLO-Cold one rol state State Validity Known group Zahlten-Hinguranage tail, 2004 nd extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 Scale Validity Known group Zahlten-Hinguranage tail, 2004 nd extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 Physical Validity Known group Zahlten-Hinguranage tail, 2004 nd extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 Physical Validity Known group Zahlten-Hinguranage al, 2004 nd extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 Physical Validity Known group Zahlten-Hinguranage 2004 nd extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 Physical Validity Known group Zahlten-Hinguranage 2004 nd extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 Physical Validity Known group
Zahten-Hinguranage al,2004ndmalignant lower extremity sarcoma68.6nd22EORTC QLQ-C30 core v3scaleValidityKnown groupZahiten-Hinguranage al,2004ndndmalignant lower extremity sarcoma68.622EORTC QLQ-C30 core v3PhysicalValidityKnown groupZahiten-Hinguranage al,2004ndmalignant lower extremity sarcoma68.6nd22EORTC QLQ-C30 core v3Single item symptomValidityKnown groupZahiten-Hinguranage al,2004ndndmalignant lower extremity sarcoma68.6nd22EORTC QLQ-C30 core v3measuresValidityKnown groupZahiten-Hinguranage al,2004ndndmalignant lower extremity sarcoma68.6nd22EORTC QLQ-C30 core v3measuresValidityKnown groupZahiten-Hinguranage al,2004ndndmalignant lower extremity sarcoma68.6nd22EORTC QLQ
al,2004ndextremity sarcoma68.6nd22EORTC QLQ-C30 core v3scaleValidityKnown groupZahiten-Hinguranage2004ndextremity sarcoma68.622EORTC QLQ-C30 core v3PhysicalValidityKnown groupZahiten-Hinguranage2004ndmalignant lower extremity sarcoma68.6nd22EORTC QLQ-C30 core v3Single item symptom measuresValidityKnown groupZahiten-Hinguranage2004ndmalignant lower extremity sarcoma68.6nd22EORTC QLQ-C30 core v3Single item symptom measuresValidityKnown groupZahiten-Hinguranage2004ndextremity sarcoma68.6nd22EORTC QLQ-C30 core v3Single item symptom symptom measuresValidityKnown groupZahiten-Hinguranage2004ndextremity sarcoma68.6nd22EORTC QLQ-C30 core v3measuresValidityKnown group
Zahlten-Hinguranage2004ndmalignant lower extremity sarcoma68.622EORTC QLQ-C30 core v3PhysicalValidityKnown groupZahlten-Hinguranage2004ndmalignant lower extremity sarcoma68.6nd22EORTC QLQ-C30 core v3Single item symptom measuresValidityKnown groupZahlten-Hinguranage2004ndmalignant lower extremity sarcoma68.6nd22EORTC QLQ-C30 core v3Single item symptom measuresValidityKnown group
Zahlten-Hinguranage2004ndmalignant lower extremity sarcoma68.622EORTC QLQ-C30 core v3PhysicalValidityKnown groupZahlten-Hinguranage2004ndmalignant lower extremity sarcoma68.6nd22EORTC QLQ-C30 core v3PhysicalValidityKnown groupZahlten-Hinguranage2004ndmalignant lower extremity sarcoma68.6nd22EORTC QLQ-C30 core v3PhysicalValidityKnown groupZahlten-Hinguranage2004ndextremity sarcoma68.6nd22EORTC QLQ-C30 core v3PhysicalValidityKnown groupZahlten-Hinguranage2004ndextremity sarcoma68.6nd22EORTC QLQ-C30 core v3Single item symptom measuresSingle item symptom measuresValidityKnown groupZahlten-Hinguranage2004ndextremity sarcoma68.6nd22EORTC QLQ-C30 core v3Single item symptom measuresValidityKnown group
Zahlten-Hinguranage et al, 2004 nd malignant lower extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 Physical Validity Known group Zahlten-Hinguranage 2004 nd extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 Physical Validity Known group Zahlten-Hinguranage 2004 nd extremity sarcoma 68.6 22 EORTC QLQ-C30 core v3 measures Validity Known group Zahlten-Hinguranage et al, nd extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 measures Validity Known group
Zahlten-Hinguranage 2004 nd nd malignant lower extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 Physical Validity Known group Zahlten-Hinguranage 2004 nd nd extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 Physical Validity Known group Zahlten-Hinguranage 2004 nd nd extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 measures Validity Known group Zahlten-Hinguranage 2004 nd nd extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 measures Validity Known group
al, 204 nd extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 Physical Validity Known group Zahlten-Hinguranage 2004 nd extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 Physical Validity Known group Zahlten-Hinguranage 2004 nd extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 measures Validity Known group al, 204 nd extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 measures Validity Known group
Zahlten-Hinguranage 2004 nd malignant lower extremity sarcoma 68.6 22 Single item EORTC QLQ-C30 core v3 Single item symptom measures Single item symptom measures Single item symptom measures Now group Zahlten-Hinguranage al, al, 2004 nd malignant lower extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 Single item symptom measures Single item symptom measures Validity Known group
Zahlten-Hinguranage 2004 nd extremity sarcoma 68.6 22 EORTC QLQ-C30 core v3 measures Validity Known group Zahlten-Hinguranage 2004 nd extremity sarcoma 68.6 1 22 EORTC QLQ-C30 core v3 measures Validity Known group
Zahlten-Hinguranage et 2004 nd extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 measures Validity Known group
Zahten-Hinguranage et al, 2004 nd extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 measures Validity Known group
al, 2004 nd extremity sarcoma 68.6 nd 22 EORTC QLQ-C30 core v3 measures Validity Known group
Zahlten-Hinguranage 2004 nd extremity sarcoma 68.6 22 EORTC QLQ-C30 core v3 Social Validity Known group
Zahlten-Hinguranage et malignant lower and and and an an an and an
Anxiety and
Giarmoudis 2009 pellow kriee ukuma 46.6 no 22 EV-50 depression validity kriewn group
Anxiety and
Giannoudis et al, 2009 below knee trauma 46.8 nd 22 EQ-5D depression Validity Known group
Giannoudis 2009 below knee trauma 46.8 nd 22 EQ-5D Mobility Validity Known group
Giannourdis et al. 2009 below knee trauma 46.8 nd 22 EO.5D Mobility Mosure group

			Comparator/Criterion/Outo	Innepoint			Strength of	le Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
			Comparisons between limb	ranaj	incluie coou	, and	Tropolly	oupportou :	Contraction	
			salvage and amputee							
Zahlten-Hinguranage et	:		patients, but no statistical							Comparisons between limb salvage and
al,	2004		testing					Unclear		amputee patients, but no statistical testing
			Comparisons between limb							
			salvage and amputee							
7-64	0004		patients, but no statistical					Lin els es		Comparisons between limb salvage and
Zaniten-Hinguranage	2004		Comparisons between limb					Unclear		amputee patients, but no statistical testing
			comparisons between limb							
Zahlten-Hinguranage et			natients but no statistical							Comparisons between limb salvage and
al.	2004		testing					Unclear		amputee patients, but no statistical testing
			Comparisons between limb							
			salvage and amputee							
			patients, but no statistical							Comparisons between limb salvage and
Zahlten-Hinguranage	2004		testing					Unclear		amputee patients, but no statistical testing
			Comparisons between limb							
7-1-14			salvage and amputee							O and a stress to the set of the
Zaniten-Hinguranage et	2004		patients, but no statistical					Unclear		comparisons between IImb salvage and
ai,	2004		Comparisons between limb					Unclear		amputee patients, but no statistical testing
			salvage and amputee							
			patients, but no statistical							Comparisons between limb salvage and
Zahlten-Hinguranage	2004		testing					Unclear		amputee patients, but no statistical testing
			Comparisons between limb							
			salvage and amputee							
Zahlten-Hinguranage et	:		patients, but no statistical							Comparisons between limb salvage and
al,	2004		testing					Unclear		amputee patients, but no statistical testing
			Comparisons between limb							
			salvage and amputee							Comparisons botwoon limb solvage and
Zahlten-Hinguranage	2004		testing					Unclear		amputee patients, but no statistical testing
Lanton i nigaranago	2001		Comparisons between limb					onoidai		ampateo patiente; pat no etatieneal teoting
			salvage and amputee							
Zahlten-Hinguranage et			patients, but no statistical							Comparisons between limb salvage and
al,	2004		testing					Unclear		amputee patients, but no statistical testing
			Comparisons between limb							
			salvage and amputee							
			patients, but no statistical							Comparisons between limb salvage and
Zaniten-Hinguranage	2004		testing					Unclear		amputee patients, but no statistical testing
			Comparisons between limb							
Zahlten-Hinguranage et			natients but no statistical							Comparisons between limb salvage and
al,	2004		testing					Unclear		amputee patients, but no statistical testing
										Patients in the IIIB, IIIC and amputation
										groups reported more problems with
										ongoing anxiety and depression than those
										in the tibial fracture and fasciotomy groups
Giannoudis	2009									(p < 0.05)
										Patients in the IIIB, IIIC and amputation
										groups reported more problems with
										in the tibial fracture and fasciotomy groups
Giannoudis et al,	2009									(p < 0.05)
				1						Patients with amputations and IIIB fractures
1										reported problems with mobility most
1										frequently. IIIC fracture patients reported
Giannoudis	2009									problems less frequently p < 0.05
	1									Patients with amputations and IIIB fractures
1										reported problems with mobility most
Giannoudis et al	2000									problems less frequently n < 0.05
Giannibuulis et al,	2009	1		1		1			1	problems less nequently p < 0.05

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
									Pain and			
Giannoudis	2009		below knee	trauma	46.8	nd	22	EQ-5D	discomfort		Validity	Known group
									Pain and			
Giannoudis et al,	2009		below knee	trauma	46.8	nd	22	EQ-5D	discomfort		Validity	Known group
Giannoudis	2009		below knee	trauma	46.8	nd	22	EQ-5D	Usual activity		Validity	Known group
Giannoudis et al,	2009		below knee	trauma	46.8	nd	22	EQ-5D	Usual activity		Validity	Known group
Eijk	2012	21958418	Transfemoral (n=17), Transtibial (n=23), transgenual (n=5), hip disarticulation (n=1), minor amputation (n=2) Transfemoral (n=112).	PAD (n=45), astreomyelitis (n=1), tumour (n=1), trauma (n=1) vascular (220),	75.2		48	FAC	Total Overall Score		Validity	Predictive
Asano	2008	18569891	Transtibial (303)	nonvascular (195)	61.9	Unilateral	415	FAI			Validity	Convergent
Miller	2004	15180125	Transfemoral (n=24) , Transtibial (n=60)	Vascular (n=34), Trauma (n=50)	56.5		84	FAI		The Frenchay Activities Index is a 15-Item self- report measure that assesses frequency of participation in domestic chores, work/leisure and outdoor activities. Scores ranging from 0 (no activity) to 45 (very high participation). The FAI is a 15-Item self-report measure that assesses frequency of participation in domestic chores, work/leisure and outdoor	Validity	Construct
Miller	2004	15100105	Transfemoral (n=24),	Vascular (n=34),	50 F		0.4	FAI		activities. Scores ranging from 0 (no activity)	Validit	Construct
winer	2004	10100125	mansubial (N=60)	rrauma (n=50)	00.0	I	04	FAI	1	to 45 (very high participation).	validity	CONSTRUCT

			0	Timepoint			0			
Author	Year	PMID	comparator/Criterion/Outc	(predictive valid)	Metric Used	Value	Strength of Property	IS ASPECT Supported?	Conclusion	Notes/Caveats
Aution	rear		onic	valia)	Metho Oseu	Value	Troperty	oupporteu.	Conclusion	Patients with IIIB and IIIC fractures reported
										ongoing problems with pain most
										frequently, with positive responses in just
										over 80% and just over 70%, respectively.
										Patients having undergone fasciotomy
										amputations with positive responses in
										around 50% of cases and closed fracture
										patients in 20% of cases. The differences
										between responses from the amputees and
										both the IIIB and IIIC groups were
										those between the simple tibial fracture and
Giannoudis	2009									all other groups (p < 0.01).
										Patients with IIIB and IIIC fractures reported
										ongoing problems with pain most
										frequently, with positive responses in just
										over 80% and just over 70%, respectively. Patients having undergone fasciotomy
										reported pain as frequently as those with
										amputations with positive responses in
										around 50% of cases and closed fracture
										patients in 20% of cases. The differences
										both the IIIB and IIIC groups were
										statisticallysignificant (p < 0.01) as were
										those between the simple tibial fracture and
Giannoudis et al,	2009									all other groups (p < 0.01).
										Patients with IIIB fractures reported
										problems with undertaking their usual
										respondents) ($p < 0.05$ compared with all
										other groups). Those with IIIC fractures,
										fasciotomies and amputations reported
										problems with similar frequency at 47%,
										significance when compared with each
										other). Those who had suffered closed tibial
										fracture recorded problems least frequently
										at 20% of respondents (p < 0.05 compared
Giannoudis	2009									with all other groups
										Patients with IIIB fractures reported
										activities most frequently (80% of
										respondents) (p < 0.05 compared with all
										other groups). Those with IIIC fractures,
										fasciotomies and amputations reported
										problems with similar frequency at 47%, 37% and 32%, respectively (no statistical
										significance when compared with each
										other). Those who had suffered closed tibial
										fracture recorded problems least frequently
Giannoudis et al	2000									at 20% of respondents (p < 0.05 compared
Giainioudis et al,	2003									
									alamifiananthy analysis in the standard	
Fiik	2012	21958418	Barthel index	12 months	Pivalue	0.003			Significantly correlated with Barthel index (Mannwhitney II):	Functional Ambulation Categories (EAC)
Lijk	2012	21000410	burther index	12 11011013	i value	0.000			baraier index (manifulatey 0),	Talletional Ambalation Gategories (1710)
Asano	2008	18569891	QoL, single item question		Beta	0.19				Multivariate regression
									The FAI did not discriminate	
Miller	2004	15180125	Transfemoral vs transtibial		Р	>=0.05		No	between Transfemoral and transfibial	
	2004	.5100120				-0.00				
									The FAL discriminated between	
									Transfemoral and transfibial	
Miller	2004	15180125	Vascular vs trauma		Р	<0.05		Yes	Vascular and trauma	

Author	Year	PMID	Amputation Level	Amputation Etiology	Age	Other Population	N	Instrument	Subscale	Description	Property	Aspect
Miller	2004	15180125	Transfemoral (n=24) , Transtibial (n=60)	Vascular (n=34), Trauma (n=50)	56.5		84	FAI		The FAI is a 15-item self-repor-t measure that assesses frequency of participation in domestic chores, work/leisure and outdoor activities. Scores ranging from 0 (no activity) to 45 (very high participation).	Validity	Convergent
Miller	2004	15180125	Transfemoral (n=24) , Transtibial (n=60)	Vascular (n=34), Trauma (n=50)	56.5		84	FAI		The FAI is a 15-item self-report measure that assesses frequency of participation in domestic chores, work/leisure and outdoor activities. Scores ranging from 0 (no activity) to 45 (very high participation).	Validity	Convergent
Miller	2004	15180125	Transfemoral (n=24) , Transtibial (n=60)	Vascular (n=34), Trauma (n=50)	56.5		84	FAI		The FAI is a 15-item self-repor-t measure that assesses frequency of participation in domestic chores, work/leisure and outdoor activities. Scores ranging from 0 (no activity) to 45 (very high participation).	Validity	Convergent
Miller	2004	15180125	Transfemoral (n=24) , Transtibial (n=60)	Vascular (n=34), Trauma (n=50)	56.5		84	FAI		The FAI is a 15-item self-repor-t measure that assesses frequency of participation in domestic chores, work/leisure and outdoor activities. Scores ranging from 0 (no activity) to 45 (very high participation).	Validity	Convergent
Miller	2004	15180125	Transfemoral (n=24) , Transtibial (n=60)	Vascular (n=34), Trauma (n=50)	56.5		84	FAI		The FAI is a 15-Item self-repor-t measure that assesses frequency of participation in domestic chores, work/leisure and outdoor activities. Scores ranging from 0 (no activity) to 45 (very high participation).	Reliability	Internal Consistency
Miller	2004	15180125	Transfemoral (n=24) , Transtibial (n=60)	Vascular (n=34), Trauma (n=50)	56.5		84	FAI		The FAI is a 15-Item self-repor-t measure that assesses frequency of participation in domestic chores, work/leisure and outdoor activities. Scores ranging from 0 (no activity) to 45 (very high participation).	Reliability	Test-retest
Miller et al	2001							FAI Modified	no subscale		Reliability	Test-retest
Miller et al	2001							FAI Modified	no subscale		Reliability	Internal consistency
Miller	2004	15180125	Transfemoral (n=24) , Transtibial (n=60)	Vascular (n=34), Trauma (n=50)	56.5		84	FAI-18		To broaden the range of activities we added three items to the existing FAI. The total score of the FAI- 1 8 ranges from 0 to 54	Validity	Construct
Miller	2004	15180125	Transfemoral (n=24), Transtibial (n=60)	Vascular (n=34), Trauma (n=50)	56.5		84	FAI-18		three items to the existing FAI. The total score of the FAI- 1.8 ranges from 0 to 54	Validity	Construct
Miller	2004	15180125	Transfemoral (n=24) , Transtibial (n=60)	Vascular (n=34), Trauma (n=50)	56.5		84	FAI-18		To broaden the range of activities we added three items to the existing FAI. The total score of the FAI- 1 8 ranges from 0 to 54 To broaden the range of activities we added	Validity	Convergent
Miller	2004	15180125	ranstemoral (n=24), Transtibial (n=60)	vascular (n=34), Trauma (n=50)	56.5		84	FAI-18		three items to the existing FAI. The total score of the FAI- 1 8 ranges from 0 to 54	Validity	Convergent

			Comparator/Criterion/Outo	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Miller	2004	15180125	Two-minute walk		Pearson r	0.526	Large	Yes	Hypothesized relationships (p <00001) between both FAI versions and the Activity- specific Balance Confidence Scale, Prosthetic Evaluation Questionnaire - Mobility Scale, 2-minute walk and timed up and go test were observed.	
									Hypothesized relationships (p <00001) between both FAI versions and the Activity- specific Balance Confidence Scale, Prosthetic Evaluation Questionnaire - Mobility Scale, 2-minute walk and timed up and	
Miller	2004	15180125	Timed up and go		Pearson r	0.386	Moderate	Yes	go test were observed. Hypothesized relationships (p <00001) between both FAI versions and the Activity- specific Balance Confidence Scale, Prosthetic Evaluation Questionnaire - Mobility Scale, 2-minute walk and timed up and on test were observed	
WINC:	2004					0.000	Moderate		Hypothesized relationships (p <00001) between both FAI versions and the Activity- specific Balance Confidence Scale, Prosthetic Evaluation Questionnaire - Mobility Scale, 2-minute walk and timed up and	
Miller	2004	15180125	ABC		Pearson r	0.505	Large	Yes	go test were observed.	
Miller	2004	15180125	nd		Cronbach's alpha	0.81	Excellent	Yes	Good internal consistency	
Miller et al	2004	15160125	nu		100	0.79	Guu	165	Strong test-retest reliability.	in this paper
					Cronbach					
Miller et al	2001	15180125	Transfemoral vs transtihial		Alpha	0.87		No	The FAI-18 did not discriminate between Transfemoral and transfibial	Alpha 0.87
	0004	45400405				-0.05		N	The FAI-18 discriminated between Transfemoral and	
Iviiler	2004	15180125	vascular vs trauma		Pearson r	0.548	Large	Yes	uaristiolai vascular and trauma Hypothesized relationships (p <00001) between both FAI versions and the Activity- specific Balance Confidence Scale, Prosthetic Evaluation Questionnaire - Mobility Scale, 2-minute walk and timed up and no test were observed	
Miller	2004	15180125	Timed up and go		Pearson r	-0.462	Moderate	Yes	Hypothesized relationships (p <00001) between both FAI versions and the Activity- specific Balance Confidence Scale, Prosthetic Evaluation Questionnaire - Mobility Scale, 2-minute walk and timed up and go test were observed.	

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
			Transfemoral (n=24) ,	Vascular (n=34),						To broaden the range of activities we added three items to the existing FAI. The total score		
Miller	2004	15180125	Transtibial (n=60)	Trauma (n=50)	56.5		84	FAI-18		of the FAI- 1 8 ranges from 0 to 54	Validity	Convergent
			Transfemoral (n=24) .	Vascular (n=34).						To broaden the range of activities we added three items to the existing FAI. The total score		
Miller	2004	15180125	Transtibial (n=60)	Trauma (n=50)	56.5		84	FAI-18		of the FAI- 1 8 ranges from 0 to 54	Validity	Convergent
Miller	2004	15180125	Transfemoral (n=24) , Transtibial (n=60)	Vascular (n=34), Trauma (n=50)	56.5		84	FAI-18		To broaden the range of activities we added three items to the existing FAI. The total score of the FAI- 1 8 ranges from 0 to 54 To broaden the range of activities we added	Reliability	Internal Consistency
Miller	2004	15180125	Transfemoral (n=24) , Transtibial (n=60)	Vascular (n=34), Trauma (n=50)	56.5		84	FAI-18		three items to the existing FAI. The total score of the FAI- 1 8 ranges from 0 to 54	Reliability	Test-retest
Kahle	2008						19	Fastest Possible Walking Speed 38m on uneven terrain (FPWS38 uneven)	Total Overall Score		Ability to measure change	Responsiveness
Kabla	2008						10	Speed 6m on even terrain	Total Overall		measure	Responsiveness
Kanie	2006						19	(FPWS6) Fastest Possible Walking	Score		Ability to	Responsiveness
Kahle	2008						19	Speed 75m on even terrain (FPWS75)	Total Overall Score		measure change	Responsiveness
Leung	1996	8831480	Transfemoral (n=8), Transtibial (n=24), Bilateral (n=1)	nd	nd		33	FIM	Admission motor subscore		Validity	Predictive
Leung	1996	8831480	Transfemoral (n=8), Transtibial (n=24), Bilateral (n=1)	nd	nd		33	FIM	Admission motor subscore		Validity	Predictive
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore, overall	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Floor/ceiling effect	Ceiling
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore, overall	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore, overall	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore, overall	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct

			Commercian/Criterian/Oute	Timepoint			Chronieth of	In Annant		
Author	Voar	PMID	comparator/Criterion/Outc	(predictive	Motric Used	Value	Strength of Property	IS ASpect	Conclusion	Notes/Caveats
Author	Tear	PMID	one	valid)	Metric Osed	value	Property	Supported ?	Hypothesized relationships (p	Notes/Caveats
									versions and the Activity-	
									specific Balance Confidence Scale Prosthetic Evaluation	
									Questionnaire - Mobility Scale,	
N 4111	0004	15100105	DEO NO		D		Maria and a		2-minute walk and timed up and	
Miller	2004	15180125	PEQ-MS		Pearson r	0.404	Moderate	res	go test were observed. Hypothesized relationships (p	
									<00001) between both FAI	
									versions and the Activity-	
									Scale, Prosthetic Evaluation	
									Questionnaire - Mobility Scale,	
Miller	2004	15180125	ABC		Pearson r	0.518	Large	Yes	go test were observed.	
							Ŭ			
Miller	2004	15180125	nd		Cronbach's alpha	0.84	Excellent	Yes	Good internal consistency	
Miller	2004	15180125	nd		ICC	0.78	Good	Vec	Strong test retest reliability	
Willer	2004	13100123	na		100	0.70	0000	103	Strong test-retest reliability.	
1Z-bl-	0000									
Kanie	2008									significant improvement after using C-Leg
Kahle	2008									signifificant improvement after using C-Leg
Kahle	2008								The educionic FIM energy is not	signifificant improvement after using C-Leg
									useful in predicting successful	
			Houghton score>=9 vs.						prosthetic rehabilitation in lower	
Leung	1996	8831480	Houghton score<9	3-12 months	Р	0.42		NO	extremity amputee patients The admission FIM score is not	
									useful in predicting successful	
Leuna	1996	8831480	DMERC functional level	3-12 months	Spearman r	0.18	Small	No	prosthetic rehabilitation in lower	
Loung	1000	0001400	Dimerco functional level		opeannann	0.10	Official	110	exacting amparee parents	
Cyril	2001		nd		%	0		No		
0	0004		Tana dikialan Tana damasal					N -		3-Month Functional Scale Scores. P-value
Cyni	2001		Transtidial vs Transfermoral		P	>0.05		INO		based on Mann-whitney U
										2 Month Eurotional Scale Sector Bivelue
Cyril	2001		ISS Score <13 vs >=13		Р	>0.05		No		based on Mann-Whitney U
										3-Month Functional Scale Scores. P-value
Cyril	2001	1	Age <35 vs >=35	1	P	>0.05	1	No	1	based on Mann-Whitney U

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Curil	2001		Transfemoral (22%), Transtibial (77%), Throuch-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore, overall	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	EIM	Amputation function subscore,	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore, overall	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cvril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amoutations were excluded	107	FIM	Amputation function subscore, overall	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore, overall	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore, overall	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Criterion
Cyril	2001		Transfemoral (22%), Transtbial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore, overall	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Criterion

			Comparator/Criterion/Outc	(predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Cyril	2001		Comorbidities yes vs no		P	>0.05		No		3-Month Functional Scale Scores. P-value based on Mann-Whitney U
Cyril	2001		Transtibial vs Transfemoral		P	>0.05		No		12-Month Functional Scale Scores. P-value based on Mann-Whitney U
										12-Month Functional Scale Scores. P-value
Cyril	2001		ISS Score <13 vs >=13		P	>0.05		No		based on Mann-Whitney U
Cyril	2001		Age <35 vs >=35		Р	>0.05		No		12-Month Functional Scale Scores. P-value based on Mann-Whitney U
Cyril	2001		Comorbidities yes vs no		Р	>0.05		Νο		12-Month Functional Scale Scores. P-value based on Mann-Whitney U
Cyril	2001		Normal Walking Speed (Yes vs No)		Pearson r	-0.06	None	Νο		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was defined as those who completed a 150 foot walk in 37.5 seconds or less, which is equivalent to the average time takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.
Cyril	2001		Walking Speed (continuous score)		Pearson r	0.13	Small	Unclear		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was defined as those who completed a 150 foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore, overall	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Criterion
Cvril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore, overall	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Divergent
01	2001		Transfemoral (22%), Transtibial (77%),			High energy lower extremity trauma patients. Foot amputation or bilateral	107		Amputation function subscore,	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes	Floor/ceiling	Flore
	2001		Transfemoral (22%), Transtibial (77%),	na	35	High energy lower extremity trauma patients. Foot amputation or bilateral	107	FIM	Amputation function subscore,	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes	Pellekiite	Hoor
Cyn	2001		Transfemoral (22%), Transtibial (77%),		30	High energy lower extremity trauma patients. Foot amputation or bilateral		- 1101	Amputation function subscore,	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes	Responsiven	
Cyril	2001		Through-knee (11%) Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	Amputations were excluded High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore, overall	following rehabilitation The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	ess Responsiven ess	nd
0.ml	2004		Transfemoral (22%), Transtibial (77%),		25	High energy lower extremity trauma patients. Foot amputation or bilateral	107		Amputation function subscore:	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes	Floor/ceiling	Celling
	2001		Transfemoral (22%), Transtibial (77%),		<u></u>	High energy lower extremity trauma patients. Foot amputation or bilateral		ir avi	Amputation function subscore:	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes	eneci	
Cyril	2001		Through-knee (11%) Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Chair transfer Amputation function subscore: Chair transfer	following rehabilitation The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity Validity	Construct

			Comparator/Criterion/Outc	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
			Return to Lisual Activity							Neturn to usual activity by 12 months after injury. Respondents reported their major activity at baseline and all subsequent follow-up periods (defined as working, laid off, looking for work, school, keeping house, retired, and other). Returning to one's usual activity was defined as resuming the same activity or to an activity
Cyril	2001		(Yes vs No)		Pearson r	0.02	None	No		o f equal or greater productivity
Cyril	2001		Physical Function Index		Pearson r	-0.12		Unclear		
Out	2001		ed		9/			No		
Cyni	2001		na		[%]	0		NO		
Cyril	2001		nd		alpha	0.55	Poor	Unclear		
Quel	2001		~		CDM .	0.40				Effect Size Statistics for Change in Scores
Cyn	2001		10		Effect size with	-0.49				Effect Size Statistics for Change in Scores
Cyril	2001		nd		baseline SD	-0.51				Between 3 and 12 Months
Gynl	2001		nu		70	33.3		TES		
Queil	2001		Transtikiel un Transform		P	-0.05		No		3-Month Functional Scale Scores. P-value
Cyril	2001		Transtemoral		<u>r</u>	20.05				paseu on mann-wnithêy U
Cyril	2001		ISS Score <13 vs >=13		Р	>0.05		No		3-Month Functional Scale Scores. P-value based on Mann-Whitney U

				A		Other Denulation						
Author	Year	PMID	Amputation Level	Amputation Etiology A	ae	Information	N	Instrument	Subscale	Description	Property	Aspect
Aution	real		Amputation Level	Lilology	ge	mormation		instrument	Subscale	The Functional Independence Measure (FIM)	roperty	Ларесс
										function in terms of need for assistance and		
										level o f independence. Developed as part o f		
						High energy lower extremity			Amputation	the Uniform Data System for Medical		
			Transfemoral (22%),			trauma patients. Foot			function	Rehabilitation, the measure was specifically		
			Transtibial (77%),		_	amputation or bilateral			subscore:	designed to evaluate functional outcomes		
Cyril	2001		Through-knee (11%)	nd 38	5	amputations were excluded	107	FIM	Chair transfer	following rehabilitation	Validity	Construct
										The Functional Independence Measure (FIM)		
										function in terms of need for assistance and		
										level of independence. Developed as part of		
						High energy lower extremity			Amputation	the Uniform Data System for Medical		
			Transfemoral (22%),			trauma patients. Foot			function	Rehabilitation, the measure was specifically		
			Transtibial (77%),			amputation or bilateral			subscore:	designed to evaluate functional outcomes		
Cyril	2001		Through-knee (11%)	nd 3	5	amputations were excluded	107	FIM	Chair transfer	following rehabilitation	Validity	Construct
										The Functional Independence Measure (FIM)		
										is an 18-item instrument that assesses		
										level of independence. Developed as part of		
						High energy lower extremity			Amputation	the Uniform Data System for Medical		
			Transfemoral (22%),			trauma patients. Foot			function	Rehabilitation, the measure was specifically		
			Transtibial (77%),			amputation or bilateral			subscore:	designed to evaluate functional outcomes		
Cyril	2001		Through-knee (11%)	nd 3	5	amputations were excluded	107	FIM	Chair transfer	following rehabilitation	Validity	Construct
										The Functional Independence Measure (FIM)		
										is an 18-item instrument that assesses		
										function in terms of need for assistance and		
									Amputation	the Uniform Date System for Medical		
			Transfemoral (22%)			trauma patients. Foot			function	Rehabilitation, the measure was specifically		
			Transtibial (77%).			amputation or bilateral			subscore:	designed to evaluate functional outcomes		
Cyril	2001		Through-knee (11%)	nd 3	5	amputations were excluded	107	FIM	Chair transfer	following rehabilitation	Validity	Construct
										The Functional Independence Measure (FIM)		
										is an 18-item instrument that assesses		
										function in terms o f need for assistance and		
						Llink anarou laurar autramitu			Ameritation	level of independence. Developed as part of		
			Transformarial (22%)			trauma patienta. Egot			function	Republication the measure was apositically		
			Transtibial (77%)			amputation or bilateral			subscore:	designed to evaluate functional outcomes		
Cyril	2001		Through-knee (11%)	nd 3	5	amputations were excluded	107	FIM	Chair transfer	following rehabilitation	Validity	Construct
			· · · /							The Functional Independence Measure (FIM)	ĺ	
										is an 18-item instrument that assesses		
										function in terms o f need for assistance and		
										level of independence. Developed as part of		
			Transfemoral (22%)			High energy lower extremity			Amputation	the Uniform Data System for Medical		
			Transtibial (77%)			amputation or hilateral			subscore:	designed to evaluate functional outcomes		
Cvril	2001		Through-knee (11%)	nd 3	5	amputations were excluded	107	FIM	Chair transfer	following rehabilitation	Validity	Construct
			·····•g·····•• (· · ···)		-							
			1									
										The European Independence Measure (EIM)		
			1							is an 18 item instrument that assesses		
										function in terms of need for assistance and		
										level o f independence. Developed as part o f		
						High energy lower extremity			Amputation	the Uniform Data System for Medical		
			Transfemoral (22%),			trauma patients. Foot			function	Rehabilitation, the measure was specifically		
L			Transtibial (77%),		_	amputation or bilateral		L	subscore:	designed to evaluate functional outcomes		
Cyril	2001		Through-knee (11%)	nd 3	5	amputations were excluded	107	FIM	Chair transfer	following rehabilitation	Validity	Criterion

Author	Year	PMID	Comparator/Criterion/Outc	(predictive valid)	Metric Used	Value	Strength of Property	Is Aspect Supported?	Conclusion	Notes/Caveats
Cvril	2001		Age <35 vs >=35		P	>0.05		No		3-Month Functional Scale Scores. P-value
Cyn	2001		Age <33 V3 2-33		1	-0.05		NO		based on wannewhiteley o
Cvril	2001		Comorbidities ves vs no		P	>0.05		No		3-Month Functional Scale Scores. P-value
oyin .	2001					- 0.00		110		
Cyril	2001		Transtibial vs Transfemoral		Р	>0.05		No		12-Month Functional Scale Scores. P-valu based on Mann-Whitney U
Cyril	2001		ISS Score <13 vs >=13		Р	>0.05		No		12-Month Functional Scale Scores. P-valu based on Mann-Whitney U
Cvril	2001		Age <35 vs >=35		Р	>0.05		No		12-Month Functional Scale Scores. P-value
oy	2001		7.90 00 10 00			0.00				
Cvril	2001		Comorbidities ves vs no		Р	>0.05		No		12-Month Functional Scale Scores. P-valu
	2001									Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not
										was constructed. Normal walking speed was defined as those who completed a 15 foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the
Cyril	2001		Normal Walking Speed (Yes vs No)		Pearson r	-0.04	None	No		number of seconds it took for individuals to walk 150 feet was used.

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
			Transfemoral (22%), Transfilial (77%)		-	High energy lower extremity trauma patients. Foot amoutation or histeral			Amputation function subscore:	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed the valuate functional outcomes		
Cyril	2001		Through-knee (11%)	nd	35	amputations were excluded	107	FIM	Chair transfer	following rehabilitation	Validity	Criterion
Cvril	2001		Transfemoral (22%), Transtibial (77%), Throuch-knee (11%)	pd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Chair transfer	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Criterion
Cyni	2001		Through-knee (11%)	na	35	amputations were excluded	107	FIM	Chair transfer	Tollowing renabilitation	validity	Criterion
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Chair transfer	Inter takatorial independence measure (Fins) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation The Eurotical Independence Measure (FIM)	Floor/ceiling effect	Floor
Cvril	2001		Transfemoral (22%), Transtibial (77%), Throuch-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Chair transfer	It is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Reliability	Internal Consistency
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Chair transfer	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Responsiven	nd
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Chair transfer	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Responsiven	nd
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Chair transfer	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part o f the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Floor/ceiling effect	Ceiling
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Climb stairs	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct

				Timepoint			0			
Author	Voar		comparator/Criterion/Outc	(predictive	Motric Used	Value	Strength of	IS ASPECT	Conclusion	Notes/Caveate
Author	Year	PMID	ome Walking Speed (continuous	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 150- foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to
Cyril	2001		score)		Pearson r	0.1	None	No		walk 150 feet was used. Return to usual activity by 12 months after
			Return to Usual Activity							injury. Respondents reported their major activity at baseline and all subsequent follow-up periods (defined as working, laid off, looking for work, school, keeping house, retired, and other). Returning to one's usual activity was defined as resuming the same activity or to an activity
Cyril	2001		(Yes vs No)		Pearson r	-0.01	None	NO		o f equal or greater productivity
Cyril	2001		nd		%	1		No		
Cyril	2001		nd		Cronbach's alpha	0.85	Excellent	Yes		
										Effect Size Statistics for Change in Scores
Cyril	2001		nd		SRM	-0.2				Between 3 and 12 Months
Oveil	2001		rd		Effect size with	0.22				Effect Size Statistics for Change in Scores
Cyril	2001		na		paseline SD	-0.23				Between 3 and 12 Months
Cvril	2001		nd		%	0		Νο		
	2001									
Cyril	2001		Transtibial vs Transfemoral		Ρ	>0.05		No		3-Month Functional Scale Scores. P-value based on Mann-Whitney U

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
			Transfemoral (22%), Transtibial (77%),			High energy lower extremity trauma patients. Foot amputation or bilateral			Amputation function subscore:	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes		
Cyril	2001		Through-knee (11%)	nd	35	amputations were excluded High energy lower extremity trauma patients. Foot	107	FIM	Climb stairs Amputation function	following rehabilitation The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically	Validity	Construct
Cvril	2001		Through-knee (11%)	nd	35	amputation or bilateral	107	FIM	SUDSCORE: Climb stairs	designed to evaluate functional outcomes	Validity	Construct
Cvril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Climb stairs	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cym	2001		Transfemoral (22%), Transtibial (77%),	10	33	High energy lower extremity trauma patients. Foot amputation or bilateral			Amputation function subscore:	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes	Validity	Constitute
Cyril	2001		Through-knee (11%)	nd	35	amputations were excluded	107	FIM	Climb stairs	following rehabilitation	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Climb stairs	In the United in Instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Climb stairs	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Climb stairs	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Climb stairs	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Criterion

			Comparator/Criterion/Outc	Timepoint			Strength of	le Aenoct		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
De coli	2001				D	> 0.05		No		3-Month Functional Scale Scores. P-value
yrii	2001		155 Scole < 15 VS >= 15		r	>0.05		INO		based on Mann-whitney O
					_					3-Month Functional Scale Scores. P-value
Cyril	2001		Age <35 vs >=35		Р	>0.05		No		based on Mann-Whitney U
										3-Month Functional Scale Scores. P-value
Syril	2001		Comorbidities yes vs no		P	>0.05		No		based on Mann-Whitney U
										12-Month Functional Scale Scores. P-valu
Cyril	2001		Transtibial vs Transfemoral		Р	>0.05		No		based on Mann-Whitney U
										12-Month Functional Scale Scores, P-value
Cyril	2001		ISS Score <13 vs >=13		Р	>0.05		No		based on Mann-Whitney U
										12-Month Functional Scale Scores, P-value
Cyril	2001		Age <35 vs >=35		Р	>0.05		No		based on Mann-Whitney U
										12 Month Euroctional Scale Scores, P.valu
Cyril	2001		Comorbidities yes vs no		Р	>0.05		No		based on Mann-Whitney U
										Walking speed at 12 months: Complete a
										measures of walking speed were used as
										criterion measures. First, a categorical variable that classified individuals as
										walking at a normal walking speed or not
										was constructed. Normal walking speed was defined as those who completed a 15
										foot walk in 37.5 seconds or less, which is
										cross a normal street. Second, a
			Normal Walking Spood (Vac							continuous variable representing the
Cyril	2001		vs No)		Pearson r	0.03	None	No		walk 150 feet was used.

			Amputation	Other Population						
Author	Year	PMID Amputation Level	Etiology Age	Information	N	Instrument	Subscale	Description	Property	Aspect
		Transfemoral (22%), Transtibial (77%)		High energy lower extremity trauma patients. Foot amountation or bilateral			Amputation function subscore:	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes		
Cyril	2001	Through-knee (11%)	nd 35	amputations were excluded	107	FIM	Climb stairs	following rehabilitation	Validity	Criterion
Cvril	2001	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd 35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Climb stairs	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Criterion
o jiii	2001	Through knoo (TT)oy			101		Chinib Claire	The Functional Independence Measure (FIM)	vanany	
Cyril	2001	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd 35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Climb stairs	is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Floor/ceiling effect	Floor
Curil	2001	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd 35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Climb stairs	Inter valicational interpendence measure (rimi) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Reliability	Internal Consistency
Cyril	2001	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd 35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Climb stairs	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Responsiven	nd
Cyril	2001	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd 35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Climb stairs	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Responsiven	nd
Cyril	2001	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd 35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Walk on level surface	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Floor/ceiling effect	Ceiling
Cyril	2001	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd 35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Walk on level surface	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct

				Timepoint			O			
Author	Voar		comparator/Criterion/Outc	(predictive	Motric Used	Value	Strength of	IS ASpect	Conclusion	Notes/Caveate
Author	Year	PMID	ome Walking Speed (continuous	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 150- foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to
Cyril	2001		score)		Pearson r	0.06	None	No		walk 150 feet was used. Return to usual activity by 12 months after injury. Respondents reported their major
Curil	2001		Return to Usual Activity		Pearson r	0.1	Small	Linclear		activity at baseline and all subsequent follow-up periods (defined as working, laid off, looking for work, school, keeping house, retired, and other). Returning to one's usual activity was defined as resuming the same activity or to an activity of equal or respect productivity.
	2001				. 50/50/11	0.1	Gridi	Choical		o requirer greater productivity
Cyril	2001		nd		%	4.7		No		
					Cronbach's					
Cyril	2001		nd		alpha	0.62	Adequate	Yes		
Cyril	2001		nd		SRM	-0.52				Effect Size Statistics for Change in Scores Between 3 and 12 Months
					Effect size with					Effect Size Statistics for Change in Scores
Cyril	2001		nd		baseline SD	-0.52				Between 3 and 12 Months
Cvril	2001		nd		%	0		No		
			-			-		-		
Cyril	2001		Transtibial vs Transfemoral		Ρ	>0.05		Νο		3-Month Functional Scale Scores. P-value based on Mann-Whitney U

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
0 - 1	0004		Transfemoral (22%), Transtibial (77%),			High energy lower extremity trauma patients. Foot amputation or bilateral	107		Amputation function subscore: Walk on level	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes		
Cyril	2001		Through-knee (11%)	nd	35	amputations were excluded	107	FIM	surface	tollowing rehabilitation	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Walk on level surface	In the United an Independence measure (Tim) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cvril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Walk on level surface	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
			Transfemoral (22%), Transtibial (77%),			High energy lower extremity trauma patients. Foot amputation or bilateral			Amputation function subscore: Walk on level	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes		
Cyril	2001		Through-knee (11%)	nd	35	amputations were excluded	107	FIM	surface	following rehabilitation	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Walk on level surface	is an 18-tem instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Walk on level surface	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Walk on level surface	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	Ind	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Walk on level surface	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Criterion

			Comparator/Criterion/Outc	Interior			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Svril	2001		ISS Score <13 vs >=13		Р	>0.05		No		3-Month Functional Scale Scores. P-value based on Mann-Whitney U
					-					
Cvril	2001		Ace <35 vs >=35		P	>0.05		No		3-Month Functional Scale Scores. P-value
<u>.</u>	2001					0.00				
Cvril	2001		Comorbidities ves vs no		P	>0.05		No		3-Month Functional Scale Scores. P-value based on Mann-Whitney U
<u>.</u>	2001					0.00				
Cvril	2001		Transtibial vs Transfemoral		P	>0.05		No		12-Month Functional Scale Scores. P-value
Sym	2001				1	-0.05		INO		based on Mannewhitney o
Curil	2001		ISS Score <13 ve >=13		D	>0.05		No		12-Month Functional Scale Scores. P-value
Jyin	2001		100 00010 110 10 20 10		1	-0.05		INO		based on Mannewhitney o
∩vril	2001		Ace <35 vs >=35		D	>0.05		No		12-Month Functional Scale Scores. P-value
/y111	2001		Age <33 V3 2-33		1	-0.05		INO		based on Mannewhitney o
Curil	2001		Comorbidities ves vs po		D	>0.05		No		12-Month Functional Scale Scores. P-value
5ym	2001					0.00		110		Walking speed at 12 months: Complete a
										150 foot walk as fast as they could. Two
										criterion measures. First, a categorical
										variable that classified individuals as walking at a normal walking speed or not
										was constructed. Normal walking speed
										foot walk in 37.5 seconds or less, which is
										equivalent to the average time it takes to
										continuous variable representing the
Cvril	2001		Normal Walking Speed (Yes		Pearson r	0.13	Small	Linclear		number of seconds it took for individuals to
yıll	2001	1	vs NU)	1	rearson r	0.13	SIIIdli	Unciear	1	Waik 100 leel was used.

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001		Transfemoral (22%), Transtibial (77%), Thrunchknee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Walk on level surface	The Functional Independence Measure (FIM) is an 18-Item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Criterion
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Walk on level surface	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Criterion
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Walk on level surface	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Floor/ceiling effect	Floor
0.41	2004		Transfemoral (22%), Transtibial (77%),		25	High energy lower extremity trauma patients. Foot amputation or bilateral	107		Amputation function subscore: Walk on level	The Functional Independence Measure (FIM) is an 18-Item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes	Deliek ^m t	
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Walk on level surface	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Responsiven	nd
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%) Transfemoral (22%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	FIM	Amputation function subscore: Walk on level surface	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Responsiven	nd
Leung	1996	8831480	Transtenioral (n=8), Transtibial (n=24), Bilateral (n=1)	nd	nd	NR-89	33	FIM	motor subscore		Validity	Convergent
Leung	1996	8831480	Transtemoral (n=8), Transtibial (n=24), Bilateral (n=1)	nd	nd		33	FIM	Discharge motor subscore		Validity	Predictive
Cox, Williams & Weaver	2011		Transfemoral (n=23), Transtibial (n=64)	Diabetes	62	nd	87	FIM	Overall		Validity	Known group
-	2.511		Transfemoral (n=23),						Total Overall		validity	i down gloup
Cox	2011		Transtibial (n=64) Transfemoral (n=17), transtibial (n=14), hindquarter (n=1), bilateral transtibial (n=1), bilateral	Diabetes	62		87	IFIM	Scale Total Overall		Responsiven	Known group
Panesar	2001		transfemoral (n=1)	nd	67		34	FIM	Scale	Ability to measure change	ess	nd

			Commerce al Critori en l'Outo	Timepoint			Charamath of	In Annant		
Author	Year	PMID	comparator/Criterion/Outc	(predictive valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Cyril	2001		Walking Speed (continuous score)		Pearson r	0	None	No		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 150- foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.
Cyril	2001		Return to Usual Activity (Yes vs No)		Pearson r	0.13	Small	Unclear		Return to usual activity by 12 months after injury. Respondents reported their major activity at baseline and all subsequent follow-up periods (defined as working, laid off, looking for work, school, keeping house, retired, and other). Returning to one's usual activity was defined as resuming the same activity or to an activity o f equal or greater productivity
Cyril	2001		nd		%	2		No		
Cyril	2001		nd		Cronbach's alpha	0.75	Adequate	Yes		
Cyril	2001		nd		SRM	-0.25				Effect Size Statistics for Change in Scores Between 3 and 12 Months
Cyril	2001		nd		Effect size with baseline SD	-0.27				Effect Size Statistics for Change in Scores Between 3 and 12 Months
Leung	1996	8831480	Houghton score		45 days (mean)	Spearman r	0.58	Large	Yes	The motor subscore at discharge correlates with the use of prosthesis
Leung	1996	8831480	Houghton score>=9 vs. Houghton score<9	3-12 months	P	0.0015		Yes	The motor subscore at discharge correlates with the use of prosthesis	
Cox, Williams &										
Weaver,	2011		below vs above knee		P value	<0.0001				
Cox	2011		below vs above knee		P value	<0.0001				
									significant changes between	
Panesar	2001		P value		<0.00001				admission and discharge	

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
			Transfemoral (n=17), transtibial (n=14), hindquarter (n=1), bilateral transtibial (n=1), bilateral						Total Overall			
Panesar	2001		transfemoral (n=1)	nd	67		34	FIM	Scale		Validity	Convergent
Dite	2007		Transtibial	nd	61.6	Unilateral	40	Four Square Step Test			Validity	Known group/Discriminant
Miller	2004	15180125	Transfemoral (n=24) , Transtibial (n=60)	Vascular (n=34), Trauma (n=50)	56.5	nd	84	Frenchay Activities Index	nd	assesses frequency of participation in domestic chores, work/leisure and outdoor activities. Scores ranging from 0 (no activity) to 45 (very high participation).	Reliability	Internal Consistency
N 111	0004	15100105	Transfemoral (n=24),	Vascular (n=34),	50.5			E	- 4	assesses frequency of participation in domestic chores, work/leisure and outdoor activities. Scores ranging from 0 (no activity)	Dellability	Testerite
Miller	2004	15180125	I ranstibial (n=60)	Trauma (n=50)	56.5	nd	84	Frenchay Activities Index	nd	to 45 (very high participation). The FAI is a 15-item self-report measure that	Reliability	l est-retest
Millor	2004	15190125	Transfemoral (n=24) ,	Vascular (n=34),	66 E	ad	94	Franchay Activitian Inday	nd	assesses frequency of participation in domestic chores, work/leisure and outdoor activities. Scores ranging from 0 (no activity) to 45 (unc) bith participation)	Volidity	Construct
	2004	15100125	Transfemoral (n=24) ,	Vascular (n=34),	50.5		04	Frenchay Activities Index	nd	The FAI is a 15-item self-report measure that assesses frequency of participation in domestic chores, work/leisure and outdoor activities. Scores ranging from 0 (no activity)	Validity	
Miller	2004	15180125	I ranstibial (n=60)	Trauma (n=50)	56.5	nd	84	Frenchay Activities Index	nd	to 45 (very high participation).	Validity	Construct
Miller	2004	15180125	Transfemoral (n=24) , Transtibial (n=60)	Vascular (n=34), Trauma (n=50)	56.5	nd	84	Frenchay Activities Index	nd	The FAI is a 15-item self-report measure that assesses frequency of participation in domestic chores, work/leisure and outdoor activities. Scores ranging from 0 (no activity) to 45 (very high participation).	Validity	Convergent
Miller	2004	15180125	Transfemoral (n=24) , Transtibial (n=60)	Vascular (n=34), Trauma (n=50)	56.5	nd	84	Frenchay Activities Index	nd	The FAI is a 15-item self-repor-t measure that assesses frequency of participation in domestic chores, work/leisure and outdoor activities. Scores ranging from 0 (no activity) to 45 (very high participation).	Validity	Convergent
Miller	2004	15180125	Transfemoral (n=24) , Transtibial (n=60)	Vascular (n=34), Trauma (n=50)	56.5	nd	84	Frenchay Activities Index	nd	The FAI is a 15-item self-repor-t measure that assesses frequency of participation in domestic chores, work/leisure and outdoor activities. Scores ranging from 0 (no activity) to 45 (very high participation).	Validity	Convergent
Miller	2004	15180125	Transfemoral (n=24) , Transtibial (n=60)	Vascular (n=34), Trauma (n=50)	56.5	nd	84	Frenchay Activities Index	nd	The FAI is a 15-item self-report measure that assesses frequency of participation in domestic chores, work/leisure and outdoor activities. Scores ranging from 0 (no activity) to 45 (very high participation).	Validity	Convergent
										To broaden the range of activities we added		<u> </u>
Miller	2004	15180125	Transtemoral (n=24), Transtibial (n=60)	vascular (n=34), Trauma (n=50)	56.5	nd	84	Frenchay Activities Index- 18	nd	three items to the existing FAI. The total score of the FAI- 1 8 ranges from 0 to 54 To broaden the range of activities we added	Reliability	Internal Consistency
Miller	2004	15180125	Transfemoral (n=24) , Transtibial (n=60)	Vascular (n=34), Trauma (n=50)	56.5	nd	84	Frenchay Activities Index- 18	nd	three items to the existing FAI. The total score of the FAI- 1 8 ranges from 0 to 54	Reliability	Test-retest
Miller	2004	15180125	Transfemoral (n=24) , Transtibial (n=60)	Vascular (n=34), Trauma (n=50)	56.5	nd	84	Frenchay Activities Index- 18	nd	To broaden the range of activities we added three items to the existing FAI. The total score of the FAI- 1 8 ranges from 0 to 54	Validitv	Construct
			Transfemoral (n=24),	Vascular (n=34),				Frenchay Activities Index-		To broaden the range of activities we added three items to the existing FAI. The total score		
Miller	2004	15180125	Transtibial (n=60)	Trauma (n=50)	56.5	nd	84	18	nd	of the FAI- 1 8 ranges from 0 to 54	Validity	Construct

			Comparator/Criterion/Outc	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
										significant kendal correlations coefficients
Panesar	2001		OPCS, AAS, FIM		P value	<0.0001				between each of the measures
					Multiple Fallers					
Dito	2007				vs nonmultiple	D Value	-0.001			
Dite	2007				Fallers	r value	<0.001			
N 4111	0004	45400405	- 4		Cronbach's	0.01	E II t	N		
Miller	2004	15180125	na		aipna	0.81	Excellent	Yes	Good Internal consistency	
Miller	2004	15180125	nd		ICC	0.79	Good	Yes	Strong test-retest reliability.	
									The FAI did not discriminate	
									between Transfemoral and	
Miller	2004	15180125	Transfemoral vs transtibial		Р	>=0.05		No	transtibial	
									The FAI discriminated between	
									Transfemoral and transtibial	
Miller	2004	15180125	Vascular vs trauma		Р	<0.05		Yes	Vascular and trauma	
									Hypothesized relationships (p	
									<00001) between both FAI	
									versions and the Activity-	
									Scale, Prosthetic Evaluation	
									Questionnaire - Mobility Scale,	
					_				2-minute walk and timed up and	
Miller	2004	15180125	I wo-minute walk		Pearson r	0.526	Large	Yes	go test were observed.	
									<pre>Appoint Appoint A</pre>	
									versions and the Activity-	
									specific Balance Confidence	
									Scale, Prosthetic Evaluation	
									Questionnaire - Mobility Scale, 2 minute walk and timed up and	
Miller	2004	15180125	Timed up and go		Pearson r	-0.486	Moderate	Yes	go test were observed.	
			i i i gi						Hypothesized relationships (p	
									<00001) between both FAI	
									versions and the Activity-	
									Scale Prosthetic Evaluation	
									Questionnaire - Mobility Scale,	
									2-minute walk and timed up and	
Miller	2004	15180125	PEQ-MS		Pearson r	0.386	Moderate	Yes	go test were observed.	
									Hypothesized relationships (p	
									versions and the Activity-	
									specific Balance Confidence	
									Scale, Prosthetic Evaluation	
									Questionnaire - Mobility Scale,	
Miller	2004	15180125	ABC		Pearson r	0.505	Large	Yes	ao test were observed	
	2001	10100120			- ouroonn	0.000	Laigo	1.00	ge teet were esserred.	
					Cronbach's					
Miller	2004	15180125	nd		alpha	0.84	Excellent	Yes	Good internal consistency	
		1								
Miller	2004	15180125	nd		ICC	0.78	Good	Yes	Strong test-retest reliability	
		1		1				1	The FAI-18 did not discriminate	
									between Transfemoral and	
Miller	2004	15180125	Transfemoral vs transtibial		Р	>=0.05		No	transtibial	
									hetween Transfermoral and	
Miller	2004	15180125	Vascular vs trauma		Р	<0.05		Yes	transtibial Vascular and trauma	
k										
Amputation Other Population										
--	--									
Author Year PMID Amputation Level Etiology Age Information N Instrument Subscale Description	Property Aspect									
To broaden the range	of activities we added									
Transfemoral (n=24), Vascular (n=34), receive the exit	sting FAI. The total score									
Miller 2004 15180125 Iranstibial (n=60) Irauma (n=50) 56.5 nd 84 18 nd of the FAI-18 range	s from 0 to 54 Validity Convergent									
To broaden the range	of activities we added									
Iranstemoral (n=24), Vascular (n=34), Frenchay Activities Index- Miller 2004 15180125 Transtbial (n=50) 56 5 nd 84 18 none of the FAL 18 rance	sting FAI. The total score									
	Validity Controlgent									
To broaden the range	e of activities we added									
Miller 2004 15180125 Trauma (n=50) 56.5 nd 84 18 nd of the FAL 3 range	s from 0 to 54 Validity Convergent									
To broaden the range	of activities we added									
Transfemoral (n=24), Vascular (n=34), Frenchay Activities Index- three items to the exit	sting FAI. The total score									
Miller 2004 15180125 Transtibial (n=60) Trauma (n=50) 56.5 nd 84 18 nd of the FAI- 18 range	from 0 to 54 Validity Convergent									
Transfemoral (n=17), Transfibil (n=23)										
transgenual (n=5), hip PAD (n=45),										
disarticulation (n=1), astromyelitis (n=1), mission approximation (n=1), astromyelitis (n=1), mission approximation (n=1), astromyelitis (n=1), mission approximation (n=1), astromyelitis (n=1), mission										
Timo amputation unnou (n=1), 75.2 48 Categories (FAC) Score	Validity Construct									
The Functional Indep	endence Measure (FIM)									
is an 18-item instruction in terms of f	ent that assesses									
level of independent	e. Developed as part o f									
High energy lower extremity the Uniform Data Sys	tem for Medical									
Intranseminari (22%), trauma patients. Foot infunctional independence Kehabilitätion, the min Transtibial (7%), amputation or bilateral Measure - Amputation designed to evaluate	functional outcomes									
Cyril 2001 0 Through-knee (11%) nd 35 amputations were excluded 107 function subscore Chair transfer following rehabilitatio	n Reliability Internal Consistency									
The Functional Indep	endence Measure (FIM)									
is an information in the information of the informa	eed for assistance and									
level o f independence	e. Developed as part o f									
	tem tor Medical									
High energy lower extremity the Uniform Data System of the Uniform Data Sys	pasure was specifically									
High energy lower extremity Transfemoral (22%), Transtibial (77%),High energy lower extremity trauma patients. Foot amputation or bilateralFunctional Independence Measure - Amputationthe Uniform Data Sys Rehabilitation, the mu designed to evaluate	functional outcomes Floor/ceiling									
Cyril 2001 0 Through-knee (11%) nd 35 amputation of bilateral amputation of bilateral 107 functional Independence Measure - Amputation the Uniform Data System Rehabilitation, the minimation of bilateral Cyril 2001 0 Through-knee (11%) nd 35 amputations were excluded 107 function subscore Chair transfer following rehabilitation	saure was specifically functional outcomes Floor/ceiling n enderen Measure (CIII)									
Cyril 2001 0 Through-knee (11%) nd 35 amputation or bilateral amputation or bilateral 107 Functional Independence function subscore The Uniform Data Sy: Rehabilitation, the minimum designed to evaluate Cyril 2001 0 Through-knee (11%) nd 35 amputations were excluded 107 function subscore Chair transfer following rehabilitation (The Functional Independence is an 18-item instrum	saure was specifically functional outcomes Floor/ceiling n effect Ceiling endence Measure (FIM) ent that assesses									
Cyril 2001 0 Transfemoral (22%), Transtbial (77%), Transtbial (77%), nd 35 High energy lower extremity trauma patients. Foot amputation or bilateral amputation or bilateral amputations were excluded Functional Independence Measure - Amputation function subscore Rehabilitation, the mu designed to evaluate following rehabilitation Cyril 0 Through-knee (11%) nd 35 amputation or bilateral amputations were excluded 107 Functional Independence function subscore The Functional Independence is an 18-item instrum function in terms of fr	A server was specifically functional outcomes Floor/ceiling endence Measure (FIM) ent that assesses eed for assistance and									
Cyril 2001 0 Transfemoral (22%), Transtibial (77%), Transtibial (77%), nd High energy lower extremity trauma patients. Foot a amputation or bilateral amputation or bilaterampateral bilatera bilatera bilatera bilatera bilatera b	In the intervention in the line of the intervention is the intervention of the interve									
Cyril20010Transfemoral (22%), Transtibial (77%).Transfemoral (22%), ndHigh energy lower extremity trauma patients. Foot amputation or bilateral amputation or bilateral amputation or bilateral amputation or bilateral amputation swere excludedFunctional Independence Measure - Amputation function subscorethe Uniform Data Sys Rehabilitation, the m designed to evaluate the Uniform Data Sys function subscoreCyril00Through-knee (11%)nd35amputation or bilateral amputation swere excluded107Functional Independence function subscoreThe Functional Independence is an 18-tem instrum function in terms of f level of independenceThe Functional Independence the Uniform Data Sys the Uniform Data SysTransfemoral (22%),Transfemoral (22%),High energy lower extremity trauma patients. FootFunctional IndependenceRehabilitation, the m m designed to evaluate	An of the specifically functional outcomes n effect Ceiling endence Measure (FIM) ent that assesses eed for assistance and e. Developed as part o f tem for Medical assure was specifically									

			Comparator/Criterion/Outc	Imepoint			Strength of	ls Asnect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
									Hypothesized relationships (p <00001) between both FAI versions and the Activity- specific Balance Confidence Scale, Prosthetic Evaluation Questionnaire - Mobility Scale, 2-minute walk and timed up and	
Miller	2004	15180125	Two-minute walk		Pearson r	0.548	Large	Yes	go test were observed. Hypothesized relationships (p <00001) between both FAI versions and the Activity- specific Balance Confidence Scale, Prosthetic Evaluation Questionnaire – Mobility Scale, 2-minute walk and timed up and	
Miller	2004	15180125	Timed up and go		Pearson r	-0.462	Moderate	Yes	go test were observed. Hypothesized relationships (p <0001) between both FAI versions and the Activity- specific Balance Confidence Scale, Prosthetic Evaluation Questionnaire - Mobility Scale, 2-minute walk and timed up and	
Miller	2004	15180125	PEQ-MS		Pearson r	0.404	Moderate	Yes	go test were observed. Hypothesized relationships (p <00001) between both FAI versions and the Activity- specific Balance Confidence Scale, Prosthetic Evaluation Questionnaire - Mobility Scale, 2-minute walk and timed up and	
Miller	2004	15180125	ABC		Pearson r	0.518	Large	Yes	go test were observed.	significantly correlated with Barthel index
Cyril	2001	0	nd		Cronbach's alpha	0.85	Excellent	Yes		(waniwilluley 0)
Cvril	2001	0	nd		%	53.3		Yes		
Cyril	2001	0	nd		%	1		No		

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Chair transfer	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Criterion
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Chair transfer	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Criterion
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Chair transfer	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Criterion
Cvril	2001	0	Transfemoral (22%), Transtibial (77%), Throuch-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Chair transfer	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Chair transfer	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001	o	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Chair transfer	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Chair transfer	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct

			Compositor/Critorion/Outo	Timepoint			Steen with al	In Annant		
Author	Year	PMID	ome	(predictive valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Cyril	2001	0	Normal Walking Speed (Yes vs No)		Pearson r	-0.04	None	No		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 150- foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.
Cyril	2001	0	Walking Speed (continuous score)		Pearson r	0.1	None	No		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 150- foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.
Cyril	2001	0	Return to Usual Activity (Yes vs No)		Pearson r	-0.01	None	No		Return to usual activity by 12 months after injury. Respondents reported their major activity at baseline and all subsequent follow-up periods (defined as working, laid off, looking for work, school, keeping house, retired, and other). Returning to one's usual activity was defined as resuming the same activity or to an activity o f equal or greater productivity
Oveil	2001		Transfibial va Transformaral		P	~0.05		No		3-Month Functional Scale Scores. P-value
Cyn	2001				1	20.00				3-Month Functional Scale Scores. P-value
Cyril	2001	0	ISS Score <13 vs >=13		P	>0.05		No		based on Mann-Whitney U
Cyril	2001	0	Age <35 vs >=35		P	>0.05		No		 Month Functional Scale Scores. P-value based on Mann-Whitney U 3-Month Functional Scale Scores. P-value
Cyril	2001	0	Comorbidities yes vs no		Р	>0.05		No		based on Mann-Whitney U

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
			Transfemoral (22%), Transtibial (77%),			High energy lower extremity trauma patients. Foot amputation or bilateral		Functional Independence Measure - Amputation		The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes		
Cyril	2001	0	Through-knee (11%)	nd	35	amputations were excluded	107	function subscore	Chair transfer	following rehabilitation	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Chair transfer	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cvril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amoutations were excluded	107	Functional Independence Measure - Amputation function subscore	Chair transfer	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through knee (11%)	nd	25	High energy lower extremity trauma patients. Foot amputation or bilateral empirtuines were excluded	107	Functional Independence Measure - Amputation		The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following robbilitation	Validity	Construct
Cvril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amoutations were excluded	107	Functional Independence Measure - Amputation function subscore	Chair transfer	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Responsiven	nd
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Chair transfer	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Responsiven	nd
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Climb stairs	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Reliability	Internal Consistency
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Climb stairs	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Floor/ceiling effect	Ceiling
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Climb stairs	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Floor/ceiling effect	Floor

			Comparator/Criterion/Outc	(predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
										12-Month Functional Scale Scores. P-value
Cyril	2001	0	Transtibial vs Transfemoral		Р	>0.05		No		based on Mann-Whitney U
Cvril	2001	0	ISS Score <13 vs >=13		P	>0.05		No		12-Month Functional Scale Scores. P-Value based on Mann-Whitney II
Cyn	2001	0	100 00010 110 10 20 10			-0.05		NO		based on Mani-Whitey o
										12-Month Functional Scale Scores. P-value
Cyril	2001	0	Age <35 vs >=35		Р	>0.05		No		based on Mann-Whitney U
										12-Month Functional Scale Scores, P-value
Cyril	2001	0	Comorbidities yes vs no		Р	>0.05		No		based on Mann-Whitney U
Cvril	2001	0	nd		SRM	-0.2				Effect Size Statistics for Change in Scores Between 3 and 12 Months
0,111	2001		10		or an	0.2				Both control and 12 months
o					Effect size with					Effect Size Statistics for Change in Scores
Cyril	2001	0	nd		baseline SD	-0.23				Between 3 and 12 Months
					Cronbach's					
Cyril	2001	0	nd		alpha	0.62	Adequate	Yes		
Cyril	2001	0	nd		%	0		No		
Cvril	2001	0	nd		%	4.7		No		

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Climb stairs	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Criterion
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Climb stairs	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Criterion
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Climb stairs	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Criterion
Cvril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Climb stairs	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Climb stairs	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Climb stairs	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Climb stairs	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct

			Compositor/Critorion/Outo	Timepoint			Steen with al	In Annant		
Author	Year	PMID	ome	(predictive valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Cyril	2001	0	Normal Walking Speed (Yes vs No)		Pearson r	0.03	None	No		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 150- foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.
Cyril	2001	0	Walking Speed (continuous score)		Pearson r	0.06	None	Νο		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 150- foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.
Cyril	2001	0	Return to Usual Activity (Yes vs No)		Pearson r	0.1	Small	Unclear		Return to usual activity by 12 months after injury. Respondents reported their major activity at baseline and all subsequent follow-up periods (defined as working, laid off, looking for work, school, keeping house, retired, and other). Returning to one's usual activity was defined as resuming the same activity or to an activity o f equal or greater productivity
Queil	2001		Tanalikistus Tanafamani			-0.05		Ne		3-Month Functional Scale Scores. P-value
Cyrii	2001				F	20.05				3-Month Functional Scale Scores. P-value
Cyril	2001	0	ISS Score <13 vs >=13		P	>0.05		No		based on Mann-Whitney U
Cyril	2001	0	Age <35 vs >=35		P	>0.05		No		3-Month Functional Scale Scores. P-value based on Mann-Whitney U 3-Month Functional Scale Scores. P-value
Cyril	2001	0	Comorbidities yes vs no		Р	>0.05		No		based on Mann-Whitney U

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Quel	2004		Transfemoral (22%), Transtibial (77%),		25	High energy lower extremity trauma patients. Foot amputation or bilateral	107	Functional Independence Measure - Amputation	Climb steins	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes	Volisiin	Construct
Cyni	2001	0	Inrougn-knee (11%)	na	35	amputations were excluded	107	function subscore	Climb stairs	Tollowing renabilitation	validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Climb stairs	is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Climb stairs	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through knoc (11%)	nd	25	High energy lower extremity trauma patients. Foot amputation or bilateral empirtuites were excluded	107	Functional Independence Measure - Amputation	Climb stairs	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes fellowing crebabilitations	Validity	Construct
Curil	2001	0	Transfemoral (22%), Transtibial (77%), Through-trage (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Climb stairs	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Responsiven	od
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Climb stairs	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Responsiven	nd
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Overall FIM- AFS	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Reliability	Internal Consistency
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Overall FIM- AFS	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Floor/ceiling effect	Ceiling
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Overall FIM- AFS	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Floor/ceiling effect	Floor

Author	Vaar	DMID	Comparator/Criterion/Outc	(predictive	Matria Llaad	Value	Strength of	Is Aspect	Conclusion	Natas/Caucata
Author	rear	PMID	ome	valid)	Metric Used	value	Property	Supported ?	Conclusion	Notes/Caveats
										12-Month Eurocional Scale Scores, P-value
Cyril	2001	0	Transtibial vs Transfemoral		Р	>0.05		No		based on Mann-Whitney U
					-					12-Month Functional Scale Scores. P-value
Cyril	2001	0	ISS Score <13 vs >=13		Р	>0.05		NO		based on Mann-Whitney U
										12 Month Euroctional Scale Scores, B value
Cyril	2001	0	Age <35 vs >=35		Р	>0.05		No		based on Mann-Whitney U
Ouril	2004	0	Comerkidition was up as		D	> 0.05		No		12-Month Functional Scale Scores. P-value
Cyni	2001	0	Comorbidities yes vs no		F	20.05		NO		based on Mann-whittley O
										Effect Size Statistics for Change in Scores
Cyril	2001	0	nd		SRM	-0.52				Between 3 and 12 Months
Cvril	2001	0	nd		Effect size with baseline SD	-0.52				Effect Size Statistics for Change in Scores Between 3 and 12 Months
oy	2001	•			baconno ob	0.02				
					Cronbach's					
Cyril	2001	0	nd		alpha	0.55	Poor	Unclear		
Cyril	2001	0	nd		%	0		No		
Cyril	2001	U	nd	1	%	U	1	NO	1	

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Overall FIM- AFS	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Criterion
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Overall FIM- AFS	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Criterion
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Overall FIM- AFS	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Criterion
Cvril	2001	0	Transfemoral (22%), Transtibial (77%), Throudh-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amoutations were excluded	107	Functional Independence Measure - Amputation function subscore	Overall FIM- AFS	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Divergent
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Overall FIM- AFS	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Overall FIM- AFS	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Overall FIM- AFS	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct

				Timepoint			Strength of			
Author	Year	PMID	ome	(predictive valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Cyril	2001	0	Normal Walking Speed (Yes vs No)		Pearson r	-0.06	None	No		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 150- foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.
			Walking Speed (continuous							Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 150- foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to
Cyril	2001	0	Return to Usual Activity (Yes vs No)		Pearson r	0.13	Small	Unclear		walk 150 feet was used. Return to usual activity by 12 months after injury. Respondents reported their major activity at baseline and all subsequent follow-up periods (defined as working, laid off, looking for work, school, keeping house, retired, and other). Returning to one's usual activity was defined as resuming the same activity or to an activity of equal or greater productivity.
Gym	2001		(165 V3 N0)		reason	0.02	None			o requeror greater productivity
Cyril	2001	0	Physical Function Index		Pearson r	-0.12		Unclear		3-Month Functional Scale Scores P-value
Cyril	2001	0	Transtibial vs Transfemoral		Ρ	>0.05		No		a Month Eurocional Social Social Public
Cyril	2001	0	ISS Score <13 vs >=13		P	>0.05		No		3-Month Functional Scale Scores. P-value based on Mann-Whitney U
Cyrii	2001	υ	Aye <35 VS >=35		۲	20.05	1	INU		based on Mann-Whitney U

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
0.1	0001		Transfemoral (22%), Transtibial (77%),		05	High energy lower extremity trauma patients. Foot amputation or bilateral	107	Functional Independence Measure - Amputation	Overall FIM-	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes	V - 11-114 -	0 and a d
Cyril	2001	0	Through-knee (11%)	nd	35	amputations were excluded	107	function subscore	AFS	following rehabilitation	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Overall FIM- AFS	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Overall FIM- AFS	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Overall FIM- AFS	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cvril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Overall FIM- AFS	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Overall FIM- AFS	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Responsiven	nd
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Overall FIM- AFS	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Responsiven	nd
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Walk on level surface	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Reliability	Internal Consistency
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Walk on level surface	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Floor/ceiling effect	Ceiling

Author	Year	PMID	Comparator/Criterion/Outc	Timepoint (predictive valid)	Metric Used	Value	Strength of	Is Aspect Supported?	Conclusion	Notes/Caveats
, tallo				randy	inotrio occu	Fuldo	Tropolty	oupportou :		
Cyril	2001	0	Comorbidities yes vs no		Р	>0.05		No		3-Month Functional Scale Scores. P-value based on Mann-Whitney U
Cyril	2001	0	Transtibial vs Transfemoral		Р	>0.05		No		12-Month Functional Scale Scores. P-value based on Mann-Whitney U
Cyril	2001	0	ISS Score <13 vs >=13		Р	>0.05		No		12-Month Functional Scale Scores. P-value based on Mann-Whitney U
Cyril	2001	0	Age <35 vs >=35		Р	>0.05		No		12-Month Functional Scale Scores. P-value based on Mann-Whitney U
										10 Marth Europhicael Ocale Ocares Durcha
Cyril	2001	0	Comorbidities yes vs no		Р	>0.05		No		based on Mann-Whitney U
										Effect Size Statistics for Change in Scores
Cyril	2001	0	nd		SRM	-0.49				Between 3 and 12 Months
					Effect size with					Effect Size Statistics for Change in Scores
Cyril	2001	0	nd		baseline SD	-0.51				Between 3 and 12 Months
					Cronbach's					
Cyril	2001	0	nd		alpha	0.75	Adequate	Yes		
Cyril	2001	0	nd	1	%	0	1	No	1	1

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Walk on level surface	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Floor/ceiling effect	Floor
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Walk on level surface	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Criterion
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Walk on level surface	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Criterion
0, 11	2001		Transfemoral (22%), Transtibial (77%),			High energy lower extremity trauma patients. Foot amputation or bilateral		Functional Independence Measure - Amputation	Walk on level	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes	Validity	e is i
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amoutations were excluded	107	Functional Independence Measure - Amputation function subscore	Walk on level	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Walk on level surface	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation The Europical Independence Measure (EIM)	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Walk on level surface	The Folicional interpendence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct

			Comparator/Criterion/Outc	Timepoint			Strength of	ls Asnect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Cyril	2001	0	nd		%	2		No		
Cyril	2001	0	Normal Walking Speed (Yes vs No)		Pearson r	0.13	Small	Unclear		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was defined as those who completed a 150- foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.
Cvril	2001	0	Walking Speed (continuous score)		Pearson r	0	None	No		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 150- foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.
Cyrii	2001		Return to Usual Activity		realson		None			Waik 100 reet was used. Return to usual activity by 12 months after injury. Respondents reported their major activity at baseline and all subsequent follow-up periods (defined as working, laid off, looking for work, school, keeping house, retired, and other). Returning to one's usual activity was defined as resuming the scame activity or to an activity.
Cyril	2001	0	(Yes vs No)		Pearson r	0.13	Small	Unclear		o f equal or greater productivity
Queil	2001		Transfilial vo Transformani		P	>0.05		No		3-Month Functional Scale Scores. P-value
Cyrii	2001		Transtolal vs. Fransfermoral			20.05				Juaseu on Mann-Wnithey U 3-Month Functional Scale Scores. P-value
Cyril	2001	0	ISS Score <13 vs >=13		Р	>0.05		No		based on Mann-Whitney U
Cyril	2001	0	Age <35 vs >=35		Р	>0.05		No		3-Month Functional Scale Scores. P-value based on Mann-Whitney U

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Curil	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Walk on level	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Walk on level surface	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Walk on level surface	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Walk on level surface	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Walk on level surface	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Walk on level surface	The Functional Independence Measure (FIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Responsiven	nd
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Functional Independence Measure - Amputation function subscore	Walk on level surface	The Functional Independence Measure (FIIM) is an 18-item instrument that assesses function in terms of need for assistance and level of independence. Developed as part of the Uniform Data System for Medical Rehabilitation, the measure was specifically designed to evaluate functional outcomes following rehabilitation	Responsiven	nd
Panesar et al	2001		Transfemoral (n=17), transtibial (n=14), hindquarter (n=1), bilateral transtibial (n=1), bilateral transfemoral (n=1)	nd	67	nd	34	Functional Independence	Total Overall Scale		Validity	Convergent
Panesar et al,	2001		Transfemoral (n=1) Transfemoral (n=17), transtibial (n=14), hindquarter (n=1), bilateral transtibial (n=1), bilateral transfemoral (n=1)	nd	67	nd	34	Functional Independence Measure (FIM)	Total Overall Scale		Ability to measure change	Responsiveness
			Transfemoral (n=8), Transtibial (n=24),					Functional Independent	Admission motor	In the most recent version of FIM, the 18 items that make up the whole FIM score have been subdivided into a motor snbscore and a		
Leung	1996	8831480	Bilateral (n=1)	nd	NR-89	nd	33	Measure	subscore	cognitive subscore	Validity	Construct

Author	Year	PMID	Comparator/Criterion/Outc	Timepoint (predictive valid)	Metric Used	Value	Strength of Property	Is Aspect Supported?	Conclusion	Notes/Caveats
					-					3-Month Functional Scale Scores. P-value
Cyril	2001	0	Comorbidities yes vs no		Р	>0.05		No		based on Mann-Whitney U
										12-Month Functional Scale Scores. P-value
Cyril	2001	0	Transtibial vs Transfemoral		Р	>0.05		No		based on Mann-Whitney U
Cyril	2001	0	ISS Score <13 vs >=13		Р	>0.05		No		12-Month Functional Scale Scores. P-value based on Mann-Whitney U
Curil	2001	0	Are <25 vo >=25		D	>0.05		No		12-Month Functional Scale Scores. P-value
Cym	2001	0	Age <35 VS >=35		F	20.05		NO		based on Manin-Whitney O
										12-Month Functional Scale Scores. P-value
Cyril	2001	0	Comorbidities yes vs no		Р	>0.05		No		based on Mann-Whitney U
										Effect Oles Obstiction for Observe in Osserve
Cyril	2001	0	nd		SRM	-0.25				Between 3 and 12 Months
Cvril	2001	0	nd		Effect size with baseline SD	-0.27				Effect Size Statistics for Change in Scores Between 3 and 12 Months
		-								
										significant kendal correlations coefficients
Panesar et al,	2001		UPCS, AAS, FIM		P value	<0.0001				between each of the measures
										significant changes between admission and
Panesar et al,	2001		nd		P value	<0.00001			The admission FIM score is not	discharge
									useful in predicting successful	
Leung	1996	8831480	Houghton score<9		Р	0.42		No	extremity amputee patients	

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Leung	1996	8831480	Transfemoral (n=8), Transtibial (n=24), Bilateral (n=1)	nd	NR-89	nd	33	Functional Independent	Admission motor subscore	In the most recent version of FIM, the 18 items that make up the whole FIM score have been subdivided into a motor subscore and a cognitive subscore.	Validity	Convergent
Leung	1996	8831480	Transfemoral (n=8), Transtibial (n=24), Bilateral (n=1)	nd	NR-89	nd	33	Functional Independent Measure	Discharge motor subscore	In the most recent version of FIM, the 18 items that make up the whole FIM score have been subdivided into a motor snbscore and a cognitive subscore	Validity	Construct
			Transfemoral (n=8), Transtibial (n=24),					Functional Independent	Discharge motor	In the most recent version of FIM, the 18 items that make up the whole FIM score have been subdivided into a motor snbscore and a		
Leung	1996	8831480	Bilateral (n=1)	nd	NR-89	nd	33	Measure	subscore	cognitive subscore	Validity	Convergent
Callaghan	2002	12227445	Unilateral transtibial	nd	nd		133	Functional Measure for Amputees	number of falls over 1 month		Reliability	Test-retest
Callaghan, Sockalingam,								Functional Measure for	Average number of falls over			
Treeweek and Condie	2002	12227445	Unilateral transtibial	nd	nd	nd	133	Amputees	1month		Reliability	Test-retest
Callaghan	2002	12227445	l Inilateral transtitial	nd	nd		133	Functional Measure for	prosthetic use per day in		Reliability	Test-retest
Callaghan, Sockalingam,	2002	12221440					100	Functional Measure for	Average prosthetic use per day in		rendbinty	
Treeweek and Condie	2002	12227445	Unilateral transtibial	nd	nd	nd	133	Amputees	hours		Reliability	Test-retest
Gallagher	2000	study 2	Partial root (n=2), below knee (n=29), through knee (n=3), above knee (n=20), hip disarticulation (n=4), bilateral (n=1), not specified (n=1)	congenital (n=7), cancer (n=13), Accident (n=27), peripheral vascular disorder (n=7), other (n=6; not described further)	47.1	18+ years old	60	Functional Measure for Amputees	Average prosthetic use per day in hours		Validity	Convergent
Gallagher	2000	study 2	Partial foot (n=2), below knee (n=29), through knee (n=3), above knee (n=20), hip disarticulation (n=4), bilateral (n=1), not specified (n=1)	Congenital (n=7), cancer (n=13), Accident (n=27), peripheral vascular disorder (n=7), other (n=6; not described further)	47.1	18+ years old	60	Functional Measure for Amputees	Average prosthetic use per day in hours	Average per day	Validity	Convergent
Gallagher	2000	study 2	Partial foot (n=2), below knee (n=29), through knee (n=3), above knee (n=20), hip disarticulation (n=4), bilateral (n=1), not specified (n=1)	Congenital (n=7), cancer (n=13), Accident (n=27), peripheral vascular disorder (n=7), other (n=6; not described further)	47.1	18+ years old	60	Functional Measure for Amputees	Average prosthetic use per day in hours	Average per day	Validity	Convergent
Callachan	2002	12227445	I Inilatoral transtitial	nd	nd		133	Functional Measure for	Average prosthetic use per weeks in		Peliability	Test refect
Galldynan	2002	12221440	ormaterar transtibilat	nu	nd		133	Ampulees	udys		Reliability	1001-101051
Callaghan, Sockalingam, Treeweek and Condie	2002	12227445	Unilateral transtibial	nd	nd	nd	133	Functional Measure for Amputees	Average prosthetic use per weeks in days		Reliability	Test-retest
Remes et al.	2010		nd	peripheral artery disease	75.17	nd	59	Geriatric Depression Scale	nd		Validitv	Known group/Discriminant
Remes	2010		nd	peripheral artery disease	75.17		59	Geriatric Depression Scale			Validity	Known group/Discriminant
			Transfemoral (n=17),									
Hanspal	1997	9331580	Transtibial (n=15) Transfemoral (n=6),	nd	66.4		32	Grade of mobility			Validity	Predictive
Coffey	2009	19900240	Transtibial (n=23), bilateral (n=9)	Diabetes-related	68 (median)	nd	38	HADS	Anxiety		Validity	Convergent
			Transfemoral (n=6), Transtibial (n=23),		- S (modian)				. and y		. canoncy	
Coffey	2009	19900240	bilateral (n=9)	Diabetes-related	68 (median)	nd	38	HADS	Anxiety		Validity	Convergent

			Timepoint						
Vear	PMID	Comparator/Criterion/Outc	(predictive	Metric Used	Value	Strength of Property	Is Aspect Supported?	Conclusion	Notes/Caveats
1996	8831480	Houghton score	valiaj	Spearman r	0 18	Small	No	The admission FIM score is not useful in predicting successful prosthetic rehabilitation in lower extremity ampute patients	NOIES CAVEALS
1996	8831480	Houghton score>=9 vs. Houghton score<9		P	0.0015		Yes	The motor subscore at discharge correlates with the use of prosthesis	
								The motor subscore at discharge correlates with the	
1996	8831480	Houghton score		Spearman r	0.58	Large	Yes	use of prosthesis	
2002	12227445			ICC	0.64				
2002	12227445			ICC	0.64				
2002	12227445			ICC	0.85				
2002	12227445			ICC	0.85				
2000	study 2	TAPES Functional restriction		Correlation r	-0.313	Moderate	Yes		p<0.02
2000	study 2	TAPES Social restriction		Correlation r	-0.376	Moderate	Yes		n<0 005
2000	study 2	TAPES Athletic activity restriction		Correlation r	-0.366	Moderate	Yes		p<0.05
2002	12227445			ICC	0.96				
2002	12227445			ICC	0.96				
2010		amputees vs control group		P value	0.071				
2010		amputees vs control group		P value	0.071				
1997	9331580	Cognitive ability	8-14 months		Pearson r	0.45	Moderate		
2009	19900240	HADS Depression		Spearman r	0.62				
2009	19900240	ABIS-R		Spearman r	0.77				
	Year 1996 1996 2002 2002 2002 2002 2002 2002 2000 200 2000 2	Year PMID 1996 8831480 1996 8831480 1996 8831480 1996 8831480 1996 8831480 1996 8831480 2002 12227445 2002 12227445 2002 12227445 2000 study 2 2001 12227445 2002 12227445 2001 12227445 2002 12227445 2001 12227445 2010 9331580 2009 19900240	Year PMID Comparator/Criterion/Outc ome 1996 8831480 Houghton score 1996 8831480 Houghton score>=9 vs. Houghton score<9	Year PMID Comparator/Criterion/Out ome Timepoint (valid) 1996 8831480 Houghton score - 1996 8831480 Houghton score>=9 vs. Houghton score<9	YearPMIDComparator/Criterion/Out valid)Timepoint wetric Used19968831480Houghton scoreSpearman r19968831480Houghton score>=9 vs. Houghton score<9	Year PMID Comparator/Criterion/Out or gredicitie Metric Used Value 1996 8831480 Houghton score Spearman r 0.18 1996 8831480 Houghton score>9 vs. Houghton score>9 vs. P 0.0015 1996 8831480 Houghton score>9 vs. Houghton score Incc 0.64 2002 12227445 Incc 0.64 0.64 2000 study 2 TAPES Functional restriction Incc 0.313 2000 study 2 TAPES Social restriction Correlation r 0.376 2000 study 2 TAPES Athletic activity Incc 0.366 2001 12227445 Incc 0.366 Incc	Year PMID Comparator/Criterion/Out ome Timepoint value Metric Used Value Strength of Property 1996 8831480 Houghton score Spearman r 0.18 Small 1996 8831480 Houghton score>9 vs. P 0.0015 Image: Spearman r 0.58 Large 1996 8831480 Houghton score Image: Spearman r 0.58 Large 2002 12227445 Image: Spearman r 0.58 Large 2002 12227445 Image: Spearman r 0.64 Image: Spearman r 0.58 Image: Spearman r 2002 12227445 Image: Spearman r 0.64 Image: Spearman r 0.64 Image: Spearman r 2002 12227445 Image: Spearman r Image: Spearman r 0.36 Image: Spearman r 0.375 Moderate 2000 study 2 TAPES Functional restriction Correlation r 0.376 Moderate 2000 study 2 TAPES Athletic activity Image: Spearman r 0.366 Image: Spearma r 0.366 <t< td=""><td>YearPMIDComparator/Criterion/Out orneTimepoint valueMetric UsedValueStrength of Propertyis Aspect Supported?1986831480Houghton score>=9 vs. Houghton score>=9 vs. PP0.015ImageYes1986831480Houghton score>=9 vs. Houghton score>=9 vs. Houghton score>=9 vs. Houghton score>=9 vs. PSpearman r0.58ImageYes200212227445ImageImageImageYesImageYes200212227445ImageImageImageImageImageImage200212227445ImageImageImageImageImageImageImage200212227445ImageImageImageImageImageImageImageImage200212227445ImageImageImageImageImageImageImageImageImageImage2004study 2TAPES Functional restrictionImage</td><td>Year Patho Comparator/Criterion/Criterion/Version Internet of the constraint of th</td></t<>	YearPMIDComparator/Criterion/Out orneTimepoint valueMetric UsedValueStrength of Propertyis Aspect Supported?1986831480Houghton score>=9 vs. Houghton score>=9 vs. PP0.015ImageYes1986831480Houghton score>=9 vs. Houghton score>=9 vs. Houghton score>=9 vs. Houghton score>=9 vs. PSpearman r0.58ImageYes200212227445ImageImageImageYesImageYes200212227445ImageImageImageImageImageImage200212227445ImageImageImageImageImageImageImage200212227445ImageImageImageImageImageImageImageImage200212227445ImageImageImageImageImageImageImageImageImageImage2004study 2TAPES Functional restrictionImage	Year Patho Comparator/Criterion/Criterion/Version Internet of the constraint of th

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
			Transfemoral (n=6), Transtibial (n=22)									
Coffev	2009	19900240	bilateral (n=9)	Diabetes-related	68 (median)	nd	38	HADS	Anxiety		Validity	Convergent
			Transfemoral (n=6),									
Coffey	2000	10000240	Transtibial (n=23), bilateral (n=9)	Disbetes related	68 (median)	nd	38	HADS	Anviety		Validity	Convergent
Colley	2003	13300240	Transfemoral (n=6),	Diabetes-related	oo (median)	10	50	TIADO	AllAlety		validity	Convergent
			Transtibial (n=23),									
Coffey	2009	19900240	bilateral (n=9) Transfemoral (n=6)	Diabetes-related	68 (median)	nd	38	HADS	Anxiety		Validity	Convergent
			Transtibial (n=23),									
Coffey	2009	19900240	bilateral (n=9)	Diabetes-related	68 (median)	nd	38	HADS	Anxiety		Validity	Convergent
			Transfemoral (n=6), Transfibial (n=23)									
Coffey	2009	19900240	bilateral (n=9)	Diabetes-related	68 (median)	nd	38	HADS	Anxiety		Validity	Convergent
			Transfemoral (n=6),									
Coffev	2009	19900240	bilateral (n=23),	Diabetes-related	68 (median)		38	HADS	Anxiety		Validity	Convergent
			Transfemoral (n=6),									
Catter	2000	10000240	Transtibial (n=23),	Dishetes related	60 (median)		20		Aminhi		Validity	Conversent
Colley	2009	19900240	Transfemoral (n=6),	Diabetes-related	08 (median)		30	HAD3	Anxiety		validity	Convergent
			Transtibial (n=23),									
Coffey	2009	19900240	bilateral (n=9) Transfemoral (n=6)	Diabetes-related	68 (median)		38	HADS	Anxiety		Validity	Convergent
			Transtibial (n=23),									
Coffey	2009	19900240	bilateral (n=9)	Diabetes-related	68 (median)		38	HADS	Anxiety		Validity	Convergent
			Transfemoral (n=6), Transfibial (n=23)									
Coffey	2009	19900240	bilateral (n=9)	Diabetes-related	68 (median)		38	HADS	Anxiety		Validity	Convergent
			Transfemoral (n=6),									
Coffev	2009	19900240	bilateral (n=23),	Diabetes-related	68 (median)		38	HADS	Anxiety		Validity	Convergent
			Transfemoral (n=6),									gem
Coffor	2000	10000240	Transtibial (n=23),	Diabatas related	69 (modian)		20		Anvioty		Volidity	Convergent
Colley	2009	19900240	Transfemoral (n=6).	Diabetes-related	66 (median)		30	HAUS	Anxiety		validity	Convergent
			Transtibial (n=23),									
Coffey	2009	19900240	bilateral (n=9)	Diabetes-related	68 (median)	nd	38	HADS	depression		Validity	Convergent
			Transtibial (n=23),									
Coffey	2009	19900240	bilateral (n=9)	Diabetes-related	68 (median)	nd	38	HADS	depression		Validity	Convergent
			Transfemoral (n=6), Transfibial (n=23)									
Coffey	2009	19900240	bilateral (n=9)	Diabetes-related	68 (median)	nd	38	HADS	depression		Validity	Convergent
			Transfemoral (n=6),									
Coffev	2009	19900240	bilateral (n=23),	Diabetes-related	68 (median)	nd	38	HADS	depression		Validity	Convergent
			Transfemoral (n=6),									
Coffey	2009	19900240	Transtibial (n=23), bilateral (n=9)	Diabetes-related	68 (median)	nd	38	HADS	depression		Validity	Convergent
Concy	2000	10000240	Transfemoral (n=6),	Diabetes related	oo (median)		00	11/100	depression		validity	Convergent
Coffee	2000	10000240	Transtibial (n=23),	Dishetes related	CO (median)	-	20		denressien		Validity	Conversent
Colley	2009	19900240	Transfemoral (n=6)	Diabetes-related	66 (median)	na	30	HAUS	depression		validity	Convergent
			Transtibial (n=23),									
Coffey	2009	19900240	bilateral (n=9)	Diabetes-related	68 (median)	nd	38	HADS	depression		Validity	Convergent
			Transtibial (n=23),									
Coffey	2009	19900240	bilateral (n=9)	Diabetes-related	68 (median)	nd	38	HADS	depression		Validity	Convergent
			Transfemoral (n=6), Transtibial (n=23)									
Coffey	2009	19900240	bilateral (n=9)	Diabetes-related	68 (median)		38	HADS	Depression		Validity	Convergent
			Transfemoral (n=6),									
Coffey	2009	19900240	i ranstibial (n=23), bilateral (n=9)	Diabetes-related	68 (median)		38	HADS	Depression		Validity	Convergent
	2000	100002-0	Transfemoral (n=6),	useres related	se (mediari)	1			- 00.000000			
Coffor	2000	10000240	Transtibial (n=23),	Diabatan related	60 (modion)		20		Depression		Volidity	Convergent
Colley	2009	19900240	Transfemoral (n=6)	Diabetes-related	oo (median)		30	IIAD0	Depression		valiuity	Convergent
			Transtibial (n=23),									
Coffey	2009	19900240	bilateral (n=9)	Diabetes-related	68 (median)		38	HADS	Depression		Validity	Convergent

			Comparator/Critorion/Outo	Timepoint (prodictive			Strongth of			
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Coffee	2000	10000240	TADES essiel restriction		Creatman r	0.41				
Colley	2009	19900240	TAPES Social restriction		Spearmann	0.41				
Coffey	2009	19900240	TAPES weight satisfaction		Spearman r	-0.39		_		
			TAPES functional							
Coffey	2009	19900240	satisfaction		Spearman r	-0.36				
Coffey	2009	19900240	TAPES general adjustment		Spearman r	-0.48				
Coffey	2009	19900240	TAPES social adjustment		Spearman r	-0.58				
Concy	2000	10000210			opourmant	0.00				
o. "										
Cottey	2009	19900240	HADS Depression		Spearman r	0.62		-		
Coffey	2009	19900240	ABIS-R		Spearman r	0.77				
Coffey	2009	19900240	TAPES social restriction		Spearman r	0.41				
Coffey	2009	19900240	TAPES weight satisfaction		Spearman r	-0.39				
Coffee	2000	10000240	TAPES functional		Creatman r	0.26				
Colley	2009	19900240	Satistaction		Spearmann	-0.30				
Coffey	2009	19900240	TAPES general adjustment		Spearman r	-0.48				
Coffey	2009	19900240	TAPES social adjustment		Spearman r	-0.58				
Coffey	2009	19900240	ABIS-R		Spearman r	0.75				
Coffey	2009	19900240	TAPES functional restriction		Spearman r	0.39				
Coffee	2000	10000240	TADES essiel restriction		Creatman r	0.54				
Colley	2009	19900240	TAPES Social restriction		Spearmann	0.54				
Coffey	2009	19900240	TAPES weight satisfaction		Spearman r	-0.43				
			TAPES functional							
Coffey	2009	19900240	satisfaction		Spearman r	-0.4				
Coffey	2009	19900240	TAPES general adjustment		Spearman r	-0.49				
Coffey	2009	19900240	TAPES social adjustment		Spearman r	-0.49				
Concy	2000	10000210			opourmant	0.10				
0	0000	10000010	TAPES adjustment to		0					
Сопеу	2009	19900240	limmitations		Spearman r	-0.44				
Coffey	2009	19900240	ABIS-R		Spearman r	0.75		_		
Coffey	2009	19900240	TAPES functional restriction		Spearman r	0.39				
Coffey	2009	19900240	TAPES social restriction		Spearman r	0.54				
Coffey	2000	19900240	TAPES weight satisfaction		Spearman r	-0.43				
Concy	2003	10000240	TA LO WEIGHT SAUSIAUUUT	1	opeannan I	0.40	1		1	

				Amputation		Other Benulation						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
			Transfemoral (n=6),									
			Transtibial (n=23),									
Coffey	2009	19900240	bilateral (n=9)	Diabetes-related	68 (median)		38	HADS	Depression		Validity	Convergent
			Transferioral (n=0), Transfibial (n=23)									
Coffey	2009	19900240	bilateral (n=9)	Diabetes-related	68 (median)		38	HADS	Depression		Validity	Convergent
			Transfemoral (n=6),		, í						,	Ŭ
o "			Transtibial (n=23),									
Cottey	2009	19900240	Dilateral (n=9)	Diabetes-related	68 (median)		38	HADS	Depression		Validity	Convergent
			Transtibial (n=23).									
Coffey	2009	19900240	bilateral (n=9)	Diabetes-related	68 (median)		38	HADS	Depression		Validity	Convergent
			Transfemoral (30%),	dysvascular or								
			Transtibial (60%),	diabetes (40%),								
			(4%) bip	trauma (35%),								
			disarticulation (4%),	congenital (8%),								
			partial foot amputation	neoplasm (5%),				Harold Wood/Stanmore	Total Overall			
Fisher and Hanspal	1998		(2%)	other (4%)	55.5	nd	107	mobility grade	Score		Validity	Construct
			Transfemoral (30%), Transfibial (60%)	dysvascular or								
			knee disarticulation	trauma (35%).								
			(4%), hip	infection (8%),								
			disarticulation (4%),	congenital (8%),								
Eishen en ditter en el	1000		paryial foot	neoplasm (5), other		- 4	407	Harold Wood/Stanmore	Total Overall) (- 11 - 11 f - 1	0
Fisher and Hanspai	1998		Transfermoral (30%)	(4%) dvevaecular.or	55.5	na	107	mobility grade	Score		validity	Convergent
			Transtibial (60%),	diabetes (40%),								
			knee disarticulation	trauma (35%),								
			(4%), hip	infection (8%),								
			disarticulation (4%),	congenital (8%),				Harold Wood/Stanmara	Total Overall			
Fisher and Hanspal	1998		amputation (2%)	(4%)	55.5	nd	107	mobility grade	Score		Validity	Convergent
			Transfemoral (30%),	dysvascular or				1,0				
			Transtibial (60%),	diabetes (40%),								
			knee disarticulation	trauma (35%),								
			(4%), np disarticulation (4%).	congenital (8%).								
			paryial foot	neoplasm (5), other				Harold Wood/Stanmore	Total Overall			
Fisher and Hanspal	1998		amputation (2%)	(4%)	55.5	nd	107	mobility grade	Score		Validity	Convergent
			Transfemoral (30%),	dysvascular or								
			I ranstibial (60%), knee disarticulation	diabetes (40%), trauma (35%)								
			(4%), hip	infection (8%),								
			disarticulation (4%),	congenital (8%),								
			partial foot amputation	neoplasm (5%),			107	Harold Wood/Stanmore	Total Overall			
Fisher and Hanspal	1998		(2%)	other (4%)	55.5	nd	107	mobility grade	Score		Validity	Convergent
]		cognitive ability. aged 17-65						
			Transfemoral (43%),	vascular or diabetes		amputation between 16-64						
			Transtibial (50%), hip	(24%), trauma		years, established prosthesis						
Fisher, Hanspal and Marka	2002		or partial foot	(64%), neoplasm	47.4	wearer, amputation at least 1	100	Harold Wood/Stanmore	Total Overall		Volidity	Convergent
IVIDI NS	2003		Transfemoral (n=51)	(6%), Outer (4%)	47.4	year previously	100	Harold Wood/Stanmore	Total Overall		validity	Concurrent/convergent/criteri
Hanspal	1991		Transtibial (n=49)	nd	72.4	nd	100	mobility grade	Score		Validity	a Validity criterion
			Transfemoral (30%),	dysvascular or								
			Transtibial (60%),	diabetes (40%),								
			(4%) hin	trauma (35%), infection (8%)								
			disarticulation (4%),	congenital (8%),								
			paryial foot	neoplasm (5), other				Harold Wood/Stanmore				
Fisher	1998		amputation (2%)	(4%)	55.5		107	mobility grade			Validity	Convergent
			Transfemoral (30%),	dysvascular or								
			knee disarticulation	trauma (35%).								
			(4%), hip	infection (8%),								
			disarticulation (4%),	congenital (8%),								
Fisher	1008		paryial toot	neoplasm (5), other	55 5		107	Harold Wood/Stanmore			Validity	Convergent
i ioridi	1000	1	ampatation (270)	(-,0)	00.0	1	107	mobility grade	1	1	valuity	oomorgeni

			Comparator/Criterion/Outo	Timepoint (predictive			Strength of	ls Asnort		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
			TAPES functional							
Coffey	2009	19900240	satisfaction		Spearman r	-0.4				
Coffey	2009	19900240	TAPES general adjustment		Spearman r	-0.49				
Coffey	2009	10000240	TAPES social adjustment		Spearman r	0.49				
Colley	2003	13300240	TAI LO SOCIAI AUJUSTITIETI		Opeannann	-0.45				
			TAPES adjustment to							
Coffey	2009	19900240	limmitations		Spearman r	-0.44				
Fisher and Hanspal	1998									significant correlation with age
	1000									significant correlation with age
			AALQ (attitude to artificial							
Fisher and Hanspal	1998		limbs questionnaire)		Kendall tau	-0.04				not statistically significant
Cick on and the second	1000		BIQ (Body image			0.00				
Fisher and Hanspai	1998		questionnaire)			0.02				not statistically significant
			HADS anviety (bosnital							
Fisher and Hanspal	1998		anxiety depression scale)			0.21				not statistically significant
			HADS depression (hospital							
Fisher and Hanspal	1998		anxiety depression scale)			0.16				not statistically significant
Fisher, Hanspal and Marka	2002		Employment questionairre		nonparametric	nd				correlation with Employment questionairre
IVIDI NS	2003		Employment questionaire		correlation	nu				significant correlation withcognitive
Hanspal	1991									assessment scale
F isher	1000		AALQ (attitude to artificial		Kennel all taxis	0.04				
ristier	1998		innus questionnaire)		rtendali tau	-0.04				not statistically significant
					1					
			BIO (Body image							
Fisher	1998		questionnaire)		Kendall tau	0.02				not statistically significant

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Fisher	1998		Transfemoral (30%), Transtibial (60%), knee disarticulation (4%), hip disarticulation (4%), paryial foot amputation (2%)	dysvascular or diabetes (40%), trauma (35%), infection (8%), congenital (8%), neoplasm (5), other (4%)	55.5		107	Harold Wood/Stanmore			Validity	Convergent
			Transfemoral (30%), Transtibial (60%), knee disarticulation (4%), hip disarticulation (4%), partial foot amputation	dysvascular or diabetes (40%), trauma (35%), infection (8%), congenital (8%), neoplasm (5%),				Harold Wood/Stanmore				
Fisher	1998		(2%) Transfemoral (30%), Transtibial (60%), knee disarticulation (4%), hip disarticulation (4%), partial foot amputation	other (4%) dysvascular or diabetes (40%), trauma (35%), infection (8%), congenital (8%), neoplasm (5%),	55.5		107	Mobility grade			Validity	Convergent
Fisher	1998		(2%) Transfemoral (43%), Transtibial (50%), hip or partial foot	other (4%) vascular or diabetes (24%), trauma (64%), neoplasm	55.5	normal or near normal cognitive ability, aged 17-65, amputation between 16-64 years, established prosthesis wearer, amputation at least 1	107	mobility grade			Validity	Construct
Fisher	2003		amputation (7%)	(8%), other (4%)	47.4	year previously	100	Mobility Grade			Validity	Convergent
Hanspal	1991		Transtibial (n=49)	nd	72.4	nd	100	mobility grade			Validity	a Validity criterion
Hafner	2007						17	Hill Assessment Index (HAI)	Total Overall Score		Ability to measure change	Responsiveness
Wong	2016	26390393	TT (n=22), TF (n=13), BTT (n=2), BTT/BFT (n=2), BFT/BTT (n=1)	vascular (28), nonvascular (12)	57.0 +- 11.9	nd	40	Houghton	mobility	Houghton scale quantities duration of daily prosthesis wear, use of prosthesis, use of assistive devices, and perceived stability when using the prosthesis on various terrains. The four questions are summated with the total score reported in a range from 0 to 12, with higher scores indicating better function. Scores of 9 or higher have been suggested to represent prosthetic use for community walking	Validity	predictive
Delvín	2004	15205762	Multiple	Multiple	60.9	nd	19	Houghton	nd	The Houghton Scale1, is an instrument that looks solely at prosthetic use in people with lower-extremity amputations; it reflects a person's perception of prosthetic use, rather than a health care provider's viewpoint, and it consiste of a use fine	Peliability	Test retect
Delvin	2004	15295762	Multiple	Multiple	60.9	nd	49	Houghton	nd	The Houghton Scale 1, is an instrument that looks solely at prosthetic use in people with lower-extremity amputations; it reflects a person's perception of prosthetic use, rather than a health care provider's viewpoint, and it consists of 4 questions	Reliability	Internal Consistency
Delvin	2004	15295762	Multiple	Multiple	65.5	nd	76	Houghton	nd	The Houghton Scale1, is an instrument that looks solely at prosthetic use in people with lower-extremity amputations; it reflects a person's perception of prosthetic use, rather than a health care provider's viewpoint, and it consists of 4 questions	Floor/ceiling effect	Floor
Delvin	2004	15295762	Multiple	Multiple	65.5	nd	76	Houghton	nd	The Houghton Scale1, is an instrument that looks solely at prosthetic use in people with lower-extremity amputations; it reflects a person's perception of prosthetic use, rather than a health care provider's viewpoint, and it consists of 4 questions	Floor/ceiling effect	Ceiling
Delvin	2004	15295762	Multiple	Multiple	65.5	nd	76	Houghton	nd	The Houghton Scale1, is an instrument that looks solely at prosthetic use in people with lower-extremity amputations; it reflects a person's perception of prosthetic use, rather than a health care provider's viewpoint, and it consists of 4 questions	Responsiven	nd

Author	Year	PMID	Comparator/Criterion/Outco	(predictive valid)	Metric Used	Value	Strength of Property	Is Aspect Supported?	Conclusion	Notes/Caveats
Fisher	1998		HADS anxiety (hospital anxiety depression scale)		Kendall tau	0.21				not statistically significant
Fisher	1998		HADS depression (hospital anxiety depression scale)		Kendall tau	0.16				not statistically significant
Fisher	1998									significant correlation with age
					Employment	nonparametri				correlation with Employment questionairre
Fisher	2003				questionairre	c correlation	nd			P<.001 significant correlation withcognitive
Hanspal	1991		Mechanical control							assessment scale
Hafner	2007		prosthetic knee versus microprocessor control prosthetic knee							significant differences between control technology
Wong	2016	26390393	predict community ambulation, initial score <7		AUC	0.885		у		
Delvin	2004	15295762	nd		ICC	0.96	Excellent	Yes	The Houghton Scale showed good test-retest reliability over a 1-week span	
Delvin	2004	15295762	nd		Cronbach's	0 71	Adequate	Yes	The internal consistency was moderate at discharge and follow-up	Values at discharge time (7 at follow up)
Bonn	2001	10200102			aprid	0.7.1	raoquato			
Dahria	2004	15005760						No	Floor and ceiling effects on the individual items were notable (as expected), although nearly	
Deivin	2004	15295762	na		%	0		NO	absent for the overall score	
									Floor and ceiling effects on the individual items were notable (as expected), although nearly	
Delvin	2004	15295762	na		%	1.3		NO	absent for the overall score	
									The effect size calculated for	
Delvin	2004	15295762	nd		Effect size	0.6		Yes	this change was .60, indicating a moderate difference	

				A		Other Denulation						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
										The Houghton Scale1, is an instrument that looks solely at prosthetic use in people with lower-extremity amputations; it reflects a person's perception of prosthetic use, rather there is better an end of the sole of the so		
Delvin	2004	15295762	Multiple	Multiple	65.5	nd	76	Houghton	nd	consists of 4 questions	Validity	Convergent
										The Houghton Scale1, is an instrument that looks solely at prosthetic use in people with lower-extremity amputations; it reflects a person's perception of prosthetic use, rather than a health care provider's viewpoint, and it		
Delvin	2004	15295762	Multiple	Multiple	65.5	nd	76	Houghton	nd	consists of 4 questions	Validity	Convergent
										looks solely at prosthetic use in people with lower-extremity amputations; it reflects a person's perception of prosthetic use, rather than a health care provider's viewpoint, and it		
Delvin	2004	15295762	Multiple	Multiple	65.5	nd	76	Houghton	nd	consists of 4 questions The Houghton Scale1 is an instrument that	Validity	Convergent
Delvin	2004	15295762	Multiple	Multiple	65.5	nd	76	Houghton	nd	looks solely at prosthetic use in people with lower-extremity amputations; it reflects a person's perception of prosthetic use, rather than a health care provider's viewpoint, and it consists of 4 questions	Validity	Convergent
Delvin	2004	15295762	Multiple	Multiple	65.5	nd	76	Houghton	nd	The Houghton Scale1, is an instrument that looks solely at prosthetic use in people with lower-extremity amputations; it reflects a person's perception of prosthetic use, rather than a health care provider's viewpoint, and it consists of 4 questions	Validitv	Construct
Delvin	2004	15295762	Multiple	Multiple	65.5	nd	76	Houghton	nd	The Houghton Scale1, is an instrument that looks solely at prosthetic use in people with lower-extremity amputations; it reflects a person's perception of prosthetic use, rather than a health care provider's viewpoint, and it consists of 4 questions	Validity	Construct
Houghton	1992	1393461	Transfemoral (n=31), Transtibial (n=56), Gritti-Stokes (n=3), Through-knee (n=1), Bilateral (n=11)	nd	Range 50-88	nd	102	Houghton	nd	Rehabilitation was assessed by the answers to four standard questions. A score of 9 was accepted as satisfactory rehabilitation and one of 6 as indicating mobility on the prosthesis around the home	Validity	Construct
Millor	2000	0	Transfemoral (26%),	Vascular (55%), Non	E9 4	University associated outpatient amputee clinic that serves the region of southwestern Omtario,	60	Houghton	nd	This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a wright of termine	Poliobility	Test retect
Winer	2000		Transfemoral (26%),	Vascular (55%), Non		University associated outpatient amputee clinic that serves the region of southwestern Omtario,				This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a	Trendbinty	
Miller	2000	0	Transtibial (74%)	vascular (45%)	58.4	Canada	60	Houghton	nd	variety of terrains.	Reliability	Internal Consistency
Millor	2000		Transfemoral (26%),	Vascular (55%), Non	E9 4	University associated outpatient amputee clinic that serves the region of southwestern Omtario,	60	Houghton	nd	I nis measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a which is if thereine	Floor/ceiling	Eleer
winer	2000		Transformeral (20%)	Vascular (45%)	00.4	University associated outpatient amputee clinic that serves the region of				This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and		
Miller	2000	0	Transtibial (74%)	vascular (47%)	59.9	Canada	329	Houghton	nd	variety o f terrains.	effect	Floor

				Timepoint			Consumation of			
Author	Year	PMID	ome	(predictive valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Aution	i cui		onic	valiaj	Metho Oseu	Value	roperty	oupporteu :	Conclusion	Holes/ouveuls
									At discharge, there was	
Delvin	2004	15295762	PCS		r (not defined)	0.393	Moderate	Yes	correlation with the PCS	Convergent validity (at discharge time)
					(
									At discharge, there was no	
Delvin	2004	15295762	MCS		r (not defined)	0.235	Small	No	correlation with the MCS	Convergent validity (at discharge time)
									At both discharge and follow-up	
									the Houghton Scale correlated	
Delvin	2004	15295762	2MWT		r (not defined)	0.62	Large	Yes	significantly with the 2MWT	Convergent validity (at discharge time)
									At both discharge and follow-up.	
									the Houghton Scale correlated	
Delvin	2004	15295762	2MWT		r (not defined)	0.653	Large	Yes	significantly with the 2MWT	Convergent validity (at follow-up)
									The Houghton Scale	
									successfully discriminated	
									between transfemoral versus	Construct validity (at both discharge and
Delvin	2004	15295762	Transfemoral vs transtibial		P	<0.05		Yes	transtibial participants	follow-up: p>0.05)
									There was no difference	
					_				between unilateral and bilateral	Construct validity (at discharge; at follow-
Delvin	2004	15295762	Unilateral vs bilateral		Р	>=0.05		NO	transtibial participants	up: p>0.05)
									than AK ones. The remaining	
									15 per cent comprised bilateral	
									(11per cent), GS (3per cent)and	
									TK (1 per cent). The numbers of	
									too small to assess comparative	
Houghton	1992	1393461	Transfemoral vs transtibial		nd	nd		Yes	rehabilitation.	
									The Houghton score displayed	
									an excelent Test-retest	
									reliability based on the ICC	
Miller	2000	0	nd		ICC	0.85	Excellent	Yes	value	
									The score displayed an	
									adequate Internal Consistency	
					Cronbach's				based on Cronbach's alpha	
Miller	2000	0	nd		alpha	0.68	Adequate	Yes	value	
Miller	2000	0	nd		0/_	0		No	I nere was no indication of floor	
IVIIIIEI	2000	v	iiu		70	0		NU	CHEOL	
		1						1		
		1						1	These sector indication (C)	
Miller	2000	0	nd		%	0.3		No	effect	
1 1 T T		1.5	1	1	1	1 · · · ·		1.17	1	

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Miller	2000	0	Transfemoral (26%), Transtibial (74%)	Vascular (55%), Non vascular (45%)	58.4	University associated outpatient amputee clinic that serves the region of southwestern Omtario, Canada	60	Houghton	nd	This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a variety of terrains.	Floor/ceiling effect	Ceilina
Miller	2000	0	Transfemoral (26%), Transtinial (74%)	Vascular (53%), Non	59.9	University associated outpatient amputee clinic that serves the region of southwestern Omtario, Canada	320	Houghton	nd	This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a variety of terrains	Floor/ceiling	Ceiling
Miller	2000	0	Transfemoral (26%), Transtibial (74%)	Vascular (55%), Non vascular (45%)	58.4	University associated outpatient amputee clinic that serves the region of southwestern Omtario, Canada	60	Houghton	nd	This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a variety of terrains.	Validity	Convergent
Miller	2000	0	Transfemoral (26%), Transtibial (74%)	Vascular (55%), Non vascular (45%)	58.4	University associated outpatient amputee clinic that serves the region of southwestern Omtario, Canada	60	Houghton	nd	This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a variety of terrains.	Validity	Convergent
Miller	2000	0	Transfemoral (26%), Transtibial (74%)	Vascular (55%), Non vascular (45%)	58.4	University associated outpatient amputee clinic that serves the region of southwestern Omtario, Canada	60	Houghton	nd	This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a variety of terrains.	Validity	Convergent
Miller	2000	0	Transfemoral (26%), Transtibial (74%)	Vascular (53%), Non vascular (47%)	59.9	University associated outpatient amputee clinic that serves the region of southwestern Omtario, Canada	329	Houghton	nd	This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a variety of terrains.	Validitv	Convergent
Miller	2000	0	Transfemoral (26%), Transtibial (74%)	Vascular (55%), Non vascular (45%)	58.4	University associated outpatient amputee clinic that serves the region of southwestern Omtario, Canada	60	Houghton	nd	This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a variety of terrains.	Validity	Convergent
Miller	2000	0	Transfemoral (26%), Transtibial (74%)	Vascular (53%), Non vascular (47%)	59.9	University associated outpatient amputee clinic that serves the region of southwestern Omtario, Canada	329	Houghton	nd	This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a variety of terrains.	Validity	Convergent
Miller	2000	0	Transfemoral (26%), Transtibial (74%)	Vascular (55%), Non vascular (45%)	58.4	University associated outpatient amputee clinic that serves the region of southwestern Omtario, Canada	60	Houghton	nd	This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a variety of terrains.	Validity	Convergent
Miller	2000	0	Transfemoral (26%), Transtibial (74%)	Vascular (53%), Non vascular (47%)	59.9	University associated outpatient amputee clinic that serves the region of southwestern Omtario, Canada	329	Houghton	nd	This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a variety of terrains.	Validity	Convergent
Miller	2000	0	Transfemoral (26%), Transtibial (74%)	Vascular (53%), Non vascular (47%)	59.9	University associated outpatient amputee clinic that serves the region of southwestern Omtario, Canada	329	Houghton	nd	This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a variety of terrains.	Validity	Construct
Miller	2000	0	Transfemoral (26%), Transtinial (74%)	Vascular (53%), Non	59.9	University associated outpatient amputee clinic that serves the region of southwestern Omtario, Canada	320	Houghton	nd	This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a variety of terrains.	Validity	Construct
WINGI	2000	~		14030ulai (4770)	00.0	ounuda	020	riougnion	IN	vancty or terrains.	valuity	Construct

			Comparator/Critorion/Outo	Timepoint			Strongth of	la Acnost		
Author	Vear	PMID	comparator/criterion/Outc	(predictive	Metric Used	Value	Strength of Property	IS Aspect	Conclusion	Notes/Caveats
Aution	i cui		onic	valia)	Metric Oscu	Value	rioperty	oupporteu :	Conclusion	Holes ouveals
									The second second section of floors	
Miller	2000	0	nd		0/_	12.0		No	I here was no indication of floor	
WINE	2000	0	IIu		70	12.5		NO	enect	
									These was no indication of	
Miller	2000	0	nd		%	6		No	ceiling effect	
		-				-				
									The Lloughton displayed been	
									correlation with the Two minute	
Miller	2000	0	Two minute walk test		Pearson r	0.64	Large	Yes	walk test	
							Ŭ			
									The Houghton displayed Large	
									correlation with the Timed up	
Miller	2000	0	Timed up and go		Pearson r	-0.6	Large	Yes	and go	
									The Houghton displayed Large	
			Activities-specific Balance						correlation with the Activities-	
Miller	2000	0	Confidence		Pearson r	0.67	Large	Yes	specific Balance Confidence	
									The Houghton displayed Large	
			Activities-specific Balance						correlation with the Activities-	
Miller	2000	0	Confidence		Pearson r	0.63	Large	Yes	specific Balance Confidence	
									The Houghton displayed Large	
			Prosthetic Profile of the						correlation with the Prosthetic	
Miller	2000		Amputee - Locomotor		Deerson r	0.6	Larga	Vee	Profile of the Amputee -	
willer	2000	0	Capabilities index		Pearson	0.0	Large	res	Ecconiciol Capabilities index	
									The Houghton displayed Large	
			Prosthetic Profile of the						correlation with the Prosthetic	
Miller	2000	0	Amputee - Locomotor Canabilities Index		Pearson r	0.59	Large	Ves	Profile of the Amputee -	
Willer	2000	Ŭ	oupublilities index		1 carson 1	0.00	Large	105		
									The Houghton displayed Large	
			Prosthetic Evaluation						Correlation with the Prosthetic	
Miller	2000	0	Questionnaire - Mobility		Pearson r	0.59	Large	Yes	Mobility	
									The Houghton displayed Large	
			Prosthetic Evaluation						Evaluation Questionnaire -	
Miller	2000	0	Questionnaire - Mobility		Pearson r	0.55	Large	Yes	Mobility	
							1			
							1			
							1		The Houghton differed between	
Miller	2000	0	Transtibial vs Transfemoral		Effect size	0.29		Yes	Transtibial and Transfemoral	
1							1			
		L					1	1.	The Houghton differed between	
Miller	2000	0	Vascular vs non-vasular	1	Effect size	0.63	1	Yes	Vascular and non-vasular	1

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Miller	2000	0	Transfemoral (26%), Transtibial (74%)	Vascular (53%), Nor	n- 59 9	University associated outpatient amputee clinic that serves the region of southwestern Omtario, Canada	329	Houghton	nd	This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a variety of terrains.	Validity	Construct
Miller	2000	0	Transfemoral (26%), Transtibial (74%)	Vascular (53%), Nor vascular (47%)	n. 59.9	University associated outpatient amputee clinic that serves the region of southwestern Omtario, Canada	329	Houghton	nd	This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a variety of terrains.	Validity	Construct
Miller	2000	0	Transfemoral (26%), Transtibial (74%)	Vascular (53%), Nor vascular (47%)	n. 59.9	University associated outpatient amputee clinic that serves the region of southwestern Omtario, Canada	329	Houghton	nd	This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a variety of terrains.	Validity	Construct
Wong	2016	26874230	Multiple	Multiple	55.5	nd	180	Houghton	nd	The 4-question self-reported Houghton Scale quantifies daily prosthetic use and function in various walking conditions. Total scores range from 0 to 12 without ceiling or floor effects, with higher scores indicating better function. 3 Houghton Scale (range 0-12) categoris: >=9 vs 6-8 vs <=5	Validity	Criterion
Wong	2016	26874230	Multiple	Multiple	55.5	nd	180	Houghton	nd	The 4-question self-reported Houghton Scale quantifies daily prosthetic use and function in various walking conditions. Total scores range from 0 to 12 without ceiling or floor effects, with higher scores indicating better function. 3 Houghton Scale (range 0-12) categoris: >=9 vs 6-8 vs <=5	Validity	Criterion
Wong	2016	26874230	Multiple	Multiple	55.5	nd	180	Houghton	nd	The 4-question self-reported Houghton Scale quantifies daily prosthetic use and function in various walking conditions. Total scores range from 0 to 12 without ceiling or floor effects, with higher scores indicating better function. 3 Houghton Scale (range 0-12) categoris: ≥ 9 vs 6-8 vs <5	Validity	Criterion
Wong	2016	26874230	Multiple	Multiple	55.5	nd	180	Houghton	nd	The 4-question self-reported Houghton Scale quantifies daily prosthetic use and function in various walking conditions. Total scores range from 0 to 12 without ceiling or floor effects, with higher scores indicating better function. 3 Houghton Scale (range 0-12) categoris: >=9 vs 6-8 vs <=5	Validity	Criterion
Wong	2016	26874230	Multiple	Multiple	55.5	nd	180	Houghton	nd	The 4-question self-reported Houghton Scale quantifies daily prosthetic use and function in various walking conditions. Total scores range from 0 to 12 without ceiling or floor effects, with higher scores indicating better function. 3 Houghton Scale (range 0-12) categoris: >=9 vs 6-8 vs <=5	Validity	Criterion
Word	2016	26874230	Multiple	Multiple	55.5	nd	180	Houghton	nd	The 4-question self-reported Houghton Scale quantifies daily prosthetic use and function in various walking conditions. Total scores range from 0 to 12 without ceiling or floor effects, with biothes scores indicating batters function.	Validity	Criterion (convergent)
wong	2010	200/4230	Interret	multiple	00.0	110		nooghton	nu	The 4-question self-reported Houghton Scale quantifies daily prosthetic use and function in various walking conditions. Total scores range from 0 to 12 without ceiling or floor effects,	valiuity	Convergent)
Wong	2016	26874230	Multiple	Multiple	55.5	nd	180	Houghton	nd	with higher scores indicating better function. The 4-question self-reported Houghton Scale quantifies daily prosthetic use and function in various walking conditions. Total scores range	Validity	Criterion (convergent)
Wong	2016	26874230	Multiple	Multiple	55.5	nd	180	Houghton	nd	with higher scores indicating better function.	Validity	Criterion (convergent)

			Comparator/Criterion/Outc	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
									The Houghton differed between	Mahiliku davida wasia sa ikam of Havabbaa
Miller	2000	0	device		Effect size	1.62		Yes	device use	scale
Miller	2000	0	Walking distance <1 block		Effect size	0.54		Ves	The Houghton differed between Walking distance <1 block and	
winer	2000	0	vs unimited		Effect size	0.54		165	uninnited	
Miller	2000	0	Automatic walking yes vs no		Effect size	0.78		Yes	The Houghton differed between Automatic walking and no automatic walking	
Wong	2016	26874230	Activities-specific Balance		P	<0.05		Ves	The 3 Houghton Scale ability categories differed significantly from each other (P<.05) for all outcome measures: Prosthetic Evaluation Questionnaire mobility subscale, ABC Scale, balance ability, TUG test, and 2MWT	Based on the ANOVA-Tukey test
Wong	2010	20074230				0.05			The 3 Houghton Scale ability categories differed significantly from each other (P<.05) for all outcome measures: Prosthetic Evaluation Questionnaire mobility subscale, ABC Scale, balance ability, TUG test, and	
Wong	2016	26874230	Timed up and go		Р	<0.05		Yes	2MWT	Based on the ANOVA-Tukey test
Wong	2016	26874230	Two minute walk test		Ρ	<0.05		Yes	categories differed significantly from each other (P<.05) for all outcome measures: Prosthetic Evaluation Questionnaire mobility subscale, ABC Scale, balance ability, TUG test, and 2MWT	Based on the ANOVA-Tukey test
Wong	2016	26874230	3-Berg Balance Scale		P	<0.05		Yes	The 3 Houghton Scale ability categories differed significantly from each other (P<.05) for all outcome measures: Prosthetic Evaluation Questionnaire mobility subscale, ABC Scale, balance ability, TUG test, and 2MWT	Based on the ANOVA-Tukey test
Wong	2016	26874230	Prosthetic Evaluation Questionnaire - Mobility subscale		Ρ	<0.05		Yes	The 3 Houghton Scale ability categories differed significantly from each other (P<.05) for all outcome measures: Prosthetic Evaluation Questionnaire mobility subscale, ABC Scale, balance ability, TUG test, and 2MWT	Based on the ANOVA-Tukey test
Wong	2016	26874230	Prosthetic Evaluation Questionnaire - Mobility		Spearman r	0.73	Large	Yes	The Houghton Scale scores correlated with performance- based balance and walking ability measures	
wong	2010	20017230	Jubbulic		opeannann	0.10	Large	1 63	ability measures	
Wong	2016	26874230	Activities-specific Balance Confidence		Spearman r	-0.76	Large	Yes	The Houghton Scale scores correlated with performance- based balance and walking ability measures	
									The Houghton Scale scores correlated with performance- based balance and walking	
Wong	2016	26874230	3-Berg Balance Scale		Spearman r	0.67	Large	Yes	ability measures	

				Amputation		Other Benulation						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Mana	2016	26974220	Multiple	Multiple	55.5		190	Haushten		The 4-question self-reported Houghton Scale quantifies daily prosthetic use and function in various walking conditions. Total scores range from 0 to 12 without ceiling or floor effects,	Validity	
vvong	2016	26874230	Multiple		55.5	na	180	Houghton	na	With higher scores indicating better function. The 4-question self-reported Houghton Scale quantifies daily prosthetic use and function in various walking conditions. Total scores range	Validity	Criterion (convergent)
Wong	2016	26874230	Multiple	Multiple	55.5	nd	180	Houghton	nd	with higher scores indicating better function.	Validity	Criterion (convergent)
			TT (n=22), TF (n=13), BTT (n=2), BTT/BFT	vascular (28),								
Wong	2016	26390393	(n=2), BFT/BTT (n=1)	nonvascular (12)	57.0 +- 11.9		40	Houghton Scale	mobility	The Houghton Scale1 is an instrument that	Validity	predictive
Deulle	0004	45005700	1 1 1 1		05.5		70	United and		looks solely at prosthetic use in people with lower-extremity amputations; it reflects a person's perception of prosthetic use, rather than a health care provider's viewpoint, and it	Floor/ceiling	0.11
Devlin	2004	15295762	Multiple	Multiple	65.5		76	Houghton Scale		Consists of 4 questions	effect	Ceiling
										looks solely at prosthetic use in people with lower-extremity amputations; it reflects a person's perception of prosthetic use, rather than a health care provider's viewpoint, and it		
Devlin	2004	15295762	Multiple	Multiple	65.5		76	Houghton Scale		consists of 4 questions	Validity	Construct
										looks solely at prosthetic use in people with lower-extremity amputations; it reflects a person's perception of prosthetic use, rather than a health care provider's viewpoint, and it		
Devlin	2004	15295762	Multiple	Multiple	65.5		76	Houghton Scale		consists of 4 questions	Validity	Construct
										The Houghton Scale1, is an instrument that looks solely at prosthetic use in people with lower-extremity amputations; it reflects a person's perception of prosthetic use, rather than a health care provider's viewpoint, and it		
Devlin	2004	15295762	Multiple	Multiple	65.5		76	Houghton Scale		consists of 4 questions	Validity	Convergent
										looks solely at prosthetic use in people with lower-extremity amputations; it reflects a person's perception of prosthetic use, rather than a health care provider's viewpoint, and it		
Devlin	2004	15295762	Multiple	Multiple	65.5		76	Houghton Scale		consists of 4 questions	Validity	Convergent
										looks solely at prosthetic use in people with lower-extremity amputations; it reflects a person's perception of prosthetic use, rather than a health care provider's viewpoint, and it		
Devlin	2004	15295762	Multiple	Multiple	65.5		76	Houghton Scale		consists of 4 questions	Validity	Convergent
										I ne noughton Scale1, is an instrument that looks solely at prosthetic use in people with lower-extremity amputations; it reflects a person's perception of prosthetic use, rather than a health care provider's viewpoint, and it		
Devlin	2004	15295762	Multiple	Multiple	65.5		76	Houghton Scale		consists of 4 questions	Validity	Convergent
										looks solely at prosthetic use in people with lower-extremity amputations; it reflects a person's perception of prosthetic use, rather than a health care provider's viewpoint, and it	Floor/ceiling	
Devlin	2004	15295762	Multiple	Multiple	65.5		76	Houghton Scale		consists of 4 questions	effect	Floor

			Comparator/Criterion/Outo	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Wong	2016	26874230	Timed up and go		Spearman r	0.67	Large	Yes	The Houghton Scale scores correlated with performance- based balance and walking ability measures	
Wong	2016	26874230	Two minute walk test		Spearman r	0.73	large	Yes	The Houghton Scale scores correlated with performance- based balance and walking ability measures	
Word	2016	26300303	predict failure to reach	12 months		0.885	Laige	103	cut off sore c=7	Houghton scale quantifies duration of daily prosthesis wear, use of prosthesis, use of assistive devices, and perceived stability when using the prosthesis on various terrains. The four questions are summated with the total score reported in a range from 0 to 12, with higher scores indicating better function. Scores of 9 or higher have been suggested to represent prosthetic use for community unalking.
wong	2010	20390393				0.885		y	Floor and ceiling effects on the individual items were notable (as expected), although nearly	
Devlin	2004	15295762	nd Transfemoral vs transtibial		<u>%</u>	<0.05		No	absent for the overall score The Houghton Scale successfully discriminated between transferioral versus transtibilit participants	Construct validity (at both discharge and follow-up: p>0.05)
Doutin	2004	15205762			P	>=0.05		No	There was no difference between unilateral and bilateral	Construct validity (at discharge; at follow-
Devlin	2004	15295762			r (not defined)	0 202	Madarata	Vee	At discharge, there was	Conversent validity (et discharge time)
	2004	13233702			I (not defined)	0.393	Moderate	TES	At discharge, there was no	convergent validity (at discharge time)
Devlin	2004	15295762	MCS		r (not defined)	0.235	Small	No	Correlation with the MCS	Convergent validity (at discharge time)
Devlin	2004	15295762	2MWT		r (not defined)	0.62	Large	Yes	Significantly with the 2MWT At both discharge and follow-up the Houghton Scale correlated	Convergent validity (at discharge time)
Devlin	2004	15295762	2MWT		r (not defined)	0.653	Large	Yes	Significantly with the 2MWT Floor and ceiling effects on the individual items were notable (as expected), although nearly	Convergent validity (at follow-up)
Devlin	2004	15295762	nd		%	0		No	absent for the overall score	

Author	Voor	BMID	Amputation Loval	Amputation	1.00	Other Population	N	Instrument	Subseele	Description	Bronorty	Acrost
Aution	Tedi	FWID	Amputation Level	Ellology	Aye	mormation	N	Instrument	Subscale	The Houghton Scale1 is an instrument that	Froperty	Aspect
										looks solely at prosthetic use in people with		
										lower-extremity amputations; it reflects a		
										person's perception of prosthetic use, rather		
										than a health care provider's viewpoint, and it		
Devlin	2004	15295762	Multiple	Multiple	60.9		49	Houghton Scale		consists of 4 questions	Reliability	Internal Consistency
										The Houghton Scale1, is an instrument that		
										looks solely at prostnetic use in people with		
										person's perception of prosthetic use rather		
										than a health care provider's viewpoint, and it	Responsiven	
Devlin	2004	15295762	Multiple	Multiple	65.5		76	Houghton Scale		consists of 4 questions	ess	nd
										The Houghton Scale1, is an instrument that		
										looks solely at prosthetic use in people with		
										lower-extremity amputations; it reflects a		
										then a health ears provider's viewpoint, and it		
Devlin	2004	15295762	Multiple	Multiple	60.9		49	Houghton Scale		consists of 4 questions	Reliability	Test-retest
	2001	10200102	manipio	manipio	00.0		10	noughton could			rtonability	
			Transfemoral (n=31),							Rehabilitation was assessed by the answers to		
			Transtibial (n=56),							four standard questions. A score of 9 was		
			Gritti-Stokes (n=3),							accepted as satisfactory rehabilitation and one		
Houghton	1002	1202461	Filotorol (n=1),	nd	Banga 50.99	nd	102	Houghton Scolo		or 6 as indicating mobility on the prostnesis	Volidity	Construct
Houghton	1992	1393401	bildteral (II-11)	nu	Range 50-66	110	102	Houghton Scale		This measure assesses the amount of time	validity	Construct
										the prosthesis is used, the manner in which		
										the prosthesis is used, whether a mobility		
										device is used when ambulating outside and		
			Transfemoral (26%),	Vascular (55%), Non	1					the perception of stability when walking over a	Floor/ceiling	
Miller	2000		Transtibial (74%)	vascular (45%)	58.4		60	Houghton Scale		variety of terrains.	effect	Ceiling
										This measure assesses the amount of time		
										the prosthesis is used, the manner in which		
										device is used when ambulating outside and		
			Transfemoral (26%),	Vascular (53%), Non						the perception of stability when walking over a	Floor/ceiling	
Miller	2000		Transtibial (74%)	vascular (47%)	59.9		329	Houghton Scale		variety of terrains.	effect	Ceiling
										This measure assesses the amount of time		
										the prosthesis is used, the manner in which		
										the prosthesis is used, whether a mobility		
			Transfemoral (26%)	Vascular (53%) Non]					the perception of stability when walking over a		
Miller	2000		Transtibial (74%)	vascular (47%)	59.9		329	Houghton Scale		variety of terrains.	Validity	Construct
										This measure assesses the amount of time		
										the prosthesis is used, the manner in which		
										the prosthesis is used, whether a mobility		
										device is used when ambulating outside and		
Miller	2000		Transfemoral (26%),	Vascular (53%), Non	50.0		220	Lleughten Coole		the perception of stability when walking over a	Volidity	Construct
	2000		rransublai (74%)	vasculai (41%)	53.3		529	noughton ocale	1	This measure assesses the amount of time	valiuity	CONSTRUCT
										the prosthesis is used the manner in which		
										the prosthesis is used, whether a mobility		
		1							1	device is used when ambulating outside and		
			Transfemoral (26%),	Vascular (53%), Non	1					the perception of stability when walking over a		
Miller	2000		Transtibial (74%)	vascular (47%)	59.9		329	Houghton Scale		variety o f terrains.	Validity	Construct
		1						1	1	This measure assesses the amount of time		
		1						1	1	the prosthesis is used, the manner in which		
		1						1	1	device is used when ambulating outside and		
		1	Transfemoral (26%)	Vascular (53%), Non	1				1	the perception of stability when walking over a		
Miller	2000	1	Transtibial (74%)	vascular (47%)	59.9		329	Houghton Scale	1	variety of terrains.	Validity	Construct
										This measure assesses the amount of time		
		1						1	1	the prosthesis is used, the manner in which		
		1							1	the prosthesis is used, whether a mobility		
1		1	Transformarial (26%)	Vacaular (52%) Nac					1	device is used when ambulating outside and		
Miller	2000	1	Transferrioral (20%),	vascular (55%), NON	50.0		320	Houghton Scale	1	variety of terrains	Validity	Construct
INTILCI	2000	1	1 anoubiai (7470)	1+430ulai (4770)	00.0	1	020	noughton oudle	1	vancey 01 terrains.	valuity	Condutuor

			Comparator/Criterion/Outc	Timepoint (predictive			Strength of	Is Aspect				
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats		
									The internal consistency was			
					Cronbach's				moderate at discharge and			
Devlin	2004	15295762	nd		alpha	0.71	Adequate	Yes	follow-up	Values at discharge time (.7 at follow up)		
									The effect size calculated for			
									this change was .60, indicating			
Devlin	2004	15295762	nd		Effect size	0.6		Yes	a moderate difference			
									The Houghton Scale showed			
									good test-retest reliability over a			
Devlin	2004	15295762	nd		ICC	0.96	Excellent	Yes	1-week span			
									BK amputees performed better			
									than AK ones. The remaining			
									15 per cent comprised bilateral			
									(11per cent), GS (3per cent)and			
									these amputation types were			
									too small to assess comparative			
Houghton	1992	1393461	Transfemoral vs transtibial		nd	nd		Yes	rehabilitation.			
-												
									There was no indication of floor			
Miller	2000		nd		%	12.9		No	effect			
Miller	2000				0/	c		Nie	I here was no indication of			
Willer	2000		nu		70	0		NO	centing effect			
N 4111	0000		Tana dikialan Tana damanal		Effect all all and	0.00			The Houghton differed between			
Miller	2000		Transtibial vs Transfemoral		Effect size	0.29		Yes	I ranstibial and I ranstemoral			
									The Houghton differed between			
Miller	2000		Vascular vs non-vasular		Effect size	0.63		Yes	Vascular and non-vasular			
									The Houghton differed between			
			Mobility device used vs no						Mobility device used and no	Mobility device use is an item of Houghton		
Miller	2000		device		Effect size	1.62		Yes	device use	scale		
		1										
									The line share different had so a			
		1	Walking distance <1 block						Walking distance <1 block and			
Miller	2000		vs unlimited		Effect size	0.54		Yes	unlimited			
		1						1				
		1										
		1										
									The Houghton differed between			
Millor	2000				Effect aize	0.79		Voo	Automatic walking and no			
	12000	1	Inductionatic walking ves vs no	1	ILTIEUL SIZE	10.70	1	1165	IQUIUTIALIC WAINITU	T. C.		
				Amputation		Other Population						
--------	------	------	--	---------------------------------------	------	------------------	-----	-----------------	----------	---	-------------------------	----------------------
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
										This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and		
Miller	2000		Transfemoral (26%), Transtibial (74%)	Vascular (55%), Non vascular (45%)	58.4		60	Houghton Scale		the perception of stability when walking over a variety o f terrains.	Validity	Convergent
			Transfemoral (26%),	Vascular (55%), Non						This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a		
Miller	2000		Transtibial (74%)	vascular (45%)	58.4		60	Houghton Scale		variety of terrains.	Validity	Convergent
Miller	2000		Transfemoral (26%), Transtibial (74%)	Vascular (55%), Non vascular (45%)	58.4		60	Houghton Scale		I his measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a variety of terrains.	Validity	Convergent
			Transfemoral (26%),	Vascular (53%), Non						This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a		
Miller	2000		Transtibial (74%)	vascular (47%)	59.9		329	Houghton Scale		variety of terrains.	Validity	Convergent
			Transfemoral (26%),	Vascular (55%), Non						This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a		
Miller	2000		Transtibial (74%)	vascular (45%)	58.4		60	Houghton Scale		variety of terrains. This measure assesses the amount of time	Validity	Convergent
Millor	2000		Transfemoral (26%),	Vascular (53%), Non	50.0		220	Heurehten Scolo		the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a wright of termine.	Volidity	Conversent
Miller	2000		Transtibiai (74%)	vascular (47%)	59.9		329	Houghton Scale		This measure assesses the amount of time	validity	Convergent
Miller	2000		Transfemoral (26%), Transtibial (74%)	Vascular (55%), Non vascular (45%)	58.4		60	Houghton Scale		the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a variety of terrains.	Validity	Convergent
Miller	2000		Transfemoral (26%), Transtibial (74%)	Vascular (53%), Non vascular (47%)	59.9		329	Houghton Scale		This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a variety of terrains.	Validity	Convergent
Miller	2000		Transfemoral (26%), Transtibial (74%)	Vascular (55%), Non vascular (45%)	58.4		60	Houghton Scale		This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a variety of terrains.	Floor/ceiling effect	Floor
Miller	2000		Transfemoral (26%), Transtibial (74%)	Vascular (53%), Non vascular (47%)	59.9		329	Houghton Scale		This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a variety of terrains.	Floor/ceiling effect	Floor
Miller	2000		Transfemoral (26%), Transtibial (74%)	Vascular (55%), Non vascular (45%)	58.4		60	Houghton Scale		This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a variety of terrains.	Reliability	Internal Consistency
			Transfemoral (26%).	Vascular (55%), Non	-					This measure assesses the amount of time the prosthesis is used, the manner in which the prosthesis is used, whether a mobility device is used when ambulating outside and the perception of stability when walking over a		
Miller	2000		Transtibial (74%)	vascular (45%)	58.4	1	60	Houghton Scale		variety of terrains.	Reliability	Test-retest

			Comparator/Criterion/Outc	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
									The Houghton displayed Large correlation with the Two minute	
Miller	2000		Two minute walk test		Pearson r	0.64	Large	Yes	walk test	
Millor	2000		Timed up and go		Pearson r	0.6	Large	Vac	The Houghton displayed Large correlation with the Timed up	
WINE	2000		Timed up and go		1 earsonn	-0.0	Large	103	and go	
Miller	2000		Activities-specific Balance Confidence		Pearson r	0.67	Large	Yes	The Houghton displayed Large correlation with the Activities- specific Balance Confidence	
Miller	2000		Activities-specific Balance Confidence		Pearson r	0.63	Large	Yes	The Houghton displayed Large correlation with the Activities- specific Balance Confidence	
Miller	2000		Prosthetic Profile of the Amputee - Locomotor Capabilities Index		Pearson r	0.6	Large	Yes	The Houghton displayed Large correlation with the Prosthetic Profile of the Amputee - Locomotor Capabilities Index	
Miller	2000		Prosthetic Profile of the Amputee - Locomotor Canabilities Index		Pearson r	0 59	Large	Yes	The Houghton displayed Large correlation with the Prosthetic Profile of the Amputee - L ocomotor Canabilities Index	
WINCI	2000		Capabilities index		1 earsonn	0.55	Large	103	Ecconicion Capabilities index	
Miller	2000		Prosthetic Evaluation Questionnaire - Mobility		Pearson r	0.59	Large	Yes	The Houghton displayed Large correlation with the Prosthetic Evaluation Questionnaire - Mobility	
Miller	2000		Prosthetic Evaluation Questionnaire - Mobility		Pearson r	0.55	Large	Yes	The Houghton displayed Large correlation with the Prosthetic Evaluation Questionnaire - Mobility	
Miller	2000		nd		%	0		No	There was no indication of floor effect	
Miller	2000		nd		%	0.3		No	There was no indication of floor effect	
Miller	2000		nd		Cronbach's alpha	0.68	Adequate	Yes	The score displayed an adequate Internal Consistency based on Cronbach's alpha value	
									The Houghton score displayed an excelent Test-retest reliability based on the ICC	
Miller	2000	1	na		ICC	0.85	Excellent	Yes	value	

Author	Year	PMID	Amputation Level	Amputation Etiology	Age	Other Population	N	Instrument	Subscale	Description	Property	Aspect
Miller	2001	11552197	below knee (73%)	Vascular (53%)	62	23-91	435	Houghton Scale			Validity	Convergent
Miller	2001	11552197	DEIOW KREE (73%)	Vascular (53%)	62	23-91	435	Houghton Scale			validity	Convergent
Miller	2001	11552197	below knee (73%)	Vascular (53%)	62	23-91	435	Houghton Scale			Validity	Convergent
											Floor/ceiling effects	
		11588750	below knee (72%),	Vascular (55%),	=0						(appropriaten	
Miller	2001	(sample 1) 11588750	below knee (28%)	Vascular (55%),	58		60	Houghton Scale		Ability to measure change	ess)	
Miller	2001	(sample 1)	above knee (28%)	nonvascular 45%)	58		55	Houghton Scale			Reliability	Internal consistency
Miller	2001	(sample 1)	above knee (28%)	nonvascular (55%),	58		55	Houghton Scale			Reliability	Test-retest
Miller	2001	11588750 (sample 1)	below knee (72%), above knee (28%)	Vascular (55%),	58		60	Houghton Scale			Validity	Convergent validity
Winici	2001	11588750	below knee (72%),	Vascular (55%),	00		00	Houghton occure			validity	Convergent validity
Miller	2001	(sample 1)	above knee (28%)	nonvascular 45%)	58		60	Houghton Scale			Validity	Convergent validity
Miller	2001	(sample 1)	above knee (28%)	nonvascular 45%)	58		60	Houghton Scale			Validity	Convergent validity
Miller	2001	11588750 (sample 1)	below knee (72%), above knee (28%)	Vascular (55%), nonvascular 45%)	58		60	Houghton Scale			Validity	Convergent validity
	2001	11588750	below knee (72%),	Vascular (55%),							valiary	
Miller	2001	(sample 1)	above knee (28%)	nonvascular 45%)	58		60	Houghton Scale			Validity Floor/ceiling	Convergent validity
											effects	
Miller	2001	11588750 (sample 2)	below knee (74%), above knee (26%)	Vascular (53%), nonvascular 47%)	60		329	Houghton Scale		Ability to measure change	(appropriaten ess)	
				, í								
		11588750	below knee (74%).	Vascular (53%).								
Miller	2001	(sample 2)	above knee (26%)	nonvascular 47%)	60		329	Houghton Scale			Validity	Construct (discriminant)
Miller	2001	11588750 (sample 2)	below knee (74%), above knee (26%)	Vascular (53%), nonvascular 47%)	60		329	Houghton Scale			Validity	Convergent validity
		11588750	below knee (74%),	Vascular (53%),								
Miller	2001	(sample 2) 11588750	below knee (26%)	nonvascular 47%) Vascular (53%).	60		329	Houghton Scale			Validity	Convergent validity
Miller	2001	(sample 2)	above knee (26%)	nonvascular 47%)	60		329	Houghton Scale			Validity	Convergent validity
										The 4-question self-reported Houghton Scale quantifies daily prosthetic use and function in		
										various walking conditions. Total scores range		
Wong	2016	26874230	Multiple	Multiple	55.5		180	Houghton Scale		from 0 to 12 without ceiling or floor effects, with higher scores indicating better function.	Validity	Criterion (convergent)
										The 4-question self-reported Houghton Scale		
										quantifies daily prosthetic use and function in		
										from 0 to 12 without ceiling or floor effects,		
Wong	2016	26874230	Multiple	Multiple	55.5		180	Houghton Scale		with higher scores indicating better function.	Validity	Criterion (convergent)
										quantifies daily prosthetic use and function in		
										various walking conditions. Total scores range		
Wong	2016	26874230	Multiple	Multiple	55.5		180	Houghton Scale		with higher scores indicating better function.	Validity	Criterion (convergent)
										The 4-question self-reported Houghton Scale		
										quantifies daily prosthetic use and function in various walking conditions. Total scores range		
										from 0 to 12 without ceiling or floor effects,		
vvong	2016	26874230	Multiple	Multiple	55.5		180	Houghton Scale		with higher scores indicating better function.	validity	Criterion (convergent)
										quantifies daily prosthetic use and function in		
										various walking conditions. Total scores range		
Wong	2016	26874230	Multiple	Multiple	55.5		180	Houghton Scale		with higher scores indicating better function.	Validity	Criterion (convergent)

			0	Timepoint			0			
A	Veee	DMID	Comparator/Criterion/Outc	(predictive	Matria Lland	Value	Strength of	Is Aspect	Construction	Natas/Causata
Author	rear	PMID	ome	valid)	Metric Used	value	Property	Supported ?	Conclusion	Notes/Caveats
					regression					
Miller	2001	11552197	Falling		coefficient	0.021				not statistically significant
	2001	11002101	. annig		standardized	0.021				not otatiotically olgrinicant
					regression					
Miller	2001	11552197	fear of falling		coefficient	0.058				not statistically significant
					standardized					
			ABC scale (balance		regression					
Miller	2001	11552197	confidence)		coefficient	0.804				statistically significant
		11588750			% at floor or					
Miller	2001	(sample 1)	NA		ceiling	13		Ves		Ceiling effect (negligible floor effects)
	2001	11588750			Cronbach					
Miller	2001	(sample 1)			Alpha	0.68	adequate			55/60 were stable
		11588750				0.85 (0.74,				
Miller	2001	(sample 1)			ICC (95% CI)	0.90)				55/60 were stable
		11588750			2 minute walk					
Miller	2001	(sample 1)			test	correlation	0.64			
Millor	2001	11588750 (comple 1)			Timed up and	corrolation	0.6			
Willer	2001	(Sample T)			g0 (10G)	correlation	-0.0			
Miller	2001	(sample 1)			ABC scale	correlation	0.67			
		11588750								
Miller	2001	(sample 1)			LCI	correlation	0.6			
		11588750								
Miller	2001	(sample 1)			PEQ mobility	correlation	0.59			
		11588750			% at floor or					
Miller	2001	(sample 2)	NA		ceiling	6		Ves		Ceiling effect (negligible floor effects)
Willer	2001	(Sumple 2)			coming	0		103		Sening criedt (riegligible riddr criedts)
						Statistically				
						significant				
			by: amputation level,;			differences in				
			amputation cause; mobility		differences	scores across				
N 4111	0004	11588750	device; walking distance;		between levels	all examined				
willer	2001	(sample 2)	automatic waiking		of factors	Tactors				
Miller	2001	(sample 2)			ABC scale	correlation	0.63			
		11588750								
Miller	2001	(sample 2)			LCI	correlation	0.59			
		11588750								
Miller	2001	(sample 2)			PEQ mobility	correlation	0.55			
									The Usershiter Orela areas	
			Dreathatic Evaluation						The Houghton Scale scores	
			Questionnaire - Mobility						based balance and walking	
Wong	2016	26874230	subscale		Spearman r	0.73	Large	Yes	ability measures	
							- 3 -			
									The Houghton Scale scores	
									correlated with performance-	
			Activities-specific Balance						based balance and walking	
Wong	2016	26874230	Confidence		Spearman r	-0.76	Large	Yes	ability measures	
									The Houghton Scale secret	
									correlated with performance-	
									based balance and walking	
Wong	2016	26874230	3-Berg Balance Scale		Spearman r	0.67	Large	Yes	ability measures	
									The Houghton Scale scores	
									correlated with performance-	
Wong	2016	26874230	Timed up and do		Spearman r	0.67	Large	Yes	ability measures	
wong	2010	20014200	rinica up ana go		opeannan I	0.01	Large	1 60	ability measures	
									The Houghton Scale scores	
									correlated with performance-	
1					1				based balance and walking	
Wong	2016	26874230	Two minute walk test	1	Spearman r	0.73	Large	Yes	ability measures	

Author	Year	PMID	Amputation Level	Amputation Etiology	Age	Other Population	N	Instrument	Subscale	Description	Property	Aspect
Wong	2016	26874230	Multiple	Multiple	55.5		180	Houghton Scale		The 4-question self-reported Houghton Scale quantifies daily prosthetic use and function in various walking conditions. Total scores range from 0 to 12 without ceiling or floor effects, with higher scores indicating better function. 3 Houghton Scale (range 0-12) categoris: >=9 vs 6-8 vs <=5	Validity	Criterion
										The 4-question self-reported Houghton Scale quantifies daily prosthetic use and function in various walking conditions. Total scores range from 0 to 12 without ceiling or floor effects, with higher scores indicating better function. 3 Houghton Scale (range 0-12) categoris: >=9		
Wong	2016	26874230	Multiple	Multiple	55.5		180	Houghton Scale		vs 6-8 vs <=5 The 4-question self-reported Houghton Scale quantifies daily prosthetic use and function in various walking conditions. Total scores range from 0 to 12 without ceiling or floor effects, with higher scores indicating better function. 3 Houghton Scale (range 0-12) categoris: >=9 vs 6-8 vs <=5	Validity	Criterion
Wong	2016	26874230	Multiple	Multiple	55.5		180	Houghton Scale		The 4-question self-reported Houghton Scale quantifies daily prosthetic use and function in various walking conditions. Total scores range from 0 to 12 without ceiling or floor effects, with higher scores indicating better function. 3 Houghton Scale (range 0-12) categoris: >=9 vs 6-8 vs <=5	Validity	Criterion
										The 4-question self-reported Houghton Scale quantifies daily prosthetic use and function in various walking conditions. Total scores range from 0 to 12 without ceiling or floor effects, with higher scores indicating better function. 3 Houghton Scale (range 0-12) categoris: >=9		
Wong	2016	26874230	Multiple Partial foot (n=2), below knee (n=29), through knee (n=3), above knee (n=20), hip disarticulation (n=4), bilateral (n=1).	Multiple Congenital (n=7), cancer (n=13), Accident (n=27), peripheral vascular disorder (n=7), other (n=6; not described	55.5		180	Houghton Scale		vs 6-8 vs <=5	Validity	Criterion
Gallagher	2000	study 2	not specified $(n=1)$ Partial foot $(n=2)$, below knee $(n=29)$, through knee $(n=3)$, above knee $(n=20)$, hip disarticulation (n=4), bilateral $(n=1)$, not specified $(n=1)$	further) Congenital (n=7), cancer (n=13), Accident (n=27), peripheral vascular disorder (n=7), other (n=6; not described further)	47.1	18+ years old	60	IES	Avoidance		Validity	Convergent
Gallagher	2000	study 2	Partial foot (n=2), below knee (n=29), through knee (n=3), above knee (n=20), hip disarticulation (n=4), bilateral (n=1), not specified (n=1)	Congenital (n=7), cancer (n=13), Accident (n=27), peripheral vascular disorder (n=7), other (n=6; not described further)	47.1	18+ years old	60	IES	Avoidance		Validity	Convergent
Gallagher	2000	study 2	Partial foot (n=2), below knee (n=29), through knee (n=3), above knee (n=20), hip disarticulation (n=4), bilateral (n=1), not specified (n=1)	Congenital (n=7), cancer (n=13), Accident (n=27), peripheral vascular disorder (n=7), other (n=6; not described further)	47.1	18+ years old	60	IES	Intrusion		Validity	Convergent

				Timepoint						
A	V	DMID	Comparator/Criterion/Outc	(predictive	Matria Llaad	Value	Strength of	Is Aspect	Construction	Natao/Causata
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
									The 3 Houghton Scale ability	
									from each other ($P < 05$) for all	
									outcome measures: Prosthetic	
									Evaluation Questionnaire	
									mobility subscale, ABC Scale,	
			Activities-specific Balance						balance ability, TUG test, and	
Wong	2016	26874230	Confidence		Р	<0.05		Yes	2MWT	Based on the ANOVA-Tukey test
									The 3 Houghton Scale ability	
									categories differed significantly	
									from each other (P<.05) for all	
									Evaluation Questionnaire	
									mobility subscale ABC Scale	
									balance ability, TUG test, and	
Wong	2016	26874230	Timed up and go		Р	<0.05		Yes	2MWT	Based on the ANOVA-Tukey test
			· · ·						The 3 Houghton Scale ability	
									categories differed significantly	
									from each other (P<.05) for all	
									outcome measures: Prosthetic	
									Evaluation Questionnaire	
									halance ability TLIC test and	
Wong	2016	26874230	Two minute walk test		Р	<0.05		Yes	2MWT	Based on the ANOVA-Tukey test
					-				The 3 Houghton Scale ability	
									categories differed significantly	
									from each other (P<.05) for all	
									outcome measures: Prosthetic	
									Evaluation Questionnaire	
									mobility subscale, ABC Scale,	
Wong	2016	26974220	2 Borg Bolonoo Soolo		в	<0.05		Voo	Dalance ability, TUG test, and	Based on the ANOVA Tukey test
wong	2010	20074230	5-Derg Dalarice Scale		1	-0.05		163	The 3 Houghton Scale ability	Dased on the ANOVA-Tukey test
									categories differed significantly	
									from each other (P<.05) for all	
									outcome measures: Prosthetic	
									Evaluation Questionnaire	
			Prosthetic Evaluation						mobility subscale, ABC Scale,	
10/	0040	00074000	Questionnaire - Mobility			-0.05			balance ability, TUG test, and	
vvong	2016	26874230	subscale		P	<0.05		res	21/11/01	Based on the ANOVA-Tukey test
					- · · ·					
Gallagher	2000	study 2	TAPES General adjustment		Correlation r	-0.455	Moderate	Yes		p<0.001
Gallagher	2000	study 2	TAPES Social adjustment		Correlation r	-0.462	Moderate	Yes		p<0.05
			TAPES Adjustment to							
Gallagher	2000	study 2	limitation		Correlation r	-0.266	Small	Yes		p<0.05
1								1		
					1					
					1					
					1					
								1		
Gallagher	2000	study 2	TAPES General adjustment		Correlation r	-0.623	Large	Yes		p<0.001

				Amputation		Other Bonulation						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
			Partial foot (n=2),	Congenital (n=7),								•
			below knee (n=29),	cancer (n=13),								
			above knee (n=20),	peripheral vascular								
			hip disarticulation	disorder (n=7), other								
Gallagher	2000	study 2	(n=4), bilateral (n=1), not specified (n=1)	(n=6; not described further)	47 1	18+ years old	60	IFS	Intrusion		Validity	Convergent
Gallagrior	2000	olddy 2	Partial foot (n=2),	Congenital (n=7),				120	ind doion		valialty	Controlgon
			below knee (n=29),	cancer (n=13),								
			through knee (n=3), above knee (n=20).	Accident (n=27), peripheral vascular								
			hip disarticulation	disorder (n=7), other								
Gallagher	2000	study 2	(n=4), bilateral (n=1), not specified (n=1)	(n=6; not described	47 1	18+ years old	60	IES	Intrusion		Validity	Convergent
Callagrio	2000	olddy 2	not opconice (n 1)	Congenital (n=2),				120	ind doion		valialty	Controlgon
				Metabolic (n=4),								
			Transfemoral (n=7), Transfibial (n=13) Hin	Vascular (n=2), Mechanical trauma								
da Silva	2011		(n=1), Knee (n=1)	(n=15)	18-69	nd	22	IPAQ	Overall		Reliability	Internal consistency
				Congenital (n=2),								
			Transfemoral (n=7),	Vascular (n=2),								
			Transtibial (n=13), Hip	Mechanical trauma								
da Silva	2011		(n=1), Knee (n=1)	(n=15) Trauma (n=8)	18-69		22	IPAQ			Reliability	Internal consistency
				Tumour (n=2),								
				Infection (n=1),								
			Transfemoral (n=24).	Post-radiation (n=1).								
Deathe and Miller	2005		Transtibial (n=69)	Congenital (n=2)	55.9	nd	93	L test	nd		Validity	Convergent
				Trauma (n=8),								
				Infection (n=1),								
			L	Vascular (n=25),								
Deathe and Miller	2005		Transtemoral (n=24), Transtibial (n=69)	Post-radiation (n=1), Congenital (n=2)	55.9	nd	93	I test	nd		Validity	Convergent
	2000		Tranociolar (1 00)	Trauma (n=8),	00.0						valialty	Controlgon
				Tumour (n=2),								
				Vascular (n=1),								
			Transfemoral (n=24),	Post-radiation (n=1),								
Deathe and Miller	2005		Transtibial (n=69)	Congenital (n=2) Trauma (n=8)	55.9	nd	93	L test	nd		Validity	Convergent
				Tumour (n=2),								
				Infection (n=1),								
			Transfemoral (n=24).	Vascular (n=25), Post-radiation (n=1).								
Deathe and Miller	2005		Transtibial (n=69)	Congenital (n=2)	55.9	nd	93	L test	nd		Validity	Convergent
				Trauma (n=8), Tumour (n=2)								
				Infection (n=1),								
				Vascular (n=25),								
Deathe and Miller	2005		Transfemoral (n=24), Transtibial (n=69)	Post-radiation (n=1), Congenital (n=2)	55.9	nd	93	L test	nd		Validity	Convergent
				Trauma (n=8),								
				Tumour (n=2),								
				Vascular (n=25),								
			Transfemoral (n=24),	Post-radiation (n=1),								
Deathe and Miller	2005		Transtibial (n=69)	Congenital (n=2) Trauma (n=8)	55.9	nd	93	L test	nd		Validity	Convergent
				Tumour (n=2),								
				Infection (n=1),								
			Transfemoral (n=24),	Post-radiation (n=1),								
Deathe and Miller	2005		Transtibial (n=69)	Congenital (n=2)	55.9	nd	93	L test	nd		Reliability	intrarater
				Trauma (n=8), Tumour (n=2)								
				Infection (n=1),								
			Transformanal (n= 0.4)	Vascular (n=25),								
Deathe and Miller	2005		Transtibial (n=69)	Congenital (n=2)	55.9	nd	93	L test	nd		Reliability	interrater

			Comparator/Criterion/Outo	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
				,						
Gallagher	2000	study 2	TAPES Social adjustment		Correlation r	-0.265	Small	Yes		p<0.001
			TAPES Adjustment to							
Gallagher	2000	study 2	limitation		Correlation r	-0.372	Moderate	Yes		p<0.01
					Cronbach					
da Silva	2011				Alpha	0.55-0.63				
					Cronbach					
da Silva	2011				Alpha	0.55-0.63				
Death a sead Miller	0005		The set Wile & Oall Test		D	0.00				
Deathe and Miller	2005	-	Timed Up & Go Test		Pearson r	0.93				
Deathe and Miller	2005		2 Minute Walk Test		Pearson r	0.86				
Deathe and while	2003		2-Willitute Walk Test		rearsonn	-0.00				
Deathe and Miller	2005		10-Meter Walk Test		Pearson r	0.97				
Deathe and Miller	2005		ABC		Pearson r	-0.48				
Deathe and Miller	2005		Frenchay Activities Index		Pearson r	-0.54				
Deathe and Miller	2005		PEQ-MS		Pearson r	-0.22				
Deathe and Miller	2005				ICC	0.97				
Boatric and Willer	2000		1	-		0.01		1		
Deathe and Miller	2005				ICC	0.96				
		1	1	1	1.4 -		1	1	i la	1

				Amputation		Other Benulation						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
				Trauma (n=8), Tumour (n=2), Infection (n=1), Vascular (n=25),								
Deathe and Miller	2005		Transfemoral (n=24), Transfibial (n=60)	Post-radiation (n=1),	55.0	nd	03	Ltest	nd		Validity	Known group
	2003		Transfemoral (n=24),	Trauma (n=8), Tumour (n=2), Infection (n=1), Vascular (n=25), Post-radiation (n=1),	0.0		55		ind.		Validity	Rhown group
Deathe and Miller	2005		Transtibial (n=69)	Congenital (n=2)	55.9	nd	93	L test	nd		Validity	Known group
Deathe	2005	15982169	Transfemoral (n=24), Transfibial (n=69)	Trauma (n=8), Tumour (n=2), Infection (n=1), Vascular (n=25), Post-radiation (n=1), Concenital (n=2)	55.9		93	I test		The L Test is a modified version of the Timed Up & Go (TUG) Test where the time it takes an individual to rise from an armless chair, walk 3 m, perform a right-angle turn, and continue walking 7 m before turning around 180° and walking back along the same path and sitting drown is recorded in seconds.	Reliability	interrater
Deatrie	2003	13302103	Transcolar (II=03)	congenital (II=2)	55.8		90	Liesi		The L Test is a modified version of the Timed	Reliability	Interrater
Deatha	0005	15000100	Transfemoral (n=24),	Trauma (n=8), Tumour (n=2), Infection (n=1), Vascular (n=25), Post-radiation (n=1),	55.0					Up & Go (TUG) Test where the time it takes an individual to rise from an armless chair, walk 3 m, perform a right-angle turn, and continue walking 7 m before turning around 180° and walking back along the same path and sitting	Dellebille	
Deathe	2005	15982169	Transtibial (n=69)	Congenital (n=2)	55.9		93	L test		down is recorded in seconds	Reliability	intrarater
Deathe	2005	15982169	Transfemoral (n=24), Transtibial (n=69)	Trauma (n=8), Tumour (n=2), Infection (n=1), Vascular (n=25), Post-radiation (n=1), Congenital (n=2)	55.9		93	L test		The Lifest is a inducined version of the tracks an individual to rise from an armless chair, walk 3 m, perform a right-angle turn, and continue walking 7 m before turning around 180° and walking back along the same path and sitting down is recorded in seconds	Validity	Convergent
Deathe	2005	15982169	Transfemoral (n=24), Transtibial (n=69)	Trauma (n=8), Tumour (n=2), Infection (n=1), Vascular (n=25), Post-radiation (n=1), Congenital (n=2)	55.9		93	L test		The L Test is a modified version of the Timed Up & Go (TUG) Test where the time it takes an individual to rise from an armless chair, walk 3 m, perform a right-angle turn, and continue walking 7 m before turning around 180° and walking back along the same path and sitting down is recorded in seconds	Validity	Convergent
Deathe	2005	15082160	Transfemoral (n=24),	Trauma (n=8), Tumour (n=2), Infection (n=1), Vascular (n=25), Post-radiation (n=1), Concential (n=2)	55.9		03	Ltect		The L Test is a modified version of the Timed Up & Go (TUG) Test where the time it takes an individual to rise from an armless chair, walk 3 m, perform a right-angle turn, and continue walking 7 m before turning around 180° and walking back along the same path and sitting down is recorded to accorde	Validity	Convergent
Deathe	2005	10902109	Translibiai (II=09)	congenitai (n=2)	00.9		30	LICOL	-	The L Test is a modified version of the Timed	validity	Convergent
Deathe	2005	15982169	Transfemoral (n=24), Transtibial (n=69)	Trauma (n=8), Tumour (n=2), Infection (n=1), Vascular (n=25), Post-radiation (n=1), Congenital (n=2)	55.9		93	L test		Up & Go (TUG) Test where the time it takes an individual to rise from an armless chair, walk 3 m, perform a right-angle turn, and continue walking 7 m before turning around 180° and walking back along the same path and sitting down is recorded in seconds	Validity	Convergent
Deathe	2005	15982169	Transfemoral (n=24), Transfibial (n=60)	Trauma (n=8), Tumour (n=2), Infection (n=1), Vascular (n=25), Post-radiation (n=1), Congenital (n=2)	55.9		93	I test		The L Test is a modified version of the Timed Up & Go (TUG) Test where the time it takes an individual to rise from an armless chair, walk 3 m, perform a right-angle turn, and continue walking 7 m before turning around 180° and walking back along the same path and sitting drown is recorded.	Validity	Convergent
Deathe	2000	13802108	Translibidi (II-09)		33.8		33	L 1001	-	The L Test is a modified version of the Timed	valluity	Convergent
			Transfemoral (n=24),	Trauma (n=8), Tumour (n=2), Infection (n=1), Vascular (n=25), Post-radiation (n=1),						Up & Go (TUG) Test where the time it takes an individual to rise from an armless chair, walk 3 m, perform a right-angle turn, and continue walking 7 m before turning around 180° and walking back along the same path and sitting		
Deathe	2005	15982169	Transtibial (n=69)	Congenital (n=2)	55.9		93	L test		down is recorded in seconds	Validity	Convergent

			Comparator/Criterion/Outo	Timepoint			Strength of	le Aspect		
Author	Year	PMID	ome	(predictive valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
, lutio				rana,		ruido	Topolly	eupperiou :		
Deathe and Miller	2005		transfemoral vs transtibial		P value	<0.001				
Deathe and Miller	2005		traumatic vs vascular		P value	<0.001				
Deatha	2005	15082160				100	0.06			
Deatrie	2005	15962169					0.96			
Deathe	2005	15982169				ICC	0.97			
					Timed "Up &					
Deathe	2005	15982169			Go" Test	Pearson r	0.93			
					2 Minute Mall					
Deathe	2005	15982169			Z-IVIIIIUte vvaik	Pearson r	-0.86			
					10-Meter Walk					
Deathe	2005	15982169			Test	Pearson r	0.97			
Deathe	2005	15982169			ABC	Pearson r	-0.48			
Bodano	2000	10002100			1.00	- ouroon -	0.10			
					Frenchay					
Deathe	2005	15982169			Activities Index	Pearson r	-0.54			
Deatha	0005	45000400			DE0.140		0.00			
Deathe	2005	15982169	1	1	IPEQ-MS	Pearson r	-0.22	1	1	1

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Deathe	2005	15982169	Transfemoral (n=24), Transtibial (n=69)	Trauma (n=8), Tumour (n=2), Infection (n=1), Vascular (n=25), Post-radiation (n=1) Congenital (n=2)	55.9		93	L test		The L Test is a modified version of the Timed Up & Go (TUG) Test where the time it takes an individual to rise from an armless chair, walk 3 m, perform a right-angle turn, and continue walking 7 m before turning around 180° and walking back along the same path and sitting down is recorded in seconds	Validity	Known group
Deathe	2005	15982169	Transfemoral (n=24), Transtibial (n=69)	Trauma (n=8), Tumour (n=2), Infection (n=1), Vascular (n=25), Post-radiation (n=1) Congenital (n=2)	55.9		93	L test		The L Test is a modified version of the Timed Up & Go (TUG) Test where the time it takes an individual to rise from an armless chair, walk 3 m, perform a right-angle turn, and continue walking 7 m before turning around 180° and walking back along the same path and sitting down is recorded in seconds	Validity	Known group
Rushton	2015	25134533	Transfemoral (18.2%), Transtibial (81.8%)	Vascular (57.6%), Non-vascular (42.4%)	60	nd	33	I -test	nd	The L Test is a modified version of the Timed Up & Go (TUG) Test where the time it takes an individual to rise from an armless chair, walk 3 m, perform a right-angle turn, and continue walking 7 m before turning around 180° and walking back along the same path and sitting down is recorded in seconds.	Validity	Criterion (convergent)
Rushton	2015	25134533	Transfemoral (18.2%), Transtibial (81.8%)	Vascular (57.6%), Non-vascular (42.4%)	60	nd	33	L-test	nd	The L Test is a modified version of the Timed Up & Go (TUG) Test where the time it takes an individual to rise from an armless chair, walk 3 m, perform a right-angle turn, and continue walking 7 m before turning around 180° and walking back along the same path and sitting down is recorded in seconds	Validity	Criterion (convergent)
			Transfemoral (18.2%),	Vascular (57.6%), Non-vascular						The L Test is a modified version of the Timed Up & Go (TUG) Test where the time it takes an individual to rise from an armless chair, walk 3 m, perform a right-angle turn, and continue walking 7 m before turning around 180° and walking back along the same path and sitting	1	
Rushton	2015	25134533	Transfemoral (18.2%), Transfemoral (18.2%), Transtibial (81.8%)	(42.4%) Vascular (57.6%), Non-vascular (42.4%)	60	nd	33	L-test	nd	Down is recorded in seconds The L Test is a modified version of the Timed Up & Go (TUG) Test where the time it takes an individual to rise from an armless chair, walk 3 m, perform a right-angle turn, and continue walking 7 m before turning around 180° and walking back along the same path and sitting down is recorded in seconds	Responsiven	nd
Rushton	2015	25134533	Transfemoral (18.2%), Transtibial (81.8%)	Vascular (57.6%), Non-vascular (42.4%)	60	nd	33	L-test	nd	The L Test is a modified version of the Timed Up & Go (TUG) Test where the time it takes an individual to rise from an armless chair, walk 3 m, perform a right-angle turn, and continue walking 7 m before turning around 180° and walking back along the same path and sitting down is recorded in seconds	Responsiven ess	nd
Rushton	2015	25134533	Transfemoral (18.2%), Transtibial (81.8%)	Vascular (57.6%), Non-vascular (42.4%)	60		33	L-test		The L Test is a modified version of the Timed Up & Go (TUG) Test where the time it takes an individual to rise from an armless chair, walk 3 m, perform a right-angle turn, and continue walking 7 m before turning around 180° and walking back along the same path and sitting down is recorded in seconds	Validity	Criterion (convergent)
Rushton	2015	25134533	Transfemoral (18.2%), Transtibial (81.8%)	Vascular (57.6%), Non-vascular (42.4%)	60		33	L-test		The L Test is a modified version of the Timed Up & Go (TUG) Test where the time it takes an individual to rise from an armless chair, walk 3 m, perform a right-angle turn, and continue walking 7 m before turning around 180° and walking back along the same path and sitting down is recorded in seconds	Validity	Criterion (convergent)
Rushton	2015	25134533	Transfemoral (18.2%), Transtibial (81.8%)	Vascular (57.6%), Non-vascular (42.4%)	60		33	L-test		The L Test is a modified version of the Timed Up & Go (TUG) Test where the time it takes an individual to rise from an armless chair, walk 3 m, perform a right-angle turn, and continue walking 7 m before turning around 180° and walking back along the same path and sitting down is recorded in seconds	Validity	Criterion (convergent)

Author	Year	PMID	Comparator/Criterion/Outc	(predictive valid)	Metric Used	Value	Strength of Property	Is Aspect Supported?	Conclusion	Notes/Caveats
Deaths	2005	45082460			transfemoral	Duelue	-0.001			
Deathe	2005	15982169			vs transtibial	P value	<0.001			
Deathe	2005	15982169			traumatic vs vascular	P value	<0.001			
Rushton	2015	25134533	Global Rating of Change		Spearman r	0.28	Small	No	GRC was not a valid reference standard criterion for assessing important change in the ability of an individual with a LLA to get up and walk with a prosthesis	
Rushton	2015	25134533	Global Rating of Change		Spearman r	0.27	Small	No	GRC was not a valid reference standard criterion for assessing important change in the ability of an individual with a LLA to get up and walk with a prosthesis	Follow-up L Test
Rushten	2015	25424522				0.27	Small	No	GRC was not a valid reference standard criterion for assessing important change in the ability of an individual with a LLA to get up and walk with a	L Test change between baseline and follow
Rushton	2015	25134533	Global Rating of Change		AUROC	0.67	Smail	No	The hypothesis that the L Test would correctly identify individuals who have and have not undergone an important change 80% of the time was not supported	up
Rushton	2015	25134533	Global Rating of Change		Minimal clinically important difference	4.5		Yes	The study provides the first estimate of a MCID value for the L Test	
Rushton	2015	25134533	Global Rating of Change		Spearman r	0.28	Small	Νο	GRC was not a valid reference standard criterion for assessing important change in the ability of an individual with a LLA to get up and walk with a prosthesis.	
Rushton	2015	25134533	Global Rating of Change		Spearman r	0.27	Small	No	GRC was not a valid reference standard criterion for assessing important change in the ability of an individual with a LLA to get up and walk with a prosthesis.	Follow-up L Test
Rushton	2015	25134533	Global Rating of Change		Spearman	0.27	Small	No	GRC was not a valid reference standard criterion for assessing important change in the ability of an individual with a LLA to get up and walk with a nrosthesis	L Test change between baseline and follow-
. taonton	2010	20104000	Sissai ruuning or onallye	1	opeannann	0.21	oniai	1.12	p. 000.10010.	9P

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Rushton	2015	25134533	Transfemoral (18.2%), Transtibial (81.8%)	Vascular (57.6%), Non-vascular (42.4%)	60		33	L-test		The L Test is a modified version of the Timed Up & Go (TUG) Test where the time it takes an individual to rise from an armless chair, walk 3 m, perform a right-angle turn, and continue walking 7 m before turning around 180° and walking back along the same path and sitting down is recorded in seconds	Responsiven	nd
Bushton	2015	25134533	Transfemoral (18.2%), Transfibial (81.8%)	Vascular (57.6%), Non-vascular (42.4%)	60		33	I -test		The L Test is a modified version of the Timed Up & Go (TUG) Test where the time it takes an individual to rise from an armless chair, walk 3 m, perform a right-angle turn, and continue walking 7 m before turning around 180° and walking back along the same path and sitting down is recorded in seconds.	Responsiven	nd
Radinton	2010	20101000	Tranociolar (o 1.070)	(12:170)							Floor/ceiling	ind ind
Miller	2001	11588750 (sample 1)	below knee (72%), above knee (28%)	Vascular (55%), nonvascular 45%) Vascular (55%)	58		60	LCI	Total Overall Score	Ability to measure change	effects (appropriaten ess)	
Miller	2001	(sample 1)	above knee (28%)	nonvascular 45%)	58		55	LCI	Score		Reliability	Internal consistency
N 4111	0004	11588750	below knee (72%),	Vascular (55%),	50				Total Overall		Dell'e bille	T
Miller	2001	(sample 1) 11588750	above knee (28%) below knee (72%)	nonvascular 45%) Vascular (55%)	58		55	LCI	Score Total Overall		Reliability	l est-retest
Miller	2001	(sample 1)	above knee (28%)	nonvascular 45%)	58		60	LCI	Score		Validity	Convergent validity
Miller	2001	11588750 (sample 1)	below knee (72%), above knee (28%)	Vascular (55%), nonvascular 45%)	58		60	LCI	Total Overall Score		Validity	Convergent validity
Miller	2001	(sample 1)	above knee (28%)	nonvascular (55%),	58		60	LCI	Score		Validity	Convergent validity
Miller	2001	11588750 (sample 2)	below knee (74%), above knee (26%)	Vascular (53%), nonvascular 47%)	60		329	LCI	Total Overall Score	Ability to measure change	Floor/ceiling effects (appropriaten ess)	
Millor	2001	11588750	below knee (74%),	Vascular (53%),	60		220		Total Overall		Volidity	Construct (discriminant)
Miller	2001	(sample 2) 11588750	below knee (26%)	Nonvascular 47%) Vascular (53%).	60		329	LUI	Score Total Overall		validity	Construct (discriminant)
Miller	2001	(sample 2)	above knee (26%)	nonvascular 47%)	60		329	LCI	Score		Validity	Convergent validity
Franchignoni	2004	15129398	Transfemoral (60%), Transtibial (40%)	Trauma (58%), PVD (32%), Other (10%)	51	recent (<1 year) unilateral LLA	50	LCI			Reliability	Test-Retest
Franchignoni	2004	15129398	Transfemoral (60%), Transtibial (40%)	(32%), Other (10%)	51	LLA	50	LCI			Validity	Convergent
Franchignoni	2004	15129398	Transfemoral (60%), Transtibial (40%)	Trauma (58%), PVD (32%), Other (10%)	51	recent (<1 year) unilateral LLA	50	LCI			Validity	Convergent
Freeshiers	0004	45400000	Transfemoral (60%),	Trauma (58%), PVD	64	recent (<1 year) unilateral	50				M-11-11-1-	0
Franchignoni	2004	15129398	Transfemoral (60%), Transfemoral (60%),	(32%), Other (10%) Trauma (58%), PVD (32%), Other (10%)	51	recent (<1 year) unilateral	50				Validity	Known group
Trancingnom	2004	10120000	Transfemoral (60%),	Trauma (58%), PVD	51	recent (<1 year) unilateral	00	201			validity	i tilowii gioup
Franchignoni	2004	15129398	Transtibial (40%)	(32%), Other (10%)	51	LLA	50	LCI			Validity	Known-group
Franchignoni	2004	15129398	Transfemoral (60%), Transtibial (40%)	(32%), Other (10%)	51	recent (<1 year) unilateral LLA recent (<1 year) unilateral	50	LCI			Validity	Predictive
Franchignoni	2004	15129398	Transtibial (40%)	(32%), Other (10%)	51	LLA	50	LCI			Validity	Predictive
Franchignoni	2004	15129398	Transfemoral (60%), Transtibial (40%)	Trauma (58%), PVD (32%), Other (10%)	51	recent (<1 year) unilateral LLA	50	LCI			Validity	Predictive
Franchignoni	2004	15120308	Transfemoral (60%), Transfibial (40%)	Trauma (58%), PVD (32%), Other (10%)	51	recent (<1 year) unilateral	50				Validity	Predictive
Franchignoni	2004	15129398	Transfemoral (60%), Transtibial (40%)	Trauma (58%), PVD (32%), Other (10%)	51	recent (<1 year) unilateral LLA	50	LCI			Validity	Predictive
Franchignoni	2004	15129398	Transfemoral (60%), Transtibial (40%)	Trauma (58%), PVD (32%), Other (10%)	51	recent (<1 year) unilateral LLA	50	LCI			Validity	Responsiveness
Dite	2007		Transtibial	nd	61.6	Linilatoral	40	1014	Advanced activity		Validity	Known group/Discriminant
DIC	2007		nanotiolai	10	01.0	ormateral	J.	2017	Subscale		Floor/ceiling	raiown group/Discriminarit
			Transfemoral (26%)		67 (nd for Locomotor		938 (n=195 for Locomotor		Advanced activity		effects (appropriaten	
Treweek	1998		transtibial (74%)	nd	Index)		Index)	LCI-4	subscale	Ability to measure change	ess)	
			Transfemoral (26%)		67 (nd for		938 (n=195		Advanced activity			
Treweek	1998		transtibial (74%)	nd	Index)		Index)	LCI-4	subscale		Validity	Known group

				Timepoint						
Author	Voar	PMID	Comparator/Criterion/Outc	(predictive	Matric Used	Value	Strength of Property	Is Aspect	Conclusion	Notes/Caveats
	Tear	FWID	one	Validy	Metric Oseu	Value	roperty	Supported ?	The hypothesis that the L Test would correctly identify individuals who have and have not undergone an important	NOIES/Caveats
									change 80% of the time was not	
Rushton	2015	25134533	Global Rating of Change		AUROC	0.67		No	supported	
Rushton	2015	25134533	Global Pating of Change		Minimal clinically important	4.5		Vac	The study provides the first estimate of a MCID value for the L Test	
Rushion	2010	20104000	Clobal realing of Change		difference	4.0		103		
Miller	2001	11588750 (sample 1)	NA		% at floor or ceiling	37		No		Ceiling effect (negligible floor effects)
Miller	2001	(sample 1)			Alpha	0.89	excellent			55/60 were stable
N 4111	0004	11588750			100 (05% 01)	0.88 (0.81,				55/00 ware stable
Miller	2001	(sample 1) 11588750			2 minute walk	0.93)				55/60 were stable
Miller	2001	(sample 1)			test	correlation	0.64			
Miller	2001	11588750 (sample 1)			Timed up and go (TUG)	correlation	-0.64			
N 4111	0001	11588750			100		0.00			
Miller	2001	(sample 1)			ABC scale	correlation	0.82			
Miller	2001	11588750 (sample 2)	NA		% at floor or ceiling	40		No		Ceiling effect (negligible floor effects)
Miller	2001	11588750 (sample 2)	amputation cause; mobility device; walking distance; automatic walking		differences between levels of factors	see notes				Only not statistically significant difference: between amputation level above or below the knee
inino.	2001	11588750	datomatio Walking		or labioro	000 110100				
Miller	2001	(sample 2)			ABC scale	correlation	0.81			
Franchignoni	2004	15129398			ICC	0.984			Among subgroup of n=37	
Franchignoni	2004	15129398	RMI		Spearman's r	0.735				
Franchignoni	2004	15129398	FIM		Spearman's r	0.612				
Franchignoni	2004	15129398	LCI-5		Spearman's r	0.994				
Franchignoni	2004	15129398	Transtibial vs transfemoral		P-value	<0.001			Did not differ for RMI or FiM	
Franchignoni	2004	15129398	209		Spearman's r	-0 554				
Franchistori	2004	45400000	THAT	0.40.4		0.007			10	
	2004	15129396		9-19 days	Spearmans	-0.007			To meters	
Franchignoni	2004	15129398	RMI	9-19 days	Spearman's r	0.752				
Franchignoni	2004	15129398	FIM	9-19 days	Spearman's r	0.617				
Franchignoni	2004	15129398	LCI-5	9-19 days	Spearman's r	0.622				
Franchignoni	2004	15129398	LCI	9-19 days	Spearman's r	0.765				
Franchignoni	2004	15129398			Effect size	1.09				
Dite	2007				Multiple Fallers vs nonmultiple Fallers	P Value	0.04			differentiated between multiple and nonmultiple fallers
Treweek	1998								slightly less ceiling effect than whole Locomotor index	
Treweek	1998									discriminated patients (mann-Whittney test) by amputation level and age (greater or less than 40) for trans tibial patients

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
					67 (nd for		938 (n=195					
Treweek	1998		Transfemoral (26%), transtibial (74%)	nd	Locomotor		for Locomotor		Basic activity		Validity	Known group
Heweek	1000			Vascular	index)		index)		Total Overall		validity	rthown group
Arwert	2007	17943683	Unilateral transtibial	insufficiency	69.8	nd	23	LCI-4	Score		Validity	Known group/Discriminant
				Amputation for vascular disease								
				and mild or					Total Overall			
Brunelli	2006	16813789	Unilateral transfemoral	hemiparesis	69		45	LCI-4	Score		Validity	Known group/Discriminant
				Amputation for vascular disease and mild or								
Brupelli	2006	16813780	I Inilateral transfermoral	moderate	69		45	LCLA	Total Overall		Validity	Known group/Discriminant
Druhem	2000	10013703	oninateral transferriora	Themparesis	03		45	201-4	00016		valuity	Known group/Discriminant
									Total Overall			
Callaghan	2002	12227445	Unilateral transtibial	nd	nd		133	LCI-4	Score		Reliability	Test-retest
Gauthier-Gagnon	1994	7993169	Transfemoral (n=35), transtibial(n=35)	Peripheral vascular disease/diabetes (70.6%), Trauma (22.8%), Tumor (4.3%), Other (4.3%)	60.6	Ulinateral	70	LCI-4	Total Overall Score		Reliability	Test-retest
Gauthier-Gagnon	1994	7993169	Transfemoral (n=35), transtibial(n=35)	Peripheral vascular disease/diabetes (70.6%), Trauma (22.8%), Tumor (4.3%), Other (4.3%)	60.6	Ulinateral	70	LCI-4	Total Overall Score		Validity	Construct
			Transformeral (429/)	PVD (46%),					Total Quarall			
Gauthier-Gagnon	1994	107175246	nd(58%)	nd(30%)	59.5	Ulinateral	70	LCI-4	Score		Reliability	Internal consistency
Gauthier-Gagnon	1994	107175246	Transfemoral (42%), nd(58%)	PVD (46%), diabetes (24%), nd(30%)	59.5	Ulinateral	70	LCI-4	Total Overall Score		Validity	Content
Grise	1993	8347072	nd	nd	55.3	nd	26	LCI-4	Score		Validity	Face/content
Panesar	2001		Transfemoral (n=17), transtibial (n=14), hindquarter (n=1), bilateral transtibial (n=1), bilateral transfemoral (n=1)	nd	67		34	LCI-4	Total Overall Score		Validity	Concurrent/convergent/criteri a Validity criterion
									Total Overall			
Traballesi	2007	16955063	Transtibial	nd	65	Bilateral	30	LCI-4	Score		Validity	Known group/Discriminant
Treweek	1998		Transfemoral (26%), transtibial (74%)	nd	67 (nd for Locomotor Index)		938 (n=195 for Locomotor Index)	LCI-4	Total Overall Score	Ability to measure change	Floor/ceiling effects (appropriaten ess)	
					67 (nd for		938 (n=195				,	
Trowook	1008		Transfemoral (26%), transtibial (74%)	nd	Locomotor		for Locomotor	ICM	Total Overall		Validity	Known group
Heweek	1330		Above knee (53%),	Peripheral vascular	index)		index)	201-4	Score		validity	Known group
Franchignoni	2007	18050010	Below knee (56%), Bilateral above knee (6%), Bilateral below knee (5%)	disease and/or DM (53%), Trauma (56%), Tumor/other (9%)	54	20-80 years old	123	LCI-5	Item 1		Validity	Structural
			Above knee (53%), Below knee (56%), Bilateral above knee	Peripheral vascular disease and/or DM (53%), Trauma								
Franchignoni	2007	18050010	(b%), Bilateral below knee (5%)	(50%), Tumor/other (9%)	54	20-80 years old	123	LCI-5	Item 1		Validity	Structural
	2007		Above knee (53%), Below knee (56%), Bilateral above knee (6%), Bilateral below	Peripheral vascular disease and/or DM (53%), Trauma (56%), Tumor/other							t direity	
Franchignoni	2007	18050010	knee (5%)	(9%)	54	20-80 years old	123	LCI-5	Item 10		Validity	Structural

			Comparator/Criterion/Outo	l imepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Treweek	1998									Significant differences by age groups and amputation level
THOMODIA	1000		groups of different tibial							differentiated between groups of different
Arwert	2007	17943683	length		ttest P	<0.05				tibial length
Brunelli	2006	16813789	Laterality of impairment: Ipsilateral vs Contralateral		P value	<0.001				differentiated between laterality of impairment and severity of hemiparesis
			Cause of amputation:							
Brunelli	2006	16813789	Atherosclerosis vs Diabetes		P value	>0.05				with the second sector of successful as a second
										moderately reliable on remaining questions
Callaghan	2002	12227445			ICC	0.74				ICC: 0.64-0.96, % agreement 20-90
Gauthier-Gagnon	1994	7993169			ICC	0.8				Locomotion index=0.80 (all items >0.75).
Cauthias Caspan	1004	7002460	Reintegration to Normal		Deersen	0.52				Deerson DNII -0.52
Gauthier-Gagnon	1994	7993109	Living (RNL) index		Pearson	0.53				Pearson RNL=0.55
					Cronbach					
Gauthier-Gagnon	1994	107175246			alpha	0.95				
Gauthier-Gagnon	1994	107175246								The LCI retains unidimentionality
										LEA, the questionaire was deemed to have
Grise	1993	8347072								face validity
										significant kendal correlations coefficients
Panesar	2001									between each of the measures
			patients with ideal stumps							LCI is significantly higher for patients with
			stump pain and flexion							combined stump pain and flexion
Traballesi	2007	16955063	deformities							deformities
Treweek	1998								ceiling effect evident	discriminated nationts (mann Whittney test
										by amputation level and age (greater or
Treweek	1998									less than 40) for trans tibial patients
Franchignoni	2007	18050010				Rasch infit	1 04			
Turiongnom	2007	10000010				Milloq	1.04			
						Rasch outfit				
Franchignoni	2007	18050010				MnSq	1			
Franchignoni	2007	18050010			Rasch infit	0.52				miefit
i ianchign0fil	2007	10000010	1	1	Politik	0.02	1	1	1	man

				Amputation		Other Reputation						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Franchignoni	2007	18050010	Above knee (53%), Below knee (56%), Bilateral above knee (6%), Bilateral below knee (5%)	Peripheral vascular disease and/or DM (53%), Trauma (56%), Tumor/other (9%)	54	20-80 years old	123	I CI-5	Item 10		Validity	Structural
ranongrioni	2007	10000010	Above knee (53%),	Peripheral vascular	04	20 00 years old	120	2010			validity	
Franchignoni	2007	18050010	Below knee (56%), Bilateral above knee (6%), Bilateral below knee (5%)	disease and/or DM (53%), Trauma (56%), Tumor/other (9%)	54	20-80 years old	123	LCI-5	Item 11		Validity	Structural
			Above knee (53%), Below knee (56%), Bilateral above knee (6%), Bilateral below	disease and/or DM (53%), Trauma (56%), Tumor/other								
Franchignoni	2007	18050010	knee (5%)	(9%)	54	20-80 years old	123	LCI-5	Item 11		Validity	Structural
Franchignoni	2007	18050010	Above knee (53%), Below knee (56%), Bilateral above knee (6%), Bilateral below knee (5%)	Peripheral vascular disease and/or DM (53%), Trauma (56%), Tumor/other (9%)	54	20-80 years old	123	I CI-5	Item 12		Validity	Structural
			Above knee (53%),	Peripheral vascular								
Franchignoni	2007	18050010	Below knee (56%), Bilateral above knee (6%), Bilateral below knee (5%)	disease and/or DM (53%), Trauma (56%), Tumor/other (9%)	54	20-80 years old	123	LCI-5	Item 12		Validity	Structural
			Above knee (53%), Below knee (56%), Bilateral above knee (6%), Bilateral below	Peripheral vascular disease and/or DM (53%), Trauma (56%), Tumor/other								
Franchignoni	2007	18050010	knee (5%)	(9%) Paripharal vacaular	54	20-80 years old	123	LCI-5	Item 13		Validity	Structural
Franchianani	2007	19050010	Above knee (55%), Below knee (56%), Bilateral above knee (6%), Bilateral below	disease and/or DM (53%), Trauma (56%), Tumor/other	54	20.90 years ald	102		Itom 12		Volidity	Structural
Franchighoni	2007	10000010	Above knee (53%)	(9%) Peripheral vascular	54	20-60 years old	123	LUI-5	item 15		validity	Structural
Franchignoni	2007	18050010	Below knee (56%), Bilateral above knee (6%), Bilateral below knee (5%)	disease and/or DM (53%), Trauma (56%), Tumor/other (9%)	54	20-80 years old	123	LCI-5	Item 14		Validity	Structural
Franchignoni	2007	18050010	Above knee (53%), Below knee (56%), Bilateral above knee (6%), Bilateral below knee (5%)	Peripheral vascular disease and/or DM (53%), Trauma (56%), Tumor/other (9%)	54	20-80 years old	123	LCI-5	Item 14		Validity	Structural
			Above knee (53%), Below knee (56%), Bilateral above knee (6%), Bilateral below	Peripheral vascular disease and/or DM (53%), Trauma (56%), Tumor/other								
⊢ranchignoni	2007	18050010	Above knee (53%)	(9%) Peripheral vascular	54	20-80 years old	123	LUI-5	item 2		validity	Structural
Franchignoni	2007	18050010	Below knee (56%), Bilateral above knee (6%), Bilateral below	disease and/or DM (53%), Trauma (56%), Tumor/other (9%)	54	20-80 years old	123	1 CL5	Item 2		Validity	Structural
a.lonighoni	2007		Above knee (53%),	Peripheral vascular			0	20.0	1.0111 &		· anancy	
Franchignoni	2007	18050010	Below knee (56%), Bilateral above knee (6%), Bilateral below knee (5%)	disease and/or DM (53%), Trauma (56%), Tumor/other (9%)	54	20-80 years old	123	LCI-5	Item 3		Validity	Structural
Franchignoni	2007	18050010	Above knee (53%), Below knee (56%), Bilateral above knee (6%), Bilateral below knee (5%)	Peripheral vascular disease and/or DM (53%), Trauma (56%), Tumor/other (0%)	54	20-80 years old	123	10-5	Item 3		Validity	Structural
n ranongnom	2001	1000010	Above knee (53%), Below knee (56%), Bilateral above knee (6%), Bilateral below	Peripheral vascular disease and/or DM (53%), Trauma (56%), Tumor/other					10110		Validity	
Franchignoni	2007	18050010	knee (5%)	(9%)	54	20-80 years old	123	LCI-5	Item 4		Validity	Structural

			0	Timepoint			Ourse 11			
Author	Voor	BMID	Comparator/Criterion/Outc	(predictive	Motrie Llood	Value	Strength of	Is Aspect	Conclusion	Notos/Coverto
Author	rear	PINID	ome	valid)	wetric Used	value	Property	Supported?	Conclusion	Notes/Caveats
					Rasch outfit					
Franchignoni	2007	18050010			MnSq	0.46				misfit
					Rasch infit					
Franchignoni	2007	18050010			MnSq	0.53				misfit
					Rooch outfit					
Franchignoni	2007	18050010			MnSa	0.49				misfit
, j										
Franchignoni	2007	18050010				Rasch infit	0.76			
rianonignom	2007	10030010				Milloq	0.70			
						Rasch outfit				
Franchignoni	2007	18050010				MnSq	0.65			
						Rasch infit				
Franchignoni	2007	18050010				MnSq	0.98			
						Rasch outfit				
Franchignoni	2007	18050010				MnSq	1.11			
						Rasch infit				
Franchignoni	2007	18050010				MnSq	1.18			
						Basah outfit				
Franchignoni	2007	18050010				MnSa	0.97			
, j						- 1				
					Development for					
Franchignoni	2007	18050010			Rasch outfit MnSg	1 16				misfit
rianonignom	2001	10000010			Milloq	1.10				mont
Franchignoni	2007	19050010				Rasch infit	1.24			
Franchighoni	2007	16050010				penim	1.24			
L					Rasch infit					
Franchignoni	2007	18050010			winSq	1.65	l			mistit
						1				
						1				
						Rasch outfit				
Franchignoni	2007	18050010				MnSq	2.1			
						1				
						Rasch infit				
Franchignoni	2007	18050010				MnSq	0.71			

				Amputation		Other Population					
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale Description	Property	Aspect
			Above knee (53%), Below knee (56%), Bilateral above knee	Peripheral vascular disease and/or DM (53%), Trauma	-						
Franchianoni	2007	19050010	(6%), Bilateral below	(56%), Tumor/other	E4	20.80 years ald	100		Itom 4	Volidity	Structural
Franchighoni	2007	18030010	Above knee (53%).	Peripheral vascular	04	20-60 years old	123	LCI-5		validity	Structural
			Below knee (56%),	disease and/or DM							
			Bilateral above knee (6%) Bilateral below	(53%), Trauma (56%), Tumor/other							
Franchignoni	2007	18050010	knee (5%)	(9%)	54	20-80 years old	123	LCI-5	Item 5	Validity	Structural
			Above knee (53%),	Peripheral vascular							
			Below knee (56%), Bilateral above knee	(53%), Trauma							
			(6%), Bilateral below	(56%), Tumor/other							
Franchignoni	2007	18050010	knee (5%)	(9%) Boriphoral vacaular	54	20-80 years old	123	LCI-5	Item 5	Validity	Structural
			Below knee (56%),	disease and/or DM							
			Bilateral above knee	(53%), Trauma							
Franchignoni	2007	18050010	(6%), Bilateral below knee (5%)	(56%), Tumor/other (9%)	54	20-80 years old	123	LCI-5	Item 6	Validity	Structural
			Above knee (53%),	Peripheral vascular	-						
			Below knee (56%), Bilateral above knee	disease and/or DM							
			(6%), Bilateral below	(56%), Tumor/other							
Franchignoni	2007	18050010	knee (5%)	(9%)	54	20-80 years old	123	LCI-5	Item 6	Validity	Structural
			Above knee (53%), Below knee (56%)	Peripheral vascular disease and/or DM							
			Bilateral above knee	(53%), Trauma							
Franchianoni	2007	19050010	(6%), Bilateral below	(56%), Tumor/other	E 4	20.90 years ald	100		Itom 7	Volidity	Structural
Franchighoni	2007	18030010	Above knee (53%),	Peripheral vascular	04	20-00 years old	123	LOI-5		Validity	Structural
			Below knee (56%),	disease and/or DM							
			Bilateral above knee	(53%), Trauma (56%), Tumor/other							
Franchignoni	2007	18050010	knee (5%)	(9%)	54	20-80 years old	123	LCI-5	Item 7	Validity	Structural
			Above knee (53%),	Peripheral vascular							
			Bilateral above knee	(53%), Trauma							
			(6%), Bilateral below	(56%), Tumor/other							
Franchignoni	2007	18050010	knee (5%) Above knee (53%)	(9%) Perinheral vascular	54	20-80 years old	123	LCI-5	Item 8	Validity	Structural
			Below knee (56%),	disease and/or DM							
			Bilateral above knee	(53%), Trauma							
Franchignoni	2007	18050010	knee (5%)	(9%)	54	20-80 years old	123	LCI-5	Item 8	Validity	Structural
-			Above knee (53%),	Peripheral vascular							
			Below knee (56%), Bilateral above knee	disease and/or DM (53%) Trauma							
			(6%), Bilateral below	(56%), Tumor/other							
Franchignoni	2007	18050010	knee (5%)	(9%) Boriphoral vacaular	54	20-80 years old	123	LCI-5	Item 9	Validity	Structural
			Below knee (56%),	disease and/or DM							
			Bilateral above knee	(53%), Trauma							
Franchignoni	2007	18050010	(6%), Bilateral below knee (5%)	(56%), Tumor/other (9%)	54	20-80 years old	123	LCI-5	Item 9	Validity	Structural
			Transfemoral (n=54), Transtibial (n=93), Hip disarticulation (n=3), Knee disarticulation (n=8), Syme (n=1), Transfemoral and transtibial (n=2), Transtibial and	Vascular (n=142), Infection (n=13),		18 years or older; they were wearing a prosthesis at the end of their rehabilitation treatment after a recent lower limb amputation; and they					
de l aat	2011		transtibial (n=7), Syme	Traumatic (n=13),	65	were able to understand and fill in the questionnaires	171	L CI-5	Total Overall	Validity	Convergent
40 Luui		1			~~	pin in alle questionnunce	1 * * *	120.0	00000	+ analy	Contrargont

			Comparator/Critorion/Outo	limepoint			Strongth of	la Acnost		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
, latinoi	. oui			(und)	incluie coou	Value	reporty	Cappendu		
						-				
Franchignoni	2007	18050010				MnSq	0.63			
Tranonigriorii	2007	10000010				Milloq	0.00			
Franchignoni	2007	18050010				Rasch Infit MnSg	0.99			
ranongrom	2001	10000010				innoq	0.00			
						Decel confi				
Franchignoni	2007	18050010				MnSa	0.81			
ranongrioni	2007	10000010				milleq	0.01			
						Develo infl				
Franchignoni	2007	18050010				Rasch Infit MnSg	1 02			
						Deceb outfit				
Franchignoni	2007	18050010				MnSq	1.07			
					Rooch infit					
Franchignoni	2007	18050010			MnSq	1.45				misfit
						Basah autfit				
Franchignoni	2007	18050010				MnSq	1.29			
						Rasch infit				
Franchignoni	2007	18050010				MnSq	0.66			
						Rasch outfit				
Franchignoni	2007	18050010				MnSq	0.67			
						Rasch infit				
Franchignoni	2007	18050010				MnSq	0.76			
						Rasch outfit				
Franchignoni	2007	18050010				MnSq	0.72			
do Loot	2011		The Rising and Sitting down		Spoorroom -	0.4				Spearman: Bioing and Sitting=0.40
ue Laal	2011	-	Questionnaire	1	opeannan r	U.4	1	1		opeannan. Rising and Sitting=0.40

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
			Transfemoral (n=55), Transtibial (n=93), Hip disarticulation (n=3), Knee disarticulation (n=8), Syme (n=1), Transfemoral and transtibial (n=2), Transtibial and transtibial (n=7). Syme	Vascular (n=143), Infection (n=13), Traumatic (n=13)		18 years or older; they were wearing a prosthesis at the end of their rehabilitation treatment after a recent lower limb amputation; and they were able to understand and			Total Overall			
de Laat	2012		and transtibial (n=3)	Oncologic (n=3)	65	fill in the questionnaires	172	LCI-5	Score		Validity	Convergent
Franchignoni	2007	18050010					123	LCI-5	Total Overall Score		Reliability	Person separation reliability
Franchignoni	2007	18050010					123	LCI-5	Score		Reliability	Item seperation reliability
Franchignoni	2007	18050010					123	LCI-5	Score		Validity	a Validity criterion
Norvell	2011	21531528	Transfemoral (n=8), Transtibial (n=52), transmetatarsal (n=27); unilateral	PVD or diabetes	62.06	55-65	87	LCI-5	Total Overall Score		Validity	Convergent
Norvell	2011	21531528	Transfemoral (n=8), Transtibial (n=52), transmetatarsal (n=27): unilateral	PVD or diabetes	62.06	55-65	87	I CI-5	Total Overall Score		Validity	Known group
Parker	2010	2010632385	Transfemoral (n=16), Transtibial (n=30), Bilateral transtibial (n=6)	Vascular (n=20), Trauma (n=26), Other (n=6)	55.2		52	LCI-5	Total Overall Score	Ability to measure change	Floor/ceiling effects (appropriaten ess)	
Parker	2010	2010632385	Transfemoral (n=16), Transtibial (n=30), Bilateral transtibial (n=6)	Vascular (n=20), Trauma (n=26), Other (n=6)	55.2		52	LCI-5	Total Overall Score	· · · · · ·	Validity	Concurrent/convergent/criteri a Validity criterion
Franchignoni	2004	15129398	Transfemoral (60%), Transtipial (40%)	Trauma (58%), PVD	51	recent (<1 year) unilateral	50	I CI-5			Validity	Convergent
	2004	15120000	Transfemoral (60%),	Trauma (58%), PVD		recent (<1 year) unilateral	50					
Franchignoni	2004	15129398	Transfemoral (60%), Transfemoral (60%),	(32%), Other (10%) Trauma (58%), PVD (32%), Other (10%)	51	LLA recent (<1 year) unilateral	50	LCI-5			Validity	Known-group
Franchignoni	2004	15129398	Transfemoral (60%), Transtibial (40%)	Trauma (58%), PVD (32%), Other (10%)	51	recent (<1 year) unilateral	50	LCI-5			Validity	Known-group
Franchignoni	2004	15129398	Transfemoral (60%), Transtibial (40%)	Trauma (58%), PVD (32%), Other (10%)	51	recent (<1 year) unilateral LLA	50	LCI-5			Validity	Predictive
Franchignoni	2004	15129398	Transfemoral (60%), Transtibial (40%)	Trauma (58%), PVD (32%), Other (10%)	51	recent (<1 year) unilateral LLA	50	LCI-5			Validity	Predictive
Franchignoni	2004	15129398	Transfemoral (60%), Transtibial (40%)	Trauma (58%), PVD (32%), Other (10%)	51	recent (<1 year) unilateral LLA	50	LCI-5			Validity	Predictive
Franchignoni	2004	15129398	Transfemoral (60%), Transtibial (40%)	Trauma (58%), PVD (32%), Other (10%)	51	recent (<1 year) unilateral	50	LCI-5			Validity	Predictive
Franchignoni	2004	15129398	Transtemoral (60%), Transtibial (40%) Above knee (53%), Below knee (56%),	(32%), Other (10%) Peripheral vascular disease and/or DM	51	recent (<1 year) unilateral LLA	50	LCI-5			Validity	Responsiveness
Franchignoni	2007	18050010	Bilateral above knee (6%), Bilateral below knee (5%)	(53%), Trauma (56%), Tumor/other (9%) Peripheral vascular	54	20-80 years old	123	LCI-5			Floor/ceiling effect	Appropriateness
Franchignoni	2007	18050010	Below knee (56%), Bilateral above knee (6%), Bilateral below knee (5%)	disease and/or DM (53%), Trauma (56%), Tumor/other (9%)	54	20-80 years old	123	LCI-5			Validity	Construct
Frankland '	0007	40050310	Above knee (53%), Below knee (56%), Bilateral above knee (6%), Bilateral below	Peripheral vascular disease and/or DM (53%), Trauma (56%), Tumor/other			100	1015			V-E-	Quarteria
Franchignoni	2007	18050010	knee (5%) Above knee (53%), Below knee (56%), Bilateral above knee	(9%) Peripheral vascular disease and/or DM (53%), Trauma	54	20-80 years old	123				Validity	Construct
Franchignoni	2007	18050010	(b%), Bilateral below knee (5%)	(56%), Tumor/other (9%)	54	20-80 years old	123	LCI-5			Validity	Construct

			Comparator/Criterion/Outo	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
de Laat	2012		The Walking Questionnaire		Spearman r	0.5				Spearman: Walking=0.50
Franchignoni	2007	18050010			P value	0.94				
Franchignoni	2007	18050010			P value	0.98				
Franchignoni	2007	18050010								Spearmans: PEQ-MS=0.77
N	0011	04504500	O stiefs stien with much life.							significant associations with 12-month
Norvell	2011	21531528	Satisfaction with mobility							satisfaction with mobilility
Norvell	2011	21531528								no difference between amputation level
Parker	2010	2010632385							half of partilpants obtained the highest score	
Parker	2010	2010632385								Spearman: TAPES activity=0.66, TUG 0.72, 2MWT=-0.84
Franchignoni	2004	15120308	PMI		Spearman's r	0.746				
Franchignoni	2004	15120209	EIM		Spearman's r	0.619				
	2004	15129596	T		Spearmans	0.018				
Franchignoni	2004	15129398	I ranstibial vs transfemoral		P-value	<0.001			Did not differ for RMI or FIM	
Franchignoni	2004	15129398	age		Spearman's r	-0.557				
Franchignoni	2004	15129398	TWT	9-19 days	Spearman's r	-0.708			10 meters	
Franchignoni	2004	15129398	RMI	9-19 days	Spearman's r	0.757				
Franchignoni	2004	15129398	FIM	9-19 days	Spearman's r	0.622				
Franchignoni	2004	15129398	LCI-5	9-19 days	Spearman's r	0.788				
Franchignoni	2004	15129398			Effect size	1.4				
										should maximum LCLE, some should floor
Franchignoni	2007	18050010			%	5				effect
Franchignoni	2007	18050010	PEQ-MS		Spearman's r	0.77	Large	Yes		p<0.001
Franchignoni	2007	18050010	PPA item 12		Spearman's r	0.47	Moderate	Yes		p<0.001
Franchignoni	2007	18050010	PPA item 14b		Spearman's r	0.34	Moderate	Yes		p<0.001

				Amputation		Other Benulation						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
			Above knee (53%),	Peripheral vascular	J							
			Below knee (56%),	disease and/or DM								
			(6%). Bilateral below	(56%), Trauma (56%), Tumor/other								
Franchignoni	2007	18050010	knee (5%)	(9%)	54	20-80 years old	123	LCI-5			Validity	Construct
			Above knee (53%),	Peripheral vascular								
			Bilateral above knee	(53%). Trauma								
			(6%), Bilateral below	(56%), Tumor/other								
Franchignoni	2007	18050010	knee (5%)	(9%)	54	20-80 years old	123	LCI-5			Validity	Construct
			Above knee (53%), Below knee (56%)	disease and/or DM								
			Bilateral above knee	(53%), Trauma								
Franchisnani	2007	10050010	(6%), Bilateral below	(56%), Tumor/other	54		100	1 0110 4			Deliebility	Internal consistency
Franchignoni	2007	18050010	Above knee (53%)	(9%) Perinheral vascular	54	20-80 years old	123	LUI10-4			Reliability	Internal consistency
			Below knee (56%),	disease and/or DM								
			Bilateral above knee	(53%), Trauma								
Franchignoni	2007	18050010	(6%), Bilateral below knee (5%)	(56%), Tumor/otner (9%)	54	20-80 years old	123	L CI10-4			Reliability	Internal consistency
			Above knee (53%),	Peripheral vascular								
			Below knee (56%),	disease and/or DM								
			(6%). Bilateral below	(53%), Trauma (56%), Tumor/other								
Franchignoni	2007	18050010	knee (5%)	(9%)	54	20-80 years old	123	LCI10-4			Reliability	Internal consistency
			Above knee (53%),	Peripheral vascular								
			Bilateral above knee	(53%). Trauma								
			(6%), Bilateral below	(56%), Tumor/other								
Franchignoni	2007	18050010	knee (5%)	(9%)	54	20-80 years old	123	LCI10-4			Reliability	Internal consistency
											Ability to	
									Community		measure	
Zidarov, et al	2009						19	Life H Short Form 3.1	life		change	Responsiveness
											Ability to	
											measure	
Zidarov, et al	2009						19	Life H Short Form 3.1	Employment		change	Responsiveness
											Ability to	
									Interpersonal		measure	
Zidarov, et al	2009						19	Life H Short Form 3.1	relations		change	Responsiveness
											Ability to	
									L		measure	
Zidarov, et al	2009						19	Life H Short Form 3.1	Recreation		change	Responsiveness
											Ability to	
											measure	
∠iuarov, et ai	2009						19	LINE IT SHORT FORM 3.1	Adcanced		change	responsiveness
	1							Locomotor Capabilities	activity			
Dite, Connor, Curtis	2007				CT (nd for		020 (= 105	Index (LCI-4 advanced	subscale		Validity	Known group/Discriminant
			Transfemoral (26%)		Locomotor		for Locomotor	Locomotor Capabilities	activity			
Treweek	1998		transtibial (74%)	nd	Index)	nd	Index)	Index (LCI-4 advanced	subscale		Validity	Known group
	1		Transfemeral (26%)		67 (nd for		938 (n=195	Locomotor Conshilition	Adcanced		Ability to	Eloor/ceiling effects
Treweek	1998		transtibial (74%)	nd	Index)	nd	Index)	Index (LCI-4 advanced	subscale		change	(appropriateness)
			· ···		67 (nd for		938 (n=195					
Trowook	1002		Transfemoral (26%),	nd	Locomotor	nd	for Locomotor	Locomotor Capabilities	Basic activity		Validity	Known group
HEWEEK	1990		udiisuulai (74%)	Vascular	muex)	nu	niuex)	Locomotor Capabilities	Total Overall		valiuity	raiowii gioup
Arwert et al	2007	17943683	Unilateral transtibial	insufficiency	69.8	nd	23	Index (LCI-4)	Score		Validity	Known group/Discriminant
	1			Amputation for								
	1			and mild or								
	1			moderate				Locomotor Capabilities	Total Overall			
Brunelli	2006	16813789	Unilateral transfemoral	hemiparesis	69	nd	45	Index (LCI-4)	Score		Validity	Known group/Discriminant

			Comparator/Criterion/Outc	Imepoint			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Franchianoni	2007	19050010	DDA itom 16h		Spoormon's r	0.42	Modorato	Voc		2-0.001
Franchighoni	2007	16050010	PPA Item Top		Spearmans	0.42	woderate	res		p<0.001
Franchignoni	2007	18050010	PPA item 18		Spearman's r	0.51	Large	Yes		p<0.001
						item				
						separation				
Franchignoni	2007	18050010				index	7.39			
						item				
						separation				
Franchignoni	2007	18050010				reliability	0.98	Excellent		
							1			
						person				
Franchignoni	2007	18050010				index	3.9			
runongrioni	2001	10000010				index	0.0			
						person				
Franchianoni	2007	19050010				separation	0.04	Excellent		
Franchighon	2007	18030010				Index	0.94	Excellent		there were significant improvements in
										scores from admission to inpatient
										rehabilitation to 3 months after discharge
Zidarov, et al	2009									P<.001
										there were significant improvements in
										rehabilitation to 3 months after discharge P
Zidarov, et al	2009									.014
										there were significant improvements in
										scores from admission to inpatient
Ziderov, et el	2000									rehabilitation to 3 months after discharge P
Zidarov, et al	2009									.400
										scores from admission to inpatient
										rehabilitation to 3 months after discharge P
Zidarov, et al	2009									.001
										there were significant improvements in
										rebabilitation to 3 months after discharge P
Zidarov, et al	2009									.38
										differentiated between multiple and
Dite, Connor,Curtis	2007									nonmultiple fallers
										discriminated patients (mann-whittney test)
Treweek	1998									less than 40) for trans tibial patients
	1000									
										slightly less ceiling effect than whole
Treweek	1998									Locomotor index
										Cignificant differences by and around and
Treweek	1998									amputation level
		1	groups of different tibial		1	1	1	1		differentiated between groups of different
Arwert et al	2007	17943683	length		ttest P	<0.05	1			tibial length
					1		1	1		
							1	1		
			Laterality of impairment				1	1		differentiated between laterality of
Brunelli	2006	16813789	Ipsilateral vs Contralateral		P value	<0.001	1	1		impairment and severity of hemiparesis
				1					1	

				Ammutation		Other Benulation						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
				Amputation for vascular disease and mild or moderate				Locomotor Canabilities	Total Overall			
Brunelli	2006	16813789	Unilateral transfemoral	hemiparesis	69	nd	45	Index (LCI-4)	Score		Validity	Known group/Discriminant
Callaghan,											-	
Sockalingam,								Locomotor Capabilities	Total Overall			
Treeweek and Condie	2002	12227445	Unilateral transtibial	nd	nd	nd	133	Index (LCI-4)	Score		Reliability	l est-retest
Franchignoni.								Locomotor Capabilities	Total Overall			
Orlandinim et al	2004							Index (LCI-4)	Score		Reliability	Test-retest
Franchignoni,								Locomotor Capabilities	Total Overall			
Orlandinim et al	2004							Index (LCI-4)	Score		Reliability	Internal consistency
Orlandinim et al	2004							Index (LCI-4)	Score		Validity	Known group/Discriminant
Franchignoni,								Locomotor Capabilities	Total Overall		1	Concurrent/convergent/criteri
Orlandinim et al	2004							Index (LCI-4)	Score		Validity	a Validity criterion
Franchianoni								Loopmator Conshilition			Ability to	
Orlandinim et al	2004							Index (LCI-4)	Score		change	Responsiveness
Gauthier-Gagnon,								Locomotor Capabilities	Total Overall		g	
Grise	1994							Index (LCI-4)	Score		Reliability	Test-retest
Gauthier-Gagnon,								Locomotor Capabilities	Total Overall			
Grise	1994							Index (LCI-4)	Score		Validity	Construct
								Locomotor Capabilities	Total Overall			
Grise	1993							Index (LCI-4)	Score		Validity	Face/content
Larsson, Johannesson								Locomotor Capabilities	Total Overall			
et al	2009							Index (LCI-4)	Score		Reliability	Test-retest
Larsson, Jonannesson	2000							Locomotor Capabilities	Total Overall		Peliability	Internal consistency
	2000								00010		recitability	Internal consistency
Larsson, Johannesson	0000							Locomotor Capabilities	Total Overall		Martin Patrice	Kanana (Diamininan)
et al	2009							Index (LCI-4)	Score		Validity	Known group/Discriminant
et al	2009							Index (LCI-4)	Score		Validity	a Validity criterion
											Ability to	, i i i i i i i i i i i i i i i i i i i
Larsson, Johannesson								Locomotor Capabilities	Total Overall		measure	Floor/ceiling effects
et al	2009							Index (LCI-4)	Score		change	(appropriateness)
Speechley	2001							Locomotor Capabilities	Score		Reliability	Test-retest
Miller, Deathe and	2001							Locomotor Capabilities	Total Overall		rtonability	
Speechley	2001							Index (LCI-4)	Score		Reliability	Internal consistency
Miller, Deathe and								Locomotor Capabilities	Total Overall			
Speechley	2001							Index (LCI-4)	Score		Validity	Known group/Discriminant
Miller, Deathe and Speechley	2001							Locomotor Capabilities	Total Overall		Validity	Concurrent/convergent/criteri
opeediley	2001							IIIdex (LOI-4)	30016		Ability to	a validity citterion
Miller, Deathe and								Locomotor Capabilities	Total Overall		measure	Floor/ceiling effects
Speechley	2001							Index (LCI-4)	Score		change	(appropriateness)
			Transfemoral (n=17), transtibial (n=14), hindquarter (n=1), bilateral transtibial (n=1), bilateral					Locomotor Capabilities	Total Overall			Concurrent/convergent/criteri
Panesar et al,	2001		transfemoral (n=1)	nd	67	nd	34	Index (LCI-4)	Score		Validity	a Validity criterion
]				Locomotor Canabilities	Total Overall			
Traballesi	2007							Index (LCI-4)	Score		Validity	Known group/Discriminant
					67 (nd for		938 (n=195					
Troweek	1000		Transfemoral (26%),	ad	Locomotor	-	for Locomotor	Locomotor Capabilities	Total Overall		Validity	
neweek	1990		uansubiai (74%)	nu	67 (nd for	nu	938 (n=195	Index (LCI-4)	SCOLE		Ability to	Known group
			Transfemoral (26%).		Locomotor		for Locomotor	Locomotor Capabilities	Total Overall		measure	Floor/ceiling effects
Treweek	1998		transtibial (74%)	nd	Index)	nd	Index)	Index (LCI-4)	Score		change	(appropriateness)

			Comparator/Criterion/Outc	I imepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
David a ll'	0000	40040700	Cause of amputation:		Duratura					
Brunelli	2006	16813789	Atherosclerosis vs Diabetes		P value	>0.05				valiable on majority of superious and
Callaghan, Sockalingam										moderately reliable on remaining questions
Treeweek and Condie	2002	12227445			ICC	0.74				ICC: 0.64-0.96. % agreement 20-90
										repeated measures ANOVA did not reveal
Franchignoni,										differences between scores at two time
Orlandinim et al	2004									points, ICC=0.984
Franchignoni,					Chronbach					
Criandinim et al	2004				Alpna	0.95				
Orlandinim et al	2004									differentiated between amputation level
Franchignoni.	2001									Spearmans: LCI-5=0.99, RMI=0.74.
Orlandinim et al	2004									FIM=0.61
Franchignoni,										significant increase during test period,
Orlandinim et al	2004									effect size 1.09
Gautnier-Gagnon, Grise	1994									Locomotion index=0.80 (all items >0.75)
Gauthier-Gagnon	1004									Eccontration index-0.00 (dimension 0.10).
Grise	1994									Pearson RNL=0.53
										assumed to have content validity once all
										experts believed that questions reflected
Grise	1993									the specific objectives of the questionnaire
Larsson, Johannesson	2000									100-0.01
	2003				Chronbach					100-0.91
et al	2009				Alpha					0.95
										differentiated between younger amputees
										and unilateral vs bilateral amputees. LCI
Larsson, Johannesson										scores >=36 were more common among
et al	2009									men
et al	2009									Pearson: TUG=-0.75, EQ-5D (QOL)=0.84
Larsson, Johannesson										23% had the maximum possible score,
et al	2009									0.7% had lowest possible score
Miller, Deathe and	0004									100 0 77
Speechley Miller, Deathe and	2001				Chronbach					ICC= 0.77
Speechlev	2001				Alpha					0.95
										Significantly discriminant of Amputation
										cause(vascular/non), Mobility Device used
										(yes/no), Walking
Miller, Deathe and	2001									distance(unlimted,<1block) and Automatic
Speechiey	2001									Pearcene: 2 min welk test=0.64 TUC=
Miller Deathe and										0.64 ABC Scale=0.82 PEO mobility=0.77
Speechley	2001									Houghton=0.60
Miller, Deathe and										
Speechley	2001									high celing effects
										significant kendal correlations coefficients
Panesar et al,	2001									between each of the measures
										LCI is significantly higher for patients with
										Ideal stumps and lower for patients with
Traballesi	2007									deformities
		1			1					discriminated patients (mann-Whittney test)
					1					by amputation level and age (greater or
Treweek	1998							_		less than 40) for trans tibial patients
					1					
Trowook	1009									ceiling effect evident
TIEWEEK	1990			1		1	1		1	celling effect evident

				Amputation		Other Bopulation						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Czerniecki, J., Turner, A.,	2012		Transfemoral (n=7), Transtibial (n=38), Transmetatarsal (n=27)	peripheral vascular disease or diabetes	nd	nd	72	Locomotor Capabilities Index (LCI-5)	Total Overall Score		Validity	Known group/Discriminant
deLaat et al,	2011		Transfemoral (n=54), Transtibial (n=93), Hip disarticulation (n=3), Knee disarticulation (n=8), Syme (n=1), Transtemoral and transtibial (n=2), Transtibial and transtibial (n=7), Syme and transtibial (n=3)	Vascular (n=142), Infection (n=13), Traumatic (n=13), Oncologic (n=3)	65	nd	171	Locomotor Capabilities Index (LCI-5)	Total Overall Score		Validity	Convergent
deLaat et al,	2012		Transfemoral (n=55), Transtibial (n=93), Hip disarticulation (n=3), Knee disarticulation (n=8), Syme (n=1), Transtibial (n=2), Transtibial and transtibial (n=7), Syme and transtibial (n=3)	Vascular (n=143), Infection (n=13), Traumatic (n=13), Oncologic (n=3)	65	18 years or older; they were wearing a prosthesis at the end of their rehabilitation treatment after a recent lower limb amputation; and they were able to understand and fill in the questionnaires	172	Locomotor Capabilities Index (LCI-5)	Total Overall Score		Validity	Convergent
Ferriero Dughi et al	1994							Locomotor Capabilities	Total Overall Score		Reliability	Internal consistency
r onnoro, Bugni, or ur	1001							Locomotor Capabilities	Total Overall		rtonability	internal condictioney
Ferriero, Dughi, et al	1994							Index (LCI-5)	Score		Validity	Known group/Discriminant
Ferriero, Dughi, et al	1994							Locomotor Capabilities Index (LCI-5)	Total Overall Score		Validity	Construct
Franchignoni, Giordnano, Ferriero et								Locomotor Capabilities	Total Overall			
al	2007							Index (LCI-5)	Score		Reliability	Item seperation reliability
Franchignoni, Giordnano, Ferriero et al Franchignoni,	2007							Locomotor Capabilities Index (LCI-5)	Total Overall Score		Reliability	Person seperation reliability
Giordnano, Ferriero et al	2007							Locomotor Capabilities Index (LCI-5)	Total Overall Score		Validity	Concurrent/convergent/criteri a Validity criterion
Franchignoni								Locomotor Capabilities	Total Overall			
Orlandinim et al	2004							Index (LCI-5)	Score		Reliability	Test-retest
Franchignoni, Odapdinim et al	2004							Locomotor Capabilities	Total Overall		Poliobility	Internal consistency
Franchignoni,	2004							Locomotor Capabilities	Total Overall		Trenability	Internal consistency
Orlandinim et al	2004							Index (LCI-5)	Score		Validity	Known group/Discriminant
Orlandinim et al	2004							Index (LCI-5)	Score		Validity	a Validity criterion
Franchignoni, Orlandinim et al	2004							Locomotor Capabilities Index (LCI-5)	Total Overall Score		Ability to measure change	Responsiveness
Norvell et al	2011							Locomotor Capabilities	Total Overall		Validity	Known group/Discriminant
Norvell et al	2011							Locomotor Capabilities	Total Overall Score		Validity	Predictive
Parker et al,	2010							Locomotor Capabilities Index (LCI-5)	Total Overall Score		Validity	Concurrent/convergent/criteri a Validity criterion
Parker et al,	2010							Locomotor Capabilities Index (LCI-5)	Total Overall Score		Ability to measure change	Floor/ceiling effects (appropriateness)
Rau et al,	2007							Locomotor Capabilities Index (LCI-5)	Total Overall Score		Ability to measure change	Responsiveness
Salavati et al	2011							Locomotor Capabilities Index (LCI-5)	Total Overall Score		Reliability	Test-retest
Salavati et al	2011							Locomotor Capabilities Index (LCI-5)	Total Overall Score		Reliability	Internal consistency
Salavati et al,	2011							Index (LCI-5)	Score		Validity	Face/content

			Comparator/Criterion/Outc	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Czerniecki, J., Turner, A.,	2012		patients ever or never at CIRU		P value	0.36				permorbid LCI score unable to significantly discriminate between patietns ever or never at CIRU
del ast et al	2011		The Rising and Sitting down		Spearman r	0.4				Spearman: Dising and Sitting=0.40
										operindin rusing and olding 0.40
deLaat et al,	2012		The Walking Questionnaire		Spearman r	0.5				Spearman: Walking=0.50
Ferriero, Dughi, et al	1994				Chronbach Alpha	0.97				
Familian Durchi at al	1001									differentiated between AK and BK
Ferriero, Dughi, et al	1994									Spearman: PEQ-mo=0.81, and correlated significantly with the other related construncts of the PPA-it (eg frequency of reactholic use)
Franchignoni,	1994									prostitetic use)
Giordnano, Ferriero et al Franchignoni	2007									0.98
Giordnano, Ferriero et al Franchignoni	2007									0.94
Giordnano, Ferriero et al	2007									Spearmans: PEQ-MS=0.77
Franchignoni, Orlandinim et al	2004									differences between scores at two time points, ICC=0.984
Franchignoni, Orlandinim et al	2004				Chronbach Alpha	0.95				
Franchignoni, Orlandinim et al	2004									differentiated between amputation level
Franchignoni, Orlandinim et al	2004									Spearmans: LCI=0.99, RMI=0.75, FIM=0.62
Franchignoni, Orlandinim et al	2004									significant increase during test period, effect size 1.40
Norvell et al	2011									no difference between amputation level
Norvell et al	2011									significant associations with 12-month satisfaction with mobiliity
Parker et al,	2010									0.72, 2MWT=-0.84
Parker et al,	2010									half of partiipants obtained the highest score
Rau et al,	2007									none
Salavati et al	2011									ICC=0.96
Salavati et al	2011				Chronbach Alpha					0.87 and 0.92 for basic and advanced
Salavati et al,	2011									v

Adard Name <					Amputation		Other Population						
based of all o	Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Control of Local Section of AL 2011 Control of AL 2011 <thcontrol 2011<="" al="" of="" th=""> Control of AL 2011</thcontrol>	Salavati et al	2011							Locomotor Capabilities	Total Overall Score		Validity	Known group/Discriminant
General et al. Dirac Description Bone More (C-5) Bone More More (C-5)		2011							Locomotor Capabilities	Total Overall		validity	renown group/Discriminant
Filter, Hong of 20 Social or relation Social	Salavati et al,	2011							Index (LCI-5)	Score		Validity	Construct
Image: Section of the sectio	Fisher, Hanspal and Marks	2003		Transfemoral (43%), Transtibial (50%), hip or partial foot amputation (7%)	vascular or diabetes (24%), trauma (64%), neoplasm (8%), other (4%)	47.4	normal or near normal cognitive ability, aged 17-65, amputation between 16-64 years, established prosthesis wearer, amputation at least 1 year previously	100	London Handicap Scale	No Subscales		Validity	Convergent
Banese Drob Mod Solutions along many bases Price Pri	Fisher	2003		Transfemoral (43%), Transtibial (50%), hip or partial foot amputation (7%)	vascular or diabetes (24%), trauma (64%), neoplasm (8%), other (4%)	47.4	normal or near normal cognitive ability, aged 17-65, amputation between 16-64 years, established prosthesis wearer, amputation at least 1 year previously	100	London Handicap Scale			Validity	Convergent
entropy Oling On State of the spectra	2				peripheral artery								Concurrent/convergent
Benes O10 of Masse N.7 Composition Same and second s	Remes	2010		nd	disease peripheral artery	/5.1/		59	LS		Self-reported Life Satisfaction score	Validity	criterion
Van de Weg 2655 1646153 Tanasticial nd 211 nd 200 Modified PEO Procession Image and comparison (controlled one), mole, mail and parison (controlled one), mail and parison (controlled one), mole, mail and parison (controlled one), mole, mail and parison (Remes	2010		nd	disease	75.17		59	LS		Self-reported Life Satisfaction score	Validity	Known group/Discriminant
visit is Wing 200 Networts Lightstow Poil PL PD PL											The questionnaire included questions on demographic variables (age, gender, marital status, level of education), reason for amputation, and time since first prosthesis. In addition, several questions concerned use,		
Van de Weg 205 1646915 Transibility nd 52.1 nd 200 Modified PEQ Satisfaction Intercopagion controlles (op), genomic mature) amputation, and time since fair possibles. In amputation, and time since fair possibles. In amputation, and time since fair possibles. In amputation, and time since fair possibles. In amputation, and time since fair possibles. In amputation, and time since fair possibles. In amputation, and time since fair possibles. In amputation, and time since fair possibles. In amputation, and tim since fair possibles. In amputation, and time since f	Van de Weg	2005	16466153	Transtibial	nd	62.1	nd	220	Modified PEQ	Problems	maintenance, and durability of the prosthesis	Reliability	Internal Consistency
Abciegater et al. 2009 1915607 nd nd 57.4 Diabetic Sudanese 60 MOS quality of fie Validity Known group Hart. 1999 1995 1915607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Bodi pain Validity Known group Hart. 1999 101 195607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Bodi pain Validity Known group Abdeigadir et al. 2009 1915607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Bodi pain Validity Known group Abdeigadir et al. 2009 1915607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Family Validity Known group Abdeigadir et al. 2009 1915607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Family Validity Known group Abdeigadir et al. 2009 1915607 nd nd 57.4 Diabetic Sudanese<	Van de Weg	2005	16466153	Transtibial	nd	62.1	nd	220	Modified PEQ	Satisfaction	demographic variables (age, gender, marital status, level of education), reason for amputation, and time since first prosthesis. In addition, several questions concerned use, maintenance, and durability of the prosthesis	Reliability	Internal Consistency
Abdelgadir et al. 2009 1915607 nd nd 57.4 Dabetic Sudanese 60 MOS Role emotional, quility of fre Number of the emotional, quility Number of the remotional, quility Number of the rem													
Hart [199] Image: Consistency of the consistenc	Abdelgadir et al	2009	19155607	nd	nd	57.4	Diabetic Sudanese	60	MOS	Role emotional, quality of life		Validity	Known group
Hert,199NoNoNoNoNoSofty pinOrdity pinValidityKnown groupAbdelgadir et al.20001915507ndnd57.4Dabele Sudanese60MOS questionnaireFamily FamilyFamilyValidityKnown groupAbdelgadir et al.20001915507ndnd57.4Dabele Sudanese60MOS questionnaireNegative familyNoValidityKnown groupAbdelgadir et al.20091915507ndnd57.4Dabele Sudanese60MOS questionnaireNegative functioningValidityKnown group/DiscriminantAbdelgadir et al.20091915507ndnd57.4Dabele Sudanese60MOS questionnaire functioningPhysical functioningValidityKnown group/DiscriminantAbdelgadir et al.20091915507ndnd57.4Dabele Sudanese60MOS questionnaire functioningPhysical functioningValidityKnown group/DiscriminantAbdelgadir et al.20091915507ndnd57.4Dabele Sudanese60MOS questionnaire functioningPhysical functioningValidityKnown group/DiscriminantAbdelgadir et al.20091915507ndnd57.4Dabele Sudanese60MOS questionnaire MOS questionnairePhysical functioningValidityKnown group/DiscriminantAbdelgadir et al.20091915507ndnd57.4Dabele Sudanese </td <td>Hart</td> <td>1999</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>MOS questionnaire</td> <td>Bodily pain</td> <td></td> <td>Reliability</td> <td>Internal consistency</td>	Hart	1999							MOS questionnaire	Bodily pain		Reliability	Internal consistency
Abdelgadir et al. 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MCS questionnaire satisfaction Validity Known group Abdelgadir et al. 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MCS questionnaire Family MCS questionnaire Family Known group Concurrent/convergent Abdelgadir et al. 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MCS questionnaire Family Known group Validity Known group Abdelgadir et al. 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MCS questionnaire functioning Concurrent/convergent/criteri Abdelgadir et al. 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MCS questionnaire functioning Validity Known group/Validity concurrent/convergent/criteri Abdelgadir et al. 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MCS questionnaire functioning Validity Known group/Clocriterini	Hart,	1999							MOS questionnaire	Bodily pain Family		Validity	Known group
Abdelgadir et al. 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Satisfaction Validity Criterion Abdelgadir et al. 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Negative Physical Validity Known group/Discriminant Abdelgadir et al. 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Physical Validity Known group/Discriminant Abdelgadir et al. 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Physical Validity Known group/Discriminant Abdelgadir et al. 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Physical Concurrent/convergent Validity Known group/Discriminant Abdelgadir et al. 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Physical Concurrent/convergent Boutoilie 19155607 <td< td=""><td>Abdelgadir et al,</td><td>2009</td><td>19155607</td><td>nd</td><td>nd</td><td>57.4</td><td>Diabetic Sudanese</td><td>60</td><td>MOS questionnaire</td><td>satisfaction</td><td></td><td>Validity</td><td>Known group</td></td<>	Abdelgadir et al,	2009	19155607	nd	nd	57.4	Diabetic Sudanese	60	MOS questionnaire	satisfaction		Validity	Known group
Abdelgadir et al,20919155607ndnd57.4Diabetic Sudanese60MOS questionnaireNegative feelingsValidityKnown groupAbdelgadir et al,200919155607ndnd57.4Diabetic Sudanese60MOS questionnairePhysical functioningValidityKnown group/DiscriminantAbdelgadir et al,200919155607ndnd57.4Diabetic Sudanese60MOS questionnairePhysical functioningValidityKnown group/DiscriminantBoutolile20081902619919Diabetic amputes68nd25MOS questionnairePhysical functioningKnown group/DiscriminantAbdelgadir et al,200919155607ndnd57.4Diabetic Sudanes	Abdelgadir et al,	2009	19155607	nd	nd	57.4	Diabetic Sudanese	60	MOS questionnaire	satisfaction		Validity	criterion
Abdelgadir et al, 2009 19156607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Physical functioning Validity Known group/Discriminant Abdelgadir et al, 2009 19156607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Physical functioning Validity Known group/Discriminant Abdelgadir et al, 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Physical functioning Validity Known group/Discriminant Abdelgadir et al, 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Physical functioning Validity Known group/Discriminant Abdelgadir et al, 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Physical functioning Validity Known group/Discriminant Boutoille 2008 19026199 19) Diabetic amputees 68 nd 25 MOS questionnaire Physical functioning Validity Known group/Discriminant Boutoill	Abdelgadir et al.	2009	19155607	nd	nd	57.4	Diabetic Sudanese	60	MOS questionnaire	Negative feelings		Validity	Known group
Addelgadir et al. 2009 19155607 nd nd pr/s product Submittant product Submittant Abdelgadir et al. 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire functioning Validity known group/Discriminant Abdelgadir et al. 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire functioning Validity known group/Discriminant Abdelgadir et al. 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire functioning Validity known group/Discriminant Abdelgadir et al. 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire functioning Validity known group/Discriminant Abdelgadir et al. 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire functioning Validity known group/Discriminant Boutoille 2008 19026199 19 Diabetic amputees 66 nd 25 </td <td>Alexa dia se al</td> <td>0000</td> <td>40455007</td> <td></td> <td>- 4</td> <td>F7 4</td> <td>Dishetis Qudernes</td> <td>00</td> <td>100</td> <td>Physical</td> <td></td> <td></td> <td>Kanana (Diamininan)</td>	Alexa dia se al	0000	40455007		- 4	F7 4	Dishetis Qudernes	00	100	Physical			Kanana (Diamininan)
Abdelgadir et al, 2009 1915607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Physical functioning Validity Concurrent/convergent/criteri a Validity Abdelgadir et al, 2009 1915607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Physical functioning Validity Known group Abdelgadir et al, 2009 1915607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Physical functioning Validity Known group Abdelgadir et al, 2009 1915607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Physical functioning Validity Known group Abdelgadir et al, 2009 1915607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Physical functioning Validity Known group/Discriminant Boutoille 2008 19026199 190 Diabetic amputees 68 nd 25 MOS questionnaire Physical functioning Known group/Discriminant Abdelgadir et al, 2009 1915607	Abdelgadir et al,	2009	19155607	nd	na	57.4	Diabetic Sudanese	60	MOS questionnaire	functioning		Validity	Known group/Discriminant
Abdelgadir et al, 2009 1915607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire functioning Validity Known group Abdelgadir et al, 2009 1915607 nd s7.4 Diabetic Sudanese 60 MOS questionnaire physical functioning	Abdelgadir et al,	2009	19155607	nd	nd	57.4	Diabetic Sudanese	60	MOS questionnaire	Physical functioning Physical		Validity	Concurrent/convergent/criteri a Validity criterion
Abdelgadir et al, 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Physical functioning Concurrent/convergent criterion Boutoille 2008 19026199 19 Diabetic amputees 68 nd 25 MOS questionnaire Physical functioning Validity Known group/Discriminant Boutoille 2008 19026199 19 Diabetic amputees 68 nd 25 MOS questionnaire Physical functioning Validity Known group/Discriminant Boutoille 2008 19026199 19 Diabetic amputees 68 nd 25 MOS questionnaire Physical functioning Validity Known group/Discriminant Abdelgadir et al, 2009 1915607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Positive feelings Concurrent/convergent Concurent/convergent Concurrent/convergent	Abdelgadir et al,	2009	19155607	nd	nd	57.4	Diabetic Sudanese	60	MOS questionnaire	functioning		Validity	Known group
Boutoille 2008 19026199 190 Diabetic amputees 68 nd 25 MOS questionnaire physical putioning Validity Known group/Discriminant Boutoille 2008 19026199 19) Diabetic amputees 68 nd 25 MOS questionnaire functioning Validity Known group/Discriminant Boutoille 2008 19026199 19) Diabetic amputees 68 nd 25 MOS questionnaire physical physical Concurrent/convergent	Abdelgadir et al,	2009	19155607	nd	nd	57.4	Diabetic Sudanese	60	MOS questionnaire	Physical functioning		Validity	Concurrent/convergent criterion
Boutoille 2008 19026199 191 Diabetic amputees 68 nd 25 MOS questionnaire Physical functioning Validity Known group/Discriminant Abdelgadir et al, 2009 1915607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Role emotional Role emotional Validity Known group/Discriminant Abdelgadir et al, 2009 1915607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Role emotional Role emotional Validity Known group Abdelgadir et al, 2009 1915607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Role emotional Validity Known group	Boutoille	2008	19026199	Transtibial (n = 6), Toe or-transmetatarsal (n = 19)	Diabetic amputees	68	nd	25	MOS questionnaire	Physical functioning		Validity	Known group/Discriminant
Abdelgadir et al, 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Feelings Concurrent/convergent Abdelgadir et al, 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Role emotional Role Validity Known group Abdelgadir et al, 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Role emotional Validity Known group	Boutoille	2008	19026199	Transtibial (n = 6), Toe- or-transmetatarsal (n = 19)	Diabetic amputees	68	nd	25	MOS questionnaire	Physical functioning		Validity	Known group/Discriminant
Abdelgadir et al, 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Role Validity Known group Abdelgadir et al, 2009 19155607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire Role physical Validity Known group	Abdelgadir et al,	2009	19155607	nd	nd	57.4	Diabetic Sudanese	60	MOS questionnaire	feelings		Validity	criterion
Abdelgadir et al, 2009 19156607 nd nd 57.4 Diabetic Sudanese 60 MOS questionnaire entrutionial Validity Known group		2000	10155607	nd	nd	57 4	Diabetic Sudances	60		Role		Validity	Known group
	Abdelgadir et al,	2009	19155607	nd	nd	57.4	Diabetic Sudanese	60	MOS questionnaire	Role physical		Validity	Known group

			Comparator/Criterion/Outc	(predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Salavati et al,	2011									differentiated between amputation level and use of walking aids
Salavati et al,	2011									Spearman: TUG=-0.65, 2MWT=0.71
Fisher, Hanspal and Marks	2003		Employment questionairre		nonparametric correlation	-0.52				correlation with Employment questionairre P<.001
Fisher	2003				Employment questionairre	nonparametri c correlation	-0.52			correlation with Employment questionairre P<.001
Remes	2010									All the QoL scores had a significant corelation with the LS score
Remes	2010		amputees vs control group		P value	0.448				
Van de Weg	2005	16466153	nd		Cronbach's alpha	0.76	Adequate	Yes	There is sufficient evidence of Internal Consistency for the PEQ-problems subscale	
Van de Weg	2005	16466153	nd		Cronbach's alpha	0.88	Excellent	Yes	There is sufficient evidence of Internal Consistency for the PEQ-satisfaction subscale	
										It includes questions over the following domains: physical functioning, physical role, negative and positive feelings, emotional role, family satisfaction, sleep and general health; The questions within each domain were summed and linearly transformed into 0-100 scales such that a
Abdelgadir et al Hart	2009	19155607	diabetic controls		P value	<0.01				high score indicates better health α (at fitting)=0.89; α (at follow-up)=0.89;
Hart,	1999									Younger(s60) patients demonstrated greater improvement in overall health status (p=.002)
Abdelgadir et al,	2009	19155607			P value	<0.01				
Abdelgadir et al,	2009	19155607			P value	<0.01				Significant positive correlation with sense of coherence (p<.0001)
Abdelgadir et al,	2009	19155607			P value	<0.01				
Abdelgadir et al,	2009	19155607			P value	<0.01				
Abdelgadir et al,	2009	19155607			P value	<0.01				Sense of coherence of LLA and physical function showed significant negative correlation (p<.0001)
Abdelgadir et al,	2009	19155607			P value	<0.01				
Abdelgadir et al,	2009	19155607			P value	<0.01				Sense of coherence of LLA and physical function showed significant negative correlation (p<.0001)
Boutoille	2008	19026199	amputee vs foot ulcer groups							no significant difference between amputee and foot ulcer groups
Boutoille	2008	19026199	amputee vs foot ulcer groups							no significant difference between amputee and foot ulcer groups
Abdelgadir et al,	2009	19155607			P value	<0.01				of coherence (p<.0001)
Abdelgadir et al,	2009	19155607			P value	<0.01				
Abdelgadir et al,	2009	19155607			P value	<0.01				

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
												Congurrant/oppyorgant
Abdelgadir et al,	2009	19155607	nd	nd	57.4	Diabetic Sudanese	60	MOS questionnaire	Role physical		Validity	criterion
Abdelgadir et al,	2009	19155607	nd	nd	57.4	Diabetic Sudanese	60	MOS questionnaire	Sleep		Validity	Known group
Abdelgadir et al.	2009	19155607	nd	nd	57.4	Diabetic Sudanese	60	MOS questionnaire	Sleep		Validity	concurrent/convergent
			Transfemoral (n=343), Transtibial (n=691), Knee disarticulation	Trauma (N=602), Dvsvascular		>18 years; unilateral LLL; no other amputations; use of a prosthesis to walk; ability to read, write, and understand				The Quality of Life in Neurological Disorders Applied CognitioneGeneral Concerns Short Form version 1.0 solicits information from respondents about the frequency with which they experience cognitive concerns over the prior 7 days. The Neuro-QoL ACGC is brief, has normative scores, and has demonstrated evidence of reliability and validity across a		
Morgan	2016	26836953	(n=40), Symes (n=12)	(N=484)	54.9	English	1086	Neuro-QoL ACGC		range of clinical populations	Validity	Construct
			Transfemoral (n=343), Transtibial (n=691), Knee disarticulation	Trauma (N=602), Dysvascular		>18 years; unilateral LLL; no other amputations; use of a prosthesis to walk; ability to read, write, and understand				The Quality of Life in Neurological Disorders Applied CognitioneGeneral Concerns Short Form version 1.0 solicits information from respondents about the frequency with which they experience cognitive concerns over the prior 7 days. The Neuro-QoL ACGC is brief, has normative scores, and has demonstrated evidence of reliability and validity across a		
Morgan	2016	26836953	(n=40), Symes (n=12)	(N=484)	54.9	English	1086	Neuro-QoL ACGC		range of clinical populations	Validity	Construct
Morgan	2016	26836953	Transfemoral (n=343), Transtibial (n=691), Knee disarticulation (n=40), Symes (n=12)	Trauma (N=602), Dysvascular (N=484)	54.9	>18 years; unilateral LLL; no other amputations; use of a prosthesis to walk; ability to read, write, and understand English	1086	Neuro-QoL ACGC		The Quality of Life in Neurological Disorders Applied CognitioneGeneral Concerns Short Form version 1.0 solicits information from respondents about the frequency with which they experience cognitive concerns over the prior 7 days. The Neuro-QoL ACGC is brief, has normative scores, and has demonstrated evidence of reliability and validity across a range of clinical populations	Validity	Construct
Morgan	2016	26836953	Transfemoral (n=343), Transtibial (n=691), Knee disarticulation (n=40). Symes (n=12)	Trauma (N=602), Dysvascular (N=484)	54.9	>18 years; unilateral LLL; no other amputations; use of a prosthesis to walk; ability to read, write, and understand Fnolish	1086	Neuro-Ool ACGC		The Quality of Life in Neurological Disorders Applied CognitioneGeneral Concerns Short Form version 1.0 solicits information from respondents about the frequency with which they experience cognitive concerns over the prior 7 days. The Neuro-QoL ACGC is brief, has normative scores, and has demonstrated evidence of reliability and validity across a range of dinical populations	Validity	Construct
morgan	2010	20000000	Both upper and lower	(11 101)	01.0	Linglion	1000				validity	
Demet et al	2002		limb amputees grouped together Both upper and lower					NHP	Emotional reactions		Reliability	Test-retest
			limb amputees						Emotional			
Demet et al,	2003		grouped together Both upper and lower					NHP	reactions		Validity	Known group
			limb amputees									
Demet et al	2002		grouped together				+	NHP	Energy		Reliability	Test-retest
Demet et al,	2003		Both upper and lower limb amputees grouped together					NHP	Energy		Validity	Known group
			limb amputees									
Demet et al	2002		grouped together					NHP	Mobility		Reliability	Test-retest
			Both upper and lower limb amputees									
Demet et al,	2003		grouped together					NHP	Mobility		Validity	Known group
Demet et al	2002		limb amputees grouped together					NHP	Pain		Reliability	Test-retest
			Both upper and lower									
Demet et al	2002		grouped together					NHP	Sleep		Reliability	Test-retest
		1	Both upper and lower		1							
Demet et al	2002		limb amputees					NHP	Social		Reliability	Test-retest
Demer er di	2002	1	Bionhen indeniei	1	1	1	1	List q	ISUIGLIUII		In concountry	100010000

			Comparator/Criterion/Outo	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
										physical showed significant negative
Abdelgadir et al,	2009	19155607			P value	<0.01				correlation (p<.0001)
Abdelgadir et al,	2009	19155607			P value	<0.01				
A la dia la andra a final	0000	40455007			Durahua	-0.01				Significant positive correlation with sense
Abdelgadir et al,	2009	19155607			P value	<0.01				of coherence (p<.0001)
Morgan	2016	26836953	Normative sample		P	<0.001		Yes	people with LLL, irrespective of etiology, report gnificantly greater cognitive concerns than the U.S. general population	Based on ttest; compared to the value of 50, the mean of the U.S. normative sample
Margan	2016	20020052	Namatio ample		D	-0.001		Yee	people with LLL, irrespective of etiology, report gnificantly greater cognitive concerns than	Fisher www.Towns.c.202
Morgan	2016	26836953	Normative sample		Р	<0.001		Yes	the U.S. general population	Etiology group: Trauma, n=602
Morgan	2016	26836953	Normative sample		Р	<0.001		Yes	people with LLL, irrespective of etiology, report gnificantly greater cognitive concerns than the U.S. general population	Etiology group: Dysvascular, n=484
Morgan	2016	26836953	Trauma (N=602) vs Dysvascular (N=484)		P	0.58		No	perceived cognitive concerns did not differ between people with traumatic and dysvascular etiologies	Based on an 1 sample, Bonferroni-adjusted ttest (p<0.01)
						0.84 (0.79-				
Demet et al	2002					0.87)				
Demet et al,	2003				P Value	0.0212				Men had a better HRQL than women in t emotional reactions (p=0.0212)
						0 75 (0 69-				
Demet et al	2002					0.8)				
Demet et al,	2003				P Value	0.026				Men had a better HRQL than womenenergy level (p=0.0260). Younger age at amputation was associated with greater energy level.
Demet et al	2002					0.81 (0.76- 0.85)				Map had a better HPOL than woman in
Demet et al,	2003				P Value	0.0017				the time of amputation was associated with less physical disability.
Demet et al	2002					0.84 (0.79- 0.87)				
Domot at al	2002					0.76 (0.7.0.0)				
Demet et di	2002	-	+	1	-	0.70 (0.7-0.8)	1	+		
						0.64 (0.56-				
Demet et al	2002					0.7)				

				Amputation		Other Benulation						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
			Both upper and lower									
			limb amputees						Social			
Demet et al,	2003		grouped together				71 (24	NHP	isolation		Validity	Known group
							amputations					
							in the year					
							2002 + 47 amputations					
							before year		Overall QOL-			
Happich et al,	2008		nd	neuropathy		nd	2002)	Norfolk QOL-DN	DN		Validity	Known group
Happich	2008		nd	neuropathy		nd	71	Norfolk QOL-DN			Validity	Known group
			Both upper and lower						Social			
Demet et al	2002		grouped together					Nottingham Health Profile	isolation		Reliability	Test-retest
			Both upper and lower						-			
Demet et al	2003		limb amputees					Nottingham Health Profile	Social		Validity	Known group
Demeteral	2000		Both upper and lower					Notangham rieatan rome	1301211011		validity	raiown group
			limb amputees						Social			
Demet et al	2003		grouped together	dvovocoulor				Nottingham Health Profile	isolation		Validity	Construct
				(46\22.9%); trauma						The Quality of Life in Neurological Conditions		
				(121/60.2%);						 Applied Cognition/General Concerns v1.0 		
			above knee (70,	infection (25/12.4%);						(NQ-ACGC) is an item bank developed to		
Hafner	2016	28273329	(131, 65.2 %)	congenital (1/0.5%)	60.2 +-11.4	nd	201	NQ-ACGC	nd	memory, attention, and decision-making	Reliability	test-retest
				dysvascular								
				(46\22.9%); trauma						The Quality of Life in Neurological Conditions		
			above knee (70,	infection (25/12.4%);						(NQ-ACGC) is an item bank developed to		
			34.8%); below knee	tumor (8/4.0%);						measure general cognitive abilities, including		
Hatner	2016	28273329	(131, 65.2 %)	congenital (1/0.5%)	60.2 +-11.4	nd	201	NQ-ACGC	nd	memory, attention, and decision-making	MDC	
				(46\22.9%); trauma						The Quality of Life in Neurological Conditions		
				(121/60.2%);						 Applied Cognition/General Concerns v1.0 		
			above knee (70,	infection (25/12.4%);						(NQ-ACGC) is an item bank developed to		
Hafner	2016	28273329	(131, 65.2 %)	congenital (1/0.5%)	60.2 +-11.4	nd	201	NQ-ACGC	nd	memory, attention, and decision-making	MDC	
				dysvascular								
				(46\22.9%); trauma						The Quality of Life in Neurological Conditions		
			above knee (70,	infection (25/12.4%);						(NQ-ACGC) is an item bank developed to		
			34.8%); below knee	tumor (8/4.0%);						measure general cognitive abilities, including		
Hatner	2016	28273329	(131, 65.2 %)	congenital (1/0.5%)	60.2 +-11.4	unilateral	201	NQ-ACGC		memory, attention, and decision-making	Reliability	test-retest
				(46\22.9%); trauma						The Quality of Life in Neurological Conditions		
				(121/60.2%);						 Applied Cognition/General Concerns v1.0 		
			above knee (70, 34.8%): below knee	infection (25/12.4%); tumor (8/4.0%):						(NQ-ACGC) is an item bank developed to measure general cognitive abilities including		
Hafner	2016	28273329	(131, 65.2 %)	congenital (1/0.5%)	60.2 +-11.4	unilateral	201	NQ-ACGC		memory, attention, and decision-making	MDC	
				dysvascular								
				(46\22.9%); trauma (121/60.2%):						Applied Cognition/General Concerns v1 0		
			above knee (70,	infection (25/12.4%);						(NQ-ACGC) is an item bank developed to		
Lisfaar	2010	20272222	34.8%); below knee	tumor (8/4.0%);	60.0	unilataral	201			measure general cognitive abilities, including	MDC	
namer	2016	28213329	(131, 05.2 %) Transfemoral (n=17)	congenital (1/0.5%)	o∪.∠ +-11.4	urmateral	201	NQ-AUGU		memory, attention, and decision-making	WIDC	
			transtibial (n=14),]								
			hindquarter (n=1),					Office of Developing				
			(n=1), bilateral]				Censuses and Surveys	Total Overall			Concurrent/convergent/criteri
Panesar et al,	2001		transfemoral (n=1)	nd	67	nd	34	Scale (OPCS)	Scale		Validity	a Validity criterion

			Comparator/Criterion/Outc	Imepoint			Strength of	le Aenoct		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Demet et al,	2003				P Value	0.0059				Men had a better HRQL than women in social isolation (p=0.0059). Younger age at amputation was associated with less social isolation. Vascular origin of amputation was associated with greater greater social isolation as compared to non-vascular etiology.
										The Norfolk score increased with increasing DN severity, reaching the highest values (worse) in patients with lower extremity
Happich et al,	2008									amputations. The Norfolk score increased with increasing DN severity, reaching the highest values (worse) in patients with lower extremity amputations.
Demet et al	2002					0.64 (0.56- 0.7)				0.64 (0.56-0.7)
Bonnot ot di	2002					0.17				
Demet et al	2003									Men scored significantly better than women (p= 0059)
Demet et al	2003									younger age, traumatic (vs. dysvascular) amputation were related to better scores of the social isolation
Hafner	2016	28273329			ICC	0.88				retest on avg 48.9 (5.2) hrs after, presented separately by MoA when differences were observed. combined ICC, MoAs were satistically constant
Hafner	2016	28273329			MDC 90	6.67				retest on avg 48.9 (5.2) hrs after, presented separately by MoA when differences were observed. combined ICC, MoAs were satistically constant
Hafner	2016	28273329			MDC 95	7.94				retest on avg 48.9 (5.2) hrs after, presented separately by MoA when differences were observed. combined ICC, MoAs were satistically constant
Hafner	2016	28273329			ICC	0.88				retest on avg 48.9 (5.2) hrs after, presented separately by MoA when differences were observed. combined ICC, MoAs were satistically constant.
Hafner	2016	28273329			MDC 90	6.67				retest on avg 48.9 (5.2) hrs after, presented separately by MoA when differences were observed. combined ICC, MoAs were satistically constant.
Hafner	2016	28273329			MDC 95	7.94				retest on avg 48.9 (5.2) hrs after, presented separately by MoA when differences were observed. combined ICC, MoAs were satistically constant.
Panecar et al	2001				P value	<0.0001				significant kendal correlations coefficients
ו מונסמו כו מו,	2001	1	01 00, AA0, 1 IIVI		value	-0.0001	1	1	1	Detween cach of the measures

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
			Transfemoral (n=17), transtibial (n=14), hindquarter (n=1), bilateral transtibial (n=1), bilateral					Office of Population Censuses and Surveys	Total Overall		Ability to measure	
Panesar et al,	2001		transfemoral (n=1)	nd	67	nd	34	Scale (OPCS)	Scale		change	Responsiveness
			Transtemoral (n=17), transtibial (n=14), hindquarter (n=1), bilateral transtibial (n=1), bilateral							Office of Population Censuses and Surveys	Responsiven	
Panesar	2001		transfemoral (n=1)	nd	67		34	OPCS		Scale: Ability to measure change	ess	nd
			Transfemoral (n=17), transtibial (n=14), hindquarter (n=1), bilateral transtibial (n=1), bilateral									Concurrent/convergent/criteri
Panesar	2001		transfemoral (n=1)	nd	67		34	OPCS			Validity	a Validity criterion
Heinemann, Bode, O'Reilly	2003				Both Children and adult amputees together Both Children			OPUS	Health-related quality of life		Reliability	Internal consistency
Heinemann, Bode,					and adult amputees				Health-related			
O'Reilly,	2003				together			OPUS	quality of life		Validity	Structural
Respik & Borgia	2011								Health-related		Peliability	Test retest
Resnik & Dorgia	2011							0103	quality of file		Ability to	1631-161631
									Health-related		measure	
Resnik & Borgia,	2011							OPUS	quality of life		change	Floor/ceiling effects
			Transfemoral (52%); through knee (5%);						Lower limb		Floor/ceiling	
Resnik	2011		transtibial (43%)		66	unilateral	44	OPUS	function	Orthotics and Prosthetics Users' Survey	effect	Appropriateness
Resnik	2011		Transfemoral (52%); through knee (5%); transtibial (43%)		66	unilateral	44	OPUS	Lower limb	Orthotics and Prosthetics Users' Survey	Minimal Detectible Change	MDC90
			Transfemoral (52%);									
Resnik	2011		through knee (5%); transtibial (43%)		66	unilateral	44	OPUS	Lower limb function	Orthotics and Prosthetics Users' Survey	Reliability	Test-retest
Heinemann	2003				Both Children and adult amputees together			OPUS	Lower limb functional		Peliability	Internal consistency
nemenianii	2003	-			logeliter			OF03	L ower limb		Reliability	(chronbach aipnas)
									functional			
Resnik and Borgia	2011							OPUS	measure		Reliability	Test-retest
									Lower limb		Ability to	
Resnik and Borgia	2011							OPUS	TUNCTIONAL		change	(appropriateness)
reshik und Borgid,	2011		Transfemoral (52%);						incusure		Eloor/ceiling	(appropriateness)
Resnik	2011		transtibial (43%)		66	unilateral	44	OPUS	Quality of life	Orthotics and Prosthetics Users' Survey	effect	Appropriateness
			Transfemoral (52%);								Minimal	
Describ	0011		through knee (5%);		<u></u>			00110	0	Orthonizer and Departmention Linear Department	Detectible	NECCO
Resflik	2011		Transfemoral (52%)		00	unilateral	44	0203	Quality of life	Ormotics and Prostnetics Users: Survey	Change	MDC30
			through knee (5%):									
Resnik	2011		transtibial (43%)		66	unilateral	44	OPUS	Quality of life	Orthotics and Prosthetics Users' Survey	Reliability	Test-retest
Resnik	2011		Transfemoral (52%); through knee (5%); transtibial (43%)		66	unilateral	44	OPUS	Satisfaction	Orthotics and Prosthetics Users' Survey	Floor/ceiling effect	Appropriateness
			Transfemoral (52%);								Minimal	
Resnik	2011		through knee (5%); transtibial (43%)		66	unilateral	44	OPUS	Satisfaction	Orthotics and Prosthetics Users' Survey	Detectible Change	MDC90
			Transfemoral (52%);				1					
Resnik	2011		through knee (5%); transtibial (43%)		66	unilateral	44	OPUS	Satisfaction	Orthotics and Prosthetics Users' Survey	Reliability	Test-retest
, toormit	2011					armatol bi			Caudiadudi		. concounty	
									Domestic			
Lerner	1991		Transtibial	Trauma	41.5	nd	20	PAIS	Environment	Psychosocial Adjustment to Illness Scale	Validity	Construct

			Comparator/Criterion/Outc	Timepoint (predictive			Strength of	Is Aspect				
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats		
										cignificant changes between education and		
Panesar et al,	2001		nd		P value	< 0.00001				discharge		
									significant changes between			
Panesar	2001		P value		<0.00001		-		admission and discharge			
										significant kendal correlations coefficients		
Panesar	2001		OPCS, AAS, FIM		P value	<0.0001				between each of the measures		
Heinemann, Bode,												
O'Reilly	2003									ICC of 0.88		
Heinemann, Bode,										3 items slightly misfit; Person separation		
O'Reilly,	2003									index: 2.74; Items separaction index: 4.79		
Resnik & Borgia	2011									0.85		
riconnic di Borgid	2011											
Describe & Description	0011									No. 6 and an an illing a first share and		
Resnik & Borgia,	2011									No floor or ceiling effect observed		
					% at the floor							
Resnik	2011		NA		or ceiling	0		Yes				
Resnik	2011		NA		MDC90	10.3						
Resnik	2011		NA		ICC (95% CI)	0.67 (NR)						
Heinemann	2003									seperation index reliability=0.94		
Resnik and Borgia	2011									ICC= 0.67		
Resnik and Borgia.	2011									None observed		
Boonik	2011		NA		% at the floor	0		Voo				
Resnik	2011		NA		or centrig	0		res				
Resnik	2011		NA		MDC90	9.2						
Resnik	2011		NA		ICC (95% CI)	0.85 (NR)						
					% at the floor							
Resnik	2011		NA		or ceiling	0		Yes				
Resnik	2011		NA		MDC90	15.7						
Resnik	2011		NA		ICC (95% CI)	0.50 (NP)						
I COTIN	2011	1	110.5		100 (85% 01)	0.00 (INIC)				Among the amputee group, patients who		
										underwent primary amputation scored		
Lerner	1991		primary amputation vs delayed amutation		P value	<0.05				worse on the PAIS than those who had delayed amputation (p< .05)		
		1	1	1			1		1	····/·································		
				Amputation		Other Population						
-----------	------	----------	--	------------	------	--	----	----------------------------------	-----------------------	--	----------	------------
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
									Extended			
									Family			
Lerner	1991		Transtibial	Trauma	41.5	nd	20	PAIS	Relationships	Psychosocial Adjustment to Illness Scale	Validity	Construct
Lorpor	1001		Transfilial	Trauma	44.5		20	DAIC	Sexual	Developerated Adjustment to Wasse Caste	Validity	Construct
Lemer	1991		Translipiai	Trauma	41.5	na	20	PAIS	Relationships	Psychosocial Adjustment to liness Scale	validity	Construct
Lerner	1991		Transtibial	Trauma	41.5	nd	20	PAIS	Social Environment	Psychosocial Adjustment to Illness Scale	Validity	Construct
										· · · · · · · · · · · · · · · · · · ·		
									Vocational			
Lerner	1991		Transtibial	Trauma	41.5	nd	20	PAIS	Environment	Psychosocial Adjustment to Illness Scale	Validity	Construct
						Canable of wellking unsided				The Patient Activity Monitor (PAM) is a		
			Transfemoral (n=12).			for a five minute period			Step length	and is specifically targeted towards evaluation		
Ramstrand	2007	17520493	Transtibial (n=10)	nd	50	without a pause	22	Patient Activity Monitor	(fast)	of amputee gait patterns	Validity	Convergent
						Canable of wellving unsided				The Patient Activity Monitor (PAM) is a		
			Transfemoral (n=12),			for a five minute period			Step length	and is specifically targeted towards evaluation		
Ramstrand	2007	17520493	Transtibial (n=10)	nd	50	without a pause	22	Patient Activity Monitor	(fast)	of amputee gait patterns	Validity	Convergent
						Capable of walking unsided				The Patient Activity Monitor (PAM) is a		
			Transfemoral (n=12),			for a five minute period			Step length	and is specifically targeted towards evaluation		
Ramstrand	2007	17520493	Transtibial (n=10)	nd	50	without a pause	22	Patient Activity Monitor	(fast)	of amputee gait patterns	Validity	Convergent
						Capable of walking upaided				The Patient Activity Monitor (PAM) is a		
			Transfemoral (n=12),			for a five minute period			Step length	and is specifically targeted towards evaluation		
Ramstrand	2007	17520493	Transtibial (n=10)	nd	50	without a pause	22	Patient Activity Monitor	(medium)	of amputee gait patterns	Validity	Convergent
						Canable of walking unaided				The Patient Activity Monitor (PAM) is a commercially available walking activity monitor		
			Transfemoral (n=12),			for a five minute period			Step length	and is specifically targeted towards evaluation		
Ramstrand	2007	17520493	Transtibial (n=10)	nd	50	without a pause	22	Patient Activity Monitor	(medium)	of amputee gait patterns	Validity	Convergent
						Capable of walking unaided				commercially available walking activity monitor		
			Transfemoral (n=12),			for a five minute period			Step length	and is specifically targeted towards evaluation		
Ramstrand	2007	17520493	Transtibial (n=10)	nd	50	without a pause	22	Patient Activity Monitor	(medium)	of amputee gait patterns	Validity	Convergent
						Capable of walking unaided				commercially available walking activity monitor		
			Transfemoral (n=12),			for a five minute period			Step length	and is specifically targeted towards evaluation		
Ramstrand	2007	17520493	Transtibial (n=10)	nd	50	without a pause	22	Patient Activity Monitor	(SIOW)	of amputee gait patterns	Validity	Convergent
						Capable of walking unaided				commercially available walking activity monitor		
Demotored	0007	47500400	Transfemoral (n=12),		50	for a five minute period	00	Define the state of the Manufact	Step length	and is specifically targeted towards evaluation	\	0
Ramstrand	2007	17520493	Transtibial (n=10)	na	50	without a pause	22	Patient Activity Monitor	(SIOW)	The Patient Activity Monitor (PAM) is a	validity	Convergent
						Capable of walking unaided				commercially available walking activity monitor		
Bomotrond	2007	17520402	Transfemoral (n=12), Transtinial (n=10)	nd	50	for a five minute period	22	Patient Activity Manitor	Step length	and is specifically targeted towards evaluation	Volidity	Convergent
Ramstrand	2007	17520435	Transcibiar (II=10)	lia	50	without a pause	22	T alient Activity Monitor	(3000)	The Patient Activity Monitor (PAM) is a	validity	Convergent
						Capable of walking unaided				commercially available walking activity monitor		
Ramstrand	2007	17520493	Transfemoral (n=12), Transfibial (n=10)	nd	50	for a five minute period	22	Patient Activity Monitor	Total step	and is specifically targeted towards evaluation	Validity	Convergent
Tambuana	2007	11020400	Transablar (II=10)		50	without a pause	~~	r daene / leavity monitor	count	The Patient Activity Monitor (PAM) is a	validity	Convergent
						Capable of walking unaided				commercially available walking activity monitor		
Ramstrand	2007	17520493	Transfemoral (n=12), Transfibial (n=10)	nd	50	for a five minute period without a pause	22	Patient Activity Monitor	l otal step count	and is specifically targeted towards evaluation of amputee gait patterns	Validity	Convergent
										The Patient Activity Monitor (PAM) is a		
			Transfemoral (n=12)]		Capable of walking unaided			Total step	commercially available walking activity monitor		
Ramstrand	2007	17520493	Transtibial (n=10)	nd	50	without a pause	22	Patient Activity Monitor	count	of amputee gait patterns	Validity	Convergent
						Operative of the state				The Patient Activity Monitor (PAM) is a		
			Transfemoral (n=12)]		capable of walking unaided			Total step	commercially available walking activity monitor and is specifically targeted towards evaluation		
Ramstrand	2007	17520493	Transtibial (n=10)	nd	50	without a pause	22	Patient Activity Monitor	count	of amputee gait patterns	Validity	Convergent
						Canable of wall-in superior				The Patient Activity Monitor (PAM) is a		
			Transfemoral (n=12)]		for a five minute period			Total step	commercially available walking activity monitor and is specifically targeted towards evaluation		
Ramstrand	2007	17520493	Transtibial (n=10)	nd	50	without a pause	22	Patient Activity Monitor	count	of amputee gait patterns	Validity	Convergent

			Comparator/Criterion/Outc	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
										Among the amputee group, patients who
			nimen (executation) (e							underwent primary amputation scored
Lerner	1991		delayed amutation		P value	<0.05				delayed amputation ($n < 05$)
Lerrier	1331		delayed andtation		i value	<0.05				Among the amputee group, patients who
										underwent primary amputation scored
			primary amputation vs							worse on the PAIS than those who had
Lerner	1991		delayed amutation		P value	<0.05				delayed amputation (p< .05)
										Among the amputee group, patients who
										underwent primary amputation scored
l erner	1001		primary amputation vs		P value	<0.05				delayed amputation (pc. 05)
Lerner	1001				i value	-0.00				Among the amputee group patients who
										underwent primary amputation scored
			primary amputation vs							worse on the PAIS than those who had
Lerner	1991		delayed amutation		P value	<0.05				delayed amputation (p< .05)
			Qualieve motion analysis							
Ramstrand	2007	17520493	systems		Pearson r	0.95	Large	Yes		
			Qualisys motion analysis							
Ramstrand	2007	17520493	systems		Pearson r	0.93	Large	Yes		Iranstemoral
			Qualisys motion analysis							
Ramstrand	2007	17520493	systems		Pearson r	0.98	Large	Yes		Transtibial
Ramstrand	2007	17520493	Qualisys motion analysis		Pearson r	0.95	Large	Ves		
ramotrana	2007	11020400	systems		1 curson 1	0.00	Large	103		
			Qualisys motion analysis							
Ramstrand	2007	17520493	systems		Pearson r	0.95	Large	Yes		Transfemoral
			Qualisys motion analysis							
Ramstrand	2007	17520493	systems		Pearson r	0.99	Large	Yes		Transtibial
			Quellaux metion englusis							
Ramstrand	2007	17520493	Quality's motion analysis		Pearson r	0.77	Large	Ves		
ramotrana	2007		oyotomo		i darodini	0	Laigo	100		
			Qualisys motion analysis							
Ramstrand	2007	17520493	systems		Pearson r	0.36	Moderate	Yes		Transfemoral
			Qualisys motion analysis							
Ramstrand	2007	17520493	systems		Pearson r	0.93	Large	Yes		Transtibial
Domotrond	2007	17520402	Qualisys motion analysis		Boomon r	0.07	Largo	Vac		Tropotibiol
Ramstranu	2007	17520495	systems		Fearsonn	0.97	Laige	165		Tansubia
			Qualisys motion analysis							
Ramstrand	2007	17520493	systems		Pearson r	0.98	Large	Yes		Transfemoral
			Qualisys motion analysis							
Ramstrand	2007	17520493	systems		Pearson r	0.98	Large	Yes		
			Quality and the second of							
Rametrand	2007	17520402	Qualisys motion analysis		Pearson r	0.07	large	Vec		
Cambuallu	2007	11320493	57510110		carsoliti	0.01	Laige	100		
			Qualisys motion analysis							
Ramstrand	2007	17520493	systems	1	Pearson r	0.91	Large	Yes	1	

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Ramstrand	2007	17520493	Transfemoral (n=12), Transtibial (n=10)	nd	50	Capable of walking unaided for a five minute period without a pause	22	Patient Activity Monitor	Total step count	The Patient Activity Monitor (PAM) is a commercially available walking activity monitor and is specifically targeted towards evaluation of amputee gait patterns	Validity	Convergent
Ramstrand	2007	17520493	Transfemoral (n=12), Transtibial (n=10)	nd	50	Capable of walking unaided for a five minute period without a pause	22	Patient Activity Monitor	Total step count	The Patient Activity Monitor (PAM) is a commercially available walking activity monitor and is specifically targeted towards evaluation of amputee gait patterns The Patient Activity Monitor (PAM) is a	Validity	Convergent
Ramstrand	2007	17520493	Transfemoral (n=12), Transtibial (n=10)	nd	50	Capable of walking unaided for a five minute period without a pause	22	Patient Activity Monitor	Total step count	commercially available walking activity monitor and is specifically targeted towards evaluation of amputee gait patterns	Validity	Convergent
Ramstrand	2007	17520493	Transfemoral (n=12), Transtibial (n=10)	nd	50	Capable of walking unaided for a five minute period without a pause	22	Patient Activity Monitor	Walking velocity	The Patient Activity Monitor (PAM) is a commercially available walking activity monitor and is specifically targeted towards evaluation of amputee gait patterns	Validity	Convergent
Ramstrand	2007	17520493	Transfemoral (n=12), Transtibial (n=10)	nd	50	Capable of walking unaided for a five minute period without a pause	22	Patient Activity Monitor	Walking velocity	The Patient Activity Monitor (PAM) is a commercially available walking activity monitor and is specifically targeted towards evaluation of amputee gait patterns	Validity	Convergent
Ramstrand	2007	17520493	Transfemoral (n=12), Transtibial (n=10)	nd	50	Capable of walking unaided for a five minute period without a pause	22	Patient Activity Monitor	Walking velocity (fast)	The Patient Activity Monitor (PAM) is a commercially available walking activity monitor and is specifically targeted towards evaluation of amputee gait patterns	Validity	Convergent
Ramstrand	2007	17520493	Transfemoral (n=12), Transtibial (n=10)	nd	50	Capable of walking unaided for a five minute period without a pause	22	Patient Activity Monitor	Walking velocity (medium)	The Patient Activity Monitor (PAM) is a commercially available walking activity monitor and is specifically targeted towards evaluation of amputee gait patterns	Validity	Convergent
Ramstrand	2007	17520493	Transfemoral (n=12), Transtibial (n=10)	nd	50	Capable of walking unaided for a five minute period without a pause	22	Patient Activity Monitor	Walking	The Patient Activity Monitor (PAM) is a commercially available walking activity monitor and is specifically targeted towards evaluation of amputee gait patterns.	Validity	Convergent
Arwert	2007	17943683	Unilateral transtibial	Vascular insufficiency	69.8	nd	23	PEQ	Ambulation		Validity	Known group/Discriminant
Legro	1998		Transfemoral (25%), transtibial (63%), through knee (3%), Symes (9%)	Trauma (67%), Chronic disease (41%), Congenital (3%), Tumor (1%)	40% over 60v		02	PEO	Ambulation		Floor/ceiling	Appropriateness
Legio	1000		Transfemoral (25%), transtibial (63%), through knee (3%),	Trauma (67%), Chronic disease (41%), Congenital	40% OVER 009							
Legro	1998		Symes (9%) Transfemoral (25%), transtibial (63%), through knee (3%).	(3%), Tumor (1%) Trauma (67%), Chronic disease (41%), Congenital	40% over 60y		92	PEQ	Ambulation		Reliability	Test-retest
Legro	1998		Symes (9%)	(3%), Tumor (1%)	40% over 60y		92	PEQ	Ambulation		Reliability	Internal consistency
Legro	1998		Transfemoral (25%), transtibial (63%), through knee (3%), Symes (9%)	Trauma (67%), Chronic disease (41%), Congenital (3%), Tumor (1%)	40% over 60y		92	PEQ	Ambulation		Validity	Construct (known groups / subgroups)
Legro	1998		Transfemoral (25%), transtibial (63%), through knee (3%), Symes (9%)	Trauma (67%), Chronic disease (41%), Congenital (3%), Tumor (1%)	40% over 60y		92	PEQ	Ambulation		Validity	Criterion
			Transfemoral (52%); through knee (5%);								Floor/ceiling	
Resnik	2011		transtibial (43%) Transfemoral (52%);		66	unilateral	44	PEQ	Ambulation		effect Minimal	Appropriateness
Resnik	2011		through knee (5%); transtibial (43%)		66	unilateral	44	PEQ	Ambulation		Detectible Change	MDC90
Resnik	2011		Transfemoral (52%); through knee (5%); transtibial (43%)		66	unilateral	44	PEQ	Ambulation		Reliability	Test-retest
Legro	1998		Transfemoral (25%), transtibial (63%), through knee (3%), Symes (9%)	Trauma (67%), Chronic disease (41%), Congenital (3%), Tumor (1%)	40% over 60v		92	PEQ	Apearance		Floor/ceiling effect	Appropriateness
			Transfemoral (25%), transtibial (63%), through knee (3%),	Trauma (67%), Chronic disease (41%), Congenital								
Legro	1998		Symes (9%)	(3%), Tumor (1%)	40% over 60y		92	PEQ	Apearance		Reliability	Test-retest

			Comparator/Criterion/Outc	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Ramstrand	2007	17520493	Hand counter		Pearson r	0.98	Large	Yes		
Ramstrand	2007	17520493	Hand counter		Pearson r	0.97	Large	Yes		
Ramstrand	2007	17520493	Hand counter		Pearson r	0.9	Large	Yes		
Ramstrand	2007	17520493	Hand counter		Pearson r	0.98	Large	Yes		Transfemoral
Ramstrand	2007	17520493	Hand counter		Pearson r	0.99	Large	Yes		Transtibial
Ramstrand	2007	17520493	Hand counter		Pearson r	0.98	Large	Yes		
Ramstrand	2007	17520493	Hand counter		Pearson r	0.99	Large	Yes		
Demotional	0007	47500400	Line di anno 1990 anno		D	0.05		N		
Ramstrand	2007	17520493	Hand counter		Pearson r	0.95	Large	Yes		differentiated between groups of different
			groups of different tibial							tibial length and Chakrabarty (residual limb
Arwert	2007	17943683	length		ttest P	<0.05				quality) points
					% at the floor					max of floor or ceiling proportion (not all
Legro	1998				or ceiling	2		Yes		scales in the same directin)
										among 61/92 people who did no have major
	1000		N14		100 (059) 01	0.90 (0.84,				change in health or prosthesis and did the
Legro	1998		NA		ICC (95% CI)	0.94)				retest
Learo	1998		NΔ		Chronbach	0.89	excellent			
Legio	1330		by: gender; age group;		Лірпа	0.03	excellent			
			comorbidities (any);		difference in					statistically difference only by gender (men
Learo	1998		since amputation		PEQ (subscale score))	see notes				higher); by comorbidities (zero comorbidities higher)
Legro	1998		SF-36 physical function		correlation	0.61				
Resnik	2011				% at the floor	0				
	2011				or coming	Ŭ				
Recnik	2011		NA			1 1				
INCOLIN	2011				INDC90	1.1				
					100 (050) 51	0.81 (0.68,				
Resnik	2011		NA		ICC (95% CI)	0.89)				
	1008				% at the floor	7		Vee		max of floor or ceiling proportion (not all
Legio	1998				or ceiling	1		res		soares in the same directin)
										among 61/92 people who did no have major
Learo	1998		NA		ICC (95% CI)	0.84 (0.76, 0.90)				change in health or prosthesis and did the
9.0		1	press a	1		2.00,	1	1	1	l

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
			Transfemoral (25%),	Trauma (67%),	Ŭ					· ·		•
			transtibial (63%),	Chronic disease								
Learo	1998		through knee (3%), Symes (9%)	(41%), Congenital (3%), Tumor (1%)	40% over 60v		92	PEQ	Apearance		Reliability	Internal consistency
			Transfemoral (25%),	Trauma (67%),			-					
			transtibial (63%),	Chronic disease								
Logro	1009		through knee (3%),	(41%), Congenital	40% over 60v		02	REO	Anooronoo		Volidity	Construct (known groups /
Legio	1990		Transfemoral (52%):	(3%), Tumor (1%)	40% Over 60y		92	FEQ	Apearance		validity	subgroups)
			through knee (5%);								Floor/ceiling	
Resnik	2011		transtibial (43%)		66	unilateral	44	PEQ	Appearance		effect	Appropriateness
			through knee (5%);								Detectible	
Resnik	2011		transtibial (43%)		66	unilateral	44	PEQ	Appearance		Change	MDC90
			Transfemoral (52%);									
Resnik	2011		through knee (5%); transtibial (43%)		66	unilateral	44	PEO	Annearance		Reliability	Test-retest
	2011		Transfemoral (25%),	Trauma (67%),		umatora			rippodranoo		rtondonity	
			transtibial (63%),	Chronic disease								
Learo	1008		through knee (3%), Symes (9%)	(41%), Congenital	40% over 60v		02	PEO	Frustration		Floor/ceiling	Appropriateness
Legio	1990		Transfemoral (25%).	(3%), Tumor (1%) Trauma (67%).	40% Over 60y		92	FEQ	Flustiation		eneci	Appropriateriess
			transtibial (63%),	Chronic disease								
	1000		through knee (3%),	(41%), Congenital	40%		02	DEO	Envotration		Deliebility	Tool voluet
Legio	1990		Transfemoral (25%)	(3%), Tumor (1%) Trauma (67%)	40% over 60y		92	PEQ	Frustration		Reliability	Test-Telest
			transtibial (63%),	Chronic disease								
			through knee (3%),	(41%), Congenital				550				
Legro	1998		Symes (9%) Transfemoral (25%)	(3%), Tumor (1%)	40% over 60y		92	PEQ	Frustration		Reliability	Internal consistency
			transtibial (63%),	Chronic disease								
			through knee (3%),	(41%), Congenital								Construct (known groups /
Legro	1998		Symes (9%)	(3%), Tumor (1%)	40% over 60y		92	PEQ	Frustration		Validity	subgroups)
			through knee (5%);								Floor/ceiling	
Resnik	2011		transtibial (43%)		66	unilateral	44	PEQ	Frustration		effect	Appropriateness
			Transfemoral (52%);								Minimal	
Resnik	2011		transtibial (43%)		66	unilateral	44	PEQ	Frustration		Change	MDC90
			Transfemoral (52%);									
Decesily.	0011		through knee (5%);					DEO	Frankrakian		Dellebille	T 4 4 4
Resnik	2011		Transfemoral (n=112)	vascular (220)	66	unilateral	44	PEQ	Frustration		Reliability	l est-retest
Asano	2008	18569891	Transtibial (303)	nonvascular (195)	61.9	Unilateral	415	PEQ	Mobility		Validity	Convergent
				Peripheral vascular								
			I Inilateral transfermoral	disease and/or								
			(53%), Unilateral	Trauma (56%),								
			transtibial (36%),	Tumour and other								
Franchignoni	2007	17351696	Bilateral (11%)	(9%) Peripheral vaceular	54		123	PEQ	Mobility		Reliability	Internal consistency
				disease and/or								
			Unilateral transfemoral	diabetes (35%),								
			(53%), Unilateral transtibial (36%)	Trauma (56%), Tumour and other								
Franchignoni	2007	17351696	Bilateral (11%)	(9%)	54		123	PEQ	Mobility		Reliability	Item seperation reliability
				Peripheral vascular	-							
				disease and/or								
			(53%), Unilateral	Trauma (56%)								
			transtibial (36%),	Tumour and other								
Franchignoni	2007	17351696	Bilateral (11%)	(9%)	54		123	PEQ	Mobility		Reliability	Person separation reliability
				Peripheral vascular								
			Unilateral transfemoral	diabetes (35%),								
			(53%), Unilateral	Trauma (56%),								
Franchignoni	2007	17351696	transtibial (36%), Bilateral (11%)	1 umour and other	54		123	PEO	Mobility		Validity	Convergent
				(- · -/	1	I	1.20	1. = =			. anany	

Author	Voar	рмір	Comparator/Criterion/Outc	Timepoint (predictive	Matric Llead	Value	Strength of	Is Aspect	Conclusion	Notoc/Cavaate
Autio	i cai		ome	valiuj	Metric Osed	value	rioperty	Supported	conclusion	Holes/Caveals
Lanza	1000				Chronbach	0.72	adaquata			
Legio	1990		by: gender: age group:		Alpha	0.75	adequate			
			comorbidities (any); amputation level; years		difference in PEQ (subscale					no statistically significant differences in any
Legro	1998		since amputation		score))	see notes				factor
Resnik	2011				% at the floor or ceiling	0				
Resnik	2011		NA		MDC90	1.4				
						0 70 /0 54				
Resnik	2011		NA		ICC (95% CI)	0.70 (0.51, 0.82)				
Legro	1998				% at the floor or ceiling	22		No		max of floor or ceiling proportion (not all scales in the same directin)
-					-					
Learo	1998		NA		ICC (95% CI)	0.64 (0.47				among 61/92 people who did no have majo change in health or prosthesis and did the retest
Logio	1000				100 (0070 01)	0.11)				liteor
					Chronbooh					
Legro	1998		NA		Alpha	0.82	excellent			
			by: gender; age group;							
			comorbidities (any); amputation level: vears		PEQ (subscale					statistically significant difference only by
Legro	1998		since amputation		score))	see notes				age group (higher in younger people)
					% at the floor					
Resnik	2011				or ceiling	0				
Resnik	2011		NA		MDC90	1.6				
						0.00.00				
Resnik	2011		NA		ICC (95% CI)	0.82 (0.69, 0.90)				
Asano	2008	18569891	QoL, single item question		Beta	-0.31				Multivariate regression
						Chronhooh				
Franchignoni	2007	17351696				Alpha	0.96			
Franchignoni	2007	17351606				Rasch Item	0.08			
riancingnom	2007	17551050				seperation	0.30			
						Rasch				
						Person				
Franchignoni	2007	17351696				seperation	0.95			
										similar (to PEQMS12/5) but slightly lower
Franchignoni	2007	17351696	LCI	1	Spearman r	1		1	1	correlations with LCI (not shown)

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
			above knee (70,	dysvascular (46\22.9%); trauma (121/60.2%); infection (25/12.4%);						12-item self-report measure assessing the		
11-6	0010	00070000	34.8%); below knee	tumor (8/4.0%);	00 0 · 44 4	- 4	004	PEO	N 4 - 1- 1114	ability to perform mobility tasks while using a	Delle billte	
Hamer	2016	282/3329	(131, 65.2 %)	dvsvascular	60.2 +-11.4	na	201	PEQ	NIODIIIty	lower limb prostnesis	Reliability	test-retest
Hafner	2016	28273329	above knee (70, 34.8%); below knee (131, 65.2 %)	(46\22.9%); trauma (121/60.2%); infection (25/12.4%); tumor (8/4.0%); congenital (1/0.5%)	60.2 +-11.4	nd	201	PEQ	Mobility	12-item self-report measure assessing the ability to perform mobility tasks while using a lower limb prosthesis	MDC	
Liefeer	2016	20272220	above knee (70, 34.8%); below knee	dysvascular (46\22.9%); trauma (121/60.2%); infection (25/12.4%); tumor (8/4.0%);	60.2 + 44.4		201		NA-bille	12-item self-report measure assessing the ability to perform mobility tasks while using a turne the performance the period.	MDC	
Hamer	2016	282/3329	(131, 65.2 %)	dvsvascular	60.2 +-11.4	na	201	PEQ	NIODIIIty	lower limb prostnesis	MDC	
Hafner	2016	28273329	above knee (70, 34.8%); below knee (131, 65.2 %)	(46\22.9%); trauma (121/60.2%); infection (25/12.4%); tumor (8/4.0%); congenital (1/0.5%)	60.2 +-11.4	unilateral	201	PEQ	Mobility	12-item self-report measure assessing the ability to perform mobility tasks while using a lower limb prosthesis	Reliability	test-retest
Hafner	2016	28273329	above knee (70, 34.8%); below knee (131, 65.2 %)	dysvascular (46\22.9%); trauma (121/60.2%); infection (25/12.4%); tumor (8/4.0%); congenital (1/0.5%)	60.2 +-11.4	unilateral	201	PEQ	Mobility	12-item self-report measure assessing the ability to perform mobility tasks while using a lower limb prosthesis	MDC	
			above knee (70, 34.8%); below knee	dysvascular (46\22.9%); trauma (121/60.2%); infection (25/12.4%); tumor (8/4.0%);						12-item self-report measure assessing the ability to perform mobility tasks while using a		
Hafner	2016	28273329	(131, 65.2 %) Transfemoral (26%), Transtibial (74%)	congenital (1/0.5%) Vascular (55%), Non- vascular (45%)	60.2 +-11.4 58.4	unilateral	60	PEQ	Mobility	Iower limb prosthesis The Prosthetic Evaluation Questionnaire (PEQ) is composed of nine sub scales assessing emotional and social health, global well-being, prosthetic function including mobility over the past forur weeks	MDC Floor/ceiling	Ceiling
												Concurrent/convergent/criteri
Miller	2004	15180125	Transfemoral (52%)					PEQ	mobility		Validity	a Validity criterion
Resnik	2011		through knee (5%); transtibial (43%)		66	unilateral	44	PEQ	Mobility		Floor/ceiling effect Minimal	Appropriateness
Resnik	2011		through knee (5%); transtibial (43%)		66	unilateral	44	PEQ	Mobility		Detectible Change	MDC90
			through knee (5%);									
Resnik	2011		transtibial (43%)		66	unilateral	44	PEQ	Mobility	The Depathetic Fuglueting Overfloored	Reliability	Test-retest
Miller	2000		Transfemoral (26%), Transtibial (74%)	Vascular (53%), Non- vascular (47%)	59.9		329	PEQ	Mobility (ambulation and transfer)	(PEQ) is composed of nine sub scales assessing emotional and social health, global well-being, prosthetic function including mobility over the past four weeks	Floor/ceiling effect	Ceiling
Miller	2000		Transfemoral (26%), Transtibial (74%)	Vascular (53%), Non- vascular (47%)	59.9		329	PEQ	Mobility (ambulation and transfer)	The Prosthetic Evaluation Questionnaire (PEQ) is composed of nine sub scales assessing emotional and social health, global well-being, prosthetic function including mobility over the past four weeks	Validity	Construct
Millor	2000		Transfemoral (26%),	Vascular (53%), Non	50.0		220	REQ	Mobility (ambulation	The Prosthetic Evaluation Questionnaire (PEQ) is composed of nine sub scales assessing emotional and social health, global well-being, prosthetic function including mability ages to page for successful and social health.	Volidit	Construct
willer	2000		i ranstibial (74%)	vascular (47%)	59.9		329	PEQ	and transfer)	The Prosthetic Evaluation Questionnaire	validity	Construct
			Transfemoral (26%),	Vascular (53%), Non-					Mobility (ambulation	(PEQ) is composed of nine sub scales assessing emotional and social health, global well-being, prosthetic function including		
Miller	2000		Transtibial (74%)	vascular (47%)	59.9		329	PEQ	and transfer)	mobility over the past four weeks	Validity	Construct

			Comparator/Criterion/Outc	(predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Hafner	2016	28273329			ICC	0.92				retest on avg 48.9 (5.2) hrs after, presented separately by MoA when differences were observed. combined ICC, MoAs were satistically constant
Hafner	2016	28273329			MDC 90	0.55				retest on avg 48.9 (5.2) hrs after, presenter separately by MoA when differences were observed. combined ICC, MoAs were satistically constant
Hafner	2016	28273329			MDC 95	0.65				retest on avg 48.9 (5.2) hrs after, presenter separately by MoA when differences were observed, combined ICC, MoAs were satistically constant
Hafner	2016	28273329			ICC	0.92				retest on avg 48.9 (5.2) hrs after, presented separately by MoA when differences were observed. combined ICC, MoAs were satistically constant.
Hafner	2016	28273329			MDC 90	0.55				retest on avg 48.9 (5.2) hrs after, presenter separately by MoA when differences were observed. combined ICC, MoAs were satistically constant.
Liefeer	2016	00070000			MDC 05	0.65				retest on avg 48.9 (5.2) hrs after, presented separately by MAA when differences were observed, combined ICC, MoAs were activitically constant
Miller	2010	20213329	nd		MDC 95	8.1		No	There was no indication of	
Miller	2000	15180125			70	0.1				Pearsons: EAI=0.30, EAI-18=0.40
Resnik	2011				% at the floor or ceiling	0				Tearsons. 174-0.00, 174-10-0.40
Resnik	2011		NA		MDC90	0.3				
Resnik	2011		NA		ICC (95% CI)	0.85 (0.74, 0.92)				
Miller	2000		nd		%	10		No	There was no indication of ceiling effect	
Miller	2000		Transtibial vs Transfemoral		Effect size	0.11		No	The Prosthetic Evaluation Questionnaire - Mobility did not differ between Transtibial and Transfemoral	p>0.05
Miller	2000		Vacular ve pop vogilar		Effect size	0.81		Ves	The Prosthetic Evaluation Questionnaire - Mobility differed between Vascular and non- vasular	
Minel	2000		Mobility device used vs no		Enect size	0.01		185	The Prosthetic Evaluation Questionnaire - Mobility differed between Mobility device used	
Miller	2000		device		Effect size	1.57		Yes	and no device use	

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Miller	2000		Transfemoral (26%), Transtibial (74%)	Vascular (53%), Non	59.9		329	PEO	Mobility (ambulation	The Prosthetic Evaluation Questionnaire (PEQ) is composed of nine sub scales assessing emotional and social health, global well-being, prosthetic function including mobility over the past four weeks	Validity	Construct
Miller	2000		Transformeral (26%)		39.9		529	FEW	Mobility	The Prosthetic Evaluation Questionnaire (PEQ) is composed of nine sub scales assessing emotional and social health, global well being anothetic function polyuting	validity	Constitut
Miller	2000		Transtibial (74%)	vascular (47%)	59.9		329	PEQ	and transfer)	mobility over the past four weeks	Validity	Construct
Miller	2000		Transfemoral (26%), Transtinial (74%)	Vascular (55%), Non	58.4		60	PEO	Mobility (ambulation	(PEQ) is composed of nine sub scales assessing emotional and social health, global well-being, prosthetic function including mobility over the nast four weeks	Validity	Convergent
			Transfemoral (26%),	Vascular (55%), Non					Mobility (ambulation	The Prosthetic Evaluation Questionnaire (PEQ) is composed of nine sub scales assessing emotional and social health, global well-being, prosthetic function including	Validity	
Miller	2000		Transtibial (74%)	vascular (45%)	58.4		60	PEQ	and transfer)	mobility over the past four weeks The Prosthetic Evaluation Questionnaire (PEQ) is composed of nine sub scales	Validity	Convergent
Miller	2000		Transfemoral (26%), Transtibial (74%)	Vascular (55%), Non vascular (45%)	58.4		60	PEQ	Mobility (ambulation and transfer)	assessing emotional and social health, global well-being, prosthetic function including mobility over the past four weeks	Validity	Convergent
			Transfemoral (26%)	Vascular (53%) Non					Mobility	The Prosthetic Evaluation Questionnaire (PEQ) is composed of nine sub scales assessing emotional and social health, global well being constitution function including		
Miller	2000		Transtibial (74%)	vascular (47%)	59.9		329	PEQ	and transfer)	mobility over the past four weeks The Prosthetic Evaluation Questionnaire	Validity	Convergent
Miller	2000		Transfemoral (26%), Transtibial (74%)	Vascular (55%), Non vascular (45%)	58.4		60	PEQ	Mobility (ambulation and transfer)	(PEQ) is composed of nine sub scales assessing emotional and social health, global well-being, prosthetic function including mobility over the past four weeks	Floor/ceiling effect	Floor
Millor	2000		Transfemoral (26%),	Vascular (53%), Non	50.0		220	PEO	Mobility (ambulation	The Prosthetic Evaluation Questionnaire (PEQ) is composed of nine sub scales assessing emotional and social health, global well-being, prosthetic function including mobility ups the part four upper	Floor/ceiling	Floor
initial initia	2000		Transfemoral (26%),	Vascular (55%), Non			525		Mobility (ambulation	The Prosthetic Evaluation Questionnaire (PEQ) is composed of nine sub scales assessing emotional and social health, global well-being, prosthetic function including	enect	
Miller	2000		Transtibial (74%)	vascular (45%)	58.4		60	PEQ	And transfer)	mobility over the past four weeks The Prosthetic Evaluation Questionnaire (PEQ) is composed of nine sub scales assessing emotional and social health, global well being exact heat four the isolation	Reliability	Internal Consistency
Miller	2000		Transferioral (26%), Transtibial (74%)	vascular (45%), Non vascular (45%)	58.4		60	PEQ	and transfer) Mobility	mobility over the past four weeks	Reliability	Test-retest
Miller	2001	11552197	below knee (73%)	Vascular (53%)	62	23-91	435	PEQ	(ambulation and transfer)		Validity	Convergent
Miller	2001	11552197	below knee (73%)	Vascular (53%)	62	23-91	435	PEQ	(ambulation and transfer)		Validity	Convergent
Miller	2001	11552197	below knee (73%)	Vascular (53%)	62	23-91	435	PEQ	Mobility (ambulation and transfer)		Validity	Convergent
		11588750	below knee (72%),	Vascular (55%),					Mobility (ambulation		Floor/ceiling effects (appropriaten	
Miller	2001	(sample 1)	above knee (28%)	nonvascular 45%) Vascular (55%)	58		60	PEQ	and transfer) Mobility (ambulation	Ability to measure change	ess)	
Miller	2001	(sample 1)	above knee (28%)	nonvascular 45%)	58		55	PEQ	and transfer) Mobility		Reliability	Internal consistency
Miller	2001	11588750 (sample 1)	below knee (72%), above knee (28%)	Vascular (55%), nonvascular 45%)	58		55	PEQ	(ambulation and transfer)		Reliability	Test-retest
Miller	2001	11588750 (sample 1)	below knee (72%), above knee (28%)	Vascular (55%), nonvascular 45%)	58		60	PEQ	(ambulation and transfer)		Validity	Convergent validity

				Timepoint			Steamath of			
Author	Year	PMID	ome	(predictive valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Autioi	i cai	r with	ome	vanu)	Metric Osec	value	rioperty	Supported	Conclusion	Notes/Caveals
									The Prosthetic Evaluation	
									Questionnaire - Mobility differed	
			Walking distance <1 block						between Walking distance <1	
Miller	2000		vs unlimited		Effect size	1.08		Yes	block and unlimited	
									The Prosthetic Evaluation	
									Questionnaire - Mobility differed	
Miller	2000				Effect size	1.00		Vee	between Automatic walking and	
willer	2000		Automatic waiking yes vs no		Ellect Size	1.32		res	no automatic waiking	
									The Prosthetic Evaluation	
									Questionnaire - Mobility	
									displayed Moderate correlation	
Miller	2000		Two minute walk test		Pearson r	0.5	Moderate	Yes	with the Two minute walk test	
									The Prosthetic Evaluation	
									Questionnaire - Mobility	
									displayed Moderate correlation	
Miller	2000		Timed up and go		Pearson r	-0.5	Moderate	Yes	with the Timed up and go	
									The Prosthetic Evaluation	
									Questionnaire - Mobility	
			A di dia ana dia Dalama						displayed Large correlation with	
Millor	2000		Activities-specific Balance		Booroop r	0.92	Lorgo	Voc	the Activities-specific Balance	
willer	2000		Confidence		realson	0.62	Laige	res	The Breathetic Evoluction	
									Questionnaire - Mobility	
									displayed Large correlation with	
			Activities-specific Balance						the Activities-specific Balance	
Miller	2000		Confidence		Pearson r	0.85	Large	Yes	Confidence	
							-			
									There was no indication of floor	
Miller	2000		nd		%	0.6		No	effect	
									There was no indication of floor	
Miller	2000		nd		0/_	0.3		No	effect	
WINCI	2000		10		70	0.0		140	Circor	
									The score displayed an	
									excelent internal Consistency	
					Cronbach's				based on Cronbach's alpha	
Miller	2000		nd		alpha	0.95	Excellent	Yes	value	
									The Prosthetic Evaluation	
									Questionnaire score displayed	
N 410	0000				100	0.77	0		an good Test-retest reliability	
wniiei	2000		nu		etandardized	0.77	GUUU	185	Dased on the ICC Value	
	1				regression					
Miller	2001	11552197	Falling		coefficient	-0.037				not statistically significant
	2001		9		standardized	5.00.	1	1		
	1				regression			1		
Miller	2001	11552197	fear of falling		coefficient	0.012				not statistically significant
-					standardized					
			ABC scale (balance		regression					
Miller	2001	11552197	confidence)		coefficient	0.723				statistically significant
	1									
	1							1		
N 410	0004	11588750			% at floor or					O allian affect (as all all a flags affects)
willer	2001	(sample 1)	INA		cening	0		TES		Centry enect (negligible floor effects)
	1	11588750			Cronbach					
Miller	2001	(sample 1)			Alpha	0.95	excellent			55/60 were stable
	2001	(Sample I)			, sprid	0.00	CAGGINGTIL	1		
	1	11588750				0.77 (0.62.				
Miller	2001	(sample 1)			ICC (95% CI)	0.85)		1		55/60 were stable
	1	. ,			. ,					
	1	11588750			2 minute walk					
Miller	2001	(sample 1)			test	correlation	0.5	1		

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
			1		J.				Mobility			
		11588750	below knee (72%),	Vascular (55%),					(ambulation			
Miller	2001	(sample 1)	above knee (28%)	nonvascular 45%)	58		60	PEQ	and transfer)		Validity	Convergent validity
		11588750	below knee (72%)	Vascular (55%)					MODIIIty			
Miller	2001	(sample 1)	above knee (28%)	nonvascular 45%)	58		60	PEQ	and transfer)		Validity	Convergent validity
		X F - 7							Mobility			
		11588750	below knee (72%),	Vascular (55%),					(ambulation			
Miller	2001	(sample 1)	above knee (28%)	nonvascular 45%)	58		60	PEQ	and transfer)		Validity	Convergent validity
									Mobility		effects	
		11588750	below knee (74%),	Vascular (53%),					(ambulation		(appropriaten	
Miller	2001	(sample 2)	above knee (26%)	nonvascular 47%)	60		329	PEQ	and transfer)	Ability to measure change	ess)	
		11588750	below knee (74%)	Vaccular (53%)					MODIlity (ambulation			
Miller	2001	(sample 2)	above knee (26%)	nonvascular 47%)	60		329	PEQ	and transfer)		Validity	Construct (discriminant)
		X F - 7							Mobility			
		11588750	below knee (74%),	Vascular (53%),					(ambulation			
Miller	2001	(sample 2)	above knee (26%)	nonvascular 47%)	60		329	PEQ	and transfer)		Validity	Convergent validity
		11588750	below knee (74%)	Vascular (53%)					MODIlity			
Miller	2001	(sample 2)	above knee (26%)	nonvascular 47%)	60		329	PEQ	and transfer)		Validity	Convergent validity
				Peripheral vascular					,			
				disease and/or								
			Unilateral transfemora	I diabetes (35%),					mehilik (
			transtibial (36%)	Tumour and other					modified			
Franchignoni	2007	17351696	Bilateral (11%)	(9%)	54		123	PEQ	(MS12/5)		Reliability	Internal consistency
				Peripheral vascular								
				disease and/or								
			Unilateral transfemora	I diabetes (35%),					mobility			
			transtibial (36%).	Tumour and other					modified			
Franchignoni	2007	17351696	Bilateral (11%)	(9%)	54		123	PEQ	(MS12/5)		Reliability	Item seperation reliability
				Peripheral vascular								
				disease and/or								
			(53%) Unilateral	Trauma (56%)					mobility			
			transtibial (36%),	Tumour and other					modified			
Franchignoni	2007	17351696	Bilateral (11%)	(9%)	54		123	PEQ	(MS12/5)		Reliability	Person separation reliability
				Peripheral vascular								
			I Inilateral transfemora	disease and/or								
			(53%). Unilateral	Trauma (56%).					mobility			
			transtibial (36%),	Tumour and other					modified			
Franchignoni	2007	17351696	Bilateral (11%)	(9%)	54		123	PEQ	(MS12/5)		Validity	Convergent
			Transfemoral (52%);						Demois and			
Resnik	2011		through knee (5%); transtibial (43%)		66	unilateral	44	PEO	response		effect	Appropriateness
			Transfemoral (52%);	1			1		. 3000100		Minimal	- FEIOPIIGCOIOGO
1			through knee (5%);						Perceived		Detectible	
Resnik	2011		transtibial (43%)		66	unilateral	44	PEQ	response		Change	MDC90
1			through knee (5%);						Perceived			
Resnik	2011		transtibial (43%)		66	unilateral	44	PEQ	response		Reliability	Test-retest
			Transfemoral (25%),	Trauma (67%),								
			transtibial (63%),	Chronic disease								
	1000		through knee (3%),	(41%), Congenital	40%		00	DEO	Perceived		Floor/ceiling	Annensistanaaa
Legiu	1990		Transfemoral (25%)	Trauma (67%)	+0% UVEL OUY		32	1 L Q	responses		CIICUL	Appropriateriess
1			transtibial (63%),	Chronic disease								
1			through knee (3%),	(41%), Congenital					Perceived		L	
Legro	1998		Symes (9%)	(3%), Tumor (1%)	40% over 60y		92	PEQ	responses		Reliability	Test-retest
1			ranstemoral (25%), transtibial (63%)	i rauma (67%), Chronic disease								
			through knee (3%).	(41%), Congenital					Perceived			
Legro	1998		Symes (9%)	(3%), Tumor (1%)	40% over 60y		92	PEQ	responses		Reliability	Internal consistency
			Transfemoral (25%),	Trauma (67%),								
			transtibial (63%),	Chronic disease					Borooivod			Construct (known groups /
Learo	1998		Symes (9%)	(3%), Tumor (1%)	40% over 60v		92	PEQ	responses		Validitv	subaroups)
- 3	1.230	1	- ,== (= ,0)	,, ·		1	11 T				,	

			Comparator/Criterion/Outo	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
		11588750			Timed up and					
Miller	2001	(sample 1)			go (TUG)	correlation	-0.5			
		` · · ·			Ŭ ()					
N 4111	0004	11588750			400		0.00			
Miller	2001	(sample 1)			ABC scale	correlation	0.82			
		11588750								
Miller	2001	(sample 1)			LCI	correlation	0.77			
		11588750			% at floor or					
Miller	2001	(sample 2)	NA		ceiling	10		Yes		Ceiling effect (negligible floor effects)
			by: amputation level,;							
		11588750	amputation cause; mobility		differences between levels					Only not statistically significant difference:
Miller	2001	(sample 2)	automatic walking		of factors	see notes				the knee
Millor	2001	11588750 (comple 2)	APC apple		correlation	0.95				
winier	2001	(sample z)	ADC Scale		correlation	0.85				
		11588750								
Miller	2001	(sample 2)	LCI		correlation	0.83				
E	0007	17054000				Chronbach	0.00			
Franchighoni	2007	17351696				Alpna	0.96			
						Basch Itom				
Franchignoni	2007	17351696				seperation	0.98			
						Rasch				
						Person				
Franchignoni	2007	17351696				seperation	0.95			
Franchianoni	2007	17251606			Spearman r	0.79				Spoormone: I CI E=0.78
Franchighoni	2007	17351090	101		Spearmann	0.76				Spearmans. LCI-5-0.78
					% at the floor					
Resnik	2011				or ceiling	0				
Resnik	2011		NA		MDC90	0.9				
Pesnik	2011		NA			0.41 (0.13,				
1 COTINC	2011				100 (00 % 01)	0.00)				
	1000				% at the floor	17		No		max of floor or ceiling proportion (not all
Legio	1990				or centry	17		NO		
										among 61/92 people who did no have majo
	1000				100 (05% 01)	0.56 (0.36,				change in health or prosthesis and did the
Legro	1998		INA		ICC (95% CI)	0.71)				retest
					Chronbach					
Legro	1998		NA		Alpha	0.89	excellent			
			comorbidities (any):		difference in					
			amputation level; years		PEQ (subscale					no statistically significant differences in any
Legro	1998		since amputation		score))	see notes				factor

			Amputation		Other Population						
Author	Year PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
		Transfemoral (52%);									
Resnik	2011	through knee (5%); transtibial (43%)		66	unilateral	44	PEO	Prostnesis		Floor/ceiling	Annronriateness
	2011	Transfemoral (52%);			amatora			dunty		Minimal	Appropriatorioco
		through knee (5%);					550	Prosthesis		Detectible	10000
Resnik	2011	transtibial (43%) Transfemoral (52%)		66	unilateral	44	PEQ	utility		Change	MDC90
		through knee (5%);						Prosthesis			
Resnik	2011	transtibial (43%)	T (070()	66	unilateral	44	PEQ	utility		Reliability	Test-retest
		Transfemoral (25%), transfibial (63%).	Trauma (67%), Chronic disease								
		through knee (3%),	(41%), Congenital					Residual limb		Floor/ceiling	
Legro	1998	Symes (9%)	(3%), Tumor (1%)	40% over 60y		92	PEQ	health		effect	Appropriateness
		Transfemoral (25%), transfibial (63%)	Trauma (67%), Chronic disease								
		through knee (3%),	(41%), Congenital					Residual limb			
Legro	1998	Symes (9%)	(3%), Tumor (1%)	40% over 60y		92	PEQ	health		Reliability	Test-retest
		transferioral (25%),	Chronic disease								
		through knee (3%),	(41%), Congenital					Residual limb			
Legro	1998	Symes (9%)	(3%), Tumor (1%)	40% over 60y		92	PEQ	health		Reliability	Internal consistency
		transtemoral (25%),	Chronic disease								
		through knee (3%),	(41%), Congenital					Residual limb			Construct (known groups /
Legro	1998	Symes (9%)	(3%), Tumor (1%)	40% over 60y		92	PEQ	health		Validity	subgroups)
		through knee (5%):						Residual limb		Floor/ceiling	
Resnik	2011	transtibial (43%)		66	unilateral	44	PEQ	health		effect	Appropriateness
		Transfemoral (52%);						De statuet Bask		Minimal	
Resnik	2011	through knee (5%); transtibial (43%)		66	unilateral	44	PEQ	Residual limb		Change	MDC90
	2011	Transfemoral (52%);			amatora			noulin		onango	1112000
Deenik	2011	through knee (5%);		66	unilataral		DEO	Residual limb		Deliability	Test retest
Resnik	2011	Transfemoral (25%)	Trauma (67%).	00	unilateral	44	PEQ	neaith		Reliability	Test-Telest
		transtibial (63%),	Chronic disease								
1.0000	1000	through knee (3%),	(41%), Congenital	40%		02	DEO	Cosial hundar		Floor/ceiling	Annenziatanaaa
Legio	1990	Transfemoral (25%).	(3%), Tuffor (1%) Trauma (67%).	40% Over 60y		92	PEQ	Social burden		eneci	Appropriateriess
		transtibial (63%),	Chronic disease								
Logro	1009	through knee (3%),	(41%), Congenital	40% over 60v		02	REO	Social burdon		Boliobility	Test retest
Legio	1990	Transfemoral (25%).	(3%), Tullior (1%) Trauma (67%).	40% Over 60y		92	FEQ	Social burden		Reliability	Test-Telest
		transtibial (63%),	Chronic disease								
Logro	1009	through knee (3%),	(41%), Congenital	40% over 60v		02	REO	Social burdon		Boliobility	Internal consistency
Legio	1990	Transfemoral (25%),	Trauma (67%),	40% Over 60y		92	FEQ	Social burden		Reliability	Internal consistency
		transtibial (63%),	Chronic disease								
Legro	1008	through knee (3%), Symes (9%)	(41%), Congenital	40% over 60v		02	PEO	Social burden		Validity	Criterion
Legio	1990	Transfemoral (25%),	Trauma (67%),	40 /0 0001 009		52		Social burgeri		validity	Citteriori
		transtibial (63%),	Chronic disease								
Learo	1998	through knee (3%), Symes (9%)	(41%), Congenital (3%), Tumor (1%)	40% over 60v		92	PEQ	Social burden		Validity	Construct (known groups /
Logio	1000	Transfemoral (25%),	Trauma (67%),	4070 0001 009		52	i Lo			validity	Subgroups)
		transtibial (63%),	Chronic disease								
Learo	1998	through knee (3%), Symes (9%)	(41%), Congenital (3%), Tumor (1%)	40% over 60v		92	PEO	Social burden		Validity	Criterion
Logio	1000	Transfemoral (52%);	(070), Tullior (170)	4070 0001 009		52	i Lo	oocial barden		validity	ontenon
		through knee (5%);								Floor/ceiling	
Resnik	2011	transtibial (43%) Transfemoral (52%):		66	unilateral	44	PEQ	Social burden		effect Minimal	Appropriateness
		through knee (5%);								Detectible	
Resnik	2011	transtibial (43%)		66	unilateral	44	PEQ	Social burden		Change	MDC90
		Transtemoral (52%);									
Resnik	2011	transtibial (43%)		66	unilateral	44	PEQ	Social burden		Reliability	Test-retest
		Transfemoral (25%),	Trauma (67%),								
		transtibial (63%), through knee (3%)	(41%). Congenital							Floor/ceiling	
Legro	1998	Symes (9%)	(3%), Tumor (1%)	40% over 60y		92	PEQ	Sounds		effect	Appropriateness

			Comparator/Criterion/Outc	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Resnik	2011				% at the floor	0				
	2011				or coming	0				
Resnik	2011		NA		MDC90	1.2				
Resnik	2011		NA		ICC (95% CI)	0.79 (0.64, 0.88)				
Legro	1998				% at the floor or ceiling	2		Yes		max of floor or ceiling proportion (not all scales in the same directin)
						0.79 (0.68,				among 61/92 people who did no have majo change in health or prosthesis and did the
Legro	1998		NA		ICC (95% CI)	0.86)				retest
Learo	1998		NA		Chronbach Alpha	0.8	excellent			
-5-			by: gender; age group; comorbidities (any); amputation level; years		difference in PEQ (subscale					statistically significant difference only by
Legro	1998		since amputation		score))	see notes				age group (older had higher PEQ scores)
Resnik	2011				% at the floor or ceiling	0				
Resnik	2011		NA		MDC90	0.8				
Resnik	2011		NA		ICC (95% CI)	0.93 (0.88, 0.96)				
Legro	1998				% at the floor or ceiling	10		Yes		max of floor or ceiling proportion (not all scales in the same directin)
						0.81 (0.69,				among 61/92 people who did no have majo change in health or prosthesis and did the
Legro	1998		NA		ICC (95% CI)	0.88)				retest
					Chronbach					
Legro	1998		NA		Alpha	0.83	excellent			
1	1000					0.50				negative correlation because the direction
Legio	1990		by: gender; age group;		correlation	-0.52				or the scales is opposite
			comorbidities (any); amputation level; years		difference in PEQ (subscale					statistically significant difference only by
Legro	1998		since amputation		score))	see notes				gender (higher in women)
Legro	1008		SE 36 social function		correlation	0.59				
Legio	1550				Correlation	0.55				
Resnik	2011				% at the floor or ceiling	0				
Resnik	2011		NA		MDC90	1.4				
						0.64 (0.43,				
Resnik	2011	+	NA		ICC (95% CI)	0.79)				
					% at the floor					max of floor or ceiling proportion (not all
Legro	1998				or ceiling	10		Yes		scales in the same directin)

				Ammutation		Other Denulation						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
			Transfemoral (25%),	Trauma (67%),	<u> </u>							
			transtibial (63%),	Chronic disease								
Legro	1998		Symes (9%)	(3%), Tumor (1%)	40% over 60y		92	PEQ	Sounds		Reliability	Test-retest
-			Transfemoral (25%),	Trauma (67%),								
			transtibial (63%),	Chronic disease								
Legro	1998		Symes (9%)	(3%), Tumor (1%)	40% over 60y		92	PEQ	Sounds		Reliability	Internal consistency
			Transfemoral (25%),	Trauma (67%),								
			transtibial (63%),	Chronic disease								Construct (known groups /
Legro	1998		Symes (9%)	(3%), Tumor (1%)	40% over 60y		92	PEQ	Sounds		Validity	subgroups)
			Transfemoral (52%);									
Resnik	2011		through knee (5%); transtibial (43%)		66	unilateral	44	PEQ	Sounds		Floor/ceiling effect	Appropriateness
rtooniit	2011		Transfemoral (52%);			amatora			oounuo		Minimal	, ppropriatorioco
Deserile	0011		through knee (5%);					550	0		Detectible	NDOOD
Resnik	2011		Transfemoral (52%):		66	unilateral	44	PEQ	Sounds		Change	MDC90
			through knee (5%);									
Resnik	2011		transtibial (43%)		66	unilateral	44	PEQ	Sounds		Reliability	Test-retest
			through knee (5%);								Floor/ceiling	
Resnik	2011		transtibial (43%)		66	unilateral	44	PEQ	Transfer		effect	Appropriateness
			Transfemoral (52%);								Minimal Detectible	
Resnik	2011		transtibial (43%)		66	unilateral	44	PEQ	Transfer		Change	MDC90
			Transfemoral (52%);									
Resnik	2011		through knee (5%); transtibial (43%)		66	unilateral	44	PEO	Transfer		Reliability	Test-retest
rtooniit	2011		Transfemoral (25%),	Trauma (67%),		amatorar			Tranoloi		rtondonity	
			transtibial (63%),	Chronic disease							Electric elliste	
Learo	1998		through knee (3%), Symes (9%)	(41%), Congenital (3%), Tumor (1%)	40% over 60v		92	PEQ	Transfers		effect	Appropriateness
- 5 -			Transfemoral (25%),	Trauma (67%),			-					
			transtibial (63%),	Chronic disease								
Legro	1998		Symes (9%)	(3%), Tumor (1%)	40% over 60y		92	PEQ	Transfers		Reliability	Test-retest
-			Transfemoral (25%),	Trauma (67%),								
			transtibial (63%),	(41%) Concenital								
Legro	1998		Symes (9%)	(3%), Tumor (1%)	40% over 60y		92	PEQ	Transfers		Reliability	Internal consistency
			Transfemoral (25%),	Trauma (67%),								
			transtibial (63%), through knee (3%).	(41%). Congenital								Construct (known groups /
Legro	1998		Symes (9%)	(3%), Tumor (1%)	40% over 60y		92	PEQ	Transfers		Validity	subgroups)
			Transfemoral (25%),	Trauma (67%),								
			through knee (3%).	(41%), Congenital							Floor/ceiling	
Legro	1998		Symes (9%)	(3%), Tumor (1%)	40% over 60y		92	PEQ	Usefulness		effect	Appropriateness
			Transfemoral (25%), transtibial (63%)	Trauma (67%), Chronic disease								
			through knee (3%),	(41%), Congenital								
Legro	1998		Symes (9%)	(3%), Tumor (1%)	40% over 60y		92	PEQ	Usefulness		Reliability	Test-retest
			Transfemoral (25%), transtibial (63%)	Trauma (67%), Chronic disease								
			through knee (3%),	(41%), Congenital								
Legro	1998		Symes (9%)	(3%), Tumor (1%)	40% over 60y		92	PEQ	Usefulness		Reliability	Internal consistency
			Transfemoral (25%), transtibial (63%)	Trauma (67%), Chronic disease								
			through knee (3%),	(41%), Congenital								Construct (known groups /
Legro	1998		Symes (9%)	(3%), Tumor (1%)	40% over 60y		92	PEQ	Usefulness		Validity	subgroups)
			transtibial (63%),	Chronic disease								
			through knee (3%),	(41%), Congenital							Floor/ceiling	
Legro	1998	+	Symes (9%)	(3%), Tumor (1%)	40% over 60y		92	PEQ	Well being		effect	Appropriateness
			transtibial (63%),	Chronic disease								
1.			through knee (3%),	(41%), Congenital				250				
Legro	1998	1	Symes (9%)	((3%), Tumor (1%)	40% over 60y	1	92	IFEQ	vvell being		Reliability	i est-retest

			Comparator/Criterion/Outc	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Legro	1998		NA		ICC (95% CI)	0.84 (0.75, 0.90)				among 61/92 people who did no have major change in health or prosthesis and did the retest
Learo	1998		NA		Chronbach	0.78	adequate			
Legio	1000		by: gender; age group; comorbidities (any); amputation level; years		difference in PEQ (subscale	0.70				no statistically significant differences in any
Legro	1998		since amputation		score))	see notes				factor
Resnik	2011				or ceiling	0				
Resnik	2011		NA		MDC90	1.7				
Resnik	2011		NA		ICC (95% CI)	0.79 (0.65, 0.88)				
Resnik	2011				% at the floor or ceiling	27				ceiling effect only
Resnik	2011		NA		MDC90	1.3				
Resnik	2011		NA		ICC (95% CI)	0.75 (0.59, 0.86)				
Legro	1998				% at the floor or ceiling	25		No		max of floor or ceiling proportion (not all scales in the same directin)
Legro	1008		NA			0.73 (0.58,				among 61/92 people who did no have major change in health or prosthesis and did the retest
Logio	1000				Chronbach	0.00)				
Legro	1998		NA		Alpha	0.47	poor			
Legro	1998		comorbidities (any); amputation level; years since amputation		difference in PEQ (subscale score))	see notes				no statistically significant differences in any factor
Legro	1998				% at the floor or ceiling	2		Yes		max of floor or ceiling proportion (not all scales in the same directin)
Learo	1998		NA		ICC (95% CI)	0.86 (0.78, 0.91)				among 61/92 people who did no have major change in health or prosthesis and did the retest
Logio	1000				Chronbach	0.01)				
Legro	1998		NA		Alpha	0.89	excellent			
Legro	1998		by: gender; age group; comorbidities (any); amputation level; years since amputation		difference in PEQ (subscale score))	see notes				no statistically significant differences in any factor
Legro	1998				% at the floor or ceiling	8		Yes		max of floor or ceiling proportion (not all scales in the same directin)
Legro	1002		NA		JCC (95% C1)	0.89 (0.80,				among 61/92 people who did no have major change in health or prosthesis and did the
Logio	1990	1	1973	1		0.00)	1	1	1	101001

			Amputation		Other Population						
Author	Year	PMID Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
		Transfemoral (25%),	Trauma (67%),								
		transtibial (63%),	Chronic disease								
Learo	1998	Symes (9%)	(3%), Tumor (1%)	40% over 60v		92	PEQ	Well being		Reliability	Internal consistency
		Transfemoral (25%),	Trauma (67%),					J			
		transtibial (63%),	Chronic disease								
	1000	through knee (3%),	(41%), Congenital	100/			PE0			V - II all to a	Oritorio
Legro	1998	Transfermoral (25%)	(3%), Tumor (1%) Trauma (67%)	40% over 60y		92	PEQ	weil being		validity	Criterion
		transtibial (63%),	Chronic disease								
		through knee (3%),	(41%), Congenital								Construct (known groups /
Legro	1998	Symes (9%)	(3%), Tumor (1%)	40% over 60y		92	PEQ	Well being		Validity	subgroups)
Ferreiro	1994						PEQ	Well-being		Reliability	Internal consistency
Legro et al	1998						PEQ	Well-being		Reliability	Internal consistency
Legro, et al	1998						PEQ	Well-being		Validity	Face/content
La sura start	4000						DEO			V - II all to a	Concurrent/convergent
Legro, et al	1998	Transformeral (52%)					PEQ	weil-being		validity	criterion
		through knee (5%);								Floor/ceiling	
Resnik	2011	transtibial (43%)		66	unilateral	44	PEQ	Well-being		effect	Appropriateness
		Transfemoral (52%);								Minimal	
Decesily.	0011	through knee (5%);					PE0			Detectible	MDOOD
Resnik	2011	Transfemoral (52%):		00	umaterai	44	PEQ	weii-beirig		Change	MDC90
		through knee (5%);									
Resnik	2011	transtibial (43%)		66	unilateral	44	PEQ	Well-being		Reliability	Test-retest
Resnik & Borgia	2011						PEQ	Well-being		Reliability	Test-retest
										Ability to	
Resnik & Borgia.	2011						PEQ	Well-being		change	Floor/ceiling effects
								Ŭ	The questionnaire included questions on	Ŭ	
									demographic variables (age, gender, marital		
									status, level of education), reason for		
									addition, several questions concerned use		
van de Weg	2005	16466153 Transtibial	nd	62.1		220	PEQ, modified	Problems	maintenance, and durability of the prosthesis	Reliability	Internal Consistency
									The questionnaire included questions on		
									demographic variables (age, gender, marital		
									status, level of education), reason for		
									addition, several questions concerned use.		
van de Weg	2005	16466153 Transtibial	nd	62.1		220	PEQ, modified	Satisfaction	maintenance, and durability of the prosthesis	Reliability	Internal Consistency
								Physical			
Hart	1999						PF-10	functioning		Reliability	Internal consistency
								Physical			
Hart	1999						PF-10	functioning		Validity	Known group/Discriminant
Hart	1999						PF-10	functioning		Validity	a Validity criterion
										Ability to	
								Physical		measure	Floor/ceiling effects
Hart	1999	<u> </u>					PF-10	functioning		change	(appropriateness)
Hart	1999			1			PF-15	functioning		Reliability	Internal consistency
	1000	1 1		1		-		Physical		. tonability	
Hart	1999						PF-15	functioning		Validity	Construct
										Ability to	
Hort	1000			1			DE 16	Physical		measure	Floor/ceiling effects
i iai t	1999	1		1	1	1	11-13	rancioning		unange	(appropriateriess)

			Comparator/Criterion/Outc	(predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
					Chronbach					
Legro	1998		NA		Alpha	0.87	excellent			
										negative correlation because the direction
Legro	1998		POMS-sf: total score		correlation	-0.49				of the scales is opposite
			by: gender; age group;							
			comorbidities (any);		difference in					
			amputation level; years		PEQ (subscale	•				no statistically significant differences in any
Legro	1998		since amputation		score))	see notes				factor
Ferreiro	1994				ICC	0.72				0.00
Legro et al	1998									0.89
Legro et al	1998									0.87
Laws shall	1000									Formative research supports content
Legro, et al	1998									validity
Leave stal	1000									moderate, negative correlation with Profile
Legro, et al	1990									of mood state.
					0/ -1 11 8					
Deenik	2011				% at the floor	24				seiling offect only
Resnik	2011				or celling	34				centrig effect only
Peenik	2011		NA		MDC00	1.4				
I Collin	2011				IVIDC30	1.4				
						0 70 (0 51				
Resnik	2011		NA		ICC (95% CI)	0.82)				
Resnik & Borgia	2011				100 (00 /0 01)	0.02)				0.7
r toornit a Dorgia	2011									
Resnik & Borgia,	2011									Strong ceiling effects, no floor effect
									There is sufficient evidence of	
					Cronbach's				Internal Consistency for the	
van de Weg	2005	16466153	nd		alpha	0.76	Adequate	Yes	PEQ-problems subscale	
									There is sufficient evidence of	
					Cronbach's				Internal Consistency for the	
van de Weg	2005	16466153	nd		alpha	0.88	Excellent	Yes	PEQ-satisfaction subscale	
					Chronbach					
Hart	1999				Alpha					0.91
										differentiated between Durable medical
										equipment regional carriers (DMERC)
										functional levels, between AK and BK
										amputations, and between younger(<60)
Hart	1999									and older (>60) clients
										Pearsons with Role physical=0.50 and 0.63
Hart	1999									at initial fitting and follow-up
										and a loss of the second second second
Llast	1000									none of less ceiling effect compared to PF-
нап	1999				Chronbooh					15
Hart	1000				Alpha					0.89
	1000	+			, upria		-			demonstrated clinically logical hierarchical
Hart	1999									ordering.
		1	1		1	1	1	1	1	
										slight ceiling effect for PF-15 compared to
Hart	1999									PF=10

Author	Year	PMID Amputatio	n Level	Amputation Etiology	Age	Other Population	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	Transfemor Transtibial Through-kn	al (22%), 77%), ee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Climb stairs	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Floor/ceiling effect	Ceiling
Cvril	2001	Transfemor Transtibia (Through 2	al (22%), 77%), ee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amoutations were excluded	107	PFI	Climb stairs	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 h, 50 h, 25 h, and 10 b object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	Transfemor Transtibial Through-kn	al (22%), 77%), ee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Climb stairs	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	Transfemor Transtibial Through-kn	al (22%), 77%), ee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Climb stairs	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of fatairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct

			Comparator/Criterion/Outc	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
o "										
Cyril	2001		nd		%	16.8		Yes		
										3 Month Eurocional Scale Scores, P. value
Cyril	2001		Transtibial vs Transfemoral		Р	>0.05		No		based on Mann-Whitney U
o "			100.0		_					3-Month Functional Scale Scores. P-value
Cyril	2001		ISS Score <13 vs >=13		Р	>0.05		NO		based on Mann-Whitney U
										3-Month Functional Scale Scores, P-value
Curil	2001	1	Age <35 ve >=35		D			Vec		based on Mann Whitney II

				Amputation	Other Population						
Author	Year	PMID	Amputation Level	Etiology Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd 35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Climb stairs	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cvril	2001		Transfemoral (22%), Transtbial (77%), Through-knee (11%)	nd 35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Climb stairs	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 h, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd 35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Climb stairs	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of fstairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd 35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Climb stairs	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct

				Comparator/Criterion/Outc	Timepoint (predictive			Strength of	Is Aspect		
Aut	hor	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
											3-Month Functional Scale Scores. P-value
Cyri	1	2001		Comorbidities yes vs no		Р	>0.05		No		based on Mann-Whitney U
											12-Month Functional Scale Scores. P-value
Cyri	I	2001		Transtibial vs Transfemoral		Р	>0.05		No		based on Mann-Whitney U
											12-Month Functional Scale Scores, P-value
Cyri	I	2001		ISS Score <13 vs >=13		Р	>0.05		No		based on Mann-Whitney U
1											
1											
1											
1											12-Month Functional Scale Scores P-value
Cyri	1	2001		Age <35 vs >=35		Р	>0.05		No		based on Mann-Whitney U

			Ar	mputation		Other Population						
Author	Year	PMID Amputation	.evel Et	tiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	Transfemoral Transtibial (7: Through-knee	(22%), %), (11%) nd	d	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Climb stairs	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	Transfemoral Transtibial (77 Through-knee	(22%), %), (11%) nd	d	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Climb stairs	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 fights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion
Cyril	2001	Transfemoral Transtibial (7 Through-knee	(22%), %), (11%) nd	d	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Climb stairs	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion
Cyril	2001	Transfemoral Transtibial (7 Through-knee	(22%), %), (11%) nd	d	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Climb stairs	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion

			Comparator/Criterion/Outo	Interpoint			Strongth of	le Asnact		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Cyril	2001		Comorbidities yes vs no		ρ	>0.05		No		12-Month Functional Scale Scores. P-value based on Mann-Whitney U
Cyril	2001		Normal Walking Speed (Yes vs No)		Pearson r	-0.39	Moderate	Yes		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 150 foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.
Cyril	2001		Walking Speed (continuous score)		Pearson r	0.41	Moderate	Yes		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 150 foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.
Cyril	2001		Return to Usual Activity (Yes vs No)		Pearson r	-0.15	Small	Unclear		Return to usual activity by 12 months after injury. Respondents reported their major activity at baseline and all subsequent follow-up periods (defined as working, laid off, looking for work, school, keeping house, retired, and other). Returning to one's usual activity was defined as resuming the same activity or to an activity o f equal or greater productivity

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Climb stairs	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) nun at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flighto 1 stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Floor/ceiling effect	Floor
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Climb stairs	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 h, 50 h, 25 hb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Reliability	Internal Consistency
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Climb stairs	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Responsiven	nd
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Climb stairs	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of fstairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Responsiven	nd

			Comparator/Criterion/Outc	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Cyril	2001		nd		%	41.1		Yes		
,										
Cvril	2001		nd		Cronbach's	0.78	Adequate	Ves		
Oyin .	2001		ing .		alpha	0.70	Adequate	105		
Curil	2001		nd		SDM	0.74				Effect Size Statistics for Change in Scores
Cym	2001		nu		SRIVI	0.74				Detween 5 and 12 Months
0	2004		ad		Effect size with	0.70				Effect Size Statistics for Change in Scores

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Run at steady pace	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores anged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Floor/ceiling effect	Ceiling
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Run at steady pace	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Run at steady pace	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 b object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Run at steady pace	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 b object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct

			Comparator/Criterion/Outc	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Cvril	2001		nd		%	85		Yes		
0,1	2001				<i>,</i> ,,					
										3-Month Functional Scale Scores. P-value
Cyril	2001		Transtibial vs Transfemoral		Р	>0.05		No		based on Mann-Whitney U
Curil	2001		ISS Sooro <12 vo >=12		D	>0.05		No		3-Month Functional Scale Scores. P-value
Cyn	2001		100 00010 110 10 2 - 10		1	-0.05		NO		based on Mann-Whitney o
										3-Month Functional Scale Scores. P-value
Curil	2001	1	Add <35 ve >=35		D	N 05		No	1	based on Menn Whitney II

					Amputation	Other Population						
Aut	thor	Year	PMID	Amputation Level	Etiology Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cyr	1	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd 35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Run at steady pace	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyr	11	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd 35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Run at steady pace	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 b object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of fatairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyr	11	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd 35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Run at steady pace	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 b object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of fatairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
	1	2001		Transfemoral (22%), Transtibial (77%), Through knee (11%)	nd 35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were avoluted	107	PEI	Run at steady	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged for 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct

				Comparator/Criterion/Outc	Timepoint (predictive			Strength of	Is Aspect		
Aut	hor	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
											3-Month Functional Scale Scores. P-value
Cyri	1	2001		Comorbidities yes vs no		Р	>0.05		No		based on Mann-Whitney U
											12-Month Functional Scale Scores. P-value
Cyri	I	2001		Transtibial vs Transfemoral		Р	>0.05		No		based on Mann-Whitney U
											12-Month Functional Scale Scores, P-value
Cyri	I	2001		ISS Score <13 vs >=13		Р	>0.05		No		based on Mann-Whitney U
1											
1											
1											
1											12-Month Functional Scale Scores P-value
Cyri	1	2001		Age <35 vs >=35		Р	>0.05		No		based on Mann-Whitney U

				Amputation	Other Population						
Author	Year	PMID	Amputation Level	Etiology Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001		Transfemoral (22%), Transtbial (77%), Through-knee (11%)	nd 35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Run at steady	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd 35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Run at steady pace	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd 35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Run at steady pace	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion
Coril	2004		Transfemoral (22%), Transtibial (77%), Through kees (19%)	nd 35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PEI	Run at steady	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 h, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of 1 mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion

			Comparator/Criterion/Outc	Interpoint			Strength of	le Asnact		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Cyril	2001		Comorbidities yes vs no		P	>0.05		No		12-Month Functional Scale Scores. P-value based on Mann-Whitney U
Cvril	2001		Normal Walking Speed (Yes		Pearson r	-0.3	None	No		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 150 foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.
Cyril	2001		Walking Speed (continuous score)		Pearson r	0.37	Moderate	Yes		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 150 foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.
Cyril	2001		Return to Usual Activity (Yes vs No)		Pearson r	-0.26	Small	Unclear		Return to usual activity by 12 months after injury. Respondents reported their major activity at baseline and all subsequent follow-up periods (defined as working, laid off, looking for work, school, keeping house, retired, and other). Returning to one's usual activity was defined as resuming the same activity or to an activity o f equal or greater productivity

				Amputation		Other Population						
Author	Year	PMID Amputati	ion Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cvril	2001	Transfem Transtibia Through-1	noral (22%), al (77%), knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amoutations were excluded	107	PFI	Run at steady	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 fights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Floor/ceiling effect	Floor
Cyril	2001	Transfem Transtibia Through-1	noral (22%), al (77%), knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Run at steady pace	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Reliability	Internal Consistency
Cyril	2001	Transfem Transtibia Through-1	noral (22%), al (77%), knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Run at steady pace	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of fatairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Responsiven	nd
Curil	2004	Transfem Transtibia	noral (22%), al (77%), knee (11%)	od	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputatione were excluded	107	PEI	Squat to pick	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Floor/ceiling	Ceiling

			Comparator/Criterion/Outc	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Cyril	2001		nd		%	2.8		No		
					Cronbach's					
Cyril	2001		nd		alpha	0.87	Excellent	Yes		
										Effect Size Statistics for Change in Scores
Cyril	2001		nd		SRM	0.36				Between 3 and 12 Months
Cyril	2001		nd		%	36.4	1	Yes		

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Squat to pick up object	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores anged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Squat to pick up object	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object, (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Squat to pick up object	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 b object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of fatairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Squat to pick up object	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 b object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct

			Comparator/Critorion/Outo	Timepoint			Strongth of	la Acnost				
Author	Year	PMID	ome	(predictive valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats		
, latito				ranaj	incluie eccu	Fullo	Tropolity	Capperiout				
										3-Month Functional Scale Scores. P-value		
Cyril	2001		Transtibial vs Transfemoral		Р	>0.05		No		based on Mann-Whitney U		
·										,		
										3-Month Functional Scale Scores. P-value		
Cyril	2001		ISS Score <13 vs >=13		Р	>0.05		No		based on Mann-Whitney U		
					_					3-Month Functional Scale Scores. P-value		
Cyril	2001		Age <35 vs >=35		Р	<=0.05		Yes		based on Mann-Whitney U		
1												
1												
1												
1												
1												
1												
1												
1												
1			1							3-Month Functional Scale Scores Pavalue		
Cvril	2001		Comorbidities yes vs po		P	>0.05		No		based on Mann-Whitney U		
~,···	2001	1	00110101010100 900 900 10	1	I.	0.00	1		1	babba bir marin mininey o		
				Amputation		Other Population						
--------	------	------	---	------------	-----	--	-----	------------	----------------------------	---	----------	-----------
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Squat to pick up object	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores anged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Squat to pick up object	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object, (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Squat to pick up object	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 b object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of fatairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Squat to pick up object	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 b object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct

			Comparator/Criterion/Outc	Interpoint			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
					_					12-Month Functional Scale Scores. P-value
Cyrii	2001		Transtidial vs. Transfermoral		P	<=0.05		res		based on Mann-Whitney U
										12-Month Functional Scale Scores. P-value
Cyril	2001		ISS Score <13 vs >=13		P	>0.05		No		based on Mann-Whitney U
										12-Month Functional Scale Scores, P-value
Cyril	2001		Age <35 vs >=35		Р	>0.05		No		based on Mann-Whitney U
										12-Month Functional Scale Scores, Pavalue
Cyril	2001		Comorbidities yes vs no		Р	>0.05		No		based on Mann-Whitney U

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Squat to pick up object	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Squat to pick up object	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 b object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Squat to pick up object	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 b object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Squat to pick up object	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 b object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Floor/ceiling effect	Floor

			Comparator/Critorion/Quto	Imepoint			Strongth of			
Author	Year	PMID	ome	(predictive valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Cyril	2001		Normal Walking Speed (Yes vs No)		Pearson r	-0.53	Large	Yes		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 150- foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.
Cyril	2001		Walking Speed (continuous score)		Pearson r	0.46	Moderate	Yes		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 150- foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.
Cyril	2001		Return to Usual Activity (Yes vs No)		Pearson r	-0.18	Small	Unclear		Return to usual activity by 12 months after injury. Respondents reported their major activity at baseline and all subsequent follow-up periods (defined as working, laid off, looking for work, school, keeping house, retired, and other). Returning to one's usual activity was defined as resuming the same activity or to an activity o f equal or greater productivity
Cyril	2001		nd		%	8.4		Νο		

			Amputation		Other Population						
Author	Year	PMID Amputation Le	el Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cvril	2001	Transfemoral (2 Transtibial (77%) Through-knee (1%), , 1%) nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Squat to pick	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Reliability	Internal Consistency
Cyril	2001	Transfemoral (2 Transtibial (77% Through-knee (%), 1%) nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Squat to pick up object	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Responsiven	nd
Cyril	2001	Transfemoral (2 Transtibial (77% Through-knee (%), ∣,	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Squat to pick up object	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of fstairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Responsiven	nd
Curil	2001	Transfemoral (2 Transtibial (77%) Through Press (1%), , ,	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PEI	Total Overall	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) nun at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Floor/ceiling	Ceiling

			Comparator/Criterion/Outc	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
					Cronbach's					
Cyril	2001		nd		alpha	0.82	Excellent	Yes		
										Effect Size Statistics for Change in Scores
Cyril	2001		nd		SRM	0.55				Between 3 and 12 Months
					Effect size with					Effect Size Statistics for Change in Scores
Cyril	2001		nd		baseline SD	0.67				Between 3 and 12 Months
Cyril	2001		nd		%	12.1		No		

				Amputation		Other Population						
Author	Year	PMID A	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	1	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bileteral amputations were excluded	107	PFI	Total Overall Score	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 h, 50 h, 25 h, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores anged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	1	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Total Overall Score	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 b object, (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	1	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Total Overall Score	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Curil	2001		Transfemoral (22%), Transfibial (77%), Transbial (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations ware excluded	107	PEI	Total Overall	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by sumption all four category scores	Validity	Construct

				Timepoint			Strongth of			
Author	Year	PMID	ome	(predictive valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Aution	rear		onic	valiaj	Metho Oscu	Value	roperty	oupporteu.	Conclusion	Notes ouveats
										3-Month Functional Scale Scores. P-value
Cyril	2001		Transtibial vs Transfemoral		Р	>0.05		No		based on Mann-Whitney U
										0 Month Functional Ocale Ocare Busilia
Cvril	2001		ISS Score <13 vs >=13		D	>0.05		No		3-Month Functional Scale Scores. P-Value
Cyn	2001		100 00010 110 10 2 - 10			-0.05		NO		based on Mann-Wintney O
										3-Month Functional Scale Scores. P-value
Cyril	2001		Age <35 vs >=35		P	>0.05		No		based on Mann-Whitney U
1										
1										
1										3-Month Functional Scale Scores. P-value
Cyril	2001		Comorbidities yes vs no		Р	>0.05		No		based on Mann-Whitney U

				Amputation		Other Population						
Author	Year	PMID A	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	1	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bileteral amputations were excluded	107	PFI	Total Overall Score	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 h, 50 h, 25 h, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores anged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	1	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Total Overall Score	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 b object, (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	1	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Total Overall Score	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Curil	2001		Transfemoral (22%), Transfibial (77%), Transbial (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations ware excluded	107	PEI	Total Overall	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by sumption all four category scores	Validity	Construct

A			Comparator/Criterion/Outc	(predictive	M-1-1-11	N-1	Strength of	Is Aspect	O-maluation.	Notes (Osuante
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
					_					12-Month Functional Scale Scores. P-value
Cyril	2001		Transtibial vs Transfemoral		Р	>0.05		No		based on Mann-Whitney U
Curil	2001		188 80000 <12 10 >=12		Р	>0.05		No		12-Month Functional Scale Scores. P-value
Cym	2001				1	-0.03		NO		based on Mannewhitney o
Cvril	2001		Aae <35 vs >=35		Р	>0.05		No		12-Month Functional Scale Scores. P-value based on Mann-Whitney U
- ,			5							
Cvril	2001		Comorbidities ves vs po		P	>0.05		No		12-Month Functional Scale Scores. P-value

			Amputation		Other Population						
Author	Year	PMID Amputation Level	Etiology Ag	ge	Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd 35		High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Total Overall Score	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 h, 50 h, 25 h, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion
Cyril	2001	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd 35	i	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Total Overall Score	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion
Cyril	2001	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd 35		High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Total Overall Score	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion
Curil	2001	Transfemoral (22%), Transtibial (77%), Transtibial (77%),	nd 35		High energy lower extremity trauma patients. Foot amputation or bilateral amputations ware excluded	107	P51	Total Overall	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by cumpting all four optogen generate	Floor/ceiling	Floor

			Comparator/Critorion/Quito	Imepoint			Strongth of	la Aspect		
Author	Year	PMID	ome	(predictive valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Cyril	2001		Normal Walking Speed (Yes vs No)		Pearson r	-0.55	Large	Yes		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 150- foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.
Cyril	2001		Walking Speed (continuous score)		Pearson r	0.57	Large	Yes		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 150- foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.
Cyril	2001		Return to Usual Activity (Yes vs No)		Pearson r	-0.27	Small	Unclear		Return to usual activity by 12 months after injury. Respondents reported their major activity at baseline and all subsequent follow-up periods (defined as working, laid off, looking for work, school, keeping house, retired, and other). Returning to one's usual activity was defined as resuming the same activity or to an activity o f equal or greater productivity
Cyril	2001		nd		%	0		Νο		

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Total Overall Score	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Reliability	Internal Consistency
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Total Overall Score	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of fatairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Responsiven	nd
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Total Overall Score	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Responsiven	nd
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Walk at steady pace	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Floor/ceiling effect	Ceiling

			Comparator/Critorion/Outo	Timepoint			Strongth of	la Acnost		
Author	Year	PMID	ome	(predictive valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
	. ou.		0.110	vana)		, and	Tropolity	Supportour		noto, our outo
					Cronbach's					
Cyril	2001		nd		alpha	0.71	Adequate	Yes		
										Effect Size Statistics for Change in Scores
Cvril	2001		nd		SRM	0.89				Between 3 and 12 Months
0	0004		- 4		Effect size with	1.00				Effect Size Statistics for Change in Scores
Cyni	2001		na		baseline SD	1.00				Between 3 and 12 Months
1										
Cyril	2001		nd		%	31.8		Yes	1	

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Walk at steady pace	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) nun at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Walk at steady pace	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of fstairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Walk at steady pace	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of fatairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Walk at steady pace	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct

			Comparator/Critorion/Outo	Timepoint			Strongth of	la Acnost		
Author	Year	PMID	ome	(predictive valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
, latito				ranaj	incluie eccu	Fullo	Tropolity	Capperiout		
										3-Month Functional Scale Scores. P-value
Cyril	2001		Transtibial vs Transfemoral		Р	>0.05		No		based on Mann-Whitney U
·										,
										3-Month Functional Scale Scores. P-value
Cyril	2001		ISS Score <13 vs >=13		Р	>0.05		No		based on Mann-Whitney U
					_					3-Month Functional Scale Scores. P-value
Cyril	2001		Age <35 vs >=35		Р	<=0.05		Yes		based on Mann-Whitney U
1										
1										
1										
1										
1										
1										
1										
1										
1			1							3-Month Functional Scale Scores Pavalue
Cvril	2001		Comorbidities yes vs po		P	>0.05		No		based on Mann-Whitney U
~,···	2001	1	00110101010100 900 900 10	1	I.	0.00	1		1	babba bir marin mininey o

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Walk at steady pace	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) nun at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Walk at steady pace	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of fstairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Walk at steady pace	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of fatairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Walk at steady pace	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct

A			Comparator/Criterion/Outc	(predictive	M-1-1-11	N-1	Strength of	Is Aspect	O-maluation.	Notes (Osuante
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
					_					12-Month Functional Scale Scores. P-value
Cyril	2001		Transtibial vs Transfemoral		Р	>0.05		No		based on Mann-Whitney U
Curil	2001		188 80000 <12 10 >=12		Р	>0.05		No		12-Month Functional Scale Scores. P-value
Cym	2001				1	-0.03		NO		based on Mannewhitney o
Cvril	2001		Aae <35 vs >=35		Р	>0.05		No		12-Month Functional Scale Scores. P-value based on Mann-Whitney U
- /			5							
Cvril	2001		Comorbidities ves vs po		P	>0.05		No		12-Month Functional Scale Scores. P-value

				Amputation		Other Population						
Author	Year	PMID Amputation	n Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	Transfemor Transtibial Through-kn	ral (22%), (77%), iee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Walk at steady pace	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 fights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion
Cyril	2001	Transfemor Transtibial Through-kn	ral (22%), (77%), nee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Walk at steady pace	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion
Cyril	2001	Transfemor Transtibial Through-kn	ral (22%), (77%), iee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Walk at steady pace	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of fstairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion
Curil	2001	Transfemor Transtibil	ral (22%), (77%), pee (11%)	pd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PEI	Walk at	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Floor/ceiling	Floor

			Comparator/Critorion/Quto	Imepoint			Strongth of	la Aspect		
Author	Year	PMID	ome	(predictive valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Cyril	2001		Normal Walking Speed (Yes vs No)		Pearson r	-0.41	Moderate	Yes		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 150- foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.
Cyril	2001		Walking Speed (continuous score)		Pearson r	0.45	Moderate	Yes		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 150- foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to waik 150 feet was used.
Cyril	2001		Return to Usual Activity (Yes vs No)		Pearson r	-0.24	Small	Unclear		Return to usual activity by 12 months after injury. Respondents reported their major activity at baseline and all subsequent follow-up periods (defined as working, laid off, looking for work, school, keeping house, retired, and other). Returning to one's usual activity was defined as resuming the same activity or to an activity o f equal or greater productivity
Cyril	2001		nd		%	17.8		Νο		

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	PFI	Walk at steady pace	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object, (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Reliability	Internal Consistency
Curil	2001		Transfemoral (22%), Transtibial (77%), Drouveh knee (11%)	rd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputation ware excluded	107	PEI	Walk at	Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by sumption 2 us	Responsiven	od
Cyril	2001		Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputations were excluded	107	PFI	Walk at steady pace	summing all four category scores Physical Function Index: Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, vin mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Responsiven	nd
Callaghan	2003	14682557	Transfemoral	Peripheral vascular disease (90%)	69	Unilateral	42	PGI			Reliability	Test-retest
Callaghan	2003	14682557	Transfemoral	Peripheral vascular disease (90%)	69	Unilateral	42	PGI			Validity	Convergent
Callaghan	2003	14682557	Transfemoral	Peripheral vascular disease (90%)	69	Unilateral	42	PGI			Validity	Convergent
Cvril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amoutations were excluried	107	Physical Function Index	Climb stairs	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing al four category scores	Reliability	Internal Consistency

			0	Timepoint			0			
Author	Year	PMID	comparator/Criterion/Outc	(predictive valid)	Metric Used	Value	Strength of Property	IS ASpect Supported?	Conclusion	Notes/Caveats
					Cronbach's					
Cyril	2001		nd		alpha	0.74	Adequate	Yes		
										Effect Size Statistics for Change in Scores
Cyril	2001		nd		SRM	0.65				Between 3 and 12 Months
Curil	2001		-		Effect size with	0.00				Effect Size Statistics for Change in Scores
Cyn	2001		na		baseline SD	0.96				Between 3 and 12 Months
Callaghan	2003	14682557			ICC	0.48				
Callaghan	2003	14682557	SF-12 PCS		Pearson r	0.11				
					_					
Callaghan	2003	14682557	SF-12 MCS		Pearson r	0.56				
					Cronhach's					
Cvril	2001	0	nd	1	alpha	0.78	Adequate	Yes		

Author	Year	PMID Amputation Level	Amputation Etiology Age	Other Population Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	Transfemoral (22%), Transtibial (77%), 0 Through-knee (11%)	nd 35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Climb stairs	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Floor/ceiling	Ceiling
Cyril	2001	Transfemoral (22%), Transtibial (77%), 0 Through-knee (11%)	nd 35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Climb stairs	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Floor/ceiling effect	Floor
Cyril	2001	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd 35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Climb stairs	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion
Cyril	2001	Transfemoral (22%), Transtibial (77%), 0 Through-knee (11%)	nd 35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Climb stairs	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion

			Comparator/Criterion/Outc	Timepoint (predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Curil	2001	0	od		94	16.8		Yes		
Cyn	2001		10		70	10.0		165		
Cyril	2001	0	nd		%	41.1		Yes		
Cyril	2001	0	Normal Walking Speed (Yes vs No)		Pearson r	-0.39	Moderate	Yes		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 150 foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.
Cyril	2001	0	Walking Speed (continuous score)		Pearson r	0.41	Moderate	Yes		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 150 foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.

Author	Year	PMID	Amputation Level	Amputation Etiology	Age	Other Population Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Climb stairs	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 block; and (4) climb 5 flights, 3 flights, and 1 block; and (4) climb 5 flights, 3 flights, and 1 at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion
Curil	2004	0	Transfemoral (22%), Transtibial (77%), Thrruch kees (11%)	pd	35	High energy lower extremity trauma patients. Foot amputation or bilateral emputatione were excluded	107	Physical Eurotion Index	Climb stairs	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed bus ummine all four category scores	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Climb stairs	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 ib, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Climb stairs	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct

				Imepoint			Strongth of	le Asnact		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Cyril	2001	0	Return to Usual Activity (Yes vs No)		Pearson r	-0.15	Small	Unclear		Return to usual activity by 12 months after injury. Respondents reported their major activity at baseline and all subsequent follow-up periods (defined as working, laid off, looking for work, school, keeping house, retired, and other). Returning to one's usual activity was defined as resuming the same activity or to an activity o f equal or greater productivity
										3-Month Functional Scale Scores. P-value
Cyril	2001	0	Transtibial vs Transfermoral		P	>0.05		No		based on Mann-Whitney U 3-Month Functional Scale Scores. P-value
Cyril	2001	0	ISS Score <13 vs >=13		P	<=0.05		No		based on Mann-Whitney U 3-Month Functional Scale Scores. P-value based on Mann-Whitney U

Author	Year	PMID	Amputation Level	Amputation Etiology	Age	Other Population Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Climb stairs	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Curil	2004	0	Transfemoral (22%), Transtibial (77%), Thrruch kees (11%)	pd	35	High energy lower extremity trauma patients. Foot amputation or bilateral emputatione were excluded	107	Physical Eurotion Index	Climb stairs	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of starts without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtbial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Climb stairs	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Climb stairs	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct

			Comparator/Criterion/Outc	(predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
										3-Month Functional Scale Scores. P-value
Cyril	2001	0	Comorbidities yes vs no		Р	>0.05		No		based on Mann-Whitney U
										12-Month Functional Scale Scores. P-value
Cyril	2001	0	Transtibial vs Transfemoral		Р	>0.05		No		based on Mann-Whitney U
										12-Month Functional Scale Scores. P-value
Cyril	2001	0	ISS Score <13 vs >=13		Р	>0.05		No		based on Mann-Whitney U
Cvril	2001	0	Age <35 vs >=35		Р	>0.05		No		12-Month Functional Scale Scores. P-value
- ,	1-001	17		1	10	0.00	1		1	on mann manoy o

Author	Voor	PMID	Amputation Loval	Amputation	4.50	Other Population	N	Instrument	Subseele	Description	Broporty	Acrest
Autnor	réar	PMID	Amputation Level	Etiology	Age		N	Instrument	Subscale	Respondents were asked to respond about	Property	Aspect
										their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, V mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficult).		
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Climb stairs	2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
C	2004	0	Transfemoral (22%), Transtbial (77%),		25	High energy lower extremity trauma patients. Foot amputation or bilateral	407	Disected Function Index	Olimba staire	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed	Responsiven	
Cyril	2001	0	Through-knee (11%)	nd	35	amputations were excluded	107	Physical Function Index	Climb stairs	by summing all four category scores	ess	nd
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Climb stairs	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, V mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Responsiven	nd
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Overall PF1	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Reliability	Internal Consistency

			Comparator/Criterion/Outc	Imepoint			Strongth of	le Asport		
Author	Year	PMID	ome	(predictive valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
				ranaj		laide	Topolly	cappondu	o o no na o na o na o na o na o na o na	
										12-Month Functional Scale Scores. P-value
Cyril	2001	0	Comorbidities yes vs no		Р	>0.05		No		based on Mann-Whitney U
										Effect Size Statistics for Change in Scores
Cyril	2001	0	nd		SRM	0.74				Between 3 and 12 Months
					Effect size with					Effect Size Statistics for Change in Scores
Cyril	2001	0	nd		baseline SD	0.79				Between 3 and 12 Months
					Crophoph's					
Curril	2001	0			CIUNDACH S	0.71	Adamusta	Vaa		
Gyrii	200 I	U	nu	1	aipila	0.71	Auequale	165		1

Author	Year	PMID Amputation	Level	Amputation Etiology	Age	Other Population Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	Transfemora Transtibial (7 0 Through-kne	I (22%), 7%), e (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Overall PFI	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Floor/ceiling effect	Ceiling
Cyril	2001	Transfemora Transtibial (7 0 Through-kne	I (22%), 7%), e (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Overall PFI	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Floor/ceiling effect	Floor
Cyril	2001	Transfemora Transtibial (7 0 Through-kne	I (22%), 7%), e (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Overall PFI	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion
Cyril	2001	Transfemora Transtibial (7 0 Through-kne	l (22%), 7%), e (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Overall PFI	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion

Author	Voor	PMID	Comparator/Criterion/Outc	(predictive	Motrio Llaged	Value	Strength of	Is Aspect	Conclusion	Notos/Coverto
Author	rear	PWID	ome	vailū)	wetric Used	value	Property	supported?	Conclusion	NOTES/CaVeats
Cyril	2001	0	nd		%	12.1		No		
Queil	2001	0	rd		01	0		No		
Cyril	2001	0	Normal Walking Speed (Yes vs No)		Pearson r	-0.55	Large	Yes		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was defined as those who completed a 150 foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.
Cyril	2001	0	Walking Speed (continuous score)		Pearson r	0.57	Large	Yes		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 150 foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.

Author	Year	PMID	Amputation Level	Amputation Etiology	Age	Other Population Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Overall PFI	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion
Curil	2004	0	Transfemoral (22%), Transtibial (77%), Droubt here (11%)	pd	35	High energy lower extremity trauma patients. Foot amputation or bilateral emputatione were excluded	107	Physical Eurotion Index	Overall PEI	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, vin mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of statis without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed bus umming all four category scores	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Overall PFI	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Overall PFI	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct

			Comparator/Criterion/Outc	Imepoint			Strength of	le Asnact		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Cyril	2001	0	Return to Usual Activity (Yes vs No)		Pearson r	-0.27	Small	Unclear		Return to usual activity by 12 months after injury. Respondents reported their major activity at baseline and all subsequent follow-up periods (defined as working, laid off, looking for work, school, keeping house, retired, and other). Returning to one's usual activity was defined as resuming the same activity or to an activity o f equal or greater productivity
										3-Month Functional Scale Scores. P-value
Cvril	2001	0	Transtibial vs Transfemoral		Р	>0.05		No		based on Mann-Whitney U
										3-Month Functional Scale Scores. P-value
Cyril	2001	0	ISS Score <13 vs >=13		9	>0.05		No		based on Mann-Whitney U 3-Month Functional Scale Scores. P-value
Cyrii	2001	υ	Age <35 vs >=35		Р	>0.05		NO		pased on Mann-Whitney U

Author	Year	PMID	Amputation Level	Amputation Etiology	Age	Other Population Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Overall PFI	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 block; and (4) climb 5 flights, 3 flights, and 1 block; and (4) climb 5 flights, 3 flights, and 1 at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Curil	2004	0	Transfemoral (22%), Transtibial (77%), Droubt here (11%)	pd	35	High energy lower extremity trauma patients. Foot amputation or bilateral emputatione were excluded	107	Physical Eurofian Index	Overall PEI	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed bus ummine all four category scores	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Overall PFI	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, of a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 block; and (4) climb 5 flights, 3 flights, and 1 block; and (4) climb 5 flights, 3 flights, and 1 block; and (4) climb 5 flights, 3 flights, and 1 block; and (4) climb 5 flights, 3 flights, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Overall PFI	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct

			Comparator/Criterion/Outc	(predictive			Strength of	Is Aspect				
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats		
										3-Month Functional Scale Scores. P-value		
Cyril	2001	0	Comorbidities yes vs no		Р	>0.05		No		based on Mann-Whitney U		
										12-Month Functional Scale Scores. P-value		
Cyril	2001	0	Transtibial vs Transfemoral		Р	>0.05		No		based on Mann-Whitney U		
										12-Month Functional Scale Scores. P-value		
Cyril	2001	0	ISS Score <13 vs >=13		Р	>0.05		No		based on Mann-Whitney U		
Cvril	2001	0	Age <35 vs >=35		Р	>0.05		No		12-Month Functional Scale Scores. P-value		
- ,	1-001	17		1	10	0.00	1		1	on mann manoy o		
Author	Year	PMID	Amputation Level	Amputation Etiology	Age	Other Population Information	N	Instrument	Subscale	Description	Property	Aspect
--------	------	------	---	------------------------	-----	--	-----	-------------------------	--------------------	--	-------------	----------------------
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Overall PFI	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cvril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Overall PFI	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Responsiven	nd
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Overall PFI	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Responsiven	nd
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Run at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Reliability	Internal Consistency

			Comparator/Criterion/Outc	Imepoint			Strongth of	le Asport		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
				ranaj		, and o	Topolly	cappondu	Contraction	10100,0010010
										12-Month Functional Scale Scores, P-value
Cvril	2001	0	Comorbidities ves vs no		Р	>0.05		No		based on Mann-Whitney U
0,111	2001	•				0.00				
										Effect Size Statistics for Chappen in Sector
Curril	2004	0	nd		CDM	0.00				Effect Size Statistics for Change in Scores
Cyni	2001	0	na		SKIVI	0.69				Between 5 and 12 Months
		_			Effect size with					Effect Size Statistics for Change in Scores
Cyril	2001	0	nd		baseline SD	1.06				Between 3 and 12 Months
					Cronbach's					
Cyril	2001	0	nd		alpha	0.87	Excellent	Yes		

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Run at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 block; and (4) climb 5 flights, 3 flights, and 1 block; and a 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Floor/ceiling effect	Ceiling
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Run at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Ni mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Floor/ceiling	Floor
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Run at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion
Curil	2001	0	Transfemoral (22%), Transtbial (77%), Thrunchknee (11%)	od	35	High energy lower extremity trauma patients. Foot amputation or bilateral apputations were excluded	107	Physical Eurofice Index	Run at steady	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores indigate function. A total score was constructed by europing all four category scores indicating better function. A total score was constructed	Validity	Criterion

				Comparator/Criterion/Outc	Timepoint (predictive			Strength of	Is Aspect		
ł	Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
	Cyril	2001	0	nd		%	85		Yes		
ł	Cyril	2001	0	nd		%	2.8		No		
	Cyril	2001	0	Normal Walking Speed (Yes vs No)		Pearson r	-0.3	None	No		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed vas defined as those who completed a 150 foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.
	Cyril	2001	0	Walking Speed (continuous score)		Pearson r	0.37	Moderate	Yes		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 150 foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.

Author	Year	PMID	Amputation Level	Amputation Etiology	Age	Other Population	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Run at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, V mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion
Cvril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Run at steady	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Run at steady pace	Respondents were asked to respond about their ability to: (1) squal and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Run at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct

				Imepoint			Strongth of	le Asnact		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Cyril	2001	0	Return to Usual Activity (Yes vs No)		Pearson r	-0.26	Small	Unclear		Return to usual activity by 12 months after injury. Respondents reported their major activity at baseline and all subsequent follow-up periods (defined as working, laid off, looking for work, school, keeping house, retired, and other). Returning to one's usual activity was defined as resuming the same activity or to an activity o f equal or greater productivity
										3-Month Functional Scale Scores. P-value
Cyril	2001	0	Transtibial vs Transfermoral		P	>0.05		No		based on Mann-Whitney U 3-Month Functional Scale Scores. P-value
Cyril	2001	0	ISS Score <13 vs >=13		P	>0.05		No		based on Mann-Whitney U 3-Month Functional Scale Scores. P-value based on Mann-Whitney U

Author	Year	PMID	Amputation Level	Amputation Etiology	Age	Other Population	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Run at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtbial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Run at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Run at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Run at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct

			Comparator/Criterion/Outc	(predictive			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
										3-Month Functional Scale Scores. P-value
Cyril	2001	0	Comorbidities yes vs no		Р	>0.05		No		based on Mann-Whitney U
										12-Month Functional Scale Scores. P-value
Cyril	2001	0	Transtibial vs Transfemoral		Р	>0.05		No		based on Mann-Whitney U
										12-Month Functional Scale Scores. P-value
Cyril	2001	0	ISS Score <13 vs >=13		Р	>0.05		No		based on Mann-Whitney U
Cvril	2001	0	Age <35 vs >=35		Р	>0.05		No		12-Month Functional Scale Scores. P-value
- ,	1-001	17		1	10	0.00	1		1	on mann manoy o

Author	Year	PMID	Amputation Level	Amputation Etiology	Age	Other Population Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Run at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Run at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block, and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Responsiven	nd
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Squat to pick up object	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block, and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, valk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Reliability	Internal Consistency
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Squat to pick up object	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block, and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Floor/ceiling effect	Ceiling

			Comparator/Criterion/Outc	Imepoint			Strongth of	le Aenoct		
Author	Year	PMID	ome	(predictive valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
				vana,		, aluo		Cupperiou		notoc, cu touto
										12-Month Functional Scale Scores. P-value
Cyril	2001	0	Comorbidities yes vs no		Р	>0.05		No		based on Mann-Whitney U
			,							
										Effect Size Statistics for Change in Scores
Cyril	2001	0	nd		SRM	0.36				Between 3 and 12 Months
Curril	2001	0			Cronbach s	0.00	Evenlent	Vee		
Cyn	2001	0	nu		aipila	0.62	Excellent	165		
Cyril	2001	0	nd		%	36.4		Yes		

Author	Year	PMID Amputation Le	Amputation el Etiology	Age	Other Population Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	Transfemoral (2 Transtibial (77% 0 Through-knee (1	%), %) nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Squat to pick up object	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Floor/ceiling	Floor
Cyril	2001	Transfemoral (2 Transtibial (77% 0 Through-knee (1	%), %) nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Squat to pick up object	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion
Cyril	2001	Transfemoral (2 Transtibial (77% 0 Through-knee (%), %) nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Squat to pick up object	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion
Cyril	2001	Transfemoral (2 Transtibial (77% 0 Through-knee (%),	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Squat to pick	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion

			Comparator/Criterion/Outc	Imepoint			Strength of	le Asnact		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Cyril	2001	0	nd		%	8.4		Νο		
Curil	2001		Normal Walking Speed (Yes		Pearson r	-0.53	Larre	Yes		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 15 foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feat was used to find was used to find the was used to find was used to be the was used to
Cyril	2001	0	Walking Speed (continuous score)		Pearson r	0.46	Moderate	Yes		Walk itso feet was used. Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was defined as those who completed a 150 foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.
Cyril	2001	0	Return to Usual Activity (Yes vs No)		Pearson r	-0.18	Small	Unclear		Return to usual activity by 12 months after injury. Respondents reported their major activity at baseline and all subsequent follow-up periods (defined as working, laid off, looking for work, school, keeping house, retired, and other). Returning to one's usual activity was defined as resuming the same activity or to an activity o f equal or greater productivity

Author	Year	PMID	Amputation Level	Amputation Etiology	Age	Other Population Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Squat to pick up object	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of starisr without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cvril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Squat to pick	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Squat to pick	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, V mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Squat to pick up object	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct

			Comparator/Critorion/Quito	Imepoint			Strongth of			
Author	Year	PMID	ome	(predictive valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
				rana,		Value	Topolty	capponeur		
										3-Month Functional Scale Scores. P-value
Cyril	2001	0	Transtibial vs Transfemoral		Р	>0.05		No		based on Mann-Whitney U
										A Marth Eventional Analy Assess Duration
Curil	2001	0	188 80010 <12 10 >=12		р	>0.05		No		3-Month Functional Scale Scores. P-value
Cym	2001	0			1	-0.05		NO		based on Mann-Whiteley C
										3-Month Functional Scale Scores. P-value
Cyril	2001	0	Age <35 vs >=35		Р	<=0.05		Yes		based on Mann-Whitney U
										3-Month Functional Scale Scores Puralue
Cvril	2001	0	Comorbidities ves vs no		Р	>0.05		No		based on Mann-Whitney U
- /		-			1			-		

Author	Year	PMID	Amputation Level	Amputation Etiology	Age	Other Population Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Squat to pick up object	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of starisr without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cvril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Squat to pick	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Squat to pick	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, V mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Squat to pick up object	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct

			Comparator/Criterion/Outc	Imepoint			Strength of	Is Aspect		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
				,						
										12-Month Functional Scale Scores, P-value
Cyril	2001	0	Transtibial vs Transfemoral		Р	<=0.05		Yes		based on Mann-Whitney U
- /		-								
										12 Month Euroctional Scale Scores, Bualue
Cvril	2001	0	ISS Score <13 vs >=13		Р	>0.05		No		based on Mann-Whitney U
- /		-								
										12-Month Functional Scale Scores, P-value
Cyril	2001	0	Age <35 vs >=35		Р	>0.05		No		based on Mann-Whitney U
			-							
		1					1			
		1								
		1								
		1								
		1								
		1								
		1								12-Month Functional Scale Scores. P-value
Cyril	2001	0	Comorbidities yes vs no		Р	>0.05		No		based on Mann-Whitney U

Author	Year	PMID	Amputation Level	Amputation Etiology	Age	Other Population Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Squat to pick up object	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Responsiven	nd
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Squat to pick up object	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block, and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, valk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score weas constructed by summing all four category scores	Responsiven	nd
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Walk at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block, and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Reliability	Internal Consistency
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Walk at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block, and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Floor/ceiling effect	Ceiling

				Commonator/Critorion/Outo	Timepoint			Steen with af			
	Author	Vear	PMID	ome	(predictive	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
	Addior	Tear		ome	vanu)	Metric Osed	value	Froperty	Supported?	Conclusion	NOLES/Caveals
	Cyril	2001	0	nd		SRM	0.55				Effect Size Statistics for Change in Scores Between 3 and 12 Months
						Effect size with					Effect Cize Statistics for Change in Secret
	Cyril	2001	0	nd		baseline SD	0.67				Between 3 and 12 Months
						Cronbach's					
	Cyril	2001	0	nd		alpha	0.74	Adequate	Yes		
ļ											
ļ											
ļ	Cyril	2001	0	nd		%	31.8		Yes		
		-				1	1 1				

Author	Year	PMID Amputation Level	Amputation Etiology Age	je	Other Population Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	Transfemoral (22%), Transtibial (77%), 0 Through-knee (11%)	nd 35		High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Walk at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Floor/ceiling effect	Floor
Cvril	2001	Transfemoral (22%), Transtibial (77%), 0 Through-knee (11%)	nd 35		High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Walk at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) una t a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing al four category scores	Validity	Criterion
Cyril	2001	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd 35		High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Walk at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion
Cyril	2001	Transfemoral (22%), Transtibial (77%), 0 Through-knee (11%)	nd 35		High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Walk at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Criterion

			Comparator/Criterion/Outc	Imepoint			Strength of	le Asnact		
Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Cyril	2001	0	nd		%	17.8		Νο		
Curil	2004		Normal Walking Speed (Yes		Peareon	0.41	Moderate	Yes		Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was constructed. Normal walking speed was defined as those who completed a 15 foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to wark 150 features used.
Cyril	2001	0	Walking Speed (continuous score)		Pearson r	0.45	Moderate	Yes		Walk 150 feet was used. Walking speed at 12 months: Complete a 150 foot walk as fast as they could. Two measures of walking speed were used as criterion measures. First, a categorical variable that classified individuals as walking at a normal walking speed or not was defined as those who completed a 151 foot walk in 37.5 seconds or less, which is equivalent to the average time it takes to cross a normal street. Second, a continuous variable representing the number of seconds it took for individuals to walk 150 feet was used.
Cyril	2001	0	Return to Usual Activity (Yes vs No)		Pearson r	-0.24	Small	Unclear		Return to usual activity by 12 months after injury. Respondents reported their major activity at baseline and all subsequent follow-up periods (defined as working, laid off, looking for work, school, keeping house, retired, and other). Returning to one's usual activity was defined as resuming the same activity or to an activity o f equal or greater productivity

Author	Year	PMID	Amputation Level	Amputation Etiology	Age	Other Population Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Walk at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cvril	2001	0	Transfemoral (22%), Transtbial (77%), Thrunch.nee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Walk at	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores indigate function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtbial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Walk at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, V mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Response were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Walk at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct

			Comparator/Critorion/Quito	Imepoint			Strongth of			
Author	Year	PMID	ome	(predictive valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
				rana,		, and o	Topolty	capponeur		
										3-Month Functional Scale Scores. P-value
Cyril	2001	0	Transtibial vs Transfemoral		Р	>0.05		No		based on Mann-Whitney U
										A Marth Eventional Analy Assess Duration
Curil	2001	0	188 80010 <12 10 >=12		р	>0.05		No		3-Month Functional Scale Scores. P-value
Cym	2001	0			1	-0.05		NO		based on Mann-Whiteley C
										3-Month Functional Scale Scores. P-value
Cyril	2001	0	Age <35 vs >=35		Р	<=0.05		Yes		based on Mann-Whitney U
										3-Month Functional Scale Scores Puralue
Cvril	2001	0	Comorbidities ves vs no		Р	>0.05		No		based on Mann-Whitney U
- /		-			1			-		

Author	Year	PMID	Amputation Level	Amputation Etiology	Age	Other Population Information	N	Instrument	Subscale	Description	Property	Aspect
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Walk at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cvril	2001	0	Transfemoral (22%), Transtbial (77%), Thrunch.nee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Walk at	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores indigate function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtbial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Walk at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, V mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Response were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct
Cyril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Walk at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight o f stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Validity	Construct

Author Year PaliD ome value Property Supporte? Conclusion Netes/Davaes Cyrll 2001 0 Transblat to Transferrord P +0.05 No 12 Month Functional Scille Scores. P-value Cyrll 2001 0 Transblat to Transferrord P +0.05 No 12 Month Functional Scille Scores. P-value Cyrll 2001 0 158 Score <13 to >-13 P +0.05 No 12 Month Functional Scille Scores. P-value Cyrll 2011 0 158 Score <13 to >-13 P +0.05 No 12 Month Functional Scille Scores. P-value Cyrll 2011 0 158 Score <13 to >-13 P +0.05 No 12 Month Functional Scille Scores. P-value Cyrll 2011 0 Age <35 to >>15 P >0.05 No 12 Month Functional Scille Scores. P-value Cyrll 2011 0 Age <35 to >>15 P >10.05 No 12 Month Functional Scille Scores. P-value Cyrll 2011 0 Age <35 to					Comparator/Criterion/Outc	I imepoint (predictive			Strength of	Is Aspect		
Cyrl 2011 0 Transtolar va Transferrora IP =0.05 No 12-Month Fructional Scale Scores, P-value Cyrl 2011 0 Transtolar va Transferrora IP =0.05 No 12-Month Fructional Scale Scores, P-value Cyrll 2011 0 ISS Score +13 ks >+13 IP =0.05 No 12-Month Fructional Scale Scores, P-value Cyrll 2011 0 ISS Score +13 ks >+13 IP =0.05 No 12-Month Fructional Scale Scores, P-value Cyrll 2011 0 ISS Score +13 ks >+13 IP =0.05 No 12-Month Fructional Scale Scores, P-value Cyrll 2011 0 Age <35 vs >>15 IP =0.05 No 12-Month Fructional Scale Scores, P-value Cyrll 2011 0 Age <35 vs >>15 IP =0.05 No 12-Month Fructional Scale Scores, P-value Cyrll 2011 0 Age <35 vs >>15 IP =0.05 No 12-Month Fructional Scale Scores, P-value Linet Fructional Scale Score, P-value 12-Month Fructional Scale		Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Oyrit 201 0 Transformer P >0.05 No 12 Month Frunctional Scale Scores: P value based on Mann-Writtery U Oyrit 201 0 rS8 Score <13 vs ><13												
Orifi 201 0 Transibility is Transformant P -0.05 No 12.44om Functional Solie Scores, Preduct based on Mann-Whitery U Orifi 201 0 ISS Score +13 vs >+13 P -0.05 No 12.44om Functional Solie Scores, Preduct based on Mann-Whitery U Orifi 201 0 ISS Score +13 vs >+13 P -0.05 No 12.44om Functional Solie Scores, Preduct based on Mann-Whitery U Orifi 201 0 Age <35 vs >+38 P -0.05 No 12.44om Functional Solie Scores, Preduct based on Mann-Whitery U Orifi 200 0 Age <35 vs >+38 P -0.05 No 12.4bom Functional Solie Scores, Preduct based on Mann-Whitery U												
Cyril 201 0 Transbial vs Transferioral P -0.05 No T2-Month Functional Scale Scores. P-value based on Mann-Writingr U Cyril 201 0 ISS Score <13 vs >=13 P -0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Writingr U Cyril 201 0 JSS Score <13 vs >=13 P -0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Writingr U Cyril 2021 0 Age <35 vs >=35 P -0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Writingr U Cyril 2021 0 Age <35 vs >=35 P -0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Writingr U												
Cyrll 201 0 Transtitual vs Transfermoni P >0.05 No 12.Month Functional Scale Scores. P value tased on Manni Whitery U Cyrll 201 0 ISS Ecore <13 vs >+13 P >0.05 No 12.Month Functional Scale Scores. P-value tased on Manni Whitery U Cyrll 201 0 ISS Ecore <13 vs >+13 P >0.05 No 12.Month Functional Scale Scores. P-value tased on Manni Whitery U Cyrll 201 0 App <30 vs >>13 P >0.05 No 12.Month Functional Scale Scores. P-value tased on Manni Whitery U Cyrll 201 0 App <30 vs >>13 P >0.05 No 12.Month Functional Scale Scores. P-value tased on Manni Whitery U Cyrll 201 0 App <30 vs >>13 P >0.05 No 12.Month Functional Scale Scores. P-value tased on Manni Whitery U												
Orgit 2001 0 Transibilit vs Transfermont P >0.05 No 12.Month Functional Scale Scores. P-value based on Mann-Whitney U Orgit 2001 0 ISS Score <13 vs >= 13 P >0.05 No 12.Month Functional Scale Scores. P-value based on Mann-Whitney U Orgit 2001 0 ISS Score <13 vs >= 13 P >0.05 No 12.Month Functional Scale Scores. P-value based on Mann-Whitney U Orgit 2001 0 Age <36 vs >= 35 P >0.05 No 12.Month Functional Scale Scores. P-value based on Mann-Whitney U Orgit 2001 0 Age <36 vs >= 35 P >0.05 No 12.Month Functional Scale Scores. P-value based on Mann-Whitney U Image: Scores. P 0.05 No 12.Month Functional Scale Scores. P-value intervalue Image: Scores. P-value												
Cyrit 201 0 Transibilit via Transfermonia p >0.05 No 12-Month Functional Scale Scores. P-value cased on Marri-Writery U Cyrit 201 0 IES Score <13 vs >= 13 p >0.05 No 12-Month Functional Scale Scores. P-value cased on Marri-Writery U Cyrit 201 0 IES Score <13 vs >= 13 p >0.05 No 12-Month Functional Scale Scores. P-value cased on Marri-Writery U Cyrit 201 0 IES Score <13 vs >= 13 p >0.05 No 12-Month Functional Scale Scores. P-value cased on Marri-Writery U Cyrit 201 0 Age <35 vs >=35 p >0.05 No 12-Month Functional Scale Scores. P-value cased on Marri-Writery U Cyrit 201 0 Age <35 vs >=35 p >0.05 No 12-Month Functional Scale Scores. P-value cased on Marri-Writery U												
Супі 201 0 Тапязіваl va Transfermonal P >0.05 No 12.440nt Functional Scale Scores, P-value Cyni 201 0 155 Score <13 va >=13 P >0.05 No 12.440nt Functional Scale Scores, P-value Cyni 201 0 155 Score <13 va >=13 P >0.05 No 12.440nt Functional Scale Scores, P-value Cyni 201 0 155 Score <13 va >=13 P >0.05 No 12.440nt Functional Scale Scores, P-value Cyni 201 0 458 Score <13 va >=13 P >0.05 No 12.440nt Functional Scale Scores, P-value Cyni 201 0 Age <35 va >>35 P >0.05 No 12.440nt Functional Scale Scores, P-value Lyni Lyni<												
Op/II 2001 0 Iterational vs Intersentional P 2005 No Description Main remaining U Gyril 2001 0 ISS Score <13 vs >=13 P >0.05 No 12-Month Functional Scale Scores, P-value Gyril 2001 0 ISS Score <13 vs >=13 P >0.05 No 12-Month Functional Scale Scores, P-value Cyril 2001 0 Age <35 vs >=35 P >0.05 No 12-Month Functional Scale Scores, P-value Cyril 2001 0 Age <35 vs >=35 P >0.05 No 12-Month Functional Scale Scores, P-value Lyrid Line		Overil	2004	0	Transfer and		D	> 0.05		No		12-Month Functional Scale Scores. P-value
Cyrll 201 0 ISS Score <13 vs >= 13 P >0.05 No 12-Month Functional Scale Scores, P-value based on Mann. Whithey U Cyrll 201 0 Age <35 vs >=35 P >0.05 No 12-Month Functional Scale Scores, P-value based on Mann. Whithey U Cyrll 201 0 Age <35 vs >=35 P >0.05 No 12-Month Functional Scale Scores, P-value based on Mann. Whithey U Lyrll 201 0 Age <35 vs >=35 P >0.05 No 12-Month Functional Scale Scores, P-value based on Mann. Whithey U Lyrll 201 0 Age <35 vs >=35 P >0.05 No 12-Month Functional Scale Scores, P-value based on Mann. Whithey U		Cyni	2001	0	Transibiar vs Transiemoral		F	>0.05		INO		based on Mann-Whitney O
Cyril 2001 0 ISS Score <13 vs >=13 P >0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Whithey U Cyril 2001 0 Age <35 vs ><35												
Cyril 201 0 ISS Score <13 vs >=13 P >0.05 No 12-Month Functional Scale Scores. P-value based on Marn-Whitney U Cyril 201 0 Age <35 vs >=35 P >0.05 No 12-Month Functional Scale Scores. P-value based on Marn-Whitney U Cyril 2001 0 Age <35 vs >=35 P >0.05 No based on Marn-Whitney U Lyril 2001 0 Age <35 vs >=35 P >0.05 No based on Marn-Whitney U Lyril 2001 0 Age <35 vs >=35 P >0.05 No based on Marn-Whitney U Lyril 201 0 Age <35 vs >=35 P >0.05 No based on Marn-Whitney U												
Oyril 2001 0 ISS Score <13 ve >=13 P >0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Whitney U Cyril 201 0 Age <35 ve >=35 P >0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Whitney U Cyril 201 0 Age <35 ve >=35 P >0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Whitney U Lyril 201 0 Age <35 ve >=35 P >0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Whitney U Lyril 201 0 Age <35 ve >=35 P >0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Whitney U												
Cyril 201 0 ISS Score <13 vs >=13 P >0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Whitney U Cyril 201 0 Age <35 vs >=35 P >0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Whitney U Cyril 201 0 Age <35 vs >=35 P >0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Whitney U Line 1 0 Age <35 vs >=35 P >0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Whitney U Line 1												
Cyril 2001 0 ISS Score <13 vs >=13 P >0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Whitney U Cyril 201 0 Age <35 vs >=35 P >0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Whitney U Cyril 2011 0 Age <35 vs >=35 P >0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Whitney U Cyril 2001 0 Age <35 vs >=35 P >0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Whitney U												
Cyril 201 0 ISS Score <13 vs >=13 P >0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Whitney U Cyril 201 0 Age <35 vs >=35 P >0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Whitney U												
Cyril 2001 0 ISS Sore <13 vs >=13 P >0.05 No based on Mann-Whitney U Cyril 201 0 Age <35 vs >=35 P >0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Whitney U												12-Month Functional Scale Scores, P-value
Cyril 201 0 Age <35 vs >=35 P >0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Whitney U Logic		Cyril	2001	0	ISS Score <13 vs >=13		Р	>0.05		No		based on Mann-Whitney U
Cyril 2001 0 Age <35 vs >=35 P >0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Whitney U Line Li												
Cyril 201 0 Age <35 vs >=35 P >0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Whitney U Line												
Cyril 2001 0 Age <35 vs >=35 P >0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Whitney U Line												
Cyril 201 0 Age <35 vs >=35 P >0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Whitney U Logical												
Cyril 201 0 Age <35 vs >=35 P >0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Whitney U Line												
Cyril 2001 0 Age <35 vs >=35 P >0.05 No 12-Month Functional Scale Scores. P-value based on Mann-Whitney U Line Li												
Cyril 2001 0 Age <35 vs >=35 P >0.05 No based on Mann-Whitney U Image: Source of the state of the st												10 Marth Engelianal Ocale Ocares During
12-Month Functional Scale Scores. P-value		Cyril	2001	0	Age <35 vs >=35		Р	>0.05		No		based on Mann-Whitney U
12-Month Functional Scale Scores. P-value												
12-Month Functional Scale Scores. P-value												
12-Month Functional Scale Scores. P-value												
12-Month Functional Scale Scores. P-value												
12-Month Functional Scale Scores. P-value												
12-Month Functional Scale Scores. P-value	ļ											
12-Month Functional Scale Scores. P-value	ļ											
Cyril 2001 0 Comorbidities yes vs no P >0.05 No based on Mann-Whitney U	ļ	Cyril	2001	0	Comorbidities yes vs no		Р	>0.05		No		12-Month Functional Scale Scores. P-value based on Mann-Whitney U

				Amputation		Other Population						
Author	Year	PMID	Amputation Level	Etiology	Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Cvril	2001	0	Transfemoral (22%), Transtibial (77%), Through-knee (11%)	nd	35	High energy lower extremity trauma patients. Foot amputation or bilateral amputations were excluded	107	Physical Function Index	Walk at steady pace	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter of a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed by summing all four category scores	Responsiven	nd
Cyrii .	2001	°	Through thee (TT76)		00		107	r nysicar r unction macx	Steady pace		000	
			Transfemoral (22%), Transtibial (77%),			High energy lower extremity trauma patients. Foot amputation or bilateral			Walk at	Respondents were asked to respond about their ability to: (1) squat and pick up a 100 lb, 50 lb, 25 lb, and 10 lb object; (2) walk at a steady pace for 3 miles, 1 mile, and a quarter o f a mile; (3) run at a steady pace without stopping for 3 miles, 1 mile, Vi mile, and 1 block; and (4) climb 5 flights, 3 flights, and 1 flight of stairs without stopping. Responses were coded as 1 (able to do without difficulty), 2 (able to do with difficulty) or 3 (unable to do at all). Four category scores (squat, walk, run and climb) were generated. Category scores ranged from 0 to 4 with lower scores indicating better function. A total score was constructed	Responsiven	
Cyril	2001	0	Through-knee (11%)	nd	35	amputations were excluded	107	Physical Function Index	steady pace	by summing all four category scores	ess	nd
Hafner	2016	28273329	above knee (70, 34.8%); below knee (131, 65.2 %)	dysvascular (46\22.9%); trauma (121/60.2%); infection (25/12.4%); tumor (8/4.0%); congenital (1/0.5%) dysvascular	60.2 +-11.4	nd	201	PLUS-M	12- item short form	item bank developed to measure perceived mobility in people with lower limb amputation	Reliability	test-retest
Hafner	2016	28273329	above knee (70, 34.8%); below knee (131, 65.2%)	(46\22.9%); trauma (121/60.2%); infection (25/12.4%); tumor (8/4.0%); congenital (1/0.5%)	60.2 +-11.4	nd	201	PI US-M	12- item short form	item bank developed to measure perceived	MDC	
			above knee (70, 34.8%); below knee	dysvascular (46\22.9%); trauma (121/60.2%); infection (25/12.4%); tumor (8/4.0%);					12- item short	item bank developed to measure perceived		
Hafner	2016	28273329	(131, 65.2 %)	congenital (1/0.5%)	60.2 +-11.4	nd	201	PLUS-M	form	mobility in people with lower limb amputation	MDC	
lafeer	2016	20272220	above knee (70, 34.8%); below knee	aysvascular (46\22.9%); trauma (121/60.2%); infection (25/12.4%); tumor (8/4.0%);	60.0 + 11.4	umilata cal	201		12- item short	item bank developed to measure perceived	Delistility	
riainer	2010	20213329	(131, 05.2 %)	congenital (1/0.5%) dvsvascular	00.2 +-11.4	unilateral	201	PLUS-M	IOF	mobility in people with lower limb amputation	Reliability	lesi-relesi
Hafner	2016	28273329	above knee (70, 34.8%); below knee (131, 65.2 %)	(46)22.9%); trauma (121/60.2%); infection (25/12.4%); tumor (8/4.0%); congenital (1/0.5%)	60.2 +-11.4	unilateral	201	PLUS-M	12- item short form	item bank developed to measure perceived mobility in people with lower limb amputation	MDC	
Hafror	2016	20272220	above knee (70, 34.8%); below knee	dysvascular (46\22.9%); trauma (121/60.2%); infection (25/12.4%); tumor (8/4.0%); epropertial (1/0.5%)	60.2 + 11.4	unilataral	201	DILISM	12- item short	item bank developed to measure perceived	MDC	
1 1011101	2010	20210329	(101,00.2 %)	10011yennai (1/0.5%)	00.2 11.4	umatera	201	1 LUG-IVI	JUIII	mobility in people with lower limb amputation	INDC	1

Author Year PMD ene valid) Metric Used Value Property Supporte? Conclusion Recent/Caveets 0/11 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0				Comparator/Criterion/Outc	Imepoint			Strength of	ls Asnort		
Cyrl 201 3 ad SRM 1.65 Effect Size Statistics for Change in Score Referent 3 and 12 Months Cyrl 2001 0 nd SRM 1.65 Referent 3 and 12 Months Cyrl 2001 0 nd SRM 0.66 Referent 3 and 12 Months Fyliner 2016 28273329 Inco Diss Referent 3 and 12 Months Heiner 2016 28273329 Inco Diss Referent 3 and 12 Months Heiner 2016 28273329 Inco Diss Referent 3 and 12 Months Heiner 2016 28273329 Inco Diss Referent 3 and 12 Months Heiner 2016 28273329 Inco Diss Referent 3 and 12 Months Heiner 2016 28273329 Inco Diss Referent 3 and 12 Months Heiner 2016 28273329 Inco Diss Referent 3 Months Heiner 2016 28273329 Inco Diss Referent 3 Months Referent 3 Months	Author	Year	PMID	ome	valid)	Metric Used	Value	Property	Supported?	Conclusion	Notes/Caveats
Cyril 2001 0 ref SRM 0.65 Effect Size Statistics for Change in Score Retword 3 and 12 Months Cyril 2001 0 ref SRM 0.65 Effect Size Statistics for Change in Score Retword 3 and 12 Months Cyril 2001 0 ref SRM 0.66 Effect Size Statistics for Change in Score Retword 3 and 12 Months Harrer 216 3873320 CCC 0.66 Effect Size Statistics for Change in Score Retword 3 and 2 Months Harrer 216 2877320 CCC 0.66 Effect Size Statistics for Change in Score Retword 3 and 2 Months Harrer 216 2877320 MDC 50 4.5 Effect Size Statistics for Change in Score Retword 3 and 2 Months Harrer 216 2877320 MDC 50 4.5 Effect Size Statistics for Change in Score Retword 3 and 2 Months Harrer 216 2873320 MDC 50 4.5 Effect Size Statistics for Change in Score Retword 3 and 2 Months Harrer 216 2873320 MDC 50 4.5 Effect Size Statistics for Change in Score Retword a distribution for the fold Monthe effect Size statis and the fold monthe fize mont					, í						
Oyrit 2001 0 od 5804 0.05 Descent 3 and 12 Months Oyrit 2001 0 od Effect 300 with 0 Descent 3 and 12 Months Oyrit 2001 0 od Descent 3 and 12 Months Descent 3 and 12 Months Infere 2016 20273329 CCC 0.66 Descent 3 and 12 Months Infere 2016 20273329 CCC 0.66 Descent 3 and 12 Months Infere 2016 20273329 CCC 0.66 Descent 3 and 20 (5.2) In a flater present of descents 4 and 20 (5.2) In a flater											
Cyrit 2011 0 nd SRM 0.05 Effect Stars Effect											
Cyril 2001 0 rd SRM 0.65 Effect Size Statistics for Change In Score Between 3 and 12 Months Cyril 2001 0 rd Effect Size Statistics for Change In Score Between 3 and 12 Months Effect Size Statistics for Change In Score Between 3 and 12 Months Cyril 2001 0 rd Effect Size Statistics for Change In Score Between 3 and 12 Months Henner 2016 28273229 Icc 0.96 Effect Size Statistics for Change In Score Between 3 and 12 Months Henner 2016 2827329 Icc 0.96 Interview With Statistics for Change In Score Between 3 and 25 Months Henner 2016 2827329 Icc 0.96 Interview With Statistics for Change In Score Between 3 and 96 (52) for after, present astectically contrast. Henner 2016 2827329 MDC 60 4.5 Interview With Statistics for Change Int											
Cyril 201 0 rd SRM 0.65 Effect Size Statistics for Change in Sorre Effect Size Statistics for Statistics for Change in Sorre Effect Size Statistics for Statistics for Statis for Sorre Effect Size Stati											
Cyril 2001 0 nd SR41 0.65 Effect Size Statistics for Change in Score Between 3 and 12 Months Cyril 2001 0 nd Effect size with baseline Si20 0.96 Effect Size Statistics for Change in Score Between 3 and 12 Months Cyril 2001 0 nd Effect size with baseline Si20 0.96 Effect Size Statistics for Change in Score Between 3 and 12 Months Heiner 2016 2827329 ICC 0.96 Effect size with baseline Si20 10.96 Heiner 2016 2827329 ICC 0.96 Effect size with baseline Si20 10.96 Heiner 2016 2827329 ICC 0.96 Effect size with baseline Si20 10.96 Heiner 2016 2827329 ICC 0.96 Effect size with baseline Si20 10.96 Heiner 2016 2827329 ICC 0.96 Effect size with baseline Si20 10.92 Heiner 2016 2827329 ICC 0.96 Effect size size size size size size size size											
Cyril 201 0 nd SRM 0.65 Effect Size Statistics for Change in Score Between 3 and 12 Months Cyril 201 0 nd Effect Size Statistics for Change in Score Between 3 and 12 Months Cyril 201 0 nd Effect Size Statistics for Change in Score Between 3 and 12 Months Lange 201 0 nd Effect Size Statistics for Change in Score Between 3 and 12 Months Lange 201 0 nd Effect Size Statistics for Change in Score Between 3 and 12 Months Lange 2016 28273329 ICC 0.96 Hafner 2016 2877329 MDC 90 4.5											
Cyril 2011 0 nd SRM 0.65 Effect Size Statistics for Change in Score Between 3 and 12 Months Cyril 2001 0 nd Effect size with baseline SD 0.88 Effect Size Statistics for Change in Score Between 3 and 12 Months Cyril 2001 0 nd Effect size with baseline SD 0.88 Effect Size Statistics for Change in Score Between 3 and 12 Months Lather 2016 28273329 Image: Size Statistics for Change in Score Between 3 and 12 Months Image: Size Statistics for Change in Score Between 3 and 12 Months Hafner 2016 28273329 Image: Size Statistics for Change in Score Between 3 and 12 Months Image: Size Statistics for Change in Score Between 3 and 12 Months Hafner 2016 28273329 Image: Size Statistics for Change in Score Between 3 and 12 Months Image: Size Statistics for Change in Score Between 3 and 12 Months Hafner 2016 28273329 Image: Size Statistics for Change in Score Between 3 and 12 Months Image: Size Statistics for Change in Score Between 3 and 12 Months Hafner 2016 28273329 Image: Size Statistics for Change in Score Between 3 and 12 Months Image: Size Statistics for Change in Score Between 3 and 12 Months Hafner 2016 28273329 Image: Size Statistics for Change in Score Between 3 and 12 Months Image: Size Statistics for Change in Score Between 3 and 12 Months and											
Cyril 201 0 no Iskde 0.05 Method Description Cyril 201 0 nd Effect size with beatine SD 0.98 Effect size Statistics for Change in Score Between 3 and 12 Morrins Cyril 2010 0 nd Effect size with beatine SD 0.98 Effect size with beatine SD 9.98 Hafner 2016 28273320 ICC 0.96 Interface statistics for Change in Score observed. combinet ICC. Mode were statistically constant Hafner 2016 28273320 ICC 0.96 Interface statistics on any 48.9 (5.2) hn after, present separately by MoA when differences were observed. combinet ICC. Mode were statistically constant Hafner 2016 28273320 MDC 95 5.36 Interface statistically constant Hafner 2016 28273320 ICC 0.96 Interface statistically constant Hafner 2016 28273320 Interface statistically constant Interface statistically constant Hafner 2016 28273320 ICC 0.96 Interface statistically constant Hafner 2016 <td>o "</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>Effect Size Statistics for Change in Scores</td>	o "										Effect Size Statistics for Change in Scores
Cyril 2011 0 nd Effect size with baseline SD 0.98 Effect Size Statistics for Change in Score Between a and 12 Months Hafner 2016 2827329 ICC 0.96 Integration of the statistical processes observed. combined ICC. MoAs were statistically constant. Hafner 2016 2827329 ICC 0.96 Integration of the statistical processes observed. combined ICC. MoAs were statistically constant. Hafner 2016 2827329 MOC 90 4.5 Integration of the statistical processes observed. combined ICC. MoAs were statistically constant. Hafner 2016 2827329 MOC 90 4.5 Integration of the statistical processes observed. combined ICC. MoAs were statistically constant. Hafner 2016 2827329 MOC 95 5.36 Integration of the statistical processes observed. combined ICC. MoAs were statistically constant. Hafner 2016 2827329 MOC 95 5.36 Integration of the statistical processes observed. combined ICC. MoAs were statistically constant. Hafner 2016 2827329 Integration of the statistical processes observed. combined ICC. MoAs were statistically constant. Integration of the statistical processes observed. combined ICC. MoAs were statistically constant. Hafner 2016 2827329 Integration of the statistical processes observed. combined ICC. MoAs were statistically constant. I	Cyril	2001	0	nd		SRM	0.65				Between 3 and 12 Months
Cyril 201 0 nd Effect size with baseline SD 0.96 Effect size with baseline SD Hafner 2016 28273329 0 0.96 Integration of the size of the size with baseline SD 0.96 Hafner 2016 28273329 ICC 0.96 Integration of the size of the siz											
Cyril 2001 0 nd Effect size with baseline SD 0.98 Effect size Statistics for Change in Score Between 3 and 12 Months Hafner 2016 2827329 ICC 0.96 reted on any 48.9 (5.2) hrs after, present separately by MoA when differences wen destatically constant Hafner 2016 2827329 ICC 0.96 reted on any 48.9 (5.2) hrs after, present separately by MoA when differences wen destatically constant Hafner 2016 2827329 MDC 90 4.5 reted on any 48.9 (5.2) hrs after, present separately by MoA when differences wen destatically constant Hafner 2016 2827329 MDC 90 4.5 reted on any 48.9 (5.2) hrs after, present separately by MoA when differences wen destruct combined ICC, MoAs were satistically constant Hafner 2016 2827329 MDC 90 4.5 reted on any 48.9 (5.2) hrs after, present separately by MoA when differences wen observed. combined ICC, MoAs were satistically constant Hafner 2016 2827329 ICC 0.96 reted on any 48.9 (5.2) hrs after, present separately by MoA when differences wen observed. combined ICC, MoAs were satistically constant. Hafner 2016 2827329 ICC 0.96 reted on any 48.9 (5.2) hrs after, present separately by MoA when differences wen observed. combined ICC, MoAs were satistically constant. Hafner 2016 2827329 MDC 90 4.											
Cyril 2001 0 nd Effect size with baseline SD 0.08 Effect Size Statistics for Change in Score Between 3 and 12 Months Hafner 2016 28273329 ICC 0.96 International second second 20 (52) Ins after, present second 20 (52) Ins after											
Cyril 2011 0 nd Effect size with baseline SD 0.86 Effect Size Statistics for Change in Soor Between 3 and 12 Months Hafner 2016 28273329 NCC 0.96 Statistics for Change in Soor Between 3 and 12 Months Hafner 2016 28273329 NCC 0.96 Statistics for Change in Soor Between 3 and 12 Months Hafner 2016 28273329 NCC 0.96 Statistically constant Hafner 2016 28273329 NDC 90 4.5 Statistically constant Hafner 2016 28273329 NDC 95 5.36 Statistically constant Hafner 2016 28273329 NDC 90 4.5 Statistically constant											
Cyril 201 0 nd Effect size with baseline SD 98 Hainer 2016 28273329 ICC 0.96											
Cyril 2001 0 nd Effect size with baseline SD 0.98 Hafner 2016 28273329 ICC 0.96 Setting of the settin											
Cyril 2011 0 nd Effect size with baseline SD 0.98 Hafner 2016 2827329 ICC 0.96											
Cyril 2001 0 nd baseline SD 0.98 Eetween 3 and 12 Months Hafner 2016 28273329 ICC 0.96 retest on avg 48.9 (5.2) hrs after, present separately by MoA when differences were observed. combined ICC, MAAs were satistically constant Hafner 2016 28273329 ICC 0.96 satistically constant Hafner 2016 28273329 MDC 90 4.5 satistically constant Hafner 2016 28273329 MDC 90 4.5 satistically constant Hafner 2016 28273329 MDC 90 5.36 satistically constant Hafner 2016 28273329 MDC 95 5.36 satistically constant Hafner 2016 28273329 ICC 0.96 satistically constant Hafner 2016 28273329 ICC 0.96 satistically constant Hafner 2016 28273329 ICC 0.96 satistically constant.						Effect size with					Effect Size Statistics for Change in Scores
Hafmer 2016 2827329 ICC 0.96 Hafmer 2016 2827329 ICC 0.96 Hafmer 2016 2827329 MDC 90 4.5 Hafmer 2016 2827329 MDC 90 4.5 Hafmer 2016 2827329 MDC 90 4.5 Hafmer 2016 28273329 MDC 95 5.36 Hafmer 2016 28273329 MDC 95 5.36 Hafmer 2016 28273329 ICCC 0.96 Hafmer 2016	Cyril	2001	0	nd		baseline SD	0.98				Between 3 and 12 Months
Hafner 2016 28273329 ICC 0.96 Separately by MAA when differences were observed. combined ICC, MAAs were satistically constant Hafner 2016 28273329 MDC 90 4.5 Separately by MAA when differences were observed. combined ICC, MAAs were satistically constant Hafner 2016 28273329 MDC 90 4.5 Separately by MAA when differences were observed. combined ICC, MAAs were satistically constant Hafner 2016 28273329 MDC 90 4.5 Separately by MAA when differences were observed. combined ICC, MAAs were satistically constant Hafner 2016 28273329 MDC 95 5.36 Separately by MAA when differences were observed. combined ICC, MAAs were satistically constant Hafner 2016 28273329 MDC 95 5.36 Separately by MAA when differences were observed. combined ICC, MAAs were satistically constant. Hafner 2016 28273329 ICC 0.96 Separately by MAA when differences were observed. combined ICC, MAAs were satistically constant. Hafner 2016 28273329 ICC 0.96 Separately by MAA when differences were observed. combined ICC, MAAs were satistically constant. Hafner 2016 28273329 ICC 0.96 Separately by M											retect on our 40.0 (5.2) has often presented
Hafner 2016 28273329 ICC 0.96 Hafner 2016 28273329 MDC 90 4.5 Hafner 2016 28273329 MDC 90 4.5 Hafner 2016 28273329 MDC 95 5.36 Hafner 2016 28273329 MDC 95 5.36 Hafner 2016 28273329 MDC 95 5.36 Hafner 2016 28273329 MDC 90 4.5											separately by MoA when differences were
Hafner 2016 2827329 MDC 90 4.5 Hafner 2016 28273329 MDC 90 4.5 Hafner 2016 28273329 MDC 95 5.36 Hafner 2016 28273329 ICC 0.96	Hafner	2016	28273329			ICC	0.96				observed. combined ICC, MoAs were satistically constant
Hafner 2016 28273329 MDC 90 4.5 separately by MoA when differences were observed. combined ICC, MAS were satistically constant Hafner 2016 28273329 MDC 95 5.36 retest on avg 48.9 (5.2) hrs after, present separately by MoA when differences were observed. combined ICC, MoAs were satistically constant Hafner 2016 28273329 MDC 95 5.36 satistically constant Hafner 2016 28273329 MDC 95 5.36 satistically constant Hafner 2016 28273329 ICC 0.96 satistically constant. Hafner 2016 28273329 MDC 90 4.5 satistically constant. Hafner 2016 28273329 MDC 90 4.5 satistically constant. Hafner 2016 28273329 MDC 90 4.5 satistically constant. Hafner 2016											
Hafner 2016 2827329 MDC 90 4.5 Hafner 2016 2827329 MDC 95 5.36 Hafner 2016 2827329 MDC 95 5.36 Hafner 2016 2827329 MDC 95 5.36 Hafner 2016 2827329 ICC 0.96											retest on avg 48.9 (5.2) hrs after, presented
Hatner 2016 28273329 MDC 90 4.5 Hafner 2016 28273329 MDC 95 5.36 Hafner 2016 28273329 MDC 95 5.36 Hafner 2016 28273329 MDC 95 5.36 Hafner 2016 28273329 ICC 0.96											observed. combined ICC, MoAs were
Hafner 2016 28273329 MDC 95 5.36 retest on avg 48.9 (5.2) hrs after, present separately by MoA when differences were observed. combined ICC, MoAs were satistically constant Hafner 2016 28273329 MDC 95 5.36 retest on avg 48.9 (5.2) hrs after, present separately by MoA when differences were observed. combined ICC, MoAs were satistically constant Hafner 2016 28273329 ICC 0.96 retest on avg 48.9 (5.2) hrs after, present separately by MoA when differences were observed. combined ICC, MoAs were satistically constant. Hafner 2016 28273329 ICC 0.96 retest on avg 48.9 (5.2) hrs after, present separately by MoA when differences were observed. combined ICC, MoAs were satistically constant. Hafner 2016 28273329 MDC 90 4.5 retest on avg 48.9 (5.2) hrs after, present separately by MoA when differences were observed. combined ICC, MoAs were satistically constant. Hafner 2016 28273329 MDC 90 4.5 retest on avg 48.9 (5.2) hrs after, present separately by MoA when differences were observed. combined ICC, MoAs were satistically constant.	Hafner	2016	28273329			MDC 90	4.5				satistically constant
Hafner 2016 2827329 MDC 95 5.36 separately by MoA when differences were observed. combined ICC, MoAs were satistically constant Hafner 2016 2827329 MDC 95 5.36 retest on avg 48.9 (5.2) hrs after, present separately by MoA when differences were observed. combined ICC, MoAs were satistically constant Hafner 2016 2827329 ICC 0.96 satistically constant Hafner 2016 2827329 ICC 0.96 satistically constant. Hafner 2016 2827329 MDC 90 4.5 satistically constant. Hafner 2016 2827329 MDC 90 4.5 satistically constant. Hafner 2016 28273329 MDC 90 4.5 satistically constant.											retest on avg 48.9 (5.2) hrs after, presented
Hafner 2016 2827329 MDC 95 5.36 Satisfically containt CC, Mons Weie Hafner 2016 2827329 ICC 0.96 satisfically constant Hafner 2016 2827329 MDC 90 4.5 satisfically constant Hafner 2016 2827329 MDC 90 4.5 satisfically constant											separately by MoA when differences were
Hafner 2016 2827329 ICC 0.96 Hafner 2016 2827329 ICC 0.96 Hafner 2016 2827329 ICC 0.96	Hafner	2016	28273329			MDC 95	5.36				satistically constant
Hafner 2016 28273329 ICC 0.96 separately by MoA when differences were observed. combined ICC, MoAs were satistically constant. Hafner 2016 28273329 ICC 0.96 retest on avg 48.9 (5.2) hrs after, present separately by MoA when differences were observed. combined ICC, MoAs were satistically constant. Hafner 2016 28273329 MDC 90 4.5 retest on avg 48.9 (5.2) hrs after, present separately by MoA when differences were observed. combined ICC, MoAs were satistically constant. Hafner 2016 28273329 MDC 90 4.5 separately by MoA when differences were observed. combined ICC, MoAs were satistically constant.											
Hafner 2016 28273329 ICC 0.96 Hafner 2016 28273329 ICC 0.96 Hafner 2016 28273329 MDC 90 4.5											retest on avg 48.9 (5.2) hrs after, presented separately by MoA when differences were
Hamer 2016 2827329 ICC 0.96 satistically constant. Hafner 2016 2827329 MDC 90 4.5 retest on avg 48.9 (5.2) hrs after, present separately by MoA when differences were observed. combined ICC, MoAs were satistically constant.	Llafaar	2016	20272220			100	0.06				observed, combined ICC, MoAs were
Hafner 2016 28273329 MDC 90 4.5 Hafner 2016 28273329 MDC 90 4.5	namer	2010	20213329				0.90				
Hafner 2016 2827329 MDC 90 4.5 separately by MoA when differences were observed. combined ICC, MoAs were satisfically constant. Hafner 2016 2827329 MDC 90 4.5 satisfically constant. Image: satisfically by MoA were differences were satisfically constant. retest on avg 48.9 (5.2) hrs after, present separately by MoA were differences were satisfically by MoA we											retest on avg 48.9 (5.2) hrs after, presented
Hafner 2016 28273329 MDC 90 4.5 satistically constant. Image: Second secon											separately by MoA when differences were observed, combined ICC, MoAs were
retest on avg 48.9 (5.2) hrs after, present separately by MoA when differences were	Hafner	2016	28273329			MDC 90	4.5				satistically constant.
retest on avg 48.9 (5.2) hrs after, present separately by MAA when differences were											
abase of a minimal ICO. Mada was											retest on avg 48.9 (5.2) hrs after, presented separately by MoA when differences were
Hafner 2016 28273329 MDC 95 5.36 observed. combined I.C., MoAs were satisfically constant.	Hafner	2016	28273329			MDC 95	5.36				observed. combined ICC, MoAs were satistically constant.

				Amputation	Other Population						
Author	Year	PMID	Amputation Level	Etiology Age	Information	N	Instrument	Subscale	Description	Property	Aspect
Hafaer	2016	28272220	above knee (70, 34.8%); below knee	dysvascular (46\22.9%); trauma (121/60.2%); infection (25/12.4%); tumor (8/4.0%); concerting (1/0.5%), 60.2 ± 11	4 pd	201		7-item short	item bank developed to measure perceived	Boliobility	toot rotoot
namer	2010	20213329	(131, 05.2 %)	dvevaecular	.4 110	201	PLUS-IVI	IOIIII	mobility in people with lower limb amputation	Reliability	lest-relest
Hafner	2016	28273329	above knee (70, 34.8%); below knee (131, 65.2 %)	(46)22.9%); trauma (121/60.2%); infection (25/12.4%); tumor (8/4.0%); congenital (1/0.5%) 60.2 +-11	.4 nd	201	PLUS-M	7-item short form	item bank developed to measure perceived mobility in people with lower limb amputation	MDC	
Hafner	2016	28273329	above knee (70, 34.8%); below knee (131, 65.2 %)	dysvascular (46\22.9%); trauma (121/60.2%); infection (25/12.4%); tumor (8/4.0%); congenital (1/0.5%) 60.2 +-11	.4 nd	201	PLUS-M	7-item short form	item bank developed to measure perceived mobility in people with lower limb amputation	MDC	
Hafner	2016	28273329	above knee (70, 34.8%); below knee (131, 65.2 %)	dysvascular (46\22.9%); trauma (121/60.2%); infection (25/12.4%); tumor (8/4.0%); congenital (1/0.5%) 60.2 +-11	.4 unilateral	201	PLUS-M	7-item short form	item bank developed to measure perceived mobility in people with lower limb amputation	Reliability	test-retest
Hafner	2016	28273329	above knee (70, 34.8%); below knee (131, 65.2 %)	dysvascular (46\22.9%); trauma (121/60.2%); infection (25/12.4%); tumor (8/4.0%); congenital (1/0.5%) 60.2 +-11	.4 unilateral	201	PLUS-M	7-item short form	item bank developed to measure perceived mobility in people with lower limb amputation	MDC	
Hafner	2016	28273329	above knee (70, 34.8%); below knee (131, 65.2 %)	dysvascular (46\22.9%); trauma (121/60.2%); infection (25/12.4%); tumor (8/4.0%); congenital (1/0.5%) 60.2 +-11	.4 unilateral	201	PLUS-M	7-item short form	item bank developed to measure perceived mobility in people with lower limb amoutation	MDC	
Hafner	2016	28273329	above knee (70, 34.8%); below knee (131, 65.2 %)	dysvascular (46\22.9%); trauma (121/60.2%); infection (25/12.4%); tumor (8/4.0%); congenital (1/0.5%) 60.2 +-11	.4 nd	201	PLUS-M	CAT	item bank developed to measure perceived mobility in people with lower limb amputation	Reliability	test-retest

Author	Year	PMID	Comparator/Criterion/Outo	(predictive valid)	Metric Used	Value	Strength of Property	Is Aspect Supported?	Conclusion	Notes/Caveats
				,						
Hafner	2016	28273329			ICC	0.95				retest on avg 48.9 (5.2) hrs after, presented separately by MoA when differences were observed. combined ICC, MoAs were satistically constant
- Idinor	2010	20270020				0.00				outoriouny conotaint
Hafner	2016	28273329			MDC 90	4.69				retest on avg 48.9 (5.2) hrs after, presenter separately by MoA when differences were observed. combined ICC, MoAs were satistically constant
Hafner	2016	28273329			MDC 95	5.59				retest on avg 48.9 (5.2) hrs after, presented separately by MoA when differences were observed. combined ICC, MoAs were satistically constant
Hafner	2016	28273329			ICC	0.95				retest on avg 48.9 (5.2) hrs after, presented separately by MoA when differences were observed. combined ICC, MoAs were satistically constant.
Hafner	2016	28273329			MDC 90	4.69				retest on avg 48.9 (5.2) hrs after, presented separately by MoA when differences were observed, combined ICC, MoAs were satistically constant.
Hafner	2016	28273329			MDC 95	5.59				retest on avg 48.9 (5.2) hrs after, presented separately by MoA when differences were observed. combined ICC, MoAs were satistically constant.
Hafner	2016	28273329			ICC	0.92				retest on avg 48.9 (5.2) hrs after, presented separately by MoA when differences were observed. combined ICC, MoAs were satistically constant

Timonoint

Study	Component Comparison	Outcome	Overall Favors* (P value)	N Total	Subgroup	N Subgroup	Comparator	N Comparator	P Diff (Categorical)
Alaranta 1994 (PMID 7991366)	Energy-storing vs. conventional ankle/foot	Movement disability index: Indoors	Energy storing (<0.001)	168	Transfemoral	27	Transtibial	141	1
Alaranta 1994 (PMID 7991366)	Energy-storing vs. conventional ankle/foot	Movement disability index: Upstairs	Energy storing (<0.001)	168	Transfemoral	27	Transtibial	141	0.59
Alaranta 1994 (PMID 7991366)	Energy-storing vs. conventional ankle/foot	Movement disability index: Downstairs	Energy storing (<0.001)	168	Transfemoral	27	Transtibial	141	0.86
Alaranta 1994 (PMID 7991366)	Energy-storing vs. conventional ankle/foot	Movement disability index: Upstairs	Energy storing (<0.001)	168	Transfemoral	27	Transtibial	141	0.59
Alaranta 1994 (PMID 7991366)	Energy-storing vs. conventional ankle/foot	Movement disability index: Uneven ground	Energy storing (<0.001)	168	Transfemoral	27	Transtibial	141	0.51
Alaranta 1994 (PMID 7991366)	Energy-storing vs. conventional ankle/foot	Movement disability index: Upstairs	Energy storing (<0.001)	168	Transfemoral	27	Transtibial	141	0.59
Alaranta 1994 (PMID 7991366)	Energy-storing vs. conventional ankle/foot	Movement disability index: Uphill street	Energy storing (<0.001)	168	Transfemoral	27	Transtibial	141	0.89
Alaranta 1994 (PMID 7991366)	Energy-storing vs. conventional ankle/foot	Movement disability index: Upstairs	Energy storing (<0.001)	168	Transfemoral	27	Transtibial	141	0.59
Alaranta 1994 (PMID 7991366)	Energy-storing vs. conventional ankle/foot	Movement disability index: Swift walking	Energy storing (<0.001)	168	Transfemoral	27	Transtibial	141	0.79
Alaranta 1994 (PMID 7991366)	Energy-storing vs. conventional ankle/foot	Movement disability index: Upstairs	Energy storing (<0.001)	168	Transfemoral	27	Transtibial	141	0.59
Alaranta 1994 (PMID 7991366)	Energy-storing vs. conventional ankle/foot	Movement disability index: Total	nd	168	Age				
Alaranta 1994 (PMID 7991366)	Energy-storing vs. conventional ankle/foot			168	Age at				
Alaranta 1994 (PMID 7991366)	Energy-storing vs. conventional ankle/foot			168	Body weight				
Alaranta 1994 (PMID 7991366)	Energy-storing vs. conventional ankle/foot			168	Body mass index				
De Asha 2014 (PMID 24997811)	Hydraulie ve rigid ankle/foot	Cait speed (m/s)	Hydraulic (0.005)	10	Transfermoral	8	Transtibial	11	0.12
De Asha 2014 (PMID 24997811)	Hydraulie vs. rigid ankle/foot	Cadence (steps/min)	Neither (0.84)	10	Transfemoral	8	Transtibial	11	0.53
De Asila 2014 (1 MiD 24337011)				13	Transiemora	0	Transubiai		0.00
Gard 2003 (PMID 15077637)	Shock absorbing vs. pon-shock absorbing pylop	Self-selected walking speed (m/s)	Neither (NS)	10	Vascular	3	Traumatic	7	0.87
Gard 2003 (PMID 15077637)	Shock absorbing vs. non-shock absorbing pylon			10	Male	9	Female	1	0.00
	Chock absorbing vs. non-shock absorbing pyton							<u> </u>	0.0002
Gard 2003 (PMID 15077637)	Shock absorbing vs. non-shock absorbing pylon			10	Age 31-46 y	5	Age 57-79 y	5	0.78
Gard 2003 (PMID 15077637)	Shock absorbing vs. non-shock absorbing pylon			10	Height 1.73-1.81 m	5	Ht 1.82-1.88 m	5	0.022
Gard 2003 (PMID 15077637)	Shock absorbing vs. non-shock absorbing pylon			10	Time since amputation 1-2 y	4	Time since amputation 4-50 y	6	0.34
Gard 2003 (PMID 15077637)	Shock absorbing vs. non-shock absorbing pylon	Fast walking speed (m/s)	Neither (NS)	10	Vascular	3	Traumatic	7	0.67
Gard 2003 (PMID 15077637)	Shock absorbing vs. non-shock absorbing pylon			10	Male	9	Female	1	<0.0001
Gard 2003 (PMID 15077637)	Shock absorbing vs. non-shock absorbing pylon			10	Age 31-46 y	5	Age 57-79 y	5	0.64
Gard 2003 (PMID 15077637)	Shock absorbing vs. non-shock absorbing pylon			10	Height 1.73-1.81 m	5	Ht 1.82-1.88 m	5	0.077
Gard 2003 (PMID 15077637)	Shock absorbing vs. non-shock absorbing pylon			10	Time since amputation 1-2 y	4	Time since amputation 4-50 y	6	0.045
Hafner 2009 (PMID 19675003)	Microprocessor vs. mechanical knee	Stair Assessment Index	Microprocessor (<0.001)	17	K level 2	8	K level 3	9	0.96
Hafner 2009 (FIVID 1907 5993)	Microprocessor vs. mechanical knee		Microprocessor (<0.001)	17	K lovel 2	8	K lovel 3	9	0.30
Hafner 2009 (FIVID 1907 3993)	Microprocessor vs. mechanical knee	Hill speed (m/s)	Microprocessor (<0.001)	17	K level 2	8	K level 3	9	0.41
Hamer 2003 (FIVID 1307333)				17		0	K lovel 3	9	0.65
Hamer 2009 (FIVID 1907 5993)	Microprocessor vs. mechanical knee	Attention speed (m/s)	Microprocessor (<0.001)	17		8	K level 3	9	0.00
Hamer 2009 (FWID 1907 5993)	Microprocessor vs. mechanical knee	Attention accuracy (% correct)	Neither (>0.05)	17		8	K lovel 3	9	0.07
Hamer 2009 (FIVID 1907 3993)			Microprocessor (0.009)	17	K lovel 2	8	K level 3	9	0.37
Hamer 2009 (FWID 1907 5953)	Microprocessor vs. mechanical knee		Neither (0.50)	17		8	K level 3	9	0.04
Hafner 2009 (PMID 19675993)	Micronrocessor vs. mechanical knee	PEO Frustration	Neither (0.11)	17	K level 2	8	K level 3	9	0.16
Hafner 2009 (PMID 19675993)	Microprocessor vs. mechanical knee	PEQ Perceived response	Neither (0.07)	17	K level 2	8	K level 3	9	0.75

Study	P Diff (Continuous)	Finding*	Difference Data*	Note	Within-Study
Alaranta 1004 (PMID 7001366)					0.0036
Alaranta 1994 (FIMID 7991300)					0.0030
Alaranta 1994 (PMID 7991300)					0.0036
Alaranta 1994 (PMID 7991300)					0.0036
Alaranta 1994 (PMID 7991300)					0.0036
Alaranta 1994 (PMID 7991300)					0.0036
Alaranta 1994 (PMID 7991366)					0.0036
Alaranta 1994 (PMID 7991366)					0.0036
Alaranta 1994 (PMID 7991366)					0.0036
Alaranta 1994 (PMID 7991366)					0.0036
Alaranta 1994 (PMID 7991366)					0.0036
Alaranta 1994 (PMID 7991366)	<0.01	Younger age weakly correlated with favoring energy storing	r=-0.30		0.0036
Alaranta 1994 (PMID 7991366)	NS				0.0036
Alaranta 1994 (PMID 7991366)	<0.01	Lighter body weight weakly correlated with favoring energy storing	r=0.29		0.0036
Alaranta 1994 (PMID 7991366)	NS				0.0036
De Asha 2014 (PMID 24997811)					0.005
De Asha 2014 (PMID 24997811)					0.005
Gard 2003 (PMID 15077637)					0.0028
Gard 2003 (PMID 15077637)		One woman favored SAP more than men did	-0.01 vs. 0.15		0.0028
Gard 2003 (PMID 15077637)	0.81			Split at median	0.0028
Gard 2003 (PMID 15077637)	0.010	Shorter favored SAP more than taller did	0.03 vs0.08; β = -1.34 (-2.25, -0.43)	Split at median, men only	0.0028
Gard 2003 (PMID 15077637)	0.76			Split at median, also NS split 1-5 vs. 25-50 y	0.0028
Gard 2003 (PMID 15077637)					0.0028
Gard 2003 (PMID 15077637)		One woman favored SAP more than men did	-0.004 vs. 0.26		0.0028
Gard 2003 (PMID 15077637)	0.84			Split at median	0.0028
Gard 2003 (PMID 15077637)	0.17			Split at median, men only	0.0028
Gard 2003 (PMID 15077637)	0.096	More recent amputation favored SAP more than more distant did	0.11 vs0.03	Split at median, similar if split 1-5 vs. 25-50 y	0.0028
Hofnor 2000 (DMID 10675002)					0.0018
Hafner 2009 (FIMID 1907 3993)					0.0010
Hamer 2009 (FIVID 1907 3993)					0.0010
Hamer 2009 (FIVID 1907 5993)					0.0010
Hamer 2009 (FIVID 19070993)					0.0010
Hefeer 2000 (PIVID 1907 5993)					0.0010
Hamer 2009 (MVID 19675993)					0.0018
Hamer 2009 (PMID 19675993)					0.0018
Hamer 2009 (PMID 19675993)					0.0018
Hamer 2009 (PMID 19675993)					0.0018
Hamer 2009 (PMID 19675993)					0.0018

Study	Component Comparison	Outcome	Overall Favors* (P value)	N Total	Subgroup	N Subgroup	Comparator	N Comparator	P Diff (Categorical)
Hafner 2009 (PMID 19675993)	Microprocessor vs. mechanical knee	PEQ Residual limb health	Neither (0.50)	17	K level 2	8	K level 3	9	0.93
Hafner 2009 (PMID 19675993)	Microprocessor vs. mechanical knee	PEQ Social burden	Neither (0.54)	17	K level 2	8	K level 3	9	1.00
Hafner 2009 (PMID 19675993)	Microprocessor vs. mechanical knee	PEQ Sounds	Neither (0.07)	17	K level 2	8	K level 3	9	0.25
Hafner 2009 (PMID 19675993)	Microprocessor vs. mechanical knee	PEQ Utility	Neither (0.07)	17	K level 2	8	K level 3	9	0.14
Hafner 2009 (PMID 19675993)	Microprocessor vs. mechanical knee	PEQ Well-being	Microprocessor (0.016)	17	K level 2	8	K level 3	9	0.83
Hafner 2009 (PMID 19675993)	Microprocessor vs. mechanical knee	Mental Energy expenditure (VAS)	Microprocessor (0.02)	17	K level 2	8	K level 3	9	0.43
Hafner 2009 (PMID 19675993)	Microprocessor vs. mechanical knee	Confidence while walking (VAS)	Microprocessor (0.001)	17	K level 2	8	K level 3	9	0.47
Hafner 2009 (PMID 19675993)	Microprocessor vs. mechanical knee	Multitasking while walking (VAS)	Microprocessor (0.002)	17	K level 2	8	K level 3	9	0.82
Hafner 2009 (PMID 19675993)	Microprocessor vs. mechanical knee	Difficulty with concentration (VAS)	Neither (0.07)	17	K level 2	8	K level 3	9	0.98
Hafner 2009 (PMID 19675993)	Microprocessor vs. mechanical knee	Activity avoidance (VAS)	Neither (0.10)	17	K level 2	8	K level 3	9	0.11
Hafner 2009 (PMID 19675993)	Microprocessor vs. mechanical knee	Frustration with falls (VAS)	Microprocessor (0.005)	17	K level 2	8	K level 3	9	0.81
Hafner 2009 (PMID 19675993)	Microprocessor vs. mechanical knee	Embarrassment with falls (VAS)	Neither (0.23)	17	K level 2	8	K level 3	9	0.87
Hafner 2009 (PMID 19675993)	Microprocessor vs. mechanical knee	Stumbles (VAS)	Microprocessor (0.05)	17	K level 2	8	K level 3	9	0.49
Hafner 2009 (PMID 19675993)	Microprocessor vs. mechanical knee	Stumbles (number)	Microprocessor (0.003)	17	K level 2	8	K level 3	9	0.40
Hafner 2009 (PMID 19675993)	Microprocessor vs. mechanical knee	Semicontrolled falls (VAS)	Neither (0.64)	17	K level 2	8	K level 3	9	0.91
Hafner 2009 (PMID 19675993)	Microprocessor vs. mechanical knee	Semicontrolled falls (number)	Microprocessor (0.03)	17	K level 2	8	K level 3	9	0.53
Hafner 2009 (PMID 19675993)	Microprocessor vs. mechanical knee	Uncontrolled falls (VAS)	Neither (0.64)	17	K level 2	8	K level 3	9	0.90
Hafner 2009 (PMID 19675993)	Microprocessor vs. mechanical knee	Uncontrolled falls (number)	Microprocessor (0.006)	17	K level 2	8	K level 3	9	0.37
			-						
	microprocessor)	harmonization of gait pattern, relief of the contralateral limb, possibility to divide attention, capability to vary gait speed, reduction of overall effort, reduction in number of aids, and change of mobility grade) Perception (of safety) Advanced maneuvers (assessed by prosthetist) Variable gait speed (capability to vary speed) Toileting Walking stairs alternatingly (up/down) HOWEVER, it is unclear which outcome(s) were used in the final models.			Many variables were statistically significant in multivariable regression analyses for different or variables and none of the regression models yield explanatory predictive power" regarding why microprocessor knee. These variables included: Age, Years wearing Prosthesis, Distance walk disease etiology, Amputation level, Bilateral amputation, No comorbidity, Diabetes mellitus, Cc circulation leg", Hip problem, Further disability, Profession, Residual limb condition, Residual li Adhesion, Number of falls per year, Mobility grade. Determined to have no overall predictive value: body mass index, neuropathy, visual impairme lower extremity, paresis upper extremity, further amputation, malformation, contralateral joint in osteoarthritis of the lower limb joints, hip contracture, Scarred residual limb, and Annual falls (y		er" regarding who would m sis, Distance walked per da betes melitus, Cardiovascu dition, Residual limb length , visual impairment, artifici intralateral joint instability/j nd Annual falls (yes/no).		
lookov 1095 (DMID 2969024)		Coit append (m/min)	Noither (0.060)	17	Veeeuler	14	Nenvegeuler	2	0.016
15aNUV 1900 (FIVIIL) 3000034)				''	vascular	14	INUTIVASCULAR	5	0.010
Isakov 1985 (PMID 3868034)	Locking vs. open knee			17	Male	16	Female	1	0.59
Isakov 1985 (PMID 3868034)	Locking vs. open knee			17	Age 26-50 y	8	Age 55-75 y	9	0.004
				0					
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee	Stumbles	Microprocessor (0.006)	15	K level 2	10	K level 3-4	5	0.14
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee		,	15	K level 2-3	4	K level 4	11	0.030
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Age 28-57	8	Age 58-83	7	0.53
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Vascular	7	Nonvascular	8	0.056
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Height 160-170 cm	5	Height 173-188 cm	10	0.44
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			14	Employed	7	Not employed	7	0.75

Study	P Diff (Continuous)	Finding*	Difference Data*	Note	Within-Study
Hofnor 2000 (PMID 10675002)					
Hamer 2009 (FMID 19075993)					0.0018
Hamer 2009 (PMID 19675993)					0.0018
Hatner 2009 (PMID 19675993)					0.0018
Hatner 2009 (PMID 19675993)					0.0018
Hatner 2009 (PMID 19675993)					0.0018
Hatner 2009 (PMID 19675993)					0.0018
Hafner 2009 (PMID 19675993)					0.0018
Hafner 2009 (PMID 19675993)					0.0018
Hafner 2009 (PMID 19675993)					0.0018
Hafner 2009 (PMID 19675993)			1		0.0018
Hafner 2009 (PMID 19675993)					0.0018
Hafner 2009 (PMID 19675993)					0.0018
Hafner 2009 (PMID 19675993)					0.0018
Hafner 2009 (PMID 19675993)					0.0018
Hafner 2009 (PMID 19675993)					0.0018
Hafner 2009 (PMID 19675993)					0.0018
Hafner 2009 (PMID 19675993)					0.0018
Hafner 2009 (PMID 19675993)					0.0018
Hahn 2016 (PMID 27828871)	However, "None or the ost benefit from a ly, Gender, Vascular lar disease, "Distortion , Residual limb loading, al hip, back pain, paresis bint replacement/pain,	The authors report that "None of the variables and none of the regression models yield explanatory predictive power" regarding who would most benefit from a microprocessor knee."		I he study was deemed to be flawed and likely biased (see text). Primary issues included the lack of a direct comparison between components, the likely biased sample population, the possibility of class imbalance, the incomplete reporting of analytic methods, the incomplete reporting of regression results, the lack of analyses of the predictive performance of the models, the lack of clarity about how to interpret their reported r- squared statistics.	
Isakov 1985 (PMID 3868034)		Nonvascular favored open knee more than	-4 08 vs 1 8		0.01
13000 (1 1012 000000 1)		vascular did	-4.00 V3. 1.0		0.01
Isakov 1985 (PMID 3868034)	1	1			0.01
Isakov 1985 (PMID 3868034)	0.014	Younger favored open knee more than older did	2.4 vs4.33	Split at arbitrary threshold; NS if split at median (58.5)	0.01
					0.00040
Kanle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)		K2-3 favored C-Leg more than K4 did	-25 vs5		0.00040
Kahle 2008 (PMID 18566922)	0.38			Split at median	0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)	0.93			Split at median, includes 1 woman	0.00040
Kahle 2008 (PMID 18566922)					0.00040

Study	Component Comparison	Outcome	Overall Favors* (P value)	N Total	Subgroup	N Subgroup	Comparator	N Comparator	P Diff (Categorical)
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Prosthesis use 6- 12 mo	9	Prosthesis use >12 mo	6	0.13
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump "firm"	7	Stump "soft" or "medium"	8	0.38
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump "medium" or "firm"	13	Stump "soft"	2	0.51
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump length 32- 43 cm	8	Stump length 11-31 cm	7	0.19
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump as percent of femur 74- 100%	8	27-73%	7	0.40
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee	Falls	Microprocessor (0.03)	15	K level 2	10	K level 3-4	5	0.48
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	K level 2-3	4	K level 4	11	0.089
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Age 28-57	8	Age 58-83	7	0.48
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Vascular	7	Nonvascular	8	0.24
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Height 160-170 cm	5	Height 173-188 cm	10	0.48
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			14	Employed	7	Not employed	7	0.15
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Prosthesis use 6- 12 mo	9	Prosthesis use >12 mo	6	0.29
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump "firm"	7	Stump "soft" or "medium"	8	0.20
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump "medium" or "firm"	13	Stump "soft"	2	0.84
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump length 32- 43 cm	8	Stump length 11-31 cm	7	0.37
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump as percent of femur 74- 100%	8	27-73%	7	0.48
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee	Self-selected walking speed	Microprocessor (0.03)	15	K level 2	10	K level 3-4	5	0.84
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	K level 2-3	4	K level 4	11	0.75
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Age 28-57	8	Age 58-83	7	0.82
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Vascular	7	Nonvascular	8	0.27
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Height 160-170 cm	5	Height 173-188 cm	10	0.20
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			14	Employed	7	Not employed	7	0.67
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Prosthesis use 6- 12 mo	9	Prosthesis use >12 mo	6	0.46
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump "firm"	7	Stump "soft" or "medium"	8	0.51
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump "medium" or "firm"	13	Stump "soft"	2	0.70
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump length 32- 43 cm	8	Stump length 11-31 cm	7	0.63
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump as percent of femur 74- 100%	8	27-73%	7	0.16
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee	Fastest walking on 75 m even terrain	Microprocessor (0.005)	15	K level 2	10	K level 3-4	5	0.64
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	K level 2-3	4	K level 4	11	0.93
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Age 28-57	8	Age 58-83	7	0.75

Study	P Diff (Continuous)	Finding*	Difference Data*	Note	Within-Study Bonferroni P
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)	0.71			Split at median	0.00040
Kahle 2008 (PMID 18566922)	0.74			Split at median, similar 100% vs. 27-79% or split at 67%	0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)	0.10			Split at median	0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)	0.48			Split at median, includes 1 woman	0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)	0.68			Split at median	0.00040
Kahle 2008 (PMID 18566922)	0.80			Split at median, similar 100% vs. 27-79% or split at 67%	0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)	0.80			Split at median	0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)	0.33			Split at median, includes 1 woman	0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)	0.50			Split at median	0.00040
Kahle 2008 (PMID 18566922)	0.49			Split at median, similar 100% vs. 27-79% or split at 67%	0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)	0.41			Split at median	0.00040

Study	Component Comparison	Outcome	Overall Favors* (P value)	N Total	Subgroup	N Subgroup	Comparator	N Comparator	P Diff (Categorical)
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Vascular	7	Nonvascular	8	0.41
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Height 160-170 cm	5	Height 173-188 cm	10	0.18
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			14	Employed	7	Not employed	7	0.76
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Prosthesis use 6- 12 mo	9	Prosthesis use >12 mo	6	0.43
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump "firm"	7	Stump "soft" or "medium"	8	0.34
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump "medium" or "firm"	13	Stump "soft"	2	0.60
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump length 32- 43 cm	8	Stump length 11-31 cm	7	0.34
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump as percent of femur 74- 100%	8	27-73%	7	0.18
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee	Fastest walking on uneven terrain	Microprocessor (<0.001)	15	K level 2	10	K level 3-4	5	0.76
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	K level 2-3	4	K level 4	11	0.068
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Age 28-57	8	Age 58-83	7	0.77
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Vascular	7	Nonvascular	8	0.13
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Height 160-170 cm	5	Height 173-188 cm	10	0.44
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			14	Employed	7	Not employed	7	0.41
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Prosthesis use 6- 12 mo	9	Prosthesis use >12 mo	6	0.94
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump "firm"	7	Stump "soft" or "medium"	8	0.12
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump "medium" or "firm"	13	Stump "soft"	2	0.052
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump length 32- 43 cm	8	Stump length 11-31 cm	7	0.30
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump as percent of femur 74- 100%	8	27-73%	7	0.77
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee	Fastest walking on 6 m even terrain	Microprocessor (0.001)	15	K level 2	10	K level 3-4	5	0.38
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	K level 2-3	4	K level 4	11	0.98
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Age 28-57	8	Age 58-83	7	0.71
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Vascular	7	Nonvascular	8	0.65
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Height 160-170 cm	5	Height 173-188 cm	10	0.64
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			14	Employed	7	Not employed	7	0.030
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Prosthesis use 6- 12 mo	9	Prosthesis use >12 mo	6	0.44
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump "firm"	7	Stump "soft" or "medium"	8	0.50
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump "medium" or "firm"	13	Stump "soft"	2	0.71
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump length 32- 43 cm	8	Stump length 11-31 cm	7	0.14

Study	P Diff (Continuous)	Finding*	Difference Data*	Note	Within-Study Bonferroni P				
Kahle 2008 (PMID 18566922)					0.00040				
Kahle 2008 (PMID 18566922)	0.26			Split at median, includes 1 woman	0.00040				
Kahle 2008 (PMID 18566922)					0.00040				
Kahle 2008 (PMID 18566922)					0.00040				
Kahle 2008 (PMID 18566922)					0.00040				
Kahle 2008 (PMID 18566922)					0.00040				
Kahle 2008 (PMID 18566922)				Split at median	0.00040				
Kahle 2008 (PMID 18566922)	0.46			Split at median, similar 100% vs. 27-79% or split at 67%	0.00040				
Kahle 2008 (PMID 18566922)					0.00040				
Kahle 2008 (PMID 18566922)					0.00040				
Kahle 2008 (PMID 18566922)	0.071			Split at median	0.00040				
Kahle 2008 (PMID 18566922)					0.00040				
Kahle 2008 (PMID 18566922)	0.41			Split at median, includes 1 woman	0.00040				
Kahle 2008 (PMID 18566922)					0.00040				
Kahle 2008 (PMID 18566922)					0.00040				
Kahle 2008 (PMID 18566922)					0.00040				
Kahle 2008 (PMID 18566922)					0.00040				
Kahle 2008 (PMID 18566922)	0.17			Split at median	0.00040				
Kahle 2008 (PMID 18566922)	0.13			Split at median, similar 100% vs. 27-79% or split at 67%	0.00040				
Kahle 2008 (PMID 18566922)					0.00040				
Kahle 2008 (PMID 18566922)					0.00040				
Kahle 2008 (PMID 18566922)	0.48			Split at median	0.00040				
Kahle 2008 (PMID 18566922)					0.00040				
Kahle 2008 (PMID 18566922)	0.79			Split at median, includes 1 woman	0.00040				
Kahle 2008 (PMID 18566922)		Employed favored C-Leg more than not employed did	-2.0 vs0.5		0.00040				
Kahle 2008 (PMID 18566922)					0.00040				
Kahle 2008 (PMID 18566922)					0.00040				
Kahle 2008 (PMID 18566922)					0.00040				
Kahle 2008 (PMID 18566922)	0.72			Split at median	0.00040				
Study	Component Comparison	Outcome	Overall Favors* (P value)	N Total	Subgroup	N Subgroup	Comparator	N Comparator	P Diff (Categorical)
-------------------------------	------------------------------------	--	---------------------------	---------	--	------------	-----------------------------	--------------	----------------------
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump as percent of femur 74- 100%	8	27-73%	7	0.36
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee	Montreal Rehabilitation Performance Profile	Microprocessor (<0.001)	15	K level 2	10	K level 3-4	5	0.15
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	K level 2-3	4	K level 4	11	0.38
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Age 28-57	8	Age 58-83	7	0.20
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Vascular	7	Nonvascular	8	0.21
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Height 160-170 cm	5	Height 173-188 cm	10	0.44
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			14	Employed	7	Not employed	7	0.32
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Prosthesis use 6- 12 mo	9	Prosthesis use >12 mo	6	0.37
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump "firm"	7	Stump "soft" or "medium"	8	0.16
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump "medium" or "firm"	13	Stump "soft"	2	0.30
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump length 32- 43 cm	8	Stump length 11-31 cm	7	0.12
Kahle 2008 (PMID 18566922)	Microprocessor vs. mechanical knee			15	Stump as percent of femur 74- 100%	8	27-73%	7	0.19
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee	Borg's Rating of Perceived Exertion test	Neither (1.00)	4	Age 33-41 y	2	Age 43-58	2	0.47
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee			4	Time since amputation 8-20	2	31-34 y	2	0.20
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee			4	Height 171-173 cm	2	Height 178-184 cm	2	0.47
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee			4	Stump length 23- 28 cm	2	32-36 cm	2	0.20
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee	Confidence (Likert)	Neither (0.32)	4	Age 33-41 y	2	Age 43-58	2	0.77
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee			4	Time since amputation 8-20	2	31-34 y	2	0.31
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee			4	Height 171-173 cm	2	Height 178-184 cm	2	0.77
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee			4	Stump length 23- 28 cm	2	32-36 cm	2	0.31
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee	Perceived stability	Neither (0.32)	4	Age 33-41 y	2	Age 43-58	2	0.77
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee			4	Time since amputation 8-20	2	31-34 y	2	0.31
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee			4	Height 171-173 cm	2	Height 178-184 cm	2	0.77
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee			4	Stump length 23- 28 cm	2	32-36 cm	2	0.31
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee	Comfort on uneven terrain	Neither (0.19)	4	Age 33-41 y	2	Age 43-58	2	0.81
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee			4	Time since amputation 8-20 y	2	31-34 y	2	0.037
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee			4	Height 171-173 cm	2	Height 178-184 cm	2	0.81

Study	P Diff (Continuous)	Finding*	Difference Data*	Note	Within-Study Bonferroni P
Kahle 2008 (PMID 18566922)	0.78		Split at median, similar 100% 27-79% or split at 67%		0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)				Split at median	0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)	0.88			Split at median, includes 1 woman	0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)					0.00040
Kahle 2008 (PMID 18566922)	0.97			Split at median	0.00040
Kahle 2008 (PMID 18566922)	0.998			Split at median, similar 100% vs. 27-79% or split at 67%	0.00040
	0.04				0.00070
Silver-Thorn 2009 (PMID none)	0.91			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.30			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.15			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.029	Shorter stump favored Total Knee 2000 more than longer stump did	β = 0.38 (0.10, 0.66)	Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.34			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.075			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.80			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.46			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.34			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.075			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.80			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.45			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.56			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.1	More recent amputation favored Total Knee 2000 more than more distant amputation did	2.5 vs. 0	Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.41			Split at median	0.00078

Study	Component Comparison	Outcome	Overall Favors* (P value)	N Total	Subgroup	N Subgroup	Comparator	N Comparator	P Diff (Categorical)
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee			4	Stump length 23- 28 cm	2	32-36 cm	2	0.037
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee	Comfort up stairs	Neither (0.092)	4	Age 33-41 y	2	Age 43-58	2	0.29
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee			4	Time since amputation 8-20	2	31-34 y	2	0.29
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee			4	Height 171-173 cm	2	Height 178-184 cm	2	0.29
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee			4	Stump length 23- 28 cm	2	32-36 cm	2	0.29
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee	Comfort in a crowd	Neither (0.39)	4	Age 33-41 y	2	Age 43-58	2	0.42
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee			4	Time since amputation 8-20	2	31-34 у	2	0.42
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee			4	Height 171-173 cm	2	Height 178-184 cm	2	0.42
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee			4	Stump length 23- 28 cm	2	32-36 cm	2	0.42
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee	Gait speed (m/s)	Neither (0.072)	5	Age 33-43 y	2	Age 49-58	3	0.67
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee			5	Time since amputation 2-8 y	3	20-34 y	2	0.14
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee			5	Height 171-178 cm	2	Height 184-185 cm	3	0.50
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee			5	Stump length 23- 28 cm	3	32-36 cm	2	0.071
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee	Cadence (steps/min)	Neither (0.20)	5	Age 33-43 y	2	Age 49-58	3	0.74
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee			5	Time since amputation 2-8 y	3	20-34 у	2	0.37
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee			5	Height 171-178 cm	2	Height 184-185 cm	3	0.16
Silver-Thorn 2009 (PMID none)	Locking vs. hydraulic knee			5	Stump length 23- 28 cm	3	32-36 cm	2	0.30
Theeven 2011 (PMID 21947182)	Microprocessor (2 settings) vs. mechanical knee	Activity time (% of up time)	Neither (0.86, 0.90)	30	K2 High, Intermediate	12, 12	K2 Low	6	
Theeven 2011 (PMID 21947182)	Microprocessor (2 settings) vs. mechanical knee	Bouts of activity (number)	Neither (0.99, 0.95)	30	K2 High, Intermediate	12, 12	K2 Low	6	
Theeven 2011 (PMID 21947182)	Microprocessor (2 settings) vs. mechanical knee	Daily activity "counts"	Neither (0.94, 0.89)	30	K2 High, Intermediate	12, 12	K2 Low	6	
Theeven 2011 (PMID 21947182)	Microprocessor (2 settings) vs. mechanical knee	PEQ Ambulation	Microprocessor A (0.01, 0.14)	30	K2 High, Intermediate	12, 12	K2 Low	6	
Theeven 2011 (PMID 21947182)	Microprocessor (2 settings) vs. mechanical knee	PEQ Appearance	Neither (0.55, 0.33)	30	K2 High, Intermediate	12, 12	K2 Low	6	
Theeven 2011 (PMID 21947182)	Microprocessor (2 settings) vs. mechanical knee	PEQ Residual limb health	Microprocessors (0.003, <0.001)	30	K2 High, Intermediate	12, 12	K2 Low	6	
Theeven 2011 (PMID 21947182)	Microprocessor (2 settings) vs. mechanical knee	PEQ Satisfaction with prosthesis	Neither (0.05, 0.14)	30	K2 High, Intermediate	12, 12	K2 Low	6	

Study	P Diff (Continuous)	Finding*	Difference Data*	Note	Within-Study
					Bonferroni P
Silver-Thorn 2009 (PMID none)	0.051	Longer stump favored Total Knee 2000 more than more shorter did	0 vs. 2.5	Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.88			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.52			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.085			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.046	Shorter stump favored Total Knee 2000 more than more longer did	β = -0.14 (-0.27, -0.01)	Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.95			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.39			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.14	_		Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.19			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.53			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.10			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.87			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.20			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.39			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.36			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.48			Split at median	0.00078
Silver-Thorn 2009 (PMID none)	0.28			Split at median	0.00078
	- 0.40 (. II+)				0.00007
Theeven 2011 (PMID 2194/182)	>0.42 (allŢ)				0.00037
Theeven 2011 (PMID 21947182)	>0.42 (all†)				0.00037
Theeven 2011 (PMID 21947182)	>0.31 (all†)				0.00037
Theeven 2011 (PMID 21947182)	>0.018 (all†)	High K2 favored microprocessor knee B more than low K2 subgroup; other comparisons P>0.13			0.00037
Theeven 2011 (PMID 21947182)	>0.69 (all†)				0.00037
Theeven 2011 (PMID 21947182)	>0.29 (all†)				0.00037
Theeven 2011 (PMID 21947182)	>0.28 (all†)				0.00037

Study	Component Comparison	Outcome	Overall Favors* (P value)	N Total	Subgroup	N Subgroup	Comparator	N Comparator	P Diff (Categorical)
Theeven 2011 (PMID 21947182)	Microprocessor (2 settings) vs. mechanical knee	PEQ Satisfaction with walking	Microprocessor A (0.003, 0.19)	30	K2 High, Intermediate	12, 12	K2 Low	6	
Theeven 2011 (PMID 21947182)	Microprocessor (2 settings) vs. mechanical knee	PEQ Sounds	Neither (0.52, 0.33)	30	K2 High, Intermediate	12, 12	K2 Low	6	
Theeven 2011 (PMID 21947182)	Microprocessor (2 settings) vs. mechanical knee	PEQ Utility	Microprocessors (0.006, 0.02)	30	K2 High, Intermediate	12, 12	K2 Low	6	
Theeven 2011 (PMID 21947182)	Microprocessor (2 settings) vs. mechanical knee	PEQ Well-being	Neither (0.30, 0.93)	30	K2 High, Intermediate	12, 12	K2 Low	6	
Theeven 2011 (PMID 21947182)	Microprocessor (2 settings) vs. mechanical knee	Perceived difficulty ambulation requiring prosthesis skill	Neither (0.63, 0.72)	30	K2 High, Intermediate	12, 12	K2 Low	6	
Theeven 2011 (PMID 21947182)	Microprocessor (2 settings) vs. mechanical knee	Perceived difficulty balance	Neither (0.56, 0.60)	30	K2 High, Intermediate	12, 12	K2 Low	6	
Theeven 2011 (PMID 21947182)	Microprocessor (2 settings) vs. mechanical knee	Perceived difficulty sitting and standing	Neither (0.62, 0.57)	30	K2 High, Intermediate	12, 12	K2 Low	6	
Theeven 2011 (PMID 21947182)	Microprocessor (2 settings) vs. mechanical knee	Performance time ambulation requiring prosthesis skill (min)	Microprocessor B (NS, 0.023)	30	K2 High, Intermediate	12, 12	K2 Low	6	
Theeven 2011 (PMID 21947182)	Microprocessor (2 settings) vs. mechanical knee	Performance time requiring balance (min)	Microprocessors (<0.001, 0.002)	30	K2 High, Intermediate	12, 12	K2 Low	6	
Theeven 2011 (PMID 21947182)	Microprocessor (2 settings) vs. mechanical knee	Performance time requiring sitting and standing (min)	Neither (0.87, 1.00)	30	K2 High, Intermediate	12, 12	K2 Low	6	
Traballesi 2011 (PMID 21684165)	Marlo Anatomic vs. Ischial Component Socket	PEQ Mobility	Marlo Anatomic Socket (0.018)	7	Male	6	Female	1	0.022
Traballesi 2011 (PMID 21684165)	Marlo Anatomic vs. Ischial Component Socket			7	Age 25-28 y	3	Age 41-46 y	4	0.42
Traballesi 2011 (PMID 21684165)	Marlo Anatomic vs. Ischial Component Socket			6	Height 174-180 cm	2	Height 184-185 cm	4	0.074
Traballesi 2011 (PMID 21684165)	Marlo Anatomic vs. Ischial Component Socket			7	Time since amputation 2-9 y	3	10-26 y	4	0.56
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee	Falls, number	Microprocessor (0.020)	8	K level 1	6	K level 2-3	2	0.12
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee			8	K level 1-2	4	K level 3	4	0.040
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee			8	Age 43-61 y	4	Age 63-74	4	0.040
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee			8	Time since amputation 0.5-2 y	4	4-47 y	4	0.73
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee			8	Bilateral	2	Unilateral	6	0.12
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee	ABC Balance	Microprocessor (0.012)	8	K level 1	6	K level 2-3	2	0.016
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee			8	K level 1-2	4	K level 3	4	0.16
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee			8	Age 43-61 y	4	Age 63-74	4	0.10
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee			8	Time since amputation 0.5-2 y	4	4-47 y	4	0.22

Study	P Diff (Continuous)	Finding*	Difference Data*	Note	Within-Study Bonferroni P
Theeven 2011 (PMID 21947182)	>0.006 (all†)	Intermediate K2 favored both microprocessor knees more than low K2 subgroup (P=0.28, 0.006), high K2 favored microprocessor knee B more than intermediate K2 subgroup (P=0.041); other comparisons P=0.066-0.44			0.00037
Theeven 2011 (PMID 21947182)	>0.33 (all†)				0.00037
Theeven 2011 (PMID 21947182)	>0.25 (all†)				0.00037
Theeven 2011 (PMID 21947182)	>0.54 (all†)				0.00037
Theeven 2011 (PMID 21947182)	>0.48 (all†)				0.00037
Theeven 2011 (PMID 21947182)	>0.69 (all†)				0.00037
Theeven 2011 (PMID 21947182)	>0.54 (all†)				0.00037
Theeven 2011 (PMID 21947182)	>0.68 (all†)				0.00037
Theeven 2011 (PMID 21947182)	>0.31 (all†)				0.00037
Theeven 2011 (PMID 21947182)	>0.51 (all†)				0.00037
			0.00		0.0074
Traballesi 2011 (PMID 21004105)		Socket more than men did	2.30 vs. 1.35		0.0071
Traballesi 2011 (PMID 21684165)	0.28			Split at median	0.0071
Traballesi 2011 (PMID 21684165)	0.017	Shorter favored Marlo Anatomical Socket more than taller did	β = -0.14 (-0.24, -0.04)	Split at median, men only	0.0071
Traballesi 2011 (PMID 21684165)	0.69			Split at median	0.0071
Mana 2015 (DMID 25769067)					0.0010
Wong 2015 (PMID 25768067)		K1-2 favored microprocessor knee more than K3 did	-2 vs0.75		0.0010
Wong 2015 (PMID 25768067)	0.027	Older favored microprocessor knee more than younger did	-0.75 vs2; β = 0.06 (0.01, 0.11)	Split at median	0.0010
Wong 2015 (PMID 25768067)	0.67			Split at median, similar split 0.5-4 vs. 17-47 y	0.0010
Wong 2015 (PMID 25768067)					0.0010
Wong 2015 (PMID 25768067)		K2-3 favored microprocessor knee more than K1 did	15.9 vs. 62.3		0.0010
Wong 2015 (PMID 25768067)					0.0010
Wong 2015 (PMID 25768067)	0.021	Younger favored microprocessor knee more than older did	β =1.9 (0.4, 3.3)		0.0010
Wong 2015 (PMID 25768067)	0.96				0.0010

Study	Component Comparison	Outcome	Overall Favors* (P value)	N Total	Subgroup	N Subgroup	Comparator	N Comparator	P Diff (Categorical)
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee			8	Bilateral	2	Unilateral	6	0.016
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee	Houghton Scale	Neither (0.058)	8	K level 1	6	K level 2-3	2	0.61
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee			8	K level 1-2	4	K level 3	4	0.37
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee			8	Age 43-61 y	4	Age 63-74	4	0.37
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee			8	Time since amputation 0.5-2 y	4	4-47 y	4	0.13
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee			8	Bilateral	2	Unilateral	6	0.61
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee	BBS Balance	Neither (0.11)	8	K level 1	6	K level 2-3	2	0.81
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee			8	K level 1-2	4	K level 3	4	0.51
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee			8	Age 43-61 y	4	Age 63-74	4	0.95
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee			8	Time since amputation 0.5-2 y	4	4-47 y	4	0.77
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee			8	Bilateral	2	Unilateral	6	0.81
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee	TUG Walking	Microprocessor (0.043)	8	K level 1	6	K level 2-3	2	0.0001
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee			8	K level 1-2	4	K level 3	4	0.24
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee			8	Age 43-61 y	4	Age 63-74	4	0.28
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee			8	Time since amputation 0.5-2 y	4	4-47 y	4	0.37
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee			8	Bilateral	2	Unilateral	6	0.0001
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee	Fear of falling	Microprocessor (0.042)	8	K level 1	6	K level 2-3	2	0.11
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee			8	K level 1-2	4	K level 3	4	0.62
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee			8	Age 43-61 y	4	Age 63-74	4	0.35
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee			8	Time since amputation 0.5-2 y	4	4-47 y	4	0.48
Wong 2015 (PMID 25768067)	Micropocessor vs. mechanical knee			8	Bilateral	2	Unilateral	6	0.11
		* Statistically significant difference favoring listed component over comparator. "Neither" does not distinguish between evidence of no difference and lack of statistical power to find a difference (due to imprecision). # 6 comparisons summarized: High vs.							
		intermediate K2, high vs. low K2, and intermediate vs. low K2 for both microprocessor knees A and B vs. mechanical knee.							

Study	P Diff (Continuous)	Finding*	Difference Data*	Note	Within-Study
					Bonferroni P
Wong 2015 (PMID 25768067)		Bilateral favored microprocessor knee more than unilateral did	62.3 vs. 15.9		0.0010
Wong 2015 (PMID 25768067)					0.0010
Wong 2015 (PMID 25768067)					0.0010
Wong 2015 (PMID 25768067)	0.10				0.0010
Wong 2015 (PMID 25768067)	0.47				0.0010
Wong 2015 (PMID 25768067)					0.0010
Wong 2015 (PMID 25768067)					0.0010
Wong 2015 (PMID 25768067)					0.0010
Wong 2015 (PMID 25768067)	0.93				0.0010
Wong 2015 (PMID 25768067)	0.33				0.0010
Wong 2015 (PMID 25768067)					0.0010
Wong 2015 (PMID 25768067)		K2-3 favored microprocessor knee more than K1 did	-2.6 vs70		0.0010
Wong 2015 (PMID 25768067)					0.0010
Wong 2015 (PMID 25768067)	0.17				0.0010
Wong 2015 (PMID 25768067)	0.78				0.0010
Wong 2015 (PMID 25768067)		Bilateral favored microprocessor knee more than unilateral did	-70 vs2.6		0.0010
Wong 2015 (PMID 25768067)					0.0010
Wong 2015 (PMID 25768067)					0.0010
Wong 2015 (PMID 25768067)	0.24				0.0010
Wong 2015 (PMID 25768067)	0.51				0.0010
Wong 2015 (PMID 25768067)					0.0010